

# Exhibit 51

United States Patent Application 20200197510

# US PATENT & TRADEMARK OFFICE

## PATENT APPLICATION FULL TEXT AND IMAGE DATABASE



( 3 of 21 )

---

<b>United States Patent Application</b>	<b>20200197510</b>
<b>Kind Code</b>	<b>A1</b>
<b>Ciaramella; Giuseppe ; et al.</b>	<b>June 25, 2020</b>

---

### RESPIRATORY VIRUS VACCINES

#### Abstract

The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

---

Inventors: **Ciaramella; Giuseppe;** (*Sudbury, MA*) ; **Himansu; Sunny;** (*Winchester, MA*)

**Applicant:**        **Name**                    **City**    **State** **Country** **Type**

**ModernaTX, Inc.** Cambridge MA    US

Assignee: **ModernaTX, Inc.**  
**Cambridge**  
**MA**

Family ID: **58558175**

Appl. No.: **16/805587**

Filed:        **February 28, 2020**

---

#### Related U.S. Patent Documents

---

<u>Application Number</u>	<u>Filing Date</u>	<u>Patent Number</u>
16368270	Mar 28, 2019	
16805587		
16040981	Jul 20, 2018	10272150
16368270		
15674599	Aug 11, 2017	10064934
16040981		
PCT/US2016/058327	Oct 21, 2016	
15674599		
62247362	Oct 28, 2015	

62247394	Oct 28, 2015
62247483	Oct 28, 2015
62247297	Oct 28, 2015
62244802	Oct 22, 2015
62244946	Oct 22, 2015
62244813	Oct 22, 2015
62244837	Oct 22, 2015
62245031	Oct 22, 2015

---

**Current U.S. Class:**

**1/1**

**Current CPC Class:**

A61K 39/215 20130101; C07K 16/10 20130101; A61K 2039/70 20130101; C12N 2760/18434 20130101; C12N 2760/18634 20130101; A61K 2039/55511 20130101; A61P 11/00 20180101; C12N 2760/18534 20130101; A61K 39/12 20130101; C07K 2317/76 20130101; A61K 2039/6018 20130101; C12N 2770/20034 20130101; C12N 2760/18034 20130101; C12N 2760/18334 20130101; A61K 2039/53 20130101; A61K 2039/55555 20130101; Y02A 50/30 20180101; C07K 16/1027 20130101; A61K 39/155 20130101

**International Class:**

A61K 39/155 20060101 A61K039/155; A61P 11/00 20060101 A61P011/00; C07K 16/10 20060101 C07K016/10; A61K 39/12 20060101 A61K039/12

---

*Claims*

---

1.-135. (canceled)

136. A composition, comprising: a ribonucleic acid (RNA) comprising an open reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein subunit formulated in a lipid nanoparticle.

137. The composition of claim 136, wherein the open reading frame encodes a BetaCoV S protein.

138. The composition of claim 136, wherein the open reading frame encodes an S protein subunit selected from an S1 subunit and an S2 subunit.

139. The composition of claim 136, wherein the RNA is a messenger RNA (mRNA) further comprising a 5' untranslated region (UTR) and a 3' UTR.

140. The composition of claim 139, wherein the mRNA further comprises a poly(A) tail.

141. The composition of claim 139, wherein the mRNA further comprises a 5' cap analog.

142. The composition of claim 141, wherein the 5' cap analog is 7mG(5')ppp(5')NlmpNp.

143. The composition of claim 136, wherein the RNA comprises a chemical modification.

144. The composition of claim 143, wherein the chemical modification is a 1-methylpseudouridine modification or a 1-ethylpseudouridine modification.

145. The composition of claim 143, wherein at least 80% of the uracil in the open reading frame has a chemical modification.
146. The composition of claim 136, wherein the lipid nanoparticle comprises an ionizable cationic lipid, a neutral lipid, a sterol, and a PEG-modified lipid.
147. The composition of claim 146, wherein the lipid nanoparticle comprises 20-60% ionizable cationic lipid, 5-25% neutral lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid.
148. The composition of claim 147, wherein the lipid nanoparticle comprises 50% ionizable cationic lipid, 10% neutral lipid, 38.5% sterol, and 1.5% PEG-modified lipid.
149. The composition of claim 146, wherein the ionizable cationic lipid has a Compound 25 structure.
150. The composition of claim 146, wherein the neutral lipid is DSPC, the sterol is cholesterol, and the PEG-modified lipid is PEG-DMG or PEG-cDMA.
151. A composition, comprising: a messenger ribonucleic acid (mRNA) comprising a 5' untranslated region (UTR), an open reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein subunit, a 3' UTR, and a poly(A) tail, formulated in a lipid nanoparticle that comprises 20-60% ionizable cationic lipid, 5-25% neutral lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid.
152. The composition of claim 151, wherein the open reading frame encodes a BetaCoV S protein.
153. The composition of claim 151, wherein the open reading frame encodes an S protein subunit selected from an S1 subunit and an S2 subunit.
154. The composition of claim 151, wherein the mRNA further comprises 5' cap analog 7mG(5')ppp(5')NlmpNp.
155. The composition of claim 151, wherein at least 80% of the uracil in the open reading frame has a chemical modification.
156. The composition of claim 155, wherein the chemical modification is a 1-methylpseudouridine modification or a 1-ethylpseudouridine modification.
157. The composition of claim 151, wherein the ionizable cationic lipid has a Compound 25 structure.
158. The composition of claim 151, wherein the neutral lipid is DSPC, the sterol is cholesterol, and the PEG-modified lipid is PEG-DMG.
159. A composition, comprising: a messenger ribonucleic acid (mRNA) comprising a 5' cap analog, a 5' untranslated region (UTR), an open reading frame encoding a betacoronavirus (BetaCoV) S protein, a 3' UTR, and a poly(A) tail, formulated in a lipid nanoparticle that comprises 20-60% ionizable cationic lipid, 5-25% DSPC, 25-55% sterol, and 0.5-15% PEG-DMG, wherein the ionizable cationic lipid has the structure of Compound 25, and wherein at least 80% of the uracil in the open reading frame has a 1-methylpseudouridine modification.
160. The composition of claim 159, wherein the 5' cap analog is 7mG(5')ppp(5')NlmpNp.
161. A lipid nanoparticle, comprising: a messenger ribonucleic acid (RNA) comprising an open reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein subunit; and a lipid mixture comprising 20-60% ionizable cationic lipid, 5-25% neutral lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid.

162. A method comprising administering to a subject the composition of claim 159.

163. The method of claim 162, wherein the composition is administered in an amount effective to induce in the subject an immune response specific to BetaCoV.

164. The method of claim 163, wherein the immune response includes induction of a measurable neutralizing antibody titer in the subject.

165. The method of claim 164, wherein the effective amount is sufficient to produce a 1,000-10,000 neutralization titer produced by neutralizing antibody against BetaCoV S protein, as measured in serum of the subject at 1-72 hours post administration.

---

### *Description*

---

#### RELATED APPLICATIONS

[0001] This application is a continuation of U.S. application Ser. No. 16/368,270, filed Mar. 28, 2019, which is a continuation of Ser. No. 16/040,981, filed Jul. 20, 2018, now U.S. Pat. No. 10,272,150, which is a continuation of U.S. application Ser. No. 15/674,599, filed Aug. 11, 2017, now U.S. Pat. No. 10,064,934, which is a continuation of International application number PCT/US2016/058327, filed Oct. 21, 2016, which claims the benefit under 35 U.S.C. .sectn. 119(e) of U.S. provisional application No. 62/244,802, filed Oct. 22, 2015, U.S. provisional application No. 62/247,297, filed Oct. 28, 2015, U.S. provisional application No. 62/244,946, filed Oct. 22, 2015, U.S. provisional application No. 62/247,362, filed Oct. 28, 2015, U.S. provisional application No. 62/244,813, filed Oct. 22, 2015, U.S. provisional application No. 62/247,394, filed Oct. 28, 2015, U.S. provisional application No. 62/244,837, filed Oct. 22, 2015, U.S. provisional application No. 62/247,483, filed Oct. 28, 2015, and U.S. provisional application No. 62/245,031, filed Oct. 22, 2015, each of which is incorporated by reference herein in its entirety.

#### BACKGROUND

[0002] Respiratory disease is a medical term that encompasses pathological conditions affecting the organs and tissues that make gas exchange possible in higher organisms, and includes conditions of the upper respiratory tract, trachea, bronchi, bronchioles, alveoli, pleura and pleural cavity, and the nerves and muscles of breathing. Respiratory diseases range from mild and self-limiting, such as the common cold, to life-threatening entities like bacterial pneumonia, pulmonary embolism, acute asthma and lung cancer. Respiratory disease is a common and significant cause of illness and death around the world. In the US, approximately 1 billion "common colds" occur each year. Respiratory conditions are among the most frequent reasons for hospital stays among children.

[0003] The human metapneumovirus (hMPV) is a negative-sense, single-stranded RNA virus of the genus Pneumovirinae and of the family Paramyxoviridae and is closely related to the avian metapneumovirus (AMPV) subgroup C. It was isolated for the first time in 2001 in the Netherlands by using the RAP-PCR (RNA arbitrarily primed PCR) technique for identification of unknown viruses growing in cultured cells. hMPV is second only to RSV as an important cause of viral lower respiratory tract illness (LRI) in young children. The seasonal epidemiology of hMPV appears to be similar to that of RSV, but the incidence of infection and illness appears to be substantially lower.

[0004] Parainfluenza virus type 3 (PIV3), like hMPV, is also a negative-sense, single-stranded sense RNA virus of the genus Pneumovirinae and of the family Paramyxoviridae and is a major cause of ubiquitous acute respiratory infections of infancy and early childhood. Its incidence peaks around 4-12 months of age, and the virus is responsible for 3-10% of hospitalizations, mainly for bronchiolitis and pneumonia. PIV3 can be fatal, and in some instances is associated with neurologic diseases, such as febrile seizures. It can also result in airway

remodeling, a significant cause of morbidity. In developing regions of the world, infants and young children are at the highest risk of mortality, either from primary PIV3 viral infection or a secondary consequences, such as bacterial infections. Human parainfluenza viruses (hPIV) types 1, 2 and 3 (hPIV1, hPIV2 and hPIV3, respectively), also like hMPV, are second only to RSV as important causes of viral LRI in young children.

[0005] RSV, too, is a negative-sense, single-stranded RNA virus of the genus Pneumovirinae and of the family Paramyxoviridae. Symptoms in adults typically resemble a sinus infection or the common cold, although the infection may be asymptomatic. In older adults (e.g., >60 years), RSV infection may progress to bronchiolitis or pneumonia. Symptoms in children are often more severe, including bronchiolitis and pneumonia. It is estimated that in the United States, most children are infected with RSV by the age of three. The RSV virion consists of an internal nucleocapsid comprised of the viral RNA bound to nucleoprotein (N), phosphoprotein (P), and large polymerase protein (L). The nucleocapsid is surrounded by matrix protein (M) and is encapsulated by a lipid bilayer into which the viral fusion (F) and attachment (G) proteins as well as the small hydrophobic protein (SH) are incorporated. The viral genome also encodes two nonstructural proteins (NS1 and NS2), which inhibit type I interferon activity as well as the M-2 protein.

[0006] The continuing health problems associated with hMPV, PIV3 and RSV are of concern internationally, reinforcing the importance of developing effective and safe vaccine candidates against these virus.

[0007] Despite decades of research, no vaccines currently exist (Sato and Wright, *Pediatr. Infect. Dis. J.* 2008; 27(10 Suppl):S123-5). Recombinant technology, however, has been used to target the formation of vaccines for hPIV-1, 2 and 3 serotypes, for example, and has taken the form of several live-attenuated intranasal vaccines. Two vaccines in particular were found to be immunogenic and well tolerated against hPIV-3 in phase I trials. hPIV1 and hPIV2 vaccine candidates remain less advanced (Durbin and Karron, *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* 2003; 37(12):1668-77).

[0008] Measles virus (MeV), like hMPV, PIV3 and RSV, is a negative-sense, single-stranded RNA virus that is the cause of measles, an infection of the respiratory system. MeV is of the genus Morbillivirus within the family Paramyxoviridae. Humans are the natural hosts of the virus; no animal reservoirs are known to exist. Symptoms of measles include fever, cough, runny nose, red eyes and a generalized, maculopapular, erythematous rash. The virus is highly contagious and is spread by coughing

[0009] In addition to hMPV, PIV, RSV and MeV, betacoronaviruses are known to cause respiratory illnesses. Betacoronaviruses (BetaCoVs) are one of four genera of coronaviruses of the subfamily Coronavirinae in the family Coronaviridae, of the order Nidovirales. They are enveloped, positive-sense, single-stranded RNA viruses of zoonotic origin. The coronavirus genera are each composed of varying viral lineages, with the betacoronavirus genus containing four such lineages. The BetaCoVs of the greatest clinical importance concerning humans are OC43 and HKU1 of the A lineage, **SARS**-CoV of the B lineage, and MERS-CoV of the C lineage. MERS-CoV is the first betacoronavirus belonging to lineage C that is known to infect humans.

[0010] The Middle East respiratory syndrome coronavirus (MERS-CoV), or EMC/2012 (HCoV-EMC/2012), initially referred to as novel coronavirus 2012 or simply novel coronavirus, was first reported in 2012 after genome sequencing of a virus isolated from sputum samples from a person who fell ill during a 2012 outbreak of a new flu. As of July 2015, MERS-CoV cases have been reported in over 21 countries. The outbreaks of MERS-CoV have raised serious concerns world-wide, reinforcing the importance of developing effective and safe vaccine candidates against MERS-CoV.

[0011] Severe acute respiratory syndrome (**SARS**) emerged in China in 2002 and spread to other countries before brought under control. Because of a concern for reemergence or a *deliberate release of the SARS* coronavirus, vaccine development was initiated.

[0012] Deoxyribonucleic acid (DNA) vaccination is one technique used to stimulate humoral and cellular immune responses to foreign antigens, such as hMPV antigens and/or PIV antigens and/or RSV antigens. The direct injection of genetically engineered DNA (e.g., naked plasmid DNA) into a living host results in a small

number of its cells directly producing an antigen, resulting in a protective immunological response. With this technique, however, comes potential problems, including the possibility of insertional mutagenesis, which could lead to the activation of oncogenes or the inhibition of tumor suppressor genes.

## SUMMARY

[0013] Provided herein are ribonucleic acid (RNA) vaccines that build on the knowledge that RNA (e.g., messenger RNA (mRNA)) can safely direct the body's cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells. The RNA (e.g., mRNA) vaccines of the present disclosure may be used to induce a balanced immune response against hMPV, PIV, RSV, MeV, and/or BetaCoV (e.g., MERS-CoV, **SARS-CoV**, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1), or any combination of two or more of the foregoing viruses, comprising both cellular and humoral immunity, without risking the possibility of insertional mutagenesis, for example. hMPV, PIV, RSV, MeV, BetaCoV (e.g., MERS-CoV, **SARS-CoV**, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1) and combinations thereof are referred to herein as "respiratory viruses." Thus, the term "respiratory virus RNA vaccines" encompasses hMPV RNA vaccines, PIV RNA vaccines, RSV RNA vaccines, MeV RNA vaccines, BetaCoV RNA vaccines, and any combination of two or more of hMPV RNA vaccines, PIV RNA vaccines, RSV RNA vaccines, MeV RNA vaccines, and BetaCoV RNA vaccines.

[0014] The RNA (e.g., mRNA) vaccines may be utilized in various settings depending on the prevalence of the infection or the degree or level of unmet medical need. The RNA (e.g. mRNA) vaccines may be utilized to treat and/or prevent a hMPV, PIV, RSV, MeV, a BetaCoV (e.g., MERS-CoV, **SARS-CoV**, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH, HCoV-HKU1), or any combination of two or more of the foregoing viruses, of various genotypes, strains, and isolates. The RNA (e.g., mRNA) vaccines have superior properties in that they produce much larger antibody titers and produce responses earlier than commercially available anti-viral therapeutic treatments. While not wishing to be bound by theory, it is believed that the RNA (e.g., mRNA) vaccines, as mRNA polynucleotides, are better designed to produce the appropriate protein conformation upon translation as the RNA (e.g., mRNA) vaccines co-opt natural cellular machinery. Unlike traditional vaccines, which are manufactured ex vivo and may trigger unwanted cellular responses, RNA (e.g., mRNA) vaccines are presented to the cellular system in a more native fashion.

[0015] In some aspects the invention is a respiratory virus vaccine, comprising at least one RNA polynucleotide having an open reading frame encoding at least one respiratory virus antigenic polypeptide, formulated in a cationic lipid nanoparticle.

[0016] Surprisingly, in some aspects, it has also been shown that efficacy of mRNA vaccines can be significantly enhanced when combined with a flagellin adjuvant, in particular, when one or more antigen-encoding mRNAs is combined with an mRNA encoding flagellin.

[0017] RNA (e.g., mRNA) vaccines combined with the flagellin adjuvant (e.g., mRNA-encoded flagellin adjuvant) have superior properties in that they may produce much larger antibody titers and produce responses earlier than commercially available vaccine formulations. While not wishing to be bound by theory, it is believed that the RNA (e.g., mRNA) vaccines, for example, as mRNA polynucleotides, are better designed to produce the appropriate protein conformation upon translation, for both the antigen and the adjuvant, as the RNA (e.g., mRNA) vaccines co-opt natural cellular machinery. Unlike traditional vaccines, which are manufactured ex vivo and may trigger unwanted cellular responses, RNA (e.g., mRNA) vaccines are presented to the cellular system in a more native fashion.

[0018] Some embodiments of the present disclosure provide RNA (e.g., mRNA) vaccines that include at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one antigenic polypeptide or an immunogenic fragment thereof (e.g., an immunogenic fragment capable of inducing an immune response to the antigenic polypeptide) and at least one RNA (e.g., mRNA polynucleotide) having an open reading frame encoding a flagellin adjuvant.

[0019] In some embodiments, at least one flagellin polypeptide (e.g., encoded flagellin polypeptide) is a flagellin protein. In some embodiments, at least one flagellin polypeptide (e.g., encoded flagellin polypeptide) is an immunogenic flagellin fragment. In some embodiments, at least one flagellin polypeptide and at least one antigenic polypeptide are encoded by a single RNA (e.g., mRNA) polynucleotide. In other embodiments, at least one flagellin polypeptide and at least one antigenic polypeptide are each encoded by a different RNA polynucleotide.

[0020] In some embodiments at least one flagellin polypeptide has at least 80%, at least 85%, at least 90%, or at least 95% identity to a flagellin polypeptide having a sequence identified by any one of SEQ ID NO: 54-56.

[0021] Provided herein, in some embodiments, is a ribonucleic acid (RNA) (e.g., mRNA) vaccine, comprising at least one (e.g., at least 2, 3, 4 or 5) RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one (e.g., at least 2, 3, 4 or 5) hMPV, PIV, RSV, MeV, or a BetaCoV (e.g., MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH, HCoV-HKU1) antigenic polypeptide, or any combination of two or more of the foregoing antigenic polypeptides. Herein, use of the term "antigenic polypeptide" encompasses immunogenic fragments of the antigenic polypeptide (an immunogenic fragment that induces (or is capable of inducing) an immune response to hMPV, PIV, RSV, MeV, or a BetaCoV), unless otherwise stated.

[0022] Also provided herein, in some embodiments, is a RNA (e.g., mRNA) vaccine comprising at least one (e.g., at least 2, 3, 4 or 5) RNA polynucleotide having an open reading frame encoding at least one (e.g., at least 2, 3, 4 or 5) hMPV, PIV, RSV, MeV, and/or a BetaCoV (e.g., MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH, HCoV-HKU1) antigenic polypeptide or an immunogenic fragment thereof, linked to a signal peptide.

[0023] Further provided herein, in some embodiments, is a nucleic acid (e.g., DNA) encoding at least one (e.g., at least 2, 3, 4 or 5) hMPV, PIV, RSV, MeV, and/or a BetaCoV (e.g., MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH, HCoV-HKU1) RNA (e.g., mRNA) polynucleotide.

[0024] Further still, provided herein, in some embodiments, is a method of inducing an immune response in a subject, the method comprising administering to the subject a vaccine comprising at least one (e.g., at least 2, 3, 4 or 5) RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one (e.g., at least 2, 3, 4 or 5) hMPV, PIV, RSV, MeV, and/or a BetaCoV (e.g., MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH, HCoV-HKU1) antigenic polypeptide, or any combination of two or more of the foregoing antigenic polypeptides.

[0025] hMPV/PIV3/RSV

[0026] In some embodiments, a RNA (e.g., mRNA) vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one hMPV, PIV3 or RSV antigenic polypeptide. In some embodiments, at least one antigenic polypeptide is a hMPV, PIV3 or RSV polyprotein. In some embodiments, at least one antigenic polypeptide is major surface glycoprotein G or an immunogenic fragment thereof. In some embodiments, at least one antigenic polypeptide is Fusion (F) glycoprotein (e.g., Fusion glycoprotein F0, F1 or F2) or an immunogenic fragment thereof. In some embodiments, at least one antigenic polypeptide is major surface glycoprotein G or an immunogenic fragment thereof and F glycoprotein or an immunogenic fragment thereof. In some embodiments, the antigenic polypeptide is nucleoprotein (N) or an immunogenic fragment thereof, phosphoprotein (P) or an immunogenic fragment thereof, large polymerase protein (L) or an immunogenic fragment thereof, matrix protein (M) or an immunogenic fragment thereof, small hydrophobic protein (SH) or an immunogenic fragment thereof nonstructural protein1 (NS1) or an immunogenic fragment thereof, or nonstructural protein 2 (NS2) and an immunogenic fragment thereof.

[0027] In some embodiments, at least one hMPV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 5-8 (Table 3; see also amino acid sequences of Table 4). In some



embodiments, the amino acid sequence of the hMPV antigenic polypeptide is, or is a fragment of, or is a homolog or variant having at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) identity to, the amino acid sequence identified by any one of SEQ ID NO: 5-8 (Table 3; see also amino acid sequences of Table 4).

[0028] In some embodiments, at least one hMPV antigenic polypeptide is encoded by a nucleic acid sequence identified by any one of SEQ ID NO: 1-4 (Table 2).

[0029] In some embodiments, at least one hMPV RNA (e.g., mRNA) polynucleotide is encoded by a nucleic acid sequence, or a fragment of a nucleotide sequence, identified by any one of SEQ ID NO: 1-4 (Table 2). In some embodiments, at least one hMPV RNA (e.g., mRNA) polynucleotide comprises a nucleic acid sequence, or a fragment of a nucleotide sequence, identified by any one of SEQ ID NO: 57-60 (Table 2).

[0030] In some embodiments, at least one antigenic polypeptide is obtained from hMPV strain CAN98-75 (CAN75) or the hMPV strain CAN97-83 (CAN83).

[0031] In some embodiments, at least one PIV3 antigenic polypeptide comprises hemagglutinin-neuraminidase, Fusion (F) glycoprotein, matrix protein (M), nucleocapsid protein (N), viral replicase (L), non-structural V protein, or an immunogenic fragment thereof.

[0032] In some embodiments, at least one PIV3 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 12-13 (Table 6; see also amino acid sequences of Table 7). In some embodiments, the amino acid sequence of the PIV3 antigenic polypeptide is, or is a fragment of, or is a homolog or variant having at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) identity to, the amino acid sequence identified by any one of SEQ ID NO: 12-13 (Table 6; see also amino acid sequences of Table 7).

[0033] In some embodiments, at least one PIV3 antigenic polypeptide is encoded by a nucleic acid sequence identified by any one of SEQ ID NO: 9-12 (Table 5; see also nucleic acid sequences of Table 7).

[0034] In some embodiments, at least one PIV3 RNA (e.g., mRNA) polynucleotide is encoded by a nucleic acid sequence, or a fragment of a nucleotide sequence, identified by any one of SEQ ID NO: 9-12 (Table 5; see also nucleic acid sequences of Table 7). In some embodiments, at least one PIV3 RNA (e.g., mRNA) polynucleotide comprises a nucleic acid sequence, or a fragment of a nucleotide sequence, identified by any one of SEQ ID NO: 61-64 (Table 5).

[0035] In some embodiments, at least one antigenic polypeptide is obtained from PIV3 strain HPIV3/Homo sapiens/PER/FLA4815/2008.

[0036] In some embodiments, at least one RSV antigenic polypeptide comprises at least one antigenic polypeptide that comprises glycoprotein G, glycoprotein F, or an immunogenic fragment thereof. In some embodiments, at least one RSV antigenic polypeptide comprises at least one antigenic polypeptide that comprises glycoprotein F and at least one or at least two antigenic polypeptide selected from G, M, N, P, L, SH, M2, NS1 and NS2.

[0037] MeV

[0038] In some embodiments, a RNA (e.g., mRNA) vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one MeV antigenic polypeptide. In some embodiments, at least one antigenic polypeptide is a hemagglutinin (HA) protein or an immunogenic fragment thereof. The HA protein may be from MeV strain D3 or B8, for example. In some embodiments, at least one antigenic polypeptide is a Fusion (F) protein or an immunogenic fragment thereof. The F protein may be from MeV strain D3 or B8, for example. In some embodiments, a MeV RNA (e.g., mRNA) vaccines comprises a least one RNA polynucleotide encoding a HA protein and a F protein. The HA and F proteins may be from MeV strain D3 or B8, for example.

[0039] In some embodiments, at least one MeV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 47-50 (Table 14). In some embodiments, the amino acid sequence of the MeV antigenic polypeptide is, or is a fragment of, or is a homolog or variant having at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) identity to, the amino acid sequence identified by any one of SEQ ID NO: 47-50 (Table 14).

[0040] In some embodiments, at least one MeV antigenic polypeptide is encoded by a nucleic acid sequence of SEQ ID NO: 35-46 (Table 13).

[0041] In some embodiments, at least one MeV RNA (e.g., mRNA) polynucleotide is encoded by a nucleic acid sequence, or a fragment of a nucleotide sequence, identified by any one of SEQ ID NO: 35-46 (Table 13). In some embodiments, at least one MeV RNA (e.g., mRNA) polynucleotide comprises a nucleic acid sequence, or a fragment of a nucleotide sequence, identified by any one of SEQ ID NO: 69-80 (Table 13).

[0042] In some embodiments, at least one antigenic polypeptide is obtained from MeV strain B3/B3.1, C2, D4, D6, D7, D8, G3, H1, Moraten, Rubeovax, MVi/New Jersey.USA/45.05, MVi/Texas.USA/4.07, AIK-C, MVi/New York.USA/26.09/3, MVi/California.USA/16.03, MVi/Virginia.USA/15.09, MVi/California.USA/8.04, or MVi/Pennsylvania.USA/20.09.

[0043] BetaCoV

[0044] In some embodiments, a RNA (e.g., mRNA) vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one BetaCoV antigenic polypeptide. In some embodiments, the BetaCoV is MERS-CoV. In some embodiments, the BetaCoV is **SARS**-CoV. In some embodiments, the BetaCoV is HCoV-OC43. In some embodiments, the BetaCoV is HCoV-229E. In some embodiments, the BetaCoV is HCoV-NL63. In some embodiments, the BetaCoV is HCoV-HKU1. In some embodiments, at least one antigenic polypeptide is a betacoronavirus structural protein. For example, a betacoronavirus structural protein may be spike protein (S), envelope protein (E), nucleocapsid protein (N), membrane protein (M) or an immunogenic fragment thereof. In some embodiments, a betacoronavirus structural protein is a spike protein (S). In some embodiments, a betacoronavirus structural protein is a S1 subunit or a S2 subunit of spike protein (S) or an immunogenic fragment thereof.

[0045] BetaCoV RNA (e.g., mRNA) polynucleotides of the vaccines provided herein may encode viral protein components of betacoronaviruses, for example, accessory proteins, replicase proteins and the like are encompassed by the present disclosure. RNA (e.g., mRNA) vaccines may include RNA polynucleotides encoding at least one accessory protein (e.g., protein 3, protein 4a, protein 4b, protein 5), at least one replicase protein (e.g., protein 1a, protein 1b), or a combination of at least one accessory protein and at least one replicase protein. The present disclosure also encompasses RNA (e.g., mRNA) vaccines comprising RNA (e.g., mRNA) polynucleotides encoding an accessory protein and/or a replicase protein in combination with at least one structural protein. Due to their surface expression properties, vaccines featuring RNA polynucleotides encoding structural proteins are believed to have preferred immunogenic activity and, hence, may be most suitable for use in the vaccines of the present disclosure.

[0046] Some embodiments of the present disclosure provide betacoronavirus (e.g., MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH, HCoV-HKU1 or a combination thereof) vaccines that include at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one betacoronavirus (e.g., MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH, HCoV-HKU1) antigenic polypeptide. Also provided herein are pan-betacoronavirus vaccines. Thus, a betacoronavirus vaccine comprising a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding any one, two, three or four of MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, and HCoV-HKU1, for example, may be effective against any one of, any combination of, or all of, MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1. Other betacoronaviruses are encompassed by the present disclosure.

[0047] In some embodiments, at least one antigenic polypeptide is a MERS-CoV structural protein. For example, a MERS-CoV structural protein may be spike protein (S), envelope protein (E), nucleocapsid protein (N), membrane protein (M) or an immunogenic fragment thereof. In some embodiments, the MERS-CoV structural protein is a spike protein (S) (see, e.g., Coleman C M et al. Vaccine 2014; 32:3169-74, incorporated herein by reference). In some embodiments, the MERS-CoV structural protein is a S1 subunit or a S2 subunit of spike protein (S) or an immunogenic fragment thereof (Li J et al. Viral Immunol 2013; 26(2):126-32; He Y et al. Biochem Biophys Res Commun 2004; 324(2):773-81, each of which is incorporated herein by reference).

[0048] In some embodiments, at least one MERS-CoV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 24-28 or 33 (Table 11). In some embodiments, the amino acid sequence of the MERS-CoV antigenic polypeptide is, or is a fragment of, or is a homolog or variant having at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) identity to, the amino acid sequence identified by any one of SEQ ID NO: 24-28 or 33 (Table 11).

[0049] In some embodiments, at least one MERS-CoV antigenic polypeptide is encoded by a nucleic acid sequence identified by any one of SEQ ID NO: 20-23 (Table 10).

[0050] In some embodiments, at least one MERS-CoV RNA (e.g., mRNA) polynucleotide is encoded by a nucleic acid sequence, or a fragment of a nucleotide sequence, identified by any one of SEQ ID NO: 20-23 (Table 10). In some embodiments, at least one MERS-CoV RNA (e.g., mRNA) polynucleotide comprises a nucleic acid sequence, or a fragment of a nucleotide sequence, identified by any one of SEQ ID NO: 65-68 (Table 10).

[0051] In some embodiments, at least one antigenic polypeptide is obtained from MERS-CoV strain Riyadh\_14\_2013, 2cEMC/2012, or Hasa\_1\_2013.

[0052] In some embodiments, at least one antigenic polypeptide is a **SARS**-CoV structural protein. For example, a **SARS**-CoV structural protein may be spike protein (S), envelope protein (E), nucleocapsid protein (N), membrane protein (M) or an immunogenic fragment thereof. In some embodiments, the **SARS**-CoV structural protein is a spike protein (S). In some embodiments, the **SARS**-CoV structural protein is a S1 subunit or a S2 subunit of spike protein (S) or an immunogenic fragment thereof.

[0053] In some embodiments, at least one **SARS**-CoV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 29, 32 or 34 (Table 11). In some embodiments, the amino acid sequence of the **SARS**-CoV antigenic polypeptide is, or is a fragment of, or is a homolog or variant having at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) identity to, the amino acid sequence identified by any one of SEQ ID NO: 29, 32 or 34 (Table 11).

[0054] In some embodiments, at least one antigenic polypeptide is a HCoV-OC43 structural protein. For example, a HCoV-OC43 structural protein may be spike protein (S), envelope protein (E), nucleocapsid protein (N), membrane protein (M) or an immunogenic fragment thereof. In some embodiments, the HCoV-OC43 structural protein is a spike protein (S). In some embodiments, the HCoV-OC43 structural protein is a S1 subunit or a S2 subunit of spike protein (S) or an immunogenic fragment thereof.

[0055] In some embodiments, at least one HCoV-OC43 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 30 (Table 11). In some embodiments, the amino acid sequence of the HCoV-OC43 antigenic polypeptide is, or is a fragment of, or is a homolog or variant having at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) identity to, the amino acid sequence identified by any one of SEQ ID NO: 30 (Table 11).

[0056] In some embodiments, an antigenic polypeptide is a HCoV-HKU1 structural protein. For example, a HCoV-HKU1 structural protein may be spike protein (S), envelope protein (E), nucleocapsid protein (N), membrane protein (M) or an immunogenic fragment thereof. In some embodiments, the HCoV-HKU1 structural protein is a spike protein (S). In some embodiments, the HCoV-HKU1 structural protein is a S1 subunit or a S2

subunit of spike protein (S) or an immunogenic fragment thereof.

[0057] In some embodiments, at least one HCoV-HKU1 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 31 (Table 11). In some embodiments, the amino acid sequence of the HCoV-HKU1 antigenic polypeptide is, or is a fragment of, or is a homolog or variant having at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) identity to, the amino acid sequence identified by any one of SEQ ID NO: 31 (Table 11).

[0058] In some embodiments, an open reading frame of a RNA (e.g., mRNA) vaccine is codon-optimized. In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide having an amino acid sequence identified by any one of SEQ ID NO: 5-8, 12-13, 24-34, or 47-50 (Tables 3, 6, 11 and 14; see also amino acid sequences of Tables 4, 7, 12 and 15) and is codon optimized mRNA.

[0059] In some embodiments, a RNA (e.g., mRNA) vaccine further comprising an adjuvant.

[0060] Tables 4, 7, 12 and 15 provide National Center for Biotechnology Information (NCBI) accession numbers of interest. It should be understood that the phrase "an amino acid sequence of Tables 4, 7, 12 and 15" refers to an amino acid sequence identified by one or more NCBI accession numbers listed in Tables 4, 7, 12 and 15. Each of the amino acid sequences, and variants having greater than 95% identity or greater than 98% identity to each of the amino acid sequences encompassed by the accession numbers of Tables 4, 7, 12 and 15 are included within the constructs (polynucleotides/polypeptides) of the present disclosure.

[0061] In some embodiments, at least one mRNA polynucleotide is encoded by a nucleic acid having a sequence identified by any one of SEQ ID NO: 1-4, 9-12, 20-23, or 35-46 (Tables 2, 5, 10 and 13; see also nucleic acid sequences of Table 7) and having less than 80% identity to wild-type mRNA sequence. In some embodiments, at least one mRNA polynucleotide is encoded by a nucleic acid having a sequence identified by any one of SEQ ID NO: 1-4, 9-12, 20-23, or 35-46 (Tables 2, 5, 10 and 13; see also nucleic acid sequences of Table 7) and having less than 75%, 85% or 95% identity to a wild-type mRNA sequence. In some embodiments, at least one mRNA polynucleotide is encoded by a nucleic acid having a sequence identified by any one of SEQ ID NO: 1-4, 9-12, 20-23, or 35-46 (Tables 2, 5, 10 and 13; see also nucleic acid sequences of Table 7) and having less than 50-80%, 60-80%, 40-80%, 30-80%, 70-80%, 75-80% or 78-80% identity to wild-type mRNA sequence. In some embodiments, at least one mRNA polynucleotide is encoded by a nucleic acid having a sequence identified by any one of SEQ ID NO: 1-4, 9-12, 20-23, or 35-46 (Tables 2, 5, 10 and 13; see also nucleic acid sequences of Table 7) and having less than 40-85%, 50-85%, 60-85%, 30-85%, 70-85%, 75-85% or 80-85% identity to wild-type mRNA sequence. In some embodiments, at least one mRNA polynucleotide is encoded by a nucleic acid having a sequence identified by any one of SEQ ID NO: 1-4, 9-12, 20-23, or 35-46 (Tables 2, 5, 10 and 13; see also nucleic acid sequences of Table 7) and having less than 40-90%, 50-90%, 60-90%, 30-90%, 70-90%, 75-90%, 80-90%, or 85-90% identity to wild-type mRNA sequence.

[0062] In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide having an amino acid sequence identified by any one of SEQ ID NO: 5-8, 12-13, 24-34, or 47-50 (Tables 3, 6, 11 and 14; see also amino acid sequences of Tables 4, 7, 12 and 15) and having at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) identity to wild-type mRNA sequence, but does not include wild-type mRNA sequence.

[0063] In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide having an amino acid sequence identified by any one of SEQ ID NO: 5-8, 12-13, 24-34, or 47-50 (Tables 3, 6, 11 and 14; see also amino acid sequences of Tables 4, 7, 12 and 15) and has less than 95%, 90%, 85%, 80% or 75% identity to wild-type mRNA sequence. In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide having an amino acid sequence identified by any one of SEQ ID NO: 5-8, 12-13, 24-34, or 47-50 (Tables 3, 6, 11 and 14; see also amino acid sequences of Tables 4, 7, 12 and 15) and has 30-80%, 40-80%, 50-80%, 60-80%, 70-80%, 75-80% or 78-80%, 30-85%, 40-85%, 50-85%, 60-85%, 70-85%, 75-85% or 78-85%, 30-90%, 40-90%, 50-90%, 60-90%, 70-90%, 75-90%, 80-90% or 85-90% identity to wild-type mRNA sequence.

[0064] In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, 12-13, 24-34, or 47-50 (Tables 3, 6, 11 and 14; see also amino acid sequences of Tables 4, 7, 12 and 15). In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide having 95%-99% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, 12-13, 24-34, or 47-50 (Tables 3, 6, 11 and 14; see also amino acid sequences of Tables 4, 7, 12 and 15).

[0065] In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, 12-13, 24-34, or 47-50 (Tables 3, 6, 11 and 14; see also amino acid sequences of Tables 4, 7, 12 and 15) and having membrane fusion activity. In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide having 95%-99% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, 12-13, 24-34, or 47-50 (Tables 3, 6, 11 and 14; see also amino acid sequences of Tables 4, 7, 12 and 15) and having membrane fusion activity.

[0066] In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide (e.g., at least one hMPV antigenic polypeptide, at least one PIV3 antigenic polypeptide, at least one RSV antigenic polypeptide, at least one MeV antigenic polypeptide, or at least one BetaCoV antigenic polypeptide, e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1, or any combination of two or more of the foregoing antigenic polypeptides) that attaches to cell receptors.

[0067] In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide (e.g., at least one hMPV antigenic polypeptide, at least one PIV3 antigenic polypeptide, at least one RSV antigenic polypeptide, at least one MeV antigenic polypeptide, or at least one BetaCoV antigenic polypeptide, e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1, or any combination of two or more of the foregoing antigenic polypeptides) that causes fusion of viral and cellular membranes.

[0068] In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide (e.g., at least one hMPV antigenic polypeptide, at least one PIV3 antigenic polypeptide, at least one RSV antigenic polypeptide, at least one MeV antigenic polypeptide, or at least one BetaCoV antigenic polypeptide, e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1, or any combination of two or more of the foregoing antigenic polypeptides) that is responsible for binding of the virus to a cell being infected.

[0069] Some embodiments of the present disclosure provide a vaccine that includes at least one ribonucleic acid (RNA) (e.g., mRNA) polynucleotide having an open reading frame encoding at least one antigenic polypeptide (e.g., at least one hMPV antigenic polypeptide, at least one PIV3 antigenic polypeptide, at least one RSV antigenic polypeptide, at least one MeV antigenic polypeptide, or at least one BetaCoV antigenic polypeptide, e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1, or any combination of two or more of the foregoing antigenic polypeptides), at least one 5' terminal cap and at least one chemical modification, formulated within a lipid nanoparticle.

[0070] In some embodiments, a 5' terminal cap is 7mG(5')ppp(5')NlmpNp.

[0071] In some embodiments, at least one chemical modification is selected from pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2'-O-methyl uridine. In some embodiments, the chemical modification is in the 5-position of the uracil. In some embodiments, the chemical modification is a N1-

methylpseudouridine. In some embodiments, the chemical modification is a N1-ethylpseudouridine.

[0072] In some embodiments, a lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol and a non-cationic lipid. In some embodiments, a cationic lipid is an ionizable cationic lipid and the non-cationic lipid is a neutral lipid, and the sterol is a cholesterol. In some embodiments, a cationic lipid is selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), (12Z,15Z)-N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine (L608), and N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]heptadecan-8-amine (L530).

[0073] In some embodiments, the lipid is

##STR00001##

[0074] In some embodiments, the lipid is

##STR00002##

[0075] In some embodiments, a lipid nanoparticle comprises compounds of Formula (I) and/or Formula (II), discussed below.

[0076] In some embodiments, a respiratory virus RNA (e.g., mRNA) vaccine is formulated in a lipid nanoparticle that comprises a compound selected from Compounds 3, 18, 20, 25, 26, 29, 30, 60, 108-112 and 122, described below.

[0077] Some embodiments of the present disclosure provide a vaccine that includes at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one antigenic polypeptide (e.g., at least one hMPV antigenic polypeptide, at least one PIV3 antigenic polypeptide, at least one RSV antigenic polypeptide, at least one MeV antigenic polypeptide, or at least one BetaCoV antigenic polypeptide, e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1, or any combination of two or more of the foregoing antigenic polypeptides), wherein at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) of the uracil in the open reading frame have a chemical modification, optionally wherein the vaccine is formulated in a lipid nanoparticle (e.g., a lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol and a non-cationic lipid).

[0078] In some embodiments, 100% of the uracil in the open reading frame have a chemical modification. In some embodiments, a chemical modification is in the 5-position of the uracil. In some embodiments, a chemical modification is a N1-methyl pseudouridine. In some embodiments, 100% of the uracil in the open reading frame have a N1-methyl pseudouridine in the 5-position of the uracil.

[0079] In some embodiments, an open reading frame of a RNA (e.g., mRNA) polynucleotide encodes at least two antigenic polypeptides (e.g., at least two hMPV antigenic polypeptides, at least two PIV3 antigenic polypeptides, at least two RSV antigenic polypeptides, at least two MeV antigenic polypeptides, or at least two BetaCoV antigenic polypeptides, e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1, or any combination of two or more of the foregoing antigenic polypeptides). In some embodiments, the open reading frame encodes at least five or at least ten antigenic polypeptides. In some embodiments, the open reading frame encodes at least 100 antigenic polypeptides. In some embodiments, the open reading frame encodes 2-100 antigenic polypeptides.

[0080] In some embodiments, a vaccine comprises at least two RNA (e.g., mRNA) polynucleotides, each having an open reading frame encoding at least one antigenic polypeptide (e.g., at least one hMPV antigenic polypeptide, at least one PIV3 antigenic polypeptide, at least one RSV antigenic polypeptide, at least one MeV antigenic polypeptide, or at least one BetaCoV antigenic polypeptide, e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1, or any combination of

two or more of the foregoing antigenic polypeptides). In some embodiments, the vaccine comprises at least five or at least ten RNA (e.g., mRNA) polynucleotides, each having an open reading frame encoding at least one antigenic polypeptide or an immunogenic fragment thereof. In some embodiments, the vaccine comprises at least 100 RNA (e.g., mRNA) polynucleotides, each having an open reading frame encoding at least one antigenic polypeptide. In some embodiments, the vaccine comprises 2-100 RNA (e.g., mRNA) polynucleotides, each having an open reading frame encoding at least one antigenic polypeptide.

[0081] In some embodiments, at least one antigenic polypeptide (e.g., at least one hMPV antigenic polypeptide, at least one PIV3 antigenic polypeptide, at least one RSV antigenic polypeptide, at least one MeV antigenic polypeptide, or at least one BetaCoV antigenic polypeptide, e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1, or any combination of two or more of the foregoing antigenic polypeptides) is fused to a signal peptide. In some embodiments, the signal peptide is selected from: a HuIgGk signal peptide (METPAQLLFLLLLWLPDTTG; SEQ ID NO: 15); IgE heavy chain epsilon-1 signal peptide (MDWTWILFLVAAATRVHS; SEQ ID NO: 16); Japanese encephalitis PRM signal sequence (MLGSNSGQRVVFILLLLVAPAYS; SEQ ID NO: 17), VSVg protein signal sequence (MKCLLYLAFLFIGVNCA; SEQ ID NO: 18) and Japanese encephalitis JEV signal sequence (MWLVSLAIVTACAGA; SEQ ID NO: 19).

[0082] In some embodiments, the signal peptide is fused to the N-terminus of at least one antigenic polypeptide. In some embodiments, a signal peptide is fused to the C-terminus of at least one antigenic polypeptide.

[0083] In some embodiments, at least one antigenic polypeptide (e.g., at least one hMPV antigenic polypeptide, at least one PIV3 antigenic polypeptide, at least one RSV antigenic polypeptide, at least one MeV antigenic polypeptide, or at least one BetaCoV antigenic polypeptide, e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1, or any combination of two or more of the foregoing antigenic polypeptides) comprises a mutated N-linked glycosylation site.

[0084] Also provided herein is a RNA (e.g., mRNA) vaccine of any one of the foregoing paragraphs (e.g., a hMPV vaccine, a PIV3 vaccine, a RSV vaccine, a MeV vaccine, or a BetaCoV vaccine, e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1, or any combination of two or more of the foregoing vaccines), formulated in a nanoparticle (e.g., a lipid nanoparticle).

[0085] In some embodiments, the nanoparticle has a mean diameter of 50-200 nm. In some embodiments, the nanoparticle is a lipid nanoparticle. In some embodiments, the lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol and a non-cationic lipid. In some embodiments, the lipid nanoparticle comprises a molar ratio of about 20-60% cationic lipid, 0.5-15% PEG-modified lipid, 25-55% sterol, and 25% non-cationic lipid. In some embodiments, the cationic lipid is an ionizable cationic lipid and the non-cationic lipid is a neutral lipid, and the sterol is a cholesterol. In some embodiments, the cationic lipid is selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319).

[0086] In some embodiments, a lipid nanoparticle comprises compounds of Formula (I) and/or Formula (II), as discussed below.

[0087] In some embodiments, a lipid nanoparticle comprises Compounds 3, 18, 20, 25, 26, 29, 30, 60, 108-112, or 122, as discussed below.

[0088] In some embodiments, the nanoparticle has a polydispersity value of less than 0.4 (e.g., less than 0.3, 0.2 or 0.1).

[0089] In some embodiments, the nanoparticle has a net neutral charge at a neutral pH value.

[0090] In some embodiments, the respiratory virus vaccine is multivalent.

[0091] Some embodiments of the present disclosure provide methods of inducing an antigen specific immune response in a subject, comprising administering to the subject any of the RNA (e.g., mRNA) vaccine as provided herein in an amount effective to produce an antigen-specific immune response. In some embodiments, the RNA (e.g., mRNA) vaccine is a hMPV vaccine, a PIV3 vaccine, a RSV vaccine, a MeV vaccine, or a BetaCoV vaccine, e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1 vaccines. In some embodiments, the RNA (e.g., mRNA) vaccine is a combination vaccine comprising a combination of any two or more of the foregoing vaccines.

[0092] In some embodiments, an antigen-specific immune response comprises a T cell response or a B cell response.

[0093] In some embodiments, a method of producing an antigen-specific immune response comprises administering to a subject a single dose (no booster dose) of a RNA (e.g., mRNA) vaccine of the present disclosure. In some embodiments, the RNA (e.g., mRNA) vaccine is a hMPV vaccine, a PIV3 vaccine, a RSV vaccine, a MeV vaccine, or a BetaCoV vaccine, e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1 vaccines. In some embodiments, the RNA (e.g., mRNA) vaccine is a combination vaccine comprising a combination of any two or more of the foregoing vaccines.

[0094] In some embodiments, a method further comprises administering to the subject a second (booster) dose of a RNA (e.g., mRNA) vaccine. Additional doses of a RNA (e.g., mRNA) vaccine may be administered.

[0095] In some embodiments, the subjects exhibit a seroconversion rate of at least 80% (e.g., at least 85%, at least 90%, or at least 95%) following the first dose or the second (booster) dose of the vaccine. Seroconversion is the time period during which a specific antibody develops and becomes detectable in the blood. After seroconversion has occurred, a virus can be detected in blood tests for the antibody. During an infection or immunization, antigens enter the blood, and the immune system begins to produce antibodies in response. Before seroconversion, the antigen itself may or may not be detectable, but antibodies are considered absent. During seroconversion, antibodies are present but not yet detectable. Any time after seroconversion, the antibodies can be detected in the blood, indicating a prior or current infection.

[0096] In some embodiments, a RNA (e.g., mRNA) vaccine is administered to a subject by intradermal or intramuscular injection.

[0097] Some embodiments, of the present disclosure provide methods of inducing an antigen specific immune response in a subject, including administering to a subject a RNA (e.g., mRNA) vaccine in an effective amount to produce an antigen specific immune response in a subject. Antigen-specific immune responses in a subject may be determined, in some embodiments, by assaying for antibody titer (for titer of an antibody that binds to a hMPV, PIV3, RSV, MeV and/or BetaCoV antigenic polypeptide) following administration to the subject of any of the RNA (e.g., mRNA) vaccines of the present disclosure. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased by at least 1 log relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased by 1-3 log relative to a control.

[0098] In some embodiments, the anti-antigenic polypeptide antibody titer produced in a subject is increased at least 2 times relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased at least 5 times relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased at least 10 times relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased 2-10 times relative to a control.

[0099] In some embodiments, the control is an anti-antigenic polypeptide antibody titer produced in a subject who has not been administered a RNA (e.g., mRNA) vaccine of the present disclosure. In some embodiments,



the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a live attenuated or inactivated hMPV, PIV3, RSV, MeV and/or BetaCoV vaccine (see, e.g., Ren J. et al. J of Gen. Virol. 2015; 96: 1515-1520), or wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a recombinant or purified hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine. In some embodiments, the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a hMPV, PIV3, RSV, MeV and/or BetaCoV virus-like particle (VLP) vaccine (see, e.g., Cox R G et al., J Virol. 2014 June; 88(11): 6368-6379).

[0100] A RNA (e.g., mRNA) vaccine of the present disclosure is administered to a subject in an effective amount (an amount effective to induce an immune response). In some embodiments, the effective amount is a dose equivalent to an at least 2-fold, at least 4-fold, at least 10-fold, at least 100-fold, at least 1000-fold reduction in the standard of care dose of a recombinant hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine, wherein the anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine, a purified hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine, a live attenuated hMPV, PIV3, RSV, MeV and/or BetaCoV vaccine, an inactivated hMPV, PIV3, RSV, MeV and/or BetaCoV vaccine, or a hMPV, PIV3, RSV, MeV and/or BetaCoV VLP vaccine. In some embodiments, the effective amount is a dose equivalent to 2-1000-fold reduction in the standard of care dose of a recombinant hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine, wherein the anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine, a purified hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine, a live attenuated hMPV, PIV3, RSV, MeV and/or BetaCoV vaccine, an inactivated hMPV, PIV3, RSV, MeV and/or BetaCoV vaccine, or a hMPV, PIV3, RSV, MeV and/or BetaCoV VLP vaccine.

[0101] In some embodiments, the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a virus-like particle (VLP) vaccine comprising structural proteins of hMPV, PIV3, RSV, MeV and/or BetaCoV.

[0102] In some embodiments, the RNA (e.g., mRNA) vaccine is formulated in an effective amount to produce an antigen specific immune response in a subject.

[0103] In some embodiments, the effective amount is a total dose of 25 .mu.g to 1000 .mu.g, or 50 .mu.g to 1000 .mu.g. In some embodiments, the effective amount is a total dose of 100 .mu.g. In some embodiments, the effective amount is a dose of 25 .mu.g administered to the subject a total of two times. In some embodiments, the effective amount is a dose of 100 .mu.g administered to the subject a total of two times. In some embodiments, the effective amount is a dose of 400 .mu.g administered to the subject a total of two times. In some embodiments, the effective amount is a dose of 500 .mu.g administered to the subject a total of two times.

[0104] In some embodiments, the efficacy (or effectiveness) of a RNA (e.g., mRNA) vaccine is greater than 60%. In some embodiments, the RNA (e.g., mRNA) polynucleotide of the vaccine at least one hMPV antigenic polypeptide, at least one PIV3 antigenic polypeptide, at least one RSV antigenic polypeptide, at least one MeV antigenic polypeptide, at least one BetaCoV antigenic polypeptide, e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1, or any combination of two or more of the foregoing antigenic polypeptides.

[0105] Vaccine efficacy may be assessed using standard analyses (see, e.g., Weinberg et al., J Infect Dis. 2010 Jun. 1; 201(11):1607-10). For example, vaccine efficacy may be measured by double-blind, randomized, clinical controlled trials. Vaccine efficacy may be expressed as a proportionate reduction in disease attack rate (AR) between the unvaccinated (ARU) and vaccinated (ARV) study cohorts and can be calculated from the relative risk (RR) of disease among the vaccinated group with use of the following formulas:

Efficacy=(ARU-ARV)/ARU.times.100; and

$\text{Efficacy}=(1-\text{RR}).\text{times}.100.$

[0106] Likewise, vaccine effectiveness may be assessed using standard analyses (see, e.g., Weinberg et al., J Infect Dis. 2010 Jun. 1; 201(11):1607-10). Vaccine effectiveness is an assessment of how a vaccine (which may have already proven to have high vaccine efficacy) reduces disease in a population. This measure can assess the net balance of benefits and adverse effects of a vaccination program, not just the vaccine itself, under natural field conditions rather than in a controlled clinical trial. Vaccine effectiveness is proportional to vaccine efficacy (potency) but is also affected by how well target groups in the population are immunized, as well as by other non-vaccine-related factors that influence the `real-world` outcomes of hospitalizations, ambulatory visits, or costs. For example, a retrospective case control analysis may be used, in which the rates of vaccination among a set of infected cases and appropriate controls are compared. Vaccine effectiveness may be expressed as a rate difference, with use of the odds ratio (OR) for developing infection despite vaccination:

$\text{Effectiveness}=(1-\text{OR}).\text{times}.100.$

[0107] In some embodiments, the efficacy (or effectiveness) of a RNA (e.g., mRNA) vaccine is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90%.

[0108] In some embodiments, the vaccine immunizes the subject against hMPV, PIV3, RSV, MeV, BetaCoV (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1), or any combination of two or more of the foregoing viruses for up to 2 years. In some embodiments, the vaccine immunizes the subject against hMPV, PIV3, RSV, MeV, BetaCoV (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1), or any combination of two or more of the foregoing viruses for more than 2 years, more than 3 years, more than 4 years, or for 5-10 years.

[0109] In some embodiments, the subject is about 5 years old or younger. For example, the subject may be between the ages of about 1 year and about 5 years (e.g., about 1, 2, 3, 5 or 5 years), or between the ages of about 6 months and about 1 year (e.g., about 6, 7, 8, 9, 10, 11 or 12 months). In some embodiments, the subject is about 12 months or younger (e.g., 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 months or 1 month). In some embodiments, the subject is about 6 months or younger.

[0110] In some embodiments, the subject was born full term (e.g., about 37-42 weeks). In some embodiments, the subject was born prematurely, for example, at about 36 weeks of gestation or earlier (e.g., about 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26 or 25 weeks). For example, the subject may have been born at about 32 weeks of gestation or earlier. In some embodiments, the subject was born prematurely between about 32 weeks and about 36 weeks of gestation. In such subjects, a RNA (e.g., mRNA) vaccine may be administered later in life, for example, at the age of about 6 months to about 5 years, or older.

[0111] In some embodiments, the subject is pregnant (e.g., in the first, second or third trimester) when administered an RNA (e.g., mRNA) vaccine. Viruses such as hMPV, PIV3 and RSV causes infections of the lower respiratory tract, mainly in infants and young children. One-third of RSV related deaths, for example, occur in the first year of life, with 99 percent of these deaths occurring in low-resource countries. It's so widespread in the United States that nearly all children become infected with the virus before their second birthdays. Thus, the present disclosure provides RNA (e.g., mRNA) vaccines for maternal immunization to improve mother-to-child transmission of protection against the virus.

[0112] In some embodiments, the subject is a young adult between the ages of about 20 years and about 50 years (e.g., about 20, 25, 30, 35, 40, 45 or 50 years old).

[0113] In some embodiments, the subject is an elderly subject about 60 years old, about 70 years old, or older (e.g., about 60, 65, 70, 75, 80, 85 or 90 years old).

[0114] In some embodiments, the subject is has a chronic pulmonary disease (e.g., chronic obstructive

pulmonary disease (COPD) or asthma). Two forms of COPD include chronic bronchitis, which involves a long-term cough with mucus, and emphysema, which involves damage to the lungs over time. Thus, a subject administered a RNA (e.g., mRNA) vaccine may have chronic bronchitis or emphysema.

[0115] In some embodiments, the subject has been exposed to hMPV, PIV3, RSV, MeV, BetaCoV (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1), or any combination of two or more of the foregoing viruses; the subject is infected with hMPV, PIV3, RSV, MeV, BetaCoV (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1), or any combination of two or more of the foregoing viruses; or subject is at risk of infection by hMPV, PIV3, RSV, MeV, BetaCoV (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1), or any combination of two or more of the foregoing viruses.

[0116] In some embodiments, the subject is immunocompromised (has an impaired immune system, e.g., has an immune disorder or autoimmune disorder).

[0117] In some embodiments the nucleic acid vaccines described herein are chemically modified. In other embodiments the nucleic acid vaccines are unmodified.

[0118] Yet other aspects provide compositions for and methods of vaccinating a subject comprising administering to the subject a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding a first respiratory virus antigenic polypeptide, wherein the RNA polynucleotide does not include a stabilization element, and wherein an adjuvant is not coformulated or co-administered with the vaccine.

[0119] In other aspects the invention is a composition for or method of vaccinating a subject comprising administering to the subject a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding a first antigenic polypeptide wherein a dosage of between 10 .mu.g/kg and 400 .mu.g/kg of the nucleic acid vaccine is administered to the subject. In some embodiments the dosage of the RNA polynucleotide is 1-5 .mu.g, 5-10 .mu.g, 10-15 .mu.g, 15-20 .mu.g, 20-25 .mu.g, 25-50 .mu.g, 30-50 .mu.g, 40-50 .mu.g, 40-60 .mu.g, 60-80 .mu.g, 60-100 .mu.g, 50-100 .mu.g, 80-120 .mu.g, 40-120 .mu.g, 40-150 .mu.g, 50-150 .mu.g, 50-200 .mu.g, 80-200 .mu.g, 100-200 .mu.g, 120-250 .mu.g, 150-250 .mu.g, 180-280 .mu.g, 200-300 .mu.g, 50-300 .mu.g, 80-300 .mu.g, 100-300 .mu.g, 40-300 .mu.g, 50-350 .mu.g, 100-350 .mu.g, 200-350 .mu.g, 300-350 .mu.g, 320-400 .mu.g, 40-380 .mu.g, 40-100 .mu.g, 100-400 .mu.g, 200-400 .mu.g, or 300-400 .mu.g per dose. In some embodiments, the nucleic acid vaccine is administered to the subject by intradermal or intramuscular injection. In some embodiments, the nucleic acid vaccine is administered to the subject on day zero. In some embodiments, a second dose of the nucleic acid vaccine is administered to the subject on day twenty one.

[0120] In some embodiments, a dosage of 25 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 100 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 50 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 75 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 150 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 400 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 200 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, the RNA polynucleotide accumulates at a 100 fold higher level in the local lymph node in comparison with the distal lymph node. In other embodiments the nucleic acid vaccine is chemically modified and in other embodiments the nucleic acid vaccine is not chemically modified.

[0121] Aspects of the invention provide a nucleic acid vaccine comprising one or more RNA polynucleotides

having an open reading frame encoding a first antigenic polypeptide, wherein the RNA polynucleotide does not include a stabilization element, and a pharmaceutically acceptable carrier or excipient, wherein an adjuvant is not included in the vaccine. In some embodiments, the stabilization element is a histone stem-loop. In some embodiments, the stabilization element is a nucleic acid sequence having increased GC content relative to wild type sequence.

[0122] Aspects of the invention provide nucleic acid vaccines comprising one or more RNA polynucleotides having an open reading frame encoding a first antigenic polypeptide, wherein the RNA polynucleotide is present in the formulation for in vivo administration to a host, which confers an antibody titer superior to the criterion for seroprotection for the first antigen for an acceptable percentage of human subjects. In some embodiments, the antibody titer produced by the mRNA vaccines of the invention is a neutralizing antibody titer. In some embodiments the neutralizing antibody titer is greater than a protein vaccine. In other embodiments the neutralizing antibody titer produced by the mRNA vaccines of the invention is greater than an adjuvanted protein vaccine. In yet other embodiments the neutralizing antibody titer produced by the mRNA vaccines of the invention is 1,000-10,000, 1,200-10,000, 1,400-10,000, 1,500-10,000, 1,000-5,000, 1,000-4,000, 1,800-10,000, 2,000-10,000, 2,000-5,000, 2,000-3,000, 2,000-4,000, 3,000-5,000, 3,000-4,000, or 2,000-2,500. A neutralization titer is typically expressed as the highest serum dilution required to achieve a 50% reduction in the number of plaques.

[0123] Also provided are nucleic acid vaccines comprising one or more RNA polynucleotides having an open reading frame encoding a first antigenic polypeptide, wherein the RNA polynucleotide is present in a formulation for in vivo administration to a host for eliciting a longer lasting high antibody titer than an antibody titer elicited by an mRNA vaccine having a stabilizing element or formulated with an adjuvant and encoding the first antigenic polypeptide. In some embodiments, the RNA polynucleotide is formulated to produce a neutralizing antibodies within one week of a single administration. In some embodiments, the adjuvant is selected from a cationic peptide and an immunostimulatory nucleic acid. In some embodiments, the cationic peptide is protamine.

[0124] Aspects provide nucleic acid vaccines comprising one or more RNA polynucleotides having an open reading frame comprising at least one chemical modification or optionally no nucleotide modification, the open reading frame encoding a first antigenic polypeptide, wherein the RNA polynucleotide is present in the formulation for in vivo administration to a host such that the level of antigen expression in the host significantly exceeds a level of antigen expression produced by an mRNA vaccine having a stabilizing element or formulated with an adjuvant and encoding the first antigenic polypeptide.

[0125] Other aspects provide nucleic acid vaccines comprising one or more RNA polynucleotides having an open reading frame comprising at least one chemical modification or optionally no nucleotide modification, the open reading frame encoding a first antigenic polypeptide, wherein the vaccine has at least 10 fold less RNA polynucleotide than is required for an unmodified mRNA vaccine to produce an equivalent antibody titer. In some embodiments, the RNA polynucleotide is present in a dosage of 25-100 micrograms.

[0126] Aspects of the invention also provide a unit of use vaccine, comprising between 10 ug and 400 ug of one or more RNA polynucleotides having an open reading frame comprising at least one chemical modification or optionally no nucleotide modification, the open reading frame encoding a first antigenic polypeptide, and a pharmaceutically acceptable carrier or excipient, formulated for delivery to a human subject. In some embodiments, the vaccine further comprises a cationic lipid nanoparticle.

[0127] Aspects of the invention provide methods of creating, maintaining or restoring antigenic memory to a respiratory virus strain in an individual or population of individuals comprising administering to said individual or population an antigenic memory booster nucleic acid vaccine comprising (a) at least one RNA polynucleotide, said polynucleotide comprising at least one chemical modification or optionally no nucleotide modification and two or more codon-optimized open reading frames, said open reading frames encoding a set of reference antigenic polypeptides, and (b) optionally a pharmaceutically acceptable carrier or excipient. In some embodiments, the vaccine is administered to the individual via a route selected from the group consisting of

intramuscular administration, intradermal administration and subcutaneous administration. In some embodiments, the administering step comprises contacting a muscle tissue of the subject with a device suitable for injection of the composition. In some embodiments, the administering step comprises contacting a muscle tissue of the subject with a device suitable for injection of the composition in combination with electroporation.

[0128] Aspects of the invention provide methods of vaccinating a subject comprising administering to the subject a single dosage of between 25 ug/kg and 400 ug/kg of a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding a first antigenic polypeptide in an effective amount to vaccinate the subject.

[0129] Other aspects provide nucleic acid vaccines comprising one or more RNA polynucleotides having an open reading frame comprising at least one chemical modification, the open reading frame encoding a first antigenic polypeptide, wherein the vaccine has at least 10 fold less RNA polynucleotide than is required for an unmodified mRNA vaccine to produce an equivalent antibody titer. In some embodiments, the RNA polynucleotide is present in a dosage of 25-100 micrograms.

[0130] Other aspects provide nucleic acid vaccines comprising an LNP formulated RNA polynucleotide having an open reading frame comprising no nucleotide modifications (unmodified), the open reading frame encoding a first antigenic polypeptide, wherein the vaccine has at least 10 fold less RNA polynucleotide than is required for an unmodified mRNA vaccine not formulated in a LNP to produce an equivalent antibody titer. In some embodiments, the RNA polynucleotide is present in a dosage of 25-100 micrograms.

[0131] The data presented in the Examples demonstrate significant enhanced immune responses using the formulations of the invention. Both chemically modified and unmodified RNA vaccines are useful according to the invention. Surprisingly, in contrast to prior art reports that it was preferable to use chemically unmodified mRNA formulated in a carrier for the production of vaccines, it is described herein that chemically modified mRNA-LNP vaccines required a much lower effective mRNA dose than unmodified mRNA, i.e., tenfold less than unmodified mRNA when formulated in carriers other than LNP. Both the chemically modified and unmodified RNA vaccines of the invention produce better immune responses than mRNA vaccines formulated in a different lipid carrier.

[0132] In other aspects the invention encompasses a method of treating an elderly subject age 60 years or older comprising administering to the subject a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding a respiratory virus antigenic polypeptide in an effective amount to vaccinate the subject.

[0133] In other aspects the invention encompasses a method of treating a young subject age 17 years or younger comprising administering to the subject a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding a respiratory virus antigenic polypeptide in an effective amount to vaccinate the subject.

[0134] In other aspects the invention encompasses a method of treating an adult subject comprising administering to the subject a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding a respiratory virus antigenic polypeptide in an effective amount to vaccinate the subject.

[0135] In some aspects the invention is a method of vaccinating a subject with a combination vaccine including at least two nucleic acid sequences encoding respiratory antigens wherein the dosage for the vaccine is a combined therapeutic dosage wherein the dosage of each individual nucleic acid encoding an antigen is a sub therapeutic dosage. In some embodiments, the combined dosage is 25 micrograms of the RNA polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments, the combined dosage is 100 micrograms of the RNA polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments the combined dosage is 50 micrograms of the RNA polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments, the combined dosage is 75 micrograms of the RNA

polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments, the combined dosage is 150 micrograms of the RNA polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments, the combined dosage is 400 micrograms of the RNA polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments, the sub therapeutic dosage of each individual nucleic acid encoding an antigen is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 micrograms. In other embodiments the nucleic acid vaccine is chemically modified and in other embodiments the nucleic acid vaccine is not chemically modified.

[0136] The RNA polynucleotide is one of SEQ ID NO: 1-4, 9-12, 20-23, 35-46, 57-61, and 64-80 and includes at least one chemical modification. In other embodiments the RNA polynucleotide is one of SEQ ID NO: 1-4, 9-12, 20-23, 35-46, 57-61, and 64-80 and does not include any nucleotide modifications, or is unmodified. In yet other embodiments the at least one RNA polynucleotide encodes an antigenic protein of any of SEQ ID NO: 5-8, 12-13, 24-34, and 47-50 and includes at least one chemical modification. In other embodiments the RNA polynucleotide encodes an antigenic protein of any of SEQ ID NO: 5-8, 12-13, 24-34, and 47-50 and does not include any nucleotide modifications, or is unmodified.

[0137] In preferred aspects, vaccines of the invention (e.g., LNP-encapsulated mRNA vaccines) produce prophylactically- and/or therapeutically- efficacious levels, concentrations and/or titers of antigen-specific antibodies in the blood or serum of a vaccinated subject. As defined herein, the term antibody titer refers to the amount of antigen-specific antibody produced in a subject, e.g., a human subject. In exemplary embodiments, antibody titer is expressed as the inverse of the greatest dilution (in a serial dilution) that still gives a positive result. In exemplary embodiments, antibody titer is determined or measured by enzyme-linked immunosorbent assay (ELISA). In exemplary embodiments, antibody titer is determined or measured by neutralization assay, e.g., by microneutralization assay. In certain aspects, antibody titer measurement is expressed as a ratio, such as 1:40, 1:100, etc.

[0138] In exemplary embodiments of the invention, an efficacious vaccine produces an antibody titer of greater than 1:40, greater than 1:100, greater than 1:400, greater than 1:1000, greater than 1:2000, greater than 1:3000, greater than 1:4000, greater than 1:500, greater than 1:6000, greater than 1:7500, greater than 1:10000. In exemplary embodiments, the antibody titer is produced or reached by 10 days following vaccination, by 20 days following vaccination, by 30 days following vaccination, by 40 days following vaccination, or by 50 or more days following vaccination. In exemplary embodiments, the titer is produced or reached following a single dose of vaccine administered to the subject. In other embodiments, the titer is produced or reached following multiple doses, e.g., following a first and a second dose (e.g., a booster dose.)

[0139] In exemplary aspects of the invention, antigen-specific antibodies are measured in units of  $\mu\text{g/ml}$  or are measured in units of IU/L (International Units per liter) or mIU/ml (milli International Units per ml). In exemplary embodiments of the invention, an efficacious vaccine produces  $>0.5 \mu\text{g/ml}$ ,  $>0.1 \mu\text{g/ml}$ ,  $>0.2 \mu\text{g/ml}$ ,  $>0.35 \mu\text{g/ml}$ ,  $>0.5 \mu\text{g/ml}$ ,  $>1 \mu\text{g/ml}$ ,  $>2 \mu\text{g/ml}$ ,  $>5 \mu\text{g/ml}$  or  $>10 \mu\text{g/ml}$ . In exemplary embodiments of the invention, an efficacious vaccine produces  $>10 \text{ mIU/ml}$ ,  $>20 \text{ mIU/ml}$ ,  $>50 \text{ mIU/ml}$ ,  $>100 \text{ mIU/ml}$ ,  $>200 \text{ mIU/ml}$ ,  $>500 \text{ mIU/ml}$  or  $>1000 \text{ mIU/ml}$ . In exemplary embodiments, the antibody level or concentration is produced or reached by 10 days following vaccination, by 20 days following vaccination, by 30 days following vaccination, by 40 days following vaccination, or by 50 or more days following vaccination. In exemplary embodiments, the level or concentration is produced or reached following a single dose of vaccine administered to the subject. In other embodiments, the level or concentration is produced or reached following multiple doses, e.g., following a first and a second dose (e.g., a booster dose.) In exemplary embodiments, antibody level or concentration is determined or measured by enzyme-linked immunosorbent assay (ELISA). In exemplary embodiments, antibody level or concentration is determined or measured by neutralization assay, e.g., by microneutralization assay.

[0140] The details of various embodiments of the disclosure are set forth in the description below. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims.

## BRIEF DESCRIPTION OF THE DRAWINGS

[0141] The foregoing and other objects, features and advantages will be apparent from the following description of particular embodiments of the disclosure, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of various embodiments of the disclosure.

[0142] FIG. 1 shows a schematic of one example of a RNA (e.g. mRNA) vaccine construct of the present disclosure. The construct depicts a human metapneumovirus and human respiratory syncytial virus full length fusion protein obtained from wild-type strains (The Journal of General Virology. 2008; 89(Pt 12):3113-3118, incorporated herein by reference).

[0143] FIGS. 2A-2C are graphs showing the levels of anti-hMPV fusion protein-specific antibodies in the serum of mice immunized with hMPV mRNA vaccines on day 0 (FIG. 2A), day 14 (FIG. 2B) and day 35 (FIG. 2C) post immunization. The mice were immunized with a single dose (2 .mu.g or 10 .mu.g) on day 0 and were given a boost dose (2 .mu.g or 10 .mu.g) on day 21. hMPV fusion protein-specific antibodies were detected at up to 1:10000 dilution of serum on day 35 for both doses.

[0144] FIGS. 3A-3C are graphs showing the result of IgG isotyping in the serum of mice immunized with hMPV mRNA vaccines. The levels of hMPV fusion protein-specific IgG2a (FIG. 3A) and IgG1 (FIG. 3B) antibodies in the serum are measured by ELISA. FIG. 3C shows that hMPV fusion protein mRNA vaccine induced a mixed Th1/Th2 cytokine response with a Th1 bias.

[0145] FIG. 4 is a graph showing in vitro neutralization of a hMPV B2 strain (TN/91-316) using the sera of mice immunized with a mRNA vaccine encoding hMPV fusion protein. Mouse serum obtained from mice receiving a 10 .mu.g or a 2 .mu.g dose contained hMPV-neutralizing antibodies.

[0146] FIGS. 5A-5C are graphs showing a Th1 cytokine response induced by a hMPV fusion peptide pool (15-mers-50 (overlap)) in splenocytes isolated from mice immunized with the hMPV mRNA vaccines. Virus-free media was used as a negative control and Concanavalin A (ConA, a positive control for splenocyte stimulation) was included. The cytokines tested included IFN-.gamma. (FIG. 5A), IL-2 (FIG. 5B) and IL12 (FIG. 5C).

[0147] FIGS. 6A-6E are graphs showing the Th2 cytokine response induced by a hMPV fusion peptide pool (15-mers-50) in splenocytes isolated from mice immunized with the hMPV mRNA vaccines. Virus-free media was used as a negative control and Concanavalin A was also included. The cytokines tested included IL-10 (FIG. 6A), TNF-.alpha. (FIG. 6B), IL4 (FIG. 6C), IL-5 (FIG. 6D) and IL-6 (FIG. 6E).

[0148] FIGS. 7A-7C are graphs showing the Th1 response induced by inactivated hMPV virus in splenocytes isolated from mice immunized with hMPV mRNA vaccines. Virus-free media was used as a negative control and Concanavalin A was included. The cytokines tested included IFN-.gamma. (FIG. 7A), IL-2 (FIG. 7B) and IL12 (FIG. 7C).

[0149] FIGS. 8A-8E are graphs showing the Th2 response induced by inactivated hMPV virus in splenocytes isolated from mice immunized with the hMPV mRNA vaccines. Virus-free media was used as a negative control and Concanavalin A was included. The cytokines tested include IL-10 (FIG. 8A), TNF-.alpha. (FIG. 8B), IL4 (FIG. 8C), IL-5 (FIG. 8D) and IL-6 (FIG. 8E).

[0150] FIGS. 9A-9B are graphs showing the results of cotton rat challenge experiments. Two different doses of the hMPV mRNA vaccines were used (2 .mu.g or 10 .mu.g doses) to immunize the cotton rats before challenge. The hMPV mRNA vaccines reduced the viral titer in the lung and nose of the cotton rat, with the 10 .mu.g dose being more effective in reducing viral titer. Use of a 10 .mu.g dose resulted in 100% protection in the lung and a .about.2 log reduction in nose viral titer. Use of a 2 .mu.g dose resulted in a 1 log reduction in lung viral titer and no reduction in nose viral titer. The vaccine was administered on Day 0, and a boost was administered on Day 21.

[0151] FIG. 10 is a graph showing the lung histopathology of cotton rats that received hMPV mRNA vaccines. Pathology associated with vaccine-enhanced disease was not observed in immunized groups.

[0152] FIG. 11 is a graph showing hMPV neutralization antibody titers in cotton rats that received hMPV mRNA vaccines (2 .mu.g or 10 .mu.g doses) on days 35 and 42 post immunization.

[0153] FIG. 12 is a graph showing the lung and nose viral load in cotton rats challenged with a hMPV/A2 strain after immunization with the indicated mRNA vaccines (hMPV mRNA vaccine or hMPV/PIV mRNA combination vaccine). Vaccinated cotton rats showed reduced lung and nose viral loads after challenge, compared to control.

[0154] FIG. 13 is a graph showing the lung and nose viral load in cotton rats challenged with PIV3 strain after immunization with indicated mRNA vaccines (PIV mRNA vaccine or hMPV/PIV combination vaccine). Vaccinated cotton rats showed reduced lung and nose viral loads after challenge, compared to control.

[0155] FIG. 14 is a graph showing hMPV neutralizing antibody titers in cotton rats that received different dosages of hMPV mRNA vaccines or hMPV/PIV combination mRNA vaccines on day 42 post immunization. The dosages of the vaccine are indicated in Table 9.

[0156] FIG. 15 is a graph showing PIV3 neutralizing antibody titers in cotton rats that received different dosages of PIV mRNA vaccines or hMPV/PIV combination mRNA vaccines on day 42 post immunization. The dosages of the vaccine are indicated in Table 9.

[0157] FIG. 16 is a graph showing the lung histopathology score of cotton rats immunized with hMPV mRNA vaccines, PIV mRNA vaccines or hMPV/PIV combination mRNA vaccines as indicated in Table 9. Low occurrence of alevolitis and interstitial pneumonia was observed, indicating no antibody-dependent enhancement (ADE) of hMPV associated diseases.

[0158] FIG. 17 is a graph showing the reciprocal MERS-CoV neutralizing antibody titers in mice immunized with betacoronavirus mRNA vaccine encoding the MERS-CoV full-length Spike protein, on days 0, 21, 42, and 56 post immunization.

[0159] FIG. 18 is a graph showing the reciprocal MERS-CoV neutralizing antibody titers in mice immunized with betacoronavirus mRNA vaccine encoding either the MERS-CoV full-length Spike protein, or the S2 subunit of the Spike protein. The full length spike protein induced a stronger immune response compared to the S2 subunit alone.

[0160] FIGS. 19A-19C are graphs showing the viral load in the nose and throat, the bronchoalveolar lavage (BAL), or the lungs of New Zealand white rabbits 4 days post challenge with MERS-CoV. The New Zealand white rabbits were immunized with one 20 .mu.g-dose (on day 0) or two 20 .mu.g-doses (on day 0 and 21) of MERS-CoV mRNA vaccine encoding the full-length Spike protein before challenge. FIG. 19A shows that two doses of MERS-CoV mRNA vaccine resulted in a 3 log reduction of viral load in the nose and led to complete protection in the throat of the New Zealand white rabbits. FIG. 19B shows that two doses of MERS-CoV mRNA vaccine resulted in a 4 log reduction of viral load in the BAL of the New Zealand white rabbits. FIG. 19C show one dose of MERS-CoV mRNA vaccine resulted in a 2 log reduction of viral load, while two doses of MERS-CoV mRNA vaccine resulted in an over 4 log reduction of viral load in the lungs of the New Zealand white rabbits.

[0161] FIGS. 20A-20B are images and graphs showing viral load or replicating virus detected by PCR in the lungs of New Zealand white rabbits 4 days post challenge with MERS-CoV. The New Zealand white rabbits were immunized with a single 20 .mu.g dose (on day 0, Group 1a) of MERS-CoV mRNA vaccine encoding the full-length Spike protein, two 20 .mu.g doses (on day 0 and 21, Group 1b) of MERS-CoV mRNA vaccine encoding the full-length Spike protein, or placebo (Group 2) before challenge. FIG. 20A shows that two doses of 20 .mu.g a MERS-CoV mRNA vaccine reduced over 99% (2 log) of viruses in the lungs of New Zealand white



rabbits. FIG. 20B shows that the group of New Zealand white rabbits that received 2 doses of 20 .mu.g MERS-CoV mRNA vaccine did not have any detectable replicating MERS-CoV virus in their lungs.

[0162] FIG. 21 is a graph showing the MERS-CoV neutralizing antibody titers in New Zealand white rabbits immunized with MERS-CoV mRNA vaccine encoding the full-length Spike protein. Immunization of the in New Zealand white rabbits were carried out as described in FIGS. 21A-21C. The results show that two doses of 20 .mu.g MERS-CoV mRNA vaccine induced a significant amount of neutralizing antibodies against MERS-CoV (EC.sub.50 between 500-1000). The MERS-CoV mRNA vaccine induced antibody titer is 3-5 fold better than any other vaccines tested in the same model.

## DETAILED DESCRIPTION

[0163] The present disclosure provides, in some embodiments, vaccines that comprise RNA (e.g., mRNA) polynucleotides encoding a human metapneumovirus (hMPV) antigenic polypeptide, a parainfluenza virus type 3 (PIV3) antigenic polypeptide, a respiratory syncytial virus (RSV) antigenic polypeptide, a measles virus (MeV) antigenic polypeptide, or a betacoronavirus antigenic polypeptide (e.g., Middle East respiratory syndrome coronavirus (MERS-CoV), **SARS**-CoV, human coronavirus (HCoV)-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH (New Haven) and HCoV-HKU1) (see, e.g., Esper F. et al. *Emerging Infectious Diseases*, 12(5), 2006; and Pyrc K. et al. *Journal of Virology*, 81(7):3051-57, 2007, the contents of each of which is here incorporated by reference in their entirety). The present disclosure also provides, in some embodiments, combination vaccines that comprise at least one RNA (e.g., mRNA) polynucleotide encoding at least two antigenic polypeptides selected from hMPV antigenic polypeptides, PIV3 antigenic polypeptides, RSV antigenic polypeptides, MeV antigenic polypeptides and BetaCoV antigenic polypeptides. Also provided herein are methods of administering the RNA (e.g., mRNA) vaccines, methods of producing the RNA (e.g., mRNA) vaccines, compositions (e.g., pharmaceutical compositions) comprising the RNA (e.g., mRNA) vaccines, and nucleic acids (e.g., DNA) encoding the RNA (e.g., mRNA) vaccines. In some embodiments, a RNA (e.g., mRNA) vaccine comprises an adjuvant, such as a flagellin adjuvant, as provided herein.

[0164] The RNA (e.g., mRNA) vaccines (e.g., hMPV, PIV3, RSV, MeV, BetaCoV RNA vaccines and combinations thereof), in some embodiments, may be used to induce a balanced immune response, comprising both cellular and humoral immunity, without many of the risks associated with DNA vaccination.

[0165] The entire contents of International Application No. PCT/US2015/02740 is incorporated herein by reference.

Human Metapneumovirus (hMPV) hMPV shares substantial homology with respiratory syncytial virus (RSV) in its surface glycoproteins. hMPV fusion protein (F) is related to other paramyxovirus fusion proteins and appears to have homologous regions that may have similar functions. The hMPV fusion protein amino acid sequence contains features characteristic of other paramyxovirus F proteins, including a putative cleavage site and potential N-linked glycosylation sites. Paramyxovirus fusion proteins are synthesized as inactive precursors (F0) that are cleaved by host cell proteases into the biologically fusion-active F1 and F2 domains (see, e.g., Cseke G. et al. *Journal of Virology* 2007; 81(2):698-707, incorporated herein by reference). hMPV has one putative cleavage site, in contrast to the two sites established for RSV F, and only shares 34% amino acid sequence identity with RSV F. F2 is extracellular and disulfide linked to F1. Fusion proteins are type I glycoproteins existing as trimers, with two 4-3 heptad repeat domains at the N- and C-terminal regions of the protein (HR1 and HR2), which form coiled-coil alpha-helices. These coiled coils become apposed in an antiparallel fashion when the protein undergoes a conformational change into the fusogenic state. There is a hydrophobic fusion peptide N proximal to the N-terminal heptad repeat, which is thought to insert into the target cell membrane, while the association of the heptad repeats brings the transmembrane domain into close proximity, inducing membrane fusion (see, e.g., Baker, K A et al. *Mol. Cell* 1999; 3:309-319). This mechanism has been proposed for a number of different viruses, including RSV, influenza virus, and human immunodeficiency virus. Fusion proteins are major antigenic determinants for all known paramyxoviruses and for other viruses that possess similar fusion proteins such as human immunodeficiency virus, influenza virus, and Ebola virus.

[0166] In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding hMPV fusion protein (F). In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding a F1 or F2 subunit of a hMPV F protein. In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding hMPV glycoprotein (G). In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding hMPV matrix protein (M). In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding hMPV phosphoprotein (P). In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding hMPV nucleoprotein (N). In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding hMPV SH protein (SH).

[0167] In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein, G protein, M protein, P protein, N protein and SH protein.

[0168] In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and G protein. In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and M protein. In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and P protein.

[0169] In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and N protein. In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and SH protein.

[0170] In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding G protein and M protein. In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding G protein and P protein. In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding G protein and N protein.

[0171] In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding G protein and SH protein.

[0172] In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein, G protein and M protein. In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein, G protein and P protein. In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein, G protein and N protein. In some embodiments, a hMPV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein, G protein and SH protein.

[0173] A hMPV vaccine may comprise, for example, at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one hMPV antigenic polypeptide identified by any one of SEQ ID NO: 5-8 (Table 3; see also amino acid sequences of Table 4).

[0174] A hMPV vaccine may comprise, for example, at least one RNA (e.g., mRNA) polynucleotide encoded by a nucleic acid (e.g., DNA) identified by any one of SEQ ID NO: 1-4 (Table 2).

[0175] The present disclosure is not limited by a particular strain of hMPV. The strain of hMPV used in a vaccine may be any strain of hMPV. Non-limiting examples of strains of hMPV for use as provide herein include the CAN98-75 (CAN75) and the CAN97-83 (CAN83) hMPV strains (Skiadopoulos M H et al. J Virol. 20014; 78(13)6927-37, incorporated herein by reference), a hMPV A1, A2, B1 or B2 strain (see, e.g., de Graaf M et al. The Journal of General Virology 2008; 89:975-83; Peret T C T et al. The Journal of Infectious Disease 2002; 185:1660-63, incorporated herein by reference), a hMPV isolate TN/92-4 (e.g., SEQ ID NO: 1 and 5), a hMPV isolate NL/1/99 (e.g., SEQ ID NO: 2 and 6), or a hMPV isolate PER/CFI0497/2010/B (e.g., SEQ ID NO:

3 and 7).

[0176] In some embodiments, at least one hMPV antigenic polypeptide is obtained from a hMPV A1, A2, B1 or B2 strain (see, e.g., de Graaf M et al. *The Journal of General Virology* 2008; 89:975-83; Peret T C T et al. *The Journal of Infectious Disease* 2002; 185:1660-63, incorporated herein by reference). In some embodiments, at least one antigenic polypeptide is obtained from the CAN98-75 (CAN75) hMPV strain. In some embodiments, at least one antigenic polypeptide is obtained from the CAN97-83 (CAN83) hMPV strain. In some embodiments, at least one antigenic polypeptide is obtained from hMPV isolate TN/92-4 (e.g., SEQ ID NO: 1 and 5). In some embodiments, at least one antigenic polypeptide is obtained from hMPV isolate NL/1/99 (e.g., SEQ ID NO: 2 and 6). In some embodiments, at least one antigenic polypeptide is obtained from hMPV isolate PER/CFI0497/2010/B (e.g., SEQ ID NO: 3 and 7).

[0177] In some embodiments, hMPV vaccines comprise RNA (e.g., mRNA) polynucleotides encoding a hMPV antigenic polypeptides having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with hMPV F protein and having F protein activity.

[0178] A protein is considered to have F protein activity if, for example, the protein acts to fuse the viral envelope and host cell plasma membrane, mediates viral entry into a host cell via an interaction with arginine-glycine-aspartate RGD-binding integrins, or a combination thereof (see, e.g., Cox R G et al. *J Virol.* 2012; 88(22):12148-60, incorporated herein by reference).

[0179] In some embodiments, hMPV vaccines comprise RNA (e.g., mRNA) polynucleotides encoding hMPV antigenic polypeptides having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with hMPV G protein and having G protein activity.

[0180] A protein is considered to have G protein activity if, for example, the protein acts to modulate (e.g., inhibit) hMPV-induced cellular (immune) responses (see, e.g., Bao X et al. *PLoS Pathog.* 2008; 4(5):e1000077, incorporated herein by reference).

### Human Parainfluenza Virus Type 3 (PIV3)

[0181] Parainfluenza viruses belong to the family Paramyxoviridae. These are enveloped viruses with a negative-sense single-stranded RNA genome. Parainfluenza viruses belong to the subfamily Paramyxoviridae, which is subdivided into three genera: *Respirovirus* (PIV-1, PIV-3, and Sendai virus (SeV)), *Rubulavirus* (PIV-2, PIV-4 and mumps virus) and *Morbillivirus* (measles virus, rinderpest virus and canine distemper virus (CDV)). Their genome, a .about.15 500 nucleotide-long negative-sense RNA molecule, encodes two envelope glycoproteins, the hemagglutinin-neuraminidase (HN), the fusion protein (F or F0), which is cleaved into F1 and F2 subunits, a matrix protein (M), a nucleocapsid protein (N) and several nonstructural proteins including the viral replicase (L). All parainfluenza viruses, except for PIV-1, express a non-structural V protein that blocks IFN signaling in the infected cell and acts therefore as a virulence factor (see, e.g., Nishio M et al. *J Virol.* 2008; 82(13):6130-38).

[0182] PIV3 hemagglutinin-neuraminidase (HN), a structural protein, is found on the viral envelope, where it is necessary for attachment and cell entry. It recognizes and binds to sialic acid-containing receptors on the host cell's surface. As a neuroaminidase, HN removes sialic acid from virus particles, preventing self-aggregation of the virus, and promoting the efficient spread of the virus. Furthermore, HN promotes the activity of the fusion (F or F0) protein, contributing to the penetration of the host cell's surface.

[0183] PIV3 fusion protein (PIV3 F) is located on the viral envelope, where it facilitates the viral fusion and cell entry. The F protein is initially inactive, but proteolytic cleavage leads to its active forms, F1 and F2, which are linked by disulfide bonds. This occurs when the HN protein binds its receptor on the host cell's surface. During early phases of infection, the F glycoprotein mediates penetration of the host cell by fusion of the viral envelope to the plasma membrane. In later stages of the infection, the F protein facilitates the fusion of the infected cells with neighboring uninfected cells, which leads to the formation of a syncytium and spread of the infection.

[0184] PIV3 matrix protein (M) is found within the viral envelope and assists with viral assembly. It interacts with the nucleocapsid and envelope glycoproteins, where it facilitates the budding of progeny viruses through its interactions with specific sites on the cytoplasmic tail of the viral glycoproteins and nucleocapsid. It also plays a role in transporting viral components to the budding site.

[0185] PIV3 phosphoprotein (P) and PIV3 large polymerase protein (L) are found in the nucleocapsid where they form part of the RNA polymerase complex. The L protein, a viral RNA-dependent RNA polymerase, facilitates genomic transcription, while the host cell's ribosomes translate the viral mRNA into viral proteins.

[0186] PIV3 V is a non-structural protein that blocks IFN signaling in the infected cell, therefore acting as a virulence factor.

[0187] PIV3 nucleoprotein (N) encapsidates the genome in a ratio of 1 N per 6 ribonucleotides, protecting it from nucleases. The nucleocapsid (NC) has a helical structure. The encapsidated genomic RNA is termed the NC and serves as template for transcription and replication. During replication, encapsidation by PIV3 N is coupled to RNA synthesis and all replicative products are resistant to nucleases. PIV3 N homo-multimerizes to form the nucleocapsid and binds to viral genomic RNA. PIV3 N binds the P protein and thereby positions the polymerase on the template.

[0188] In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding PIV3 fusion protein (F). In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding a F1 or F2 subunit of a PIV3 F protein. In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding PIV3 hemagglutinin-neuraminidase (HN) (see, e.g., van Wyke Coelingh K L et al. J Virol. 1987; 61(5):1473-77, incorporated herein by reference). In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding PIV3 matrix protein (M). In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding PIV3 phosphoprotein (P). In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding PIV3 nucleoprotein (N).

[0189] In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein, HN protein, M protein, P protein, and N protein.

[0190] In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and HN protein. In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and M protein. In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and P protein. In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and N protein.

[0191] In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding HN protein and M protein. In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding HN protein and P protein. In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding HN protein and N protein.

[0192] In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein, HN protein and M protein. In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein, HN protein and P protein. In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein, HN protein and N protein.

[0193] A PIV3 vaccine may comprise, for example, at least one RNA (e.g., mRNA) polynucleotide having an

open reading frame encoding at least one PIV3 antigenic polypeptide identified by any one of SEQ ID NO: 12-13 (Table 6; see also amino acid sequences of Table 7).

[0194] A PIV3 vaccine may comprise, for example, at least one RNA (e.g., mRNA) polynucleotide encoded by a nucleic acid (e.g., DNA) identified by any one of SEQ ID NO: 9-12 (Table 5; see also nucleic acid sequences of Table 7).

[0195] The present disclosure is not limited by a particular strain of PIV3. The strain of PIV3 used in a vaccine may be any strain of PIV3. A non-limiting example of a strain of PIV3 for use as provide herein includes HPIV3/Homo sapiens/PER/FLA4815/2008.

[0196] In some embodiments, PIV3 vaccines comprise RNA (e.g., mRNA) polynucleotides encoding a PIV3 antigenic polypeptides having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with PIV3 F protein and having F protein activity.

[0197] In some embodiments, PIV3 vaccines comprise RNA (e.g., mRNA) polynucleotides encoding PIV3 antigenic polypeptides having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with PIV3 hemagglutinin-neuraminidase (HN) and having hemagglutinin-neuraminidase activity.

[0198] A protein is considered to have hemagglutinin-neuraminidase activity if, for example, it is capable of both receptor binding and receptor cleaving. Such proteins are major surface glycoproteins that have functional sites for cell attachment and for neuraminidase activity. They are able to cause red blood cells to agglutinate and to cleave the glycosidic linkages of neuraminic acids, so they have the potential to both bind a potential host cell and then release the cell if necessary, for example, to prevent self-aggregation of the virus.

[0199] In some embodiments, PIV3 vaccines comprise RNA (e.g., mRNA) polynucleotides encoding PIV3 antigenic polypeptides having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with PIV3 HN, F (e.g., F, F1 or F2), M, N, L or V and having HN, F (e.g., F, F1 or F2), M, N, L or V activity, respectively.

## Respiratory Syncytial Virus (RSV)

[0200] RSV is a negative-sense, single-stranded RNA virus of the genus Pneumovirinae. The virus is present in at least two antigenic subgroups, known as Group A and Group B, primarily resulting from differences in the surface G glycoproteins. Two RSV surface glycoproteins--G and F--mediate attachment with and attachment to cells of the respiratory epithelium. F surface glycoproteins mediate coalescence of neighboring cells. This results in the formation of syncytial cells. RSV is the most common cause of bronchiolitis. Most infected adults develop mild cold-like symptoms such as congestion, low-grade fever, and wheezing. Infants and small children may suffer more severe symptoms such as bronchiolitis and pneumonia. The disease may be transmitted among humans via contact with respiratory secretions.

[0201] The genome of RSV encodes at least three surface glycoproteins, including F, G, and SH, four nucleocapsid proteins, including L, P, N, and M2, and one matrix protein, M. Glycoprotein F directs viral penetration by fusion between the virion and the host membrane. Glycoprotein G is a type II transmembrane glycoprotein and is the major attachment protein. SH is a short integral membrane protein. Matrix protein M is found in the inner layer of the lipid bilayer and assists virion formation. Nucleocapsid proteins L, P, N, and M2 modulate replication and transcription of the RSV genome. It is thought that glycoprotein G tethers and stabilizes the virus particle at the surface of bronchial epithelial cells, while glycoprotein F interacts with cellular glycosaminoglycans to mediate fusion and delivery of the RSV virion contents into the host cell (Krzyzaniak M A et al. PLoS Pathog 2013; 9(4)).

[0202] In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein. In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding G protein. In some embodiments, a PIV3 vaccine of the present

disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding L protein. In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding P protein. In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding N protein. In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding M2 protein. In some embodiments, a PIV3 vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding M protein.

[0203] In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein, G protein, L protein, P protein, N protein, M2 protein and M protein.

[0204] In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and G protein. In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and L protein. In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and P protein. In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and N protein. In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and M2 protein. In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and M protein.

[0205] In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding G protein and L protein. In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding G protein and P protein. In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding G protein and N protein. In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding G protein and M2 protein. In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding G protein and M protein.

[0206] In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein, G protein and L protein. In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein, G protein and P protein. In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein, G protein and N protein. In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein, G protein and M2 protein. In some embodiments, a RSV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein, G protein and M protein.

[0207] The present disclosure is not limited by a particular strain of RSV. The strain of RSV used in a vaccine may be any strain of RSV.

[0208] In some embodiments, RSV vaccines comprise RNA (e.g., mRNA) polynucleotides encoding a RSV antigenic polypeptides having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with RSV F protein and having F protein activity.

[0209] In some embodiments, RSV vaccines comprise RNA (e.g., mRNA) polynucleotides encoding RSV antigenic polypeptides having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with RSV G protein and having G protein activity.

[0210] A protein is considered to have G protein activity if, for example, the protein acts to modulate (e.g., inhibit) hMPV-induced cellular (immune) responses (see, e.g., Bao X et al. PLoS Pathog. 2008; 4(5):e1000077, incorporated herein by reference).

Measles Virus (MeV)

[0211] Molecular epidemiologic investigations and virologic surveillance contribute notably to the control and prevention of measles. Nearly half of measles-related deaths worldwide occur in India, yet virologic surveillance data are incomplete for many regions of the country. Previous studies have documented the presence of measles virus genotypes D4, D7, and D8 in India, and genotypes D5, D9, D11, H1, and G3 have been detected in neighboring countries. Recently, MeV genotype B3 was detected in India (Kuttiatt V S et al. *Emerg Infect Dis.* 2014; 20(10): 1764-66).

[0212] The glycoprotein complex of paramyxoviruses mediates receptor binding and membrane fusion. In particular, the MeV fusion (F) protein executes membrane fusion, after receptor binding by the hemagglutinin (HA) protein (Muhlebach M D et al. *Journal of Virology* 2008; 82(22):11437-45). The MeV P gene codes for three proteins: P, an essential polymerase cofactor, and V and C, which have multiple functions but are not strictly required for viral propagation in cultured cells. V shares the amino-terminal domain with P but has a zinc-binding carboxyl-terminal domain, whereas C is translated from an overlapping reading frame. The MeV C protein is an infectivity factor. During replication, the P protein binds incoming monomeric nucleocapsid (N) proteins with its amino-terminal domain and positions them for assembly into the nascent ribonucleocapsid. The P protein amino-terminal domain is natively unfolded (Deveaux P et al. *Journal of Virology* 2004; 78(21): 11632-40).

[0213] In some embodiments, a MeV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding HA protein. In some embodiments, a MeV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein. In some embodiments, a MeV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding P protein. In some embodiments, a MeV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding V protein. In some embodiments, a MeV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding C protein.

[0214] In some embodiments, a MeV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding HA protein, F protein, P protein, V protein and C protein.

[0215] In some embodiments, a MeV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding HA protein and F protein. In some embodiments, a MeV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding HA protein and P protein. In some embodiments, a MeV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding HA protein and V protein. In some embodiments, a MeV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding HA protein and C protein.

[0216] In some embodiments, a MeV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and P protein. In some embodiments, a MeV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and V protein. In some embodiments, a MeV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding F protein and C protein.

[0217] In some embodiments, a MeV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding HA protein, F protein and P protein. In some embodiments, a MeV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding HA protein, F protein and V protein. In some embodiments, a MeV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding HA protein, F protein and C protein.

[0218] In some embodiments, MeV vaccines comprise RNA (e.g., mRNA) encoding a MeV antigenic polypeptide having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with MeV HA protein and having MeV HA protein activity.

[0219] In some embodiments, MeV vaccines comprise RNA (e.g., mRNA) encoding a MeV antigenic polypeptide having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with MeV F

protein and having MeV F protein activity.

[0220] A protein is considered to have HA protein activity if the protein mediates receptor binding and/or membrane fusion. MeV F protein executes membrane fusion, after receptor binding by the MeV HA protein.

[0221] A MeV vaccine may comprise, for example, at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one MeV antigenic polypeptide identified by any one of SEQ ID NO: 47-50 (Table 14; see also amino acid sequences of Table 15).

[0222] A MeV vaccine may comprise, for example, at least one RNA (e.g., mRNA) polynucleotide identified by any one of SEQ ID NO: 37, 40, 43, 46 (Table 13).

[0223] A MeV vaccine may comprise, for example, at least one RNA (e.g., mRNA) polynucleotide encoded by a nucleic acid (e.g., DNA) identified by any one of SEQ ID NO: 35, 36, 38, 39, 41, 42, 44 and 45 (Table 13).

[0224] The present disclosure is not limited by a particular strain of MeV. The strain of MeV used in a vaccine may be any strain of MeV. Non-limiting examples of strains of MeV for use as provide herein include B3/B3.1, C2, D4, D6, D7, D8, G3, H1, Moraten, Rubeovax, MVi/New Jersey.USA/45.05, MVi/Texas.USA/4.07, AIK-C, MVi/New York.USA/26.09/3, MVi/California.USA/16.03, MVi/Virginia.USA/15.09, MVi/California.USA/8.04, and MVi/Pennsylvania.USA/20.09.

[0225] MeV proteins may be from MeV genotype D4, D5, D7, D8, D9, D11, H1, G3 or B3. In some embodiments, a MeV HA protein or a MeV F protein is from MeV genotype D8. In some embodiments, a MeV HA protein or a MeV F protein is from MeV genotype B3.

#### Betacoronaviruses (BetaCoV)

[0226] MERS-CoV. MERS-CoV is a positive-sense, single-stranded RNA virus of the genus Betacoronavirus. The genomes are phylogenetically classified into two clades, clade A and clade B. It has a strong tropism for non-ciliated bronchial epithelial cells, evades the innate immune response and antagonizes interferon (IFN) production in infected cells. Dipeptyl peptidase 4 (DDP4, also known as CD26) has been identified as a functional cellular receptor for MERS-CoV. Its enzymatic activity is not required for infection, although its amino acid sequence is highly conserved across species and is expressed in the human bronchial epithelium and kidneys. Most infected individuals develop severe acute respiratory illnesses, including fever, cough, and shortness of breath, and the virus can be fatal. The disease may be transmitted among humans, generally among those in close contact.

[0227] The genome of MERS-CoV encodes at least four unique accessory proteins, such as 3, 4a, 4b and 5, two replicase proteins (open reading frame 1a and 1b), and four major structural proteins, including spike (S), envelope (E), nucleocapsid (N), and membrane (M) proteins (Almazan F et al. MBio 2013; 4(5):e00650-13). The accessory proteins play nonessential roles in MERS-CoV replication, but they are likely structural proteins or interferon antagonists, modulating in vivo replication efficiency and/or pathogenesis, as in the case of **SARS-CoV** (Almazan F et al. MBio 2013; 4(5):e00650-13; Totura A L et al. Curr Opin Virol 2012; 2(3):264-75; Scobey T et al. Proc Natl Acad Sci USA 2013; 110(40):16157-62). The other proteins of MERS-CoV maintain different functions in virus replication. The E protein, for example, involves in virulence, and deleting the E-coding gene results in replication-competent and propagation-defective viruses or attenuated viruses (Almazan F et al. MBio 2013; 4(5):e00650-13). The S protein is particularly essential in mediating virus binding to cells expressing receptor dipeptidyl peptidase-4 (DPP4) through receptor-binding domain (RBD) in the S1 subunit, whereas the S2 subunit subsequently mediates virus entry via fusion of the virus and target cell membranes (Li F. J Virol 2015; 89(4):1954-64; Raj V S et al. Nature 2013; 495(7440):251-4).

[0228] In some embodiments, a MERS-CoV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding S protein. In some embodiments, a MERS-CoV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding the S1 subunit of the S protein. In some embodiments,



a MERS-CoV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding the S2 subunit of the S protein. In some embodiments, a MERS-CoV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding E protein. In some embodiments, a MERS-CoV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding N protein. In some embodiments, a MERS-CoV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding M protein.

[0229] In some embodiments, a MERS-CoV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding S protein (S, S1 and/or S2), E protein, N protein and M protein.

[0230] In some embodiments, a MERS-CoV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding S protein (S, S1 and/or S2) and E protein. In some embodiments, a MERS-CoV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding S protein (S, S1 and/or S2) and N protein. In some embodiments, a MERS-CoV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding S protein (S, S1 and/or S2) and M protein.

[0231] In some embodiments, a MERS-CoV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding S protein (S, S1 and/or S2), E protein and M protein. In some embodiments, a MERS-CoV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding S protein (S, S1 and/or S2), E protein and N protein. In some embodiments, a MERS-CoV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding S protein (S, S1 and/or S2), M protein and N protein. In some embodiments, a MERS-CoV vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding E protein, M protein and N protein.

[0232] A MERS-CoV vaccine may comprise, for example, at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one MERS-CoV antigenic polypeptide identified by any one of SEQ ID NO: 24-38 or 33 (Table 11; see also amino acid sequences of Table 12).

[0233] A MERS-CoV vaccine may comprise, for example, at least one RNA (e.g., mRNA) polynucleotide encoded by a nucleic acid (e.g., DNA) identified by any one of SEQ ID NO: 20-23 (Table 10).

[0234] The present disclosure is not limited by a particular strain of MERS-CoV. The strain of MERS-CoV used in a vaccine may be any strain of MERS-CoV. Non-limiting examples of strains of MERS-CoV for use as provide herein include Riyadh\_14\_2013, and 2cEMC/2012, Hasa\_1\_2013.

[0235] **SARS-CoV**. The genome of **SARS-CoV** includes of a single, positive-strand RNA that is approximately 29,700 nucleotides long. The overall genome organization of **SARS-CoV** is similar to that of other coronaviruses. The reference genome includes 13 genes, which encode at least 14 proteins. Two large overlapping reading frames (ORFs) encompass 71% of the genome. The remainder has 12 potential ORFs, including genes for structural proteins S (spike), E (small envelope), M (membrane), and N (nucleocapsid). Other potential ORFs code for unique putative **SARS-CoV**-specific polypeptides that lack obvious sequence similarity to known proteins. A detailed analysis of the **SARS-CoV** genome has been published in J Mol Biol 2003; 331: 991-1004.

[0236] In some embodiments, a **SARS-CoV** vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding S protein (S, S1 and/or S2), E protein, N protein and M protein.

[0237] In some embodiments, a **SARS-CoV** vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding S protein (S, S1 and/or S2) and E protein. In some embodiments, a **SARS-CoV** vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding S protein (S, S1 and/or S2) and N protein. In some embodiments, a **SARS-CoV** vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding S protein (S, S1 and/or S2) and M protein.

[0238] In some embodiments, a **SARS-CoV** vaccine of the present disclosure comprises a RNA (e.g., mRNA)

polynucleotide encoding S protein (S, S1 and/or S2), E protein and M protein. In some embodiments, a **SARS-CoV** vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding S protein (S, S1 and/or S2), E protein and N protein. In some embodiments, a **SARS-CoV** vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding S protein (S, S1 and/or S2), M protein and N protein. In some embodiments, a **SARS-CoV** vaccine of the present disclosure comprises a RNA (e.g., mRNA) polynucleotide encoding E protein, M protein and N protein.

[0239] A **SARS-CoV** vaccine may comprise, for example, at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one **SARS-CoV** antigenic polypeptide identified by any one of SEQ ID NO: 29, 32 or 34 (Table 11; see also amino acid sequences of Table 12).

[0240] The present disclosure is not limited by a particular strain of **SARS-CoV**. The strain of **SARS-CoV** used in a vaccine may be any strain of **SARS-CoV**.

[0241] HCoV-OC43.

[0242] Human coronavirus OC43 is an enveloped, positive-sense, single-stranded RNA virus in the species Betacoronavirus-1 (genus Betacoronavirus, subfamily Coronavirinae, family Coronaviridae, order Nidovirales). Four HCoV-OC43 genotypes (A to D), have been identified with genotype D most likely arising from recombination. The complete genome sequencing of two genotype C and D strains and bootscan analysis shows recombination events between genotypes B and C in the generation of genotype D. Of 29 strains identified, none belong to the more ancient genotype A. Along with HCoV-229E, a species in the Alphacoronavirus genus, HCoV-OC43 are among the known viruses that cause the common cold. Both viruses can cause severe lower respiratory tract infections, including pneumonia in infants, the elderly, and immunocompromised individuals such as those undergoing chemotherapy and those with HIV-AIDS.

[0243] HCoV-HKU1.

[0244] Human coronavirus HKU1 (HCoV-H KU 1) is a positive-sense, single-stranded RNA virus with the HE gene, which distinguishes it as a group 2, or betacoronavirus. It was discovered in January 2005 in two patients in Hong Kong. The genome of HCoV-HKU1 is a 29,926-nucleotide, polyadenylated RNA. The GC content is 32%, the lowest among all known coronaviruses. The genome organization is the same as that of other group II coronaviruses, with the characteristic gene order 1a, 1b, HE, S, E, M, and N. Furthermore, accessory protein genes are present between the S and E genes (ORF4) and at the position of the N gene (ORF8). The TRS is presumably located within the AAUCUAAAC sequence, which precedes each ORF except E. As in sialodacryoadenitis virus and mouse hepatitis virus (MHV), translation of the E protein possibly occurs via an internal ribosomal entry site. The 3' untranslated region contains a predicted stem-loop structure immediately downstream of the N ORF (nucleotide position 29647 to 29711). Further downstream, a pseudoknot structure is present at nucleotide position 29708 to 29760. Both RNA structures are conserved in group II coronaviruses and are critical for virus replication.

[0245] HCoV-NL63.

[0246] The RNA genome of human coronavirus NL63 (HCoV-NL63) is 27,553 nucleotides, with a poly(A) tail (FIG. 1). With a GC content of 34%, HCoV-NL63 has one of the lowest GC contents of the coronaviruses, for which GC content ranges from 32 to 42%. Untranslated regions of 286 and 287 nucleotides are present at the 5' and 3' termini, respectively. Genes predicted to encode the S, E, M, and N proteins are found in the 3' part of the HCoV-NL63 genome. The HE gene, which is present in some group II coronaviruses, is absent, and there is only a single, monocistronic accessory protein ORF (ORF3) located between the S and E genes. Subgenomic mRNAs are generated for all ORFs (S, ORF3, E, M, and N), and the core sequence of the TRS of HCoV-NL63 is defined as AACUAAA. This sequence is situated upstream of every ORF except for the E ORF, which contains the suboptimal core sequence AACUAUA. Interestingly, a 13-nucleotide sequence with perfect homology to the leader sequence is situated upstream of the suboptimal E TRS. Annealing of this 13-nucleotide sequence to the leader sequence may act as a compensatory mechanism for the disturbed leader-TRS/body-TRS interaction.

[0247] HCoV-229E.

[0248] Human coronavirus 229E (HCoV-229E) is a single-stranded, positive-sense, RNA virus species in the Alphacoronavirus genus of the subfamily Coronavirinae, in the family Coronaviridae, of the order Nidovirales. Along with Human coronavirus OC43, it is responsible for the common cold. HCoV-NL63 and HCoV-229E are two of the four human coronaviruses that circulate worldwide. These two viruses are unique in their relationship towards each other. Phylogenetically, the viruses are more closely related to each other than to any other human coronavirus, yet they only share 65% sequence identity. Moreover, the viruses use different receptors to enter their target cell. HCoV-NL63 is associated with croup in children, whereas all signs suggest that the virus probably causes the common cold in healthy adults. HCoV-229E is a proven common cold virus in healthy adults, so it is probable that both viruses induce comparable symptoms in adults, even though their mode of infection differs (HCoV-NL63 and HCoV-229E are two of the four human coronaviruses that circulate worldwide. These two viruses are unique in their relationship towards each other. Phylogenetically, the viruses are more closely related to each other than to any other human coronavirus, yet they only share 65% sequence identity. Moreover, the viruses use different receptors to enter their target cell. HCoV-NL63 is associated with croup in children, whereas all signs suggest that the virus probably causes the common cold in healthy adults. HCoV-229E is a proven common cold virus in healthy adults, so it is probable that both viruses induce comparable symptoms in adults, even though their mode of infection differs (Dijkman R. et al. J Formos Med Assoc. 2009 April; 108(4):270-9, the contents of which is incorporated herein by reference in their entirety).

#### Combination Vaccines

[0249] Embodiments of the present disclosure also provide combination RNA (e.g., mRNA) vaccines. A "combination RNA (e.g., mRNA) vaccine" of the present disclosure refers to a vaccine comprising at least one (e.g., at least 2, 3, 4, or 5) RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a combination of any two or more (or all of) antigenic polypeptides selected from hMPV antigenic polypeptides, PIV3 antigenic polypeptides, RSV antigenic polypeptides, MeV antigenic polypeptides, and BetaCoV antigenic polypeptides (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1).

[0250] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a hMPV antigenic polypeptide, a PIV3 antigenic polypeptide, a RSV antigenic polypeptide, a MeV antigenic polypeptide, and a BetaCoV antigenic polypeptide (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1).

[0251] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a hMPV antigenic polypeptide and a PIV3 antigenic polypeptide.

[0252] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a hMPV antigenic polypeptide and a RSV antigenic polypeptide.

[0253] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a hMPV antigenic polypeptide and a MeV antigenic polypeptide.

[0254] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a hMPV antigenic polypeptide and a BetaCoV antigenic polypeptide.

[0255] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a PIV3 antigenic polypeptide and a RSV antigenic polypeptide.

[0256] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a PIV3 antigenic polypeptide and a MeV antigenic polypeptide.

[0257] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a PIV3 antigenic polypeptide and a BetaCoV antigenic polypeptide (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1).

[0258] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a RSV antigenic polypeptide and a MeV antigenic polypeptide.

[0259] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a RSV antigenic polypeptide and a BetaCoV antigenic polypeptide (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1).

[0260] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a MeV antigenic polypeptide and a BetaCoV antigenic polypeptide (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1).

[0261] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a hMPV antigenic polypeptide, a PIV3 antigenic polypeptide, a RSV antigenic polypeptide and a MeV antigenic polypeptide.

[0262] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a hMPV antigenic polypeptide, a PIV3 antigenic polypeptide, a RSV antigenic polypeptide and a BetaCoV antigenic polypeptide (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1).

[0263] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a hMPV antigenic polypeptide, a PIV3 antigenic polypeptide, a MeV antigenic polypeptide and a BetaCoV antigenic polypeptide (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1).

[0264] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a hMPV antigenic polypeptide, a RSV antigenic polypeptide, a MeV antigenic polypeptide and a BetaCoV antigenic polypeptide (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1).

[0265] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a PIV3 antigenic polypeptide, a RSV antigenic polypeptide, a MeV antigenic polypeptide and a BetaCoV antigenic polypeptide (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1).

[0266] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a hMPV antigenic polypeptide, a PIV3 antigenic polypeptide and a RSV antigenic polypeptide.

[0267] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a hMPV antigenic polypeptide, a PIV3 antigenic polypeptide and a MeV antigenic polypeptide.

[0268] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a hMPV antigenic polypeptide, a PIV3 antigenic polypeptide and a BetaCoV antigenic polypeptide (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1).

[0269] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a hMPV antigenic polypeptide, a RSV antigenic polypeptide and a MeV antigenic

polypeptide.

[0270] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a hMPV antigenic polypeptide, a RSV antigenic polypeptide and a BetaCoV antigenic polypeptide (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1).

[0271] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a hMPV antigenic polypeptide, a MeV antigenic polypeptide and a BetaCoV antigenic polypeptide (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1).

[0272] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a PIV3 antigenic polypeptide, a RSV antigenic polypeptide and a MeV antigenic polypeptide.

[0273] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a PIV3 antigenic polypeptide, a RSV antigenic polypeptide and a BetaCoV antigenic polypeptide (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1).

[0274] In some embodiments, a combination RNA (e.g., mRNA) vaccine comprises a RNA (e.g., mRNA) polynucleotide encoding a RSV antigenic polypeptide, a MeV antigenic polypeptide and a BetaCoV antigenic polypeptide (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1).

[0275] Other combination respiratory virus RNA (e.g., mRNA) vaccines are encompassed by the present disclosure.

[0276] It has been discovered that the mRNA vaccines described herein are superior to current vaccines in several ways. First, the lipid nanoparticle (LNP) delivery is superior to other formulations including a protamine base approach described in the literature and no additional adjuvants are to be necessary. The use of LNPs enables the effective delivery of chemically modified or unmodified mRNA vaccines. Additionally it has been demonstrated herein that both modified and unmodified LNP formulated mRNA vaccines were superior to conventional vaccines by a significant degree. In some embodiments the mRNA vaccines of the invention are superior to conventional vaccines by a factor of at least 10 fold, 20 fold, 40 fold, 50 fold, 100 fold, 500 fold or 1,000 fold.

[0277] Although attempts have been made to produce functional RNA vaccines, including mRNA vaccines and self-replicating RNA vaccines, the therapeutic efficacy of these RNA vaccines have not yet been fully established. Quite surprisingly, the inventors have discovered, according to aspects of the invention a class of formulations for delivering mRNA vaccines in vivo that results in significantly enhanced, and in many respects synergistic, immune responses including enhanced antigen generation and functional antibody production with neutralization capability. These results can be achieved even when significantly lower doses of the mRNA are administered in comparison with mRNA doses used in other classes of lipid based formulations. The formulations of the invention have demonstrated significant unexpected in vivo immune responses sufficient to establish the efficacy of functional mRNA vaccines as prophylactic and therapeutic agents. Additionally, self-replicating RNA vaccines rely on viral replication pathways to deliver enough RNA to a cell to produce an immunogenic response. The formulations of the invention do not require viral replication to produce enough protein to result in a strong immune response. Thus, the mRNA of the invention are not self-replicating RNA and do not include components necessary for viral replication.

[0278] The invention involves, in some aspects, the surprising finding that lipid nanoparticle (LNP) formulations significantly enhance the effectiveness of mRNA vaccines, including chemically modified and unmodified

mRNA vaccines. The efficacy of mRNA vaccines formulated in LNP was examined in vivo using several distinct antigens. The results presented herein demonstrate the unexpected superior efficacy of the mRNA vaccines formulated in LNP over other commercially available vaccines.

[0279] In addition to providing an enhanced immune response, the formulations of the invention generate a more rapid immune response with fewer doses of antigen than other vaccines tested. The mRNA-LNP formulations of the invention also produce quantitatively and qualitatively better immune responses than vaccines formulated in a different carriers.

[0280] The data described herein demonstrate that the formulations of the invention produced significant unexpected improvements over existing antigen vaccines. Additionally, the mRNA-LNP formulations of the invention are superior to other vaccines even when the dose of mRNA is lower than other vaccines. Mice immunized with either 10 .mu.g or 2 .mu.g doses of an hMPV fusion protein mRNA LNP vaccine or a PIV3 mRNA LNP vaccine produced neutralizing antibodies which for instance, successfully neutralized the hMPV B2 virus. A 10 .mu.g dose of mRNA vaccine protected 100% of mice from lethal challenge and drastically reduced the viral titer after challenge (.about.2 log reduction).

[0281] Two 20 .mu.g doses of MERS-CoV mRNA LNP vaccine significantly reduced viral load and induced significant amount of neutralizing antibodies against MERS-CoV (EC.sub.50 between 500-1000). The MERS-CoV mRNA vaccine induced antibody titer was 3-5 fold better than any other vaccines tested in the same model.

[0282] The LNP used in the studies described herein has been used previously to deliver siRNA in various animal models as well as in humans. In view of the observations made in association with the siRNA delivery of LNP formulations, the fact that LNP is useful in vaccines is quite surprising. It has been observed that therapeutic delivery of siRNA formulated in LNP causes an undesirable inflammatory response associated with a transient IgM response, typically leading to a reduction in antigen production and a compromised immune response. In contrast to the findings observed with siRNA, the LNP-mRNA formulations of the invention are demonstrated herein to generate enhanced IgG levels, sufficient for prophylactic and therapeutic methods rather than transient IgM responses.

#### Nucleic Acids/Polynucleotides

[0283] Respiratory virus vaccines, as provided herein, comprise at least one (one or more) ribonucleic acid (RNA) (e.g., mRNA) polynucleotide having an open reading frame encoding at least one antigenic polypeptide selected from hMPV, PIV3, RSV, MeV and BetaCoV (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1) antigenic polypeptides. The term "nucleic acid" includes any compound and/or substance that comprises a polymer of nucleotides (nucleotide monomer). These polymers are referred to as polynucleotides. Thus, the terms "nucleic acid" and "polynucleotide" are used interchangeably.

[0284] Nucleic acids may be or may include, for example, ribonucleic acids (RNAs), deoxyribonucleic acids (DNAs), threose nucleic acids (TNAs), glycol nucleic acids (GNAs), peptide nucleic acids (PNAs), locked nucleic acids (LNAs, including LNA having a .beta.-D-ribo configuration, .alpha.-LNA having an .alpha.-L-ribo configuration (a diastereomer of LNA), 2'-amino-LNA having a 2'-amino functionalization, and 2'-amino-.alpha.-LNA having a 2'-amino functionalization), ethylene nucleic acids (ENA), cyclohexenyl nucleic acids (CeNA) or chimeras or combinations thereof.

[0285] In some embodiments, polynucleotides of the present disclosure function as messenger RNA (mRNA). "Messenger RNA" (mRNA) refers to any polynucleotide that encodes a (at least one) polypeptide (a naturally-occurring, non-naturally-occurring, or modified polymer of amino acids) and can be translated to produce the encoded polypeptide in vitro, in vivo, in situ or ex vivo. The skilled artisan will appreciate that, except where otherwise noted, polynucleotide sequences set forth in the instant application will recite "T"s in a representative DNA sequence but where the sequence represents RNA (e.g., mRNA), the "T"s would be substituted for "U"s. Thus, any of the RNA polynucleotides encoded by a DNA identified by a particular sequence identification

number may also comprise the corresponding RNA (e.g., mRNA) sequence encoded by the DNA, where each "T" of the DNA sequence is substituted with "U."

[0286] The basic components of an mRNA molecule typically include at least one coding region, a 5' untranslated region (UTR), a 3' UTR, a 5' cap and a poly-A tail. Polynucleotides of the present disclosure may function as mRNA but can be distinguished from wild-type mRNA in their functional and/or structural design features, which serve to overcome existing problems of effective polypeptide expression using nucleic-acid based therapeutics.

[0287] In some embodiments, a RNA polynucleotide of an RNA (e.g., mRNA) vaccine encodes 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-10, 4-9, 4-8, 4-7, 4-6, 4-5, 5-10, 5-9, 5-8, 5-7, 5-6, 6-10, 6-9, 6-8, 6-7, 7-10, 7-9, 7-8, 8-10, 8-9 or 9-10 antigenic polypeptides. In some embodiments, a RNA (e.g., mRNA) polynucleotide of a respiratory virus vaccine encodes at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 antigenic polypeptides. In some embodiments, a RNA (e.g., mRNA) polynucleotide of a respiratory virus vaccine encodes at least 100 or at least 200 antigenic polypeptides. In some embodiments, a RNA polynucleotide of an respiratory virus vaccine encodes 1-10, 5-15, 10-20, 15-25, 20-30, 25-35, 30-40, 35-45, 40-50, 1-50, 1-100, 2-50 or 2-100 antigenic polypeptides.

[0288] Polynucleotides of the present disclosure, in some embodiments, are codon optimized. Codon optimization methods are known in the art and may be used as provided herein. Codon optimization, in some embodiments, may be used to match codon frequencies in target and host organisms to ensure proper folding; bias GC content to increase mRNA stability or reduce secondary structures; minimize tandem repeat codons or base runs that may impair gene construction or expression; customize transcriptional and translational control regions; insert or remove protein trafficking sequences; remove/add post translation modification sites in encoded protein (e.g. glycosylation sites); add, remove or shuffle protein domains; insert or delete restriction sites; modify ribosome binding sites and mRNA degradation sites; adjust translational rates to allow the various domains of the protein to fold properly; or to reduce or eliminate problem secondary structures within the polynucleotide. Codon optimization tools, algorithms and services are known in the art--non-limiting examples include services from GeneArt (Life Technologies), DNA2.0 (Menlo Park Calif.) and/or proprietary methods. In some embodiments, the open reading frame (ORF) sequence is optimized using optimization algorithms.

[0289] In some embodiments, a codon optimized sequence shares less than 95% sequence identity, less than 90% sequence identity, less than 85% sequence identity, less than 80% sequence identity, or less than 75% sequence identity to a naturally-occurring or wild-type sequence (e.g., a naturally-occurring or wild-type mRNA sequence encoding a polypeptide or protein of interest (e.g., an antigenic protein or antigenic polypeptide)).

[0290] In some embodiments, a codon-optimized sequence shares between 65% and 85% (e.g., between about 67% and about 85%, or between about 67% and about 80%) sequence identity to a naturally-occurring sequence or a wild-type sequence (e.g., a naturally-occurring or wild-type mRNA sequence encoding a polypeptide or protein of interest (e.g., an antigenic protein or polypeptide)). In some embodiments, a codon-optimized sequence shares between 65% and 75%, or about 80% sequence identity to a naturally-occurring sequence or wild-type sequence (e.g., a naturally-occurring or wild-type mRNA sequence encoding a polypeptide or protein of interest (e.g., an antigenic protein or polypeptide)).

[0291] In some embodiments a codon-optimized RNA (e.g., mRNA) may, for instance, be one in which the levels of G/C are enhanced. The G/C-content of nucleic acid molecules may influence the stability of the RNA. RNA having an increased amount of guanine (G) and/or cytosine (C) residues may be functionally more stable than nucleic acids containing a large amount of adenine (A) and thymine (T) or uracil (U) nucleotides. WO02/098443 discloses a pharmaceutical composition containing an mRNA stabilized by sequence modifications in the translated region. Due to the degeneracy of the genetic code, the modifications work by substituting existing codons for those that promote greater RNA stability without changing the resulting amino acid. The approach is limited to coding regions of the RNA.

Antigens/Antigenic Polypeptides

[0292] In some embodiments, an antigenic polypeptide (e.g., a hMPV, PIV3, RSV, MeV or BetaCoV antigenic polypeptide) is longer than 25 amino acids and shorter than 50 amino acids. Polypeptides include gene products, naturally occurring polypeptides, synthetic polypeptides, homologs, orthologs, paralogs, fragments and other equivalents, variants, and analogs of the foregoing. A polypeptide may be a single molecule or may be a multi-molecular complex such as a dimer, trimer or tetramer. Polypeptides may also comprise single chain polypeptides or multichain polypeptides, such as antibodies or insulin, and may be associated or linked to each other. Most commonly, disulfide linkages are found in multichain polypeptides. The term "polypeptide" may also apply to amino acid polymers in which at least one amino acid residue is an artificial chemical analogue of a corresponding naturally-occurring amino acid.

[0293] A "polypeptide variant" is a molecule that differs in its amino acid sequence relative to a native sequence or a reference sequence. Amino acid sequence variants may possess substitutions, deletions, insertions, or a combination of any two or three of the foregoing, at certain positions within the amino acid sequence, as compared to a native sequence or a reference sequence. Ordinarily, variants possess at least 50% identity to a native sequence or a reference sequence. In some embodiments, variants share at least 80% identity or at least 90% identity with a native sequence or a reference sequence.

[0294] In some embodiments "variant mimics" are provided. A "variant mimic" contains at least one amino acid that would mimic an activated sequence. For example, glutamate may serve as a mimic for phospho-threonine and/or phospho-serine. Alternatively, variant mimics may result in deactivation or in an inactivated product containing the mimic. For example, phenylalanine may act as an inactivating substitution for tyrosine, or alanine may act as an inactivating substitution for serine.

[0295] "Orthologs" refers to genes in different species that evolved from a common ancestral gene by speciation. Normally, orthologs retain the same function in the course of evolution. Identification of orthologs is important for reliable prediction of gene function in newly sequenced genomes.

[0296] "Analog" is meant to include polypeptide variants that differ by one or more amino acid alterations, for example, substitutions, additions or deletions of amino acid residues that still maintain one or more of the properties of the parent or starting polypeptide.

[0297] The present disclosure provides several types of compositions that are polynucleotide or polypeptide based, including variants and derivatives. These include, for example, substitutional, insertional, deletion and covalent variants and derivatives. The term "derivative" is synonymous with the term "variant" and generally refers to a molecule that has been modified and/or changed in any way relative to a reference molecule or a starting molecule.

[0298] As such, polynucleotides encoding peptides or polypeptides containing substitutions, insertions and/or additions, deletions and covalent modifications with respect to reference sequences, in particular the polypeptide sequences disclosed herein, are included within the scope of this disclosure. For example, sequence tags or amino acids, such as one or more lysines, can be added to peptide sequences (e.g., at the N-terminal or C-terminal ends). Sequence tags can be used for peptide detection, purification or localization. Lysines can be used to increase peptide solubility or to allow for biotinylation. Alternatively, amino acid residues located at the carboxy and amino terminal regions of the amino acid sequence of a peptide or protein may optionally be deleted providing for truncated sequences. Certain amino acids (e.g., C-terminal residues or N-terminal residues) alternatively may be deleted depending on the use of the sequence, as for example, expression of the sequence as part of a larger sequence that is soluble, or linked to a solid support.

[0299] "Substitutional variants" when referring to polypeptides are those that have at least one amino acid residue in a native or starting sequence removed and a different amino acid inserted in its place at the same position. Substitutions may be single, where only one amino acid in the molecule has been substituted, or they may be multiple, where two or more (e.g., 3, 4 or 5) amino acids have been substituted in the same molecule.



[0300] As used herein the term "conservative amino acid substitution" refers to the substitution of an amino acid that is normally present in the sequence with a different amino acid of similar size, charge, or polarity. Examples of conservative substitutions include the substitution of a non-polar (hydrophobic) residue such as isoleucine, valine and leucine for another non-polar residue. Likewise, examples of conservative substitutions include the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, and between glycine and serine. Additionally, the substitution of a basic residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue such as aspartic acid or glutamic acid for another acidic residue are additional examples of conservative substitutions. Examples of non-conservative substitutions include the substitution of a non-polar (hydrophobic) amino acid residue such as isoleucine, valine, leucine, alanine, methionine for a polar (hydrophilic) residue such as cysteine, glutamine, glutamic acid or lysine and/or a polar residue for a non-polar residue.

[0301] "Features" when referring to polypeptide or polynucleotide are defined as distinct amino acid sequence-based or nucleotide-based components of a molecule respectively.

[0302] Features of the polypeptides encoded by the polynucleotides include surface manifestations, local conformational shape, folds, loops, half-loops, domains, half-domains, sites, termini and any combination(s) thereof.

[0303] As used herein when referring to polypeptides the term "domain" refers to a motif of a polypeptide having one or more identifiable structural or functional characteristics or properties (e.g., binding capacity, serving as a site for protein-protein interactions).

[0304] As used herein when referring to polypeptides the terms "site" as it pertains to amino acid based embodiments is used synonymously with "amino acid residue" and "amino acid side chain." As used herein when referring to polynucleotides the terms "site" as it pertains to nucleotide based embodiments is used synonymously with "nucleotide." A site represents a position within a peptide or polypeptide or polynucleotide that may be modified, manipulated, altered, derivatized or varied within the polypeptide-based or polynucleotide-based molecules.

[0305] As used herein the terms "termini" or "terminus" when referring to polypeptides or polynucleotides refers to an extremity of a polypeptide or polynucleotide respectively. Such extremity is not limited only to the first or final site of the polypeptide or polynucleotide but may include additional amino acids or nucleotides in the terminal regions. Polypeptide-based molecules may be characterized as having both an N-terminus (terminated by an amino acid with a free amino group (NH<sub>2</sub>)) and a C-terminus (terminated by an amino acid with a free carboxyl group (COOH)). Proteins are in some cases made up of multiple polypeptide chains brought together by disulfide bonds or by non-covalent forces (multimers, oligomers). These proteins have multiple N- and C-termini. Alternatively, the termini of the polypeptides may be modified such that they begin or end, as the case may be, with a non-polypeptide based moiety such as an organic conjugate.

[0306] As recognized by those skilled in the art, protein fragments, functional protein domains, and homologous proteins are also considered to be within the scope of polypeptides of interest. For example, provided herein is any protein fragment (meaning a polypeptide sequence at least one amino acid residue shorter than a reference polypeptide sequence but otherwise identical) of a reference protein having a length of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or longer than 100 amino acids. In another example, any protein that includes a stretch of 20, 30, 40, 50, or 100 (contiguous) amino acids that are 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% identical to any of the sequences described herein can be utilized in accordance with the disclosure. In some embodiments, a polypeptide includes 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations as shown in any of the sequences provided herein or referenced herein. In another example, any protein that includes a stretch of 20, 30, 40, 50, or 100 amino acids that are greater than 80%, 90%, 95%, or 100% identical to any of the sequences described herein, wherein the protein has a stretch of 5, 10, 15, 20, 25, or 30 amino acids that are less than 80%, 75%, 70%, 65% to 60% identical to any of the sequences described herein can be utilized in accordance with the disclosure.

[0307] Polypeptide or polynucleotide molecules of the present disclosure may share a certain degree of sequence

similarity or identity with the reference molecules (e.g., reference polypeptides or reference polynucleotides), for example, with art-described molecules (e.g., engineered or designed molecules or wild-type molecules). The term "identity," as known in the art, refers to a relationship between the sequences of two or more polypeptides or polynucleotides, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between two sequences as determined by the number of matches between strings of two or more amino acid residues or nucleic acid residues. Identity measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (e.g., "algorithms"). Identity of related peptides can be readily calculated by known methods. "% identity" as it applies to polypeptide or polynucleotide sequences is defined as the percentage of residues (amino acid residues or nucleic acid residues) in the candidate amino acid or nucleic acid sequence that are identical with the residues in the amino acid sequence or nucleic acid sequence of a second sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent identity. Methods and computer programs for the alignment are well known in the art. Identity depends on a calculation of percent identity but may differ in value due to gaps and penalties introduced in the calculation. Generally, variants of a particular polynucleotide or polypeptide have at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% but less than 100% sequence identity to that particular reference polynucleotide or polypeptide as determined by sequence alignment programs and parameters described herein and known to those skilled in the art. Such tools for alignment include those of the BLAST suite (Stephen F. Altschul, et al. (1997). "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," *Nucleic Acids Res.* 25:3389-3402). Another popular local alignment technique is based on the Smith-Waterman algorithm (Smith, T. F. & Waterman, M. S. (1981) "Identification of common molecular subsequences." *J. Mol. Biol.* 147:195-197). A general global alignment technique based on dynamic programming is the Needleman-Wunsch algorithm (Needleman, S. B. & Wunsch, C.D. (1970) "A general method applicable to the search for similarities in the amino acid sequences of two proteins." *J. Mol. Biol.* 48:443-453). More recently, a Fast Optimal Global Sequence Alignment Algorithm (FOGSAA) was developed that purportedly produces global alignment of nucleotide and protein sequences faster than other optimal global alignment methods, including the Needleman-Wunsch algorithm. Other tools are described herein, specifically in the definition of "identity" below.

[0308] As used herein, the term "homology" refers to the overall relatedness between polymeric molecules, e.g. between nucleic acid molecules (e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules. Polymeric molecules (e.g. nucleic acid molecules (e.g. DNA molecules and/or RNA molecules) and/or polypeptide molecules) that share a threshold level of similarity or identity determined by alignment of matching residues are termed homologous. Homology is a qualitative term that describes a relationship between molecules and can be based upon the quantitative similarity or identity. Similarity or identity is a quantitative term that defines the degree of sequence match between two compared sequences. In some embodiments, polymeric molecules are considered to be "homologous" to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical or similar. The term "homologous" necessarily refers to a comparison between at least two sequences (polynucleotide or polypeptide sequences). Two polynucleotide sequences are considered homologous if the polypeptides they encode are at least 50%, 60%, 70%, 80%, 90%, 95%, or even 99% for at least one stretch of at least 20 amino acids. In some embodiments, homologous polynucleotide sequences are characterized by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. For polynucleotide sequences less than 60 nucleotides in length, homology is determined by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. Two protein sequences are considered homologous if the proteins are at least 50%, 60%, 70%, 80%, or 90% identical for at least one stretch of at least 20 amino acids.

[0309] Homology implies that the compared sequences diverged in evolution from a common origin. The term "homolog" refers to a first amino acid sequence or nucleic acid sequence (e.g., gene (DNA or RNA) or protein sequence) that is related to a second amino acid sequence or nucleic acid sequence by descent from a common ancestral sequence. The term "homolog" may apply to the relationship between genes and/or proteins separated by the event of speciation or to the relationship between genes and/or proteins separated by the event of genetic duplication. "Orthologs" are genes (or proteins) in different species that evolved from a common ancestral gene (or protein) by speciation. Typically, orthologs retain the same function in the course of evolution. "Paralogs" are

genes (or proteins) related by duplication within a genome. Orthologs retain the same function in the course of evolution, whereas paralogs evolve new functions, even if these are related to the original one.

[0310] The term "identity" refers to the overall relatedness between polymeric molecules, for example, between polynucleotide molecules (e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules. Calculation of the percent identity of two polynucleic acid sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two nucleic acid sequences can be determined using methods such as those described in Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; each of which is incorporated herein by reference. For example, the percent identity between two nucleic acid sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4:11-17), which has been incorporated into the ALIGN program (version 2.0) using a PAM 120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent identity between two nucleic acid sequences can, alternatively, be determined using the GAP program in the GCG software package using an NWSgapdna.CMP matrix. Methods commonly employed to determine percent identity between sequences include, but are not limited to those disclosed in Carillo, H., and Lipman, D., SIAM J Applied Math., 48:1073 (1988); incorporated herein by reference. Techniques for determining identity are codified in publicly available computer programs. Exemplary computer software to determine homology between two sequences include, but are not limited to, GCG program package, Devereux, J., et al., Nucleic Acids Research, 12(1), 387 (1984)), BLASTP, BLASTN, and FASTA Altschul, S. F. et al., J. Molec. Biol., 215, 403 (1990)).

### Multiprotein and Multicomponent Vaccines

[0311] The present disclosure encompasses respiratory virus vaccines comprising multiple RNA (e.g., mRNA) polynucleotides, each encoding a single antigenic polypeptide, as well as respiratory virus vaccines comprising a single RNA polynucleotide encoding more than one antigenic polypeptide (e.g., as a fusion polypeptide). Thus, a vaccine composition comprising a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a first antigenic polypeptide and a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a second antigenic polypeptide encompasses (a) vaccines that comprise a first RNA polynucleotide encoding a first antigenic polypeptide and a second RNA polynucleotide encoding a second antigenic polypeptide, and (b) vaccines that comprise a single RNA polynucleotide encoding a first and second antigenic polypeptide (e.g., as a fusion polypeptide). RNA (e.g., mRNA) vaccines of the present disclosure, in some embodiments, comprise 2-10 (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or 10), or more, RNA polynucleotides having an open reading frame, each of which encodes a different antigenic polypeptide (or a single RNA polynucleotide encoding 2-10, or more, different antigenic polypeptides). The antigenic polypeptides may be selected from hMPV, PIV3, RSV, MEV and BetaCoV (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1) antigenic polypeptides.

[0312] In some embodiments, a respiratory virus vaccine comprises a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a viral capsid protein, a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a viral premembrane/membrane protein, and a RNA (e.g., mRNA) polynucleotide

having an open reading frame encoding a viral envelope protein. In some embodiments, a respiratory virus vaccine comprises a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a viral fusion (F) protein and a RNA polynucleotide having an open reading frame encoding a viral major surface glycoprotein (G protein). In some embodiments, a vaccine comprises a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a viral F protein. In some embodiments, a vaccine comprises a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a viral G protein. In some embodiments, a vaccine comprises a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HN protein.

[0313] In some embodiments, a multicomponent vaccine comprises at least one RNA (e.g., mRNA) polynucleotide encoding at least one antigenic polypeptide fused to a signal peptide (e.g., any one of SEQ ID NO: 15-19). The signal peptide may be fused at the N-terminus or the C-terminus of an antigenic polypeptide. An antigenic polypeptide fused to a signal peptide may be selected from hMPV, PIV3, RSV, MEV and BetaCoV (e.g., selected from MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and HCoV-HKU1) antigenic polypeptides.

### Signal Peptides

[0314] In some embodiments, antigenic polypeptides encoded by respiratory virus RNA (e.g., mRNA) polynucleotides comprise a signal peptide. Signal peptides, comprising the N-terminal 15-60 amino acids of proteins, are typically needed for the translocation across the membrane on the secretory pathway and, thus, universally control the entry of most proteins both in eukaryotes and prokaryotes to the secretory pathway. Signal peptides generally include three regions: an N-terminal region of differing length, which usually comprises positively charged amino acids; a hydrophobic region; and a short carboxy-terminal peptide region. In eukaryotes, the signal peptide of a nascent precursor protein (pre-protein) directs the ribosome to the rough endoplasmic reticulum (ER) membrane and initiates the transport of the growing peptide chain across it for processing. ER processing produces mature proteins, wherein the signal peptide is cleaved from precursor proteins, typically by a ER-resident signal peptidase of the host cell, or they remain uncleaved and function as a membrane anchor. A signal peptide may also facilitate the targeting of the protein to the cell membrane. The signal peptide, however, is not responsible for the final destination of the mature protein. Secretory proteins devoid of additional address tags in their sequence are by default secreted to the external environment. During recent years, a more advanced view of signal peptides has evolved, showing that the functions and immunodominance of certain signal peptides are much more versatile than previously anticipated.

[0315] Respiratory virus vaccines of the present disclosure may comprise, for example, RNA (e.g., mRNA) polynucleotides encoding an artificial signal peptide, wherein the signal peptide coding sequence is operably linked to and is in frame with the coding sequence of the antigenic polypeptide. Thus, respiratory virus vaccines of the present disclosure, in some embodiments, produce an antigenic polypeptide comprising an antigenic polypeptide (e.g., hMPV, PIV3, RSV, MeV or BetaCoV) fused to a signal peptide. In some embodiments, a signal peptide is fused to the N-terminus of the antigenic polypeptide. In some embodiments, a signal peptide is fused to the C-terminus of the antigenic polypeptide.

[0316] In some embodiments, the signal peptide fused to the antigenic polypeptide is an artificial signal peptide. In some embodiments, an artificial signal peptide fused to the antigenic polypeptide encoded by the RNA (e.g., mRNA) vaccine is obtained from an immunoglobulin protein, e.g., an IgE signal peptide or an IgG signal peptide. In some embodiments, a signal peptide fused to the antigenic polypeptide encoded by a RNA (e.g., mRNA) vaccine is an Ig heavy chain epsilon-1 signal peptide (IgE HC SP) having the sequence of: MDWTWILFLVAAATRVHS (SEQ ID NO: 16). In some embodiments, a signal peptide fused to the antigenic polypeptide encoded by the (e.g., mRNA) RNA (e.g., mRNA) vaccine is an IgGk chain V-III region HAH signal peptide (IgGk SP) having the sequence of METPAQLLFLLLLWLPDTTG (SEQ ID NO: 15). In some embodiments, the signal peptide is selected from: Japanese encephalitis PRM signal sequence (MLGSNSGQRVVF TILLLLVAPAYS; SEQ ID NO: 17), VSVg protein signal sequence (MKCLLYLAFLFIGVNCA; SEQ ID NO: 18) and Japanese encephalitis JEV signal sequence (MWLVSLAIVTACAGA; SEQ ID NO: 19).

[0317] In some embodiments, the antigenic polypeptide encoded by a RNA (e.g., mRNA) vaccine comprises an amino acid sequence identified by any one of SEQ ID NO: 5-8, 12-13, 24-34, 47-50 or 54-56 (Tables 3, 6, 11, 14 or 17; see also amino acid sequences of Tables 4, 7, 12 or 15) fused to a signal peptide identified by any one of SEQ ID NO: 15-19 (Table 8). The examples disclosed herein are not meant to be limiting and any signal peptide that is known in the art to facilitate targeting of a protein to ER for processing and/or targeting of a protein to the cell membrane may be used in accordance with the present disclosure.

[0318] A signal peptide may have a length of 15-60 amino acids. For example, a signal peptide may have a length of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 amino acids. In some embodiments, a signal peptide has a length of 20-60, 25-60, 30-60, 35-60, 40-60, 45-60, 50-60, 55-60, 15-55, 20-55, 25-55, 30-55, 35-55, 40-55, 45-55, 50-55, 15-50, 20-50, 25-50, 30-50, 35-50, 40-50, 45-50, 15-45, 20-45, 25-45, 30-45, 35-45, 40-45, 15-40, 20-40, 25-40, 30-40, 35-40, 15-35, 20-35, 25-35, 30-35, 15-30, 20-30, 25-30, 15-25, 20-25, or 15-20 amino acids.

[0319] A signal peptide is typically cleaved from the nascent polypeptide at the cleavage junction during ER processing. The mature antigenic polypeptide produced by a respiratory virus RNA (e.g., mRNA) vaccine of the present disclosure typically does not comprise a signal peptide.

### Chemical Modifications

[0320] Respiratory virus vaccines of the present disclosure, in some embodiments, comprise at least RNA (e.g. mRNA) polynucleotide having an open reading frame encoding at least one antigenic polypeptide that comprises at least one chemical modification.

[0321] The terms "chemical modification" and "chemically modified" refer to modification with respect to adenosine (A), guanosine (G), uridine (U), thymidine (T) or cytidine (C) ribonucleosides or deoxyribnucleosides in at least one of their position, pattern, percent or population. Generally, these terms do not refer to the ribonucleotide modifications in naturally occurring 5'-terminal mRNA cap moieties. With respect to a polypeptide, the term "modification" refers to a modification relative to the canonical set 20 amino acids. Polypeptides, as provided herein, are also considered "modified" if they contain amino acid substitutions, insertions or a combination of substitutions and insertions.

[0322] Polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides), in some embodiments, comprise various (more than one) different modifications. In some embodiments, a particular region of a polynucleotide contains one, two or more (optionally different) nucleoside or nucleotide modifications. In some embodiments, a modified RNA polynucleotide (e.g., a modified mRNA polynucleotide), introduced to a cell or organism, exhibits reduced degradation in the cell or organism, respectively, relative to an unmodified polynucleotide. In some embodiments, a modified RNA polynucleotide (e.g., a modified mRNA polynucleotide), introduced into a cell or organism, may exhibit reduced immunogenicity in the cell or organism, respectively (e.g., a reduced innate response).

[0323] Modifications of polynucleotides include, without limitation, those described herein. Polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) may comprise modifications that are naturally-occurring, non-naturally-occurring or the polynucleotide may comprise a combination of naturally-occurring and non-naturally-occurring modifications. Polynucleotides may include any useful modification, for example, of a sugar, a nucleobase, or an internucleoside linkage (e.g., to a linking phosphate, to a phosphodiester linkage or to the phosphodiester backbone).

[0324] Polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides), in some embodiments, comprise non-natural modified nucleotides that are introduced during synthesis or post-synthesis of the polynucleotides to achieve desired functions or properties. The modifications may be present on an internucleotide linkage, purine or pyrimidine bases, or sugars. The modification may be introduced with chemical synthesis or with a polymerase enzyme at the terminal of a chain or anywhere else in the chain. Any of

the regions of a polynucleotide may be chemically modified.

[0325] The present disclosure provides for modified nucleosides and nucleotides of a polynucleotide (e.g., RNA polynucleotides, such as mRNA polynucleotides). A "nucleoside" refers to a compound containing a sugar molecule (e.g., a pentose or ribose) or a derivative thereof in combination with an organic base (e.g., a purine or pyrimidine) or a derivative thereof (also referred to herein as "nucleobase"). A nucleotide" refers to a nucleoside, including a phosphate group. Modified nucleotides may be synthesized by any useful method, such as, for example, chemically, enzymatically, or recombinantly, to include one or more modified or non-natural nucleosides. Polynucleotides may comprise a region or regions of linked nucleosides. Such regions may have variable backbone linkages. The linkages may be standard phosphodiester linkages, in which case the polynucleotides would comprise regions of nucleotides.

[0326] Modified nucleotide base pairing encompasses not only the standard adenosine-thymine, adenosine-uracil, or guanosine-cytosine base pairs, but also base pairs formed between nucleotides and/or modified nucleotides comprising non-standard or modified bases, wherein the arrangement of hydrogen bond donors and hydrogen bond acceptors permits hydrogen bonding between a non-standard base and a standard base or between two complementary non-standard base structures. One example of such non-standard base pairing is the base pairing between the modified nucleotide inosine and adenine, cytosine or uracil. Any combination of base/sugar or linker may be incorporated into polynucleotides of the present disclosure.

[0327] Modifications of polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) that are useful in the vaccines of the present disclosure include, but are not limited to the following: 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine; 2-methylthio-N6-methyladenosine; 2-methylthio-N6-threonyl carbamoyladenosine; N6-glyciny carbamoyladenosine; N6-isopentenyladenosine; N6-methyladenosine; N6-threonyl carbamoyladenosine; 1,2'-O-dimethyladenosine; 1-methyladenosine; 2'-O-methyladenosine; 2'-O-ribosyladenosine (phosphate); 2-methyladenosine; 2-methylthio-N6 isopentenyladenosine; 2-methylthio-N6-hydroxynorvalyl carbamoyladenosine; 2'-O-methyladenosine; 2'-O-ribosyladenosine (phosphate); Isopentenyladenosine; N6-(cis-hydroxyisopentenyl)adenosine; N6,2'-O-dimethyladenosine; N6,2'-O-dimethyladenosine; N6,N6,2'-O-trimethyladenosine; N6,N6-dimethyladenosine; N6-acetyladenosine; N6-hydroxynorvalyl carbamoyladenosine; N6-methyl-N6-threonyl carbamoyladenosine; 2-methyladenosine; 2-methylthio-N6-isopentenyladenosine; 7-deaza-adenosine; N1-methyl-adenosine; N6,N6 (dimethyl)adenine; N6-cis-hydroxy-isopentenyl-adenosine; .alpha.-thio-adenosine; 2 (amino)adenine; 2 (aminopropyl)adenine; 2 (methylthio) N6 (isopentenyl)adenine; 2-(alkyl)adenine; 2-(aminoalkyl)adenine; 2-(aminopropyl)adenine; 2-(halo)adenine; 2-(halo)adenine; 2-(propyl)adenine; 2'-Amino-2'-deoxy-ATP; 2'-Azido-2'-deoxy-ATP; 2'-Deoxy-2'-a-aminoadenosine TP; 2'-Deoxy-2'-a-azidoadenosine TP; 6 (alkyl)adenine; 6 (methyl)adenine; 6-(alkyl)adenine; 6-(methyl)adenine; 7 (deaza)adenine; 8 (alkenyl)adenine; 8 (alkynyl)adenine; 8 (amino)adenine; 8 (thioalkyl)adenine; 8-(alkenyl)adenine; 8-(alkyl)adenine; 8-(alkynyl)adenine; 8-(amino)adenine; 8-(halo)adenine; 8-(hydroxyl)adenine; 8-(thioalkyl)adenine; 8-(thiol)adenine; 8-azido-adenosine; aza adenine; deaza adenine; N6 (methyl)adenine; N6-(isopentyl)adenine; 7-deaza-8-aza-adenosine; 7-methyladenine; 1-Deazaadenosine TP; 2'Fluoro-N6-Bz-deoxyadenosine TP; 2'-OMe-2-Amino-ATP; 2'O-methyl-N6-Bz-deoxyadenosine TP; 2'-a-Ethynyladenosine TP; 2-aminoadenine; 2-Aminoadenosine TP; 2-Amino-ATP; 2'-a-Trifluoromethyladenosine TP; 2-Azidoadenosine TP; 2'-b-Ethynyladenosine TP; 2-Bromoadenosine TP; 2'-b-Trifluoromethyladenosine TP; 2-Chloroadenosine TP; 2'-Deoxy-2',2'-difluoroadenosine TP; 2'-Deoxy-2'-a-mercaptoadenosine TP; 2'-Deoxy-2'-a-thiomethoxyadenosine TP; 2'-Deoxy-2'-b-aminoadenosine TP; 2'-Deoxy-2'-b-azidoadenosine TP; 2'-Deoxy-2'-b-bromoadenosine TP; 2'-Deoxy-2'-b-chloroadenosine TP; 2'-Deoxy-2'-b-fluoroadenosine TP; 2'-Deoxy-2'-b-iodoadenosine TP; 2'-Deoxy-2'-b-mercaptoadenosine TP; 2'-Deoxy-2'-b-thiomethoxyadenosine TP; 2-Fluoroadenosine TP; 2-Iodoadenosine TP; 2-Mercaptoadenosine TP; 2-methoxyadenine; 2-methylthio-adenine; 2-Trifluoromethyladenosine TP; 3-Deaza-3-bromoadenosine TP; 3-Deaza-3-chloroadenosine TP; 3-Deaza-3-fluoroadenosine TP; 3-Deaza-3-iodoadenosine TP; 3-Deazaadenosine TP; 4'-Azidoadenosine TP; 4'-Carbocyclic adenosine TP; 4'-Ethynyladenosine TP; 5'-Homo-adenosine TP; 8-Aza-ATP; 8-bromo-adenosine TP; 8-Trifluoromethyladenosine TP; 9-Deazaadenosine TP; 2-aminopurine; 7-deaza-2,6-diaminopurine; 7-deaza-8-aza-2,6-diaminopurine; 7-deaza-8-aza-2-aminopurine; 2,6-diaminopurine; 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine; 2-thiocytidine; 3-methylcytidine; 5-formylcytidine; 5-hydroxymethylcytidine; 5-methylcytidine; N4-acetylcytidine; 2'-O-methylcytidine; 2'-O-methylcytidine; 5,2'-O-

dimethylcytidine; 5-formyl-2'-O-methylcytidine; Lysidine; N4,2'-O-dimethylcytidine; N4-acetyl-2'-O-methylcytidine; N4-methylcytidine; N4,N4-Dimethyl-2'-OMe-Cytidine TP; 4-methylcytidine; 5-aza-cytidine; Pseudo-iso-cytidine; pyrrolo-cytidine; alpha.-thio-cytidine; 2-(thio)cytosine; 2'-Amino-2'-deoxy-CTP; 2'-Azido-2'-deoxy-CTP; 2'-Deoxy-2'-a-aminocytidine TP; 2'-Deoxy-2'-a-azidocytidine TP; 3 (deaza) 5 (aza)cytosine; 3 (methyl)cytosine; 3-(alkyl)cytosine; 3-(deaza) 5 (aza)cytosine; 3-(methyl)cytidine; 4,2'-O-dimethylcytidine; 5 (halo)cytosine; 5 (methyl)cytosine; 5 (propynyl)cytosine; 5 (trifluoromethyl)cytosine; 5-(alkyl)cytosine; 5-(alkynyl)cytosine; 5-(halo)cytosine; 5-(propynyl)cytosine; 5-(trifluoromethyl)cytosine; 5-bromo-cytidine; 5-iodo-cytidine; 5-propynyl cytosine; 6-(azo)cytosine; 6-aza-cytidine; aza cytosine; deaza cytosine; N4 (acetyl)cytosine; 1-methyl-1-deaza-pseudoisocytidine; 1-methyl-pseudoisocytidine; 2-methoxy-5-methylcytidine; 2-methoxy-cytidine; 2-thio-5-methyl-cytidine; 4-methoxy-1-methyl-pseudoisocytidine; 4-methoxy-pseudoisocytidine; 4-thio-1-methyl-1-deaza-pseudoisocytidine; 4-thio-1-methyl-pseudoisocytidine; 4-thio-pseudoisocytidine; 5-aza-zebularine; 5-methyl-zebularine; pyrrolo-pseudoisocytidine; Zebularine; (E)-5-(2-Bromo-vinyl)cytidine TP; 2,2'-anhydro-cytidine TP hydrochloride; 2'Fluor-N4-Bz-cytidine TP; 2'Fluoro-N4-Acetyl-cytidine TP; 2'-O-Methyl-N4-Acetyl-cytidine TP; 2'O-methyl-N4-Bz-cytidine TP; 2'-a-Ethynylcytidine TP; 2'-a-Trifluoromethylcytidine TP; 2'-b-Ethynylcytidine TP; 2'-b-Trifluoromethylcytidine TP; 2'-Deoxy-2',2'-difluorocytidine TP; 2'-Deoxy-2'-a-mercaptocytidine TP; 2'-Deoxy-2'-a-thiomethoxycytidine TP; 2'-Deoxy-2'-b-aminocytidine TP; 2'-Deoxy-2'-b-azidocytidine TP; 2'-Deoxy-2'-b-bromocytidine TP; 2'-Deoxy-2'-b-chlorocytidine TP; 2'-Deoxy-2'-b-fluorocytidine TP; 2'-Deoxy-2'-b-iodocytidine TP; 2'-Deoxy-2'-b-mercaptocytidine TP; 2'-Deoxy-2'-b-thiomethoxycytidine TP; 2'-O-Methyl-5-(1-propynyl)cytidine TP; 3'-Ethynylcytidine TP; 4'-Azidocytidine TP; 4'-Carbocyclic cytidine TP; 4'-Ethynylcytidine TP; 5-(1-Propynyl)aracytidine TP; 5-(2-Chloro-phenyl)-2-thiocytidine TP; 5-(4-Amino-phenyl)-2-thiocytidine TP; 5-Aminoallyl-CTP; 5-Cyanocytidine TP; 5-Ethynylara-cytidine TP; 5-Ethynylcytidine TP; 5'-Homo-cytidine TP; 5-Methoxycytidine TP; 5-Trifluoromethyl-Cytidine TP; N4-Amino-cytidine TP; N4-Benzoyl-cytidine TP; Pseudoisocytidine; 7-methylguanosine; N2,2'-O-dimethylguanosine; N2-methylguanosine; Wyosine; 1,2'-O-dimethylguanosine; 1-methylguanosine; 2'-O-methylguanosine; 2'-O-ribosylguanosine (phosphate); 2'-O-methylguanosine; 2'-O-ribosylguanosine (phosphate); 7-aminomethyl-7-deazaguanosine; 7-cyano-7-deazaguanosine; Archaeosine; Methylwyosine; N2,7-dimethylguanosine; N2,N2,2'-O-trimethylguanosine; N2,N2,7-trimethylguanosine; N2,N2-dimethylguanosine; N2,7,2'-O-trimethylguanosine; 6-thio-guanosine; 7-deaza-guanosine; 8-oxo-guanosine; N1-methyl-guanosine; a-thio-guanosine; 2 (propyl)guanane; 2-(alkyl)guanane; 2'-Amino-2'-deoxy-GTP; 2'-Azido-2'-deoxy-GTP; 2'-Deoxy-2'-a-aminoguanosine TP; 2'-Deoxy-2'-a-azidoguanosine TP; 6 (methyl)guanane; 6-(alkyl)guanane; 6-(methyl)guanane; 6-methyl-guanosine; 7 (alkyl)guanane; 7 (deaza)guanane; 7 (methyl)guanane; 7-(alkyl)guanane; 7-(deaza)guanane; 7-(methyl)guanane; 8 (alkyl)guanane; 8 (alkynyl)guanane; 8 (halo)guanane; 8 (thioalkyl)guanane; 8-(alkenyl)guanane; 8-(alkyl)guanane; 8-(alkynyl)guanane; 8-(amino)guanane; 8-(halo)guanane; 8-(hydroxyl)guanane; 8-(thioalkyl)guanane; 8-(thiol)guanane; aza guanane; deaza guanane; N (methyl)guanane; N-(methyl)guanane; 1-methyl-6-thio-guanosine; 6-methoxy-guanosine; 6-thio-7-deaza-8-aza-guanosine; 6-thio-7-deaza-guanosine; 6-thio-7-methyl-guanosine; 7-deaza-8-aza-guanosine; 7-methyl-8-oxo-guanosine; N2,N2-dimethyl-6-thio-guanosine; N2-methyl-6-thio-guanosine; 1-Me-GTP; 2'Fluoro-N2-isobutyl-guanosine TP; 2'O-methyl-N2-isobutyl-guanosine TP; 2'-a-Ethynylguanosine TP; 2'-a-Trifluoromethylguanosine TP; 2'-b-Ethynylguanosine TP; 2'-b-Trifluoromethylguanosine TP; 2'-Deoxy-2',2'-difluoroguanosine TP; 2'-Deoxy-2'-a-mercaptoguanosine TP; 2'-Deoxy-2'-a-thiomethoxyguanosine TP; 2'-Deoxy-2'-b-aminoguanosine TP; 2'-Deoxy-2'-b-azidoguanosine TP; 2'-Deoxy-2'-b-bromoguanosine TP; 2'-Deoxy-2'-b-chloroguanosine TP; 2'-Deoxy-2'-b-fluoroguanosine TP; 2'-Deoxy-2'-b-iodoguanosine TP; 2'-Deoxy-2'-b-mercaptoguanosine TP; 2'-Deoxy-2'-b-thiomethoxyguanosine TP; 4'-Azidoguanosine TP; 4'-Carbocyclic guanosine TP; 4'-Ethynylguanosine TP; 5'-Homo-guanosine TP; 8-bromo-guanosine TP; 9-Deazaguanosine TP; N2-isobutyl-guanosine TP; 1-methylinosine; Inosine; 1,2'-O-dimethylinosine; 2'-O-methylinosine; 7-methylinosine; 2'-O-methylinosine; Epoxyqueuosine; galactosyl-queuosine; Mannosylqueuosine; Queuosine; allyl-amino-thymidine; aza thymidine; deaza thymidine; deoxy-thymidine; 2'-O-methyluridine; 2-thiouridine; 3-methyluridine; 5-carboxymethyluridine; 5-hydroxyuridine; 5-methyluridine; 5-taurinomethyl-2-thiouridine; 5-taurinomethyluridine; Dihydrouridine; Pseudouridine; (3-(3-amino-3-carboxypropyl)uridine; 1-methyl-3-(3-amino-5-carboxypropyl)pseudouridine; 1-methylpseudouridine; 1-methyl-pseudouridine; 2'-O-methyluridine; 2'-O-methylpseudouridine; 2'-O-methyluridine; 2-thio-2'-O-methyluridine; 3-(3-amino-3-carboxypropyl)uridine; 3,2'-O-dimethyluridine; 3-Methyl-pseudo-Uridine TP; 4-thiouridine; 5-(carboxyhydroxymethyl)uridine; 5-(carboxyhydroxymethyl)uridine methyl ester; 5,2'-O-dimethyluridine; 5,6-dihydro-uridine; 5-aminomethyl-2-thiouridine; 5-carbamoylmethyl-2'-O-methyluridine; 5-

carbamoylmethyluridine; 5-carboxyhydroxymethyluridine; 5-carboxyhydroxymethyluridine methyl ester; 5-carboxymethylaminomethyl-2'-O-methyluridine; 5-carboxymethylaminomethyl-2-thiouridine; 5-carboxymethylaminomethyl-2-thiouridine; 5-carboxymethylaminomethyluridine; 5-carboxymethylaminomethyluridine; 5-Carbamoylmethyluridine TP; 5-methoxycarbonylmethyl-2'-O-methyluridine; 5-methoxycarbonylmethyl-2-thiouridine; 5-methoxycarbonylmethyluridine; 5-methoxyuridine; 5-methyl-2-thiouridine; 5-methylaminomethyl-2-selenouridine; 5-methylaminomethyl-2-thiouridine; 5-methylaminomethyluridine; 5-Methyldihydrouridine; 5-Oxyacetic acid-Uridine TP; 5-Oxyacetic acid-methyl ester-Uridine TP; N1-methyl-pseudo-uridine; uridine 5-oxyacetic acid; uridine 5-oxyacetic acid methyl ester; 3-(3-Amino-3-carboxypropyl)-Uridine TP; 5-(iso-Pentenylaminomethyl)-2-thiouridine TP; 5-(iso-Pentenylaminomethyl)-2'-O-methyluridine TP; 5-(iso-Pentenylaminomethyl)uridine TP; 5-propynyl uracil; .alpha.-thio-uridine; 1 (aminoalkylamino-carbonylethylenyl)-2(thio)-pseudouracil; 1 (aminoalkylaminocarbonylethylenyl)-2,4-(dithio)pseudouracil; 1 (aminoalkylaminocarbonylethylenyl)-4 (thio)pseudouracil; 1 (aminoalkylaminocarbonylethylenyl)-pseudouracil; 1 (aminocarbonylethylenyl)-2(thio)-pseudouracil; 1 (aminocarbonylethylenyl)-2,4-(dithio)pseudouracil; 1 (aminocarbonylethylenyl)-4 (thio)pseudouracil; 1 (aminocarbonylethylenyl)-pseudouracil; 1 substituted 2(thio)-pseudouracil; 1 substituted 2,4-(dithio)pseudouracil; 1 substituted 4 (thio)pseudouracil; 1 substituted pseudouracil; 1-(aminoalkylamino-carbonylethylenyl)-2-(thio)-pseudouracil; 1-Methyl-3-(3-amino-3-carboxypropyl) pseudouridine TP; 1-Methyl-3-(3-amino-3-carboxypropyl)pseudo-UTP; 1-Methyl-pseudo-UTP; 2 (thio)pseudouracil; 2' deoxy uridine; 2' fluorouridine; 2-(thio)uracil; 2,4-(dithio)pseudouracil; 2' methyl, 2' amino, 2' azido, 2' fluoro-guanosine; 2'-Amino-2'-deoxy-UTP; 2'-Azido-2'-deoxy-UTP; 2'-Azido-deoxyuridine TP; 2'-O-methylpseudouridine; 2' deoxy uridine; 2' fluorouridine; 2'-Deoxy-2'-a-aminouridine TP; 2'-Deoxy-2'-a-azidouridine TP; 2-methylpseudouridine; 3 (3 amino-3 carboxypropyl)uracil; 4 (thio)pseudouracil; 4-(thio)pseudouracil; 4-(thio)uracil; 4-thiouracil; 5 (1,3-diazole-1-alkyl)uracil; 5 (2-aminopropyl)uracil; 5 (aminoalkyl)uracil; 5 (dimethylaminoalkyl)uracil; 5 (guanidiniumalkyl)uracil; 5 (methoxycarbonylmethyl)-2-(thio)uracil; 5 (methoxycarbonyl-methyl)uracil; 5 (methyl) 2 (thio)uracil; 5 (methyl) 2,4 (dithio)uracil; 5 (methyl) 4 (thio)uracil; 5 (methylaminomethyl)-2 (thio)uracil; 5 (methylaminomethyl)-2,4 (dithio)uracil; 5 (methylaminomethyl)-4 (thio)uracil; 5 (propynyl)uracil; 5 (trifluoromethyl)uracil; 5-(2-aminopropyl)uracil; 5-(alkyl)-2-(thio)pseudouracil; 5-(alkyl)-2,4 (dithio)pseudouracil; 5-(alkyl)-4 (thio)pseudouracil; 5-(alkyl)pseudouracil; 5-(alkyl)uracil; 5-(alkynyl)uracil; 5-(allylamino)uracil; 5-(cyanoalkyl)uracil; 5-(dialkylaminoalkyl)uracil; 5-(dimethylaminoalkyl)uracil; 5-(guanidiniumalkyl)uracil; 5-(halo)uracil; 5-(1,3-diazole-1-alkyl)uracil; 5-(methoxy)uracil; 5-(methoxycarbonylmethyl)-2-(thio)uracil; 5-(methoxycarbonyl-methyl)uracil; 5-(methyl) 2(thio)uracil; 5-(methyl) 2,4 (dithio)uracil; 5-(methyl) 4 (thio)uracil; 5-(methyl)-2-(thio)pseudouracil; 5-(methyl)-2,4 (dithio)pseudouracil; 5-(methyl)-4 (thio)pseudouracil; 5-(methyl)pseudouracil; 5-(methylaminomethyl)-2 (thio)uracil; 5-(methylaminomethyl)-2,4(dithio)uracil; 5-(methylaminomethyl)-4 (thio)uracil; 5-(propynyl)uracil; 5-(trifluoromethyl)uracil; 5-aminoallyl-uridine; 5-bromo-uridine; 5-iodo-uridine; 5-uracil; 6 (azo)uracil; 6-(azo)uracil; 6-aza-uridine; allylamino-uracil; aza uracil; deaza uracil; N3 (methyl)uracil; Pseudo-UTP-1-2-ethanoic acid; Pseudouracil; 4-Thio-pseudo-UTP; 1-carboxymethyl-pseudouridine; 1-methyl-1-deaza-pseudouridine; 1-propynyl-uridine; 1-taurinomethyl-1-methyl-uridine; 1-taurinomethyl-4-thio-uridine; 1-taurinomethyl-pseudouridine; 2-methoxy-4-thio-pseudouridine; 2-thio-1-methyl-1-deaza-pseudouridine; 2-thio-1-methyl-pseudouridine; 2-thio-5-aza-uridine; 2-thio-dihydropseudouridine; 2-thio-dihydrouridine; 2-thio-pseudouridine; 4-methoxy-2-thio-pseudouridine; 4-methoxy-pseudouridine; 4-thio-1-methyl-pseudouridine; 4-thio-pseudouridine; 5-aza-uridine; Dihydropseudouridine; (.+.) 1-(2-Hydroxypropyl)pseudouridine TP; (2R)-1-(2-Hydroxypropyl)pseudouridine TP; (2S)-1-(2-Hydroxypropyl)pseudouridine TP; (E)-5-(2-Bromo-vinyl)ara-uridine TP; (E)-5-(2-Bromo-vinyl)uridine TP; (Z)-5-(2-Bromo-vinyl)ara-uridine TP; (Z)-5-(2-Bromo-vinyl)uridine TP; 1-(2,2,2-Trifluoroethyl)-pseudo-UTP; 1-(2,2,3,3,3-Pentafluoropropyl)pseudouridine TP; 1-(2,2-Diethoxyethyl)pseudouridine TP; 1-(2,4,6-Trimethylbenzyl)pseudouridine TP; 1-(2,4,6-Trimethyl-benzyl)pseudo-UTP; 1-(2,4,6-Trimethyl-phenyl)pseudo-UTP; 1-(2-Amino-2-carboxyethyl)pseudo-UTP; 1-(2-Amino-ethyl)pseudo-UTP; 1-(2-Hydroxyethyl)pseudouridine TP; 1-(2-Methoxyethyl)pseudouridine TP; 1-(3,4-Bis-trifluoromethoxybenzyl)pseudouridine TP; 1-(3,4-Dimethoxybenzyl)pseudouridine TP; 1-(3-Amino-3-carboxypropyl)pseudo-UTP; 1-(3-Amino-propyl)pseudo-UTP; 1-(3-Cyclopropyl-prop-2-ynyl)pseudouridine TP; 1-(4-Amino-4-carboxybutyl)pseudo-UTP; 1-(4-Amino-benzyl)pseudo-UTP; 1-(4-Amino-butyl)pseudo-UTP; 1-(4-Amino-phenyl)pseudo-UTP; 1-(4-Azidobenzyl)pseudouridine TP; 1-(4-Bromobenzyl)pseudouridine TP; 1-(4-Chlorobenzyl)pseudouridine TP; 1-(4-Fluorobenzyl)pseudouridine TP; 1-(4-Iodobenzyl)pseudouridine TP; 1-



(4-Methanesulfonylbenzyl)pseudouridine TP; 1-(4-Methoxybenzyl)pseudouridine TP; 1-(4-Methoxybenzyl)pseudo-UTP; 1-(4-Methoxy-phenyl)pseudo-UTP; 1-(4-Methylbenzyl)pseudouridine TP; 1-(4-Methylbenzyl)pseudo-UTP; 1-(4-Nitrobenzyl)pseudouridine TP; 1-(4-Nitro-benzyl)pseudo-UTP; 1-(4-Nitrophenyl)pseudo-UTP; 1-(4-Thiomethoxybenzyl)pseudouridine TP; 1-(4-Trifluoromethoxybenzyl)pseudouridine TP; 1-(4-Trifluoromethylbenzyl)pseudouridine TP; 1-(5-Amino-pentyl)pseudo-UTP; 1-(6-Amino-hexyl)pseudo-UTP; 1,6-Dimethyl-pseudo-UTP; 1-[3-(2-{2-[2-(2-Aminoethoxy)-ethoxy]-ethoxy}-ethoxy)-propionyl]pseudouridine TP; 1-{3-[2-(2-Aminoethoxy)-ethoxy]-propionyl} pseudouridine TP; 1-Acetylpsudouridine TP; 1-Alkyl-6-(1-propynyl)-pseudo-UTP; 1-Alkyl-6-(2-propynyl)-pseudo-UTP; 1-Alkyl-6-allyl-pseudo-UTP;

1-Alkyl-6-ethynyl-pseudo-UTP; 1-Alkyl-6-homoallyl-pseudo-UTP; 1-Alkyl-6-vinyl-pseudo-UTP; 1-Allylpsudouridine TP; 1-Aminomethyl-pseudo-UTP; 1-Benzoylpsudouridine TP; 1-Benzylpsudouridine TP; 1-Benzylloxymethylpsudouridine TP; 1-Benzyl-pseudo-UTP; 1-Biotinyl-PEG2-pseudouridine TP; 1-Biotinylpsudouridine TP; 1-Butyl-pseudo-UTP; 1-Cyanomethylpsudouridine TP; 1-Cyclobutylmethyl-pseudo-UTP; 1-Cyclobutyl-pseudo-UTP; 1-Cycloheptylmethyl-pseudo-UTP; 1-Cycloheptyl-pseudo-UTP; 1-Cyclohexylmethyl-pseudo-UTP; 1-Cyclohexyl-pseudo-UTP; 1-Cyclooctylmethyl-pseudo-UTP; 1-Cyclooctyl-pseudo-UTP; 1-Cyclopentylmethyl-pseudo-UTP; 1-Cyclopentyl-pseudo-UTP; 1-Cyclopropylmethyl-pseudo-UTP; 1-Cyclopropyl-pseudo-UTP; 1-Ethyl-pseudo-UTP; 1-Hexyl-pseudo-UTP; 1-Homoallylpsudouridine TP; 1-Hydroxymethylpsudouridine TP; 1-iso-propyl-pseudo-UTP; 1-Me-2-thio-pseudo-UTP; 1-Me-4-thio-pseudo-UTP; 1-Me-alpha-thio-pseudo-UTP; 1-Methanesulfonylmethylpsudouridine TP; 1-Methoxymethylpsudouridine TP; 1-Methyl-6-(2,2,2-Trifluoroethyl)pseudo-UTP; 1-Methyl-6-(4-morpholino)-pseudo-UTP; 1-Methyl-6-(4-thiomorpholino)-pseudo-UTP; 1-Methyl-6-(substituted phenyl)pseudo-UTP; 1-Methyl-6-amino-pseudo-UTP; 1-Methyl-6-azido-pseudo-UTP; 1-Methyl-6-bromo-pseudo-UTP; 1-Methyl-6-butyl-pseudo-UTP; 1-Methyl-6-chloro-pseudo-UTP; 1-Methyl-6-cyano-pseudo-UTP; 1-Methyl-6-dimethylamino-pseudo-UTP; 1-Methyl-6-ethoxy-pseudo-UTP; 1-Methyl-6-ethylcarboxylate-pseudo-UTP; 1-Methyl-6-ethyl-pseudo-UTP; 1-Methyl-6-fluoro-pseudo-UTP; 1-Methyl-6-formyl-pseudo-UTP; 1-Methyl-6-hydroxyamino-pseudo-UTP; 1-Methyl-6-hydroxy-pseudo-UTP; 1-Methyl-6-iodo-pseudo-UTP; 1-Methyl-6-iso-propyl-pseudo-UTP; 1-Methyl-6-methoxy-pseudo-UTP; 1-Methyl-6-methylamino-pseudo-UTP; 1-Methyl-6-phenyl-pseudo-UTP; 1-Methyl-6-propyl-pseudo-UTP; 1-Methyl-6-tert-butyl-pseudo-UTP; 1-Methyl-6-trifluoromethoxy-pseudo-UTP; 1-Methyl-6-trifluoromethyl-pseudo-UTP; 1-Morpholinomethylpsudouridine TP; 1-Pentyl-pseudo-UTP; 1-Phenyl-pseudo-UTP; 1-Pivaloylpsudouridine TP; 1-Propargylpsudouridine TP; 1-Propyl-pseudo-UTP; 1-propynyl-pseudouridine; 1-p-tolyl-pseudo-UTP; 1-tert-Butyl-pseudo-UTP; 1-Thiomethoxymethylpsudouridine TP; 1-Thiomorpholinomethylpsudouridine TP; 1-Trifluoroacetylpsudouridine TP; 1-Trifluoromethyl-pseudo-UTP; 1-Vinylpsudouridine TP; 2,2'-anhydro-uridine TP; 2'-bromo-deoxyuridine TP; 2'-F-5-Methyl-2'-deoxy-UTP; 2'-OMe-5-Me-UTP; 2'-OMe-pseudo-UTP; 2'-a-Ethynyluridine TP; 2'-a-Trifluoromethyluridine TP; 2'-b-Ethynyluridine TP; 2'-b-Trifluoromethyluridine TP; 2'-Deoxy-2',2'-difluorouridine TP; 2'-Deoxy-2'-a-mercaptopuridine TP; 2'-Deoxy-2'-a-thiomethoxyuridine TP; 2'-Deoxy-2'-b-aminouridine TP; 2'-Deoxy-2'-b-azidouridine TP; 2'-Deoxy-2'-b-bromouridine TP; 2'-Deoxy-2'-b-chlorouridine TP; 2'-Deoxy-2'-b-fluorouridine TP; 2'-Deoxy-2'-b-iodouridine TP; 2'-Deoxy-2'-b-mercaptopuridine TP; 2'-Deoxy-2'-b-thiomethoxyuridine TP; 2-methoxy-4-thio-uridine; 2-methoxyuridine; 2'-O-Methyl-5-(1-propynyl)uridine TP; 3-Alkyl-pseudo-UTP; 4'-Azidouridine TP; 4'-Carbocyclic uridine TP; 4'-Ethynyluridine TP; 5-(1-Propynyl)ara-uridine TP; 5-(2-Furanyl)uridine TP; 5-Cyanouridine TP; 5-Dimethylaminouridine TP; 5'-Homo-uridine TP; 5-iodo-2'-fluoro-deoxyuridine TP; 5-Phenylethynyluridine TP; 5-Trideuteromethyl-6-deuterouridine TP; 5-Trifluoromethyl-Uridine TP; 5-Vinylarauridine TP; 6-(2,2,2-Trifluoroethyl)-pseudo-UTP; 6-(4-Morpholino)-pseudo-UTP; 6-(4-Thiomorpholino)-pseudo-UTP; 6-(Substituted-Phenyl)-pseudo-UTP; 6-Amino-pseudo-UTP; 6-Azido-pseudo-UTP; 6-Bromo-pseudo-UTP; 6-Butyl-pseudo-UTP; 6-Chloro-pseudo-UTP; 6-Cyano-pseudo-UTP; 6-Dimethylamino-pseudo-UTP; 6-Ethoxy-pseudo-UTP; 6-Ethylcarboxylate-pseudo-UTP; 6-Ethyl-pseudo-UTP; 6-Fluoro-pseudo-UTP; 6-Formyl-pseudo-UTP; 6-Hydroxyamino-pseudo-UTP; 6-Hydroxy-pseudo-UTP; 6-Iodo-pseudo-UTP; 6-iso-Propyl-pseudo-UTP; 6-Methoxy-pseudo-UTP; 6-Methylamino-pseudo-UTP; 6-Methyl-pseudo-UTP; 6-Phenyl-pseudo-UTP; 6-Phenyl-pseudo-UTP; 6-Propyl-pseudo-UTP; 6-tert-Butyl-pseudo-UTP; 6-Trifluoromethoxy-pseudo-UTP; 6-Trifluoromethyl-pseudo-UTP; Alpha-thio-pseudo-UTP; Pseudouridine 1-(4-methylbenzenesulfonic acid) TP; Pseudouridine 1-(4-methylbenzoic acid) TP; Pseudouridine TP 1-[3-(2-ethoxy)]propionic acid; Pseudouridine TP 1-[3-{2-(2-[2-(2-ethoxy)-ethoxy]-ethoxy)-ethoxy}]propionic acid; Pseudouridine TP 1-[3-{2-(2-[2-(2-

ethoxy)-ethoxy}-ethoxy]-ethoxy)-ethoxy}]propionic acid; Pseudouridine TP 1-[3-{2-(2-[2-ethoxy]-ethoxy)-ethoxy}]propionic acid; Pseudouridine TP 1-[3-{2-(2-ethoxy)-ethoxy}] propionic acid; Pseudouridine TP 1-methylphosphonic acid; Pseudouridine TP 1-methylphosphonic acid diethyl ester; Pseudo-UTP-N1-3-propionic acid; Pseudo-UTP-N1-4-butanoic acid; Pseudo-UTP-N1-5-pentanoic acid; Pseudo-UTP-N1-6-hexanoic acid; Pseudo-UTP-N1-7-heptanoic acid; Pseudo-UTP-N1-methyl-p-benzoic acid; Pseudo-UTP-N1-p-benzoic acid; Wybutosine; Hydroxywybutosine; Isowyosine; Peroxywybutosine; undermodified hydroxywybutosine; 4-demethylwyosine; 2,6-(diamino)purine; 1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 1,3-(diazia)-2-(oxo)-phenthiazin-1-yl; 1,3-(diazia)-2-(oxo)-phenoxazin-1-yl; 1,3,5-(triazia)-2,6-(dioxo)-naphthalene; 2 (amino)purine; 2,4,5-(trimethyl)phenyl; 2' methyl, 2' amino, 2' azido, 2' fluoro-cytidine; 2' methyl, 2' amino, 2' azido, 2' fluoro-adenine; 2' methyl, 2' amino, 2' azido, 2' fluoro-uridine; 2'-amino-2'-deoxyribose; 2-amino-6-Chloro-purine; 2-aza-inosinyl; 2'-azido-2'-deoxyribose; 2'fluoro-2'-deoxyribose; 2'-fluoro-modified bases; 2'-O-methyl-ribose; 2-oxo-7-aminopyridopyrimidin-3-yl; 2-oxo-pyridopyrimidine-3-yl; 2-pyridinone; 3 nitropyrrole; 3-(methyl)-7-(propynyl)isocarbostyryl; 3-(methyl)isocarbostyryl; 4-(fluoro)-6-(methyl)benzimidazole; 4-(methyl)benzimidazole; 4-(methyl)indolyl; 4,6-(dimethyl)indolyl; 5 nitroindole; 5 substituted pyrimidines; 5-(methyl)isocarbostyryl; 5-nitroindole; 6-(aza)pyrimidine; 6-(azo)thymine; 6-(methyl)-7-(aza)indolyl; 6-chloro-purine; 6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; 7-(aminoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenthiazin-1-yl; 7-(aminoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7-(aminoalkylhydroxy)-1,3-(diazia)-2-(oxo)-phenoxazin-1-yl; 7-(aminoalkylhydroxy)-1,3-(diazia)-2-(oxo)-phenoxazin-1-yl; 7-(aza)indolyl; 7-(guanidiniumalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7-(guanidiniumalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenthiazin-1-yl; 7-(guanidiniumalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7-(guanidiniumalkylhydroxy)-1,3-(diazia)-2-(oxo)-phenoxazin-1-yl; 7-(guanidiniumalkylhydroxy)-1,3-(diazia)-2-(oxo)-phenthiazin-1-yl; 7-(guanidiniumalkylhydroxy)-1,3-(diazia)-2-(oxo)-phenoxazin-1-yl; 7-(propynyl)isocarbostyryl; 7-(propynyl)isocarbostyryl, propynyl-7-(aza)indolyl; 7-deaza-inosinyl; 7-substituted 1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7-substituted 1,3-(diazia)-2-(oxo)-phenoxazin-1-yl; 9-(methyl)-imidizopyridinyl; Aminoindolyl; Anthracenyl; bis-ortho-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; bis-ortho-substituted-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; Difluorotolyl; Hypoxanthine; Imidizopyridinyl; Inosinyl; Isocarbostyryl; Isoguanisine; N2-substituted purines; N6-methyl-2-amino-purine; N6-substituted purines; N-alkylated derivative; Naphthalenyl; Nitrobenzimidazolyl; Nitroimidazolyl; Nitroindazolyl; Nitropyrazolyl; Nubularine; O6-substituted purines; O-alkylated derivative; ortho-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; ortho-substituted-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; Oxoformycin TP; para-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; para-substituted-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; Pentacenyl; Phenanthracenyl; Phenyl; propynyl-7-(aza)indolyl; Pyrenyl; pyridopyrimidin-3-yl; pyridopyrimidin-3-yl, 2-oxo-7-amino-pyridopyrimidin-3-yl; pyrrolo-pyrimidin-2-on-3-yl; Pyrrolopyrimidinyl; Pyrrolopyrizinyl; Stilbenzyl; substituted 1,2,4-triazoles; Tetracenyl; Tubercidine; Xanthine; Xanthosine-5'-TP; 2-thio-zebularine; 5-aza-2-thio-zebularine; 7-deaza-2-amino-purine; pyridin-4-one ribonucleoside; 2-Amino-ribose-TP; Formycin A TP; Formycin B TP; Pyrrolosine TP; 2'-OH-ara-adenosine TP; 2'-OH-ara-cytidine TP; 2'-OH-ara-uridine TP; 2'-OH-ara-guanosine TP; 5-(2-carbomethoxyvinyl)uridine TP; and N6-(19-Aminopentaaxanonadecyl)adenosine TP.

[0328] In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) include a combination of at least two (e.g., 2, 3, 4 or more) of the aforementioned modified nucleobases.

[0329] In some embodiments, modified nucleobases in polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) are selected from the group consisting of pseudouridine (.psi.), N1-methylpseudouridine (m.sup.1.psi.), N1-ethylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2'-O-methyl uridine. In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) include a combination of at least two (e.g., 2, 3, 4 or more) of the aforementioned modified nucleobases.

[0330] In some embodiments, modified nucleobases in polynucleotides (e.g., RNA polynucleotides, such as

mRNA polynucleotides) are selected from the group consisting of 1-methyl-pseudouridine (m.sub.1.psi.), 5-methoxy-uridine (mo.sup.5U), 5-methyl-cytidine (m.sup.5C), pseudouridine (.psi.), .alpha.-thio-guanosine and .alpha.-thio-adenosine. In some embodiments, polynucleotides includes a combination of at least two (e.g., 2, 3, 4 or more) of the aforementioned modified nucleobases.

[0331] In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise pseudouridine (.psi.) and 5-methyl-cytidine (m.sup.5C). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 1-methyl-pseudouridine (m.sup.1.psi.). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 1-methyl-pseudouridine (m.sup.1.psi.) and 5-methyl-cytidine (m.sup.5C). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 2-thiouridine (s.sup.2U). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 2-thiouridine and 5-methyl-cytidine (m.sup.5C). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise methoxy-uridine (mo.sup.5U). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 5-methoxy-uridine (mo.sup.5U) and 5-methyl-cytidine (m.sup.5C). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 2'-O-methyl uridine. In some embodiments polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 2'-O-methyl uridine and 5-methyl-cytidine (m.sup.5C). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise N6-methyl-adenosine (m.sup.6A). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise N6-methyl-adenosine (m.sup.6A) and 5-methyl-cytidine (m.sup.5C).

[0332] In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) are uniformly modified (e.g., fully modified, modified throughout the entire sequence) for a particular modification. For example, a polynucleotide can be uniformly modified with 5-methyl-cytidine (m.sup.5C), meaning that all cytosine residues in the mRNA sequence are replaced with 5-methyl-cytidine (m.sup.5C). Similarly, a polynucleotide can be uniformly modified for any type of nucleoside residue present in the sequence by replacement with a modified residue such as those set forth above.

[0333] Exemplary nucleobases and nucleosides having a modified cytosine include N4-acetyl-cytidine (ac4C), 5-methyl-cytidine (m5C), 5-halo-cytidine (e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm5C), 1-methyl-pseudoisocytidine, 2-thio-cytidine (s2C), and 2-thio-5-methyl-cytidine.

[0334] In some embodiments, a modified nucleobase is a modified uridine. Exemplary nucleobases and In some embodiments, a modified nucleobase is a modified cytosine. nucleosides having a modified uridine include 5-cyano uridine, and 4'-thio uridine.

[0335] In some embodiments, a modified nucleobase is a modified adenine. Exemplary nucleobases and nucleosides having a modified adenine include 7-deaza-adenine, 1-methyl-adenosine (m1A), 2-methyl-adenine (m2A), and N6-methyl-adenosine (m6A).

[0336] In some embodiments, a modified nucleobase is a modified guanine. Exemplary nucleobases and nucleosides having a modified guanine include inosine (I), 1-methyl-inosine (m1I), wyosine (imG), methylwyosine (mimG), 7-deaza-guanosine, 7-cyano-7-deaza-guanosine (preQ0), 7-aminomethyl-7-deaza-guanosine (preQ1), 7-methyl-guanosine (m7G), 1-methyl-guanosine (m1G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine.

[0337] The polynucleotides of the present disclosure may be partially or fully modified along the entire length of the molecule. For example, one or more or all or a given type of nucleotide (e.g., purine or pyrimidine, or any one or more or all of A, G, U, C) may be uniformly modified in a polynucleotide of the disclosure, or in a given predetermined sequence region thereof (e.g., in the mRNA including or excluding the polyA tail). In some embodiments, all nucleotides X in a polynucleotide of the present disclosure (or in a given sequence region thereof) are modified nucleotides, wherein X may any one of nucleotides A, G, U, C, or any one of the

combinations A+G, A+U, A+C, G+U, G+C, U+C, A+G+U, A+G+C, G+U+C or A+G+C.

[0338] The polynucleotide may contain from about 1% to about 100% modified nucleotides (either in relation to overall nucleotide content, or in relation to one or more types of nucleotide, i.e., any one or more of A, G, U or C) or any intervening percentage (e.g., from 1% to 20%, from 1% to 25%, from 1% to 50%, from 1% to 60%, from 1% to 70%, from 1% to 80%, from 1% to 90%, from 1% to 95%, from 10% to 20%, from 10% to 25%, from 10% to 50%, from 10% to 60%, from 10% to 70%, from 10% to 80%, from 10% to 90%, from 10% to 95%, from 10% to 100%, from 20% to 25%, from 20% to 50%, from 20% to 60%, from 20% to 70%, from 20% to 80%, from 20% to 90%, from 20% to 95%, from 20% to 100%, from 50% to 60%, from 50% to 70%, from 50% to 80%, from 50% to 90%, from 50% to 95%, from 50% to 100%, from 70% to 80%, from 70% to 90%, from 70% to 95%, from 70% to 100%, from 80% to 90%, from 80% to 95%, from 80% to 100%, from 90% to 95%, from 90% to 100%, and from 95% to 100%). Any remaining percentage is accounted for by the presence of unmodified A, G, U, or C.

[0339] The polynucleotides may contain at a minimum 1% and at maximum 100% modified nucleotides, or any intervening percentage, such as at least 5% modified nucleotides, at least 10% modified nucleotides, at least 25% modified nucleotides, at least 50% modified nucleotides, at least 80% modified nucleotides, or at least 90% modified nucleotides. For example, the polynucleotides may contain a modified pyrimidine such as a modified uracil or cytosine. In some embodiments, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90% or 100% of the uracil in the polynucleotide is replaced with a modified uracil (e.g., a 5-substituted uracil). The modified uracil can be replaced by a compound having a single unique structure, or can be replaced by a plurality of compounds having different structures (e.g., 2, 3, 4 or more unique structures). In some embodiments, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90% or 100% of the cytosine in the polynucleotide is replaced with a modified cytosine (e.g., a 5-substituted cytosine). The modified cytosine can be replaced by a compound having a single unique structure, or can be replaced by a plurality of compounds having different structures (e.g., 2, 3, 4 or more unique structures).

[0340] Thus, in some embodiments, the RNA (e.g., mRNA) vaccines comprise a 5'UTR element, an optionally codon optimized open reading frame, and a 3'UTR element, a poly(A) sequence and/or a polyadenylation signal wherein the RNA is not chemically modified.

[0341] In some embodiments, the modified nucleobase is a modified uracil. Exemplary nucleobases and nucleosides having a modified uracil include pseudouridine (.psi.), pyridin-4-one ribonucleoside, 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine (s.sup.2U), 4-thio-uridine (s.sup.4U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uridine (ho.sup.5U), 5-aminoallyl-uridine, 5-halo-uridine (e.g., 5-iodo-uridine or 5-bromo-uridine), 3-methyl-uridine (m.sup.3U), 5-methoxy-uridine (mo.sup.5U), uridine 5-oxyacetic acid (cmo.sup.5U), uridine 5-oxyacetic acid methyl ester (mcmo.sup.5U), 5-carboxymethyl-uridine (cm.sup.5U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine (chm.sup.5U), 5-carboxyhydroxymethyl-uridine methyl ester (mchm.sup.5U), 5-methoxycarbonylmethyl-uridine (mcm.sup.5U), 5-methoxycarbonylmethyl-2-thio-uridine (mcm.sup.5s2U), 5-aminomethyl-2-thio-uridine (nm.sup.5s2U), 5-methylaminomethyl-uridine (mnm.sup.5U), 5-methylaminomethyl-2-thio-uridine (mnm.sup.5s2U), 5-methylaminomethyl-2-seleno-uridine (mnm.sup.5se.sup.2U), 5-carbamoylmethyl-uridine (ncm.sup.5U), 5-carboxymethylaminomethyl-uridine (cmnm.sup.5U), 5-carboxymethylaminomethyl-2-thio-uridine (cmnm.sup.5s2U), 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyl-uridine (.tau.m.sup.5U), 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine (m.sup.5s2U), 1-taurinomethyl-4-thio-pseudouridine, 5-methyl-uridine (m.sup.5U, i.e., having the nucleobase deoxythymine), 1-methyl-pseudouridine (m.sub.1.psi.), 5-methyl-2-thio-uridine (m5s.sup.2U), 1-methyl-4-thio-pseudouridine (m.sup.1s.sup.4.psi.), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m.sup.3.psi.), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-dihydrouridine, 5-methyldihydrouridine (m.sup.5D), 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine, 3-(3-amino-3-carboxypropyl)uridine (acp.sup.3U), 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp.sup.3.psi.), 5-(isopentenylaminomethyl)uridine (inm.sup.5U), 5-(isopentenylaminomethyl)-2-thio-uridine (inm.sup.5s2U), .alpha.-thio-uridine, 2'-O-methyl-uridine (Um), 5,2'-

O-dimethyl-uridine (m.sup.5Um), 2'-O-methyl-pseudouridine (.psi.m), 2-thio-2'-O-methyl-uridine (s.sup.2Um), 5-methoxycarbonylmethyl-2'-O-methyl-uridine (mcm.sup.5Um), 5-carbamoylmethyl-2'-O-methyl-uridine (ncm.sup.5Um), 5-carboxymethylaminomethyl-2'-O-methyl-uridine (cmnm.sup.5Um), 3,2'-O-dimethyl-uridine (m.sup.3Um), and 5-(isopentenylaminomethyl)-2'-O-methyl-uridine (inm.sup.5Um), 1-thio-uridine, deoxythymidine, 2'-F-ara-uridine, 2'-F-uridine, 2'-OH-ara-uridine, 5-(2-carbomethoxyvinyl) uridine, and 5-[3-(1-E-propenylamino)]uridine.

[0342] In some embodiments, the modified nucleobase is a modified cytosine. Exemplary nucleobases and nucleosides having a modified cytosine include 5-aza-cytidine, 6-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine (m.sup.3C), N4-acetyl-cytidine (ac.sup.4C), 5-formylcytidine (f.sup.5C), N4-methyl-cytidine (m.sup.4C), 5-methyl-cytidine (m.sup.5C), 5-halo-cytidine (e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm.sup.5C), 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine (s.sup.2C), 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, lysidine (k.sub.2C), .alpha.-thio-cytidine, 2'-O-methyl-cytidine (Cm), 5,2'-O-dimethylcytidine (m.sup.5Cm), N4-acetyl-2'-O-methyl-cytidine (ac.sup.4Cm), N4,2'-O-dimethylcytidine (m.sup.4Cm), 5-formyl-2'-O-methyl-cytidine (f.sup.5Cm), N4,N4,2'-O-trimethyl-cytidine (m.sup.4.sub.2Cm), 1-thio-cytidine, 2'-F-ara-cytidine, 2'-F-cytidine, and 2'-OH-ara-cytidine.

[0343] In some embodiments, the modified nucleobase is a modified adenine. Exemplary nucleobases and nucleosides having a modified adenine include 2-amino-purine, 2, 6-diaminopurine, 2-amino-6-halo-purine (e.g., 2-amino-6-chloro-purine), 6-halo-purine (e.g., 6-chloro-purine), 2-amino-6-methyl-purine, 8-azido-adenosine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-amino-purine, 7-deaza-8-aza-2-amino-purine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyl-adenosine (m.sup.1A), 2-methyl-adenine (m.sup.2A), N6-methyl-adenosine (m.sup.6A), 2-methylthio-N6-methyl-adenosine (ms.sup.2m6A), N6-isopentenyl-adenosine (i.sup.6A), 2-methylthio-N6-isopentenyl-adenosine (ms.sup.2i.sup.6A), N6-(cis-hydroxyisopentenyl)adenosine (io.sup.6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine (ms.sup.2io.sup.6A), N6-glycylcarbamoyl-adenosine (g.sup.6A), N6-threonylcarbamoyl-adenosine (t.sup.6A), N6-methyl-N6-threonylcarbamoyl-adenosine (m.sup.6t.sup.6A), 2-methylthio-N6-threonylcarbamoyl-adenosine (ms.sup.2g.sup.6A), N6,N6-dimethyl-adenosine (m.sup.6.sub.2A), N6-hydroxynorvalylcarbamoyl-adenosine (hn.sup.6A), 2-methylthio-N6-hydroxynorvalylcarbamoyl-adenosine (ms.sup.2hn.sup.6A), N6-acetyl-adenosine (ac.sup.6A), 7-methyl-adenine, 2-methylthio-adenine, 2-methoxy-adenine, .alpha.-thio-adenosine, 2'-O-methyl-adenosine (Am), N6,2'-O-dimethyl-adenosine (m.sup.6Am), N6,N6,2'-O-trimethyl-adenosine (m.sup.62Am), 1,2'-O-dimethyl-adenosine (m.sup.1Am), 2'-O-ribosyladenosine (phosphate) (Ar(p)), 2-amino-N6-methyl-purine, 1-thio-adenosine, 8-azido-adenosine, 2'-F-ara-adenosine, 2'-F-adenosine, 2'-OH-ara-adenosine, and N6-(19-amino-pentaoxonadecyl)-adenosine.

[0344] In some embodiments, the modified nucleobase is a modified guanine. Exemplary nucleobases and nucleosides having a modified guanine include inosine (I), 1-methyl-inosine (m.sup.1I), wyosine (imG), methylwyosine (mimG), 4-demethyl-wyosine (imG-14), isowyosine (imG2), wybutosine (yW), peroxywybutosine (o.sub.2yW), hydroxywybutosine (OhyW), undermodified hydroxywybutosine (OhyW\*), 7-deaza-guanosine, queuosine (Q), epoxyqueuosine (oQ), galactosyl-queuosine (galQ), mannosyl-queuosine (manQ), 7-cyano-7-deaza-guanosine (preQ.sub.0), 7-aminomethyl-7-deaza-guanosine (preQ.sub.1), archaeosine (G.sup.+), 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine (m.sup.7G), 6-thio-7-methyl-guanosine, 7-methyl-inosine, 6-methoxy-guanosine, 1-methyl-guanosine (mG), N2-methyl-guanosine (m.sup.2G), N2,N2-dimethyl-guanosine (m.sup.22G), N2,7-dimethyl-guanosine (m.sup.2,7G), N2,N2,7-dimethyl-guanosine (m.sup.2,2,7G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, N2,N2-dimethyl-6-thio-guanosine, .alpha.-thio-guanosine, 2'-O-methyl-guanosine (Gm), N2-methyl-2'-O-methyl-guanosine (m.sup.2Gm), N2,N2-dimethyl-2'-O-methyl-guanosine (m.sup.2.sub.2Gm), 1-methyl-2'-O-methyl-guanosine (m.sup.1Gm), N2,7-dimethyl-2'-O-methyl-guanosine (m.sup.2,7Gm), 2'-O-methyl-inosine (Im), 1,2'-O-dimethyl-inosine (m.sup.1Im), 2'-O-ribosylguanosine (phosphate) (Gr(p)), 1-thio-guanosine, 06-methyl-guanosine, 2'-F-ara-guanosine, and 2'-F-guanosine.

## N-Linked Glycosylation Site Mutants

[0345] N-linked glycans of viral proteins play important roles in modulating the immune response. Glycans can be important for maintaining the appropriate antigenic conformations, shielding potential neutralization epitopes, and may alter the proteolytic susceptibility of proteins. Some viruses have putative N-linked glycosylation sites. Deletion or modification of an N-linked glycosylation site may enhance the immune response. Thus, the present disclosure provides, in some embodiments, RNA (e.g., mRNA) vaccines comprising nucleic acids (e.g., mRNA) encoding antigenic polypeptides that comprise a deletion or modification at one or more N-linked glycosylation sites.

## In vitro Transcription of RNA (e.g., mRNA)

[0346] Respiratory virus vaccines of the present disclosure comprise at least one RNA polynucleotide, such as a mRNA (e.g., modified mRNA). mRNA, for example, is transcribed in vitro from template DNA, referred to as an "in vitro transcription template." In some embodiments, an in vitro transcription template encodes a 5' untranslated (UTR) region, contains an open reading frame, and encodes a 3' UTR and a polyA tail. The particular nucleic acid sequence composition and length of an in vitro transcription template will depend on the mRNA encoded by the template.

[0347] A "5' untranslated region" (5'UTR) refers to a region of an mRNA that is directly upstream (i.e., 5') from the start codon (i.e., the first codon of an mRNA transcript translated by a ribosome) that does not encode a polypeptide.

[0348] A "3' untranslated region" (3'UTR) refers to a region of an mRNA that is directly downstream (i.e., 3') from the stop codon (i.e., the codon of an mRNA transcript that signals a termination of translation) that does not encode a polypeptide.

[0349] An "open reading frame" is a continuous stretch of DNA beginning with a start codon (e.g., methionine (ATG)), and ending with a stop codon (e.g., TAA, TAG or TGA) and encodes a polypeptide.

[0350] A "polyA tail" is a region of mRNA that is downstream, e.g., directly downstream (i.e., 3'), from the 3' UTR that contains multiple, consecutive adenosine monophosphates. A polyA tail may contain 10 to 300 adenosine monophosphates. For example, a polyA tail may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290 or 300 adenosine monophosphates. In some embodiments, a polyA tail contains 50 to 250 adenosine monophosphates. In a relevant biological setting (e.g., in cells, in vivo) the poly(A) tail functions to protect mRNA from enzymatic degradation, e.g., in the cytoplasm, and aids in transcription termination, export of the mRNA from the nucleus and translation.

[0351] In some embodiments, a polynucleotide includes 200 to 3,000 nucleotides. For example, a polynucleotide may include 200 to 500, 200 to 1000, 200 to 1500, 200 to 3000, 500 to 1000, 500 to 1500, 500 to 2000, 500 to 3000, 1000 to 1500, 1000 to 2000, 1000 to 3000, 1500 to 3000, or 2000 to 3000 nucleotides.

## Flagellin Adjuvants

[0352] Flagellin is an approximately 500 amino acid monomeric protein that polymerizes to form the flagella associated with bacterial motion. Flagellin is expressed by a variety of flagellated bacteria (*Salmonella typhimurium* for example) as well as non-flagellated bacteria (such as *Escherichia coli*). Sensing of flagellin by cells of the innate immune system (dendritic cells, macrophages, etc.) is mediated by the Toll-like receptor 5 (TLR5) as well as by Nod-like receptors (NLRs) Ipaf and Naip5. TLRs and NLRs have been identified as playing a role in the activation of innate immune response and adaptive immune response. As such, flagellin provides an adjuvant effect in a vaccine.

[0353] The nucleotide and amino acid sequences encoding known flagellin polypeptides are publicly available in the NCBI GenBank database. The flagellin sequences from *S. Typhimurium*, *H. Pylori*, *V. Cholera*, *S. marcescens*, *S. flexneri*, *T. Pallidum*, *L. pneumophila*, *B. burgdorferi*, *C. difficile*, *R. meliloti*, *A. tumefaciens*, *R. lupini*, *B. clarridgeiae*, *P. Mirabilis*, *B. subtilus*, *L. monocytogenes*, *P. aeruginosa*, and *E. coli*, among others are known.

[0354] A flagellin polypeptide, as used herein, refers to a full length flagellin protein, immunogenic fragments thereof, and peptides having at least 50% sequence identity to a flagellin protein or immunogenic fragments thereof. Exemplary flagellin proteins include flagellin from *Salmonella typhi* (UniProt Entry number: Q56086), *Salmonella typhimurium* (AOAOC9DGO9), *Salmonella enteritidis* (AOAOC9BAB7), and *Salmonella choleraesuis* (Q6V2X8), and SEQ ID NO: 54-56 (Table 17). In some embodiments, the flagellin polypeptide has at least 60%, 70%, 75%, 80%, 90%, 95%, 97%, 98%, or 99% sequence identity to a flagellin protein or immunogenic fragments thereof.

[0355] In some embodiments, the flagellin polypeptide is an immunogenic fragment. An immunogenic fragment is a portion of a flagellin protein that provokes an immune response. In some embodiments, the immune response is a TLR5 immune response. An example of an immunogenic fragment is a flagellin protein in which all or a portion of a hinge region has been deleted or replaced with other amino acids. For example, an antigenic polypeptide may be inserted in the hinge region. Hinge regions are the hypervariable regions of a flagellin. Hinge regions of a flagellin are also referred to as "D3 domain or region," "propeller domain or region," "hypervariable domain or region" and "variable domain or region." "At least a portion of a hinge region," as used herein, refers to any part of the hinge region of the flagellin, or the entirety of the hinge region. In other embodiments an immunogenic fragment of flagellin is a 20, 25, 30, 35, or 40 amino acid C-terminal fragment of flagellin.

[0356] The flagellin monomer is formed by domains D0 through D3. D0 and D1, which form the stem, are composed of tandem long alpha helices and are highly conserved among different bacteria. The D1 domain includes several stretches of amino acids that are useful for TLR5 activation. The entire D1 domain or one or more of the active regions within the domain are immunogenic fragments of flagellin. Examples of immunogenic regions within the D1 domain include residues 88-114 and residues 411-431 (in *Salmonella typhimurium* FliC flagellin. Within the 13 amino acids in the 88-100 region, at least 6 substitutions are permitted between *Salmonella* flagellin and other flagellins that still preserve TLR5 activation. Thus, immunogenic fragments of flagellin include flagellin like sequences that activate TLR5 and contain a 13 amino acid motif that is 53% or more identical to the *Salmonella* sequence in 88-100 of FliC (LQRVRELAVQSAN; SEQ ID NO: 84).

[0357] In some embodiments, the RNA (e.g., mRNA) vaccine includes an RNA that encodes a fusion protein of flagellin and one or more antigenic polypeptides. A "fusion protein" as used herein, refers to a linking of two components of the construct. In some embodiments, a carboxy-terminus of the antigenic polypeptide is fused or linked to an amino terminus of the flagellin polypeptide. In other embodiments, an amino-terminus of the antigenic polypeptide is fused or linked to a carboxy-terminus of the flagellin polypeptide. The fusion protein may include, for example, one, two, three, four, five, six or more flagellin polypeptides linked to one, two, three, four, five, six or more antigenic polypeptides. When two or more flagellin polypeptides and/or two or more antigenic polypeptides are linked such a construct may be referred to as a "multimer."

[0358] Each of the components of a fusion protein may be directly linked to one another or they may be connected through a linker. For instance, the linker may be an amino acid linker. The amino acid linker encoded for by the RNA (e.g., mRNA) vaccine to link the components of the fusion protein may include, for instance, at least one member selected from the group consisting of a lysine residue, a glutamic acid residue, a serine residue and an arginine residue. In some embodiments the linker is 1-30, 1-25, 1-25, 5-10, 5, 15, or 5-20 amino acids in length.

[0359] In other embodiments the RNA (e.g., mRNA) vaccine includes at least two separate RNA polynucleotides, one encoding one or more antigenic polypeptides and the other encoding the flagellin polypeptide. The at least two RNA polynucleotides may be co-formulated in a carrier such as a lipid

nanoparticle.

## Broad Spectrum RNA (e.g., mRNA) Vaccines

[0360] There may be situations where persons are at risk for infection with more than one strain of hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1). RNA (e.g., mRNA) therapeutic vaccines are particularly amenable to combination vaccination approaches due to a number of factors including, but not limited to, speed of manufacture, ability to rapidly tailor vaccines to accommodate perceived geographical threat, and the like. Moreover, because the vaccines utilize the human body to produce the antigenic protein, the vaccines are amenable to the production of larger, more complex antigenic proteins, allowing for proper folding, surface expression, antigen presentation, etc. in the human subject. To protect against more than one strain of hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1), a combination vaccine can be administered that includes RNA (e.g., mRNA) encoding at least one antigenic polypeptide protein (or antigenic portion thereof) of a first respiratory virus and further includes RNA encoding at least one antigenic polypeptide protein (or antigenic portion thereof) of a second respiratory virus. RNA (e.g., mRNA) can be co-formulated, for example, in a single lipid nanoparticle (LNP) or can be formulated in separate LNPs for co-administration.

## Methods of Treatment

[0361] Provided herein are compositions (e.g., pharmaceutical compositions), methods, kits and reagents for prevention and/or treatment of respiratory diseases/infections in humans and other mammals. Respiratory virus RNA (e.g. mRNA) vaccines can be used as therapeutic or prophylactic agents, alone or in combination with other vaccine(s). They may be used in medicine to prevent and/or treat respiratory disease/infection. In exemplary aspects, the RNA (e.g., mRNA) vaccines of the present disclosure are used to provide prophylactic protection from hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1). Prophylactic protection from hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1) can be achieved following administration of a RNA (e.g., mRNA) vaccine of the present disclosure. Respiratory virus RNA (e.g., mRNA) vaccines of the present disclosure may be used to treat or prevent viral "co-infections" containing two or more respiratory infections. Vaccines can be administered once, twice, three times, four times or more, but it is likely sufficient to administer the vaccine once (optionally followed by a single booster). It is possible, although less desirable, to administer the vaccine to an infected individual to achieve a therapeutic response. Dosing may need to be adjusted accordingly.

[0362] A method of eliciting an immune response in a subject against hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1) is provided in aspects of the present disclosure. The method involves administering to the subject a respiratory virus RNA (e.g., mRNA) vaccine comprising at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1) antigenic polypeptide thereof, thereby inducing in the subject an immune response specific to hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1) antigenic polypeptide or an immunogenic fragment thereof, wherein anti-antigenic polypeptide antibody titer in the subject is increased following vaccination relative to anti-antigenic polypeptide antibody titer in a subject vaccinated with a prophylactically effective dose of a traditional vaccine against hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1). An "anti-antigenic polypeptide antibody" is a serum antibody the binds specifically to the antigenic polypeptide.

[0363] In some embodiments, a RNA (e.g., mRNA) vaccine (e.g., a hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or



HCoV-HKU1 RNA vaccine) capable of eliciting an immune response is administered intramuscularly via a composition including a compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) (e.g., Compound 3, 18, 20, 25, 26, 29, 30, 60, 108-112, or 122).

[0364] A prophylactically effective dose is a therapeutically effective dose that prevents infection with the virus at a clinically acceptable level. In some embodiments the therapeutically effective dose is a dose listed in a package insert for the vaccine. A traditional vaccine, as used herein, refers to a vaccine other than the RNA (e.g., mRNA) vaccines of the present disclosure. For instance, a traditional vaccine includes but is not limited to live/attenuated microorganism vaccines, killed/inactivated microorganism vaccines, subunit vaccines, protein antigen vaccines, DNA vaccines, VLP vaccines, etc. In exemplary embodiments, a traditional vaccine is a vaccine that has achieved regulatory approval and/or is registered by a national drug regulatory body, for example the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA).

[0365] In some embodiments the anti-antigenic polypeptide antibody titer in the subject is increased 1 log to 10 log following vaccination relative to anti-antigenic polypeptide antibody titer in a subject vaccinated with a prophylactically effective dose of a traditional vaccine against hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1).

[0366] In some embodiments the anti-antigenic polypeptide antibody titer in the subject is increased 1 log, 2 log, 3 log, 5 log or 10 log following vaccination relative to anti-antigenic polypeptide antibody titer in a subject vaccinated with a prophylactically effective dose of a traditional vaccine against hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1).

[0367] A method of eliciting an immune response in a subject against hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1) is provided in other aspects of the disclosure. The method involves administering to the subject a respiratory virus RNA (e.g., mRNA) vaccine comprising at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1) antigenic polypeptide or an immunogenic fragment thereof, thereby inducing in the subject an immune response specific to hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1) antigenic polypeptide or an immunogenic fragment thereof, wherein the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine against the hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1) at 2 times to 100 times the dosage level relative to the RNA (e.g., mRNA) vaccine.

[0368] In some embodiments, the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine at 2, 3, 4, 5, 10, 50, 100 times the dosage level relative to the hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1) RNA (e.g., mRNA) vaccine.

[0369] In some embodiments the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine at 10-100 times, or 100-1000 times, the dosage level relative to the hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1) RNA (e.g., mRNA) vaccine.

[0370] In some embodiments the immune response is assessed by determining [protein] antibody titer in the subject.

[0371] Some aspects of the present disclosure provide a method of eliciting an immune response in a subject

against a In some embodiments the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine at 2, 3, 4, 5, 10, 50, 100 times the dosage level relative to the hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1) RNA (e.g., mRNA) vaccine by administering to the subject a respiratory virus RNA (e.g., mRNA) vaccine comprising at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1) antigenic polypeptide, thereby inducing in the subject an immune response specific to the antigenic polypeptide or an immunogenic fragment thereof, wherein the immune response in the subject is induced 2 days to 10 weeks earlier relative to an immune response induced in a subject vaccinated with a prophylactically effective dose of a traditional vaccine against the hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1). In some embodiments, the immune response in the subject is induced in a subject vaccinated with a prophylactically effective dose of a traditional vaccine at 2 times to 100 times the dosage level relative to the RNA (e.g., mRNA) vaccine.

[0372] In some embodiments, the immune response in the subject is induced 2 days earlier, or 3 days earlier, relative to an immune response induced in a subject vaccinated with a prophylactically effective dose of a traditional vaccine.

[0373] In some embodiments the immune response in the subject is induced 1 week, 2 weeks, 3 weeks, 5 weeks, or 10 weeks earlier relative to an immune response induced in a subject vaccinated with a prophylactically effective dose of a traditional vaccine.

[0374] Also provided herein is a method of eliciting an immune response in a subject against hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1) by administering to the subject a respiratory virus RNA (e.g., mRNA) vaccine having an open reading frame encoding a first antigenic polypeptide, wherein the RNA polynucleotide does not include a stabilization element, and wherein an adjuvant is not co-formulated or co-administered with the vaccine.

#### Therapeutic and Prophylactic Compositions

[0375] Provided herein are compositions (e.g., pharmaceutical compositions), methods, kits and reagents for prevention, treatment or diagnosis of hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1) in humans and other mammals, for example. Respiratory virus RNA (e.g. mRNA) vaccines can be used as therapeutic or prophylactic agents. They may be used in medicine to prevent and/or treat infectious disease. In some embodiments, the respiratory RNA (e.g., mRNA) vaccines of the present disclosure are used for the priming of immune effector cells, for example, to activate peripheral blood mononuclear cells (PBMCs) *ex vivo*, which are then infused (re-infused) into a subject.

[0376] In some embodiments, respiratory virus vaccine containing RNA (e.g., mRNA) polynucleotides as described herein can be administered to a subject (e.g., a mammalian subject, such as a human subject), and the RNA (e.g., mRNA) polynucleotides are translated *in vivo* to produce an antigenic polypeptide.

[0377] The respiratory virus RNA (e.g., mRNA) vaccines may be induced for translation of a polypeptide (e.g., antigen or immunogen) in a cell, tissue or organism. In some embodiments, such translation occurs *in vivo*, although such translation may occur *ex vivo*, in culture or *in vitro*. In some embodiments, the cell, tissue or organism is contacted with an effective amount of a composition containing a respiratory virus RNA (e.g., mRNA) vaccine that contains a polynucleotide that has at least one a translatable region encoding an antigenic polypeptide.

[0378] An "effective amount" of an respiratory virus RNA (e.g. mRNA) vaccine is provided based, at least in

part, on the target tissue, target cell type, means of administration, physical characteristics of the polynucleotide (e.g., size, and extent of modified nucleosides) and other components of the vaccine, and other determinants. In general, an effective amount of the respiratory virus RNA (e.g., mRNA) vaccine composition provides an induced or boosted immune response as a function of antigen production in the cell, preferably more efficient than a composition containing a corresponding unmodified polynucleotide encoding the same antigen or a peptide antigen. Increased antigen production may be demonstrated by increased cell transfection (the percentage of cells transfected with the RNA, e.g., mRNA, vaccine), increased protein translation from the polynucleotide, decreased nucleic acid degradation (as demonstrated, for example, by increased duration of protein translation from a modified polynucleotide), or altered antigen specific immune response of the host cell.

[0379] In some embodiments, RNA (e.g. mRNA) vaccines (including polynucleotides their encoded polypeptides) in accordance with the present disclosure may be used for treatment of hMPV, PIV3, RSV, MeV and/or BetaCoV (including MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH and/or HCoV-HKU1).

[0380] Respiratory RNA (e.g. mRNA) vaccines may be administered prophylactically or therapeutically as part of an active immunization scheme to healthy individuals or early in infection during the incubation phase or during active infection after onset of symptoms. In some embodiments, the amount of RNA (e.g., mRNA) vaccine of the present disclosure provided to a cell, a tissue or a subject may be an amount effective for immune prophylaxis.

[0381] Respiratory virus RNA (e.g. mRNA) vaccines may be administered with other prophylactic or therapeutic compounds. As a non-limiting example, a prophylactic or therapeutic compound may be an adjuvant or a booster. As used herein, when referring to a prophylactic composition, such as a vaccine, the term "booster" refers to an extra administration of the prophylactic (vaccine) composition. A booster (or booster vaccine) may be given after an earlier administration of the prophylactic composition. The time of administration between the initial administration of the prophylactic composition and the booster may be, but is not limited to, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 15 minutes, 20 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 36 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 10 days, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 18 months, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years, 17 years, 18 years, 19 years, 20 years, 25 years, 30 years, 35 years, 40 years, 45 years, 50 years, 55 years, 60 years, 65 years, 70 years, 75 years, 80 years, 85 years, 90 years, 95 years or more than 99 years. In some embodiments, the time of administration between the initial administration of the prophylactic composition and the booster may be, but is not limited to, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months or 1 year.

[0382] In some embodiments, respiratory virus RNA (e.g. mRNA) vaccines may be administered intramuscularly or intradermally, similarly to the administration of inactivated vaccines known in the art.

[0383] Respiratory virus RNA (e.g. mRNA) vaccines may be utilized in various settings depending on the prevalence of the infection or the degree or level of unmet medical need. As a non-limiting example, the RNA (e.g., mRNA) vaccines may be utilized to treat and/or prevent a variety of respiratory infections. RNA (e.g., mRNA) vaccines have superior properties in that they produce much larger antibody titers and produce responses early than commercially available anti-viral agents/compositions.

[0384] Provided herein are pharmaceutical compositions including respiratory virus RNA (e.g. mRNA) vaccines and RNA (e.g. mRNA) vaccine compositions and/or complexes optionally in combination with one or more pharmaceutically acceptable excipients.

[0385] Respiratory virus RNA (e.g. mRNA) vaccines may be formulated or administered alone or in conjunction with one or more other components. For instance, hMPV/PIV3/RSV RNA (e.g., mRNA) vaccines (vaccine

compositions) may comprise other components including, but not limited to, adjuvants.

[0386] In some embodiments, respiratory virus (e.g. mRNA) vaccines do not include an adjuvant (they are adjuvant free).

[0387] Respiratory virus RNA (e.g. mRNA) vaccines may be formulated or administered in combination with one or more pharmaceutically-acceptable excipients. In some embodiments, vaccine compositions comprise at least one additional active substances, such as, for example, a therapeutically-active substance, a prophylactically-active substance, or a combination of both. Vaccine compositions may be sterile, pyrogen-free or both sterile and pyrogen-free. General considerations in the formulation and/or manufacture of pharmaceutical agents, such as vaccine compositions, may be found, for example, in Remington: The Science and Practice of Pharmacy 21st ed., Lippincott Williams & Wilkins, 2005 (incorporated herein by reference in its entirety).

[0388] In some embodiments, respiratory virus RNA (e.g. mRNA) vaccines are administered to humans, human patients or subjects. For the purposes of the present disclosure, the phrase "active ingredient" generally refers to the RNA (e.g., mRNA) vaccines or the polynucleotides contained therein, for example, RNA polynucleotides (e.g., mRNA polynucleotides) encoding antigenic polypeptides.

[0389] Formulations of the respiratory virus vaccine compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing the active ingredient (e.g., mRNA polynucleotide) into association with an excipient and/or one or more other accessory ingredients, and then, if necessary and/or desirable, dividing, shaping and/or packaging the product into a desired single- or multi-dose unit.

[0390] Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition in accordance with the disclosure will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100%, e.g., between 0.5 and 50%, between 1-30%, between 5-80%, at least 80% (w/w) active ingredient.

[0391] Respiratory virus RNA (e.g. mRNA) vaccines can be formulated using one or more excipients to: (1) increase stability; (2) increase cell transfection; (3) permit the sustained or delayed release (e.g., from a depot formulation); (4) alter the biodistribution (e.g., target to specific tissues or cell types); (5) increase the translation of encoded protein in vivo; and/or (6) alter the release profile of encoded protein (antigen) in vivo. In addition to traditional excipients such as any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, excipients can include, without limitation, lipidoids, liposomes, lipid nanoparticles, polymers, lipoplexes, core-shell nanoparticles, peptides, proteins, cells transfected with respiratory virus RNA (e.g. mRNA) vaccines (e.g., for transplantation into a subject), hyaluronidase, nanoparticle mimics and combinations thereof.

### Stabilizing Elements

[0392] Naturally-occurring eukaryotic mRNA molecules have been found to contain stabilizing elements, including, but not limited to untranslated regions (UTR) at their 5'-end (5'UTR) and/or at their 3'-end (3'UTR), in addition to other structural features, such as a 5'-cap structure or a 3'-poly(A) tail. Both the 5'UTR and the 3'UTR are typically transcribed from the genomic DNA and are elements of the premature mRNA. Characteristic structural features of mature mRNA, such as the 5'-cap and the 3'-poly(A) tail are usually added to the transcribed (premature) mRNA during mRNA processing. The 3'-poly(A) tail is typically a stretch of adenine nucleotides added to the 3'-end of the transcribed mRNA. It can comprise up to about 400 adenine nucleotides. In some embodiments the length of the 3'-poly(A) tail may be an essential element with respect to the stability of the individual mRNA.

[0393] In some embodiments the RNA (e.g., mRNA) vaccine may include one or more stabilizing elements.

Stabilizing elements may include for instance a histone stem-loop. A stem-loop binding protein (SLBP), a 32 kDa protein has been identified. It is associated with the histone stem-loop at the 3'-end of the histone messages in both the nucleus and the cytoplasm. Its expression level is regulated by the cell cycle; it peaks during the S-phase, when histone mRNA levels are also elevated. The protein has been shown to be essential for efficient 3'-end processing of histone pre-mRNA by the U7 snRNP. SLBP continues to be associated with the stem-loop after processing, and then stimulates the translation of mature histone mRNAs into histone proteins in the cytoplasm. The RNA binding domain of SLBP is conserved through metazoa and protozoa; its binding to the histone stem-loop depends on the structure of the loop. The minimum binding site includes at least three nucleotides 5' and two nucleotides 3' relative to the stem-loop.

[0394] In some embodiments, the RNA (e.g., mRNA) vaccines include a coding region, at least one histone stem-loop, and optionally, a poly(A) sequence or polyadenylation signal. The poly(A) sequence or polyadenylation signal generally should enhance the expression level of the encoded protein. The encoded protein, in some embodiments, is not a histone protein, a reporter protein (e.g. Luciferase, GFP, EGFP, .beta.-Galactosidase, EGFP), or a marker or selection protein (e.g. alpha-Globin, Galactokinase and Xanthine:guanine phosphoribosyl transferase (GPT)).

[0395] In some embodiments, the combination of a poly(A) sequence or polyadenylation signal and at least one histone stem-loop, even though both represent alternative mechanisms in nature, acts synergistically to increase the protein expression beyond the level observed with either of the individual elements. It has been found that the synergistic effect of the combination of poly(A) and at least one histone stem-loop does not depend on the order of the elements or the length of the poly(A) sequence.

[0396] In some embodiments, the RNA (e.g., mRNA) vaccine does not comprise a histone downstream element (HDE). "Histone downstream element" (HDE) includes a purine-rich polynucleotide stretch of approximately 15 to 20 nucleotides 3' of naturally occurring stem-loops, representing the binding site for the U7 snRNA, which is involved in processing of histone pre-mRNA into mature histone mRNA. Ideally, the inventive nucleic acid does not include an intron.

[0397] In some embodiments, the RNA (e.g., mRNA) vaccine may or may not contain an enhancer and/or promoter sequence, which may be modified or unmodified or which may be activated or inactivated. In some embodiments, the histone stem-loop is generally derived from histone genes, and includes an intramolecular base pairing of two neighbored partially or entirely reverse complementary sequences separated by a spacer, including (e.g., consisting of) a short sequence, which forms the loop of the structure. The unpaired loop region is typically unable to base pair with either of the stem loop elements. It occurs more often in RNA, as is a key component of many RNA secondary structures, but may be present in single-stranded DNA as well. Stability of the stem-loop structure generally depends on the length, number of mismatches or bulges, and base composition of the paired region. In some embodiments, wobble base pairing (non-Watson-Crick base pairing) may result. In some embodiments, the at least one histone stem-loop sequence comprises a length of 15 to 45 nucleotides.

[0398] In other embodiments the RNA (e.g., mRNA) vaccine may have one or more AU-rich sequences removed. These sequences, sometimes referred to as AURES are destabilizing sequences found in the 3'UTR. The AURES may be removed from the RNA (e.g., mRNA) vaccines. Alternatively the AURES may remain in the RNA (e.g., mRNA) vaccine.

## Nanoparticle Formulations

[0399] In some embodiments, respiratory virus RNA (e.g. mRNA) vaccines are formulated in a nanoparticle. In some embodiments, respiratory virus RNA (e.g. mRNA) vaccines are formulated in a lipid nanoparticle. In some embodiments, respiratory virus RNA (e.g. mRNA) vaccines are formulated in a lipid-polycation complex, referred to as a cationic lipid nanoparticle. As a non-limiting example, the polycation may include a cationic peptide or a polypeptide such as, but not limited to, polylysine, polyornithine and/or polyarginine. In some embodiments, respiratory virus RNA (e.g., mRNA) vaccines are formulated in a lipid nanoparticle that includes a non-cationic lipid such as, but not limited to, cholesterol or dioleoyl phosphatidylethanolamine (DOPE).

[0400] A lipid nanoparticle formulation may be influenced by, but not limited to, the selection of the cationic lipid component, the degree of cationic lipid saturation, the nature of the PEGylation, ratio of all components and biophysical parameters such as size. In one example by Semple et al. (Nature Biotech. 2010 28:172-176), the lipid nanoparticle formulation is composed of 57.1% cationic lipid, 7.1% dipalmitoylphosphatidylcholine, 34.3% cholesterol, and 1.4% PEG-c-DMA. As another example, changing the composition of the cationic lipid can more effectively deliver siRNA to various antigen presenting cells (Basha et al. Mol Ther. 2011 19:2186-2200).

[0401] In some embodiments, lipid nanoparticle formulations may comprise 35 to 45% cationic lipid, 40% to 50% cationic lipid, 50% to 60% cationic lipid and/or 55% to 65% cationic lipid. In some embodiments, the ratio of lipid to RNA (e.g., mRNA) in lipid nanoparticles may be 5:1 to 20:1, 10:1 to 25:1, 15:1 to 30:1 and/or at least 30:1.

[0402] In some embodiments, the ratio of PEG in the lipid nanoparticle formulations may be increased or decreased and/or the carbon chain length of the PEG lipid may be modified from C14 to C18 to alter the pharmacokinetics and/or biodistribution of the lipid nanoparticle formulations. As a non-limiting example, lipid nanoparticle formulations may contain 0.5% to 3.0%, 1.0% to 3.5%, 1.5% to 4.0%, 2.0% to 4.5%, 2.5% to 5.0% and/or 3.0% to 6.0% of the lipid molar ratio of PEG-c-DOMG (R-3-[(omega-methoxy-poly(ethyleneglycol)2000)carbonyl]-1,2-dimyristyl-oxypropyl-3-amine) (also referred to herein as PEG-DOMG) as compared to the cationic lipid, DSPC and cholesterol. In some embodiments, the PEG-c-DOMG may be replaced with a PEG lipid such as, but not limited to, PEG-DSG (1,2-Distearoyl-sn-glycerol, methoxypolyethylene glycol), PEG-DMG (1,2-Dimyristoyl-sn-glycerol) and/or PEG-DPG (1,2-Dipalmitoyl-sn-glycerol, methoxypolyethylene glycol). The cationic lipid may be selected from any lipid known in the art such as, but not limited to, Dlin-MC3-DMA, Dlin-DMA, C12-200 and Dlin-KC2-DMA.

[0403] In some embodiments, an respiratory virus RNA (e.g. mRNA) vaccine formulation is a nanoparticle that comprises at least one lipid. The lipid may be selected from, but is not limited to, Dlin-DMA, Dlin-K-DMA, 98N12-5, C12-200, Dlin-MC3-DMA, Dlin-KC2-DMA, DODMA, PLGA, PEG, PEG-DMG, PEGylated lipids and amino alcohol lipids. In some embodiments, the lipid may be a cationic lipid such as, but not limited to, Dlin-DMA, Dlin-D-DMA, Dlin-MC3-DMA, Dlin-KC2-DMA, DODMA and amino alcohol lipids. The amino alcohol cationic lipid may be the lipids described in and/or made by the methods described in U.S. Patent Publication No. US20130150625, herein incorporated by reference in its entirety. As a non-limiting example, the cationic lipid may be 2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-[(9Z,2Z)-octadeca-9,12-dien-1-yloxy]methyl}propan-1-ol (Compound 1 in US20130150625); 2-amino-3-[(9Z)-octadec-9-en-1-yloxy]-2-[(9Z)-octadec-9-en-1-yloxy]methyl}propan-1-ol (Compound 2 in US20130150625); 2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-[(octyloxy)methyl]propa- n-1-ol (Compound 3 in US20130150625); and 2-(dimethylamino)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-[(9Z,12Z)-oc- tadeca-9,12-dien-1-yloxy]methyl}propan-1-ol (Compound 4 in US20130150625); or any pharmaceutically acceptable salt or stereoisomer thereof.

[0404] Lipid nanoparticle formulations typically comprise a lipid, in particular, an ionizable cationic lipid, for example, 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (Dlin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (Dlin-MC3-DMA), or di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), and further comprise a neutral lipid, a sterol and a molecule capable of reducing particle aggregation, for example a PEG or PEG-modified lipid.

[0405] In some embodiments, a lipid nanoparticle formulation consists essentially of (i) at least one lipid selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (Dlin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (Dlin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319); (ii) a neutral lipid selected from DSPC, DPPC, POPC, DOPE and SM; (iii) a sterol, e.g., cholesterol; and (iv) a PEG-lipid, e.g., PEG-DMG or PEG-cDMA, in a molar ratio of 20-60% cationic lipid:5-25% neutral lipid:25-55% sterol; 0.5-15% PEG-lipid.

[0406] In some embodiments, a lipid nanoparticle formulation includes 25% to 75% on a molar basis of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), e.g., 35 to 65%, 45 to 65%, 60%, 57.5%, 50% or 40% on a molar basis.

[0407] In some embodiments, a lipid nanoparticle formulation includes 0.5% to 15% on a molar basis of the neutral lipid, e.g., 3 to 12%, 5 to 10% or 15%, 10%, or 7.5% on a molar basis. Examples of neutral lipids include, without limitation, DSPC, POPC, DPPC, DOPE and SM. In some embodiments, the formulation includes 5% to 50% on a molar basis of the sterol (e.g., 15 to 45%, 20 to 40%, 40%, 38.5%, 35%, or 31% on a molar basis. A non-limiting example of a sterol is cholesterol. In some embodiments, a lipid nanoparticle formulation includes 0.5% to 20% on a molar basis of the PEG or PEG-modified lipid (e.g., 0.5 to 10%, 0.5 to 5%, 1.5%, 0.5%, 1.5%, 3.5%, or 5% on a molar basis. In some embodiments, a PEG or PEG modified lipid comprises a PEG molecule of an average molecular weight of 2,000 Da. In some embodiments, a PEG or PEG modified lipid comprises a PEG molecule of an average molecular weight of less than 2,000, for example around 1,500 Da, around 1,000 Da, or around 500 Da. Non-limiting examples of PEG-modified lipids include PEG-distearoyl glycerol (PEG-DMG) (also referred herein as PEG-C14 or C, 14-PEG), PEG-cDMA (further discussed in Reyes et al. J. Controlled Release, 107, 276-287 (2005) the contents of which are herein incorporated by reference in their entirety).

[0408] In some embodiments, lipid nanoparticle formulations include 25-75% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 0.5-15% of the neutral lipid, 5-50% of the sterol, and 0.5-20% of the PEG or PEG-modified lipid on a molar basis.

[0409] In some embodiments, lipid nanoparticle formulations include 35-65% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 3-12% of the neutral lipid, 15-45% of the sterol, and 0.5-10% of the PEG or PEG-modified lipid on a molar basis.

[0410] In some embodiments, lipid nanoparticle formulations include 45-65% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 5-10% of the neutral lipid, 25-40% of the sterol, and 0.5-10% of the PEG or PEG-modified lipid on a molar basis.

[0411] In some embodiments, lipid nanoparticle formulations include 60% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 7.5% of the neutral lipid, 31% of the sterol, and 1.5% of the PEG or PEG-modified lipid on a molar basis.

[0412] In some embodiments, lipid nanoparticle formulations include 50% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 10% of the neutral lipid, 38.5% of the sterol, and 1.5% of the PEG or PEG-modified lipid on a molar basis.

[0413] In some embodiments, lipid nanoparticle formulations include 50% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 10% of the neutral lipid, 35% of the sterol, 4.5% or

5% of the PEG or PEG-modified lipid, and 0.5% of the targeting lipid on a molar basis.

[0414] In some embodiments, lipid nanoparticle formulations include 40% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 15% of the neutral lipid, 40% of the sterol, and 5% of the PEG or PEG-modified lipid on a molar basis.

[0415] In some embodiments, lipid nanoparticle formulations include 57.2% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 7.1% of the neutral lipid, 34.3% of the sterol, and 1.4% of the PEG or PEG-modified lipid on a molar basis.

[0416] In some embodiments, lipid nanoparticle formulations include 57.5% of a cationic lipid selected from the PEG lipid is PEG-cDMA (PEG-cDMA is further discussed in Reyes et al. (J. Controlled Release, 107, 276-287 (2005), the contents of which are herein incorporated by reference in their entirety), 7.5% of the neutral lipid, 31.5% of the sterol, and 3.5% of the PEG or PEG-modified lipid on a molar basis.

[0417] In some embodiments, lipid nanoparticle formulations consists essentially of a lipid mixture in molar ratios of 20-70% cationic lipid: 5-45% neutral lipid: 20-55% cholesterol: 0.5-15% PEG-modified lipid. In some embodiments, lipid nanoparticle formulations consists essentially of a lipid mixture in a molar ratio of 20-60% cationic lipid:5-25% neutral lipid:25-55% cholesterol:0.5-15% PEG-modified lipid.

[0418] In some embodiments, the molar lipid ratio is 50/10/38.5/1.5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG, PEG-DSG or PEG-DPG), 57.2/7.1/34.3/1.4 (mol % cationic lipid/neutral lipid, e.g., DPPC/Chol/PEG-modified lipid, e.g., PEG-cDMA), 40/15/40/5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG), 50/10/35/4.5/0.5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DSG), 50/10/35/5 (cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG), 40/10/40/10 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA), 35/15/40/10 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA) or 52/13/30/5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA).

[0419] Non-limiting examples of lipid nanoparticle compositions and methods of making them are described, for example, in Semple et al. (2010) Nat. Biotechnol. 28:172-176; Jayarama et al. (2012), Angew. Chem. Int. Ed., 51: 8529-8533; and Maier et al. (2013) Molecular Therapy 21, 1570-1578 (the contents of each of which are incorporated herein by reference in their entirety).

[0420] In some embodiments, lipid nanoparticle formulations may comprise a cationic lipid, a PEG lipid and a structural lipid and optionally comprise a non-cationic lipid. As a non-limiting example, a lipid nanoparticle may comprise 40-60% of cationic lipid, 5-15% of a non-cationic lipid, 1-2% of a PEG lipid and 30-50% of a structural lipid. As another non-limiting example, the lipid nanoparticle may comprise 50% cationic lipid, 10% non-cationic lipid, 1.5% PEG lipid and 38.5% structural lipid. As yet another non-limiting example, a lipid nanoparticle may comprise 55% cationic lipid, 10% non-cationic lipid, 2.5% PEG lipid and 32.5% structural lipid. In some embodiments, the cationic lipid may be any cationic lipid described herein such as, but not limited to, DLin-KC2-DMA, DLin-MC3-DMA and L319.

[0421] In some embodiments, the lipid nanoparticle formulations described herein may be 4 component lipid nanoparticles. The lipid nanoparticle may comprise a cationic lipid, a non-cationic lipid, a PEG lipid and a structural lipid. As a non-limiting example, the lipid nanoparticle may comprise 40-60% of cationic lipid, 5-15% of a non-cationic lipid, 1-2% of a PEG lipid and 30-50% of a structural lipid. As another non-limiting example, the lipid nanoparticle may comprise 50% cationic lipid, 10% non-cationic lipid, 1.5% PEG lipid and 38.5% structural lipid. As yet another non-limiting example, the lipid nanoparticle may comprise 55% cationic lipid,



10% non-cationic lipid, 2.5% PEG lipid and 32.5% structural lipid. In some embodiments, the cationic lipid may be any cationic lipid described herein such as, but not limited to, DLin-KC2-DMA, DLin-MC3-DMA and L319.

[0422] In some embodiments, the lipid nanoparticle formulations described herein may comprise a cationic lipid, a non-cationic lipid, a PEG lipid and a structural lipid. As a non-limiting example, the lipid nanoparticle comprise 50% of the cationic lipid DLin-KC2-DMA, 10% of the non-cationic lipid DSPC, 1.5% of the PEG lipid PEG-DOMG and 38.5% of the structural lipid cholesterol. As a non-limiting example, the lipid nanoparticle comprise 50% of the cationic lipid DLin-MC3-DMA, 10% of the non-cationic lipid DSPC, 1.5% of the PEG lipid PEG-DOMG and 38.5% of the structural lipid cholesterol. As a non-limiting example, the lipid nanoparticle comprise 50% of the cationic lipid DLin-MC3-DMA, 10% of the non-cationic lipid DSPC, 1.5% of the PEG lipid PEG-DMG and 38.5% of the structural lipid cholesterol. As yet another non-limiting example, the lipid nanoparticle comprise 55% of the cationic lipid L319, 10% of the non-cationic lipid DSPC, 2.5% of the PEG lipid PEG-DMG and 32.5% of the structural lipid cholesterol.

[0423] Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a vaccine composition may vary, depending upon the identity, size, and/or condition of the subject being treated and further depending upon the route by which the composition is to be administered. For example, the composition may comprise between 0.1% and 99% (w/w) of the active ingredient. By way of example, the composition may comprise between 0.1% and 100%, e.g., between 0.5 and 50%, between 1-30%, between 5-80%, at least 80% (w/w) active ingredient.

[0424] In some embodiments, the respiratory virus RNA (e.g. mRNA) vaccine composition may comprise the polynucleotide described herein, formulated in a lipid nanoparticle comprising MC3, Cholesterol, DSPC and PEG2000-DMG, the buffer trisodium citrate, sucrose and water for injection. As a non-limiting example, the composition comprises: 2.0 mg/mL of drug substance (e.g., polynucleotides encoding H10N8 hMPV), 21.8 mg/mL of MC3, 10.1 mg/mL of cholesterol, 5.4 mg/mL of DSPC, 2.7 mg/mL of PEG2000-DMG, 5.16 mg/mL of trisodium citrate, 71 mg/mL of sucrose and 1.0 mL of water for injection.

[0425] In some embodiments, a nanoparticle (e.g., a lipid nanoparticle) has a mean diameter of 10-500 nm, 20-400 nm, 30-300 nm, 40-200 nm. In some embodiments, a nanoparticle (e.g., a lipid nanoparticle) has a mean diameter of 50-150 nm, 50-200 nm, 80-100 nm or 80-200 nm.

### Liposomes, Lipoplexes, and Lipid Nanoparticles

[0426] The RNA (e.g., mRNA) vaccines of the disclosure can be formulated using one or more liposomes, lipoplexes, or lipid nanoparticles. In some embodiments, pharmaceutical compositions of RNA (e.g., mRNA) vaccines include liposomes. Liposomes are artificially-prepared vesicles which may primarily be composed of a lipid bilayer and may be used as a delivery vehicle for the administration of nutrients and pharmaceutical formulations. Liposomes can be of different sizes such as, but not limited to, a multilamellar vesicle (MLV) which may be hundreds of nanometers in diameter and may contain a series of concentric bilayers separated by narrow aqueous compartments, a small unicellular vesicle (SUV) which may be smaller than 50 nm in diameter, and a large unilamellar vesicle (LUV) which may be between 50 and 500 nm in diameter. Liposome design may include, but is not limited to, opsonins or ligands in order to improve the attachment of liposomes to unhealthy tissue or to activate events such as, but not limited to, endocytosis. Liposomes may contain a low or a high pH in order to improve the delivery of the pharmaceutical formulations.

[0427] The formation of liposomes may depend on the physicochemical characteristics such as, but not limited to, the pharmaceutical formulation entrapped and the liposomal ingredients, the nature of the medium in which the lipid vesicles are dispersed, the effective concentration of the entrapped substance and its potential toxicity, any additional processes involved during the application and/or delivery of the vesicles, the optimization size, polydispersity and the shelf-life of the vesicles for the intended application, and the batch-to-batch reproducibility and possibility of large-scale production of safe and efficient liposomal products.

[0428] In some embodiments, pharmaceutical compositions described herein may include, without limitation,

liposomes such as those formed from 1,2-dioleoyloxy-N,N-dimethylaminopropane (DODMA) liposomes, DiLa2 liposomes from Marina Biotech (Bothell, Wash.), 1,2-dilinoleyloxy-3-dimethylaminopropane (DLin-DMA), 2,2-dilinoleyloxy-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), and MC3 (US20100324120; herein incorporated by reference in its entirety) and liposomes which may deliver small molecule drugs such as, but not limited to, DOXIL.RTM. from Janssen Biotech, Inc. (Horsham, Pa.).

[0429] In some embodiments, pharmaceutical compositions described herein may include, without limitation, liposomes such as those formed from the synthesis of stabilized plasmid-lipid particles (SPLP) or stabilized nucleic acid lipid particle (SNALP) that have been previously described and shown to be suitable for oligonucleotide delivery in vitro and in vivo (see Wheeler et al. *Gene Therapy*. 1999 6:271-281; Zhang et al. *Gene Therapy*. 1999 6:1438-1447; Jeffs et al. *Pharm Res*. 2005 22:362-372; Morrissey et al., *Nat Biotechnol*. 2005 2:1002-1007; Zimmermann et al., *Nature*. 2006 441:111-114; Heyes et al. *J Contr Rel*. 2005 107:276-287; Semple et al. *Nature Biotech*. 2010 28:172-176; Judge et al. *J Clin Invest*. 2009 119:661-673; deFougerolles *Hum Gene Ther*. 2008 19:125-132; U.S. Patent Publication No US20130122104; all of which are incorporated herein in their entireties). The original manufacture method by Wheeler et al. was a detergent dialysis method, which was later improved by Jeffs et al. and is referred to as the spontaneous vesicle formation method. The liposome formulations are composed of 3 to 4 lipid components in addition to the polynucleotide. As an example a liposome can contain, but is not limited to, 55% cholesterol, 20% distearylphosphatidyl choline (DSPC), 10% PEG-S-DSG, and 15% 1,2-dioleoyloxy-N,N-dimethylaminopropane (DODMA), as described by Jeffs et al. As another example, certain liposome formulations may contain, but are not limited to, 48% cholesterol, 20% DSPC, 2% PEG-c-DMA, and 30% cationic lipid, where the cationic lipid can be 1,2-distearloxy-N,N-dimethylaminopropane (DSDMA), DODMA, DLin-DMA, or 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA), as described by Heyes et al.

[0430] In some embodiments, liposome formulations may comprise from about 25.0% cholesterol to about 40.0% cholesterol, from about 30.0% cholesterol to about 45.0% cholesterol, from about 35.0% cholesterol to about 50.0% cholesterol and/or from about 48.5% cholesterol to about 60% cholesterol. In some embodiments, formulations may comprise a percentage of cholesterol selected from the group consisting of 28.5%, 31.5%, 33.5%, 36.5%, 37.0%, 38.5%, 39.0% and 43.5%. In some embodiments, formulations may comprise from about 5.0% to about 10.0% DSPC and/or from about 7.0% to about 15.0% DSPC.

[0431] In some embodiments, the RNA (e.g., mRNA) vaccine pharmaceutical compositions may be formulated in liposomes such as, but not limited to, DiLa2 liposomes (Marina Biotech, Bothell, Wash.), SMARTICLES.RTM. (Marina Biotech, Bothell, Wash.), neutral DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) based liposomes (e.g., siRNA delivery for ovarian cancer (Landen et al. *Cancer Biology & Therapy* 2006 5(12)1708-1713); herein incorporated by reference in its entirety) and hyaluronan-coated liposomes (Quiet Therapeutics, Israel).

[0432] In some embodiments, the cationic lipid may be a low molecular weight cationic lipid such as those described in U.S. Patent Application No. 20130090372, the contents of which are herein incorporated by reference in their entirety.

[0433] In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in a lipid vesicle, which may have crosslinks between functionalized lipid bilayers.

[0434] In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in a lipid-polycation complex. The formation of the lipid-polycation complex may be accomplished by methods known in the art and/or as described in U.S. Pub. No. 20120178702, herein incorporated by reference in its entirety. As a non-limiting example, the polycation may include a cationic peptide or a polypeptide such as, but not limited to, polylysine, polyornithine and/or polyarginine. In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in a lipid-polycation complex, which may further include a non-cationic lipid such as, but not limited to, cholesterol or dioleoyl phosphatidylethanolamine (DOPE).

[0435] In some embodiments, the ratio of PEG in the lipid nanoparticle (LNP) formulations may be increased or

decreased and/or the carbon chain length of the PEG lipid may be modified from C14 to C18 to alter the pharmacokinetics and/or biodistribution of the LNP formulations. As a non-limiting example, LNP formulations may contain from about 0.5% to about 3.0%, from about 1.0% to about 3.5%, from about 1.5% to about 4.0%, from about 2.0% to about 4.5%, from about 2.5% to about 5.0% and/or from about 3.0% to about 6.0% of the lipid molar ratio of PEG-c-DOMG (R-3-[(omega.-methoxy-poly(ethyleneglycol)2000)carbomoyl]-1,2-dimyristyl-oxypropyl-3-amine) (also referred to herein as PEG-DOMG) as compared to the cationic lipid, DSPC and cholesterol. In some embodiments, the PEG-c-DOMG may be replaced with a PEG lipid such as, but not limited to, PEG-DSG (1,2-Distearoyl-sn-glycerol, methoxypolyethylene glycol), PEG-DMG (1,2-Dimyristoyl-sn-glycerol) and/or PEG-DPG (1,2-Dipalmitoyl-sn-glycerol, methoxypolyethylene glycol). The cationic lipid may be selected from any lipid known in the art such as, but not limited to, DLin-MC3-DMA, DLin-DMA, C12-200 and DLin-KC2-DMA.

[0436] In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in a lipid nanoparticle.

[0437] In some embodiments, the RNA (e.g., mRNA) vaccine formulation comprising the polynucleotide is a nanoparticle which may comprise at least one lipid. The lipid may be selected from, but is not limited to, DLin-DMA, DLin-K-DMA, 98N12-5, C12-200, DLin-MC3-DMA, DLin-KC2-DMA, DODMA, PLGA, PEG, PEG-DMG, PEGylated lipids and amino alcohol lipids. In another aspect, the lipid may be a cationic lipid such as, but not limited to, DLin-DMA, DLin-D-DMA, DLin-MC3-DMA, DLin-KC2-DMA, DODMA and amino alcohol lipids. The amino alcohol cationic lipid may be the lipids described in and/or made by the methods described in U.S. Patent Publication No. US20130150625, herein incorporated by reference in its entirety. As a non-limiting example, the cationic lipid may be 2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-[[9Z,2Z)-octadeca-9,12-dien-1-yloxy]methyl}propan-1-ol (Compound 1 in US20130150625); 2-amino-3-[(9Z)-octadec-9-en-1-yloxy]-2-[[9Z)-octadec-9-en-1-yloxy]methyl}propan-1-ol (Compound 2 in US20130150625); 2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-[(octyloxy)methyl]propan-1-ol (Compound 3 in US20130150625); and 2-(dimethylamino)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-[[9Z,12Z)-octadeca-9,12-dien-1-yloxy]methyl}propan-1-ol (Compound 4 in US20130150625); or any pharmaceutically acceptable salt or stereoisomer thereof.

[0438] Lipid nanoparticle formulations typically comprise a lipid, in particular, an ionizable cationic lipid, for example, 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), or di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), and further comprise a neutral lipid, a sterol and a molecule capable of reducing particle aggregation, for example a PEG or PEG-modified lipid.

[0439] In some embodiments, the lipid nanoparticle formulation consists essentially of (i) at least one lipid selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319); (ii) a neutral lipid selected from DSPC, DPPC, POPC, DOPE and SM; (iii) a sterol, e.g., cholesterol; and (iv) a PEG-lipid, e.g., PEG-DMG or PEG-cDMA, in a molar ratio of about 20-60% cationic lipid:5-25% neutral lipid:25-55% sterol; 0.5-15% PEG-lipid.

[0440] In some embodiments, the formulation includes from about 25% to about 75% on a molar basis of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), e.g., from about 35 to about 65%, from about 45 to about 65%, about 60%, about 57.5%, about 50% or about 40% on a molar basis.

[0441] In some embodiments, the formulation includes from about 0.5% to about 15% on a molar basis of the neutral lipid e.g., from about 3 to about 12%, from about 5 to about 10% or about 15%, about 10%, or about 7.5% on a molar basis. Examples of neutral lipids include, but are not limited to, DSPC, POPC, DPPC, DOPE and SM. In some embodiments, the formulation includes from about 5% to about 50% on a molar basis of the sterol (e.g., about 15 to about 45%, about 20 to about 40%, about 40%, about 38.5%, about 35%, or about 31% on a molar basis. An exemplary sterol is cholesterol. In some embodiments, the formulation includes from about

0.5% to about 20% on a molar basis of the PEG or PEG-modified lipid (e.g., about 0.5 to about 10%, about 0.5 to about 5%, about 1.5%, about 0.5%, about 1.5%, about 3.5%, or about 5% on a molar basis. In some embodiments, the PEG or PEG modified lipid comprises a PEG molecule of an average molecular weight of 2,000 Da. In other embodiments, the PEG or PEG modified lipid comprises a PEG molecule of an average molecular weight of less than 2,000, for example around 1,500 Da, around 1,000 Da, or around 500 Da. Examples of PEG-modified lipids include, but are not limited to, PEG-distearoyl glycerol (PEG-DMG) (also referred herein as PEG-C14 or C, 14-PEG), PEG-cDMA (further discussed in Reyes et al. J. Controlled Release, 107, 276-287 (2005) the contents of which are herein incorporated by reference in their entirety) In some embodiments, the formulations of the present disclosure include 25-75% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 0.5-15% of the neutral lipid, 5-50% of the sterol, and 0.5-20% of the PEG or PEG-modified lipid on a molar basis.

[0442] In some embodiments, the formulations of the present disclosure include 35-65% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 3-12% of the neutral lipid, 15-45% of the sterol, and 0.5-10% of the PEG or PEG-modified lipid on a molar basis.

[0443] In some embodiments, the formulations of the present disclosure include 45-65% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 5-10% of the neutral lipid, 25-40% of the sterol, and 0.5-10% of the PEG or PEG-modified lipid on a molar basis.

[0444] In some embodiments, the formulations of the present disclosure include about 60% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 7.5% of the neutral lipid, about 31% of the sterol, and about 1.5% of the PEG or PEG-modified lipid on a molar basis.

[0445] In some embodiments, the formulations of the present disclosure include about 50% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 10% of the neutral lipid, about 38.5% of the sterol, and about 1.5% of the PEG or PEG-modified lipid on a molar basis.

[0446] In some embodiments, the formulations of the present disclosure include about 50% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 10% of the neutral lipid, about 35% of the sterol, about 4.5% or about 5% of the PEG or PEG-modified lipid, and about 0.5% of the targeting lipid on a molar basis.

[0447] In some embodiments, the formulations of the present disclosure include about 40% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 15% of the neutral lipid, about 40% of the sterol, and about 5% of the PEG or PEG-modified lipid on a molar basis.

[0448] In some embodiments, the formulations of the present disclosure include about 57.2% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-

(dimethylamino)butanoyloxy)heptadecanedioate (L319), about 7.1% of the neutral lipid, about 34.3% of the sterol, and about 1.4% of the PEG or PEG-modified lipid on a molar basis.

[0449] In some embodiments, the formulations of the present disclosure include about 57.5% of a cationic lipid selected from the PEG lipid is PEG-cDMA (PEG-cDMA is further discussed in Reyes et al. (J. Controlled Release, 107, 276-287 (2005), the contents of which are herein incorporated by reference in their entirety), about 7.5% of the neutral lipid, about 31.5% of the sterol, and about 3.5% of the PEG or PEG-modified lipid on a molar basis.

[0450] In some embodiments, lipid nanoparticle formulation consists essentially of a lipid mixture in molar ratios of about 20-70% cationic lipid:5-45% neutral lipid:20-55% cholesterol:0.5-15% PEG-modified lipid; more preferably in a molar ratio of about 20-60% cationic lipid:5-25% neutral lipid:25-55% cholesterol:0.5-15% PEG-modified lipid.

[0451] In some embodiments, the molar lipid ratio is approximately 50/10/38.5/1.5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG, PEG-DSG or PEG-DPG), 57.2/7.1134.3/1.4 (mol % cationic lipid/neutral lipid, e.g., DPPC/Chol/PEG-modified lipid, e.g., PEG-cDMA), 40/15/40/5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG), 50/10/35/4.5/0.5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DSG), 50/10/35/5 (cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG), 40/10/40/10 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA), 35/15/40/10 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA) or 52/13/30/5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA).

[0452] Examples of lipid nanoparticle compositions and methods of making same are described, for example, in Semple et al. (2010) Nat. Biotechnol. 28:172-176; Jayarama et al. (2012), Angew. Chem. Int. Ed., 51: 8529-8533; and Maier et al. (2013) Molecular Therapy 21, 1570-1578 (the contents of each of which are incorporated herein by reference in their entirety).

[0453] In some embodiments, the lipid nanoparticle formulations described herein may comprise a cationic lipid, a PEG lipid and a structural lipid and optionally comprise a non-cationic lipid. As a non-limiting example, the lipid nanoparticle may comprise about 40-60% of cationic lipid, about 5-15% of a non-cationic lipid, about 1-2% of a PEG lipid and about 30-50% of a structural lipid. As another non-limiting example, the lipid nanoparticle may comprise about 50% cationic lipid, about 10% non-cationic lipid, about 1.5% PEG lipid and about 38.5% structural lipid. As yet another non-limiting example, the lipid nanoparticle may comprise about 55% cationic lipid, about 10% non-cationic lipid, about 2.5% PEG lipid and about 32.5% structural lipid. In some embodiments, the cationic lipid may be any cationic lipid described herein such as, but not limited to, DLin-KC2-DMA, DLin-MC3-DMA and L319.

[0454] In some embodiments, the lipid nanoparticle formulations described herein may be 4 component lipid nanoparticles. The lipid nanoparticle may comprise a cationic lipid, a non-cationic lipid, a PEG lipid and a structural lipid. As a non-limiting example, the lipid nanoparticle may comprise about 40-60% of cationic lipid, about 5-15% of a non-cationic lipid, about 1-2% of a PEG lipid and about 30-50% of a structural lipid. As another non-limiting example, the lipid nanoparticle may comprise about 50% cationic lipid, about 10% non-cationic lipid, about 1.5% PEG lipid and about 38.5% structural lipid. As yet another non-limiting example, the lipid nanoparticle may comprise about 55% cationic lipid, about 10% non-cationic lipid, about 2.5% PEG lipid and about 32.5% structural lipid. In some embodiments, the cationic lipid may be any cationic lipid described herein such as, but not limited to, DLin-KC2-DMA, DLin-MC3-DMA and L319.

[0455] In some embodiments, the lipid nanoparticle formulations described herein may comprise a cationic lipid, a non-cationic lipid, a PEG lipid and a structural lipid. As a non-limiting example, the lipid nanoparticle comprise about 50% of the cationic lipid DLin-KC2-DMA, about 10% of the non-cationic lipid DSPC, about 1.5% of the PEG lipid PEG-DOMG and about 38.5% of the structural lipid cholesterol. As a non-limiting example, the lipid nanoparticle comprise about 50% of the cationic lipid DLin-MC3-DMA, about 10% of the

non-cationic lipid DSPC, about 1.5% of the PEG lipid PEG-DOMG and about 38.5% of the structural lipid cholesterol. As a non-limiting example, the lipid nanoparticle comprise about 50% of the cationic lipid DLin-MC3-DMA, about 10% of the non-cationic lipid DSPC, about 1.5% of the PEG lipid PEG-DMG and about 38.5% of the structural lipid cholesterol. As yet another non-limiting example, the lipid nanoparticle comprise about 55% of the cationic lipid L319, about 10% of the non-cationic lipid DSPC, about 2.5% of the PEG lipid PEG-DMG and about 32.5% of the structural lipid cholesterol.

[0456] As a non-limiting example, the cationic lipid may be selected from (20Z,23Z)-N,N-dimethylnonacos-20,23-dien-10-amine, (17Z,20Z)-N,N-dimethylhexacos-17,20-dien-9-amine, (1Z,19Z)-N,N-dimethylpentacos-16,19-dien-8-amine, (13Z,16Z)-N,N-dimethyldocosa-13,16-dien-5-amine, (12Z,15Z)-N,N-dimethylhenicos-12,15-dien-4-amine, (14Z,17Z)-N,N-dimethyltricos-14,17-dien-6-amine, (15Z,18Z)-N,N-dimethyltetracos-15,18-dien-7-amine, (18Z,21Z)-N,N-dimethylheptacos-18,21-dien-10-amine, (15Z,18Z)-N,N-dimethyltetracos-15,18-dien-5-amine, (14Z,17Z)-N,N-dimethyltricos-14,17-dien-4-amine, (19Z,22Z)-N,N-dimethylheptacos-19,22-dien-9-amine, (18Z,21Z)-N,N-dimethylheptacos-18,21-dien-8-amine, (17Z,20Z)-N,N-dimethylhexacos-17,20-dien-7-amine, (16Z,19Z)-N,N-dimethylpentacos-16,19-dien-6-amine, (22Z,25Z)-N,N-dimethylhentriaconta-22,25-dien-10-amine, (21Z,24Z)-N,N-dimethyltriaconta-21,24-dien-9-amine, (18Z)-N,N-dimethylheptacos-18-en-10-amine, (17Z)-N,N-dimethylhexacos-17-en-9-amine, (19Z,22Z)-N,N-dimethylheptacos-19,22-dien-7-amine, N,N-dimethylheptacos-10-amine, (20Z,23Z)-N-ethyl-N-methylnonacos-20,23-dien-10-amine, 1-[(11Z,14Z)-1-nonylicos-11,14-dien-1-yl] pyrrolidine, (20Z)-N,N-dimethylheptacos-20-en-10-amine, (15Z)-N,N-dimethylheptacos-15-en-10-amine, (14Z)-N,N-dimethylnonacos-14-en-10-amine, (17Z)-N,N-dimethylnonacos-17-en-10-amine, (24Z)-N,N-dimethyltriaconta-24-en-10-amine, (20Z)-N,N-dimethylnonacos-20-en-10-amine, (22Z)-N,N-dimethylhentriaconta-22-en-10-amine, (16Z)-N,N-dimethylpentacos-16-en-8-amine, (12Z,15Z)-N,N-dimethyl-2-nonylhenicos-12,15-dien-1-amine, (13Z,16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl] eptadecan-8-amine, 1-[(1S,2R)-2-hexylcyclopropyl]-N,N-dimethylnonadecan-10-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]nonadecan-10-amine, N,N-dimethyl-21-[(1S,2R)-2-octylcyclopropyl]henicosan-10-amine, N,N-dimethyl-1-[(1S,2S)-2-[(1R,2R)-2-pentylcyclopropyl]methyl]cyclopropyl]nonadecan-10-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]hexadecan-8-amine, N,N-dimethyl-[(1R,2S)-2-undecylcyclopropyl]tetradecan-5-amine, N,N-dimethyl-3-{7-[(1S,2R)-2-octylcyclopropyl]heptyl} dodecan-1-amine, 1-[(1R,2S)-2-heptylcyclopropyl]-N,N-dimethyloctadecan-9-amine, 1-[(1S,2R)-2-decylcyclopropyl]-N,N-dimethylpentadecan-6-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]pentadecan-8-amine, R-N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octyloxy)propan-2-amine, S-N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octyloxy)propan-2-amine, 1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-[(octyloxy)methyl]ethyl}pyrrolidine, (2S)-N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-[(5Z)-oct-5-en-1-yloxy]propan-2-amine, 1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-[(octyloxy)methyl]ethyl}azetidene, (2S)-1-(hexyloxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, (2S)-1-(heptyloxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, N,N-dimethyl-1-(nonyloxy)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, N,N-dimethyl-1-[(9Z)-octadec-9-en-1-yloxy]-3-(octyloxy)propan-2-amine; (2S)-N,N-dimethyl-1-[(6Z,9Z,12Z)-octadeca-6,9,12-trien-1-yloxy]-3-(octyloxy)propan-2-amine, (2S)-1-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(pentyloxy)propan-2-amine, (2S)-1-(hexyloxy)-3-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethylpropan-2-amine, 1-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, 1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, (2S)-1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-3-(hexyloxy)-N,N-dimethylpropan-2-amine, (2S)-1-[(13Z)-docos-13-en-1-yloxy]-3-(hexyloxy)-N,N-dimethylpropan-2-amine, 1-[(13Z)-docos-13-en-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, 1-[(9Z)-hexadec-9-en-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, (2R)-N,N-dimethyl-H(1-metoyloctyl)oxy]-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, (2R)-1-[(3,7-dimethyloctyl)oxy]-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, N,N-dimethyl-1-(octyloxy)-3-[(8-[(1S,2S)-2-[(1R,2R)-2-pentylcyclopropyl]methyl]cyclopropyl]octyl)oxy]propan-2-amine, N,N-dimethyl-1-[(8-(2-octylcyclopropyl)octyl)oxy]-3-(octyloxy)propan-2-amine and (11E,20Z,23Z)-N,N-dimethylnonacos-11,20,23-trien-10-amine or a pharmaceutically acceptable salt or stereoisomer thereof.

[0457] In some embodiments, the LNP formulations of the RNA (e.g., mRNA) vaccines may contain PEG-DOMG at 3% lipid molar ratio. In some embodiments, the LNP formulations of the RNA (e.g., mRNA)

vaccines may contain PEG-c-DOMG at 1.5% lipid molar ratio.

[0458] In some embodiments, the pharmaceutical compositions of the RNA (e.g., mRNA) vaccines may include at least one of the PEGylated lipids described in International Publication No. WO2012099755, the contents of which are herein incorporated by reference in their entirety.

[0459] In some embodiments, the LNP formulation may contain PEG-DMG 2000 (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]). In some embodiments, the LNP formulation may contain PEG-DMG 2000, a cationic lipid known in the art and at least one other component. In some embodiments, the LNP formulation may contain PEG-DMG 2000, a cationic lipid known in the art, DSPC and cholesterol. As a non-limiting example, the LNP formulation may contain PEG-DMG 2000, DLin-DMA, DSPC and cholesterol. As another non-limiting example the LNP formulation may contain PEG-DMG 2000, DLin-DMA, DSPC and cholesterol in a molar ratio of 2:40:10:48 (see e.g., Geall et al., Nonviral delivery of self-amplifying RNA (e.g., mRNA) vaccines, PNAS 2012; PMID: 22908294, the contents of each of which are herein incorporated by reference in their entirety).

[0460] The lipid nanoparticles described herein may be made in a sterile environment.

[0461] In some embodiments, the LNP formulation may be formulated in a nanoparticle such as a nucleic acid-lipid particle. As a non-limiting example, the lipid particle may comprise one or more active agents or therapeutic agents; one or more cationic lipids comprising from about 50 mol % to about 85 mol % of the total lipid present in the particle; one or more non-cationic lipids comprising from about 13 mol % to about 49.5 mol % of the total lipid present in the particle; and one or more conjugated lipids that inhibit aggregation of particles comprising from about 0.5 mol % to about 2 mol % of the total lipid present in the particle.

[0462] The nanoparticle formulations may comprise a phosphate conjugate. The phosphate conjugate may increase in vivo circulation times and/or increase the targeted delivery of the nanoparticle. As a non-limiting example, the phosphate conjugates may include a compound of any one of the formulas described in International Application No. WO2013033438, the contents of which are herein incorporated by reference in its entirety.

[0463] The nanoparticle formulation may comprise a polymer conjugate. The polymer conjugate may be a water soluble conjugate. The polymer conjugate may have a structure as described in U.S. Patent Application No. 20130059360, the contents of which are herein incorporated by reference in its entirety. In some embodiments, polymer conjugates with the polynucleotides of the present disclosure may be made using the methods and/or segmented polymeric reagents described in U.S. Patent Application No. 20130072709, the contents of which are herein incorporated by reference in its entirety. In some embodiments, the polymer conjugate may have pendant side groups comprising ring moieties such as, but not limited to, the polymer conjugates described in U.S. Patent Publication No. US20130196948, the contents which are herein incorporated by reference in its entirety.

[0464] The nanoparticle formulations may comprise a conjugate to enhance the delivery of nanoparticles of the present disclosure in a subject. Further, the conjugate may inhibit phagocytic clearance of the nanoparticles in a subject. In one aspect, the conjugate may be a "self" peptide designed from the human membrane protein CD47 (e.g., the "self" particles described by Rodriguez et al. (Science 2013 339, 971-975), herein incorporated by reference in its entirety). As shown by Rodriguez et al., the self peptides delayed macrophage-mediated clearance of nanoparticles which enhanced delivery of the nanoparticles. In another aspect, the conjugate may be the membrane protein CD47 (e.g., see Rodriguez et al. Science 2013 339, 971-975, herein incorporated by reference in its entirety). Rodriguez et al. showed that, similarly to "self" peptides, CD47 can increase the circulating particle ratio in a subject as compared to scrambled peptides and PEG coated nanoparticles.

[0465] In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure are formulated in nanoparticles which comprise a conjugate to enhance the delivery of the nanoparticles of the present disclosure in a subject. The conjugate may be the CD47 membrane or the conjugate may be derived from the CD47 membrane protein, such as the "self" peptide described previously. In some embodiments, the nanoparticle may

comprise PEG and a conjugate of CD47 or a derivative thereof. In some embodiments, the nanoparticle may comprise both the "self" peptide described above and the membrane protein CD47.

[0466] In some embodiments, a "self" peptide and/or CD47 protein may be conjugated to a virus-like particle or pseudovirion, as described herein for delivery of the RNA (e.g., mRNA) vaccines of the present disclosure.

[0467] In some embodiments, RNA (e.g., mRNA) vaccine pharmaceutical compositions comprising the polynucleotides of the present disclosure and a conjugate that may have a degradable linkage. Non-limiting examples of conjugates include an aromatic moiety comprising an ionizable hydrogen atom, a spacer moiety, and a water-soluble polymer. As a non-limiting example, pharmaceutical compositions comprising a conjugate with a degradable linkage and methods for delivering such pharmaceutical compositions are described in U.S. Patent Publication No. US20130184443, the contents of which are herein incorporated by reference in their entirety.

[0468] The nanoparticle formulations may be a carbohydrate nanoparticle comprising a carbohydrate carrier and a RNA (e.g., mRNA) vaccine. As a non-limiting example, the carbohydrate carrier may include, but is not limited to, an anhydride-modified phytoglycogen or glycogen-type material, phytoglycogen octenyl succinate, phytoglycogen beta-dextrin, anhydride-modified phytoglycogen beta-dextrin. (See e.g., International Publication No. WO2012109121; the contents of which are herein incorporated by reference in their entirety).

[0469] Nanoparticle formulations of the present disclosure may be coated with a surfactant or polymer in order to improve the delivery of the particle. In some embodiments, the nanoparticle may be coated with a hydrophilic coating such as, but not limited to, PEG coatings and/or coatings that have a neutral surface charge. The hydrophilic coatings may help to deliver nanoparticles with larger payloads such as, but not limited to, RNA (e.g., mRNA) vaccines within the central nervous system. As a non-limiting example nanoparticles comprising a hydrophilic coating and methods of making such nanoparticles are described in U.S. Patent Publication No. US20130183244, the contents of which are herein incorporated by reference in their entirety.

[0470] In some embodiments, the lipid nanoparticles of the present disclosure may be hydrophilic polymer particles. Non-limiting examples of hydrophilic polymer particles and methods of making hydrophilic polymer particles are described in U.S. Patent Publication No. US20130210991, the contents of which are herein incorporated by reference in their entirety.

[0471] In some embodiments, the lipid nanoparticles of the present disclosure may be hydrophobic polymer particles.

[0472] Lipid nanoparticle formulations may be improved by replacing the cationic lipid with a biodegradable cationic lipid which is known as a rapidly eliminated lipid nanoparticle (reLNP). Ionizable cationic lipids, such as, but not limited to, DLinDMA, DLin-KC2-DMA, and DLin-MC3-DMA, have been shown to accumulate in plasma and tissues over time and may be a potential source of toxicity. The rapid metabolism of the rapidly eliminated lipids can improve the tolerability and therapeutic index of the lipid nanoparticles by an order of magnitude from a 1 mg/kg dose to a 10 mg/kg dose in rat. Inclusion of an enzymatically degraded ester linkage can improve the degradation and metabolism profile of the cationic component, while still maintaining the activity of the reLNP formulation. The ester linkage can be internally located within the lipid chain or it may be terminally located at the terminal end of the lipid chain. The internal ester linkage may replace any carbon in the lipid chain.

[0473] In some embodiments, the internal ester linkage may be located on either side of the saturated carbon.

[0474] In some embodiments, an immune response may be elicited by delivering a lipid nanoparticle which may include a nanospecies, a polymer and an immunogen. (U.S. Publication No. 20120189700 and International Publication No. WO2012099805; each of which is herein incorporated by reference in their entirety). The polymer may encapsulate the nanospecies or partially encapsulate the nanospecies. The immunogen may be a recombinant protein, a modified RNA and/or a polynucleotide described herein. In some embodiments, the lipid



nanoparticle may be formulated for use in a vaccine such as, but not limited to, against a pathogen.

[0475] Lipid nanoparticles may be engineered to alter the surface properties of particles so the lipid nanoparticles may penetrate the mucosal barrier. Mucus is located on mucosal tissue such as, but not limited to, oral (e.g., the buccal and esophageal membranes and tonsil tissue), ophthalmic, gastrointestinal (e.g., stomach, small intestine, large intestine, colon, rectum), nasal, respiratory (e.g., nasal, pharyngeal, tracheal and bronchial membranes), genital (e.g., vaginal, cervical and urethral membranes). Nanoparticles larger than 10-200 nm which are preferred for higher drug encapsulation efficiency and the ability to provide the sustained delivery of a wide array of drugs have been thought to be too large to rapidly diffuse through mucosal barriers. Mucus is continuously secreted, shed, discarded or digested and recycled so most of the trapped particles may be removed from the mucosa tissue within seconds or within a few hours. Large polymeric nanoparticles (200 nm-500 nm in diameter) which have been coated densely with a low molecular weight polyethylene glycol (PEG) diffused through mucus only 4 to 6-fold lower than the same particles diffusing in water (Lai et al. PNAS 2007 104(5):1482-487; Lai et al. Adv Drug Deliv Rev. 2009 61(2): 158-171; each of which is herein incorporated by reference in their entirety). The transport of nanoparticles may be determined using rates of permeation and/or fluorescent microscopy techniques including, but not limited to, fluorescence recovery after photobleaching (FRAP) and high resolution multiple particle tracking (MPT). As a non-limiting example, compositions which can penetrate a mucosal barrier may be made as described in U.S. Pat. No. 8,241,670 or International Patent Publication No. WO2013110028, the contents of each of which are herein incorporated by reference in its entirety.

[0476] The lipid nanoparticle engineered to penetrate mucus may comprise a polymeric material (i.e. a polymeric core) and/or a polymer-vitamin conjugate and/or a tri-block co-polymer. The polymeric material may include, but is not limited to, polyamines, polyethers, polyamides, polyesters, polycarbamates, polyureas, polycarbonates, poly(styrenes), polyimides, polysulfones, polyurethanes, polyacetylenes, polyethylenes, polyethyleneimines, polyisocyanates, polyacrylates, polymethacrylates, polyacrylonitriles, and polyarylates. The polymeric material may be biodegradable and/or biocompatible. Non-limiting examples of biocompatible polymers are described in International Patent Publication No. WO2013116804, the contents of which are herein incorporated by reference in their entirety. The polymeric material may additionally be irradiated. As a non-limiting example, the polymeric material may be gamma irradiated (see e.g., International App. No. WO201282165, herein incorporated by reference in its entirety). Non-limiting examples of specific polymers include poly(caprolactone) (PCL), ethylene vinyl acetate polymer (EVA), poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid) (PLGA), poly(L-lactic acid-co-glycolic acid) (PLLGA), poly(D,L-lactide) (PDLA), poly(L-lactide) (PLLA), poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone-co-glycolide), poly(D,L-lactide-co-PEO-co-D,L-lactide), poly(D,L-lactide-co-PPO-co-D,L-lactide), polyalkyl cyanoacrylate, polyurethane, poly-L-lysine (PLL), hydroxypropyl methacrylate (HPMA), polyethyleneglycol, poly-L-glutamic acid, poly(hydroxy acids), polyanhydrides, polyorthoesters, poly(ester amides), polyamides, poly(ester ethers), polycarbonates, polyalkylenes such as polyethylene and polypropylene, polyalkylene glycols such as poly(ethylene glycol) (PEG), polyalkylene oxides (PEO), polyalkylene terephthalates such as poly(ethylene terephthalate), polyvinyl alcohols (PVA), polyvinyl ethers, polyvinyl esters such as poly(vinyl acetate), polyvinyl halides such as poly(vinyl chloride) (PVC), polyvinylpyrrolidone, polysiloxanes, polystyrene (PS), polyurethanes, derivatized celluloses such as alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, hydroxypropylcellulose, carboxymethylcellulose, polymers of acrylic acids, such as poly(methyl(meth)acrylate) (PMMA), poly(ethyl(meth)acrylate), poly(butyl(meth)acrylate), poly(isobutyl(meth)acrylate), poly(hexyl(meth)acrylate), poly(isodecyl(meth)acrylate), poly(lauryl(meth)acrylate), poly(phenyl(meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate) and copolymers and mixtures thereof, polydioxanone and its copolymers, polyhydroxyalkanoates, polypropylene fumarate, polyoxymethylene, poloxamers, poly(ortho)esters, poly(butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), PEG-PLGA-PEG and trimethylene carbonate, polyvinylpyrrolidone. The lipid nanoparticle may be coated or associated with a co-polymer such as, but not limited to, a block co-polymer (such as a branched polyether-polyamide block copolymer described in International Publication No. WO2013012476, herein incorporated by reference in its entirety), and (poly(ethylene glycol))-(poly(propylene oxide))-(poly(ethylene glycol)) triblock copolymer (see e.g., U.S. Publication 20120121718 and U.S. Publication 20100003337 and U.S. Pat. No.

8,263,665, the contents of each of which is herein incorporated by reference in their entirety). The co-polymer may be a polymer that is generally regarded as safe (GRAS) and the formation of the lipid nanoparticle may be in such a way that no new chemical entities are created. For example, the lipid nanoparticle may comprise poloxamers coating PLGA nanoparticles without forming new chemical entities which are still able to rapidly penetrate human mucus (Yang et al. *Angew. Chem. Int. Ed.* 2011 50:2597-2600; the contents of which are herein incorporated by reference in their entirety). A non-limiting scalable method to produce nanoparticles which can penetrate human mucus is described by Xu et al. (see, e.g., *J Control Release* 2013, 170(2):279-86; the contents of which are herein incorporated by reference in their entirety).

[0477] The vitamin of the polymer-vitamin conjugate may be vitamin E. The vitamin portion of the conjugate may be substituted with other suitable components such as, but not limited to, vitamin A, vitamin E, other vitamins, cholesterol, a hydrophobic moiety, or a hydrophobic component of other surfactants (e.g., sterol chains, fatty acids, hydrocarbon chains and alkylene oxide chains).

[0478] The lipid nanoparticle engineered to penetrate mucus may include surface altering agents such as, but not limited to, polynucleotides, anionic proteins (e.g., bovine serum albumin), surfactants (e.g., cationic surfactants such as for example dimethyldioctadecylammonium bromide), sugars or sugar derivatives (e.g., cyclodextrin), nucleic acids, polymers (e.g., heparin, polyethylene glycol and poloxamer), mucolytic agents (e.g., N-acetylcysteine, mugwort, bromelain, papain, clerodendrum, acetylcysteine, bromhexine, carbocysteine, eprazinone, mesna, ambroxol, sobrerol, domiodol, letosteine, stepronin, tiopronin, gelsolin, thymosin .beta.4 dornase alfa, neltexine, erdosteine) and various DNases including rhDNase. The surface altering agent may be embedded or enmeshed in the particle's surface or disposed (e.g., by coating, adsorption, covalent linkage, or other process) on the surface of the lipid nanoparticle. (see e.g., U.S. Publication 20100215580 and U.S. Publication 20080166414 and US20130164343; the contents of each of which are herein incorporated by reference in their entirety).

[0479] In some embodiments, the mucus penetrating lipid nanoparticles may comprise at least one polynucleotide described herein. The polynucleotide may be encapsulated in the lipid nanoparticle and/or disposed on the surface of the particle. The polynucleotide may be covalently coupled to the lipid nanoparticle. Formulations of mucus penetrating lipid nanoparticles may comprise a plurality of nanoparticles. Further, the formulations may contain particles which may interact with the mucus and alter the structural and/or adhesive properties of the surrounding mucus to decrease mucoadhesion, which may increase the delivery of the mucus penetrating lipid nanoparticles to the mucosal tissue.

[0480] In some embodiments, the mucus penetrating lipid nanoparticles may be a hypotonic formulation comprising a mucosal penetration enhancing coating. The formulation may be hypotonic for the epithelium to which it is being delivered. Non-limiting examples of hypotonic formulations may be found in International Patent Publication No. WO2013110028, the contents of which are herein incorporated by reference in their entirety.

[0481] In some embodiments, in order to enhance the delivery through the mucosal barrier the RNA (e.g., mRNA) vaccine formulation may comprise or be a hypotonic solution. Hypotonic solutions were found to increase the rate at which muco-inert particles such as, but not limited to, mucus-penetrating particles, were able to reach the vaginal epithelial surface (see e.g., Ensign et al. *Biomaterials* 2013 34(28):6922-9, the contents of which are herein incorporated by reference in their entirety).

[0482] In some embodiments, the RNA (e.g., mRNA) vaccine is formulated as a lipoplex, such as, without limitation, the ATUPLEX.TM. system, the DACC system, the DBTC system and other siRNA-lipoplex technology from Silence Therapeutics (London, United Kingdom), STEMFECT.TM. from STEMGENT.RTM. (Cambridge, Mass.), and polyethylenimine (PEI) or protamine-based targeted and non-targeted delivery of nucleic acids (Aleku et al. *Cancer Res.* 2008 68:9788-9798; Strumberg et al. *Int J Clin Pharmacol Ther* 2012 50:76-78; Santel et al., *Gene Ther* 2006 13:1222-1234; Santel et al., *Gene Ther* 2006 13:1360-1370; Gutbier et al., *Pulm Pharmacol. Ther.* 2010 23:334-344; Kaufmann et al. *Microvasc Res* 2010 80:286-293 Weide et al. *J Immunother.* 2009 32:498-507; Weide et al. *J Immunother.* 2008 31:180-188; Pascolo *Expert Opin. Biol.*

Ther. 4:1285-1294; Fotin-Mleczek et al., 2011 J. Immunother. 34:1-15; Song et al., Nature Biotechnol. 2005, 23:709-717; Peer et al., Proc Natl Acad Sci USA. 2007 6; 104:4095-4100; deFougerolles Hum Gene Ther. 2008 19:125-132, the contents of each of which are incorporated herein by reference in their entirety).

[0483] In some embodiments, such formulations may also be constructed or compositions altered such that they passively or actively are directed to different cell types in vivo, including but not limited to hepatocytes, immune cells, tumor cells, endothelial cells, antigen presenting cells, and leukocytes (Akinc et al. Mol Ther. 2010 18:1357-1364; Song et al., Nat Biotechnol. 2005 23:709-717; Judge et al., J Clin Invest. 2009 119:661-673; Kaufmann et al., Microvasc Res 2010 80:286-293; Santel et al., Gene Ther 2006 13:1222-1234; Santel et al., Gene Ther 2006 13:1360-1370; Gutbier et al., Pulm Pharmacol. Ther. 2010 23:334-344; Basha et al., Mol. Ther. 2011 19:2186-2200; Fenske and Cullis, Expert Opin Drug Deliv. 2008 5:25-44; Peer et al., Science. 2008 319:627-630; Peer and Lieberman, Gene Ther. 2011 18:1127-1133, the contents of each of which are incorporated herein by reference in their entirety). One example of passive targeting of formulations to liver cells includes the DLin-DMA, DLin-KC2-DMA and DLin-MC3-DMA-based lipid nanoparticle formulations, which have been shown to bind to apolipoprotein E and promote binding and uptake of these formulations into hepatocytes in vivo (Akinc et al. Mol Ther. 2010 18:1357-1364, the contents of which are incorporated herein by reference in their entirety). Formulations can also be selectively targeted through expression of different ligands on their surface as exemplified by, but not limited by, folate, transferrin, N-acetylgalactosamine (GalNAc), and antibody targeted approaches (Kolhatkar et al., Curr Drug Discov Technol. 2011 8:197-206; Musacchio and Torchilin, Front Biosci. 2011 16:1388-1412; Yu et al., Mol Membr Biol. 2010 27:286-298; Patil et al., Crit Rev Ther Drug Carrier Syst. 2008 25:1-61; Benoit et al., Biomacromolecules. 2011 12:2708-2714; Zhao et al., Expert Opin Drug Deliv. 2008 5:309-319; Akinc et al., Mol Ther. 2010 18:1357-1364; Srinivasan et al., Methods Mol Biol. 2012 820:105-116; Ben-Arie et al., Methods Mol Biol. 2012 757:497-507; Peer 2010 J Control Release. 20:63-68; Peer et al., Proc Natl Acad Sci USA. 2007 104:4095-4100; Kim et al., Methods Mol Biol. 2011 721:339-353; Subramanya et al., Mol Ther. 2010 18:2028-2037; Song et al., Nat Biotechnol. 2005 23:709-717; Peer et al., Science. 2008 319:627-630; Peer and Lieberman, Gene Ther. 2011 18:1127-1133, the contents of each of which are incorporated herein by reference in their entirety).

[0484] In some embodiments, the RNA (e.g., mRNA) vaccine is formulated as a solid lipid nanoparticle. A solid lipid nanoparticle (SLN) may be spherical with an average diameter between 10 to 1000 nm. SLN possess a solid lipid core matrix that can solubilize lipophilic molecules and may be stabilized with surfactants and/or emulsifiers. In some embodiments, the lipid nanoparticle may be a self-assembly lipid-polymer nanoparticle (see Zhang et al., ACS Nano, 2008, 2 (8), pp 1696-1702; the contents of which are herein incorporated by reference in their entirety). As a non-limiting example, the SLN may be the SLN described in International Patent Publication No. WO2013105101, the contents of which are herein incorporated by reference in their entirety. As another non-limiting example, the SLN may be made by the methods or processes described in International Patent Publication No. WO2013105101, the contents of which are herein incorporated by reference in their entirety.

[0485] Liposomes, lipoplexes, or lipid nanoparticles may be used to improve the efficacy of polynucleotides directed protein production as these formulations may be able to increase cell transfection by the RNA (e.g., mRNA) vaccine; and/or increase the translation of encoded protein. One such example involves the use of lipid encapsulation to enable the effective systemic delivery of polyplex plasmid DNA (Heyes et al., Mol Ther. 2007 15:713-720; the contents of which are incorporated herein by reference in their entirety). The liposomes, lipoplexes, or lipid nanoparticles may also be used to increase the stability of the polynucleotide.

[0486] In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure can be formulated for controlled release and/or targeted delivery. As used herein, "controlled release" refers to a pharmaceutical composition or compound release profile that conforms to a particular pattern of release to effect a therapeutic outcome. In some embodiments, the RNA (e.g., mRNA) vaccines may be encapsulated into a delivery agent described herein and/or known in the art for controlled release and/or targeted delivery. As used herein, the term "encapsulate" means to enclose, surround or encase. As it relates to the formulation of the compounds of the disclosure, encapsulation may be substantial, complete or partial. The term "substantially encapsulated" means that at least greater than 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99, 99.9, 99.9 or greater than 99.999% of the

pharmaceutical composition or compound of the disclosure may be enclosed, surrounded or encased within the delivery agent. "Partially encapsulation" means that less than 10, 10, 20, 30, 40 50 or less of the pharmaceutical composition or compound of the disclosure may be enclosed, surrounded or encased within the delivery agent. Advantageously, encapsulation may be determined by measuring the escape or the activity of the pharmaceutical composition or compound of the disclosure using fluorescence and/or electron micrograph. For example, at least 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99, 99.9, 99.99 or greater than 99.99% of the pharmaceutical composition or compound of the disclosure are encapsulated in the delivery agent.

[0487] In some embodiments, the controlled release formulation may include, but is not limited to, tri-block co-polymers. As a non-limiting example, the formulation may include two different types of tri-block co-polymers (International Pub. No. WO2012131104 and WO2012131106, the contents of each of which are incorporated herein by reference in their entirety).

[0488] In some embodiments, the RNA (e.g., mRNA) vaccines may be encapsulated into a lipid nanoparticle or a rapidly eliminated lipid nanoparticle and the lipid nanoparticles or a rapidly eliminated lipid nanoparticle may then be encapsulated into a polymer, hydrogel and/or surgical sealant described herein and/or known in the art. As a non-limiting example, the polymer, hydrogel or surgical sealant may be PLGA, ethylene vinyl acetate (EVAc), poloxamer, GELSITE.RTM. (Nanotherapeutics, Inc. Alachua, Fla.), HYLENEX.RTM. (Halozyme Therapeutics, San Diego Calif.), surgical sealants such as fibrinogen polymers (Ethicon Inc. Cornelia, Ga.), TISSELL.RTM. (Baxter International, Inc Deerfield, Ill.), PEG-based sealants, and COSEAL.RTM. (Baxter International, Inc Deerfield, Ill.).

[0489] In some embodiments, the lipid nanoparticle may be encapsulated into any polymer known in the art which may form a gel when injected into a subject. As another non-limiting example, the lipid nanoparticle may be encapsulated into a polymer matrix which may be biodegradable.

[0490] In some embodiments, the RNA (e.g., mRNA) vaccine formulation for controlled release and/or targeted delivery may also include at least one controlled release coating. Controlled release coatings include, but are not limited to, OPADRY.RTM., polyvinylpyrrolidone/vinyl acetate copolymer, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, EUDRAGIT RL.RTM., EUDRAGIT RS.RTM. and cellulose derivatives such as ethylcellulose aqueous dispersions (AQUACOAT.RTM. and SURELEASE.RTM.).

[0491] In some embodiments, the RNA (e.g., mRNA) vaccine controlled release and/or targeted delivery formulation may comprise at least one degradable polyester which may contain polycationic side chains. Degradable polyesters include, but are not limited to, poly(serine ester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester), and combinations thereof. In some embodiments, the degradable polyesters may include a PEG conjugation to form a PEGylated polymer.

[0492] In some embodiments, the RNA (e.g., mRNA) vaccine controlled release and/or targeted delivery formulation comprising at least one polynucleotide may comprise at least one PEG and/or PEG related polymer derivatives as described in U.S. Pat. No. 8,404,222, the contents of which are incorporated herein by reference in their entirety.

[0493] In some embodiments, the RNA (e.g., mRNA) vaccine controlled release delivery formulation comprising at least one polynucleotide may be the controlled release polymer system described in US20130130348, the contents of which are incorporated herein by reference in their entirety.

[0494] In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure may be encapsulated in a therapeutic nanoparticle, referred to herein as "therapeutic nanoparticle RNA (e.g., mRNA) vaccines." Therapeutic nanoparticles may be formulated by methods described herein and known in the art such as, but not limited to, International Pub Nos. WO2010005740, WO2010030763, WO2010005721, WO2010005723, WO2012054923, U.S. Publication Nos. US20110262491, US20100104645, US20100087337, US20100068285, US20110274759, US20100068286, US20120288541, US20130123351 and US20130230567 and U.S. Pat. Nos.

8,206,747, 8,293,276, 8,318,208 and 8,318,211; the contents of each of which are herein incorporated by reference in their entirety. In some embodiments, therapeutic polymer nanoparticles may be identified by the methods described in US Pub No. US20120140790, the contents of which are herein incorporated by reference in their entirety.

[0495] In some embodiments, the therapeutic nanoparticle RNA (e.g., mRNA) vaccine may be formulated for sustained release. As used herein, "sustained release" refers to a pharmaceutical composition or compound that conforms to a release rate over a specific period of time. The period of time may include, but is not limited to, hours, days, weeks, months and years. As a non-limiting example, the sustained release nanoparticle may comprise a polymer and a therapeutic agent such as, but not limited to, the polynucleotides of the present disclosure (see International Pub No. 2010075072 and US Pub No. US20100216804, US20110217377 and US20120201859, the contents of each of which are incorporated herein by reference in their entirety). In another non-limiting example, the sustained release formulation may comprise agents which permit persistent bioavailability such as, but not limited to, crystals, macromolecular gels and/or particulate suspensions (see U.S. Patent Publication No US20130150295, the contents of each of which are incorporated herein by reference in their entirety).

[0496] In some embodiments, the therapeutic nanoparticle RNA (e.g., mRNA) vaccines may be formulated to be target specific. As a non-limiting example, the therapeutic nanoparticles may include a corticosteroid (see International Pub. No. WO2011084518, the contents of which are incorporated herein by reference in their entirety). As a non-limiting example, the therapeutic nanoparticles may be formulated in nanoparticles described in International Pub No. WO2008121949, WO2010005726, WO2010005725, WO2011084521 and US Pub No. US20100069426, US20120004293 and US20100104655, the contents of each of which are incorporated herein by reference in their entirety.

[0497] In some embodiments, the nanoparticles of the present disclosure may comprise a polymeric matrix. As a non-limiting example, the nanoparticle may comprise two or more polymers such as, but not limited to, polyethylenes, polycarbonates, polyanhydrides, polyhydroxyacids, polypropylfumerates, polycaprolactones, polyamides, polyacetals, polyethers, polyesters, poly(orthoesters), polycyanoacrylates, polyvinyl alcohols, polyurethanes, polyphosphazenes, polyacrylates, polymethacrylates, polycyanoacrylates, polyureas, polystyrenes, polyamines, polylysine, poly(ethylene imine), poly(serine ester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester) or combinations thereof.

[0498] In some embodiments, the therapeutic nanoparticle comprises a diblock copolymer. In some embodiments, the diblock copolymer may include PEG in combination with a polymer such as, but not limited to, polyethylenes, polycarbonates, polyanhydrides, polyhydroxyacids, polypropylfumerates, polycaprolactones, polyamides, polyacetals, polyethers, polyesters, poly(orthoesters), polycyanoacrylates, polyvinyl alcohols, polyurethanes, polyphosphazenes, polyacrylates, polymethacrylates, polycyanoacrylates, polyureas, polystyrenes, polyamines, polylysine, poly(ethylene imine), poly(serine ester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester) or combinations thereof. In yet another embodiment, the diblock copolymer may be a high-X diblock copolymer such as those described in International Patent Publication No. WO2013120052, the contents of which are incorporated herein by reference in their entirety.

[0499] As a non-limiting example the therapeutic nanoparticle comprises a PLGA-PEG block copolymer (see U.S. Publication No. US20120004293 and U.S. Pat. No. 8,236,330, each of which is herein incorporated by reference in their entirety). In another non-limiting example, the therapeutic nanoparticle is a stealth nanoparticle comprising a diblock copolymer of PEG and PLA or PEG and PLGA (see U.S. Pat. No. 8,246,968 and International Publication No. WO2012166923, the contents of each of which are herein incorporated by reference in their entirety). In yet another non-limiting example, the therapeutic nanoparticle is a stealth nanoparticle or a target-specific stealth nanoparticle as described in U.S. Patent Publication No. US20130172406, the contents of which are herein incorporated by reference in their entirety.

[0500] In some embodiments, the therapeutic nanoparticle may comprise a multiblock copolymer (see e.g., U.S. Pat. Nos. 8,263,665 and 8,287,910 and U.S. Patent Pub. No. US20130195987, the contents of each of which are

herein incorporated by reference in their entirety).

[0501] In yet another non-limiting example, the lipid nanoparticle comprises the block copolymer PEG-PLGA-PEG (see e.g., the thermosensitive hydrogel (PEG-PLGA-PEG) was used as a TGF-beta1 gene delivery vehicle in Lee et al. Thermosensitive Hydrogel as a Tgf-beta.1 Gene Delivery Vehicle Enhances Diabetic Wound Healing. *Pharmaceutical Research*, 2003 20(12): 1995-2000; as a controlled gene delivery system in Li et al. Controlled Gene Delivery System Based on Thermosensitive Biodegradable Hydrogel. *Pharmaceutical Research* 2003 20(6):884-888; and Chang et al., Non-ionic amphiphilic biodegradable PEG-PLGA-PEG copolymer enhances gene delivery efficiency in rat skeletal muscle. *J Controlled Release*. 2007 118:245-253, the contents of each of which are herein incorporated by reference in their entirety). The RNA (e.g., mRNA) vaccines of the present disclosure may be formulated in lipid nanoparticles comprising the PEG-PLGA-PEG block copolymer.

[0502] In some embodiments, the therapeutic nanoparticle may comprise a multiblock copolymer (see e.g., U.S. Pat. Nos. 8,263,665 and 8,287,910 and U.S. Patent Pub. No. US20130195987, the contents of each of which are herein incorporated by reference in their entirety).

[0503] In some embodiments, the block copolymers described herein may be included in a polyion complex comprising a non-polymeric micelle and the block copolymer. (see e.g., U.S. Publication No. 20120076836, the contents of which are herein incorporated by reference in their entirety).

[0504] In some embodiments, the therapeutic nanoparticle may comprise at least one acrylic polymer. Acrylic polymers include but are not limited to, acrylic acid, methacrylic acid, acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, amino alkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), polycyanoacrylates and combinations thereof.

[0505] In some embodiments, the therapeutic nanoparticles may comprise at least one poly(vinyl ester) polymer. The poly(vinyl ester) polymer may be a copolymer such as a random copolymer. As a non-limiting example, the random copolymer may have a structure such as those described in International Application No. WO2013032829 or U.S. Patent Publication No US20130121954, the contents of each of which are herein incorporated by reference in their entirety. In some embodiments, the poly(vinyl ester) polymers may be conjugated to the polynucleotides described herein.

[0506] In some embodiments, the therapeutic nanoparticle may comprise at least one diblock copolymer. The diblock copolymer may be, but it not limited to, a poly(lactic) acid-poly(ethylene)glycol copolymer (see, e.g., International Patent Publication No. WO2013044219, the contents of which are herein incorporated by reference in their entirety). As a non-limiting example, the therapeutic nanoparticle may be used to treat cancer (see International publication No. WO2013044219, the contents of which are herein incorporated by reference in their entirety).

[0507] In some embodiments, the therapeutic nanoparticles may comprise at least one cationic polymer described herein and/or known in the art.

[0508] In some embodiments, the therapeutic nanoparticles may comprise at least one amine-containing polymer such as, but not limited to polylysine, polyethylene imine, poly(amidoamine) dendrimers, poly(beta-amino esters) (see, e.g., U.S. Pat. No. 8,287,849, the contents of which are herein incorporated by reference in their entirety) and combinations thereof.

[0509] In some embodiments, the nanoparticles described herein may comprise an amine cationic lipid such as those described in International Patent Application No. WO2013059496, the contents of which are herein incorporated by reference in their entirety. In some embodiments, the cationic lipids may have an amino-amine or an amino-amide moiety.

[0510] In some embodiments, the therapeutic nanoparticles may comprise at least one degradable polyester

which may contain polycationic side chains. Degradable polyesters include, but are not limited to, poly(serine ester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester), and combinations thereof. In some embodiments, the degradable polyesters may include a PEG conjugation to form a PEGylated polymer.

[0511] In some embodiments, the synthetic nanocarriers may contain an immunostimulatory agent to enhance the immune response from delivery of the synthetic nanocarrier. As a non-limiting example, the synthetic nanocarrier may comprise a Th1 immunostimulatory agent, which may enhance a Th1-based response of the immune system (see International Pub No. WO2010123569 and U.S. Publication No. US20110223201, the contents of each of which are herein incorporated by reference in their entirety).

[0512] In some embodiments, the synthetic nanocarriers may be formulated for targeted release. In some embodiments, the synthetic nanocarrier is formulated to release the polynucleotides at a specified pH and/or after a desired time interval. As a non-limiting example, the synthetic nanoparticle may be formulated to release the RNA (e.g., mRNA) vaccines after 24 hours and/or at a pH of 4.5 (see International Publication Nos. WO2010138193 and WO2010138194 and US Pub Nos. US20110020388 and US20110027217, each of which is herein incorporated by reference in their entirety).

[0513] In some embodiments, the synthetic nanocarriers may be formulated for controlled and/or sustained release of the polynucleotides described herein. As a non-limiting example, the synthetic nanocarriers for sustained release may be formulated by methods known in the art, described herein and/or as described in International Pub No. WO2010138192 and US Pub No. 20100303850, each of which is herein incorporated by reference in their entirety.

[0514] In some embodiments, the RNA (e.g., mRNA) vaccine may be formulated for controlled and/or sustained release wherein the formulation comprises at least one polymer that is a crystalline side chain (CYSC) polymer. CYSC polymers are described in U.S. Pat. No. 8,399,007, herein incorporated by reference in its entirety.

[0515] In some embodiments, the synthetic nanocarrier may be formulated for use as a vaccine. In some embodiments, the synthetic nanocarrier may encapsulate at least one polynucleotide which encode at least one antigen. As a non-limiting example, the synthetic nanocarrier may include at least one antigen and an excipient for a vaccine dosage form (see International Publication No. WO2011150264 and U.S. Publication No. US20110293723, the contents of each of which are herein incorporated by reference in their entirety). As another non-limiting example, a vaccine dosage form may include at least two synthetic nanocarriers with the same or different antigens and an excipient (see International Publication No. WO2011150249 and U.S. Publication No. US20110293701, the contents of each of which are herein incorporated by reference in their entirety). The vaccine dosage form may be selected by methods described herein, known in the art and/or described in International Publication No. WO2011150258 and U.S. Publication No. US20120027806, the contents of each of which are herein incorporated by reference in their entirety).

[0516] In some embodiments, the synthetic nanocarrier may comprise at least one polynucleotide which encodes at least one adjuvant. As non-limiting example, the adjuvant may comprise dimethyldioctadecylammonium-bromide, dimethyldioctadecylammonium-chloride, dimethyldioctadecylammonium-phosphate or dimethyldioctadecylammonium-acetate (DDA) and an apolar fraction or part of said apolar fraction of a total lipid extract of a mycobacterium (see, e.g., U.S. Pat. No. 8,241,610, the content of which is herein incorporated by reference in its entirety). In some embodiments, the synthetic nanocarrier may comprise at least one polynucleotide and an adjuvant. As a non-limiting example, the synthetic nanocarrier comprising and adjuvant may be formulated by the methods described in International Publication No. WO2011150240 and U.S. Publication No. US20110293700, the contents of each of which are herein incorporated by reference in their entirety.

[0517] In some embodiments, the synthetic nanocarrier may encapsulate at least one polynucleotide that encodes a peptide, fragment or region from a virus. As a non-limiting example, the synthetic nanocarrier may include, but is not limited to, any of the nanocarriers described in International Publication No. WO2012024621, WO201202629, WO2012024632 and U.S. Publication No. US20120064110, US20120058153 and

US20120058154, the contents of each of which are herein incorporated by reference in their entirety.

[0518] In some embodiments, the synthetic nanocarrier may be coupled to a polynucleotide which may be able to trigger a humoral and/or cytotoxic T lymphocyte (CTL) response (see, e.g., International Publication No. WO2013019669, the contents of which are herein incorporated by reference in their entirety).

[0519] In some embodiments, the RNA (e.g., mRNA) vaccine may be encapsulated in, linked to and/or associated with zwitterionic lipids. Non-limiting examples of zwitterionic lipids and methods of using zwitterionic lipids are described in U.S. Patent Publication No. US20130216607, the contents of which are herein incorporated by reference in their entirety. In some aspects, the zwitterionic lipids may be used in the liposomes and lipid nanoparticles described herein.

[0520] In some embodiments, the RNA (e.g., mRNA) vaccine may be formulated in colloid nanocarriers as described in U.S. Patent Publication No. US20130197100, the contents of which are herein incorporated by reference in their entirety.

[0521] In some embodiments, the nanoparticle may be optimized for oral administration. The nanoparticle may comprise at least one cationic biopolymer such as, but not limited to, chitosan or a derivative thereof. As a non-limiting example, the nanoparticle may be formulated by the methods described in U.S. Publication No. 20120282343, the contents of which are herein incorporated by reference in their entirety.

[0522] In some embodiments, LNPs comprise the lipid KL52 (an amino-lipid disclosed in U.S. Application Publication No. 2012/0295832, the contents of which are herein incorporated by reference in their entirety. Activity and/or safety (as measured by examining one or more of ALT/AST, white blood cell count and cytokine induction, for example) of LNP administration may be improved by incorporation of such lipids. LNPs comprising KL52 may be administered intravenously and/or in one or more doses. In some embodiments, administration of LNPs comprising KL52 results in equal or improved mRNA and/or protein expression as compared to LNPs comprising MC3.

[0523] In some embodiments, RNA (e.g., mRNA) vaccine may be delivered using smaller LNPs. Such particles may comprise a diameter from below 0.1  $\mu\text{m}$  up to 100  $\mu\text{m}$  such as, but not limited to, less than 0.1  $\mu\text{m}$ , less than 1.0  $\mu\text{m}$ , less than 5  $\mu\text{m}$ , less than 10  $\mu\text{m}$ , less than 15  $\mu\text{m}$ , less than 20  $\mu\text{m}$ , less than 25  $\mu\text{m}$ , less than 30  $\mu\text{m}$ , less than 35  $\mu\text{m}$ , less than 40  $\mu\text{m}$ , less than 50  $\mu\text{m}$ , less than 55  $\mu\text{m}$ , less than 60  $\mu\text{m}$ , less than 65  $\mu\text{m}$ , less than 70  $\mu\text{m}$ , less than 75  $\mu\text{m}$ , less than 80  $\mu\text{m}$ , less than 85  $\mu\text{m}$ , less than 90  $\mu\text{m}$ , less than 95  $\mu\text{m}$ , less than 100  $\mu\text{m}$ , less than 125  $\mu\text{m}$ , less than 150  $\mu\text{m}$ , less than 175  $\mu\text{m}$ , less than 200  $\mu\text{m}$ , less than 225  $\mu\text{m}$ , less than 250  $\mu\text{m}$ , less than 275  $\mu\text{m}$ , less than 300  $\mu\text{m}$ , less than 325  $\mu\text{m}$ , less than 350  $\mu\text{m}$ , less than 375  $\mu\text{m}$ , less than 400  $\mu\text{m}$ , less than 425  $\mu\text{m}$ , less than 450  $\mu\text{m}$ , less than 475  $\mu\text{m}$ , less than 500  $\mu\text{m}$ , less than 525  $\mu\text{m}$ , less than 550  $\mu\text{m}$ , less than 575  $\mu\text{m}$ , less than 600  $\mu\text{m}$ , less than 625  $\mu\text{m}$ , less than 650  $\mu\text{m}$ , less than 675  $\mu\text{m}$ , less than 700  $\mu\text{m}$ , less than 725  $\mu\text{m}$ , less than 750  $\mu\text{m}$ , less than 775  $\mu\text{m}$ , less than 800  $\mu\text{m}$ , less than 825  $\mu\text{m}$ , less than 850  $\mu\text{m}$ , less than 875  $\mu\text{m}$ , less than 900  $\mu\text{m}$ , less than 925  $\mu\text{m}$ , less than 950  $\mu\text{m}$ , less than 975  $\mu\text{m}$ , or less than 1000  $\mu\text{m}$ .

[0524] In some embodiments, RNA (e.g., mRNA) vaccines may be delivered using smaller LNPs, which may comprise a diameter from about 1  $\text{nm}$  to about 100  $\text{nm}$ , from about 1  $\text{nm}$  to about 10  $\text{nm}$ , about 1  $\text{nm}$  to about 20  $\text{nm}$ , from about 1  $\text{nm}$  to about 30  $\text{nm}$ , from about 1  $\text{nm}$  to about 40  $\text{nm}$ , from about 1  $\text{nm}$  to about 50  $\text{nm}$ , from about 1  $\text{nm}$  to about 60  $\text{nm}$ , from about 1  $\text{nm}$  to about 70  $\text{nm}$ , from about 1  $\text{nm}$  to about 80  $\text{nm}$ , from about 1  $\text{nm}$  to about 90  $\text{nm}$ , from about 5  $\text{nm}$  to about from 100  $\text{nm}$ , from about 5  $\text{nm}$  to about 10  $\text{nm}$ , about 5  $\text{nm}$  to about 20  $\text{nm}$ , from about 5  $\text{nm}$  to about 30  $\text{nm}$ , from about 5  $\text{nm}$  to about 40  $\text{nm}$ , from about 5  $\text{nm}$  to about 50  $\text{nm}$ , from about 5  $\text{nm}$  to about 60  $\text{nm}$ , from about 5  $\text{nm}$  to about 70  $\text{nm}$ , from about 5  $\text{nm}$  to about 80  $\text{nm}$ , from about 5  $\text{nm}$  to about 90  $\text{nm}$ , about 10 to about 50  $\text{nm}$ , from about 20 to about 50  $\text{nm}$ , from about 30 to about 50  $\text{nm}$ , from about 40 to about 50  $\text{nm}$ , from about 20 to about 60  $\text{nm}$ , from about 30 to about 60  $\text{nm}$ , from about 40 to about 60  $\text{nm}$ , from about 20 to about 70  $\text{nm}$ , from about 30 to about 70  $\text{nm}$ , from about 40 to about 70  $\text{nm}$ , from about 50 to about 70  $\text{nm}$ , from about 60 to about 70  $\text{nm}$ , from about 20 to about 80  $\text{nm}$ , from about 30 to about 80  $\text{nm}$ , from about 40 to about 80  $\text{nm}$ , from about 50 to about 80  $\text{nm}$ , from about 60 to about 80  $\text{nm}$ , from about 20 to about 90  $\text{nm}$ , from about 30 to about 90  $\text{nm}$ , from about 40 to about 90  $\text{nm}$ , from about 50 to about 90  $\text{nm}$ ,



from about 60 to about 90 nm and/or from about 70 to about 90 nm.

[0525] In some embodiments, such LNPs are synthesized using methods comprising microfluidic mixers. Examples of microfluidic mixers may include, but are not limited to, a slit interdigital micromixer including, but not limited to those manufactured by Microinnova (Allerheiligen bei Wildon, Austria) and/or a staggered herringbone micromixer (SHM) (Zhigaltsev, I. V. et al., Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing have been published (Langmuir. 2012. 28:3633-40; Belliveau, N. M. et al., Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Molecular Therapy-Nucleic Acids. 2012. 1:e37; Chen, D. et al., Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J Am Chem Soc. 2012. 134(16):6948-51, the contents of each of which are herein incorporated by reference in their entirety). In some embodiments, methods of LNP generation comprising SHM, further comprise the mixing of at least two input streams wherein mixing occurs by microstructure-induced chaotic advection (MICA). According to this method, fluid streams flow through channels present in a herringbone pattern causing rotational flow and folding the fluids around each other. This method may also comprise a surface for fluid mixing wherein the surface changes orientations during fluid cycling. Methods of generating LNPs using SHM include those disclosed in U.S. Application Publication Nos. 2004/0262223 and 2012/0276209, the contents of each of which are herein incorporated by reference in their entirety.

[0526] In some embodiments, the RNA (e.g., mRNA) vaccine of the present disclosure may be formulated in lipid nanoparticles created using a micromixer such as, but not limited to, a Slit Interdigital Microstructured Mixer (SIMM-V2) or a Standard Slit Interdigital Micro Mixer (SSIMM) or Caterpillar (CPMM) or Impinging-jet (IJMM) from the Institut für Mikrotechnik Mainz GmbH, Mainz Germany).

[0527] In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure may be formulated in lipid nanoparticles created using microfluidic technology (see, e.g., Whitesides, George M. The Origins and the Future of Microfluidics. Nature, 2006 442: 368-373; and Abraham et al. Chaotic Mixer for Microchannels. Science, 2002 295: 647-651; each of which is herein incorporated by reference in its entirety). As a non-limiting example, controlled microfluidic formulation includes a passive method for mixing streams of steady pressure-driven flows in micro channels at a low Reynolds number (see, e.g., Abraham et al. Chaotic Mixer for Microchannels. Science, 2002 295: 647-651, the contents of which are herein incorporated by reference in their entirety).

[0528] In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure may be formulated in lipid nanoparticles created using a micromixer chip such as, but not limited to, those from Harvard Apparatus (Holliston, Mass.) or Dolomite Microfluidics (Royston, UK). A micromixer chip can be used for rapid mixing of two or more fluid streams with a split and recombine mechanism.

[0529] In some embodiments, the RNA (e.g., mRNA) vaccines of the disclosure may be formulated for delivery using the drug encapsulating microspheres described in International Patent Publication No. WO2013063468 or U.S. Pat. No. 8,440,614, the contents of each of which are herein incorporated by reference in their entirety. The microspheres may comprise a compound of the formula (I), (II), (III), (IV), (V) or (VI) as described in International Patent Publication No. WO2013063468, the contents of which are herein incorporated by reference in their entirety. In some embodiments, the amino acid, peptide, polypeptide, lipids (APPL) are useful in delivering the RNA (e.g., mRNA) vaccines of the disclosure to cells (see International Patent Publication No. WO2013063468, the contents of which are herein incorporated by reference in their entirety).

[0530] In some embodiments, the RNA (e.g., mRNA) vaccines of the disclosure may be formulated in lipid nanoparticles having a diameter from about 10 to about 100 nm such as, but not limited to, about 10 to about 20 nm, about 10 to about 30 nm, about 10 to about 40 nm, about 10 to about 50 nm, about 10 to about 60 nm, about 10 to about 70 nm, about 10 to about 80 nm, about 10 to about 90 nm, about 20 to about 30 nm, about 20 to about 40 nm, about 20 to about 50 nm, about 20 to about 60 nm, about 20 to about 70 nm, about 20 to about 80 nm, about 20 to about 90 nm, about 20 to about 100 nm, about 30 to about 40 nm, about 30 to about 50 nm, about 30 to about 60 nm, about 30 to about 70 nm, about 30 to about 80 nm, about 30 to about 90 nm, about 30

to about 100 nm, about 40 to about 50 nm, about 40 to about 60 nm, about 40 to about 70 nm, about 40 to about 80 nm, about 40 to about 90 nm, about 40 to about 100 nm, about 50 to about 60 nm, about 50 to about 70 nm, about 50 to about 80 nm, about 50 to about 90 nm, about 50 to about 100 nm, about 60 to about 70 nm, about 60 to about 80 nm, about 60 to about 90 nm, about 60 to about 100 nm, about 70 to about 80 nm, about 70 to about 90 nm, about 70 to about 100 nm, about 80 to about 90 nm, about 80 to about 100 nm and/or about 90 to about 100 nm.

[0531] In some embodiments, the lipid nanoparticles may have a diameter from about 10 to 500 nm.

[0532] In some embodiments, the lipid nanoparticle may have a diameter greater than 100 nm, greater than 150 nm, greater than 200 nm, greater than 250 nm, greater than 300 nm, greater than 350 nm, greater than 400 nm, greater than 450 nm, greater than 500 nm, greater than 550 nm, greater than 600 nm, greater than 650 nm, greater than 700 nm, greater than 750 nm, greater than 800 nm, greater than 850 nm, greater than 900 nm, greater than 950 nm or greater than 1000 nm.

[0533] In some embodiments, the lipid nanoparticle may be a limit size lipid nanoparticle described in International Patent Publication No. WO2013059922, the contents of which are herein incorporated by reference in their entirety. The limit size lipid nanoparticle may comprise a lipid bilayer surrounding an aqueous core or a hydrophobic core; where the lipid bilayer may comprise a phospholipid such as, but not limited to, diacylphosphatidylcholine, a diacylphosphatidylethanolamine, a ceramide, a sphingomyelin, a dihydrosphingomyelin, a cephalin, a cerebroside, a C8-C20 fatty acid diacylphosphatidylcholine, and 1-palmitoyl-2-oleoyl phosphatidylcholine (POPC). In some embodiments, the limit size lipid nanoparticle may comprise a polyethylene glycol-lipid such as, but not limited to, DLPE-PEG, DMPE-PEG, DPPC-PEG and DSPE-PEG.

[0534] In some embodiments, the RNA (e.g., mRNA) vaccines may be delivered, localized and/or concentrated in a specific location using the delivery methods described in International Patent Publication No. WO2013063530, the contents of which are herein incorporated by reference in their entirety. As a non-limiting example, a subject may be administered an empty polymeric particle prior to, simultaneously with or after delivering the RNA (e.g., mRNA) vaccines to the subject. The empty polymeric particle undergoes a change in volume once in contact with the subject and becomes lodged, embedded, immobilized or entrapped at a specific location in the subject.

[0535] In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in an active substance release system (see, e.g., U.S. Patent Publication No. US20130102545, the contents of which are herein incorporated by reference in their entirety). The active substance release system may comprise 1) at least one nanoparticle bonded to an oligonucleotide inhibitor strand which is hybridized with a catalytically active nucleic acid and 2) a compound bonded to at least one substrate molecule bonded to a therapeutically active substance (e.g., polynucleotides described herein), where the therapeutically active substance is released by the cleavage of the substrate molecule by the catalytically active nucleic acid.

[0536] In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in a nanoparticle comprising an inner core comprising a non-cellular material and an outer surface comprising a cellular membrane. The cellular membrane may be derived from a cell or a membrane derived from a virus. As a non-limiting example, the nanoparticle may be made by the methods described in International Patent Publication No. WO2013052167, the contents of which are herein incorporated by reference in their entirety. As another non-limiting example, the nanoparticle described in International Patent Publication No. WO2013052167, the contents of which are herein incorporated by reference in their entirety, may be used to deliver the RNA (e.g., mRNA) vaccines described herein.

[0537] In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in porous nanoparticle-supported lipid bilayers (protocells). Protocells are described in International Patent Publication No. WO2013056132, the contents of which are herein incorporated by reference in their entirety.

[0538] In some embodiments, the RNA (e.g., mRNA) vaccines described herein may be formulated in polymeric nanoparticles as described in or made by the methods described in U.S. Pat. Nos. 8,420,123 and 8,518,963 and European Patent No. EP2073848B1, the contents of each of which are herein incorporated by reference in their entirety. As a non-limiting example, the polymeric nanoparticle may have a high glass transition temperature such as the nanoparticles described in or nanoparticles made by the methods described in U.S. Pat. No. 8,518,963, the contents of which are herein incorporated by reference in their entirety. As another non-limiting example, the polymer nanoparticle for oral and parenteral formulations may be made by the methods described in European Patent No. EP2073848B1, the contents of which are herein incorporated by reference in their entirety.

[0539] In some embodiments, the RNA (e.g., mRNA) vaccines described herein may be formulated in nanoparticles used in imaging. The nanoparticles may be liposome nanoparticles such as those described in U.S. Patent Publication No US20130129636, herein incorporated by reference in its entirety. As a non-limiting example, the liposome may comprise gadolinium(III)2-{4,7-bis-carboxymethyl-10-[(N,N-distearylamidomethyl-N'-amido-methyl)-1,4,7,10-tetra-azacyclododec-1-yl]}-acetic acid and a neutral, fully saturated phospholipid component (see, e.g., U.S. Patent Publication No US20130129636, the contents of which are herein incorporated by reference in their entirety).

[0540] In some embodiments, the nanoparticles which may be used in the present disclosure are formed by the methods described in U.S. Patent Application No. US20130130348, the contents of which are herein incorporated by reference in their entirety.

[0541] The nanoparticles of the present disclosure may further include nutrients such as, but not limited to, those which deficiencies can lead to health hazards from anemia to neural tube defects (see, e.g., the nanoparticles described in International Patent Publication No WO2013072929, the contents of which are herein incorporated by reference in their entirety). As a non-limiting example, the nutrient may be iron in the form of ferrous, ferric salts or elemental iron, iodine, folic acid, vitamins or micronutrients.

[0542] In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure may be formulated in a swellable nanoparticle. The swellable nanoparticle may be, but is not limited to, those described in U.S. Pat. No. 8,440,231, the contents of which are herein incorporated by reference in their entirety. As a non-limiting embodiment, the swellable nanoparticle may be used for delivery of the RNA (e.g., mRNA) vaccines of the present disclosure to the pulmonary system (see, e.g., U.S. Pat. No. 8,440,231, the contents of which are herein incorporated by reference in their entirety).

[0543] The RNA (e.g., mRNA) vaccines of the present disclosure may be formulated in polyanhydride nanoparticles such as, but not limited to, those described in U.S. Pat. No. 8,449,916, the contents of which are herein incorporated by reference in their entirety.

[0544] The nanoparticles and microparticles of the present disclosure may be geometrically engineered to modulate macrophage and/or the immune response. In some embodiments, the geometrically engineered particles may have varied shapes, sizes and/or surface charges in order to incorporate the polynucleotides of the present disclosure for targeted delivery such as, but not limited to, pulmonary delivery (see, e.g., International Publication No WO2013082111, the contents of which are herein incorporated by reference in their entirety). Other physical features the geometrically engineering particles may have include, but are not limited to, fenestrations, angled arms, asymmetry and surface roughness, charge which can alter the interactions with cells and tissues. As a non-limiting example, nanoparticles of the present disclosure may be made by the methods described in International Publication No WO2013082111, the contents of which are herein incorporated by reference in their entirety.

[0545] In some embodiments, the nanoparticles of the present disclosure may be water soluble nanoparticles such as, but not limited to, those described in International Publication No. WO2013090601, the contents of which are herein incorporated by reference in their entirety. The nanoparticles may be inorganic nanoparticles which have a compact and zwitterionic ligand in order to exhibit good water solubility. The nanoparticles may

also have small hydrodynamic diameters (HD), stability with respect to time, pH, and salinity and a low level of non-specific protein binding.

[0546] In some embodiments the nanoparticles of the present disclosure may be developed by the methods described in U.S. Patent Publication No. US20130172406, the contents of which are herein incorporated by reference in their entirety.

[0547] In some embodiments, the nanoparticles of the present disclosure are stealth nanoparticles or target-specific stealth nanoparticles such as, but not limited to, those described in U.S. Patent Publication No. US20130172406, the contents of which are herein incorporated by reference in their entirety. The nanoparticles of the present disclosure may be made by the methods described in U.S. Patent Publication No. US20130172406, the contents of which are herein incorporated by reference in their entirety.

[0548] In some embodiments, the stealth or target-specific stealth nanoparticles may comprise a polymeric matrix. The polymeric matrix may comprise two or more polymers such as, but not limited to, polyethylenes, polycarbonates, polyanhydrides, polyhydroxyacids, polypropylfumerates, polycaprolactones, polyamides, polyacetals, polyethers, polyesters, poly(orthoesters), polycyanoacrylates, polyvinyl alcohols, polyurethanes, polyphosphazenes, polyacrylates, polymethacrylates, polycyanoacrylates, polyureas, polystyrenes, polyamines, polyesters, polyanhydrides, polyethers, polyurethanes, polymethacrylates, polyacrylates, polycyanoacrylates or combinations thereof.

[0549] In some embodiments, the nanoparticle may be a nanoparticle-nucleic acid hybrid structure having a high density nucleic acid layer. As a non-limiting example, the nanoparticle-nucleic acid hybrid structure may be made by the methods described in U.S. Patent Publication No. US20130171646, the contents of which are herein incorporated by reference in their entirety. The nanoparticle may comprise a nucleic acid such as, but not limited to, polynucleotides described herein and/or known in the art.

[0550] At least one of the nanoparticles of the present disclosure may be embedded in the core a nanostructure or coated with a low density porous 3-D structure or coating which is capable of carrying or associating with at least one payload within or on the surface of the nanostructure. Non-limiting examples of the nanostructures comprising at least one nanoparticle are described in International Patent Publication No. WO2013123523, the contents of which are herein incorporated by reference in their entirety.

[0551] In some embodiments the RNA (e.g., mRNA) vaccine may be associated with a cationic or polycationic compounds, including protamine, nucleoline, spermine or spermidine, or other cationic peptides or proteins, such as poly-L-lysine (PLL), polyarginine, basic polypeptides, cell penetrating peptides (CPPs), including HIV-binding peptides, HIV-1 Tat (HIV), Tat-derived peptides, Penetratin, VP.sup.22 derived or analog peptides, Pestivirus Erns, HSV, VP.sup.22 (Herpes simplex), MAP, KALA or protein transduction domains (PTDs), PpT620, prolin-rich peptides, arginine-rich peptides, lysine-rich peptides, MPG-peptide(s), Pep-1, L-oligomers, Calcitonin peptide(s), Antennapedia-derived peptides (particularly from Drosophila antennapedia), pAntp, pIsl, FGF, Lactoferrin, Transportan, Buforin-2, Bac715-24, SynB, SynB(1), pVEC, hCT-derived peptides, SAP, histones, cationic polysaccharides, for example chitosan, polybrene, cationic polymers, e.g. polyethyleneimine (PEI), cationic lipids, e.g. DOTMA: [1-(2,3-sioleyloxy)propyl]-N,N,N-trimethylammonium chloride, DMRIE, di-C14-amidine, DOTIM, SAINT, DC-Chol, BGTC, CTAP, DOPC, DODAP, DOPE: Dioleyl phosphatidylethanol-amine, DOSPA, DODAB, DOIC, DMEPC, DOGS: Dioctadecylamidoglycylspermin, DIMRI: Dimyristoxypropyl dimethyl hydroxyethyl ammonium bromide, DOTAP: dioleoyloxy-3-(trimethylammonio)propane, DC-6-14: O,O-ditetradecanoyl-N-.alpha.-trimethylammonioacetyl)diethanolamine chloride, CLIP1: rac-[(2,3-dioctadecyloxypropyl)(2-hydroxyethyl)]-dimethylammonium chloride, CLIP6: rac-[2(2,3-dihexadecyloxypropyloxymethyloxy)ethyl]-trimethylammonium, CLIP9: rac-[2(2,3-dihexadecyloxypropyloxysuccinyloxy)ethyl]-trimethylammonium, oligofectamine, or cationic or polycationic polymers, e.g. modified polyaminoacids, such as beta-aminoacid-polymers or reversed polyamides, etc., modified polyethylenes, such as PVP (poly(N-ethyl-4-vinylpyridinium bromide)), etc., modified acrylates, such as pDMAEMA (poly(dimethylaminoethyl methylacrylate)), etc., modified amidoamines such as pAMAM (poly(amidoamine)), etc., modified polybetaminoester (PBAE), such as diamine end modified 1,4 butanediol

diacrylate-co-5-amino-1-pentanol polymers, etc., dendrimers, such as polypropylamine dendrimers or pAMAM based dendrimers, etc., polyimine(s), such as PEI: poly(ethyleneimine), poly(propyleneimine), etc., polyallylamine, sugar backbone based polymers, such as cyclodextrin based polymers, dextran based polymers, chitosan, etc., silan backbone based polymers, such as PMOXA-PDMS copolymers, etc., blockpolymers consisting of a combination of one or more cationic blocks (e.g. selected from a cationic polymer as mentioned above) and of one or more hydrophilic or hydrophobic blocks (e.g. polyethyleneglycole), etc.

[0552] In other embodiments the RNA (e.g., mRNA) vaccine is not associated with a cationic or polycationic compounds.

[0553] In some embodiments, a nanoparticle comprises compounds of Formula (I):

##STR00003##

[0554] or a salt or isomer thereof, wherein:

[0555] R.sub.1 is selected from the group consisting of C.sub.5-30 alkyl, C.sub.5-20 alkenyl, --R\*YR", --YR", and --R"M'R';

[0556] R.sub.2 and R.sub.3 are independently selected from the group consisting of H, C.sub.1-14 alkyl, C.sub.2-14 alkenyl, --R\*YR", --YR", and --R\*OR", or R.sub.2 and R.sub.3, together with the atom to which they are attached, form a heterocycle or carbocycle;

[0557] R.sub.4 is selected from the group consisting of a C.sub.3-6

carbocycle, --(CH.sub.2).sub.nQ, --(CH.sub.2).sub.nCHQR,

[0558] --CHQR, --CQ(R).sub.2, and unsubstituted C.sub.1-6 alkyl, where Q is selected from a carbocycle, heterocycle, --OR, --O(CH.sub.2).sub.nN(R).sub.2, --C(O)OR, --OC(O)R, --CX.sub.3, --CX.sub.2H, --CXH.sub.2, --CN, --N(R).sub.2, --C(O)N(R).sub.2, --N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)C(O)N(R).sub.2, --N(R)C(S)N(R).sub.2, --N(R)R.sub.8, --O(CH.sub.2).sub.nOR, --N(R)C(.dbd.NR.sub.9)N(R).sub.2, --N(R)C(.dbd.CHR.sub.9)N(R).sub.2, --OC(O)N(R).sub.2, --N(R)C(O)OR, --N(OR)C(O)R, --N(OR)S(O).sub.2R, --N(OR)C(O)OR, --N(OR)C(O)N(R).sub.2, --N(OR)C(S)N(R).sub.2, --N(OR)C(.dbd.NR.sub.9)N(R).sub.2, --N(OR)C(.dbd.CHR.sub.9)N(R).sub.2, --C(.dbd.NR.sub.9)N(R).sub.2, --C(.dbd.NR.sub.9)R, --C(O)N(R)O R, and --C(R)N(R).sub.2C(O)OR, and each n is independently selected from 1, 2, 3, 4, and 5;

[0559] each R.sub.5 is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0560] each R.sub.6 is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0561] M and M' are independently selected from --C(O)O--, --OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--, --C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--, --S--S--, an aryl group, and a heteroaryl group;

[0562] R.sub.7 is selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0563] R.sub.8 is selected from the group consisting of C.sub.3-6 carbocycle and heterocycle;

[0564] R.sub.9 is selected from the group consisting of H, CN, NO.sub.2, C.sub.1-6 alkyl, --OR, --S(O).sub.2R, --S(O).sub.2N(R).sub.2, C.sub.2-6 alkenyl, C.sub.3-6 carbocycle and heterocycle;

[0565] each R is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0566] each R' is independently selected from the group consisting of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R\*YR", --YR", and H;

[0567] each R" is independently selected from the group consisting of C.sub.3-14 alkyl and C3-14 alkenyl;

[0568] each R\* is independently selected from the group consisting of C.sub.1-12 alkyl and C.sub.2-12 alkenyl;

[0569] each Y is independently a C3-6 carbocycle;

[0570] each X is independently selected from the group consisting of F, Cl, Br, and I; and

[0571] m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

[0572] In some embodiments, a subset of compounds of Formula (I) includes those in which when R.sub.4 is --(CH.sub.2).sub.nQ, --(CH.sub.2).sub.nCHQR, --CHQR, or --CQ(R).sub.2, then (i) Q is not --N(R).sub.2 when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or 7-membered heterocycloalkyl when n is 1 or 2.

[0573] In some embodiments, another subset of compounds of Formula (I) includes those in which

[0574] R.sub.1 is selected from the group consisting of C.sub.5-30 alkyl, C.sub.5-20 alkenyl, --R\*YR", --YR", and --R"M'R';

[0575] R.sub.2 and R.sub.3 are independently selected from the group consisting of H, C.sub.1-14 alkyl, C.sub.2-14 alkenyl, --R\*YR", --YR", and --R\*OR", or R.sub.2 and R.sub.3, together with the atom to which they are attached, form a heterocycle or carbocycle;

[0576] R.sub.4 is selected from the group consisting of a C.sub.3-6 carbocycle, --(CH.sub.2).sub.nQ, --(CH.sub.2).sub.nCHQR,

--CHQR, --CQ(R).sub.2, and unsubstituted C.sub.1-6 alkyl, where Q is selected from a C.sub.3-6 carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, --OR, --O(CH.sub.2)N(R).sub.2, --C(O)OR, --OC(O)R, --CX.sub.3, --CX.sub.2H, --CXH.sub.2, --CN, --C(O)N(R).sub.2, --N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)C(O)N(R).sub.2, --N(R)C(S)N(R).sub.2, --CRN(R).sub.2C(O)OR, --N(R)R.sub.8, --O(CH.sub.2).sub.nOR, --N(R)C(.dbd.NR.sub.9)N(R).sub.2, --N(R)C(.dbd.CHR.sub.9)N(R).sub.2, --OC(O)N(R).sub.2, --N(R)C(O)OR, --N(OR)C(O)R, --N(OR)S(O).sub.2R, --N(OR)C(O)OR, --N(OR)C(O)N(R).sub.2, --N(OR)C(S)N(R).sub.2, --N(OR)C(.dbd.NR.sub.9)N(R).sub.2, --N(OR)C(.dbd.CHR.sub.9)N(R).sub.2, --C(.dbd.NR.sub.9)N(R).sub.2, --C(.dbd.NR.sub.9)R, --C(O)N(R)O R, and a 5- to 14-membered heterocycloalkyl having one or more heteroatoms selected from N, O, and S which is substituted with one or more substituents selected from oxo (.dbd.O), OH, amino, mono- or di-alkylamino, and C.sub.1-3 alkyl, and each n is independently selected from 1, 2, 3, 4, and 5;

[0577] each R.sub.5 is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0578] each R.sub.6 is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0579] M and M' are independently selected from --C(O)O--, --OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--, --C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--, --S--S--, an aryl group, and a heteroaryl group;

[0580] R.sub.7 is selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0581] R.sub.8 is selected from the group consisting of C.sub.3-6 carbocycle and heterocycle;

[0582] R.sub.9 is selected from the group consisting of H, CN, NO.sub.2, C.sub.1-6 alkyl, --OR, --S(O).sub.2R, --S(O).sub.2N(R).sub.2, C.sub.2-6 alkenyl, C.sub.3-6 carbocycle and heterocycle;

[0583] each R is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0584] each R' is independently selected from the group consisting of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R\*YR", --YR", and H;

[0585] each R" is independently selected from the group consisting of C.sub.3-14 alkyl and C.sub.3-14 alkenyl;

[0586] each R\* is independently selected from the group consisting of C.sub.1-12 alkyl and C.sub.2-12 alkenyl;

[0587] each Y is independently a C.sub.3-6 carbocycle;

[0588] each X is independently selected from the group consisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts or isomers thereof.

[0589] In some embodiments, another subset of compounds of Formula (I) includes those in which

[0590] R.sub.1 is selected from the group consisting of C.sub.5-30 alkyl, C.sub.5-20 alkenyl, --R\*YR", --YR", and --R"M'R';

[0591] R.sub.2 and R.sub.3 are independently selected from the group consisting of H, C.sub.1-14 alkyl, C.sub.2-14 alkenyl, --R\*YR", --YR", and --R\*OR", or R.sub.2 and R.sub.3, together with the atom to which they are attached, form a heterocycle or carbocycle;

[0592] R.sub.4 is selected from the group consisting of a C.sub.3-6

carbocycle, --(CH.sub.2).sub.nQ, --(CH.sub.2).sub.nCHQR, --CHQR, --CQ(R).sub.2, and unsubstituted C.sub.1-6 alkyl, where Q is selected from a C.sub.3-6 carbocycle, a 5- to 14-membered heterocycle having one or more heteroatoms selected from N, O, and S, --OR, --O(CH.sub.2).sub.nN(R).sub.2, --C(O)OR, --OC(O)R, --CX.sub.3, --CX.sub.2H, --CXH.sub.2, --CN, --C(O)N(R).sub.2, --N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)C(O)N(R).sub.2, --N(R)C(S)N(R).sub.2, --CRN(R).sub.2C(O)OR, --N(R)R.sub.8, --O(CH.sub.2).sub.nOR, --N(R)C(.dbd.NR.sub.9)N(R).sub.2, --N(R)C(.dbd.CHR.sub.9)N(R).sub.2, --OC(O)N(R).sub.2, --N(R)C(O)OR, --N(OR)C(O)R, --N(OR)S(O).sub.2R, --N(OR)C(O)OR, --N(OR)C(O)N(R).sub.2, --N(OR)C(S)N(R).sub.2, --N(OR)C(.dbd.NR.sub.9)N(R).sub.2, --N(OR)C(.dbd.CHR.sub.9)N(R).sub.2, --C(.dbd.NR.sub.9)R, --C(O)N(R)OR, and --C(.dbd.NR.sub.9)N(R).sub.2, and each n is independently selected from 1, 2, 3, 4, and 5; and when Q is a 5- to 14-membered heterocycle and (i) R.sub.4 is --(CH.sub.2).sub.nQ in which n is 1 or 2, or (ii) R.sub.4 is --(CH.sub.2).sub.nCHQR in which n is 1, or (iii) R.sub.4 is --CHQR, and --CQ(R).sub.2, then Q is either a 5- to 14-membered heteroaryl or 8- to 14-membered heterocycloalkyl;

[0593] each R.sub.5 is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0594] each R.sub.6 is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0595] M and M' are independently selected from --C(O)O--, --OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--, --C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--, --S--S--, an aryl group, and a heteroaryl group;

[0596] R.sub.7 is selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0597] R.sub.8 is selected from the group consisting of C.sub.3-6 carbocycle and heterocycle;

[0598] R.sub.9 is selected from the group consisting of H, CN, NO.sub.2, C.sub.1-6 alkyl, --OR, --S(O).sub.2R, --S(O).sub.2N(R).sub.2, C.sub.2-6 alkenyl, C.sub.3-6 carbocycle and heterocycle;

[0599] each R is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0600] each R' is independently selected from the group consisting of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R\*YR", --YR", and H;

[0601] each R" is independently selected from the group consisting of C.sub.3-14 alkyl and C.sub.3-14 alkenyl;

[0602] each R\* is independently selected from the group consisting of C.sub.1-12 alkyl and C.sub.2-12 alkenyl;

[0603] each Y is independently a C.sub.3-6 carbocycle;

[0604] each X is independently selected from the group consisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,

[0605] or salts or isomers thereof.

[0606] In some embodiments, another subset of compounds of Formula (I) includes those in which

[0607] R.sub.1 is selected from the group consisting of C.sub.5-30 alkyl, C.sub.5-20 alkenyl, --R\*YR", --YR", and --R"M'R';

[0608] R.sub.2 and R.sub.3 are independently selected from the group consisting of H, C.sub.1-14 alkyl, C.sub.2-14 alkenyl, --R\*YR", --YR", and --R\*OR", or R.sub.2 and R.sub.3, together with the atom to which they are attached, form a heterocycle or carbocycle;

[0609] R.sub.4 is selected from the group consisting of a C.sub.3-6

carbocycle, --(CH.sub.2).sub.nQ, --(CH.sub.2).sub.nCHQR, --CHQR, --CQ(R).sub.2, and unsubstituted C.sub.1-6 alkyl, where Q is selected from a C.sub.3-6 carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, --OR, --O(CH.sub.2).sub.nN(R).sub.2, --C(O)OR, --OC(O)R, --CX.sub.3, --CX.sub.2H, --CXH.sub.2, --CN, --C(O)N(R).sub.2, --N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)C(O)N(R).sub.2, --N(R)C(S)N(R).sub.2, --CRN(R).sub.2C(O)OR, --N(R)R.sub.8, --O(CH.sub.2).sub.nOR, --N(R)C(.dbd.NR.sub.9)N(R).sub.2, --N(R)C(.dbd.CHR.sub.9)N(R).sub.2, --OC(O)N(R).sub.2, --N(R)C(O)OR, --N(OR)C(O)R, --N(OR)S(O).sub.2R, --N(OR)C(O)OR, --N(OR)C(O)N(R).sub.2, --N(OR)C(S)N(R).sub.2, --N(OR)C(.dbd.NR.sub.9)N(R).sub.2, --N(OR)C(.dbd.CHR.sub.9)N(R).sub.2, --C(.dbd.NR.sub.9)R, --C(O)N(R)OR, and --C(.dbd.NR.sub.9)N(R).sub.2, and each n is independently selected from 1, 2, 3, 4, and 5;

[0610] each R.sub.5 is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0611] each R.sub.6 is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H; M and M' are independently selected from --C(O)O--, --OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--, --C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--, --S--S--, an aryl group, and a heteroaryl group;

[0612] R.sub.7 is selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0613] R.sub.8 is selected from the group consisting of C.sub.3-6 carbocycle and heterocycle;



[0614] R.sub.9 is selected from the group consisting of H, CN, NO.sub.2, C.sub.1-6 alkyl, --OR, --S(O).sub.2R, --S(O).sub.2N(R).sub.2, C.sub.2-6 alkenyl, C.sub.3-6 carbocycle and heterocycle;

[0615] each R is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0616] each R' is independently selected from the group consisting of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R\*YR", --YR", and H;

[0617] each R" is independently selected from the group consisting of C.sub.3-14 alkyl and C.sub.3-14 alkenyl;

[0618] each R\* is independently selected from the group consisting of C.sub.1-12 alkyl and C.sub.2-12 alkenyl;

[0619] each Y is independently a C.sub.3-6 carbocycle;

[0620] each X is independently selected from the group consisting of F, Cl, Br, and I; and

[0621] m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,

[0622] or salts or isomers thereof.

[0623] In some embodiments, another subset of compounds of Formula (I) includes those in which

[0624] R.sub.1 is selected from the group consisting of C.sub.5-30 alkyl, C.sub.5-20 alkenyl, --R\*YR", --YR", and --R"M'R';

[0625] R.sub.2 and R.sub.3 are independently selected from the group consisting of H, C.sub.2-14 alkyl, C.sub.2-14 alkenyl, --R\*YR", --YR", and --R\*OR", or R.sub.2 and R.sub.3, together with the atom to which they are attached, form a heterocycle or carbocycle;

[0626] R.sub.4 is --(CH.sub.2).sub.nQ or --(CH.sub.2).sub.nCHQR, where Q is --N(R).sub.2, and n is selected from 3, 4, and 5;

[0627] each R.sub.5 is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0628] each R.sub.6 is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0629] M and M' are independently selected from --C(O)O--, --OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--, --C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--, --S--S--, an aryl group, and a heteroaryl group;

[0630] R.sub.7 is selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0631] each R is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0632] each R' is independently selected from the group consisting of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R\*YR", --YR", and H;

[0633] each R" is independently selected from the group consisting of C.sub.3-14 alkyl and C.sub.3-14 alkenyl;

[0634] each R\* is independently selected from the group consisting of C.sub.1-12 alkyl and C.sub.1-12 alkenyl;

[0635] each Y is independently a C.sub.3-6 carbocycle;

[0636] each X is independently selected from the group consisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts or isomers thereof.

[0637] In some embodiments, another subset of compounds of Formula (I) includes those in which

[0638] R.sub.1 is selected from the group consisting of C.sub.5-30 alkyl, C.sub.5-20 alkenyl, --R\*YR", --YR", and --R"M'R';

[0639] R.sub.2 and R.sub.3 are independently selected from the group consisting of C.sub.1-14 alkyl, C.sub.2-14 alkenyl, --R\*YR", --YR", and --R\*OR", or R.sub.2 and R.sub.3, together with the atom to which they are attached, form a heterocycle or carbocycle;

[0640] R.sub.4 is selected from the group consisting of --(CH.sub.2).sub.nQ, --(CH.sub.2).sub.nCHQR, --CHQR, and --CQ(R).sub.2, where Q is --N(R).sub.2, and n is selected from 1, 2, 3, 4, and 5;

[0641] each R.sub.5 is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0642] each R.sub.6 is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0643] M and M' are independently selected from --C(O)O--, --OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--, --C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--, --S--S--, an aryl group, and a heteroaryl group;

[0644] R.sub.7 is selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0645] each R is independently selected from the group consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;

[0646] each R' is independently selected from the group consisting of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R\*YR", --YR", and H;

[0647] each R" is independently selected from the group consisting of C.sub.3-14 alkyl and C.sub.3-14 alkenyl;

[0648] each R\* is independently selected from the group consisting of C.sub.1-12 alkyl and C.sub.1-12 alkenyl;

[0649] each Y is independently a C.sub.3-6 carbocycle;

[0650] each X is independently selected from the group consisting of F, Cl, Br, and I; and

[0651] m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts or isomers thereof.

[0652] In some embodiments, a subset of compounds of Formula (I) includes those of Formula (IA):

##STR00004##

[0653] or a salt or isomer thereof, wherein 1 is selected from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; M.sub.1 is a bond or M'; R.sub.4 is unsubstituted C.sub.1-3 alkyl, or --(CH.sub.2).sub.nQ, in which Q is OH, --NHC(S)N(R).sub.2, --NHC(O)N(R).sub.2, --N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)R.sub.8, --NHC(.dbd.NR.sub.9)N(R).sub.2, --NHC(.dbd.CHR.sub.9)N(R).sub.2, --OC(O)N(R).sub.2, --N(R)C(O)OR, heteroaryl or heterocycloalkyl; M and M' are independently selected

from --C(O)O--, --OC(O)--, --C(O)N(R)--, --P(O)(OR')O--, --S--S--, an aryl group, and a heteroaryl group; and R.sub.2 and R.sub.3 are independently selected from the group consisting of H, C.sub.1-14 alkyl, and C.sub.2-14 alkenyl.

[0654] In some embodiments, a subset of compounds of Formula (I) includes those of Formula (II):

##STR00005##

or a salt or isomer thereof, wherein 1 is selected from 1, 2, 3, 4, and 5; M.sub.1 is a bond or M'; R.sub.4 is unsubstituted C.sub.1-3 alkyl, or --(CH.sub.2).sub.nQ, in which n is 2, 3, or 4, and Q is OH, --NHC(S)N(R).sub.2, --NHC(O)N(R).sub.2, --N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)R.sub.8, --NHC(.dbd.NR.sub.9)N(R).sub.2, --NHC(.dbd.CHR.sub.9)N(R).sub.2, --OC(O)N(R).sub.2, --N(R)C(O)OR, heteroaryl or heterocycloalkyl; M and M' are independently selected from --C(O)O--, --OC(O)--, --C(O)N(R)--, --P(O)(OR')O--, --S--S--, an aryl group, and a heteroaryl group; and R.sub.2 and R.sub.3 are independently selected from the group consisting of H, C.sub.1-14 alkyl, and C.sub.2-14 alkenyl.

[0655] In some embodiments, a subset of compounds of Formula (I) includes those of Formula (IIa), (IIb), (IIc), or (IIE):

##STR00006##

[0656] or a salt or isomer thereof, wherein R.sub.4 is as described herein.

[0657] In some embodiments, a subset of compounds of Formula (I) includes those of Formula (IId):

##STR00007##

[0658] or a salt or isomer thereof, wherein n is 2, 3, or 4; and m, R', R'', and R.sub.2 through R.sub.6 are as described herein. For example, each of R.sub.2 and R.sub.3 may be independently selected from the group consisting of C.sub.5-14 alkyl and C.sub.5-14 alkenyl.

[0659] In some embodiments, a subset of compounds of Formula (I) includes those of Formula (IIa), (IIb), (IIc), or (IIE):

##STR00008##

[0660] or a salt or isomer thereof, wherein R.sub.4 is as described herein.

[0661] In some embodiments, a subset of compounds of Formula (I) includes those of Formula (IId):

##STR00009##

[0662] or a salt or isomer thereof, wherein n is 2, 3, or 4; and m, R', R'', and R.sub.2 through R.sub.6 are as described herein. For example, each of R.sub.2 and R.sub.3 may be independently selected from the group consisting of C.sub.5-14 alkyl and C.sub.5-14 alkenyl.

[0663] In some embodiments, the compound of Formula (I) is selected from the group consisting of:

##STR00010## ##STR00011## ##STR00012## ##STR00013## ##STR00014## ##STR00015##  
##STR00016## ##STR00017## ##STR00018##

[0664] In further embodiments, the compound of Formula (I) is selected from the group consisting of:

##STR00019##

[0665] In some embodiments, the compound of Formula (I) is selected from the group consisting of:

##STR00020## ##STR00021## ##STR00022## ##STR00023## ##STR00024## ##STR00025##  
##STR00026## ##STR00027## ##STR00028## ##STR00029## ##STR00030## ##STR00031##  
##STR00032## ##STR00033## ##STR00034## ##STR00035## ##STR00036## ##STR00037##  
##STR00038## ##STR00039## ##STR00040## ##STR00041## ##STR00042## ##STR00043##  
##STR00044## ##STR00045## ##STR00046## ##STR00047## ##STR00048##

and salts and isomers thereof.

[0666] In some embodiments, a nanoparticle comprises the following compound:

##STR00049##

or salts and isomers thereof.

[0667] In some embodiments, the disclosure features a nanoparticle composition including a lipid component comprising a compound as described herein (e.g., a compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIE)).

[0668] In some embodiments, the disclosure features a pharmaceutical composition comprising a nanoparticle composition according to the preceding embodiments and a pharmaceutically acceptable carrier. For example, the pharmaceutical composition is refrigerated or frozen for storage and/or shipment (e.g., being stored at a temperature of 4.degree. C. or lower, such as a temperature between about -150.degree. C. and about 0.degree. C. or between about -80.degree. C. and about -20.degree. C. (e.g., about -5.degree. C., -10.degree. C., -15.degree. C., -20.degree. C., -25.degree. C., -30.degree. C., -40.degree. C., -50.degree. C., -60.degree. C., -70.degree. C., -80.degree. C., -90.degree. C., -130.degree. C. or -150.degree. C.)). For example, the pharmaceutical composition is a solution that is refrigerated for storage and/or shipment at, for example, about -20.degree. C., -30.degree. C., -40.degree. C., -50.degree. C., -60.degree. C., -70.degree. C., or -80.degree. C.

[0669] In some embodiments, the disclosure provides a method of delivering a therapeutic and/or prophylactic (e.g., RNA, such as mRNA) to a cell (e.g., a mammalian cell). This method includes the step of administering to a subject (e.g., a mammal, such as a human) a nanoparticle composition including (i) a lipid component including a phospholipid (such as a polyunsaturated lipid), a PEG lipid, a structural lipid, and a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIE) and (ii) a therapeutic and/or prophylactic, in which administering involves contacting the cell with the nanoparticle composition, whereby the therapeutic and/or prophylactic is delivered to the cell.

[0670] In some embodiments, the disclosure provides a method of producing a polypeptide of interest in a cell (e.g., a mammalian cell). The method includes the step of contacting the cell with a nanoparticle composition including (i) a lipid component including a phospholipid (such as a polyunsaturated lipid), a PEG lipid, a structural lipid, and a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIE) and (ii) an mRNA encoding the polypeptide of interest, whereby the mRNA is capable of being translated in the cell to produce the polypeptide.

[0671] In some embodiments, the disclosure provides a method of treating a disease or disorder in a mammal (e.g., a human) in need thereof. The method includes the step of administering to the mammal a therapeutically effective amount of a nanoparticle composition including (i) a lipid component including a phospholipid (such as a polyunsaturated lipid), a PEG lipid, a structural lipid, and a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIE) and (ii) a therapeutic and/or prophylactic (e.g., an mRNA).

[0672] In some embodiments, the disease or disorder is characterized by dysfunctional or aberrant protein or polypeptide activity. For example, the disease or disorder is selected from the group consisting of rare diseases,

infectious diseases, cancer and proliferative diseases, genetic diseases (e.g., cystic fibrosis), autoimmune diseases, diabetes, neurodegenerative diseases, cardio- and reno-vascular diseases, and metabolic diseases.

[0673] In some embodiments, the disclosure provides a method of delivering (e.g., specifically delivering) a therapeutic and/or prophylactic to a mammalian organ (e.g., a liver, spleen, lung, or femur). This method includes the step of administering to a subject (e.g., a mammal) a nanoparticle composition including (i) a lipid component including a phospholipid, a PEG lipid, a structural lipid, and a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and (ii) a therapeutic and/or prophylactic (e.g., an mRNA), in which administering involves contacting the cell with the nanoparticle composition, whereby the therapeutic and/or prophylactic is delivered to the target organ (e.g., a liver, spleen, lung, or femur).

[0674] In some embodiments, the disclosure features a method for the enhanced delivery of a therapeutic and/or prophylactic (e.g., an mRNA) to a target tissue (e.g., a liver, spleen, lung, or femur). This method includes administering to a subject (e.g., a mammal) a nanoparticle composition, the composition including (i) a lipid component including a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe), a phospholipid, a structural lipid, and a PEG lipid; and (ii) a therapeutic and/or prophylactic, the administering including contacting the target tissue with the nanoparticle composition, whereby the therapeutic and/or prophylactic is delivered to the target tissue.

[0675] In some embodiments, the disclosure features a method of lowering immunogenicity comprising introducing the nanoparticle composition of the disclosure into cells, wherein the nanoparticle composition reduces the induction of the cellular immune response of the cells to the nanoparticle composition, as compared to the induction of the cellular immune response in cells induced by a reference composition which comprises a reference lipid instead of a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe). For example, the cellular immune response is an innate immune response, an adaptive immune response, or both.

[0676] The disclosure also includes methods of synthesizing a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and methods of making a nanoparticle composition including a lipid component comprising the compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).

#### Modes of Vaccine Administration

[0677] Respiratory virus RNA (e.g. mRNA) vaccines may be administered by any route which results in a therapeutically effective outcome. These include, but are not limited, to intradermal, intramuscular, and/or subcutaneous administration. The present disclosure provides methods comprising administering RNA (e.g., mRNA) vaccines to a subject in need thereof. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease, the particular composition, its mode of administration, its mode of activity, and the like. Respiratory virus RNA (e.g., mRNA) vaccines compositions are typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of RNA (e.g., mRNA) vaccine compositions may be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective, prophylactically effective, or appropriate imaging dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.

[0678] In some embodiments, respiratory virus RNA (e.g. mRNA) vaccines compositions may be administered at dosage levels sufficient to deliver 0.0001 mg/kg to 100 mg/kg, 0.001 mg/kg to 0.05 mg/kg, 0.005 mg/kg to 0.05 mg/kg, 0.001 mg/kg to 0.005 mg/kg, 0.05 mg/kg to 0.5 mg/kg, 0.01 mg/kg to 50 mg/kg, 0.1 mg/kg to 40 mg/kg, 0.5 mg/kg to 30 mg/kg, 0.01 mg/kg to 10 mg/kg, 0.1 mg/kg to 10 mg/kg, or 1 mg/kg to 25 mg/kg, of subject body weight per day, one or more times a day, per week, per month, etc. to obtain the desired therapeutic, diagnostic, prophylactic, or imaging effect (see, e.g., the range of unit doses described in International

Publication No WO2013078199, the contents of which are herein incorporated by reference in their entirety). The desired dosage may be delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, every four weeks, every 2 months, every three months, every 6 months, etc. In some embodiments, the desired dosage may be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations). When multiple administrations are employed, split dosing regimens such as those described herein may be used. In exemplary embodiments, respiratory virus RNA (e.g., mRNA) vaccine compositions may be administered at dosage levels sufficient to deliver 0.0005 mg/kg to 0.01 mg/kg, e.g., about 0.0005 mg/kg to about 0.0075 mg/kg, e.g., about 0.0005 mg/kg, about 0.001 mg/kg, about 0.002 mg/kg, about 0.003 mg/kg, about 0.004 mg/kg or about 0.005 mg/kg.

[0679] In some embodiments, respiratory virus RNA (e.g., mRNA) vaccine compositions may be administered once or twice (or more) at dosage levels sufficient to deliver 0.025 mg/kg to 0.250 mg/kg, 0.025 mg/kg to 0.500 mg/kg, 0.025 mg/kg to 0.750 mg/kg, or 0.025 mg/kg to 1.0 mg/kg.

[0680] In some embodiments, respiratory virus RNA (e.g., mRNA) vaccine compositions may be administered twice (e.g., Day 0 and Day 7, Day 0 and Day 14, Day 0 and Day 21, Day 0 and Day 28, Day 0 and Day 60, Day 0 and Day 90, Day 0 and Day 120, Day 0 and Day 150, Day 0 and Day 180, Day 0 and 3 months later, Day 0 and 6 months later, Day 0 and 9 months later, Day 0 and 12 months later, Day 0 and 18 months later, Day 0 and 2 years later, Day 0 and 5 years later, or Day 0 and 10 years later) at a total dose of or at dosage levels sufficient to deliver a total dose of 0.0100 mg, 0.025 mg, 0.050 mg, 0.075 mg, 0.100 mg, 0.125 mg, 0.150 mg, 0.175 mg, 0.200 mg, 0.225 mg, 0.250 mg, 0.275 mg, 0.300 mg, 0.325 mg, 0.350 mg, 0.375 mg, 0.400 mg, 0.425 mg, 0.450 mg, 0.475 mg, 0.500 mg, 0.525 mg, 0.550 mg, 0.575 mg, 0.600 mg, 0.625 mg, 0.650 mg, 0.675 mg, 0.700 mg, 0.725 mg, 0.750 mg, 0.775 mg, 0.800 mg, 0.825 mg, 0.850 mg, 0.875 mg, 0.900 mg, 0.925 mg, 0.950 mg, 0.975 mg, or 1.0 mg. Higher and lower dosages and frequency of administration are encompassed by the present disclosure. For example, a respiratory virus RNA (e.g., mRNA) vaccine composition may be administered three or four times.

[0681] In some embodiments, respiratory virus RNA (e.g., mRNA) vaccine compositions may be administered twice (e.g., Day 0 and Day 7, Day 0 and Day 14, Day 0 and Day 21, Day 0 and Day 28, Day 0 and Day 60, Day 0 and Day 90, Day 0 and Day 120, Day 0 and Day 150, Day 0 and Day 180, Day 0 and 3 months later, Day 0 and 6 months later, Day 0 and 9 months later, Day 0 and 12 months later, Day 0 and 18 months later, Day 0 and 2 years later, Day 0 and 5 years later, or Day 0 and 10 years later) at a total dose of or at dosage levels sufficient to deliver a total dose of 0.010 mg, 0.025 mg, 0.100 mg or 0.400 mg.

[0682] In some embodiments, the respiratory virus RNA (e.g., mRNA) vaccine for use in a method of vaccinating a subject is administered to the subject as a single dosage of between 10 .mu.g/kg and 400 .mu.g/kg of the nucleic acid vaccine (in an effective amount to vaccinate the subject). In some embodiments the RNA (e.g., mRNA) vaccine for use in a method of vaccinating a subject is administered to the subject as a single dosage of between 10 .mu.g and 400 .mu.g of the nucleic acid vaccine (in an effective amount to vaccinate the subject). In some embodiments, a respiratory virus RNA (e.g., mRNA) vaccine for use in a method of vaccinating a subject is administered to the subject as a single dosage of 25-1000 .mu.g (e.g., a single dosage of mRNA encoding hMPV, PIV3, RSV, MeV and/or BetaCoV antigen). In some embodiments, a respiratory virus RNA (e.g., mRNA) vaccine is administered to the subject as a single dosage of 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000 .mu.g. For example, a respiratory virus RNA (e.g., mRNA) vaccine may be administered to a subject as a single dose of 25-100, 25-500, 50-100, 50-500, 50-1000, 100-500, 100-1000, 250-500, 250-1000, or 500-1000 .mu.g. In some embodiments, a respiratory virus RNA (e.g., mRNA) vaccine for use in a method of vaccinating a subject is administered to the subject as two dosages, the combination of which equals 25-1000 .mu.g of the respiratory virus RNA (e.g., mRNA) vaccine.

[0683] A respiratory virus RNA (e.g. mRNA) vaccine pharmaceutical composition described herein can be formulated into a dosage form described herein, such as an intranasal, intratracheal, or injectable (e.g., intravenous, intraocular, intravitreal, intramuscular, intradermal, intracardiac, intraperitoneal, and subcutaneous).

## Respiratory Virus RNA (e.g., mRNA) Vaccine Formulations and Methods of Use

[0684] Some aspects of the present disclosure provide formulations of the respiratory virus RNA (e.g., mRNA) vaccine, wherein the RNA (e.g., mRNA) vaccine is formulated in an effective amount to produce an antigen specific immune response in a subject (e.g., production of antibodies specific to an hMPV, PIV3, RSV, MeV and/or BetaCoV antigenic polypeptide). "An effective amount" is a dose of an RNA (e.g., mRNA) vaccine effective to produce an antigen-specific immune response. Also provided herein are methods of inducing an antigen-specific immune response in a subject.

[0685] In some embodiments, the antigen-specific immune response is characterized by measuring an anti-hMPV, anti-PIV3, anti-RSV, anti-MeV and/or anti-BetaCoV antigenic polypeptide antibody titer produced in a subject administered a respiratory virus RNA (e.g., mRNA) vaccine as provided herein. An antibody titer is a measurement of the amount of antibodies within a subject, for example, antibodies that are specific to a particular antigen (e.g., an anti-hMPV, anti-PIV3, anti-RSV, anti-MeV and/or anti-BetaCoV antigenic polypeptide) or epitope of an antigen. Antibody titer is typically expressed as the inverse of the greatest dilution that provides a positive result. Enzyme-linked immunosorbent assay (ELISA) is a common assay for determining antibody titers, for example.

[0686] In some embodiments, an antibody titer is used to assess whether a subject has had an infection or to determine whether immunizations are required. In some embodiments, an antibody titer is used to determine the strength of an autoimmune response, to determine whether a booster immunization is needed, to determine whether a previous vaccine was effective, and to identify any recent or prior infections. In accordance with the present disclosure, an antibody titer may be used to determine the strength of an immune response induced in a subject by the respiratory virus RNA (e.g., mRNA) vaccine.

[0687] In some embodiments, an anti-antigenic polypeptide (e.g., an anti-hMPV, anti-PIV3, anti-RSV, anti-MeV and/or anti-BetaCoV antigenic polypeptide) antibody titer produced in a subject is increased by at least 1 log relative to a control. For example, anti-antigenic polypeptide antibody titer produced in a subject may be increased by at least 1.5, at least 2, at least 2.5, or at least 3 log relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased by 1, 1.5, 2, 2.5 or 3 log relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased by 1-3 log relative to a control. For example, the anti-antigenic polypeptide antibody titer produced in a subject may be increased by 1-1.5, 1-2, 1-2.5, 1-3, 1.5-2, 1.5-2.5, 1.5-3, 2-2.5, 2-3, or 2.5-3 log relative to a control.

[0688] In some embodiments, the anti-antigenic polypeptide (e.g., an anti-hMPV, anti-PIV3, anti-RSV, anti-MeV and/or anti-BetaCoV antigenic polypeptide) antibody titer produced in a subject is increased at least 2 times relative to a control. For example, the anti-antigenic polypeptide antibody titer produced in a subject may be increased at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, or at least 10 times relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased 2, 3, 4, 5, 6, 7, 8, 9, or 10 times relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in a subject is increased 2-10 times relative to a control. For example, the anti-antigenic polypeptide antibody titer produced in a subject may be increased 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-10, 4-9, 4-8, 4-7, 4-6, 4-5, 5-10, 5-9, 5-8, 5-7, 5-6, 6-10, 6-9, 6-8, 6-7, 7-10, 7-9, 7-8, 8-10, 8-9, or 9-10 times relative to a control.

[0689] A control, in some embodiments, is the anti-antigenic polypeptide (e.g., an anti-hMPV, anti-PIV3, anti-RSV, anti-MeV and/or anti-BetaCoV antigenic polypeptide) antibody titer produced in a subject who has not been administered a respiratory virus RNA (e.g., mRNA) vaccine of the present disclosure. In some embodiments, a control is an anti-antigenic polypeptide (e.g., an anti-hMPV, anti-PIV3, anti-RSV, anti-MeV and/or anti-BetaCoV antigenic polypeptide) antibody titer produced in a subject who has been administered a live attenuated hMPV, PIV3, RSV, MeV and/or BetaCoV vaccine. An attenuated vaccine is a vaccine produced by reducing the virulence of a viable (live). An attenuated virus is altered in a manner that renders it harmless or

less virulent relative to live, unmodified virus. In some embodiments, a control is an anti-antigenic polypeptide (e.g., an anti-hMPV, anti-PIV3, anti-RSV, anti-MeV and/or anti-BetaCoV antigenic polypeptide) antibody titer produced in a subject administered inactivated hMPV, PIV3, RSV, MeV and/or BetaCoV vaccine. In some embodiments, a control is an anti-antigenic polypeptide (e.g., an anti-hMPV, anti-PIV3, anti-RSV, anti-MeV and/or anti-BetaCoV antigenic polypeptide) antibody titer produced in a subject administered a recombinant or purified hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine. Recombinant protein vaccines typically include protein antigens that either have been produced in a heterologous expression system (e.g., bacteria or yeast) or purified from large amounts of the pathogenic organism. In some embodiments, a control is an anti-antigenic polypeptide (e.g., an anti-hMPV, anti-PIV3, anti-RSV, anti-MeV and/or anti-BetaCoV antigenic polypeptide) antibody titer produced in a subject who has been administered an hMPV, PIV3, RSV, MeV and/or BetaCoV virus-like particle (VLP) vaccine. For example, an hMPV VLP vaccine used as a control may be a hMPV VLPs, comprising (or consisting of) viral matrix (M) and fusion (F) proteins, generated by expressing viral proteins in suspension-adapted human embryonic kidney epithelial (293-F) cells (see, e.g., Cox R G et al., *J Virol.* 2014 June; 88(11): 6368-6379, the contents of which are herein incorporated by reference).

[0690] In some embodiments, an effective amount of a respiratory virus RNA (e.g., mRNA) vaccine is a dose that is reduced compared to the standard of care dose of a recombinant hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine. A "standard of care," as provided herein, refers to a medical or psychological treatment guideline and can be general or specific. "Standard of care" specifies appropriate treatment based on scientific evidence and collaboration between medical professionals involved in the treatment of a given condition. It is the diagnostic and treatment process that a physician/clinician should follow for a certain type of patient, illness or clinical circumstance. A "standard of care dose," as provided herein, refers to the dose of a recombinant or purified hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine, or a live attenuated or inactivated hMPV, PIV3, RSV, MeV and/or BetaCoV vaccine, that a physician/clinician or other medical professional would administer to a subject to treat or prevent hMPV, PIV3, RSV, MeV and/or BetaCoV, or a hMPV-, PIV3-, RSV-, MeV- and/or BetaCoV-related condition, while following the standard of care guideline for treating or preventing hMPV, PIV3, RSV, MeV and/or BetaCoV, or a hMPV-, PIV3-, RSV-, MeV- and/or BetaCoV-related condition.

[0691] In some embodiments, the anti-antigenic polypeptide (e.g., an anti-hMPV, anti-PIV3, anti-RSV, anti-MeV and/or anti-BetaCoV antigenic polypeptide) antibody titer produced in a subject administered an effective amount of a respiratory virus RNA (e.g., mRNA) vaccine is equivalent to an anti-antigenic polypeptide (e.g., an anti-hMPV, anti-PIV3, anti-RSV, anti-MeV and/or anti-BetaCoV antigenic polypeptide) antibody titer produced in a control subject administered a standard of care dose of a recombinant or purified hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine or a live attenuated or inactivated hMPV, PIV3, RSV, MeV and/or BetaCoV vaccine.

[0692] In some embodiments, an effective amount of a respiratory virus RNA (e.g., mRNA) vaccine is a dose equivalent to an at least 2-fold reduction in a standard of care dose of a recombinant or purified hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine. For example, an effective amount of a respiratory virus RNA (e.g., mRNA) vaccine may be a dose equivalent to an at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold reduction in a standard of care dose of a recombinant or purified hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine. In some embodiments, an effective amount of a respiratory virus RNA (e.g., mRNA) vaccine is a dose equivalent to an at least at least 100-fold, at least 500-fold, or at least 1000-fold reduction in a standard of care dose of a recombinant or purified hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine. In some embodiments, an effective amount of a respiratory virus RNA (e.g., mRNA) vaccine is a dose equivalent to a 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 20-, 50-, 100-, 250-, 500-, or 1000-fold reduction in a standard of care dose of a recombinant or purified hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine. In some embodiments, the anti-antigenic polypeptide antibody titer produced in a subject administered an effective amount of a respiratory virus RNA (e.g., mRNA) vaccine is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant or protein hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine or a live attenuated or inactivated hMPV, PIV3, RSV, MeV and/or BetaCoV vaccine. In some embodiments, an effective amount of a respiratory virus RNA (e.g., mRNA) vaccine is a dose equivalent to a 2-fold to 1000-fold (e.g., 2-



fold to 100-fold, 10-fold to 1000-fold) reduction in the standard of care dose of a recombinant or purified hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine, wherein the anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant or purified hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine or a live attenuated or inactivated hMPV, PIV3, RSV, MeV and/or BetaCoV vaccine.

[0693] In some embodiments, the effective amount of a respiratory virus RNA (e.g., mRNA) vaccine is a dose equivalent to a 2 to 1000-, 2 to 900-, 2 to 800-, 2 to 700-, 2 to 600-, 2 to 500-, 2 to 400-, 2 to 300-, 2 to 200-, 2 to 100-, 2 to 90-, 2 to 80-, 2 to 70-, 2 to 60-, 2 to 50-, 2 to 40-, 2 to 30-, 2 to 20-, 2 to 10-, 2 to 9-, 2 to 8-, 2 to 7-, 2 to 6-, 2 to 5-, 2 to 4-, 2 to 3-, 3 to 1000-, 3 to 900-, 3 to 800-, 3 to 700-, 3 to 600-, 3 to 500-, 3 to 400-, 3 to 3 to 00-, 3 to 200-, 3 to 100-, 3 to 90-, 3 to 80-, 3 to 70-, 3 to 60-, 3 to 50-, 3 to 40-, 3 to 30-, 3 to 20-, 3 to 10-, 3 to 9-, 3 to 8-, 3 to 7-, 3 to 6-, 3 to 5-, 3 to 4-, 4 to 1000-, 4 to 900-, 4 to 800-, 4 to 700-, 4 to 600-, 4 to 500-, 4 to 400-, 4 to 4 to 00-, 4 to 200-, 4 to 100-, 4 to 90-, 4 to 80-, 4 to 70-, 4 to 60-, 4 to 50-, 4 to 40-, 4 to 30-, 4 to 20-, 4 to 10-, 4 to 9-, 4 to 8-, 4 to 7-, 4 to 6-, 4 to 5-, 4 to 4-, 5 to 1000-, 5 to 900-, 5 to 800-, 5 to 700-, 5 to 600-, 5 to 500-, 5 to 400-, 5 to 300-, 5 to 200-, 5 to 100-, 5 to 90-, 5 to 80-, 5 to 70-, 5 to 60-, 5 to 50-, 5 to 40-, 5 to 30-, 5 to 20-, 5 to 10-, 5 to 9-, 5 to 8-, 5 to 7-, 5 to 6-, 6 to 1000-, 6 to 900-, 6 to 800-, 6 to 700-, 6 to 600-, 6 to 500-, 6 to 400-, 6 to 300-, 6 to 200-, 6 to 100-, 6 to 90-, 6 to 80-, 6 to 70-, 6 to 60-, 6 to 50-, 6 to 40-, 6 to 30-, 6 to 20-, 6 to 10-, 6 to 9-, 6 to 8-, 6 to 7-, 7 to 1000-, 7 to 900-, 7 to 800-, 7 to 700-, 7 to 600-, 7 to 500-, 7 to 400-, 7 to 300-, 7 to 200-, 7 to 100-, 7 to 90-, 7 to 80-, 7 to 70-, 7 to 60-, 7 to 50-, 7 to 40-, 7 to 30-, 7 to 20-, 7 to 10-, 7 to 9-, 7 to 8-, 8 to 1000-, 8 to 900-, 8 to 800-, 8 to 700-, 8 to 600-, 8 to 500-, 8 to 400-, 8 to 300-, 8 to 200-, 8 to 100-, 8 to 90-, 8 to 80-, 8 to 70-, 8 to 60-, 8 to 50-, 8 to 40-, 8 to 30-, 8 to 20-, 8 to 10-, 8 to 9-, 9 to 1000-, 9 to 900-, 9 to 800-, 9 to 700-, 9 to 600-, 9 to 500-, 9 to 400-, 9 to 300-, 9 to 200-, 9 to 100-, 9 to 90-, 9 to 80-, 9 to 70-, 9 to 60-, 9 to 50-, 9 to 40-, 9 to 30-, 9 to 20-, 9 to 10-, 10 to 1000-, 10 to 900-, 10 to 800-, 10 to 700-, 10 to 600-, 10 to 500-, 10 to 400-, 10 to 300-, 10 to 200-, 10 to 100-, 10 to 90-, 10 to 80-, 10 to 70-, 10 to 60-, 10 to 50-, 10 to 40-, 10 to 30-, 10 to 20-, 20 to 1000-, 20 to 900-, 20 to 800-, 20 to 700-, 20 to 600-, 20 to 500-, 20 to 400-, 20 to 300-, 20 to 200-, 20 to 100-, 20 to 90-, 20 to 80-, 20 to 70-, 20 to 60-, 20 to 50-, 20 to 40-, 20 to 30-, 30 to 1000-, 30 to 900-, 30 to 800-, 30 to 700-, 30 to 600-, 30 to 500-, 30 to 400-, 30 to 300-, 30 to 200-, 30 to 100-, 30 to 90-, 30 to 80-, 30 to 70-, 30 to 60-, 30 to 50-, 30 to 40-, 40 to 1000-, 40 to 900-, 40 to 800-, 40 to 700-, 40 to 600-, 40 to 500-, 40 to 400-, 40 to 300-, 40 to 200-, 40 to 100-, 40 to 90-, 40 to 80-, 40 to 70-, 40 to 60-, 40 to 50-, 50 to 1000-, 50 to 900-, 50 to 800-, 50 to 700-, 50 to 600-, 50 to 500-, 50 to 400-, 50 to 300-, 50 to 200-, 50 to 100-, 50 to 90-, 50 to 80-, 50 to 70-, 50 to 60-, 60 to 1000-, 60 to 900-, 60 to 800-, 60 to 700-, 60 to 600-, 60 to 500-, 60 to 400-, 60 to 300-, 60 to 200-, 60 to 100-, 60 to 90-, 60 to 80-, 60 to 70-, 70 to 1000-, 70 to 900-, 70 to 800-, 70 to 700-, 70 to 600-, 70 to 500-, 70 to 400-, 70 to 300-, 70 to 200-, 70 to 100-, 70 to 90-, 70 to 80-, 80 to 1000-, 80 to 900-, 80 to 800-, 80 to 700-, 80 to 600-, 80 to 500-, 80 to 400-, 80 to 300-, 80 to 200-, 80 to 100-, 80 to 90-, 90 to 1000-, 90 to 900-, 90 to 800-, 90 to 700-, 90 to 600-, 90 to 500-, 90 to 400-, 90 to 300-, 90 to 200-, 90 to 100-, 100 to 1000-, 100 to 900-, 100 to 800-, 100 to 700-, 100 to 600-, 100 to 500-, 100 to 400-, 100 to 300-, 100 to 200-, 200 to 1000-, 200 to 900-, 200 to 800-, 200 to 700-, 200 to 600-, 200 to 500-, 200 to 400-, 200 to 300-, 300 to 1000-, 300 to 900-, 300 to 800-, 300 to 700-, 300 to 600-, 300 to 500-, 300 to 400-, 400 to 1000-, 400 to 900-, 400 to 800-, 400 to 700-, 400 to 600-, 400 to 500-, 500 to 1000-, 500 to 900-, 500 to 800-, 500 to 700-, 500 to 600-, 600 to 1000-, 600 to 900-, 600 to 800-, 600 to 700-, 700 to 1000-, 700 to 900-, 700 to 800-, 800 to 1000-, 800 to 900-, or 900 to 1000-fold reduction in the standard of care dose of a recombinant hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant or purified hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine or a live attenuated or inactivated hMPV, PIV3, RSV, MeV and/or BetaCoV vaccine. In some embodiments, the effective amount is a dose equivalent to (or equivalent to an at least) 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 110-, 120-, 130-, 140-, 150-, 160-, 170-, 1280-, 190-, 200-, 210-, 220-, 230-, 240-, 250-, 260-, 270-, 280-, 290-, 300-, 310-, 320-, 330-, 340-, 350-, 360-, 370-, 380-, 390-, 400-, 410-, 420-, 430-, 440-, 450-, 4360-, 470-, 480-, 490-, 500-, 510-, 520-, 530-, 540-, 550-, 560-, 5760-, 580-, 590-, 600-, 610-, 620-, 630-, 640-, 650-, 660-, 670-, 680-, 690-, 700-, 710-, 720-, 730-, 740-, 750-, 760-, 770-, 780-, 790-, 800-, 810-, 820-, 830-, 840-, 850-, 860-, 870-, 880-, 890-, 900-, 910-, 920-, 930-, 940-, 950-, 960-, 970-, 980-, 990-, or 1000-fold reduction in the standard of care dose of a recombinant hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine. In some embodiments, an anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer

produced in a control subject administered the standard of care dose of a recombinant or purified hMPV, PIV3, RSV, MeV and/or BetaCoV protein vaccine or a live attenuated or inactivated hMPV, PIV3, RSV, MeV and/or BetaCoV vaccine.

[0694] In some embodiments, the effective amount of a respiratory virus RNA (e.g., mRNA) vaccine is a total dose of 50-1000 .mu.g. In some embodiments, the effective amount of a respiratory virus RNA (e.g., mRNA) vaccine is a total dose of 50-1000, 50-900, 50-800, 50-700, 50-600, 50-500, 50-400, 50-300, 50-200, 50-100, 50-90, 50-80, 50-70, 50-60, 60-1000, 60-900, 60-800, 60-700, 60-600, 60-500, 60-400, 60-300, 60-200, 60-100, 60-90, 60-80, 60-70, 70-1000, 70-900, 70-800, 70-700, 70-600, 70-500, 70-400, 70-300, 70-200, 70-100, 70-90, 70-80, 80-1000, 80-900, 80-800, 80-700, 80-600, 80-500, 80-400, 80-300, 80-200, 80-100, 80-90, 90-1000, 90-900, 90-800, 90-700, 90-600, 90-500, 90-400, 90-300, 90-200, 90-100, 100-1000, 100-900, 100-800, 100-700, 100-600, 100-500, 100-400, 100-300, 100-200, 200-1000, 200-900, 200-800, 200-700, 200-600, 200-500, 200-400, 200-300, 300-1000, 300-900, 300-800, 300-700, 300-600, 300-500, 300-400, 400-1000, 400-900, 400-800, 400-700, 400-600, 400-500, 500-1000, 500-900, 500-800, 500-700, 500-600, 600-1000, 600-900, 600-800, 600-700, 700-1000, 700-900, 700-800, 800-1000, 800-900, or 900-1000 .mu.g. In some embodiments, the effective amount of a respiratory virus RNA (e.g., mRNA) vaccine is a total dose of 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000 .mu.g. In some embodiments, the effective amount is a dose of 25-500 .mu.g administered to the subject a total of two times. In some embodiments, the effective amount of a respiratory virus RNA (e.g., mRNA) vaccine is a dose of 25-500, 25-400, 25-300, 25-200, 25-100, 25-50, 50-500, 50-400, 50-300, 50-200, 50-100, 100-500, 100-400, 100-300, 100-200, 150-500, 150-400, 150-300, 150-200, 200-500, 200-400, 200-300, 250-500, 250-400, 250-300, 300-500, 300-400, 350-500, 350-400, 400-500 or 450-500 .mu.g administered to the subject a total of two times. In some embodiments, the effective amount of a respiratory virus RNA (e.g., mRNA) vaccine is a total dose of 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 .mu.g administered to the subject a total of two times.

#### Examples of Additional Embodiments of the Disclosure

[0695] Additional embodiments of the present disclosure are encompassed by the following numbered paragraphs:

1. A respiratory virus vaccine, comprising: at least one ribonucleic acid (RNA) polynucleotide having an open reading frame encoding at least one, at least two, at least three, at least four or at least five antigenic polypeptides selected from human metapneumovirus (hMPV) antigenic polypeptides or immunogenic fragments thereof, human parainfluenza virus type 3 (PIV3) antigenic polypeptides or immunogenic fragments thereof, respiratory syncytial virus (RSV) antigenic polypeptides or immunogenic fragments thereof, measles virus (MeV) antigenic polypeptides or immunogenic fragments thereof, and betacoronavirus (BetaCoV) antigenic polypeptides or immunogenic fragments thereof. 2. The respiratory virus vaccine of paragraph 1, comprising:

[0696] at least one RNA polynucleotide having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof and a PIV3 antigenic polypeptide or an immunogenic fragment thereof; or

[0697] at least two RNA polynucleotides, one having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof and one having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof.

3. The respiratory virus vaccine of paragraph 2, wherein the hMPV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 5-8 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, and/or wherein the PIV3 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 12-13 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 12-13. 4. The respiratory virus vaccine of paragraph 1, comprising:

[0698] at least one RNA polynucleotide having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof and a RSV antigenic polypeptide or an immunogenic fragment thereof; or

[0699] at least two RNA polynucleotides, one having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof and one having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof.

5. The respiratory virus vaccine of paragraph 4, wherein the hMPV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 5-8 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8. 6. The respiratory virus vaccine of paragraph 1, comprising:

[0700] at least one RNA polynucleotide having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof and MeV antigenic polypeptide or an immunogenic fragment thereof; or

[0701] at least two RNA polynucleotides, one having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof and one having an open reading frame encoding a MeV antigenic polypeptide or an immunogenic fragment thereof.

7. The respiratory virus vaccine of paragraph 6, wherein the hMPV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 5-8 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, and/or wherein the MeV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 47-50 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 47-50. 8. The respiratory virus vaccine of paragraph 1, comprising:

[0702] at least one RNA polynucleotide having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof and a BetaCoV antigenic polypeptide or an immunogenic fragment thereof; or

[0703] at least two RNA polynucleotides, one having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof and one having an open reading frame encoding a BetaCoV antigenic polypeptide or an immunogenic fragment thereof.

9. The respiratory virus vaccine of paragraph 8, wherein the hMPV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 5-8 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, and/or wherein the BetaCoV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 24-34 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 24-34. 10. The respiratory virus vaccine of paragraph 1, comprising:

[0704] at least one RNA polynucleotide having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof and a RSV antigenic polypeptide or an immunogenic fragment thereof; or

[0705] at least two RNA polynucleotides, one having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof and one having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof.

11. The respiratory virus vaccine of paragraph 10, wherein the PIV3 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 12-13 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 12-13. 12. The respiratory virus vaccine of paragraph 1, comprising:

[0706] at least one RNA polynucleotide having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof and a MeV antigenic polypeptide or an immunogenic fragment thereof; or

[0707] at least two RNA polynucleotides, one having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof and one having an open reading frame encoding a MeV antigenic polypeptide or an immunogenic fragment thereof.

13. The respiratory virus vaccine of paragraph 12, wherein the PIV3 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 12-13 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 12-13, and/or wherein the MeV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 47-50 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 47-50. 14. The respiratory virus vaccine of paragraph 1, comprising:

[0708] at least one RNA polynucleotide having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof and a BetaCoV antigenic polypeptide or an immunogenic fragment thereof; or

[0709] at least two RNA polynucleotides, one having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof and one having an open reading frame encoding a BetaCoV antigenic polypeptide or an immunogenic fragment thereof.

15. The respiratory virus vaccine of paragraph 14, wherein the PIV3 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 12-13 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 12-13, and/or wherein the BetaCoV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 24-34 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 24-34. 16. The respiratory virus vaccine of paragraph 1, comprising:

[0710] at least one RNA polynucleotide having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof and a MeV antigenic polypeptide or an immunogenic fragment thereof; or

[0711] at least two RNA polynucleotides, one having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof and one having an open reading frame encoding a MeV antigenic polypeptide or an immunogenic fragment thereof.

17. The respiratory virus vaccine of paragraph 16, wherein the MeV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 47-50 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 47-50. 18. The respiratory virus vaccine of paragraph 1, comprising:

[0712] at least one RNA polynucleotide having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof and a BetaCoV antigenic polypeptide or an immunogenic fragment thereof; or

[0713] at least two RNA polynucleotides, one having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof and one having an open reading frame encoding a BetaCoV antigenic polypeptide or an immunogenic fragment thereof.

19. The respiratory virus vaccine of paragraph 18, wherein the BetaCoV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 24-34 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 24-34. 20. The respiratory virus vaccine of paragraph 1, comprising:

[0714] at least one RNA polynucleotide having an open reading frame encoding a MeV antigenic polypeptide or an immunogenic fragment thereof and a BetaCoV antigenic polypeptide or an immunogenic fragment thereof; or

[0715] at least two RNA polynucleotides, one having an open reading frame encoding a MeV antigenic polypeptide or an immunogenic fragment thereof and one having an open reading frame encoding a BetaCoV

antigenic polypeptide or an immunogenic fragment thereof.

21. The respiratory virus vaccine of paragraph 20, wherein the MeV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 47-50 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 47-50, and/or wherein the BetaCoV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 24-34 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 24-34. 22. The respiratory virus vaccine of paragraph 1, comprising:

[0716] at least one RNA polynucleotide having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, a PIV3 antigenic polypeptide or an immunogenic fragment thereof, and a RSV antigenic polypeptide or an immunogenic fragment thereof; or

[0717] at least two or three RNA polynucleotides, one having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof, and one having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof.

23. The respiratory virus vaccine of paragraph 22, wherein the hMPV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 5-8 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, and/or wherein the PIV3 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 12-13 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 12-13. 24. The respiratory virus vaccine of paragraph 1, comprising:

[0718] at least one RNA polynucleotide having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, a PIV3 antigenic polypeptide or an immunogenic fragment thereof, and a MeV antigenic polypeptide or an immunogenic fragment thereof; or

[0719] at least two or three RNA polynucleotides, one having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof, and one having an open reading frame encoding a MeV antigenic polypeptide or an immunogenic fragment thereof.

25. The respiratory virus vaccine of paragraph 24, wherein the hMPV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 5-8 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, wherein the PIV3 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 12-13 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 12-13, and/or wherein the MeV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 47-50 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 47-50. 26. The respiratory virus vaccine of paragraph 1, comprising:

[0720] at least one RNA polynucleotide having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, a PIV3 antigenic polypeptide or an immunogenic fragment thereof, and a BetaCoV antigenic polypeptide or an immunogenic fragment thereof; or

[0721] at least two or three RNA polynucleotides, one having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof, and one having an open reading frame encoding a BetaCoV antigenic polypeptide or an immunogenic fragment thereof.

27. The respiratory virus vaccine of paragraph 26, wherein the hMPV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 5-8 or an amino acid sequence having at least 90% or 95%

identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, wherein the PIV3 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 12-13 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 12-13 and/or wherein the BetaCoV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 23-34 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 23-34. 28. The respiratory virus vaccine of paragraph 1, comprising:

[0722] at least one RNA polynucleotide having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, a RSV antigenic polypeptide or an immunogenic fragment thereof, and a MeV antigenic polypeptide or an immunogenic fragment thereof; or

[0723] at least two or three RNA polynucleotides, one having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof, and one having an open reading frame encoding a MeV antigenic polypeptide or an immunogenic fragment thereof.

29. The respiratory virus vaccine of paragraph 28, wherein the hMPV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 5-8 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, and/or wherein the MeV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 47-50 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 47-50. 30. The respiratory virus vaccine of paragraph 1, comprising:

[0724] at least one RNA polynucleotide having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, a RSV antigenic polypeptide or an immunogenic fragment thereof, and a BetaCoV antigenic polypeptide or an immunogenic fragment thereof; or

[0725] at least two or three RNA polynucleotides, one having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof, and one having an open reading frame encoding a BetaCoV antigenic polypeptide or an immunogenic fragment thereof.

31. The respiratory virus vaccine of paragraph 30, wherein the hMPV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 5-8 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, and/or wherein the BetaCoV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 23-34 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 23-34. 32. The respiratory virus vaccine of paragraph 1, comprising:

[0726] at least one RNA polynucleotide having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, a MeV antigenic polypeptide or an immunogenic fragment thereof, and a BetaCoV antigenic polypeptide or an immunogenic fragment thereof; or

[0727] at least two or three RNA polynucleotides, one having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a MeV antigenic polypeptide or an immunogenic fragment thereof, and one having an open reading frame encoding a BetaCoV antigenic polypeptide or an immunogenic fragment thereof.

33. The respiratory virus vaccine of paragraph 32, wherein the hMPV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 5-8 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, wherein the MeV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 47-50 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO:

47-50, and/or wherein the BetaCoV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 23-34 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 23-34. 34. The respiratory virus vaccine of paragraph 1, comprising:

[0728] at least one RNA polynucleotide having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof, a RSV antigenic polypeptide or an immunogenic fragment thereof, and a MeV antigenic polypeptide or an immunogenic fragment thereof; or

[0729] at least two or three RNA polynucleotides, one having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof, and one having an open reading frame encoding a MeV antigenic polypeptide or an immunogenic fragment thereof.

35. The respiratory virus vaccine of paragraph 34, wherein the PIV3 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 12-13 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 12-13, and/or wherein the MeV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 47-50 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 47-50. 36. The respiratory virus vaccine of paragraph 1, comprising:

[0730] at least one RNA polynucleotide having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof, a RSV antigenic polypeptide or an immunogenic fragment thereof, and a BetaCoV antigenic polypeptide or an immunogenic fragment thereof; or

[0731] at least two or three RNA polynucleotides, one having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof, and one having an open reading frame encoding a BetaCoV antigenic polypeptide or an immunogenic fragment thereof.

37. The respiratory virus vaccine of paragraph 36, wherein the PIV3 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 12-13 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 12-13, and/or wherein the BetaCoV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 23-34 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 23-34. 38. The respiratory virus vaccine of paragraph 1, comprising:

[0732] at least one RNA polynucleotide having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof, a MeV antigenic polypeptide or an immunogenic fragment thereof, and a BetaCoV antigenic polypeptide or an immunogenic fragment thereof; or

[0733] at least two or three RNA polynucleotides, one having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a MeV antigenic polypeptide or an immunogenic fragment thereof, and one having an open reading frame encoding a BetaCoV antigenic polypeptide or an immunogenic fragment thereof.

39. The respiratory virus vaccine of paragraph 38, wherein the MeV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 47-50 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 47-50, and/or wherein the BetaCoV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 23-34 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 23-34. 40. The respiratory virus vaccine of paragraph 1, comprising:

[0734] at least one RNA polynucleotide having an open reading frame encoding a PIV3 antigenic polypeptide or

an immunogenic fragment thereof, a MeV antigenic polypeptide or an immunogenic fragment thereof, and a BetaCoV antigenic polypeptide or an immunogenic fragment thereof; or

[0735] at least two or three RNA polynucleotides, one having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a MeV antigenic polypeptide or an immunogenic fragment thereof, and one having an open reading frame encoding a BetaCoV antigenic polypeptide or an immunogenic fragment thereof.

41. The respiratory virus vaccine of paragraph 40, wherein the PIV3 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 12-13 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 12-13, wherein the MeV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 47-50 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 47-50, and/or wherein the BetaCoV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 23-34 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 23-34. 42. The respiratory virus vaccine of paragraph 1, comprising:

[0736] at least one RNA polynucleotide having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, a PIV3 antigenic polypeptide or an immunogenic fragment thereof, a RSV antigenic polypeptide or an immunogenic fragment thereof, and a MeV antigenic polypeptide or an immunogenic fragment thereof; or

[0737] at least two, three or four RNA polynucleotides, one having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof, and one having an open reading frame encoding a MeV antigenic polypeptide or an immunogenic fragment thereof.

43. The respiratory virus vaccine of paragraph 42, wherein the hMPV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 5-8 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, wherein the PIV3 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 12-13 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 12-13, and/or wherein the MeV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 47-50 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 47-50. 44. The respiratory virus vaccine of paragraph 1, comprising:

[0738] at least one RNA polynucleotide having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, a PIV3 antigenic polypeptide or an immunogenic fragment thereof, a RSV antigenic polypeptide or an immunogenic fragment thereof, and a BetaCoV antigenic polypeptide or an immunogenic fragment thereof; or

[0739] at least two, three or four RNA polynucleotides, one having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof, and one having an open reading frame encoding a BetaCoV antigenic polypeptide or an immunogenic fragment thereof.

45. The respiratory virus vaccine of paragraph 44, wherein the hMPV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 5-8 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, wherein the PIV3 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 12-13 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO:



12-13, and/or wherein the BetaCoV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 24-34 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 24-34. 46. The respiratory virus vaccine of paragraph 1, comprising:

[0740] at least one RNA polynucleotide having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, a PIV3 antigenic polypeptide or an immunogenic fragment thereof, a MeV antigenic polypeptide or an immunogenic fragment thereof, and a BetaCoV antigenic polypeptide or an immunogenic fragment thereof; or

[0741] at least two, three or four RNA polynucleotides, one having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a MeV antigenic polypeptide or an immunogenic fragment thereof, and one having an open reading frame encoding a BetaCoV antigenic polypeptide or an immunogenic fragment thereof.

47. The respiratory virus vaccine of paragraph 46, wherein the hMPV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 5-8 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, wherein the PIV3 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 12-13 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 12-13, wherein the MeV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 47-50 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 47-50, and/or wherein the BetaCoV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 24-34 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 24-34. 48. The respiratory virus vaccine of paragraph 1, comprising:

[0742] at least one RNA polynucleotide having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, a RSV antigenic polypeptide or an immunogenic fragment thereof, a MeV antigenic polypeptide or an immunogenic fragment thereof, and a BetaCoV antigenic polypeptide or an immunogenic fragment thereof; or

[0743] at least two, three or four RNA polynucleotides, one having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a MeV antigenic polypeptide or an immunogenic fragment thereof, and one having an open reading frame encoding a BetaCoV antigenic polypeptide or an immunogenic fragment thereof.

49. The respiratory virus vaccine of paragraph 48, wherein the hMPV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 5-8 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, wherein the MeV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 47-50 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 47-50, and/or wherein the BetaCoV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 24-34 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 24-34. 50. The respiratory virus vaccine of paragraph 1, comprising:

[0744] at least one RNA polynucleotide having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof, a RSV antigenic polypeptide or an immunogenic fragment thereof, a MeV antigenic polypeptide or an immunogenic fragment thereof, and a BetaCoV antigenic polypeptide or an immunogenic fragment thereof; or

[0745] at least two, three or four RNA polynucleotides, one having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a MeV antigenic polypeptide or an immunogenic fragment thereof, and one having an open reading frame encoding a BetaCoV antigenic polypeptide or an immunogenic fragment thereof.

51. The respiratory virus vaccine of paragraph 50, wherein the PIV3 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 12-13 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 12-13, wherein the MeV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 47-50 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 47-50, and/or wherein the BetaCoV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 24-34 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 24-34. 52. The respiratory virus vaccine of paragraph 1, comprising:

[0746] at least one RNA polynucleotide having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, a PIV3 antigenic polypeptide or an immunogenic fragment thereof, a RSV antigenic polypeptide or an immunogenic fragment thereof, a MeV antigenic polypeptide or an immunogenic fragment thereof, and a BetaCoV antigenic polypeptide or an immunogenic fragment thereof; or

[0747] at least two, three, four or five RNA polynucleotides, one having an open reading frame encoding a hMPV antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a PIV3 antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a RSV antigenic polypeptide or an immunogenic fragment thereof, one having an open reading frame encoding a MeV antigenic polypeptide or an immunogenic fragment thereof, and one having an open reading frame encoding a BetaCoV antigenic polypeptide or an immunogenic fragment thereof.

53. The respiratory virus vaccine of paragraph 52, wherein the hMPV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 5-8 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 5-8, wherein the PIV3 antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 12-13 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 12-13, wherein the MeV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 47-50 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 47-50, and/or wherein the BetaCoV antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 24-34 or an amino acid sequence having at least 90% or 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 24-34. 54. The vaccine of any one of paragraphs 1-53, wherein at least one RNA polynucleotide has less than 80% identity to wild-type mRNA sequence. 55. The vaccine of any one of paragraphs 1-53, wherein at least one RNA polynucleotide has at least 80% identity to wild-type mRNA sequence, but does not include wild-type mRNA sequence. 56. The vaccine of any one of paragraphs 1-55, wherein at least one antigenic polypeptide has membrane fusion activity, attaches to cell receptors, causes fusion of viral and cellular membranes, and/or is responsible for binding of the virus to a cell being infected. 57. The vaccine of any one of paragraphs 1-56, wherein at least one RNA polynucleotide comprises at least one chemical modification. 58. The vaccine of paragraph 57, wherein the chemical modification is selected from pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2'-O-methyl uridine. 59. The vaccine of paragraph 57 or 58, wherein the chemical modification is in the 5-position of the uracil. 60. The vaccine of any one of paragraphs 57-59, wherein the chemical modification is a N1-methylpseudouridine or N1-ethylpseudouridine. 61. The vaccine of any one of paragraphs 57-60, wherein at least 80%, at least 90% or 100% of the uracil in the open reading frame have a chemical modification. 62. The vaccine of any one of paragraphs

1-61, wherein at least one RNA polynucleotide further encodes at least one 5' terminal cap, optionally wherein the 5' terminal cap is 7mG(5')ppp(5')NlmpNp. 63. The vaccine of any one of paragraphs 1-62, wherein at least one antigenic polypeptide or immunogenic fragment thereof is fused to a signal peptide selected from: a HuIgGk signal peptide (METPAQLLFLLLLWLPDTTG; SEQ ID NO: 15); IgE heavy chain epsilon-1 signal peptide (MDWTWILFLVAAATRVHS; SEQ ID NO: 16); Japanese encephalitis PRM signal sequence (MLGSNSGQRVVFTILLLLVAPAYS; SEQ ID NO: 17), VSVg protein signal sequence (MKCLLYLAFLFIGVNCA; SEQ ID NO: 18) and Japanese encephalitis JEV signal sequence (MWLVSLAIVTACAGA; SEQ ID NO: 19). 64. The vaccine of paragraph 63, wherein the signal peptide is fused to the N-terminus or the C-terminus of at least one antigenic polypeptide. 65. The vaccine of any one of paragraphs 1-64, wherein the antigenic polypeptide or immunogenic fragment thereof comprises a mutated N-linked glycosylation site. 66. The vaccine of any one of paragraphs 1-65 formulated in a nanoparticle, optionally a lipid nanoparticle. 67. The vaccine of paragraph 66, wherein the lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol and a non-cationic lipid; optionally wherein the lipid nanoparticle carrier comprises a molar ratio of about 20-60% cationic lipid, 0.5-15% PEG-modified lipid, 25-55% sterol, and 25% non-cationic lipid; optionally wherein the cationic lipid is an ionizable cationic lipid and the non-cationic lipid is a neutral lipid, and the sterol is a cholesterol; and optionally wherein the cationic lipid is selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319). Formula (II) 68. The vaccine of paragraph 66 or 67, wherein the nanoparticle (e.g., lipid nanoparticle) comprises a compound of Formula (I) and/or Formula (II), optionally Compound 3, 18, 20, 25, 26, 29, 30, 60, 108-112, or 122. 69. The vaccine of any one of paragraphs 1-68 further comprising an adjuvant, optionally a flagellin protein or peptide that optionally comprises an amino acid sequence identified by any one of SEQ ID NO: 54-56. 70. The vaccine of any one of paragraphs 1-69, wherein the open reading frame is codon-optimized. 71. The vaccine of any one of paragraphs 1-70 formulated in an effective amount to produce an antigen-specific immune response. 72. A method of inducing an immune response in a subject, the method comprising administering to the subject the vaccine of any one of paragraphs 1-71 in an amount effective to produce an antigen-specific immune response in the subject. 73. The method of paragraph 72, wherein the subject is administered a single dose of the vaccine, or wherein the subject is administered a first dose and then a booster dose of the vaccine. 74. The method of paragraph 72 or 73, wherein the vaccine is administered to the subject by intradermal injection or intramuscular injection. 75. The method of any one of paragraphs 72-74, wherein an anti-antigenic polypeptide antibody titer produced in the subject is increased by at least 1 log relative to a control, and/or wherein the anti-antigenic polypeptide antibody titer produced in the subject is increased at least 2 times relative to a control. 76. The method of any one of paragraphs 72-75, wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has not been administered a vaccine against the virus, and/or wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a live attenuated vaccine or an inactivated vaccine against the virus, and/or, wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a recombinant protein vaccine or purified protein vaccine against the virus, and/or wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a VLP vaccine against the virus. 77. The method of any one of paragraphs 72-76, wherein the effective amount is a dose equivalent to an at least 2-fold reduction in the standard of care dose of a recombinant protein vaccine or a purified protein vaccine against the virus, and wherein an anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant protein vaccine or a purified protein vaccine against the virus, respectively; and/or wherein the effective amount is a dose equivalent to an at least 2-fold reduction in the standard of care dose of a live attenuated vaccine or an inactivated vaccine against the virus, and wherein an anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a live attenuated vaccine or an inactivated vaccine against the virus, respectively; and/or wherein the effective amount is a dose equivalent to an at least 2-fold reduction in the standard of care dose of a VLP vaccine against the virus, and wherein an anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a VLP vaccine against the virus. 78. The method of any one of paragraphs 72-77, wherein the effective amount is a total dose of 50 .mu.g-1000 .mu.g, optionally wherein the effective amount is a dose of 25 .mu.g, 100 .mu.g,

400 .mu.g, or 500 .mu.g administered to the subject a total of two times. 79. The method of any one of paragraphs 72-78, wherein the efficacy of the vaccine against the virus is greater than 65%; and/or wherein the vaccine immunizes the subject against the virus for up to 2 years or wherein the vaccine immunizes the subject against the virus for more than 2 years. 80. The method of any one of paragraphs 72-79, wherein the subject has an age of about 5 years old or younger or wherein the subject has an age of about 60 years old or older; and/or wherein the subject has a chronic pulmonary disease; and/or the subject has been exposed to the virus, wherein the subject is infected with the virus, or wherein the subject is at risk of infection by the virus; and/or wherein the subject is immunocompromised. 81. The respiratory virus vaccine of any one of paragraphs 1-71, comprising at least one (e.g., at least two, at least three, at least four, or at least five) RNA polynucleotide having an open reading frame encoding at least one (e.g., at least two, at least three, at least four, or at least five) antigenic polypeptide selected from hMPV antigenic polypeptides (SEQ ID NO: 5-8), PIV3 antigenic polypeptides (SEQ ID NO: 12-13), RSV antigenic polypeptides, MeV antigenic polypeptides (SEQ ID NO: 47-50) and BetaCoV antigenic polypeptides (e.g., MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH or HCoV-HKU1; (SEQ ID NO: 24-34)), formulated in a cationic lipid nanoparticle

[0748] (a) having a molar ratio of about 20-60% cationic lipid, about 5-25% non-cationic lipid, about 25-55% sterol, and about 0.5-15% PEG-modified lipid, and/or

[0749] (b) comprising a compound of Formula (I) and/or Formula (II), wherein the at least one (e.g., at least two, at least three, at least four, or at least five) RNA polynucleotide comprises at least one chemical modification.

82. The respiratory virus vaccine of any one of paragraphs 1-71, comprising at least one (e.g., at least two, at least three, at least four, or at least five) RNA polynucleotide having an open reading frame encoding at least one (e.g., at least two, at least three, at least four, or at least five) antigenic polypeptide selected from hMPV antigenic polypeptides (SEQ ID NO: 5-8), PIV3 antigenic polypeptides (SEQ ID NO: 12-13), RSV antigenic polypeptides, MeV antigenic polypeptides (SEQ ID NO: 47-50) and BetaCoV antigenic polypeptides (e.g., MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH or HCoV-HKU1; (SEQ ID NO: 24-34)), formulated in a cationic lipid nanoparticle

[0750] (a) having a molar ratio of about 20-60% cationic lipid, about 5-25% non-cationic lipid, about 25-55% sterol, and about 0.5-15% PEG-modified lipid, and/or

[0751] (b) comprising at least one (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14) Compound selected from Compounds 3, 18, 20, 25, 26, 29, 30, 60, 108-112 and 122.

83. The respiratory virus vaccine of paragraphs 81 or 82, wherein the at least one antigenic polypeptide is selected from hMPV antigenic polypeptides (e.g., SEQ ID NO: 5-8). 84. The respiratory virus vaccine of any one of paragraphs 81-83, wherein the at least one antigenic polypeptide is selected from PIV3 antigenic polypeptides (e.g., SEQ ID NO: 12-13). 85. The respiratory virus vaccine of any one of paragraphs 81-84, wherein the at least one antigenic polypeptide is selected from RSV antigenic polypeptides. 86. The respiratory virus vaccine of any one of paragraphs 81-85, wherein the at least one antigenic polypeptide is selected from MeV antigenic polypeptides (e.g., SEQ ID NO: 47-50). 87. The respiratory virus vaccine of any one of paragraphs 81-86, wherein the at least one antigenic polypeptide is selected from BetaCoV antigenic polypeptides (e.g., SEQ ID NO: 24-34). 88. The respiratory virus vaccine of paragraph 87, wherein the BetaCoV antigenic polypeptides are MERS antigenic polypeptides. 89. The respiratory virus vaccine of paragraph 87, wherein the BetaCoV antigenic polypeptides are **SARS** antigenic polypeptides. 90. The respiratory virus vaccine of any one of paragraphs 81-89, wherein the at least one (e.g., at least two, at least three, at least four, or at least five) RNA polynucleotide comprises at least one chemical modification (e.g., selected from pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2'-O-methyl uridine). 91. A respiratory virus vaccine, comprising:

[0752] at least one messenger ribonucleic acid (mRNA) polynucleotide having a 5' terminal cap, an open reading frame encoding at least one respiratory virus antigenic polypeptide, and a 3' polyA tail. 92. The vaccine of paragraph 91, wherein the at least one mRNA polynucleotide comprises a sequence identified by any one of SEQ ID NO: 57-80. 93. The vaccine of paragraph 91 or 92, wherein the 5' terminal cap is or comprises 7mG(5')ppp(5')NlmpNp. 94. The vaccine of any one of paragraphs 91-93, wherein 100% of the uracil in the open reading frame is modified to include N1-methyl pseudouridine at the 5-position of the uracil. 95. The vaccine of any one of paragraphs 91-94, wherein the vaccine is formulated in a lipid nanoparticle comprising: DLin-MC3-DMA; cholesterol; 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC); and polyethylene glycol (PEG)2000-DMG. 96. The vaccine of paragraph 95, wherein the lipid nanoparticle further comprises trisodium citrate buffer, sucrose and water. 97. A respiratory syncytial virus (RSV) vaccine, comprising:

[0753] at least one messenger ribonucleic acid (mRNA) polynucleotide having a 5' terminal cap 7mG(5')ppp(5')NlmpNp, a sequence identified by any one of SEQ ID NO: 57-80 and a 3' polyA tail, formulated in a lipid nanoparticle comprising DLin-MC3-DMA, cholesterol, 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), and polyethylene glycol (PEG)2000-DMG, wherein the uracil nucleotides of the sequence identified by any one of SEQ ID NO: 57-80 are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.

[0754] This disclosure is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The disclosure is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of "including," "comprising," or "having," "containing," "involving," and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

## EXAMPLES

### Example 1: Manufacture of Polynucleotides

[0755] According to the present disclosure, the manufacture of polynucleotides and/or parts or regions thereof may be accomplished utilizing the methods taught in International Publication WO2014/152027, entitled "Manufacturing Methods for Production of RNA Transcripts," the contents of which is incorporated herein by reference in its entirety.

[0756] Purification methods may include those taught in International Publication WO2014/152030 and International Publication WO2014/152031, each of which is incorporated herein by reference in its entirety.

[0757] Detection and characterization methods of the polynucleotides may be performed as taught in International Publication WO2014/144039, which is incorporated herein by reference in its entirety.

[0758] Characterization of the polynucleotides of the disclosure may be accomplished using polynucleotide mapping, reverse transcriptase sequencing, charge distribution analysis, detection of RNA impurities, or any combination of two or more of the foregoing. "Characterizing" comprises determining the RNA transcript sequence, determining the purity of the RNA transcript, or determining the charge heterogeneity of the RNA transcript, for example. Such methods are taught in, for example, International Publication WO2014/144711 and International Publication WO2014/144767, the content of each of which is incorporated herein by reference in its entirety.

### Example 2: Chimeric Polynucleotide Synthesis

[0759] According to the present disclosure, two regions or parts of a chimeric polynucleotide may be joined or ligated using triphosphate chemistry. A first region or part of 100 nucleotides or less is chemically synthesized with a 5' monophosphate and terminal 3'desOH or blocked OH, for example. If the region is longer than 80 nucleotides, it may be synthesized as two strands for ligation.

[0760] If the first region or part is synthesized as a non-positionally modified region or part using in vitro transcription (IVT), conversion the 5'monophosphate with subsequent capping of the 3' terminus may follow.

[0761] Monophosphate protecting groups may be selected from any of those known in the art.

[0762] The second region or part of the chimeric polynucleotide may be synthesized using either chemical synthesis or IVT methods. IVT methods may include an RNA polymerase that can utilize a primer with a modified cap. Alternatively, a cap of up to 130 nucleotides may be chemically synthesized and coupled to the IVT region or part.

[0763] For ligation methods, ligation with DNA T4 ligase, followed by treatment with DNase should readily avoid concatenation.

[0764] The entire chimeric polynucleotide need not be manufactured with a phosphate-sugar backbone. If one of the regions or parts encodes a polypeptide, then such region or part may comprise a phosphate-sugar backbone.

[0765] Ligation is then performed using any known click chemistry, orthoclick chemistry, solulink, or other bioconjugate chemistries known to those in the art.

[0766] Synthetic Route

[0767] The chimeric polynucleotide may be made using a series of starting segments. Such segments include:

[0768] (a) a capped and protected 5' segment comprising a normal 3'OH (SEG. 1)

[0769] (b) a 5' triphosphate segment, which may include the coding region of a polypeptide and a normal 3'OH (SEG. 2)

[0770] (c) a 5' monophosphate segment for the 3' end of the chimeric polynucleotide (e.g., the tail) comprising cordycepin or no 3'OH (SEG. 3)

[0771] After synthesis (chemical or IVT), segment 3 (SEG. 3) may be treated with cordycepin and then with pyrophosphatase to create the 5' monophosphate.

[0772] Segment 2 (SEG. 2) may then be ligated to SEG. 3 using RNA ligase. The ligated polynucleotide is then purified and treated with pyrophosphatase to cleave the diphosphate. The treated SEG.2-SEG. 3 construct may then be purified and SEG. 1 is ligated to the 5' terminus. A further purification step of the chimeric polynucleotide may be performed.

[0773] Where the chimeric polynucleotide encodes a polypeptide, the ligated or joined segments may be represented as: 5'UTR (SEG. 1), open reading frame or ORF (SEG. 2) and 3'UTR+PolyA (SEG. 3).

[0774] The yields of each step may be as much as 90-95%.

Example 3: PCR for cDNA Production

[0775] PCR procedures for the preparation of cDNA may be performed using 2.times.KAPA HIFI.TM. HotStart ReadyMix by Kapa Biosystems (Woburn, Mass.). This system includes 2.times.KAPA ReadyMix 12.5 .mu.l; Forward Primer (10 .mu.M) 0.75 .mu.l; Reverse Primer (10 .mu.M) 0.75 al; Template cDNA 100 ng; and dH.sub.2O diluted to 25.0 .mu.l. The reaction conditions may be at 95.degree. C. for 5 min. The reaction may be performed for 25 cycles of 98.degree. C. for 20 sec, then 58.degree. C. for 15 sec, then 72.degree. C. for 45 sec, then 72.degree. C. for 5 min, then 4.degree. C. to termination.

[0776] The reaction may be cleaned up using Invitrogen's PURELINK.TM. PCR Micro Kit (Carlsbad, Calif.) per manufacturer's instructions (up to 5 g). Larger reactions may require a cleanup using a product with a larger capacity. Following the cleanup, the cDNA may be quantified using the NANODROP.TM. and analyzed by agarose gel electrophoresis to confirm that the cDNA is the expected size. The cDNA may then be submitted for sequencing analysis before proceeding to the in vitro transcription reaction.

#### Example 4: In Vitro Transcription (IVT)

[0777] The in vitro transcription reaction generates RNA polynucleotides. Such polynucleotides may comprise a region or part of the polynucleotides of the disclosure, including chemically modified RNA (e.g., mRNA) polynucleotides. The chemically modified RNA polynucleotides can be uniformly modified polynucleotides. The in vitro transcription reaction utilizes a custom mix of nucleotide triphosphates (NTPs). The NTPs may comprise chemically modified NTPs, or a mix of natural and chemically modified NTPs, or natural NTPs.

[0778] A typical in vitro transcription reaction includes the following:

TABLE-US-00001 1) Template cDNA 1.0 .mu.g 2) 10x transcription buffer 2.0 .mu.l (400 mM Tris-HCl pH 8.0, 190 mM MgCl.sub.2, 50 mM DTT, 10 mM Spermidine) 3) Custom NTPs (25 mM each) 0.2 .mu.l 4) RNase Inhibitor 20 U 5) T7 RNA polymerase 3000 U 6) dH.sub.2O up to 20.0 .mu.l. and 7) Incubation at 37.degree. C. for 3 hr-5 hrs.

[0779] The crude IVT mix may be stored at 4.degree. C. overnight for cleanup the next day. 1 U of RNase-free DNase may then be used to digest the original template. After 15 minutes of incubation at 37.degree. C., the mRNA may be purified using Ambion's MEGACLEAR.TM. Kit (Austin, Tex.) following the manufacturer's instructions. This kit can purify up to 500 .mu.g of RNA. Following the cleanup, the RNA polynucleotide may be quantified using the NanoDrop and analyzed by agarose gel electrophoresis to confirm the RNA polynucleotide is the proper size and that no degradation of the RNA has occurred.

#### Example 5: Enzymatic Capping

[0780] Capping of a RNA polynucleotide is performed as follows where the mixture includes: IVT RNA 60 .mu.g-180 .mu.g and dH.sub.2O up to 72 al. The mixture is incubated at 65.degree. C. for 5 minutes to denature RNA, and then is transferred immediately to ice.

[0781] The protocol then involves the mixing of 10.times. Capping Buffer (0.5 M Tris-HCl (pH 8.0), 60 mM KCl, 12.5 mM MgCl.sub.2) (10.0 .mu.l); 20 mM GTP (5.0 .mu.l); 20 mM S-Adenosyl Methionine (2.5 .mu.l); RNase Inhibitor (100 U); 2'-O-Methyltransferase (400U); Vaccinia capping enzyme (Guanylyl transferase) (40 U); dH.sub.2O (Up to 28 .mu.l); and incubation at 37.degree. C. for 30 minutes for 60 .mu.g RNA or up to 2 hours for 180 .mu.g of RNA.

[0782] The RNA polynucleotide may then be purified using Ambion's MEGACLEAR.TM. Kit (Austin, Tex.) following the manufacturer's instructions. Following the cleanup, the RNA may be quantified using the NANODROP.TM. (ThermoFisher, Waltham, Mass.) and analyzed by agarose gel electrophoresis to confirm the RNA polynucleotide is the proper size and that no degradation of the RNA has occurred. The RNA polynucleotide product may also be sequenced by running a reverse-transcription-PCR to generate the cDNA for sequencing.

#### Example 6: PolyA Tailing Reaction

[0783] Without a poly-T in the cDNA, a poly-A tailing reaction must be performed before cleaning the final product. This is done by mixing capped IVT RNA (100 .mu.l); RNase Inhibitor (20 U); 10.times. Tailing Buffer (0.5 M Tris-HCl (pH 8.0), 2.5 M NaCl, 100 mM MgCl.sub.2) (12.0 .mu.l); 20 mM ATP (6.0 .mu.l); Poly-A Polymerase (20 U); dH.sub.2O up to 123.5 al and incubation at 37.degree. C. for 30 min. If the poly-A tail is already in the transcript, then the tailing reaction may be skipped and proceed directly to cleanup with Ambion's

MEGACLEAR.TM. kit (Austin, Tex.) (up to 500 .mu.g). Poly-A Polymerase may be a recombinant enzyme expressed in yeast.

[0784] It should be understood that the processivity or integrity of the polyA tailing reaction may not always result in an exact size polyA tail. Hence, polyA tails of approximately between 40-200 nucleotides, e.g., about 40, 50, 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 150-165, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164 or 165 are within the scope of the present disclosure.

#### Example 76: Natural 5' Caps and 5' Cap Analogues

[0785] 5'-capping of polynucleotides may be completed concomitantly during the in vitro-transcription reaction using the following chemical RNA cap analogs to generate the 5'-guanosine cap structure according to manufacturer protocols: 3'-O-Me-m7G(5')ppp(5') G [the ARCA cap]; G(5')ppp(5')A; G(5')ppp(5')G; m7G(5')ppp(5')A; m7G(5')ppp(5')G (New England BioLabs, Ipswich, Mass.). 5'-capping of modified RNA may be completed post-transcriptionally using a Vaccinia Virus Capping Enzyme to generate the "Cap 0" structure: m7G(5')ppp(5')G (New England BioLabs, Ipswich, Mass.). Cap 1 structure may be generated using both Vaccinia Virus Capping Enzyme and a 2'-O methyl-transferase to generate: m7G(5')ppp(5')G-2'-O-methyl. Cap 2 structure may be generated from the Cap 1 structure followed by the 2'-O-methylation of the 5'-antepenultimate nucleotide using a 2'-O methyl-transferase. Cap 3 structure may be generated from the Cap 2 structure followed by the 2'-O-methylation of the 5'-preantepenultimate nucleotide using a 2'-O methyl-transferase. Enzymes are preferably derived from a recombinant source.

[0786] When transfected into mammalian cells, the modified mRNAs have a stability of between 12-18 hours or more than 18 hours, e.g., 24, 36, 48, 60, 72 or greater than 72 hours.

#### Example 86: Capping Assays

##### Protein Expression Assay

[0787] Polynucleotides (e.g., mRNA) encoding a polypeptide, containing any of the caps taught herein, can be transfected into cells at equal concentrations. The amount of protein secreted into the culture medium can be assayed by ELISA at 6, 12, 24 and/or 36 hours post-transfection. Synthetic polynucleotides that secrete higher levels of protein into the medium correspond to a synthetic polynucleotide with a higher translationally-competent cap structure.

##### Purity Analysis Synthesis

[0788] RNA (e.g., mRNA) polynucleotides encoding a polypeptide, containing any of the caps taught herein can be compared for purity using denaturing Agarose-Urea gel electrophoresis or HPLC analysis. RNA polynucleotides with a single, consolidated band by electrophoresis correspond to the higher purity product compared to polynucleotides with multiple bands or streaking bands. Chemically modified RNA polynucleotides with a single HPLC peak also correspond to a higher purity product. The capping reaction with a higher efficiency provides a more pure polynucleotide population.

##### Cytokine Analysis

[0789] RNA (e.g., mRNA) polynucleotides encoding a polypeptide, containing any of the caps taught herein can be transfected into cells at multiple concentrations. The amount of pro-inflammatory cytokines, such as TNF-alpha and IFN-beta, secreted into the culture medium can be assayed by ELISA at 6, 12, 24 and/or 36 hours post-transfection. RNA polynucleotides resulting in the secretion of higher levels of pro-inflammatory cytokines into the medium correspond to a polynucleotides containing an immune-activating cap structure.

##### Capping Reaction Efficiency



[0790] RNA (e.g., mRNA) polynucleotides encoding a polypeptide, containing any of the caps taught herein can be analyzed for capping reaction efficiency by LC-MS after nuclease treatment. Nuclease treatment of capped polynucleotides yield a mixture of free nucleotides and the capped 5'-5'-triphosphate cap structure detectable by LC-MS. The amount of capped product on the LC-MS spectra can be expressed as a percent of total polynucleotide from the reaction and correspond to capping reaction efficiency. The cap structure with a higher capping reaction efficiency has a higher amount of capped product by LC-MS.

#### Example 96: Agarose Gel Electrophoresis of Modified RNA or RT PCR Products

[0791] Individual RNA polynucleotides (200-400 ng in a 20  $\mu$ l volume) or reverse transcribed PCR products (200-400 ng) may be loaded into a well on a non-denaturing 1.2% Agarose E-Gel (Invitrogen, Carlsbad, Calif.) and run for 12-15 minutes, according to the manufacturer protocol.

#### Example 106: Nanodrop Modified RNA Quantification and UV Spectral Data

[0792] Chemically modified RNA polynucleotides in TE buffer (1  $\mu$ l) are used for Nanodrop UV absorbance readings to quantitate the yield of each polynucleotide from an chemical synthesis or in vitro transcription reaction.

#### Example 116: Formulation of Modified mRNA Using Lipidoids

[0793] RNA (e.g., mRNA) polynucleotides may be formulated for in vitro experiments by mixing the polynucleotides with the lipidoid at a set ratio prior to addition to cells. In vivo formulation may require the addition of extra ingredients to facilitate circulation throughout the body. To test the ability of these lipidoids to form particles suitable for in vivo work, a standard formulation process used for siRNA-lipidoid formulations may be used as a starting point. After formation of the particle, polynucleotide is added and allowed to integrate with the complex. The encapsulation efficiency is determined using a standard dye exclusion assays.

#### Example 126: Immunogenicity Study

[0794] The instant study is designed to test the immunogenicity in mice of candidate hMPV vaccines comprising a mRNA polynucleotide encoding Fusion (F) glycoprotein, major surface glycoprotein G, or a combination thereof, obtained from hMPV.

[0795] Mice are immunized intravenously (IV), intramuscularly (IM), or intradermally (ID) with candidate vaccines. Candidate vaccines are chemically modified or unmodified. A total of four immunizations are given at 3-week intervals (i.e., at weeks 0, 3, 6, and 9), and sera are collected after each immunization until weeks 33-51. Serum antibody titers against Fusion (F) glycoprotein or major surface glycoprotein (G) protein are determined by ELISA. Sera collected from each mouse during weeks 10-16 are pooled, and total IgG purified. Purified antibodies are used for immunoelectron microscopy, antibody-affinity testing, and in vitro protection assays.

#### Example 13: hMPV Rodent Challenge

[0796] The instant study is designed to test the efficacy in cotton rats of candidate hMPV vaccines against a lethal challenge using an hMPV vaccine comprising mRNA encoding Fusion (F) glycoprotein, major surface glycoprotein G, or a combination of both antigens obtained from hMPV. Cotton rats are challenged with a lethal dose of the hMPV.

[0797] Animals are immunized intravenously (IV), intramuscularly (IM), or intradermally (ID) at week 0 and week 3 with candidate hMPV vaccines with and without adjuvant. Candidate vaccines are chemically modified or unmodified. The animals are then challenged with a lethal dose of hMPV on week 7 via IV, IM or ID. Endpoint is day 13 post infection, death or euthanasia. Animals displaying severe illness as determined by >30% weight loss, extreme lethargy or paralysis are euthanized. Body temperature and weight are assessed and recorded daily.

[0798] In experiments where a lipid nanoparticle (LNP) formulation is used, the formulation may include a cationic lipid, non-cationic lipid, PEG lipid and structural lipid in the ratios 50:10:1.5:38.5. The cationic lipid is DLin-KC2-DMA (50 mol %) or DLin-MC3-DMA (50 mol %), the non-cationic lipid is DSPC (10 mol %), the PEG lipid is PEG-DOMG (1.5 mol %) and the structural lipid is cholesterol (38.5 mol %), for example.

#### Example 146: Immunogenicity of hMPV mRNA Vaccine in BALB/c Mice

[0799] The instant study was designed to test the immunogenicity in BALB/c mice of hMPV vaccines comprising an mRNA polynucleotide encoding the hMPV Fusion (F) glycoprotein. The mRNA polynucleotide encodes the full-length fusion protein and comprises the wild-type nucleotide sequence obtained from the hMPV A2a strain. Mice were divided into 3 groups (n=8 for each group) and immunized intramuscularly (IM) with PBS, a 10 .mu.g dose of mRNA vaccines encoding hMPV fusion protein, or a 2 .mu.g dose of mRNA vaccines encoding hMPV fusion protein. A total of two immunizations were given at 3-week intervals (i.e., at weeks 0, and 3 weeks), and sera were collected after each immunization according to the schedule described in Table 1. Serum antibody titers against hMPV fusion glycoprotein were determined by ELISA and antibodies were detected in the sera collected on day 14 onward. Both vaccine doses tested induced comparable levels of immune response in mice (FIGS. 2A-2C).

[0800] Additionally, mice sera were used for IgG isotyping (FIGS. 3A-3C). Both hMPV fusion protein-specific IgG1 and IgG2a were detected in mice sera. hMPV fusion protein mRNA vaccine also induced Th1 and Th2 cytokine responses, with a Th1 bias.

[0801] Sera from mice immunized with either 10 .mu.g or 2 .mu.g doses of the hMPV fusion protein mRNA vaccine contain neutralizing antibodies. The ability of these antibodies to neutralize hMPV B2 strain was also tested. The antibody-containing sera successfully neutralized the hMPV B2 virus (FIG. 4).

#### Example 156: T-cell Stimulation

[0802] The instant study was designed to test T-cell stimulation in the splenocytes of mice immunized with mRNA vaccines encoding hMPV fusion protein, as described herein. Immunization of BALB/c mice was performed as described in Example 14. The splenocytes for each group were pooled and split into two parts. One part of splenocytes from each group of mice was stimulated with hMPV-free media, Concanavalin A or a hMPV fusion protein peptide pool comprising 15-mers (15 amino acids long); while the other part of splenocytes from each group of mice was stimulated with hMPV-free media, Concanavalin A or inactivated hMPV virus. Secreted mouse cytokines were measured using the Meso Scale Discovery (MSD) assay.

[0803] Cytokines specific to Th1 or Th2 responses were measured. For Th1 response, IFN-.gamma., IL2 and IL12 were detected from splenocytes stimulated with the hMPV fusion protein peptide pool at a level comparable to that of Concanavalin A (FIGS. 5A-5C). For a Th2 response, the hMPV fusion protein peptide pool induced the secretion of detectable IL10, TNF-.alpha., IL4 and IL6, but not IL5, while Concanavalin A stimulated the secretion of all the above-mentioned Th2 cytokines (FIGS. 6A-6E) at a much higher level.

[0804] In contrast, inactivated hMPV virus only induced the secretion of IL2 in the Th1 response comparable to that of Concanavalin A (FIGS. 7A-7C). For the Th2 response, the inactivated hMPV virus induced the secretion of detectable IL10, TNF-.alpha., IL4 and IL6, but not IL5, while Concanavalin A stimulated the secretion of all the above-mentioned Th2 cytokines (FIGS. 8A-8E) at a much higher level.

#### Example 16: hMPV Rodent Challenge in Cotton Rats Immunized with mRNA Vaccine Encoding hMPV Fusion Protein

[0805] The instant study was designed to test the efficacy in cotton rats of hMPV vaccines against a lethal challenge. mRNA vaccines encoding hMPV fusion protein were used. The mRNA polynucleotide encodes a full-length fusion protein and comprises the wild-type nucleotide sequence obtained from the hMPV A2a strain.

[0806] Cotton rats were immunized intramuscularly (IM) at week 0 and week 3 with the mRNA vaccines encoding hMPV fusion protein with either 2 .mu.g or 10 .mu.g doses for each immunization. The animals were then challenged with a lethal dose of hMPV in week 7 post initial immunization via IV, IM or ID. The endpoint was day 13 post infection, death or euthanasia. Viral titers in the noses and lungs of the cotton rats were measured. The results (FIGS. 9A and 9B) show that a 10 .mu.g dose of mRNA vaccine protected the cotton mice 100% in the lung and drastically reduced the viral titer in the nose after challenge (.about.2 log reduction). Moreover, a 2 .mu.g dose of mRNA vaccine showed a 1 log reduction in lung viral titer in the cotton mice challenged.

[0807] Further, the histopathology of the lungs of the cotton mice immunized and challenged showed no pathology associated with vaccine-enhanced disease (FIG. 10).

#### Example 176: Immunogenicity Study

[0808] The instant study is designed to test the immunogenicity in mice of candidate PIV3 vaccines comprising a mRNA polynucleotide encoding hemagglutinin-neuraminidase or fusion protein (F or F0) obtained from PIV3.

[0809] Mice are immunized intravenously (IV), intramuscularly (IM), or intradermally (ID) with candidate vaccines. Candidate vaccines are chemically modified or unmodified. A total of four immunizations are given at 3-week intervals (i.e., at weeks 0, 3, 6, and 9), and sera are collected after each immunization until weeks 33-51. Serum antibody titers against hemagglutinin-neuraminidase or fusion protein (F or F0) are determined by ELISA. Sera collected from each mouse during weeks 10-16 are, optionally, pooled, and total IgGs are purified. Purified antibodies are used for immunoelectron microscopy, antibody-affinity testing, and in vitro protection assays.

#### Example 186: PIV3 Rodent Challenge

[0810] The instant study is designed to test the efficacy in cotton rats of candidate PIV3 vaccines against a lethal challenge using a PIV3 vaccine comprising mRNA encoding hemagglutinin-neuraminidase or fusion protein (F or F0) obtained from PIV3. Cotton rats are challenged with a lethal dose of the PIV3.

[0811] Animals are immunized intravenously (IV), intramuscularly (IM), or intradermally (ID) at week 0 and week 3 with candidate PIV3 vaccines with and without adjuvant. Candidate vaccines are chemically modified or unmodified. The animals are then challenged with a lethal dose of PIV3 on week 7 via IV, IM or ID. Endpoint is day 13 post infection, death or euthanasia. Animals displaying severe illness as determined by >30% weight loss, extreme lethargy or paralysis are euthanized. Body temperature and weight are assessed and recorded daily.

[0812] In experiments where a lipid nanoparticle (LNP) formulation is used, the formulation may include a cationic lipid, non-cationic lipid, PEG lipid and structural lipid in the ratios 50:10:1.5:38.5. The cationic lipid is DLin-KC2-DMA (50 mol %) or DLin-MC3-DMA (50 mol %), the non-cationic lipid is DSPC (10 mol %), the PEG lipid is PEG-DOMG (1.5 mol %) and the structural lipid is cholesterol (38.5 mol %), for example.

#### Example 19: hMPV/PIV Cotton Rat Challenge

[0813] The instant study was designed to test the efficacy in cotton rats of candidate hMPV mRNA vaccines, PIV3 mRNA vaccines, or hMPV/PIV combination mRNA vaccines against a lethal challenge using PIV3 strain or hMPV/A2 strain. The study design is shown in Table 9.

[0814] Cotton rats of 10-12 weeks old were divided into 12 groups (n=5), and each group was vaccinated with mRNA vaccines indicated in Table 9. The PIV3 vaccine comprises mRNA encoding hemagglutinin-neuraminidase or fusion protein (F or F0) obtained from PIV3. The hMPV mRNA vaccine encodes the full-length hMPV fusion protein. The hMPV/PIV combination mRNA vaccine is a mixture of the PIV3 vaccine and hMPV vaccine at a 1:1 ratio.

[0815] Cotton rats were immunized intramuscularly (IM) at week 0 and week 3 with candidate vaccines with the doses indicated in Table 9. Cotton rats immunized with hMPV mRNA vaccines or hMPV/PIV combination mRNA vaccines were challenged with a lethal dose of hMPV/A2 strain on week 7 via IM. Cotton rats immunized with PIV mRNA vaccines or hMPV/PIV combination mRNA vaccines were challenged with a lethal dose of PIV3 strain on week 7 via IM.

[0816] The endpoint was day 13 post infection, death or euthanasia. Animals displaying severe illness as determined by >30% weight loss, extreme lethargy or paralysis were euthanized. Body temperature and weight were assessed and recorded daily.

[0817] Lung and nose hMPV/A2 (FIG. 12) or PIV3 (FIG. 13) viral titers were assessed. Lung histopathology of the immunized and challenged cotton rat immunized and challenged were assessed to determine pathology associated with vaccine enhance disease. Neutralization antibody titers in the serum of immunized cotton rats on day 0 and 42 post immunization were assessed (FIG. 11).

[0818] hMPV/A2 (FIG. 14) or PIV3 (FIG. 15) neutralizing antibody titers in the serum samples of the immunized cotton rat 42 days post immunization were measured. All mRNA vaccines tested induced strong neutralizing antibodies cotton rats. Lung histopathology of the immunized cotton rats were also evaluated (FIG. 16). Low occurrence of alevolitis and interstitial pneumonia was observed, indicating no antibody-dependent enhancement (ADE) of hMPV or PIV associated diseases.

#### Example 206: Betacoronavirus Immunogenicity Study

[0819] The instant study is designed to test the immunogenicity in rabbits of candidate betacoronavirus (e.g., MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH or HCoV-HKU1 or a combination thereof) vaccines comprising a mRNA polynucleotide encoding the spike (S) protein, the S subunit (S1) of the spike protein, or the S2 subunit (S2) of the spike protein obtained from a betacoronavirus (e.g., MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH or HCoV-HKU1).

[0820] Rabbits are vaccinated on week 0 and 3 via intravenous (IV), intramuscular (IM), or intradermal (ID) routes. One group remains unvaccinated and one is administered inactivated betacoronavirus. Serum is collected from each rabbit on weeks 1, 3 (pre-dose) and 5. Individual bleeds are tested for anti-S, anti-S1 or anti-S2 activity via a virus neutralization assay from all three time points, and pooled samples from week 5 only are tested by Western blot using inactivated betacoronavirus (e.g., inactivated MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH or HCoV-HKU1).

[0821] In experiments where a lipid nanoparticle (LNP) formulation is used, the formulation may include a cationic lipid, non-cationic lipid, PEG lipid and structural lipid in the ratios 50:10:1.5:38.5. The cationic lipid is DLin-KC2-DMA (50 mol %) or DLin-MC3-DMA (50 mol %), the non-cationic lipid is DSPC (10 mol %), the PEG lipid is PEG-DOMG (1.5 mol %) and the structural lipid is cholesterol (38.5 mol %), for example.

#### Example 21: Betacoronavirus Challenge

[0822] The instant study is designed to test the efficacy in rabbits of candidate betacoronavirus (e.g., MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-HKU1 or a combination thereof) vaccines against a lethal challenge using a betacoronavirus (e.g., MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-HKU1 or a combination thereof) vaccine comprising mRNA encoding the spike (S) protein, the S1 subunit (S1) of the spike protein, or the S2 subunit (S2) of the spike protein obtained from betacoronavirus (e.g., MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH or HCoV-HKU1). Rabbits are challenged with a lethal dose (10.times.LD<sub>90</sub>; .about.100 plaque-forming units; PFU) of betacoronavirus (e.g., MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH or HCoV-HKU1).

[0823] The animals used are 6-8 week old female rabbits in groups of 10. Rabbits are vaccinated on weeks 0 and

3 via an IM, ID or IV route of administration. Candidate vaccines are chemically modified or unmodified. Rabbit serum is tested for microneutralization (see Example 14). Rabbits are then challenged with .about.1 LD90 of betacoronavirus (e.g., MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH or HCoV-HKU1) on week 7 via an IN, IM, ID or IV route of administration. Endpoint is day 13 post infection, death or euthanasia. Animals displaying severe illness as determined by >30% weight loss, extreme lethargy or paralysis are euthanized. Body temperature and weight are assessed and recorded daily.

#### Example 226: Microneutralization Assay

[0824] Nine serial 2-fold dilutions (1:50-1:12,800) of rabbit serum are made in 50 al virus growth medium (VGM) with trypsin in 96 well microtiter plates. Fifty microliters of virus containing .about.50 pfu of betacoronavirus (e.g., MERS-CoV, **SARS**-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH or HCoV-HKU1) is added to the serum dilutions and allowed to incubate for 60 minutes at room temperature (RT). Positive control wells of virus without sera and negative control wells without virus or sera are included in triplicate on each plate. While the serum-virus mixtures incubate, a single cell suspension of Madin-Darby Canine-Kidney cells are prepared by trypsinizing (Gibco 0.5% bovine pancrease trypsin in EDTA) a confluent monolayer and suspended cells are transferred to a 50 ml centrifuge tube, topped with sterile PBS and gently mixed. The cells are then pelleted at 200 g for 5 minutes, supernatant aspirated and cells resuspended in PBS. This procedure is repeated once and the cells are resuspended at a concentration of 3.times.10.sup.5/ml in VGM with porcine trypsin. Then, 100 al of cells are added to the serum-virus mixtures and the plates incubated at 35.degree. C. in CO.sub.2 for 5 days. The plates are fixed with 80% acetone in phosphate buffered saline (PBS) for 15 minutes at RT, air dried and then blocked for 30 minutes containing PBS with 0.5% gelatin and 2% FCS. An antibody to the S proteins, S1 protein or S2 protein is diluted in PBS with 0.5% gelatin/2% FCS/0.5% Tween 20 and incubated at RT for 2 hours. Wells are washed and horseradish peroxidase-conjugated goat anti-mouse IgG added, followed by another 2 hour incubation. After washing, O-phenylenediamine dihydrochloride is added and the neutralization titer is defined as the titer of serum that reduced color development by 50% compared to the positive control wells.

#### Example 236: MERS CoV Vaccine Immunogenicity Study in Mice

[0825] The instant study was designed to test the immunogenicity in mice of candidate MERS-CoV vaccines comprising a mRNA polynucleotide encoding the full-length Spike (S) protein, or the S2 subunit (S2) of the Spike protein obtained from MERS-CoV.

[0826] Mice were vaccinated with a 10 .mu.g dose of MERS-CoV mRNA vaccine encoding either the full-length MERS-CoV Spike (S) protein, or the S2 subunit (S2) of the Spike protein on days 0 and 21. Sera were collected from each mice on days 0, 21, 42, and 56. Individual bleeds were tested for anti-S, anti-S2 activity via a virus neutralization assay from all four time points.

[0827] As shown in FIG. 17, the MERS-CoV vaccine encoding the full-length S protein induced strong immune response after the boost dose on day 21. Further, full-length S protein vaccine generated much higher neutralizing antibody titers as compared to S2 alone (FIG. 18).

#### Example 246: MERS CoV Vaccine Immunogenicity Study in New Zealand White Rabbits

[0828] The instant study was designed to test the immunogenicity of candidate MERS-CoV mRNA vaccines encoding the full-length Spike (S) protein. The New Zealand white rabbits used in this study weighed about 4-5 kg. The rabbits were divided into three groups (Group 1a, Group 1b, and Group 2, n=8). Rabbits in Group 1a were immunized intramuscularly (IM) with one 20 .mu.g dose of the MERS-CoV mRNA vaccine encoding the full-length Spike protein on day 0. Rabbits in Group 1b were immunized intramuscularly (IM) with one 20 .mu.g dose of the MERS-CoV mRNA vaccine encoding the full-length Spike protein on day 0, and again on day 21 (booster dose). Group 2 received placebo (PBS). The immunized rabbits were then challenged and samples were collected 4 days after challenge. The viral loads in the lungs, bronchoalveolar lavage (Bal), nose, and throat of the rabbits were determined, e.g., via quantitative PCR. Replicating virus in the lung tissues of the rabbits

were also detected. Lung histopathology were evaluated and the neutralizing antibody titers in serum samples of the rabbits were determined.

[0829] Two 20 .mu.g doses of MERS-CoV mRNA vaccine resulted in a 3 log reduction of viral load in the nose and led to complete protection in the throat of the New Zealand white rabbits (FIG. 19A). Two 20 .mu.g doses of MERS-CoV mRNA vaccine also resulted in a 4 log reduction of viral load in the BAL of the New Zealand white rabbits (FIG. 19B). One 20 .mu.g dose of MERS-CoV mRNA vaccine resulted in a 2 log reduction of viral load, while two 20 .mu.g doses of MERS-CoV mRNA vaccine resulted in an over 4 log reduction of viral load in the lungs of the New Zealand white rabbits (FIG. 19C).

[0830] Quantitative PCR results show that two 20 .mu.g doses of MERS-CoV mRNA vaccine reduced over 99% (2 log) of viruses in the lungs of New Zealand white rabbits (FIG. 20A). No replicating virus were detected in the lungs (FIG. 20B).

[0831] Further, as shown in FIG. 21, two 20 .mu.g doses of MERS-CoV mRNA vaccine induced significant amount of neutralizing antibodies against MERS-CoV (EC.sub.50 between 500-1000). The MERS-CoV mRNA vaccine induced antibody titer is 3-5 fold better than any other vaccines tested in the same model.

#### Example 256: Immunogenicity Study

[0832] The instant study is designed to test the immunogenicity in mice of candidate MeV vaccines comprising a mRNA polynucleotide encoding MeV hemagglutinin (HA) protein, MeV Fusion (F) protein or a combination of both.

[0833] Mice are immunized intravenously (IV), intramuscularly (IM), or intradermally (ID) with candidate vaccines. Up to three immunizations are given at 3-week intervals (i.e., at weeks 0, 3, 6, and 9), and sera are collected after each immunization until weeks 33-51. Serum antibody titers against MeV HA protein or MeV F protein are determined by ELISA.

#### Example 266: MeV Rodent Challenge

[0834] The instant study is designed to test the efficacy in transgenic mice of candidate MeV vaccines against a lethal challenge using a MeV vaccine comprising mRNA encoding MeV HA protein or MeV F protein. The transgenic mice express human receptor CD46 or signaling lymphocyte activation molecule (SLAM) (also referred to as CD150). Humans are the only natural host for MeV infection, thus transgenic lines are required for this study. CD46 is a complement regulatory protein that protects host tissue from complement deposition by binding to complement components C3b and C4b. Its expression on murine fibroblast and lymphoid cell lines renders these otherwise refractory cells permissive for MeV infection, and the expression of CD46 on primate cells parallels the clinical tropism of MeV infection in humans and nonhuman primates (Rall G F et al. PNAS USA 1997; 94(9):4659-63). SLAM is a type 1 membrane glycoprotein belonging to the immunoglobulin superfamily. It is expressed on the surface of activated lymphocytes, macrophages, and dendritic cells and is thought to play an important role in lymphocyte signaling. SLAM is a receptor for both wild-type and vaccine MeV strains (Sellin C I et al. J Virol. 2006; 80(13):6420-29).

[0835] CD46 or SLAM/CD150 transgenic mice are challenged with a lethal dose of the MeV. Animals are immunized intravenously (IV), intramuscularly (IM), or intradermally (ID) at week 0 and week 3 with candidate MeV vaccines with and without adjuvant. The animals are then challenged with a lethal dose of MeV on week 7 via IV, IM or ID. Endpoint is day 13 post infection, death or euthanasia. Animals displaying severe illness as determined by >30% weight loss, extreme lethargy or paralysis are euthanized. Body temperature and weight are assessed and recorded daily.

[0836] In experiments where a lipid nanoparticle (LNP) formulation is used, the formulation may include a cationic lipid, non-cationic lipid, PEG lipid and structural lipid in the ratios 50:10:1.5:38.5. The cationic lipid is DLin-KC2-DMA (50 mol %), the non-cationic lipid is DSPC (10 mol %), the PEG lipid is PEG-DOMG (1.5

mol %) and the structural lipid is cholesterol (38.5 mol %), for example.

TABLE-US-00002 TABLE 1 hMPV Immunogenicity studies bleeding schedule Animal groups Day (n = 8)  
vaccine -2 0 7 14 21 28 35 56 Placebo Group PBS Pre-Bleed Prime Bleeds Bleeds Bleeds/ Bleeds Bleeds  
Harvest 1 (n = 8) (IM) Boost Splens/ 10 .mu.g Group 10 .mu.g Terminal Dose 2 (n = 8) (IM) Bleeds 2 .mu.g  
Group 2 .mu.g Dose 3 (n = 8) (IM) Total n = 24

[0837] Each of the sequences described herein encompasses a chemically modified sequence or an unmodified sequence which includes no nucleotide modifications.

TABLE-US-00003 TABLE 2 SEQ ID Description Sequence NO: hMPV Nucleic Acid Sequences

gi|22891979|gb| ATGAGCTGGAAGGTGGTATTATCTTCAGCCTGCTGATTA 1 EF051124.1|Human  
CACCTCAACACGGCCTGAAGGAGAGCTACCTGGAAGAGA metapneumovirus  
GCTGCTCCACCATCACCGAGGGCTACCTGAGCGTGCTGC isolate TN/92-4  
GGACCGGCTGGTACACCAACGTGTTACCCTGGAGGTGG fusion protein gene,  
GCGACGTGGAGAACCTGACCTGCAGCGACGGCCCTAGCC complete genome  
TGATCAAGACCGAGCTGGACCTGACCAAGAGCGCTCTGA  
GAGAGCTGAAGACCGTGTCCGCCGACCAGCTGGCCAGAG  
AGGAACAGATCGAGAACCCTCGGCAGAGCAGATTTCGTGC  
TGGGCGCCATCGCTCTGGGAGTCGCCGCTGCCGCTGCAG  
TGACAGCTGGAGTGGCCATTGCTAAGACCATCAGACTGG  
AAAGCGAGGTGACAGCCATCAACAATGCCCTGAAGAAG  
ACCAACGAGGCCGTGAGCACCCCTGGGCAATGGAGTGAGA  
GTGCTGGCCACAGCCGTGCGGGAGCTGAAGGACTTCGTG  
AGCAAGAACCTGACCAGAGCCATCAACAAGAACAAGTG  
CGACATCGATGACCTGAAGATGGCCGTGAGCTTCTCCA  
GTTCAACAGACGGTTCCTGAACGTGGTGAGACAGTTCTC  
CGACAACGCTGGAATCACACCTGCCATTAGCCTGGACCT  
GATGACCGACGCCGAGCTGGCTAGAGCCGTGCCCAACAT  
GCCACCAGCGCTGGCCAGATCAAGCTGATGCTGGAGAA  
CAGAGCCATGGTGC GGAGAAAGGGCTTCGGCATCCTGAT  
TGGGGTGTATGGAAGCTCCGTGATCTACATGGTGCAGCT  
GCCCATCTTCGGCGTGATCGACACACCCTGCTGGATCGTG  
AAGGCCGCTCCTAGCTGCTCCGAGAAGAAAGGAAACTAT  
GCCTGTCTGCTGAGAGAGGACCAGGGCTGGTACTGCCAG  
AACGCCGAAGCACAGTGTACTATCCCAACGAGAAGGAC  
TGCGAGACCAGAGGCGACCACGTGTTCTGCGACACCGCT  
GCCGGAATCAACGTGGCCGAGCAGAGCAAGGAGTGCAA  
CATCAACATCAGCACAACCAACTACCCCTGCAAGGTGAG  
CACCGGACGGCACCCCATCAGCATGGTGGCTCTGAGCCC  
TCTGGGCGCTCTGGTGGCCTGCTATAAGGGCGTGTCTGT  
AGCATCGGCAGCAATCGGGTGGGCATCATCAAGCAGCTG  
ACAAGGGATGCTCCTACATACCAACCAGGACGCCGAC  
ACCGTGACCATCGACAACACCGTGTACCAGCTGAGCAAG  
GTGGAGGGCGAGCAGCACGTGATCAAGGGCAGACCCGT  
GAGCTCCAGCTTCGACCCCATCAAGTTCCCTGAGGACCA  
GTTCAACGTGGCCCTGGACCAGGTGTTTGAGAACATCGA  
GAACAGCCAGGCCCTGGTGGACCAGAGCAACAGAATCCT  
GTCCAGCGCTGAGAAGGGCAACACCGGCTTCATCATTGT  
GATCATTCTGATCGCCGTGCTGGGCAGCTCCATGATCCTG  
GTGAGCATCTTCATCATTATCAAGAAGACCAAGAAACCC  
ACCGGAGCCCCTCCTGAGCTGAGCGCGTGACCAACAAT GGCTTCATTCCCCACA ACTGA  
gb|AY525843.1|: ATGTCTTGGAAGTGATGATCATCATTTTCGTTACTCATAA 2 3065-4684 Human  
CACCCCAGCACGGGCTAAAGGAGAGTTATTTGGAAGAAT metapneumovirus

CATGTAGTACTATAACTGAGGGATACCTCAGTGTTTTAAG isolate NL/1/99,  
AACAGGCTGGTACACTAATGTCTTCACATTAGAAGTTGGT complete genome  
GATGTTGAAAATCTTACATGTAAGTGGACCTAGCTTAA  
TCAAAACAGAACTTGATCTAACAAAAAGTGCTTTAAGGG  
AACTCAAAACAGTCTCTGCTGATCAGTTGGCGAGAGAGG  
AGCAAATTGAAAATCCCAGACAATCAAGATTTGTCTTAG  
GTGCGATAGCTCTCGGAGTTGCTACAGCAGCAGCAGTCA  
CAGCAGGCATTGCAATAGCCAAAACCATAAGGCTTGAGA  
GTGAGGTGAATGCAATTAAGGTGCTCTCAAACAACTA  
ATGAAGCAGTATCCACATTAGGGAATGGTGTGCGGGTCC  
TAGCCACTGCAGTGAGAGAGCTAAAAGAATTTGTGAGCA  
AAAACCTGACTAGTGCAATCAACAGGAACAAATGTGACA  
TTGCTGATCTGAAGATGGCTGTCAGCTTCAGTCAATTCAA  
CAGAAGATTTCTAAATGTTGTGCGGCAGTTTTTCAGACAAT  
GCAGGGATAACACCAGCAATATCATTGGACCTGATGACT  
GATGCTGAGTTGGCCAGAGCTGTATCATAATGCCAACA  
TCTGCAGGGCAGATAAACTGATGTTGGAGAACCGCGCA  
ATGGTAAGGAGAAAAGGATTTGGAATCCTGATAGGGGTC  
TACGGAAGCTCTGTGATTTACATGGTTCAATTGCCGATCT  
TTGGTGTATAGATACACCTTGTGGATCATCAAGGCAGC  
TCCCTCTTGCTCAGAAAAAACGGGAATTATGCTTGCCTC  
CTAAGAGAGGATCAAGGGTGGTATTGTAAAAATGCAGGA  
TCTACTGTTTACTACCCAAATGAAAAAGACTGCGAAACA  
AGAGGTGATCATGTTTTTTGTGACACAGCAGCAGGGATC  
AATGTTGCTGAGCAATCAAGAGAATGCAACATCAACATA  
TCTACTACCAACTACCCATGCAAAGTCAGCACAGGAAGA  
CACCTATAAGCATGGTTGCACTATCACCTCTCGGTGCTT  
TGGTGGCTTGCTATAAAGGGGTAAGCTGCTCGATTGGCA GCAATTGGGT  
TGGAATCATCAAACAATTACCCAAAGGCTGCTCATAAT  
AACCAACCAGGATGCAGACACTGTAACAATTGACAATAC  
CGTGTATCAACTAAGCAAAGTTGAAGGTGAACAGCATGT  
AATAAAAGGGAGACCAGTTTCAAGCAGTTTTTGATCCAAT  
CAAGTTTCCTGAGGATCAGTTCAATGTTGCGCTTGATCAA  
GTCTTCGAAAGCATTGAGAACAGTCAGGCACTAGTGGAC  
CAGTCAAACAAAATTCTAAACAGTGCAGAAAAAGGAAA  
CACTGGTTTCATTATCGTAGTAATTTTGGTTGCTGTTCTTG  
GTCTAACCATGATTTCAAGTGCATCATCATAATCAA  
GAAAACAAGGAAGCCCACAGGAGCACCTCCAGAGCTGA  
ATGGTGTACCAACGGCGGTTTCATACCACATAGTTA gb|KJ627414.1|:  
ATGTCTTGGAAGTGATGATTATCATTTCGTTACTCATAA 3 3015-4634 Human  
CACCTCAGCATGGACTAAAAGAAAGTTATTTAGAAGAAT metapneumovirus  
CATGTAGTACTATAACTGAAGGATATCTCAGTGTTTTAAG strain hMPV/Homo  
AACAGGTTGGTACACCAATGTCTTTACATTAGAAGTTGGT sapiens/PER/CFI04  
GATGTTGAAAATCTTACATGTAAGTGGACCTAGCTTAA 97/2010/B,  
TCAAAACAGAACTTGACCTAACCAAAAAGTGCTTTAAGAG complete genome  
AACTCAAAACAGTTTCTGCTGATCAGTTAGCGAGAGAAG  
AACAAATTGAAAATCCCAGACAATCAAGGTTTGTCTAG  
GTGCAATAGCTCTTGGAGTTGCCACAGCAGCAGCAGTCA  
CAGCAGGCATTGCAATAGCCAAAACCTATAAGGCTTGAGA  
GTGAAGTGAATGCAATCAAAGGTGCTCTCAAACAACCA  
ATGAGGCAGTATCAACACTAGGAAATGGAGTGCAGGGTCC  
TAGCCACTGCAGTAAGAGAGCTGAAAGAATTTGTGAGCA  
AAAACCTGACTAGTGCGATCAACAAGAACAAGTGTGACA  
TTGCTGATTTGAAGATGGCTGTCAGCTTCAGTCAAGTTCAA



CAGAAGATTCCTAAATGTTGTGCGGCAGTTTTTCAGACAAT  
GCAGGGATAACACCAGCAATATCATTGGACCTGATGAAT  
GATGCTGAGCTGGCCAGAGCTGTATCATACATGCCAACA  
TCTGCAGGACAGATAAAACTAATGTTAGAGAACCGTGCA  
ATGGTGAGGAGAAAAGGATTTGGAATCTTGATAGGGGTC  
TACGGAAGCTCTGTGATTTACATGGTCCAGCTGCCGATCT  
TTGGTGTCTATAAATACACCTTGTGGATAATCAAGGCAGC  
TCCCTCTTGTTCAGAAAAAGATGGAAATTATGCTTGCCTC  
CTAAGAGAGGATCAAGGGTGGTATTGTAAAAATGCAGGA  
TCCACTGTTTACTACCCAAATGAAAAAGACTGCGAAACA  
AGAGGTGATCATGTTTTTTGTGACACAGCAGCAGGGATC  
AATGTTGCTGAGCAATCAAGAGAATGCAACATCAACATA  
TCTACCACCAACTACCCATGCAAAGTCAGCACAGGAAGA  
CACCTATCAGCATGGTTGCACTATCACCTCTCGGTGCTT  
TGGTAGCTTGCTACAAAGGGGTTAGCTGCTCGACTGGCA  
GTAATCAGGTTGGAATAATCAAACAACCTAAAGGCT  
GCTCATACTAACTAACCAGGACGCAGACACTGTAACAA  
TTGACAACACTGTGTATCAACTAAGCAAAGTTGAGGGTG  
AACAGCATGTAATAAAAGGGAGACCAGTTTCAAGCAGTT  
TTGATCCAATCAGGTTTCCTGAGGATCAGTTCAATGTTGC  
GCTTGATCAAGTCTTTGAAAGCATTGAAAACAGTCAAGC  
ACTAGTGGACCAGTCAAACAAAATTCTGAACAGTGCAGA AAAAGGAAACACTGGT  
TTCATTATTGTAATAATTTTGATTGCTGTTCTTGGGTTAAC  
CATGATTCAGTGAGCATCATCATCATAATCAAAAAAAC  
AAGGAAGCCCACAGGGGCACCTCCGGAGCTGAATGGTGT  
TACCAACGGCGGTTTCATACCGCATAGTTAG gb|KJ723483.1|:  
ATGGAGTTGCCAATCCTCAAACAAATGCAATTACCACA 4 5586-7310 Human  
ATCCTTGCTGCAGTCACACTCTGTTTCGCTTCCAGTCAA respiratory  
ACATCACTGAAGAATTTTATCAATCAACATGCAGTGCAG syncytial virus  
TTAGCAAAGGCTATCTTAGTGCTCTAAGAACTGGTTGGTA strain RSV A/Homo  
TACTAGTGTATAACTATAGAATTAAGTAATATCAAGGA sapiens/USA/84I-  
AAATAAGTGTAATGGAACAGATGCTAAGGTAAAATTGAT 215A-01/1984,  
AAAACAAGAATTAGATAAATATAAAAATGCTGTAACAGA complete genome  
ATTGCAGTTGCTCATGCAAAGCACACCAGCAGCCAACAA  
TCGAGCCAGAAGAGAACTACCAAGGTTTATGAATTATAC  
ACTCAATAATACCAAAAATACCAATGTAACATTAAGCAA  
GAAAAGGAAAAGAAGATTTCTTGGCTTTTTGTTAGGTGTT  
GGATCTGCAATCGCCAGTGGCATTGCTGTATCTAAGGTCC  
TGCACCTAGAAGGGGAAGTGAACAAAATCAAAGTGCTC  
TACTATCCACAAACAAGGCTGTAGTCAGCTTATCAAATG  
GAGTTAGTGTCTTAACCAGCAAAGTGTTAGACCTCAAAA  
ACTATATAGATAAACAGTTGTTACCTATTGTGAACAAGC  
AAAGCTGCAGCATATCAAACATTGAAACTGTGATAGAGT  
TCCAACAAAAGAACAACAGACTACTAGAGATTACCAGGG  
AATTTAGTGTTAATGCAGGTGTAACCTACACCTGTAAGCAC  
TTATATGTTAACTAATAGTGAATTATTATCATTAATCAAT  
GATATGCCTATAACAAATGATCAGAAAAAGTTAATGTCC  
AACAAATGTTCAAATAGTTAGACAGCAAAGTTACTCTATC  
ATGTCCATAATAAAGGAGGAAGTCTTAGCATATGTAGTA  
CAATTACCACTATATGGTGTAAATAGATACACCCTGTTGGA  
AACTGCACACATCCCCTCTATGTACAACCAACACAAAGG  
AAGGGTCCAACATCTGCTTAACAAGAACCGACAGAGGAT  
GGTATTGTGACAATGCAGGATCAGTATCTTTCTTCCCACA  
AGCTGAAACATGTAAAGTTCAATCGAATCGGGTATTTTGT

GACACAATGAACAGTTTAAACATTACCAAGTGAAGTAAAT  
CTCTGCAACATTGACATATTC AACCCCAAATATGATTGCA  
AAATTATGACTTCAAAAACAGATGTAAGCAGCTCCGTTA  
TCACATCTCTAGGAGCCATTGTGTCATGCTATGGCAAAC  
TAAATGTACAGCATCCAATAAAAATCGTGGGATCATAAA  
GACATTTTCTAACGGGTGTGATTATGTATCAAATAAGGG  
GGTGGATACTGTGTCTGTAGGTAATACATTATATTATGTA  
ATAAGCAAGAAGGCCAAAAGTCTCTATGTAAAAGGTGAA  
CCAATAATAAATTTCTATGACCCATTAGTGTTCCCCTCTG  
ATGAATTTGATGCATCAATATCTCAAGTCAATGAGAAGA  
TTAACCAGAGCCTAGCATTATTCGTAAATCCGATGAATT  
ATTACATAATGTAAATGCTGGTAAATCCACCACAAATAT  
CATGATAACTACTATAATTATAGTGATTATAGTAATATTG  
TTATCATTAATTGCAGTTGGACTGCTCCTATACTGCAAGG  
CCAGAAGCACACCAGTCACACTAAGTAAGGATCAACTGA  
GTGGTATAAATAATATTGCATTTAGTAACTGA hMPV mRNA Sequences gi|122891979|gb|  
AUGAGCUGGAAGGUGGUGAUUAUCUUCAGCCUGCUGAU 57 EF051124.1|Human  
UACACCUCAACACGGCCUGAAGGAGAGCUACCUGGAAG metapneumovirus  
AGAGCUGCUCCACCAUCACCGAGGGCUACCUGAGCGUG isolate TN/92-4  
CUGCGGACCGGCUGGUACACCAACGUGUUCACCCUGGA fusion protein gene,  
GGUGGGCGACGUGGAGAACCUGACCUGCAGCGACGGCC complete genome  
CUAGCCUGAUCAAGACCGAGCUGGACCUGACCAAGAGC  
GCUCUGAGAGAGCUGAAGACCGUGUCCGCCGACCAGCU  
GGCCAGAGAGGAACAGAUCGAGAACCCUCGGCAGAGCA  
GAUUCGUGCUGGGCGCCAUCGCUCUGGGAGUCGCCGCU  
GCCGCUGCAGUGACAGCUGGAGUGGCCAUUGC UAAGAC  
CAUCAGACUGGAAAGCGAGGUGACAGCCAUCAACAAUG  
CCUGAAGAAGACCAACGAGGCCGUGAGCACCCUGGGC  
AAUGGAGUGAGAGUGCUGGCCACAGCCGUGCGGGAGCU  
GAAGGACUUCGUGAGCAAGAACCUGACCAGAGCCAUCA  
ACAAGAACAAGUGCGACAUCGAUGACCUGAAGAUGGCC  
GUGAGCUUCUCCAGUUCAACAGACGGUUCUGAACGU  
GGUGAGACAGUUCUCCGACAACGCUGGAAUCACACCUG  
CCAUUAGCCUGGACCUGAUGACCGACGCCGAGCUGGCU  
AGAGCCGUGCCCAACAUGCCCACCAGCGCUGGCCAGAU  
CAAGCUGAUGCUGGAGAACAGAGCCAUGGUGCGGAGAA  
AGGGCUUCGGCAUCCUGAUUGGGGUGUAUGGAAGCUCC  
GUGAUCUACAUGGUGCAGCUGCCCAUCUUCGGCGUGAU  
CGACACACCCUGCUGGAUCGUGAAGGCCGCUCCUAGCU  
GCUCCGAGAAGAAAGGAAACUAUGCCUGUCUGCUGAGA  
GAGGACCAGGGCUGGUACUGCCAGAACGCCGGAAGCAC  
AGUGUACUAUCCCAACGAGAAGGACUGCGAGACCAGAG  
GCGACCACGUGUUCUGCGACACCGCUGCCGGAUCAAAC  
GUGGCCGAGCAGAGCAAGGAGUGCAACAUCAACAUCAG  
CACAACCAACUACCCUGCAAGGUGAGCACCGGACGGC  
ACCCCAUCAGCAUGGUGGCUCUGAGCCCUCUGGGCGCU  
CUGGUGGCCUGCUAUAAGGGCGUGUCCUGUAGCAUCGG  
CAGCAAUCGGGUGGGCAUCAUCAAGCAGCUGAACAAGG  
GAUGCUCUACAUCACCAACCAGGACGCCGACACCGUG  
ACCAUCGACAACACCGUGUACCAGCUGAGCAAGGUGGA  
GGGCGAGCAGCACGUGAUAAGGGCAGACCCGUGAGCU  
CCAGCUUCGACCCCAUCAAGUUCUCCUGAGGACCAGUUC  
AACGUGGCCUUGGACCAGGUGUUUGAGAACAUCGAGAA  
CAGCCAGGCCUUGGUGGACCAGAGCAACAGAAUCCUGU

CCAGCGCUGAGAAGGGCAACACCGGCUUCAUCAUUGUG  
AUCAUUCUGAUCGCCGUGCUGGGCAGCUCCAUGAUCCU  
GGUGAGCAUCUUCAUCAUUUAUCAAGAAGACCAAGAAAC  
CCACCGGAGCCCCUCCUGAGCUGAGCGGCGUGACCAAC AAUGGCUUCAUUCCCCACAACUGA  
gb|AY525843.1|: AUGUCUUGGAAAGUGAUGAUCAUCAUUUCGUUACUCAU 58 3065-4684 Human  
AACACCCCAGCACGGGCUAAAGGAGAGUUUUUGGAAG metapneumovirus  
AAUCAUGUAGUACUAUAACUGAGGGAUACCUCAGUGUU isolate NL/1/99,  
UUAAGAACAGGCUGGUACACUAAUGUCUUCACAUUAGA complete genome  
AGUUGGUGAUGUUUGAAAUCUUAUGUACUGAUGGA  
CCUAGCUUAAUCAAAAACAGAACUUGAUCUAAACAAAAG  
UGCUIUAAGGGAACUAAAACAGUCUCUGCUGAUCAGU  
UGGCGAGAGAGGAGCAAUUGAAAUCCCAGACAAUCA  
AGAUUUGUCUUAGGUGCGAUAGCUCUCGGAGUUGCUCAC  
AGCAGCAGCAGUCACAGCAGGCAUUGCAAUAGCCAAA  
CCAUAAGGCUUGAGAGUGAGGUGAAUGCAAUUAAGG  
UGCUCUCAAAACAAACUAAUGAAGCAGUAUCCACAUUAG  
GGAAUGGUGUGCGGGUCCUAGCCACUGCAGUGAGAGAG  
CUAAAAGAAUUUGUGAGCAAAAACCUAGUCUAGUGCAAU  
CAACAGGAACAAUUGUGACAUUGCUGAUCUGAAGAUGG  
CUGUCAGCUUCAGUCAAUUCAACAGAAGAUUUCUAAA  
GUUGUGCGGCAGUUUUCAGACAAUGCAGGGUAACACC  
AGCAAUAUCAUUGGACCUGAUGACUGAUGCUGAGUUGG  
CCAGAGCUGUAUCAUACAUGCCAACAUCUGCAGGGCAG  
AUAAAACUGAUGUUGGAGAACCGCGCAAUGGUAAGGAG  
AAAAGGAUUUGGAAUCCUGAUAGGGGUCUACGGAAGCU  
CUGUGAUUUACAUGGUUCAAUUGCCGAUCUUUGGUGUC  
AUAGAUACACCUUGUUGGAUCAUCAAGGCAGCUCCCUC  
UUGCUCAGAAAAAACGGGAAUUAUGCUUGCCUCCUAA  
GAGAGGAUCAAGGGUGGUAUUGUAAAAAUGCAGGAUC

UACUGUUUACUACCCAAAUGAAAAAGACUGCGAAACAA  
GAGGUGAUCAUGUUUUUGUGACACAGCAGCAGGGAU  
AAUGUUGCUGAGCAAUCAAGAGAAUGCAACAUCAACAU  
AUCUACUACCAACUACCCAUGCAAAGUCAGCACAGGAA  
GACACCCUAUAAGCAUGGUUGCACUAUCACCUCUCGGU  
GCUUUGGUGGCUUGCUAUAAAGGGGUAAGCUGCUCGAU UGGCAGCAAUUGGGU  
UGGAAUCAUCAAAACAAUACCCAAAGGCUGCUCUAACA  
UAACCAACCAGGAUGCAGACACUGUAACAAUUGACAAU  
ACCGUGUAUCAACUAAGCAAAGUUGAAGGUGAACAGCA  
UGUAAUAAAAGGGAGACCAGUUUCAAGCAGUUUUGAUC  
CAAUCAAGUUUCCUGAGGAUCAGUUCAAUGUUGCGCUU  
GAUCAAGUCUUCGAAAGCAUUGAGAACAGUCAGGCACU  
AGUGGACCAGUCAAAACAAAUUCUAAAACAGUGCAGAAA  
AAGGAAACACUGGUUUCAUUAUCGUAGUAAUUUUGGU  
UGCUGUUCUUGGUCUAAACCAUGAUUUCAGUGAGCAUCA  
UCAUCAUAAUCAAGAAAACAAGGAAGCCCACAGGAGCA  
CCUCCAGAGCUGAAUGGUGUCACCAACGGCGGUUCAU ACCACAUAGUUAG gb|KJ627414.1|:  
AUGUCUUGGAAAGUGAUGAUUAUCAUUUCGUUACUCAU 59 3015-4634 Human  
AACACCUCAGCAUGGACUAAAAGAAAGUUAUUUAGAAG metapneumovirus  
AAUCAUGUAGUACUAUAACUGAAGGAUAUCUCAGUGUU strain hMPV/Homo  
UUAAGAACAGGUUGGUACACCAAUGUCUUUACAUUAGA sapiens/PER/CFI04  
AGUUGGUGAUGUUUGAAAUCUUAUGUACUGAUGGA 97/2010/B,  
CCUAGCUUAAUCAAAAACAGAACUUGACCUAACCAAAAAG complete genome  
UGCUIUAAGAGAACUAAAACAGUUUCUGCUGAUCAGU

UAGCGAGAGAAGAACA AAUUGAAAAUCCCAGACAAUCA  
AGGUUUGUCCUAGGUGCAAUAGCUCUUGGAGUUGCCAC  
AGCAGCAGCAGUCACAGCAGGCAUUGCAAUAGCCAAA  
CUAUAAGGCUUGAGAGUGAAGUGAAUGCAAUCAAGG  
UGCUCUCAAAACAACCAAUGAGGCAGUAUCAACACUAG  
GAAUUGGAGUGCGGGUCCUAGCCACUGCAGUAAGAGAG  
CUGAAAGAAUUUGUGAGCAAAAACCUAGACUAGUGCGAU  
CAACAAGAACAAGUGUGACA UUGCUGAUUUGAAGAUGG  
CUGUCAGCUUCAGUCAGUUCAACAGAAGAUUCCUAAA  
GUUGUGCGGCAGUUUCAGACAAUGCAGGGAUAAACACC  
AGCAAUAUCAUUGGACCUGAUGAAUGAUGCUGAGCUGG  
CCAGAGCUGUAUCAUCAUGCCAACAUCUGCAGGACAG  
AUAAAACUAAUGUUAGAGAACCGUGCAAUGGUGAGGA  
GAAAAGGAUUUGGAAUCUUGAUAGGGGUCUACGGAAG  
CUCUGUGAUUUACAUGGUCCAGCUGCCGAUCUUUGGUG  
UCAUAAAUACACCUUGUUGGAUAAUCAAGGCAGCUC  
UCUUGUUCAGAAAAAGAUGGAAAUUUGCUUGCCUCCU  
AAGAGAGGAUCAAGGGUGGUUUGUAAAAAUGCAGGA  
UCCACUGUUUACUACCCAAAUGAAAAAGACUGCGAAAC  
AAGAGGUGAUCAUGUUUUUUGUGACACAGCAGCAGGGA  
UCAAUGUUGCUGAGCAAUCAAGAGAAUGCAACAUCAAC  
AUAUUCUACCACCAACUACCCAUGCAAAGUCAGCACAGG  
AAGACACCCUAUCAGCAUGGUUGCACUAUCACCUCUCG  
GUGCUUUGGUAGCUUGCUACAAAGGGGUUAGCUGCUCG  
ACUGGCAGUAAUCAGGUUGGAAUAAUCAAAACUACC  
UAAAGGCUGCUCAUACAUAACUAAACCAGGACGCAGACA  
CUGUAACAAUUGACAACACUGUGUAUCAACUAAAGCAA  
GUUGAGGGUGAACAGCAUGUAAUAAAAGGGAGACCAG  
UUUCAAGCAGUUUUGAUCCAUCAGGUUCCUGAGGAU  
CAGUUCAAUGUUGCGCUUGAUCAAGUCUUUGAAAGCAU  
UGAAAACAGUCAAGCACUAGUGGACCAGUCAAAACAAA  
UUCUGAACAGUGCAGAAAAAGGAAACACUGGU  
UUCAUUAUUGUAAUAAUUUUGAUUGCUGUUCUUGGGU  
UAACCAUGAUUUCAGUGAGCAUCAUCAUAAUCAA  
AAAACAAGGAAGCCCACAGGGGCACCUCCGGAGCUGAA  
UGGUGUUACCAACGGCGGUUUCAUACCGCAUAGUUAG gb|KJ723483.1|:  
AUGGAGUUGCCAAUCCUCAAAACAAAUGCAAUACCAC 60 5586-7310 Human  
AAUCCUUGCUGCAGUCACACUCUGUUUCGCUUCCAGUC respiratory  
AAAACAUCACUGAAGAAUUUUAUCAAUCAACAUGCAGU syncytial virus  
GCAGUUAGCAAAGGCUAUCUUAGUGCUCUAAGAACUGG strain RSV A/Homo  
UUGGUUAUCUAGUGUUUAACUAUAGAAUUAAGUAAU sapiens/USA/84I-  
AUCAAGGAAAAUAGUGUAAUGGAACAGAUGCUAAGG 215A-01/1984,  
UAAAAUUGAUAAAACAAGAAUUGAUAAAUAUAAAA complete genome  
UGCUGUAACAGAAUUGCAGUUGCUCUAGCAAAGCACAC  
CAGCAGCCAACAUCGAGCCAGAAGAGAACUACCAAGG  
UUUAUGAAUUAUACACUCAUAAUACCAAAAAUACCAA  
UGUAACAUAUAGCAAGAAAAGGAAAAGAAGAUUUCU  
GGCUUUUUGUAGGUGUUGGAUCUGCAAUCGCCAGUGG  
CAUUGCUGUAUCUAAAGGUCCUGCACCUAGAAGGGGAAG  
UGAACAAAAUCAAAAGUGCUCUACUACCACAAACAAG  
GCUGUAGUCAGCUUAUCAAAUGGAGUUAGUGUCUUAAC  
CAGCAAAGUGUUAGACCUCAAAACUAUAUAGAUAAAC  
AGUUGUUAACCUAUUGUGAACAAGCAAAGCUGCAGCAUA  
UCAAACAUUGAAACUGUGAUAGAGUCCAACAAAAGAA

CAACAGACUACUAGAGAUUACCAGGGAAUUUAGUGUUA  
AUGCAGGUGUAACUACACCUGUAAGCACUUAUAUGUUA  
ACUAAUAGUGAAUUAUUAUCAUUAUCAAUGUAUGCC  
UAUAACAAAUGAUCAGAAAAAGUUAUUGUCCAACAAUG  
UUCAAAUAGUUAGACAGCAAAGUUACUCUAUCAUGUCC  
AUAUAAAAGGAGGAAGUCUUAGCAUAUGUAGUACAAU  
UACCACUUAUUGGUGUAAUAGAUACACCCUGUUGGAAA  
CUGCACACAUCCCCUCUAUGUACAACCAACACAAAGGA  
AGGGUCCAACAUCUGCUUAACAAGAACCGACAGAGGAU  
GGUAUUGUGACAAUGCAGGAUCAGUAUCUUUCUCCCA  
CAAGCUGAAACAUGUAAAGUUCAAUCGAAUCGGGUAAU  
UUGUGACACAAUGAACAGUUUAACAUAUACCAAGUGAAG  
UAAAUCUCUGCAACAUUGACAUAUUAACCCCAAUAU  
GAUUGCAAAAUAUGACUUCAAAAACAGAUGUAAGCAG  
CUCCGUUAUCACAUCUCUAGGAGCCAUUGUGUCAUGCU  
AUGGCAAAACUAAAUGUACAGCAUCCAUAUAAAAUCGU  
GGGAUCAUAAAGACAUUUUCUAACGGGUGUGAUUAUG  
UAUCAAAUAAGGGGGUGGAUACUGUGUCUGUAGGUAA  
UACAUUAUUAUUGUAAAUAAGCAAGAAGGCAAAGU  
CUCUAUGUAAAAGGUGAACCAUAUAAUAAUUCUAUGA  
CCAUAUAGUGUCCCCUCUGAUGAAUUUGAUGCAUCAA  
UAUCUCAAGUCAUUGAGAAGAUUAACCAGAGCCUAGCA  
UUUAUUCGUAUAAUCCGAUGAAUUAUUAUUAUGUAA  
AUGCUGGUAUAAUCCACCACAAUAUCAUGAUAAUCUACU  
AUAAUUAUAGUGAUUAUAGUAAUUAUUGUUAUCAUUA  
UUGCAGUUGGACUGCUCCUAUACUGCAAGGCCAGAAGC  
ACACCAGUCACACUAAGUAAGGAUCAACUGAGUGGUAAU AAAUAAUUAUUGCAUUUAGUAAACUGA

TABLE-US-00004 TABLE 3 hMPV Amino Acid Sequences SEQ ID Description Sequence NO:  
gi|122891979|gb|MSWKVVIIFSLITPQHGLKESYLEESCSTITEGYLSVLRTGW 5 EF051124.1|Human  
YTNVFTLEVGDVENLTCSDBGPSLIKTELDLTKSALRELKTVS metapneumovirus  
ADQLAREEQIENPRQSRFVLGAIALGVAAAAVAVTAGVAIAK isolate TN/92-4  
TIRLESEVTAINNALKKTNEAVSTLGNVVRVLATAVRELKD fusion protein gene,  
FVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFS complete cds  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLNRA  
MVRKGFILIGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPS  
CSEKKGNYACLLREDQGWYCNAGSTVYYPNEKDCETR  
DHVFCDTAAGINVAEQSKECNINISTTNYPCVKVSTGRHPISM  
VALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQD  
ADTVTIDNTVYQLSKVEGEQHVIVKGRPVSSSFDPIKFPEDQF  
NVALDQVFENIENSQALVDQSNRILSSAEKGNTGFIIIVILIAV  
LGSSMILVSIFIIKKTKKPTGAPPELSGVTNNGFIPHN gb|AY525843.1|:  
MSWKVMIIISLLITPQHGLKESYLEESCSTITEGYLSVLRTGW 6 3065-4684 Human  
YTNVFTLEVGDVENLTCTDGPSTLIKTELDLTKSALRELKTVS metapneumovirus  
ADQLAREEQIENPRQSRFVLGAIALGVATAAAVAVTAGIAIAKT isolate NL/1/99,  
IRLESEVNAIKGALKQTNEAVSTLGNVVRVLATAVRELKEF complete cds  
VSKNLTSAINRNKCDIADLKMAVSFSQFNRRFLNVVRQFSD  
NAGITPAISLDLMTDAELARAVSYMPTSAGQIKLMLNRAM  
VRRKGFILIGVYGSSVIYMVQLPIFGVIDTPCWIKAAPSCS  
EKNGNYACLLREDQGWYCKNAGSTVYYPNEKDCETR  
VFCDTAAGINVAEQSRECNINISTTNYPCVKVSTGRHPISMVA  
LSPLGALVACYKGVSCSIGSNWVGIIKQLPKGCSYITNQDAD  
TVTIDNTVYQLSKVEGEQHVIVKGRPVSSSFDPIKFPEDQFNV  
ALDQVFESIENSQALVDQSNKILNSAEKGNTGFIIIVILVAVL

GLTMISVSIIIIKKTRKPTGAPPELNGVTNGGFIPHS gb|KJ627414.1|:  
MSWKVMIISLLITPQHGLKESYLEESCSTITEGYLSVLRTGW 7 3015-4634 Human  
YTNVFTLEVGDVENLTCTDGPSTLIKTELDLTKSALRELKTVS metapneumovirus  
ADQLAREEQIENPRQSRFVLGAIALGVATAAAVTAGIAIAKT strain hMPV/Homo  
IRLESEVNAIKGALKTTNEAVSTLGNVVRVLATAVRELKEF sapiens/PER/CFI04  
VSKNLTSAINKNKCDIADLKMVFSFSQFNRRFLNVVRQFSD 97/2010/B,  
NAGITPAISLDMNDAELARAVSYMPTSAGQIKLMLENRAM complete cds  
VRRKGFILIGVYGSSVIYMVQLPIFGVINTPCWIKAAPSCS  
EKDGNACLLREDQGWYCKNAGSTVYYPNEKDCETRGDH  
VFCDTAAGINVAEQSRECNINISTTNYPCVKVSTGRHPISMVA  
LSPLGALVACYKGVSCSTGSNQGVIKQLPKGCSYITNQDAD  
TVTIDNTVYQLSKVEGEQHVIVKGRPVSSSFDPIRFPEDQFNV  
ALDQVFESIENSQALVDQSNKILNSAEKGNTGFIIIVIIIAVLG  
LTMISVSIIIIKKTRKPTGAPPELNGVTNGGFIPHS gb|KJ723483.1|:  
MELPILKTNAITTLAAVTLCFASSQNITEEFYQSTCSAVSKG 8 5586-7310 Human  
YLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDK respiratory  
YKNAVTELQLLMQSTPAANNRARELPRFMNYTLNNTKNT syncytial virus  
NVTLSKRRRFLGFLGVSIAIASGIAVSKVLHLEGEVNI strain RSA/Homo  
KSALLSTNKAVVSLNGVSVLTSKVLDLKNIYDKQLLPIVN sapiens/USA/84I-  
KQSCSISNIETVIEFQQKNRLLLEITREFSVNAGVTTPVSTYM 215A-01/1984,  
LTNSELLSLINDMPITNDQKKLMSNNVQIVRQSYSIMSIIKE complete cds  
EVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTR  
TDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTL  
SEVNLNIDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGK  
TKCTASNKNRGIKTFSNGCDYVSNKGVDTVSVGNTLYYVN  
KQEGKSLYVKGEPIINFYDPLVFPDEFDASISQVNEKINQSL  
AFIRKSDELLHNVNAGKSTTNIMITTIIIVIIIVILLSLIAVGLLL YCKARSTPVTLSKDQLSGINNIAFSN

TABLE-US-00005 TABLE 4 hMPV NCBI Accession Numbers (Amino Acid Sequences) Virus GenBank  
Accession F [Human metapneumovirus] [Human AEK26895.1 metapneumovirus] fusion glycoprotein [Human  
metapneumovirus] ACJ53565.1 fusion glycoprotein [Human metapneumovirus] ACJ53566.1 fusion  
glycoprotein [Human metapneumovirus] ACJ53569.1 fusion protein [Human metapneumovirus] AEZ52347.1  
fusion glycoprotein [Human metapneumovirus] ACJ53574.1 fusion glycoprotein [Human metapneumovirus]  
AHV79473.1 fusion glycoprotein [Human metapneumovirus] ACJ53570.1 fusion glycoprotein [Human  
metapneumovirus] ACJ53567.1 fusion protein [Human metapneumovirus] AAS22125.1 fusion glycoprotein  
[Human metapneumovirus] AHV79795.1 fusion glycoprotein [Human metapneumovirus] AHV79455.1 fusion  
glycoprotein [Human metapneumovirus] ACJ53568.1 fusion protein [Human metapneumovirus] AAS22109.1  
fusion glycoprotein [Human metapneumovirus] AGU68417.1 fusion glycoprotein [Human metapneumovirus]  
AGJ74228.1 fusion glycoprotein [Human metapneumovirus] ACJ53575.1 fusion protein [Human  
metapneumovirus] AAU25820.1 fusion glycoprotein [Human metapneumovirus] AGU68377.1 fusion  
glycoprotein [Human metapneumovirus] AGU68371.1 fusion glycoprotein [Human metapneumovirus]  
AGJ74087.1 fusion glycoprotein [Human metapneumovirus] ACJ53560.1 fusion glycoprotein [Human  
metapneumovirus] AHV79858.1 fusion glycoprotein [Human metapneumovirus] ACJ53577.1 fusion protein  
[Human metapneumovirus] AAS22085.1 fusion protein [Human metapneumovirus] AEZ52348.1 fusion  
glycoprotein [Human metapneumovirus] AGJ74044.1 fusion glycoprotein [Human metapneumovirus]  
ACJ53563.1 fusion glycoprotein precursor [Human YP\_012608.1 metapneumovirus] fusion glycoprotein  
[Human metapneumovirus] AGJ74053.1 fusion protein [Human metapneumovirus] BAM37562.1 fusion  
glycoprotein [Human metapneumovirus] ACJ53561.1 fusion glycoprotein [Human metapneumovirus]  
AGU68387.1 fusion [Human metapneumovirus] AGL74060.1 fusion glycoprotein precursor [Human  
AAV88364.1 metapneumovirus] fusion protein [Human metapneumovirus] AAN52910.1 fusion protein [Human  
metapneumovirus] AAN52915.1 fusion protein [Human metapneumovirus] BAM37564.1 fusion glycoprotein  
precursor [Human BAH59618.1 metapneumovirus] fusion protein [Human metapneumovirus] AAQ90144.1  
fusion glycoprotein [Human metapneumovirus] AHV79446.1 fusion protein [Human metapneumovirus]  
AEL87260.1 fusion glycoprotein [Human metapneumovirus] AHV79867.1 fusion protein [Human

metapneumovirus] ABQ66027.2 fusion glycoprotein [Human metapneumovirus] ACJ53621.1 fusion protein [Human metapneumovirus] AAN52911.1 fusion glycoprotein [Human metapneumovirus] AHV79536.1 fusion glycoprotein [Human metapneumovirus] AGU68411.1 fusion protein [Human metapneumovirus] AEZ52346.1 fusion protein [Human metapneumovirus] AAN52913.1 fusion protein [Human metapneumovirus] AAN52908.1 fusion glycoprotein [Human metapneumovirus] ACJ53553.1 fusion glycoprotein [Human metapneumovirus] AIY25727.1 fusion protein [Human metapneumovirus] ABM67072.1 fusion protein [Human metapneumovirus] AEZ52361.1 fusion protein [Human metapneumovirus] AAS22093.1 fusion glycoprotein [Human metapneumovirus] AGH27049.1 fusion protein [Human metapneumovirus] AAK62968.2 fusion glycoprotein [Human metapneumovirus] ACJ53556.1 fusion glycoprotein [Human metapneumovirus] ACJ53620.1 fusion protein [Human metapneumovirus] ABQ58820.1 F [Human metapneumovirus] [Human AEK26886.1 metapneumovirus] fusion glycoprotein [Human metapneumovirus] ACJ53619.1 fusion glycoprotein [Human metapneumovirus] ACJ53555.1 fusion [Human metapneumovirus] AGL74057.1 fusion protein [Human metapneumovirus] ABD27850.1 fusion protein [Human metapneumovirus] AEZ52349.1 fusion protein [Human metapneumovirus] ABD27848.1 fusion protein [Human metapneumovirus] ABD27846.1 fusion protein [Human metapneumovirus] ABQ66021.1 fusion protein [Human metapneumovirus] AFM57710.1 fusion protein [Human metapneumovirus] AFM57709.1 fusion protein [Human metapneumovirus] ABH05968.1 fusion protein [Human metapneumovirus] AEZ52350.1 fusion protein [Human metapneumovirus] AFM57712.1 fusion protein [Human metapneumovirus] AEZ52364.1 fusion protein [Human metapneumovirus] AAN52912.1 fusion protein [Human metapneumovirus] AEZ52363.1 fusion [Human metapneumovirus] AGL74059.1 fusion glycoprotein [Human metapneumovirus] ACJ53583.1 fusion protein [Human metapneumovirus] AEZ52356.1 fusion protein [Human metapneumovirus] AEZ52353.1 fusion glycoprotein [Human metapneumovirus] ACJ53581.1 fusion glycoprotein [Human metapneumovirus] ACJ53578.1 fusion protein [Human metapneumovirus] AAS22117.1 fusion protein [Human metapneumovirus] BAN75965.1 fusion protein [Human metapneumovirus] AGF92105.1 fusion protein [Human metapneumovirus] AAS22077.1 fusion protein [Human metapneumovirus] AAN52909.1 fusion glycoprotein [Human metapneumovirus] ACJ53586.1 fusion protein [Human metapneumovirus] AAQ90145.1 fusion glycoprotein [Human metapneumovirus] AGT75042.1 fusion [Human metapneumovirus] AGL74058.1 fusion protein [Human metapneumovirus] AEL87263.1 fusion glycoprotein [Human metapneumovirus] AGH27057.1 fusion glycoprotein [Human metapneumovirus] AHV79491.1 F [Human metapneumovirus] [Human AEK26906.1 metapneumovirus] fusion glycoprotein [Human metapneumovirus] ACJ53580.1 fusion protein [Human metapneumovirus] AEZ52354.1 fusion protein [Human metapneumovirus] AAN52914.1 G [Human metapneumovirus] [Human AEK26901.1 metapneumovirus] glycoprotein [Human metapneumovirus] AFI56738.1 glycoprotein [Human metapneumovirus] AFI56739.1 glycoprotein [Human metapneumovirus] AFI56745.1 G protein [Human metapneumovirus] AAQ62718.1 G protein [Human metapneumovirus] AAQ62719.1 attachment glycoprotein G [Human AGH27104.1 metapneumovirus] G protein [Human metapneumovirus] AAQ62729.1 G protein [Human metapneumovirus] AAQ62728.1 glycoprotein [Human metapneumovirus] AFI56753.1 glycoprotein [Human metapneumovirus] AFI56746.1 glycoprotein [Human metapneumovirus] AFI56750.1 glycoprotein [Human metapneumovirus] AFI56747.1 G protein [Human metapneumovirus] AAQ62721.1 glycoprotein [Human metapneumovirus] AAT46573.1 glycoprotein [Human metapneumovirus] AFI56748.1 glycoprotein [Human metapneumovirus] AFI56736.1 glycoprotein [Human metapneumovirus] AFI56749.1 attachment glycoprotein G [Human AGH27131.1 metapneumovirus] attachment glycoprotein G [Human AHV79558.1 metapneumovirus] glycoprotein [Human metapneumovirus] AFI56740.1 glycoprotein [Human metapneumovirus] AFI56741.1 glycoprotein [Human metapneumovirus] AFI56744.1 attachment glycoprotein G [Human AHV79790.1 metapneumovirus] attachment glycoprotein G [Human AGH27122.1 metapneumovirus] attachment glycoprotein G [Human AHV79763.1 metapneumovirus] attachment glycoprotein G [Human AGZ48849.1 metapneumovirus] glycoprotein [Human metapneumovirus] AFI56743.1 attachment glycoprotein G [Human AHV79450.1 metapneumovirus] glycoprotein [Human metapneumovirus] AFI56751.1 attachment glycoprotein [Human metapneumovirus] AAS48482.1 attachment glycoprotein G [Human AHV79889.1 metapneumovirus] attachment surface glycoprotein [Human AGW43050.1 metapneumovirus] glycoprotein [Human metapneumovirus] AFI56754.1 attachment glycoprotein G [Human AHV79601.1 metapneumovirus] glycoprotein [Human metapneumovirus] AFI56752.1 attachment glycoprotein G [Human AHV79871.1 metapneumovirus] G protein [Human metapneumovirus] AEZ68099.1 attachment glycoprotein G [Human AHV79817.1 metapneumovirus] attachment glycoprotein G [Human AHV79943.1 metapneumovirus] attachment glycoprotein G [Human BAN75968.1 metapneumovirus] attachment surface glycoprotein [Human

AGW43045.1 metapneumovirus] attachment glycoprotein G [Human AHV79628.1 metapneumovirus] attachment glycoprotein [Human metapneumovirus] AFK49783.1 G protein [Human metapneumovirus] AAQ62723.1 attachment glycoprotein [Human metapneumovirus] ABD27839.1 attachment surface glycoprotein [Human AGW43046.1 metapneumovirus] G protein [Human metapneumovirus] AAQ62717.1 glycoprotein [Human metapneumovirus] AFI56742.1 attachment protein [Human metapneumovirus] ABQ44522.1 glycoprotein [Human metapneumovirus] AFI56735.1 attachment surface glycoprotein [Human AGW43065.1 metapneumovirus] G protein [Human metapneumovirus] AAQ62724.1 attachment surface glycoprotein [Human AGW43075.1 metapneumovirus] attachment surface glycoprotein [Human AGW43062.1 metapneumovirus] glycoprotein [Human metapneumovirus] AAT46579.1 attachment surface glycoprotein [Human AGW43064.1 metapneumovirus] attachment surface glycoprotein [Human AGW43054.1 metapneumovirus] attachment surface glycoprotein [Human AGW43042.1 metapneumovirus] attachment surface glycoprotein [Human AGW43078.1 metapneumovirus] attachment surface glycoprotein [Human AGW43067.1 metapneumovirus] G protein [Human metapneumovirus] AAQ62722.1 attachment surface glycoprotein [Human AGW43063.1 metapneumovirus] glycoprotein [Human metapneumovirus] AAT46571.1 glycoprotein [Human metapneumovirus] AAT46578.1 attachment glycoprotein G [Human AGJ74232.1 metapneumovirus] glycoprotein [Human metapneumovirus] AAT46580.1 glycoprotein [Human metapneumovirus] AAT46574.1 attachment surface glycoprotein [Human AGW43061.1 metapneumovirus] attachment glycoprotein [Human metapneumovirus] AFK49791.1 attachment surface glycoprotein [Human AGW43047.1 metapneumovirus] glycoprotein [Human metapneumovirus] ABC26386.1 attachment glycoprotein [Human metapneumovirus] AAS48466.1 attachment surface glycoprotein [Human AGW43048.1 metapneumovirus] attachment glycoprotein G [Human AGH27140.1 metapneumovirus] attachment surface glycoprotein [Human AGW43049.1 metapneumovirus] attachment glycoprotein G [Human AGJ74082.1 metapneumovirus] attachment glycoprotein G [Human AHV79442.1 metapneumovirus] attachment glycoprotein G [Human AGJ74091.1 metapneumovirus] attachment glycoprotein G [Human AHV79477.1 metapneumovirus] attachment surface glycoprotein [Human AGW43056.1 metapneumovirus] attachment protein [Human metapneumovirus] ABQ44523.1 attachment glycoprotein G [Human BAH59622.1 metapneumovirus] attachment surface glycoprotein [Human AGW43070.1 metapneumovirus] glycoprotein [Human metapneumovirus] AAT46585.1 attachment glycoprotein G [Human AGU68409.1 metapneumovirus] attachment glycoprotein G [Human AGJ74223.1 metapneumovirus] attachment glycoprotein [Human metapneumovirus] AAS22129.1 attachment glycoprotein G [Human AGJ74048.1 metapneumovirus] G protein [Human metapneumovirus] AAQ62725.1 glycoprotein [Human metapneumovirus] ABC26384.1 attachment protein [Human metapneumovirus] ABQ44525.1 attachment glycoprotein G [Human YP\_012612.1 metapneumovirus] attachment surface glycoprotein [Human AGW43071.1

metapneumovirus] attachment glycoprotein G [Human AGJ74162.1 metapneumovirus] attachment glycoprotein G [Human AGH27095.1 metapneumovirus] attachment glycoprotein G [Human AHV79531.1 metapneumovirus] G protein [Human metapneumovirus] AAQ62726.1 attachment glycoprotein [Human metapneumovirus] AAS48465.1 attachment surface glycoprotein [Human AGW43058.1 metapneumovirus] P [Human metapneumovirus] [Human AEK26894.1 metapneumovirus] phosphoprotein [Human metapneumovirus] AHV79631.1 phosphoprotein [Human metapneumovirus] AHV79901.1 phosphoprotein [Human metapneumovirus] AHV79570.1 phosphoprotein [Human metapneumovirus] AGJ74076.1 phosphoprotein [Human metapneumovirus] AAS22123.1 phosphoprotein [Human metapneumovirus] ABB16895.1 phosphoprotein [Human metapneumovirus] AHV79579.1 phosphoprotein [Human metapneumovirus] AGJ74244.1 phosphoprotein [Human metapneumovirus] AHV79856.1 phosphoprotein [Human metapneumovirus] ACJ70113.1 phosphoprotein [Human metapneumovirus] AGZ48843.1 phosphoprotein [Human metapneumovirus] AHV79498.1 phosphoprotein [Human metapneumovirus] AHV79480.1 phosphoprotein [Human metapneumovirus] ABQ43382.1 phosphoprotein [Human metapneumovirus] AAS22107.1 phosphoprotein [Human metapneumovirus] ABB16898.1 phosphoprotein [Human metapneumovirus] AGH27134.1 phosphoprotein [Human metapneumovirus] ABB16899.1 phosphoprotein [Human metapneumovirus] AGH27098.1 phosphoprotein [Human metapneumovirus] AAN52866.1 phosphoprotein [Human metapneumovirus] AAS22083.1 phosphoprotein [Human metapneumovirus] YP\_012606.1 phosphoprotein [Human metapneumovirus] AHV79973.1 phosphoprotein [Human metapneumovirus] AHV79462.1 phosphoprotein [Human metapneumovirus] AGJ74042.1 phosphoprotein [Human metapneumovirus] AAV88362.1 P [Human metapneumovirus] [Human AIL23591.1



metapneumovirus] phosphoprotein [Human metapneumovirus] AHV79453.1 phosphoprotein [Human metapneumovirus] AGJ74261.1 phosphoprotein [Human metapneumovirus] AGH27116.1 phosphoprotein [Human metapneumovirus] ABB16444.1 phosphoprotein [Human metapneumovirus] ABB16445.1 phosphoprotein [Human metapneumovirus] AHV79507.1 phosphoprotein [Human metapneumovirus] BAH59616.1 phosphoprotein [Human metapneumovirus] ABB16443.1 phosphoprotein [Human metapneumovirus] ABQ43388.1 phosphoprotein [Human metapneumovirus] ABQ43389.1 phosphoprotein [Human metapneumovirus] ABQ43395.1 phosphoprotein [Human metapneumovirus] ABQ43385.1 phosphoprotein [Human metapneumovirus] AAP84042.1 phosphoprotein [Human metapneumovirus] AAN52868.1 phosphoprotein [Human metapneumovirus] AAP84041.1 phosphoprotein [Human metapneumovirus] AGH27080.1 phosphoprotein [Human metapneumovirus] ABQ43387.1 phosphoprotein [Human metapneumovirus] AAS22099.1 phosphoprotein [Human metapneumovirus] ABB16896.1 phosphoprotein [Human metapneumovirus] AGJ74094.1 phosphoprotein [Human metapneumovirus] AEZ68089.1 phosphoprotein [Human metapneumovirus] ABK97002.1 phosphoprotein [Human metapneumovirus] AAP13486.1 phosphoprotein [Human metapneumovirus] AHV79444.1 phosphoprotein [Human metapneumovirus] AHV79865.1 phosphoprotein [Human metapneumovirus] AGJ74226.1 phosphoprotein [Human metapneumovirus] ABQ43383.1 phosphoprotein [Human metapneumovirus] AAN52863.1 phosphoprotein [Human metapneumovirus] AHV79775.1 phosphoprotein [Human metapneumovirus] AEZ68094.1 phosphoprotein [Human metapneumovirus] AHV79883.1 phosphoprotein [Human metapneumovirus] AEZ68092.1 phosphoprotein [Human metapneumovirus] ABQ43390.1 phosphoprotein [Human metapneumovirus] ABQ43386.1 phosphoprotein [Human metapneumovirus] ABQ43391.1 phosphoprotein [Human metapneumovirus] ACS16062.1 phosphoprotein [Human metapneumovirus] AEZ68090.1 phosphoprotein [Human metapneumovirus] AAK62967.1 phosphoprotein [Human metapneumovirus] AEZ68093.1 phosphoprotein [Human metapneumovirus] AEZ68088.1 phosphoprotein [Human metapneumovirus] ABQ43392.1 phosphoprotein [Human metapneumovirus] ABQ43393.1 phosphoprotein [Human metapneumovirus] ABQ43384.1 phosphoprotein [Human metapneumovirus] ABQ43394.1 phosphoprotein [Human metapneumovirus] ABK96999.1 phosphoprotein [Human metapneumovirus] AHV79489.1 phosphoprotein [Human metapneumovirus] AGJ74235.1 phosphoprotein [Human metapneumovirus] AAS22075.1 phosphoprotein [Human metapneumovirus] AAS22115.1 phosphoprotein [Human metapneumovirus] AII17601.1 phosphoprotein [Human metapneumovirus] ABK97000.1 phosphoprotein [Human metapneumovirus] AHV79561.1 phosphoprotein [Human metapneumovirus] AGT75040.1 phosphoprotein [Human metapneumovirus] AAN52864.1 phosphoprotein [Human metapneumovirus] ABK97001.1 phosphoprotein [Human metapneumovirus] AGT74979.1 phosphoprotein [Human metapneumovirus] AHV79955.1 phosphoprotein [Human metapneumovirus] AGH27055.1 phosphoprotein [Human metapneumovirus] AAV88361.1 phosphoprotein [Human metapneumovirus] ABQ43397.1 phosphoprotein [Human metapneumovirus] AGJ74173.1 P [Human metapneumovirus] [Human AEK26904.1 metapneumovirus] phosphoprotein [Human metapneumovirus] ACJ70104.1 phosphoprotein [Human metapneumovirus] ABK97003.1 phosphoprotein [Human metapneumovirus] AGT74955.1 phosphoprotein [Human metapneumovirus] AAN52856.1 phosphoprotein [Human metapneumovirus] AAN52862.1 phosphoprotein [Human metapneumovirus] AGJ74138.1 phosphoprotein [Human metapneumovirus] AHV79613.1 phosphoprotein [Human metapneumovirus] AGJ74060.1 phosphoprotein [Human metapneumovirus] AAQ67684.1 phosphoprotein [Human metapneumovirus] AEA02278.1 N [Human metapneumovirus] [Human AEK26899.1 metapneumovirus] nucleoprotein [Human metapneumovirus] ACS16061.1 nucleoprotein [Human metapneumovirus] AAS88425.1 nucleoprotein [Human metapneumovirus] YP\_012605.1 nucleoprotein [Human metapneumovirus] AHV79882.1 nucleoprotein [Human metapneumovirus] AHV79774.1 nucleocapsid protein [Human metapneumovirus] AAN52886.1 nucleoprotein [Human metapneumovirus] AAS22082.1 nucleoprotein [Human metapneumovirus] AHV79864.1 nucleoprotein [Human metapneumovirus] AHV79828.1 nucleoprotein [Human metapneumovirus] AGJ74084.1 nucleocapsid protein [Human metapneumovirus] AAN52888.1 N [Human metapneumovirus] [Human AIL23590.1 metapneumovirus] nucleoprotein [Human metapneumovirus] AAK62966.1 nucleoprotein [Human metapneumovirus] AHV79972.1 nucleoprotein [Human metapneumovirus] AHV79470.1 nucleoprotein [Human metapneumovirus] AHV79452.1 nucleoprotein [Human metapneumovirus] AGJ74243.1 nucleoprotein [Human metapneumovirus] AHV79533.1 nucleoprotein [Human metapneumovirus] AGJ74181.1 nucleoprotein [Human metapneumovirus] AHV79497.1 nucleoprotein [Human metapneumovirus] AHV79702.1 nucleoprotein [Human metapneumovirus] AHV79648.1 nucleoprotein [Human metapneumovirus] AHV79435.1 putative

nucleoprotein [Human metapneumovirus] AGJ74260.1 nucleocapsid protein [Human metapneumovirus] AAN52887.1 nucleoprotein [Human metapneumovirus] AGU68386.1 nucleocapsid protein [Human metapneumovirus] AAN52899.1 nucleoprotein [Human metapneumovirus] AAR17673.1 nucleocapsid protein [Human metapneumovirus] AAN52898.1 nucleoprotein [Human metapneumovirus] AEA02277.1 nucleoprotein [Human metapneumovirus] AHV79612.1 nucleoprotein [Human metapneumovirus] AGU68416.1 nucleoprotein [Human metapneumovirus] AGU68408.1 nucleoprotein [Human metapneumovirus] AGU68370.1 nucleoprotein [Human metapneumovirus] AAQ67683.1 nucleoprotein [Human metapneumovirus] AGJ74137.1 nucleoprotein [Human metapneumovirus] AGU68344.1 nucleocapsid protein [Human metapneumovirus] ABK96997.1 nucleoprotein [Human metapneumovirus] AGU68413.1 nucleocapsid protein [Human metapneumovirus] AAN52891.1 nucleoprotein [Human metapneumovirus] AGU68360.1 nucleoprotein [Human metapneumovirus] AGU68353.1 nucleocapsid protein [Human metapneumovirus] ABK96996.1 nucleoprotein [Human metapneumovirus] AAR17666.1 N [Human metapneumovirus] [Human AEK26903.1 metapneumovirus] nucleoprotein [Human metapneumovirus] AGT75039.1 nucleoprotein [Human metapneumovirus] AGU68410.1 nucleoprotein [Human metapneumovirus] AAS22074.1 nucleoprotein [Human metapneumovirus] AHV79560.1 nucleoprotein [Human metapneumovirus] AGT74978.1 nucleoprotein [Human metapneumovirus] AGJ74128.1 nucleoprotein [Human metapneumovirus] AAR17663.1 nucleoprotein [Human metapneumovirus] AAR17662.1 nucleoprotein [Human metapneumovirus] AAR17664.1 nucleoprotein [Human metapneumovirus] AAR17657.1 nucleoprotein [Human metapneumovirus] AAR17659.1 nucleoprotein [Human metapneumovirus] AAR17661.1 nucleoprotein [Human metapneumovirus] AGU68352.1 nucleoprotein [Human metapneumovirus] AGU68373.1 nucleoprotein [Human metapneumovirus] AGU68376.1 nucleoprotein [Human metapneumovirus] AGU68342.1 nucleoprotein [Human metapneumovirus] AGU68365.1 nucleoprotein [Human metapneumovirus] AGU68363.1 nucleoprotein [Human metapneumovirus] AGU68398.1 nucleoprotein [Human metapneumovirus] AGU68348.1 nucleoprotein [Human metapneumovirus] AGU68354.1 nucleoprotein [Human metapneumovirus] AGU68391.1 nucleoprotein [Human metapneumovirus] AGU68389.1 nucleoprotein [Human metapneumovirus] AGU68399.1 nucleoprotein [Human metapneumovirus] AGU68337.1 nucleoprotein [Human metapneumovirus] AAR17660.1 nucleoprotein [Human metapneumovirus] AAR17667.1 nucleoprotein [Human metapneumovirus] AGU68402.1 nucleoprotein [Avian metapneumovirus type C] CDN30025.1 nucleoprotein [Avian metapneumovirus] AGZ87947.1 Nucleoprotein [Avian metapneumovirus type C] CAL25113.1 nucleocapsid protein [Avian metapneumovirus] ABO42286.1 nucleocapsid protein [Avian metapneumovirus] AAK38430.1 nucleocapsid protein [Avian metapneumovirus] AAK54155.1 nucleocapsid protein [Avian metapneumovirus] AAK38426.1 nucleocapsid protein [Avian metapneumovirus] AAK38425.1 nucleocapsid protein [Avian metapneumovirus] AAK38424.1 nucleocapsid protein [Avian metapneumovirus] AAF05909.1 nucleocapsid protein [Avian metapneumovirus] AAK38435.1 nucleocapsid protein [Avian metapneumovirus] AAK38428.1 nucleoprotein [Human metapneumovirus] AAR17669.1 nucleocapsid protein [Avian metapneumovirus] AAK38429.1 nucleocapsid protein [Avian metapneumovirus] AAK38427.1 nucleocapsid protein [Avian metapneumovirus] AAK38423.1 nucleocapsid protein [Avian metapneumovirus] AAK38434.1 nucleoprotein [Human metapneumovirus] AGU68338.1 nucleoprotein [Avian metapneumovirus] YP\_443837.1 nucleoprotein [Human metapneumovirus] AGU68384.1 nucleocapsid protein [Avian metapneumovirus] AAK38431.1 nucleoprotein [Human metapneumovirus] AGU68405.1 nucleoprotein [Human metapneumovirus] AGU68382.1 nucleoprotein [Human metapneumovirus] AGU68395.1 nucleocapsid [Human metapneumovirus] AAL35389.3 nucleoprotein [Human metapneumovirus] AEZ68064.1

TABLE-US-00006 TABLE 5 SEQ ID Description Sequence NO: PIV3 Nucleic Acid Sequences

>gb|KJ672601.1|: ATGCCAATTTCAATACTGTTAATTATTACAACCATGATC 9 4990-6609 Human  
 ATGGCATCACACTGCCAAATAGACATCACAAAACCTACA parainfluenza virus  
 GCATGTAGGTGTATTGGTCAACAGTCCCAAAGGGATGA 3 strain  
 AGATATCACAAAACCTTCGAAACAAGATATCTAATCCTGA HPIV3/Homo  
 GTCTCATACCAAAAATAGAAGATTCTAACTCTTGTGGTG sapiens/PER/FLA  
 ACCAACAGATCAAGCAATACAAGAGGTTATTGGATAGA 4815/2008[fusion  
 CTGATCATTCTTTATATGATGGACTAAGATTACAGAAG glycoprotein F0]  
 GATGTGATAGTACTAATCAAGAATCCAATGAAAACAC  
 TGATCCCAGAACAGAACGATTCTTTGGAGGGGTAATTGG  
 AACTATTGCTCTAGGAGTAGCAACCTCAGCACAAATTAC  
 AGCAGCAGTTGCTCTGGTTGAAGCCAAGCAGGCAAGAT

CAGACATTGAAAACTCAAGGAAGCAATCAGGGACACA  
AATAAAGCAGTGCAGTCAGTTCAGAGCTCTGTAGGAAA  
TTTGATAGTAGCAATTAATCAGTCCAGGATTATGTCAA  
CAAAGAAATCGTGCCATCGATTGCGAGACTAGGTTGTG  
AAGCAGCAGGACTTCAGTTAGGGATTGCATTAACACAG  
CATTACTCAGAATTAACAAATATATTTGGTGATAACATA  
GGATCGTTACAAGAAAAAGGAATAAAATTACAAGGTAT  
AGCATCATTATACCGTACAAATATCACAGAAATATTCAC  
AACATCAACAGTTGACAAATATGATATTTATGATCTATT  
ATTTACAGAATCAATAAAGGTGAGAGTTATAGATGTTGA  
TTTGAATGATTACTCAATAACCCTCCAAGTCAGACTCCC  
TTTATTGACCAGACTGCTGAACACTCAAATCTACAAAGT  
AGATTCCATATCATACAATATCCAAAATAGAGAATGGTA  
TATCCCTCTTCCCAGCCATATCATGACGAAAGGGGCATT  
TCTAGGTGGAGCAGATGTCAAAGAATGCATAGAAGCAT  
TCAGCAGTTATATATGCCCTTCTGATCCAGGATTTGACT  
AAACCATGAAATGGAGAGCTGTCTATCAGGAAACATAT  
CCCAATGTCCAAGAACCACAGTCACATCAGACATAGTTC  
CTAGGTATGCATTTGTCAATGGAGGAGTGGTTGCGAATT  
GTATAACAACACTACATGTACATGCAATGGTATCGGTAATA  
GAATCAACCAACCACCTGATCAAGGAGTCAAATTATA  
ACACATAAAGAATGTAATACAATAGGTATCAACGGAAT  
GCTATTTCAACACAACAAGAAGGAAGTCTTGCATTCTA  
CACACCAGACGACATAACATTAACAATTCTGTTGCACT  
TGATCCGATTGACATATCAATCGAGCTCAACAAGGCCAA  
ATCAGATCTTGAGGAATCAAAGAATGGATAAGAAGGT  
CAAATCAAAGCTAGATTCTATTGGAAGTTGGCATCAAT  
CTAGCACTACAATCATAGTTATTTTGATAATGATGATTA  
TATTGTTTATAATTAATAACAATAATTACAATTGCAA  
TTAAGTATTACAGAATTCAAAAGAGAAATCGAGTGGAT  
CAAATGATAAGCCGTATGTATTAACAAACAAG gi|612507167|gb|  
ATGGAATACTGGAAGCACACCAACCACGGAAAGGATGC 10 AHX22430.1|  
TGGTAATGAGCTGGAGACATCCACAGCCACTCATGGCA hemagglutinin-  
ACAAGCTACCAACAAGATAACATATATATTGTGGACG neuraminidase  
ATAACCCTGGTGTTATTATCAATAGTCTTCATCATAGTG [Human  
CTAACTAATTCCATCAAAGTGAAAAGGCCCGCGAATC parainfluenza  
ATTGCTACAAGACATAAATAATGAGTTTATGGAAGTTAC virus 3  
AGAAAAGATCCAAGTGGCATCGGATAATACTAATGATC  
TAATACAGTCAGGAGTGAATACAAGGCTTCTTACAATTC  
AGAGTCATGTCCAGAATTATATACCAATATCATTGACAC  
AACAAATATCGGATCTTAGGAAATTCATTAGTGAAATTA  
CAATTAGAAATGATAATCAAGAAGTGCCACCACAAAGA  
ATAACACATGATGTGGGTATAAAACCTTTAAATCCAGAT  
GATTTCTGGAGATGCACGTCTGGTCTTCCATCTTTGATG  
AAAACCTCCAAAATAAGATTAATGCCGGGACCAGGATT  
ATTAGCTATGCCAACGACTGTTGATGGCTGTGTCAGAAC  
CCCCTCCTTAGTGATAAATGATCTGATTTATGCTTACAC  
CTCAAATCTAATTACTCGAGGTTGCCAGGATATAGGGAA  
ATCATATCAAGTATTACAGATAGGGATAATAACTGTAAA  
CTCAGACTTGGTACCTGACTTAAATCCTAGGATCTCTCA  
TACCTTCAACATAAATGACAATAGAAAGTCATGTTCTCT  
AGCACTCCTAAATACAGATGTATATCAACTGTGTTCAAC  
CCCAAAGTTGATGAAAGATCAGATTATGCATCATCAG  
GCATAGAAGATATTGTAAGTATGATATTGTCAATTATGATG

GCTCAATCTCGACAACAAGATTTAAGAATAATAATATAA  
GTTTTGATCAACCATATGCGGCATTATACCCATCTGTTG  
GACCAGGGATATACTACAAAGGCAAAATAATATTTCTC  
GGGTATGGAGGTCTTGAACATCCAATAAATGAGAATGC  
AATCTGCAACACAACACTGGGTGTCCTGGGAAAACACAGA  
GAGACTGTAATCAAGCATCTCATAGTCCATGGTTTTTCAG  
ATAGAAGGATGGTCAACTCTATAATTGTTGTTGACAAGG  
GCTTGAACCTCAGTTCCAAAATTGAAGGTATGGACGATAT  
CTATGAGACAAAATTAAGTGGGGGTCAGAAGGAAGATTA  
CTTCTACTAGGTAACAAGATCTACATATACACAAGATCT  
ACAAGTTGGCACAGCAAGTTACAATTAGGAATAATTGA  
CATTACTGACTACAGTGATATAAGGATAAAATGGACAT  
GGCATAATGTGCTATCAAGACCAGGAAACAATGAATGT  
CCATGGGGACATTCATGTCCGGATGGATGTATAACGGG  
AGTATATACCGATGCATATCCACTCAATCCCACAGGAAG  
CATTGTATCATCTGTTCATATTGGACTCACAAAATCGAG  
AGTCAACCCAGTCATAACTTACTCAACAGCAACCGAAA  
GGGTAAACGAGCTGGCTATCCGAAACAAAACACTCTCA  
GCTGGGTACACAACAACAAGCTGCATTACACACTATAA  
CAAAGGGTATTGTTTTTCATATAGTAGAAATAAATCATAA  
AAGCTTAAACACATTTCAACCCATGTTGTTCAAACAGA GATTCCAAAAGCTGCAGT  
HPIV3\_HN\_Codon ATGGAATACTGGAAGCACACCAACCACGGCAAGGACGC 11 Optimized  
CGGCAACGAGCTGGAACCAGCACAGCCACACACGGCA  
ACAAGCTGACCAACAAGATCACCTACATCCTGTGGACC  
ATCACCCCTGGTGCTGCTGAGCATCGTGTTTCATCATCGTG  
CTGACCAATAGCATCAAGAGCGAGAAGGCCAGAGAGAG  
CCTGCTGCAGGACATCAACAACGAGTTCATGGAAGTGA  
CCGAGAAGATCCAGGTGGCCAGCGACAACACCAACGAC  
CTGATCCAGAGCGGCGTGAACACCCGGCTGCTGACCATC  
CAGAGCCACGTGCAGAACTACATCCCCATCAGCCTGACC  
CAGCAGATCAGCGACCTGCGGAAGTTCATCAGCGAGAT  
CACCATCCGGAACGACAACCAGGAAGTGCCCCCCCAGA  
GAATCACCCACGACGTGGGCATCAAGCCCCTGAACCCC  
GACGATTTCTGGCGGTGTACAAGCGGCCTGCCAGCCTG  
ATGAAGACCCCCAAGATCCGGCTGATGCCTGGCCCTGG  
ACTGCTGGCCATGCCTACCACAGTGGATGGCTGTGTGCG  
GACCCCCAGCCTCGTGATCAACGATCTGATCTACGCCTA  
CACCAGCAACCTGATCACCCGGGGCTGCCAGGATATCG  
GCAAGAGCTACCAGGTGCTGCAGATCGGCATCATCACC  
GTGAACTCCGACCTGGTGCCCGACCTGAACCCTCGGATC  
AGCCACACCTTCAACATCAACGACAACAGAAAGAGCTG  
CAGCCTGGCTCTGCTGAACACCGACGTGTACCAGCTGTG  
CAGCACCCCCAAGGTGGACGAGAGAAGCGACTACGCCA  
GCAGCGGCATCGAGGATATCGTGCTGGACATCGTGAAC  
TACGACGGCAGCATCAGCACCAACCCGGTTCAAGAACAA  
CAACATCAGCTTCGACCAGCCCTACGCCGCCCTGTACCC  
TTCTGTGGGCCCTGGCATCTACTACAAGGGCAAGATCAT  
CTTCCTGGGCTACGGCGGCCTGGAACACCCCATCAACGA  
GAACGCCATCTGCAACACCACCGGCTGCCCTGGCAAGA  
CCCAGAGAGACTGCAATCAGGCCAGCCACAGCCCCTGG  
TTCAGCGACCGCAGAATGGTCAACTCTATCATCGTGGTG  
GACAAGGGCCTGAACAGCGTGCCCAAGCTGAAAGTGTG  
GACAATCAGCATGCGCCAGAACTACTGGGGCAGCGAGG  
GCAGACTTCTGCTGCTGGGAAACAAGATCTACATCTACA

CCCGGTCCACCAGCTGGCACAGCAAACCTGCAGCTGGGA  
ATCATCGACATCACCGACTACAGCGACATCCGGATCAA  
GTGGACCTGGCACAACGTGCTGAGCAGACCCGGCAACA  
ATGAGTGCCCTTGGGGCCACAGCTGCCCCGATGGATGTA  
TCACCGGCGTGTACACCGACGCCTACCCCCTGAATCCTA  
CCGGCTCCATCGTGTCCAGCGTGATCCTGGACAGCCAGA  
AAAGCAGAGTGAACCCCGTGATCACATACAGCACCGCC  
ACCGAGAGAGTGAACGAACTGGCCATCAGAAACAAGAC  
CCTGAGCGCCGGCTACACCACCACAAGCTGCATCACAC  
ACTACAACAAGGGTACTGCTTCCACATCGTGGAATCA  
ACCACAAGTCCCTGAACACCTTCCAGCCCATGCTGTTCA AGACCGAGATCCCCAAGAGCTGCTCC  
HPIV3\_F\_Codon ATGCCCATCAGCATCCTGCTGATCATCACCAATGATC 12 Optimized  
ATGGCCAGCCACTGCCAGATCGACATACCAAGCTGCA  
GCACGTGGGCGTGCTCGTGAACAGCCCCAAGGGCATGA  
AGATCAGCCAGAACTTCGAGACACGCTACCTGATCCTGA  
GCCTGATCCCCAAGATCGAGGACAGCAACAGCTGCGGC  
GACCAGCAGATCAAGCAGTACAAGCGGCTGCTGGACAG  
ACTGATCATCCCCCTGTACGACGGCCTGCGGCTGCAGAA  
AGACGTGATCGTGACCAACCAGGAAAGCAACGAGAACA  
CCGACCCCCGGACCGAGAGATTCTTCGGCGGCGTGATCG  
GCACAATCGCCCTGGGAGTGGCCACAAGCGCCCAGATT  
ACAGCCGCTGTGGCCCTGGTGGAAAGCCAAGCAGGCCAG  
AAGCGACATCGAGAAGCTGAAAGAGGCCATCCGGGACA  
CCAACAAGGCCGTGCAGAGCGTGCAGTCCAGCGTGGGC  
AATCTGATCGTGGCCATCAAGTCCGTGCAGGACTACGTG  
AACAAAGAAATCGTGCCCTCTATCGCCCGGCTGGGCTGT  
GAAGCTGCCGGACTGCAGCTGGGCATTGCCCTGACACA  
GCACTACAGCGAGCTGACCAACATCTTCGGCGACAACA  
TCGGCAGCCTGCAGGAAAAGGGCATTAAAGCTGCAGGGA  
ATCGCCAGCCTGTACCGCACCAACATCACCGAGATCTTC  
ACCACCAGCACCGTGGATAAGTACGACATCTACGACCT  
GCTGTTACCGAGAGCATCAAAGTGCGCGTGATCGACGT  
GGACCTGAACGACTACAGCATCACCTGCAAGTGCGGC  
TGCCCCTGCTGACCAGACTGCTGAACACCCAGATCTACA  
AGGTGGACAGCATCTCCTACAACATCCAGAACCGCGAG  
TGGTACATCCCTCTGCCCAGCCACATTATGACCAAGGGC  
GCCTTTCTGGGCGGAGCCGACGTGAAAGAGTGCATCGA  
GGCCTTCAGCAGCTACATCTGCCCCAGCGACCCTGGCTT  
CGTGCTGAACCACGAGATGGAAAGCTGCCTGAGCGGCA  
ACATCAGCCAGTGCCCCAGAACCACCGTGACCTCCGAC  
ATCGTGCCAGATACGCCTTCGTGAATGGCGGCGTGGTG  
GCCAACTGCATCACACCACCTGTACCTGCAACGGCATC  
GGCAACCGGATCAACCAGCCTCCCGATCAGGGCGTGAA  
GATTATCACCCACAAAGAGTGTAACACCATCGGCATCA  
ACGGCATGCTGTTCAATACCAACAAAGAGGGCACCCCTG  
GCCTTCTACACCCCCGACGATATCACCTGAACAACCTCC  
GTGGCTCTGGACCCCATCGACATCTCCATCGAGCTGAAC  
AAGGCCAAGAGCGACCTGGAAGAGTCCAAAGAGTGGAT  
CCGGCGGAGCAACCAGAAGCTGGACTCTATCGGCAGCT  
GGCACCAGAGCAGCACCACCATCATCGTGATCCTGATTA  
TGATGATTATCCTGTTTCATCATCAACATTACCATCATCAC  
TATCGCCATTAAGTACTACCGGATCCAGAAACGGAACC  
GGGTGGACCAGAATGACAAGCCCTACGTGCTGACAAAC AAG PIV3 mRNA Sequences  
>gb|KJ672601.1|: AUGCCAAUUUCAUACUGUUAAUUUAUACAACCAUGA 61 4990-6609 Human

UCAUGGCAUCACACUGCCAAAUAAGACAUCACAAAACU parainfluenza virus  
ACAGCAUGUAGGUGUAUUGGUCAACAGUCCCAAAGGG 3 strain  
AUGAAGAUUCACAAAACUUCGAAACAAGAUUCUAA HPIV3/Homo  
UCCUGAGUCUCAUACCAAAAAUAGAAGAUUCUAACUC sapiens/PER/FLA  
UUGUGGUGACCAACAGAUCAAGCAAUACAAGAGGUUA 4815/2008 [fusion  
UUGGAUAGACUGAUCAUCCUUUAUAUGAUGGACUAA glycoprotein F0]  
GAUUACAGAAGGAUGUGAUAGUGACUAAUCAAGAAUC  
CAAUGAAAACACUGAUCCCAGAACAGAACGAUUCUUU  
GGAGGGGUAUUGGAACU AUUGCUCUAGGAGUAGCAA  
CCUCAGCACAAAUAACAGCAGCAGUUGCUCUGGUUGA  
AGCCAAGCAGGCAAGAUCAGACAUUGAAAAACUCAAG  
GAAGCAAUCAGGGACACAAAUAAGCAGUGCAGUCAG  
UUCAGAGCUCUGUAGGAAAUUUGAUAGUAGCAAUUA  
AUCAGUCCAGGAUU AUGUCAACAAAGAAAUCGUGCCA  
UCGAUUGCGAGACUAGGUUGUGAAGCAGCAGGACUUC  
AGUUAGGGAUUGCAUUAACACAGCAUUCUCAGAAU  
AACAAAUAU AUUUGGUGAUACAUAAGGAUCGUUACAA  
GAAAAGGAUAAAUAACAAGGUUAAGCAUCAUUAU  
ACCGUACAAAUAUCACAGAAAUAUUCACAACAUAAC  
AGUUGACAAAUAUGAUUUUAUGAUCUAUUUUACA  
GAAUCAAUAAAGGUGAGAGUUAUAGAUGUUGAUUUGA  
AUGAUUACUCAUAACCCUCCAAGUCAGACUCCCUU  
AUUGACCAGACUGCUGAACACUCAAAUCUACAAAGUA  
GAUUCCAUAUCAUAACAUAUCCAAAAUAGAGAAUGGU  
AUUCCCUUCUCCCAGCCAUAUCAUGACGAAAGGGGC  
AUUUCUAGGUGGAGCAGAUGUCAAGAAUGCAUAGAA  
GCAUUCAGCAGUUAUAUUGCCCUUCUGAUCCAGGAU  
UUGUACUAAACCAUGAAAUGGAGAGCUGUCUAUCAGG  
AAACAUAUCCCAAUGUCCAAGAACCACAGUCACAUCA  
GACAUAGUUCUAGGUUAUGCAUUGUCAUUGGAGGAG  
UGGUUGCGAAUUGUAUAACAACUACAUGUACAUGCAA  
UGGUAUCGGUAAUAGAAUCAACCAACCACCGAUCAA  
GGAGUCAAAAUAUAACACAUAAGAAUGUAAUACAA  
UAGGUUAUCAAACGGAAUGCUAUUCAACACAACAAGA  
AGGAACUCUUGCAUUCUACACACCAGACGACAUACA  
UUAACAUAUUCUGUUGCACUUGAUCCGAUUGACAUAU  
CAAUCGAGCUCAACAAGGCCAAAUCAGAUUCUUGAGGA  
AUCAAAGAAUGGAUAAGAAGGUCAAUAACAAGCUA  
GAUUCUAUUGGAAGUUGGCAUCAAUUCUAGCACUACA  
UCAUAGUUAUUUGAUAAUGAUGAUUAUAUUGUUUAU  
AAUUAUAUAACAUAUAUACAUAUGCAAUAAGUAU  
UACAGAAUUCAAAAGAGAAAUCGAGUGGAUCAAAAUG  
AUAAGCCGU AUGUAUUAACAACAAG gi|612507167|gb|  
AUGGAAUACUGGAAGCACACCAACCACGGAAAGGAUG 62 AHX22430.1|  
CUGGUAAUGAGCUGGAGACAUCCACAGCCACUCAUGG hemagglutinin-  
CAACAAGCUCACCAACAAGAUACAUAUAUUGUGG neuraminidase  
ACGAUAACCCUGGUGUUAUUAUCAAUAGUCUUCAUCA [Human  
UAGUGCUAACUAAUCCAUCAAAAAGUGAAAAGGCCCG parainfluenza  
CGAAUCAUUGCUACAAGACAUAUAUAUGAGUUUAUG virus 3  
GAAGUUACAGAAAAGAUCCAAGUGGCAUCGGAAUAAUA  
CUAAUGAUCUAAUACAGUCAGGAGUGAAUACAAGGCU  
UCUUAACAUAUCAGAGUCAUGUCCAGAAUUAUAUACCA  
AUUAUCAUUGACACAACAUAUCGGAUCUUAAGGAAU  
UCAUUAUGUAAAUAACAUAUAGAAAUGAUAAUCAAGA

AGUGCCACCACAAAGAAUAACACAUGAUGUGGGUAUA  
AAACCUUUAUUUCCAGAUGAUUUUCUGGAGAUGCACGU  
CUGGUCUCCAUCUUUGAUGAAAACUCCAAAAUAAG  
AUUAAUGCCGGGACCAGGAUUUUAUAGCUAUGCCAACG  
ACUGUUGAUGGCUGUGUCAGAACCCCGUCCUAGUGA  
UAAAUGAUCUGAUUUUAGCUUACACCUCAAAUCUAAU  
UACUCGAGGUUGCCAGGAUAUAGGGAAAUCAUAUCA

GUUUACAGAUAGGGAUAAUAACUGUAAACUCAGACU  
UGGUACCUGACUAAAUCCUAGGAUCUCUCAUACCUU  
CAACAUAAAUGACAAUAGAAAGUCAUGUUCUCUAGCA  
CUCCUAAAUAACAGAUUAUAUCAACUGUGUUCAACCC  
CAAAGUUGAUGAAAGAUCAUUAUGCAUCAUCAGG  
CAUAGAAGAUUUUGUACUUGAUUUUGUCAUUUAUGAU  
GGUCUAAUCUCGACAACAAGAUUUUAAAGAAUAAUAAU  
UAAGUUUUGAUCAACCAUAUGCGGCAUUUAUACCCAUC  
UGUUGGACCAGGGAUUAACUACAAAGGCAAAAUAUA  
UUUCUCGGGUUUGGAGGUCUUGAACAUCCAUAUAAUG  
AGAAUGCAAUCUGCAACACAACUGGGUGUCCUGGGAA  
AACACAGAGAGACUGUAAUCAAGCAUCUCAUAGUCCA  
UGGUUUUCAGAUAGAAGGAUGGUCAACUCUAAUAAUUG  
UUGUUGACAAGGGCUUGAACUCAGUCCAAAAUUGAA  
GGUAUGGACGAUAUCUAUGAGACAAAUAUCUGGGGG  
UCAGAAGGAAGAUUACUUCUACUAGGUAACAAGAUUCU  
ACAUUAACACAAGAUCUACAAGUUGGCACAGCAAGUU  
ACAAUAGGAAUAAUUGACAUUACUGACUACAGUGAU  
AUAAGGAUAAAUGGACAUGGCAUAAUGUGCUAUCAA  
GACCAGGAAACAUGAAUGUCCAUGGGGACAUUCAUG  
UCCGGAUGGAUGUAUAACGGGAGUAUAUACCGAUGCA  
UAUCCACUCAAUCCCACAGGAAGCAUUGUAUCAUCUG  
UCAUAUUGGACUCACAAAUAUCGAGAGUCAACCCAGU  
CAUAACUUAUCUACACAGCAACCGAAAGGGUAAACGAG  
CUGGCUAUCCGAAACAAAACACUCUCAGCUGGGUACA  
CAACAACAAGCUGCAUUACACACUAUAACAAAGGGUA  
UUGUUUUCAUUAAGUAGAAAUAUAAUCAUAAAAGCUUA  
AACACAUUUAACCCAUGUUGUUCAAAACAGAGAUUC

CAAAAAGCUGCAGU HPIV3\_HN\_Codon  
AUGGAAUACUGGAAGCACACCAACCACGGCAAGGACG 63 Optimized

CCGGCAACGAGCUGGAAACCAGCACAGCCACACACGGC  
AACAAAGCUGACCAACAAGAUCACCUACAUCUGUGGA  
CCAUCACCCUGGUGCUGCUGAGCAUCGUGUUCAUCAUC  
GUGCUGACCAAUAGCAUCAAGAGCGAGAAGGCCAGAG  
AGAGCCUGCUGCAGGACAUCAACAACGAGUUCAUGGA  
AGUGACCGAGAAGAUCAGGUGGCCAGCGACAACACC  
AACGACCUGAUCCAGAGCGGGGUGAACACCCGGCUGCU  
GACCAUCCAGAGCCACGUGCAGAACUACAUCCCAUCA  
GCCUGACCCAGCAGAUCAGCGACCUGCGGAAGUUCAUC  
AGCGAGAUCACCAUCCGGAACGACAACCAGGAAGUGC  
CCCCCAGAGAAUCACCCACGACGUGGGCAUCAAGCCC  
CUGAACCCCGACGAUUUCUGGCGGUGUACAAGCGGCC  
UGCCCAGCCUGAUGAAGACCCCAAGAUCGGCUGAUG  
CCUGGCCUGGACUGCUGGCCAUGCCUACCACAGUGGA  
UGGCUGUGUGCGGACCCCCAGCCUCGUGAUCAACGAUC  
UGAUCUACGCCUACACCAGCAACCUGAUCACCCGGGGC  
UGCCAGGAUAUCGGCAAGAGCUACCAGGUGCUGCAGA

UCGGCAUCAUCACCGUGAACUCCGACCUGGUGCCCGAC  
CUGAACCCUCGGAUCAGCCACACCUUCAACAUCAACGA  
CAACAGAAAGAGCUGCAGCCUGGCUCUGCUGAACACC  
GACGUGUACCAGCUGUGCAGCACCCCAAGGUGGACG  
AGAGAAGCGACUACGCCAGCAGCGGCAUCGAGGAUUA  
CGUGCUGGACAUCGUGAACUACGACGGCAGCAUCAGC  
ACCACCCGGUUCAAGAACAACAUCAGCUUCGACCA  
GCCCUACGCCGCCUGUACCCUUCUGUGGGCCCUGGCA  
UCUACUACAAGGGCAAGAUCUUCUCCUGGGCUACGG  
CGGCCUGGAACACCCCAUCAACGAGAACGCCAUCUGCA  
ACACCACCGGCUGCCCUGGCAAGACCCAGAGAGACUGC  
AAUCAGGCCAGCCACAGCCCCUGGUUCAGCGACCGCAG  
AAUGGUCAACUCUAUCAUCGUGGUGGACAAGGGCCUG  
AACAGCGUGCCCAAGCUGAAAGUGUGGACAAUCAGCA  
UGC GCCAGAACUACUGGGGCAGCGAGGGCAGACUUCU  
GCUGCUGGGAAACAAGAUCUACAUCUACACCCGGUCC  
ACCAGCUGGCACAGCAAACUGCAGCUGGGAAUCAUCG  
ACAUCACCGACUACAGCGACAUCCGGAUCAAGUGGACC  
UGGCACAACGUGCUGAGCAGACCCGGCAACAAUGAGU  
GCCCUUGGGGCCACAGCUGCCCCGAUGGAUGUAUCACC  
GGCGUGUACACCGACGCCUACCCCCUGAAUCCUACCGG  
CUCCAUCGUGUCCAGCGUGAUCCUGGACAGCCAGAAA  
AGCAGAGUGAACCCCGUGAUCACAUACAGCACCGCCAC  
CGAGAGAGUGAACGAACUGGCCAUCAGAAACAAGACC  
CUGAGCGCCGGCUACACCACCACAAGCUGCAUCACACA  
CUACAACAAGGGCUACUGCUUCCACAUCGUGGAAAUC  
AACCACAAGUCCUGAACACCUUCCAGCCAUGCUGUU  
CAAGACCGAGAUCCCCAAGAGCUGCUC HPIV3\_F\_Codon  
AUGCCCAUCAGCAUCCUGCUGAUCUACCCACAAUGAU 64 Optimized mRNA  
CAUGGCCAGCCACUGCCAGAUCGACAUCACCAAGCUGC sequence  
AGCACGUGGGCGUGCUCGUGAACAGCCCCAAGGGCAU  
GAAGAUCAGCCAGAACUUCGAGACACGCUACCUGAUC  
CUGAGCCUGAUCCCCAAGAUCGAGGACAGCAACAGCU  
GCGGCGACCAGCAGAUCAAGCAGUACAAGCGGCUGCU  
GGACAGACUGAUCAUCCCCUGUACGACGGCCUGCGGC  
UGCAGAAAGACGUGAUCGUGACCAACCAGGAAAGCAA  
CGAGAACACCGACCCCCGGACCGAGAGAUUCUUCGGCG  
GCGUGAUCGGCACAUCGCCUGGGAGUGGCCACAAG  
CGCCCAGAUUACAGCCGCUUGGGCCCUGGUGGAAGCCA  
AGCAGGCCAGAAGCGACAUCGAGAAGCUGAAAGAGGC  
CAUCCGGGACACCAACAAGGCCGUGCAGAGCGUGCAG  
UCCAGCGUGGGCAAUCUGAUCGUGGCCAUCAAGUCCG  
UGCAGGACUACGUGAACAAAGAAAUCGUGCCCUCUAU  
CGCCCGGCUGGGCUGUGAAGCUGCCGGACUGCAGCUG  
GGCAUUGCCCUGACACAGCACUACAGCGAGCUGACCAA  
CAUCUUCGGCGACAACAUCGGCAGCCUGCAGGAAAAG  
GGCAUUAAGCUGCAGGGAAUCGCCAGCCUGUACCGCA  
CCAACAUCACCGAGAUCUUCACCACCAGCACCGUGGAU  
AAGUACGACAUCUACGACCUGCUGUUCACCGAGAGCA  
UCAAGUGCGCGUGAUCGACGUGGACCUGAACGACUA  
CAGCAUCACCCUGCAAGUGCGGCUGCCCCUGCUGACCA  
GACUGCUGAACACCCAGAUCUACAAGGUGGACAGCAU  
CUCCUACAACAUCAGAACCGCGAGUGGUACAUCCUC  
UGCCCAGCCACAUAUGACCAAGGGCGCCUUCUGGGC



GGAGCCGACGUGAAAGAGUGCAUCGAGGCCUUCAGCA  
GCUACAUCUGCCCCAGCGACCCUGGCUUCGUGCUGAAC  
CACGAGAUGGAAAGCUGCCUGAGCGGCAACAUCAGCC  
AGUGCCCCAGAACCACCGUGACCUCGACAUCGUGCCC  
AGAUACGCCUUCGUGAAUGGCGGCGUGGUGGCCAACU  
GCAUCACCACCACCGUGUACCUGCAACGGCAUCGGCAAC  
CGGAUCAACCAGCCUCCCGAUCAGGGGCGUGAAGAUA  
UCACCCACAAAGAGUGUAACACCAUCGGCAUCAACGGC  
AUGCUGUCAAUACCAACAAAGAGGGCACCCUGGCCU  
UCUACACCCCCGACGAUAUCACCCUGAACAAACUCCGUG  
GCUCUGGACCCCAUCGACAUCUCCAUCGAGCUGAACAA  
GGCCAAGAGCGACCUGGAAGAGUCCAAAGAGUGGAUC  
CGGCGGAGCAACCAGAAGCUGGACUCUAUCGGCAGCU  
GGCACCAGAGCAGCACCACCAUCAUCGUGAUCCUGAUU  
AUGAUGAUUAUCCUGUUAUCAUCAACAUAUACCAUCA  
UCACUAUCGCCAUUAAGUACUACCGGAUCCAGAAACG  
GAACCGGGUGGACCAGAAUGACAAGCCUACGUGCUG ACAAACAAG

TABLE-US-00007 TABLE 6 PIV3 Amino Acid Sequences SEQ ID Description Sequence NO:  
>gi|612507166|gb| MPISILLIITMIMASHCQIDITKLQHVGLVNSPKGMKISQ 13 AHX22429.1|  
NFETRYLILSLIPKIEDNSCGDQQIKQYKRLLDRLIPLYDG fusion glycoprotein  
LRLQKDVIIVTNQESNENTDPRTERFFGGVIGTIALGVATSA F0 [Human  
QITAAVALVEAKQARSIEKLKEAIRDTNKAVQSVQSSVG parainfluenza virus  
NLIVAIVSVQDYVNKEIVPSIARLGCEAAGLQLGIALTQHYS 3]  
ELTNIFGDNIGSLQEKGIKLGQIASLYRTNITEIFTTSTVDKY  
DIYDLLFTESIKVRVIDVDLNDYSITLQVRLPLLRLNLTQIY  
KVDSISYNIQNREWIPLPSHIMTKGAFLGGADVKECIEAFS  
SYICPSDPGFVLNHEMESCLSGNISQCPRTTIVTSDIVPRYAF  
VNGGVVANCITTTCTCNGIGNRINQPPDQGVKIITHKECNTI  
GINGMLFNTNKEGTLAFYTPDDITLNNVALDPIDISIELNK  
AKSDLSEESKEWIRRSNQKLDISGSHWQSSTIIVILIMMIILFI  
INITIITIAIKYYRIQKRNRVDQNDKPYVLTNK gi|612507167|gb|  
MEYWKHTNHGKDAGNELETSTATHGNKLTNKITYILWTIT 14 AHX22430.1|  
LVLLSIVFIIIVLTNSIKSEKARESLQDINNEFMEVTEKIQVA hemagglutinin-  
SDNTNDLIQSGVNTRLLTIQSHVQNYIPISLTQQISDLRKFIS neuraminidase  
EITIRNDNQEVPPQRITHDVGIKPLNPDDFWRCTSGLPSLMK [Human  
TPKIRLMPGPGLLAMPTTVDGCVRTPSLVINDLIYAYTSNLI parainfluenza virus  
TRGCQDIGKSYQVLQIGIITVNSDLVLDLNPRIHTFNINDN 3|  
RKSCSLALLNTDVYQLCSTPKVDERSDYASSGIEDIVLDIV  
NYDGSISTTRFKNNNISFDQPYAALYPSVGPGIYYKGIIFL  
GYGGLEHPINENAICNTTGCPCGKTQRDCNQASHSPWFSDR  
RMVNSIIVVDKGLNSVPKLVWTISMQRQNYWGSEGRLLLL  
GNKIYIYTRSTSWHKLQLGIIDITDYSDIRIKWTWHNVLSR  
PGNNECPWGHSCPDGCITGVYTDAYPLNPTGSIVSSVILDS  
QKSRVNPVITYSTATERVNELAIRNKTLSAGYTTTSCITHY  
NKGYCFHIVEINHKSLENTFQPMLFKTEIPKSCS

TABLE-US-00008 TABLE 7 PIV3 NCBI Accession Numbers (Nucleic Acid and Amino Acid Sequences)  
GenBank Description Accession Fusion glycoprotein F0 [Human KJ672601.1]: parainfluenza virus 3]  
HPIV3/Homo 4990-6609 sapiens/PER/FLA4815/2008 AHX22429 (Fusion protein) hemagglutinin-  
neuraminidase [Human KJ672601.1]: parainfluenza virus 3] HPIV3/Homo 6724-8442  
sapiens/PER/FLA4815/2008 AHX22430 (HN protein) Recombinant PIV3/PIV1 virus fusion AF016281  
glycoprotein (F) and hemagglutinin AAC23947 (HN) genes, complete cds; and RNA (hemagglutinin) dependent  
RNA polymerase (L) gene, partial cds. Recombinant PIV3/PIV1 virus fusion AF016281 glycoprotein (F) and

hemagglutinin AAC23947 (HN) genes, complete cds; and RNA (fusion protein) dependent RNA polymerase (L) gene, partial cds. hemagglutinin-neuraminidase [Human BAO32044.1 parainfluenza virus 3] hemagglutinin-neuraminidase [Human BAO32051.1 parainfluenza virus 3] C protein [Human parainfluenza virus 3] NP\_599251.1 C protein [Human parainfluenza virus 3] ABZ85670.1 C protein [Human parainfluenza virus 3] AGT75164.1 C protein [Human parainfluenza virus 3] AAB48686.1 C protein [Human parainfluenza virus 3] AHX22115.1 C protein [Human parainfluenza virus 3] AGW51066.1 C protein [Human parainfluenza virus 3] AGW51162.1 C protein [Human parainfluenza virus 3] AGT75252.1 C protein [Human parainfluenza virus 3] AGT75188.1 C protein [Human parainfluenza virus 3] AGW51218.1 C protein [Human parainfluenza virus 3] AGW51074.1 C protein [Human parainfluenza virus 3] AGT75323.1 C protein [Human parainfluenza virus 3] AGT75307.1 C protein [Human parainfluenza virus 3] AHX22131.1 C protein [Human parainfluenza virus 3] AGW51243.1 C protein [Human parainfluenza virus 3] AGT75180.1 C protein [Human parainfluenza virus 3] AGT75212.1 C protein [Human parainfluenza virus 3] AGW51186.1 C protein [Human parainfluenza virus 3] AHX22075.1 C protein [Human parainfluenza virus 3] AHX22163.1 C protein [Human parainfluenza virus 3] AGT75196.1 C protein [Human parainfluenza virus 3] AHX22491.1 C protein [Human parainfluenza virus 3] AHX22139.1 C protein [Human parainfluenza virus 3] AGW51138.1 C protein [Human parainfluenza virus 3] AGW51114.1 C protein [Human parainfluenza virus 3] AGT75220.1 C protein [Human parainfluenza virus 3] AHX22251.1 RecName: Full = Protein C; AltName: P06165.1 Full = VP18 protein C protein [Human parainfluenza virus 3] AHX22187.1 C protein [Human parainfluenza virus 3] AGT75228.1 C protein [Human parainfluenza virus 3] AHX22179.1 C protein [Human parainfluenza virus 3] AHX22427.1 C protein [Human parainfluenza virus 3] AGW51210.1 nonstructural protein C [Human BAA00922.1 parainfluenza virus 3] C protein [Human parainfluenza virus 3] AHX22315.1 C protein [Human parainfluenza virus 3] AGW51259.1 C protein [Human parainfluenza virus 3] AHX22435.1 C protein [Human parainfluenza virus 3] AHX22123.1 C protein [Human parainfluenza virus 3] AHX22299.1 C protein [Human parainfluenza virus 3] AGW51267.1 unnamed protein product [Human CAA28430.1 parainfluenza virus 3] C protein [Human parainfluenza virus 3] AGW51178.1 C protein [Human parainfluenza virus 3] AHX22411.1 RecName: Full = Protein C P06164.1 phosphoprotein [Human parainfluenza virus 3] NP\_067149.1 phosphoprotein [Human parainfluenza virus 3] AAB48685.1 phosphoprotein [Human parainfluenza virus 3] AHX22498.1 phosphoprotein [Human parainfluenza virus 3] AHX22490.1 phosphoprotein [Human parainfluenza virus 3] AGT75259.1 phosphoprotein [Human parainfluenza virus 3] AGW51137.1 phosphoprotein [Human parainfluenza virus 3] AGW51145.1 phosphoprotein [Human parainfluenza virus 3] AGT75298.1 phosphoprotein [Human parainfluenza virus 3] AGW51113.1 phosphoprotein [Human parainfluenza virus 3] AGT75203.1 phosphoprotein [Human parainfluenza virus 3] AGT75163.1 phosphoprotein [Human parainfluenza virus 3] AHX22506.1 phosphoprotein [Human parainfluenza virus 3] AGW51129.1 phosphoprotein [Human parainfluenza virus 3] AHX22194.1 phosphoprotein [Human parainfluenza virus 3] AGT75211.1 phosphoprotein [Human parainfluenza virus 3] AHX22258.1 phosphoprotein [Human parainfluenza virus 3] AGW51121.1 phosphoprotein [Human parainfluenza virus 3] AGT75282.1 phosphoprotein [Human parainfluenza virus 3] AHX22146.1 phosphoprotein [Human parainfluenza virus 3] AHX22138.1 phosphoprotein [Human parainfluenza virus 3] AHX22322.1 phosphoprotein [Human parainfluenza virus 3] AHX22370.1 phosphoprotein [Human parainfluenza virus 3] AHX22098.1 phosphoprotein [Human parainfluenza virus 3] AHX22130.1 phosphoprotein [Human parainfluenza virus 3] AHX22418.1 phosphoprotein [Human parainfluenza virus 3] AHX22114.1 phosphoprotein [Human parainfluenza virus 3] AHX22410.1 phosphoprotein [Human parainfluenza virus 3] AGT75306.1 phosphoprotein [Human parainfluenza virus 3] AHX22170.1 phosphoprotein [Human parainfluenza virus 3] AHX22266.1 phosphoprotein [Human parainfluenza virus 3] AHX22090.1 phosphoprotein [Human parainfluenza virus 3] AGT75195.1 phosphoprotein [Human parainfluenza virus 3] AHX22226.1 phosphoprotein [Human parainfluenza virus 3] AHX22178.1 phosphoprotein [Human parainfluenza virus 3] AHX22122.1 phosphoprotein [Human parainfluenza virus 3] AHX22186.1 phosphoprotein [Human parainfluenza virus 3] AHX22066.1 phosphoprotein [Human parainfluenza virus 3] AHX22522.1 phosphoprotein [Human parainfluenza virus 3] AGW51225.1 phosphoprotein [Human parainfluenza virus 3] BAN29032.1 phosphoprotein [Human parainfluenza virus 3] ABZ85669.1 phosphoprotein [Human parainfluenza virus 3] AHX22426.1 phosphoprotein [Human parainfluenza virus 3] AHX22058.1 phosphoprotein [Simian Agent 10] ADR00400.1 phosphoprotein [Human parainfluenza virus 3] AHX22250.1 phosphoprotein [Human parainfluenza virus 3] AHX22434.1 phosphoprotein [Human parainfluenza virus 3] AHX22298.1 phosphoprotein [Human parainfluenza virus 3] AHX22442.1 phosphoprotein [Human parainfluenza virus 3]

AHX22074.1 phosphoprotein [Human parainfluenza virus 3] AGW51153.1 phosphoprotein [Human parainfluenza virus 3] AGW51241.1 phosphoprotein [Human parainfluenza virus 3] AHX22210.1 phosphoprotein [Human parainfluenza virus 3] AGW51105.1 phosphoprotein [Human parainfluenza virus 3] AGT75251.1 phosphoprotein [Human parainfluenza virus 3] AHX22362.1 phosphoprotein [Human parainfluenza virus 3] AHX22474.1 phosphoprotein [Human parainfluenza virus 3] AGW51217.1 phosphoprotein [Human parainfluenza virus 3] AIG60038.1 phosphoprotein [Human parainfluenza virus 3] AHX22378.1 phosphoprotein [Human parainfluenza virus 3] AGW51057.1 phosphoprotein [Human parainfluenza virus 3] AGT75187.1 phosphoprotein [Human parainfluenza virus 3] AGW51233.1 phosphoprotein [Human parainfluenza virus 3] AHX22482.1 phosphoprotein [Human parainfluenza virus 3] AGW51161.1 phosphoprotein [Human parainfluenza virus 3] AHX22306.1 phosphoprotein [Human parainfluenza virus 3] AHX22162.1 phosphoprotein [Human parainfluenza virus 3] ACJ70087.1 phosphoprotein [Human parainfluenza virus 3] AHX22466.1 phosphoprotein [Human parainfluenza virus 3] AHX22346.1 phosphoprotein [Human parainfluenza virus 3] AGW51089.1 phosphoprotein [Human parainfluenza virus 3] AGW51073.1 phosphoprotein [Human parainfluenza virus 3] AGW51185.1 phosphoprotein [Human parainfluenza virus 3] AGW51065.1 phosphoprotein [Human parainfluenza virus 3] ABY47603.1 phosphoprotein [Human parainfluenza virus 3] AGW51049.1 phosphoprotein [Human parainfluenza virus 3] AHX22330.1 phosphoprotein [Human parainfluenza virus 3] AGW51250.1 phosphoprotein [Human parainfluenza virus 3] AGT75227.1 phosphoprotein [Human parainfluenza virus 3] AGW51282.1 phosphoprotein [Human parainfluenza virus 3] AGW51209.1 phosphoprotein [Human parainfluenza virus 3] AGW51193.1 phosphoprotein [Human parainfluenza virus 3] AGT75322.1 phosphoprotein [Human parainfluenza virus 3] AGT75219.1 phosphoprotein [Human parainfluenza virus 3] AGW51258.1 phosphoprotein [Human parainfluenza virus 3] AGW51041.1 phosphoprotein [Human parainfluenza virus 3] ACD99698.1 phosphoprotein [Human parainfluenza virus 3] AGW51266.1 phosphoprotein [Human parainfluenza virus 3] AGT75179.1 phosphoprotein [Human parainfluenza virus 3] AHX22282.1 phosphoprotein [Human parainfluenza virus 3] AGW51169.1 phosphoprotein [Human parainfluenza virus 3] AGW51274.1 phosphoprotein [Human parainfluenza virus 3] AGW51201.1 phosphoprotein [Human parainfluenza virus 3] AGW51177.1 RecName: Full = Phosphoprotein; Short = Protein P P06162.1 P protein [Human parainfluenza virus 3] AAA66818.1 phosphoprotein [Human parainfluenza virus 3] AAA46866.1 phosphoprotein [Human parainfluenza virus 3] BAA00031.1 polymerase-associated nucleocapsid phosphoprotein RRNZP5 (version 2)-parainfluenza virus type 3 [Human parainfluenza virus 3] phosphoprotein [Human parainfluenza virus 3] AGT75171.1 phosphoprotein [Human parainfluenza virus 3] BAA00921.1 D protein [Human parainfluenza virus 3] NP\_599250.1 D protein [Human parainfluenza virus 3] AHX22377.1 D protein [Human parainfluenza virus 3] AHX22121.1 D protein [Human parainfluenza virus 3] AGT75297.1 D protein [Human parainfluenza virus 3] AGW51136.1 D protein [Human parainfluenza virus 3] AGW51242.1 D protein [Human parainfluenza virus 3] AGW51112.1 D protein [Human parainfluenza virus 3] AHX22497.1 D protein [Human parainfluenza virus 3] AHX22145.1 D protein [Human parainfluenza virus 3] AGT75202.1 D protein [Human parainfluenza virus 3] AHX22385.1 D protein [Human parainfluenza virus 3] AGW51216.1 D protein [Human parainfluenza virus 3] AGT75281.1 D protein [Human parainfluenza virus 3] AGT75194.1 D protein [Human parainfluenza virus 3] AHX22521.1 D protein [Human parainfluenza virus 3] AGW51120.1 D protein [Human parainfluenza virus 3] AGT75313.1 D protein [Human parainfluenza virus 3] AHX22249.1 D protein [Human parainfluenza virus 3] AHX22097.1 D protein [Human parainfluenza virus 3] AGW51144.1 D protein [Human parainfluenza virus 3] AHX22089.1 D protein [Human parainfluenza virus 3] AHX22225.1 D protein [Human parainfluenza virus 3] AHX22137.1 D protein [Human parainfluenza virus 3] AHX22065.1 D protein [Human parainfluenza virus 3] AGW51224.1 D protein [Human parainfluenza virus 3] AGT75210.1 D protein [Human parainfluenza virus 3] AHX22393.1 D protein [Human parainfluenza virus 3] AGT75258.1 D protein [Human parainfluenza virus 3] AHX22345.1 D protein [Human parainfluenza virus 3] AGT75250.1 D protein [Human parainfluenza virus 3] AHX22113.1 D protein [Human parainfluenza virus 3] AGW51232.1 D protein [Human parainfluenza virus 3] AHX22057.1 D protein [Human parainfluenza virus 3] AHX22209.1 D protein [Human parainfluenza virus 3] AGW51056.1 D protein [Human parainfluenza virus 3] AHX22161.1 D protein [Simian Agent 10] ADR00402.1 D protein [Human parainfluenza virus 3] AHX22361.1 D protein [Human parainfluenza virus 3] AGW51281.1 D protein [Human parainfluenza virus 3] AGW51184.1 D protein [Human parainfluenza virus 3] AGW51160.1 D protein [Human parainfluenza virus 3] AHX22465.1 D protein [Human parainfluenza virus 3] AHX22329.1 D protein [Human parainfluenza virus 3] AGW51064.1 D protein [Human parainfluenza virus 3] AGW51040.1 D protein [Human parainfluenza virus 3] AGT75226.1 D protein

[Human parainfluenza virus 3] AHX22425.1 D protein [Human parainfluenza virus 3] AHX22305.1 D protein [Human parainfluenza virus 3] AGW51249.1 D protein [Human parainfluenza virus 3] AHX22481.1 D protein [Human parainfluenza virus 3] AHX22281.1 D protein [Human parainfluenza virus 3] AGW51048.1 D protein [Human parainfluenza virus 3] AHX22297.1 D protein [Human parainfluenza virus 3] AGW51088.1 D protein [Human parainfluenza virus 3] AGT75305.1 D protein [Human parainfluenza virus 3] AHX22185.1 D protein [Human parainfluenza virus 3] AGW51104.1 D protein [Human parainfluenza virus 3] AHX22081.1 D protein [Human parainfluenza virus 3] AGW51192.1 D protein [Human parainfluenza virus 3] AHX22489.1 D protein [Human parainfluenza virus 3] AHX22441.1 D protein [Human parainfluenza virus 3] AHX22409.1 D protein [Human parainfluenza virus 3] AHX22369.1 D protein [Human parainfluenza virus 3] AHX22321.1 D protein [Human parainfluenza virus 3] AHX22073.1 D protein [Human parainfluenza virus 3] AGW51152.1 D protein [Human parainfluenza virus 3] AGW51072.1 D protein [Human parainfluenza virus 3] AGT75321.1 D protein [Human parainfluenza virus 3] AHX22257.1 D protein [Human parainfluenza virus 3] AHX22129.1 D protein [Human parainfluenza virus 3] AHX22417.1 D protein [Human parainfluenza virus 3] AGT75218.1

D protein [Human parainfluenza virus 3] AHX22265.1 D protein [Human parainfluenza virus 3] AGT75178.1 D protein [Human parainfluenza virus 3] AHX22433.1 D protein [Human parainfluenza virus 3] AGW51273.1 D protein [Human parainfluenza virus 3] AGW51208.1 D protein [Human parainfluenza virus 3] AGT75170.1 D protein [Human parainfluenza virus 3] AGT75162.1 D protein [Human parainfluenza virus 3] AGW51257.1 D protein [Human parainfluenza virus 3] AGW51200.1 D protein [Human parainfluenza virus 3] AGW51176.1 D protein [Human parainfluenza virus 3] AGT75186.1 D protein [Human parainfluenza virus 3] AGW51265.1 D protein [Human parainfluenza virus 3] AGW51168.1

TABLE-US-00009 TABLE 8 Signal Peptides SEQ ID Description Sequence NO: HuIgG.sub.k signal METPAQLLFLLLLWLPDTTG 15 peptide IgE heavy chain MDWTWILFLVAAATRVHS 16 epsilon -1 signal peptide Japanese MLGSNSGQRVVFILLLVAPAYS 17 encephalitis PRM signal sequence VSVg protein MKCLLYLAFLFIGVNCA 18 signal sequence Japanese MWLVSLAIVTACAGA 19 encephalitis JEV signal sequence

TABLE-US-00010 TABLE 9 hMPV/PIV Cotton Rat Challenge Study Design Group n Test Article [conc]/.mu.g Route Challenge 1 5 Placebo n/a IM hMPV/A2 2 5 hMPV vaccine mRNA 30 IM hMPV/A2 3 5 hMPV vaccine mRNA 15 IM hMPV/A2 4 5 hMPV vaccine mRNA 10 IM hMPV/A2 5 5 hMPV/PIV3 vaccine 30 IM hMPV/A2 mRNA (15/15) 6 5 FI-hMPV n/a IM hMPV/A2 7 5 Placebo n/a IM PIV3 8 5 PIV3 vaccine mRNA 30 IM PIV3 9 5 PIV3 vaccine mRNA 15 IM PIV3 10 5 PIV3 vaccine mRNA 10 IM PIV3 11 5 hMPV/PIV3 vaccine 30 IM PIV3 mRNA (15/15) 12 5 FI-PIV3 n/a IM PIV3 60

TABLE-US-00011 TABLE 10 SEQ ID Strain Nucleic Acid Sequence NO: Betacoronavirus Nucleic Acid Sequence gb|KJ156934.1|:21 ATGATACTCAGTGTCTACTGATGTTCTTGTTAACACC 20 405-25466 Middle TACAGAAAGTTACGTTGATGTAGGGCCAGATTCTGTAAAG East respiratory TCTGCTTGATTGAGGTTGATATACAACAGACCTTCTTTGA syndrome TAAACTTGGCCTAGGCCAATTGATGTTTCTAAGGCTGAC coronavirus GGTATTATATACCCTCAAGGCCGTACATATTCTAACATAA isolate CTATCACTTATCAAGGTCTTTTTCCCTATCAGGGAGACCAT Riyadh\_14\_2013, GGTGATATGTATGTTTACTCTGCAGGACATGCTACAGGCA spike protein CAACTCCACAAAAGTTGTTTGTAGCTAACTATTCTCAGGA (nucleotide) CGTCAAACAGTTTGCTAATGGGTTTGTCGTCGGTATAGGA GCAGCTGCCAATTCCTACTGGCACTGTTATTATTAGCCCATC TACCAGCGCTACTATACGAAAATTTACCCTGCTTTTATGC TGGGTTCTTCAGTTGGTAATTTCTCAGATGGTAAAATGGG CCGCTTCTTCAATCATACTCTAGTTCTTTTGCCCGATGGAT GTGGCACTTTACTTAGAGCTTTTTATTGTATTCTAGAGCCT CGCTCTGGAAATCATTGTCCTGCTGGCAATTCCTATACTTCTTTGCCACTTATCACACTCCTGCAACAGATTGTTCTGATG GCAATTACAATCGTAATGCCAGTCTGAACTCTTTTAAGGA GTATTTTAATTTACGTAAGTGCACCTTTATGTACACTTATA

ACATTACCGAAGATGAGATTTTAGAGTGGTTTGGCATTAC  
ACAAACTGCTCAAGGTGTTACCTCTTCTCATCTCGGTATG  
TTGATTTGTACGGCGGCAATATGTTTCAATTTGCCACCTTG  
CCTGTTTATGATACTATTAAGTATTATTCTATCATTCTCA  
CAGTATTCGTTCTATCCAAAGTGATAGAAAAGCTTGGGCT  
GCCTTCTACGTATATAAACTTCAACCGTTAACTTTCTGTT  
GGATTTTTCTGTTGATGGTTATATACGCAGAGCTATAGACT  
GTGGTTTTAATGATTTGTCACAACCTCCACTGCTCATATGAA  
TCCTTCGATGTTGAATCTGGAGTTTATTTCAGTTTCGTCTTT  
CGAAGCAAACCTTCTGGCTCAGTTGTGGAACAGGCTGAA  
GGTGTGGAATGTGATTTTTACCTCTTCTGTCTGGCACACC  
TCCTCAGGTTTATAATTTCAAGCGTTTGGTTTTTACCAATT  
GCAATTATAATCTTACCAAATTGCTTTCACTTTTTTCTGTG  
AATGATTTTACTTGTAGTCAAATATCTCCAGCAGCAATTGC  
TAGCAACTGTTATTCTTCACTGATTTTGGATTATTTTTCAT  
ACCCACTTAGTATGAAATCCGATCTCAGTGTTAGTTCTGCT  
GGTCCAATATCCCAGTTTAAATTATAAACAGTCCTTTTCTAA  
TCCCACATGTTTGATCTTAGCGACTGTTCTCATAACCTTA  
CTACTATTAAGCCTCTTAAAGTACAGCTATATTAACAA  
GTGCTCTCGTCTTCTTTCTGATGATCGTACTGAAGTACCTC  
AGTTAGTGAACGCTAATCAATACTCACCTGTGTATCCATT  
GTCCCATCCACTGTGTGGGAAGACGGTGATTATTATAGGA  
AACAACTATCTCCACTTGAAGGTGGTGGCTGGCTTGTGTC  
TAGTGGCTCAACTGTTGCCATGACTGAGCAATTACAGATG  
GGCTTTGGTATTACAGTTCAATATGGTACAGACACCAATA  
GTGTTTGCCCCAAGCTTGAATTTGCTAATGACACAAAAT  
TGCCTCTCAATTAGGCAATTGCGTGGAATATCCCTCTATG  
GTGTTTCGGGCCGTGGTGTTTTTTCAGAATTGCACAGCTGTA  
GGTGTTCGACAGCAGCGCTTTGTTTATGATGCGTACCAGA  
ATTTAGTTGGCTATTATTCTGATGATGGCAACTACTACTGT  
CTGCGTGCTTGTGTTAGTGTTCCCTGTTTCTGTCATCTATGA  
TAAAGAACTAAAACCCACGCTACTCTATTTGGTAGTGTT  
GCATGTGAACACATTTCTTCTACCATGTCTCAATACTCCCG  
TTCTACGCGATCAATGCTTAAACGGCGAGATTCTACATAT  
GGCCCCCTTCAGACACCTGTTGGTTGTGTCCTAGGACTTGT  
TAATTCCTCTTTGTTTCGTAGAGGACTGCAAGTTGCCTCTCG  
GTCAATCTCTCTGTGCTCTTCTGACACACCTAGTACTCTC  
ACACCTCGCAGTGTGCGCTCTGTGCCAGGTGAAATGCGCT  
TGGCATCCATTGCTTTTAAATCATCCCATTCAGGTTGATCAA  
CTTAATAGTAGTTATTTTAAATTAAGTATACCCACTAATTT  
TTCCTTTGGTGTGACTCAGGAGTACATTCAGACAACCATTTC  
AGAAAGTTACTGTTGATTGTAAACAGTACGTTTGCAATGG  
TTTCCAGAAGTGTGAGCAATTACTGCGCGAGTATGGCCAG  
TTTTGTTCCAAAATAAACAGGCTCTCCATGGTGCCAATTT  
ACGCCAGGATGATTCTGTACGTAATTTGTTTGGCGAGCGTG  
AAAAGCTCTCAATCATCTCCTATCATAACCAGGTTTTGGAG  
GTGACTTTAATTTGACACTTCTAGAACCTGTTTCTATATCT  
ACTGGCAGTCGTAGTGCACGTAGTGCTATTGAGGATTTGC  
TATTTGACAAAGTCACTATAGCTGATCCTGGTTATATGCA  
AGGTTACGATGATTGTATGCAGCAAGGTCCAGCATCAGCT  
CGTGATCTTATTTGTGCTCAATATGTGGCTGGTTATAAAGT  
ATTACCTCCTCTTATGGATGTTAATATGGAAGCCGCGTATA  
CTTCATCTTTGCTTGGCAGCATAGCAGGTGTTGGCTGGACT  
GCTGGCTTATCCTCCTTTGCTGCTATTCCATTTGCACAGAG

TATYTTTTATAGGTTAAACGGTGTGGCATTACTCAACAG  
GTTCTTTCAGAGAACCAAAAGCTTATTGCCAATAAGTTTA  
ATCAGGCTCTGGGAGCTATGCAAACAGGCTTCACTACAAC  
TAATGAAGCTTTTCGGAAGGTTTCAGGATGCTGTGAACAAC  
AATGCACAGGCTCTATCCAAATTAGCTAGCGAGCTATCTA  
ATACTTTTGGTGTCTATTTCCGCCTCTATTGGAGACATCATA  
CAACGTCTTGATGTTCTCGAACAGGACGCCCAAATAGACA  
GACTTATTAATGGCCGTTTGACAACACTAAATGCTTTTGT  
GCACAGCAGCTTGTTTCGTTCCGAATCAGCTGCTCTTTCCGC  
TCAATTGGCTAAAGATAAAGTCAATGAGTGTGTCAAGGCA  
CAATCCAAGCGTTCTGGATTTTGCGGTCAAGGCACACATA  
TAGTGTCCTTTGTGTAAATGCCCTAATGGCCTTACTTT  
ATGCATGTTGGTTATTACCCTAGCAACCACATTGAGGTTGT  
TTCTGCTTATGGTCTTTGCGATGCAGCTAACCTACTAATT  
GTATAGCCCCTGTTAATGGCTACTTTATTAATAACTAATAAC  
ACTAGGATTGTTGATGAGTGGTCATATACTGGCTCGTCCTT  
CTATGCACCTGAGCCCATCACCTCTCTTAATACTAAGTATG  
TTGCACCACAGGTGACATACCAAAACATTTCTACTAACCT  
CCCTCCTCCTTCTCGGCAATCCACCGGGATTGACTTCC  
AAGATGAGTTGGATGAGTTTTTCAAAAATGTTAGCACCAG  
TATACCTAATTTTGGTTCTCTAACACAGATTAATACTACAT  
TACTCGATCTTACCTACGAGATGTTGTCTCTTCAACAAGTT  
GTAAAGCCCTTAATGAGTCTTACATAGACCTTAAAGAGC  
TTGGCAATTATACTTATTACAACAATGGCCGTGGTACAT  
TTGGCTTGGTTTCATTGCTGGGCTTGTTCCTTAGCTCTAT  
GCGTCTTCTTCACTGTGCTGCACTGGTTGTGGCACAAAC  
TGATGGGAAACTTAAGTGTAATCGTTGTTGTGATAGAT  
ACGAGGAATACGACCTCGAGCCGCATAAGGTTTCATGTTCA CTAA MERS S FL  
ATGATACTCAGTGTCTACTGATGTTCTTGTTAACACC 21 SPIKE  
TACAGAAAGTTACGTTGATGTAGGGCCAGATTCTGTTAAG 2cEMC/2012  
TCTGCTTGATTGAGGTTGATATAACAGACTTTCTTTGA (XbaI change  
TAAACTTGGCCTAGGCCAATTGATGTTTCTAAGGCTGAC (T to G))  
GGTATTATATACCCTCAAGGCCGTACATATTCTAACATAA (nucleotide)  
CTATCACTTATCAAGGTCTTTTTCCCTATCAGGGAGACCAT  
GGTGATATGTATGTTTACTCTGCAGGACATGCTACAGGCA  
CAACTCCACAAAAGTTGTTTGTAGCTAACTATTCTCAGGA  
CGTCAAACAGTTTGCTAATGGGTTTGTTCGTCCGTATAGGA  
GCAGCTGCCAATCCACTGGCACTGTTATTATTAGCCCATC  
TACCAGCGCTACTATACGAAAATTTACCCTGCTTTTATGC  
TGGGTTCTTCAGTTGGTAATTTCTCAGATGGTAAAATGGG  
CCGCTTCTTCAATCACTCTAGTTCTTTTGCCCGATGGAT  
GTGGCACTTTACTTAGAGCTTTTTATTGTATTCTGGAGCCT  
CGCTCTGGAAATCATTGTCCTGCTGGCAATTCCTATACTTC  
TTTTGCCACTTATCACACTCCTGCAACAGATTGTTCTGATG  
GCAATTACAATCGTAATGCCAGTCTGAACTCTTTTAAGGA  
GTATTTAATTTACGTAACTGCACCTTTATGTACACTTATA  
ACATTACCGAAGATGAGATTTTAGAGTGGTTTGGCATTAC  
ACAAACTGCTCAAGGTGTTACCTCTTCTCATCTCGGTATG  
TTGATTTGTACGGCGGCAATATGTTTCAATTTGCCACCTTG  
CCTGTTTATGATACTATTAAGTATTATTCTATCATTCTCA  
CAGTATTCGTTCTATCCAAAGTGATAGAAAAGCTTGGGCT  
GCCTTCTACGTATATAAACTTCAACCGTTAACTTTCCTGTT  
GGATTTTCTGTTGATGGTTATATACGCAGAGCTATAGACT  
GTGGTTTTAATGATTTGTCACAACCTCCACTGCTCATATGAA

TCCTTCGATGTTGAATCTGGAGTTTATTCAGTTTCGTCTTT  
CGAAGCAAACCTTCTGGCTCAGTTGTGGAACAGGCTGAA  
GGTGTGGAATGTGATTTTTACCTCTTCTGTCTGGCACACC  
TCCTCAGGTTTATAATTTCAAGCGTTTGGTTTTTACCAATT  
GCAATTATAATCTTACCAAATTGCTTTCACTTTTTTCTGTG  
AATGATTTTACTTGTAGTCAAATATCTCCAGCAGCAATTGC  
TAGCAACTGTTATTCTTCACTGATTTTGGATTACTTTTTCAT  
ACCCACTTAGTATGAAATCCGATCTCAGTGTTAGTTCTGCT  
GGTCCAATATCCCAGTTTAATTATAAACAGTCCTTTTCTAA  
TCCCACATGTTTGATTTTAGCGACTGTTCCCTCATAACCTTA  
CTACTATTAAGCCTCTTAAGTACAGCTATATTAACAA  
GTGCTCTCGTCTTCTTTCTGATGATCGTACTGAAGTACCTC  
AGTTAGTGAACGCTAATCAATACTCACCTGTGTATCCATT  
GTCCCATCCACTGTGTGGGAAGACGGTGATTATTATAGGA  
AACAACTATCTCCACTTGAAGGTGGTGGCTGGCTTGTGTC  
TAGTGGCTCAACTGTTGCCATGACTGAGCAATTACAGATG  
GGCTTTGGTATTACAGTTCAATATGGTACAGACACCAATA  
GTGTTTGCCCCAAGCTTGAATTTGCTAATGACACAAAAT  
TGCCTCTCAATTAGGCAATTGCGTGGAATATCCCTCTATG  
GTGTTTCGGGCCGTGGTGTTTTTTCAGAATTGCACAGCTGTA  
GGTGTTCGACAGCAGCGCTTTGTTTATGATGCGTACCAGA  
ATTTAGTTGGCTATTATTCTGATGATGGCAACTACTACTGT  
TTGCGTGCTTGTGTTAGTGTTCCCTGTTTCTGTCATCTATGAT  
AAAGAACTAAAACCCACGCTACTCTATTTGGTAGTGTTG  
CATGTGAACACATTTCTTCTACCATGTCTCAATACTCCCGT  
TCTACGCGATCAATGCTTAAACGGCGAGATTCTACATATG  
GCCCCCTTCAGACACCTGTTGGTTGTGTCCTAGGACTTGTT  
AATTCCTCTTTGTTTCGTAGAGGACTGCAAGTTGCCTCTTGG  
TCAATCTCTCTGTGCTCTTCCCTGACACACCTAGTACTCTCA  
CACCTCGCAGTGTGCGCTCTGTTCCAGGTGAAATGCGCTT  
GGCATCCATTGCTTTTAAATCATCCTATTCAGGTTGATCAAC  
TTAATAGTAGTTATTTTAAATTAAGTATAACCCACTAATTTT  
TCCTTTGGTGTGACTCAGGAGTACATTCAGACAACCATTC  
AGAAAGTTACTGTTGATTGTAAACAGTACGTTTGCAATGG  
TTTCCAGAAGTGTGAGCAATTACTGCGCGAGTATGGCCAG  
TTTTGTTCCAAAATAAACAGGCTCTCCATGGTGCCAATTT  
ACGCCAGGATGATTCTGTACGTAATTTGTTTGGCGAGCGTG  
AAAAGCTCTCAATCATCTCCTATCATAACAGGTTTTGGAG  
GTGACTTTAATTTGACACTTCTGGAACCTGTTTCTATATCT  
ACTGGCAGTCGTAGTGCACGTAGTGCTATTGAGGATTTGC  
TATTTGACAAAGTCACTATAGCTGATCCTGGTTATATGCA  
AGGTTACGATGATTGCATGCAGCAAGGTCCAGCATCAGCT  
CGTGATCTTATTTGTGCTCAATATGTGGCTGGTTACAAAGT  
ATTACCTCCTCTTATGGATGTTAATATGGAAGCCGCGTATA  
CTTCATCTTTGCTTGGCAGCATAGCAGGTGTTGGCTGGACT  
GCTGGCTTATCCTCCTTTGCTGCTATTCCATTTGCACAGAG  
TATCTTTTATAGGTTAAACGGTGTTGGCATTACTCAACAGG  
TTCTTTCAGAGAACCAAAGCTTATTGCCAATAAGTTTAA  
TCAGGCTCTGGGAGCTATGCAAACAGGCTTCACTACAAC  
AATGAAGCTTTTCAGAAGGTTTCAGGATGCTGTGAACAACA  
ATGCACAGGCTCTATCCAAATTAGCTAGCGAGCTATCTAA  
TACTTTTGGTGTCTATTTCCGCCTCTATTGGAGACATCATA  
AACGTCTTGATGTTCTCGAACAGGACGCCCAAATAGACAG  
ACTTATTAATGGCCGTTTGACAACACTAAATGCTTTTGTG

CACAGCAGCTTGTTCGTTCCGAATCAGCTGCTCTTTCCGCT  
CAATTGGCTAAAGATAAAGTCAATGAGTGTGTCAAGGCAC  
AATCCAAGCGTTCTGGATTTTGCGGTCAAGGCACACATAT  
AGTGTCTTTGTTGTAATGCCCTAATGGCCTTTACTTCA  
TGCATGTTGGTTATTACCCTAGCAACCACATTGAGGTTGTT  
TCTGCTTATGGTCTTTGCGATGCAGCTAACCTACTAATTG  
TATAGCCCCTGTAAATGGCTACTTTATTAATAAATAACA  
CTAGGATTGTTGATGAGTGGTCATATACTGGCTCGTCCTTC  
TATGCACCTGAGCCCATTACCTCCCTTAATACTAAGTATGT  
TGCACCACAGGTGACATACCAAAAACATTTCTACTAACCTC  
CCTCCTCCTTCTCGGCAATTCCACCGGGATTGACTTCCA  
AGATGAGTTGGATGAGTTTTTCAAAAATGTTAGCACCAGT  
ATACCTAATTTTGGTTCCCTAACACAGATTAATACTACATT  
ACTCGATCTTACCTACGAGATGTTGTCTCTTCAACAAGTTG  
TTAAAGCCCTAATGAGTCTTACATAGACCTTAAAGAGCT  
TGGCAATTATACTTATTACAACAATGGCCGTGGTACATT  
TGGCTTGGTTTCATTGCTGGGCTTGTTCCTTAGCTCTATG  
CGTCTTCTCATACTGTGCTGCACTGGTTGTGGCACAACCT  
GTATGGGAAAACCTAAGTGAATCGTTGTTGTGATAGATA  
CGAGGAATACGACCTCGAGCCGCATAAGGTTTCATGTTTAC TAA Novel\_MERS\_  
ATGATCCACTCCGTGTTCCCTCCTCATGTTCCCTGTTGACCCC 22 S2\_subunit\_  
CACTGAGTCAGACTGCAAGCTCCCGCTGGGACAGTCCCTG trimeric  
TGTGCGCTGCCTGACACTCCTAGCACTCTGACCCACGCTC vaccine  
CGTGCGGTTCGGTGCCTGGCGAAATGCGGCTGGCCTCCATC (nucleotide)  
GCCTTCAATCACCCAATCCAAGTGGATCAGCTGAATAGCT  
CGTATTTCAAGCTGTCCATCCCCACGAACTTCTCGTTCGGG  
GTCACCCAGGAGTACATCCAGACCACAATTCAGAAGGTCA  
CCGTGCGATTGCAAGCAATACGTGTGCAACGGCTTCCAGAA  
GTGCGAGCAGCTGCTGAGAGAATACGGGCAGTTTTGCAGC  
AAGATCAACCAGGCGCTGCATGGAGCTAACTTGCGCCAGG  
ACGACTCCGTGCGCAACCTCTTTGCCTCTGTGAAGTCATCC  
CAGTCCTCCCCAATCATCCCGGGATTTCGGAGGGGACTTCA  
ACCTGACCCTCCTGGAGCCCGTGTGATCAGCACCGGTAG  
CAGATCGGCGCGCTCAGCCATTGAAGATCTTCTGTTCGAC  
AAGGTCACCATCGCCGATCCGGGCTACATGCAGGGATACG  
ACGACTGTATGCAGCAGGGACCAGCCTCCGCGAGGGACCT  
CATCTGCGCGCAATACGTGGCCGGGTACAAAGTGCTGCCT  
CCTCTGATGGATGTGAACATGGAGGCCGCTTATACTTCGT  
CCCTGCTCGGCTCTATCGCCGGCGTGGGGTGGACCGCCGG  
CCTGTCCTCCTTCGCCGCTATCCCCTTTGCACAATCCATTT  
TCTACCGGCTCAACGGCGTGGGCATTACTCAACAAGTCCT  
GTCGGAGAACCAGAAGTTGATCGCAAACAAGTTCAATCA  
GGCCCTGGGGGCCATGCAGACTGGATTCCTACGACTAAC  
GAAGCGTTCCAGAAGGTCAGGACGCTGTGAACAACAAC  
GCCAGGCGCTCTCAAAGCTGGCCTCCGAACTCAGCAACA  
CCTTCGGAGCCATCAGCGCATCGATCGGTGACATAATTCA  
GCGGCTGGACGTGCTGGAGCAGGACGCCAGATCGACCG  
CCTCATCAACGGACGGCTGACCACCTTGAATGCCTTCGTG  
GCACAACAGCTGGTCCGGAGCGAATCAGCGGCACTTTCCG  
CCCAACTCGCCAAGGACAAAGTCAACGAATGCGTGAAGG  
CCCAGTCCAAGAGGTCCGGTTTCTGCGGTCAAGGAACCCA  
TATTGTGTCCTTCGTGCTGAACGCGCCCAACGGTCTGTACT  
TTATGCACGTGCGCTACTACCCGAGCAATCATATCGAAGT  
GGTGTCCGCCTACGGCCTGTGCGATGCCGCTAACCCCACT



AACTGTATTGCCCTGTGAACGGATATTTTATTAAGACCA  
ACAACACCCGCATTGTGGACGAATGGTCATACACCGGTT  
GTCCTTCTACGCGCCCGAGCCATCACTTCACTGAACACC  
AAATACGTGGCTCCGCAAGTGACCTACCAGAACATCTCCA  
CCAATTTGCCGCGCCGCTGCTCGGAAACAGCACCGGAAT

TGATTTCCAAGATGAACTGGACGAATTCTTCAAGAACGTG  
TCCACTTCCATTCCCAACTTCGGAAGCCTGACACAGATCA  
ACACCACCCTTCTCGACCTGACCTACGAGATGCTGAGCCT  
TCAACAAGTGGTCAAGGCCCTGAACGAGAGCTACATCGAC  
CTGAAGGAGCTGGGCAACTATACTACTACAACAAGTGGC  
CGGACAAGATTGAGGAGATTCTGTGCGAAAATCTACCACAT  
TGAAAACGAGATCGCCAGAATCAAGAAGCTTATCGGCGA AGCC MERS\_S0\_Full-  
ATGGAAACCCCTGCCAGCTGCTGTTCTGCTGCTGCTGTG 23 length Spike  
GCTGCCTGATACCACCGGCAGCTATGTGGACGTGGGCCCC protein  
GATAGCGTGAAGTCCGCTGTATCGAAGTGGACATCCAGC (nucleotide,  
AGACCTTTTTTCGACAAGACCTGGCCAGACCCATCGACGT codon  
GTCCAAGGCCGACGGCATCATCTATCCACAAGGCCGGACC optimized)  
TACAGCAACATCACCATTACCTACCAGGGCCTGTTCCCAT  
ATCAAGGCGACCACGGCGATATGTACGTGTACTCTGCCGG  
CCACGCCACCGGCACCACACCCAGAACTGTTTCGTGGCC  
AACTACAGCCAGGACGTGAAGCAGTTCGCCAACGGCTTCG  
TCGTGCGGATTGGCGCCGCTGCCAATAGCACCGGCACAGT  
GATCATCAGCCCCAGCACAGCGCCACCATCCGGAAGATC  
TACCCCGCCTTCATGCTGGGCAGCTCCGTGGGCAATTTCA  
GCGACGGCAAGATGGGCCGGTTCTTCAACCACACCCTGGT  
GCTGCTGCCGATGGCTGTGGCACACTGCTGAGAGCCTTC  
TACTGCATCCTGGAACCCAGAAGCGGCAACCACTGCCCTG  
CCGGCAATAGCTACACCAGCTTCGCCACCTACCACACACC  
CGCCACCGATTGCTCCGACGGCAACTACAACCGGAACGCC  
AGCCTGAACAGCTTCAAAGAGTACTTCAACCTGCGGAACT  
GCACCTTCATGTACACCTACAATATCACCGAGGACGAGAT  
CCTGGAATGGTTCGGCATCACCCAGACCGCCAGGGCGTG  
CACCTGTTACAGCAGCAGATACGTGGACCTGTACGGCGGCA  
ACATGTTCCAGTTTGCCACCCTGCCCGTGTACGACACCATC  
AAGTACTACAGCATCATCCCCACAGCATCCGGTCCATCC  
AGAGCGACAGAAAAGCCTGGGCCGCCTTCTACGTGTACAA  
GCTGCAGCCCCTGACCTTCCTGCTGGACTTCAGCGTGGAC  
GGCTACATCAGACGGGCCATCGACTGCGGCTTCAACGACC  
TGAGCCAGCTGCACTGCTCCTACGAGAGCTTCGACGTGGA  
AAGCGGCGTGTACAGCGTGTCCAGCTTCGAGGCCAAGCCT  
AGCGGCAGCGTGGTGAACAGGCTGAGGGCGTGAATGC  
GACTTCAGCCCTCTGCTGAGCGGCACCCCTCCCCAGGTGT  
ACAACCTCAAGCGGCTGGTGTTCACCAACTGCAATTACAA  
CCTGACCAAGCTGCTGAGCCTGTTCTCCGTGAACGACTTC  
ACCTGTAGCCAGATCAGCCCTGCCGCCATTGCCAGCAACT  
GCTACAGCAGCCTGATCCTGGACTACTTCAGCTACCCCT  
GAGCATGAAGTCCGATCTGAGCGTGTCCCTCCGCCGGACCC  
ATCAGCCAGTTCAACTACAAGCAGAGCTTCAGCAACCCTA  
CCTGCCTGATTCTGGCCACCGTGCCCCACAATCTGACCAC  
CATACCAAGCCCCTGAAGTACAGCTACATCAACAAGTGC  
AGCAGACTGCTGTCCGACGACCGGACCGAAGTGCCCCAGC  
TCGTGAACGCCAACCAGTACAGCCCTGCGTGTCCATCGT  
GCCAGCACCGTGTGGGAGGACGGCGACTACTACAGAAA

GCAGCTGAGCCCCCTGGAAGGCGGCGGATGGCTGGTGGCT  
TCTGGAAGCACAGTGGCCATGACCGAGCAGCTGCAGATG  
GGCTTTGGCATCACCGTGCAGTACGGCACCGACACCAACA  
GCGTGTGCCCAAGCTGGAATTCGCCAATGACACCAAGAT  
CGCCAGCCAGCTGGGAAACTGCGTGGAATACTCCCTGTAT  
GGCGTGTCCGGACGGGGCGTGTTCCAGAATTGCACAGCAG  
TGGGAGTGCGGCAGCAGAGATTCGTGTACGATGCCTACCA  
GAACCTCGTGGGCTACTACAGCGACGACGGCAATTACTAC  
TGCCTGCGGGCCTGTGTGTCCGTGCCCGTGTCCGTGATCTA  
CGACAAAGAGACAAAGACCCACGCCACACTGTTCCGGCTCC  
GTGGCCTGCGAGCACATCAGCTCCACCATGAGCCAGTACT  
CCCCTCCACCCGGTCCATGCTGAAGCGGAGAGATAGCAC  
CTACGGCCCCCTGCAGACACCTGTGGGATGTGTGCTGGGC  
CTCGTGAACAGCTCCCTGTTTGTGGAAGATTGCAAGCTGC  
CCCTGGGCCAGAGCCTGTGTGCCCTGCCAGATACCCCTAG  
CACCTGACCCCTAGAAGCGTGCCTCTGTGCCCGGCGAA  
ATGCGGCTGGCCTCTATCGCCTTCAATCACCCCATCCAGGT  
GGACCAGCTGAACTCCAGCTACTTCAAGCTGAGCATCCCC  
ACCAACTTCAGCTTCGGCGTGACCCAGGAGTACATCCAGA  
CCACAATCCAGAAAGTGACCGTGGACTGCAAGCAGTACGT  
GTGCAACGGCTTTCAGAAGTGCGAACAGCTGCTGCGCGAG  
TACGGCCAGTTCTGCAGCAAGATCAACCAGGCCCTGCACG  
GCGCCAACCTGAGACAGGATGACAGCGTGCGGAACCTGTT  
CGCCAGCGTGAAAAGCAGCCAGTCCAGCCCCATCATCCCT  
GGCTTCGGCGGCGACTTTAACCTGACCCTGCTGGAACCTG  
TGTCATCAGCACCGGCTCCAGAAGCGCCAGATCCGCCAT  
CGAGGACCTGCTGTTTCGACAAAGTGACCATTGCCGACCCC  
GGCTACATGCAGGGCTACGACGATTGCATGCAGCAGGGCC  
CAGCCAGCGCCAGGGATCTGATCTGTGCCCAGTATGTGGC  
CGGCTACAAGGTGCTGCCCCCCTGATGGACGTGAACATG  
GAAGCCGCCTACACCTCCAGCCTGCTGGGCTCTATTGCTG  
GCGTGGGATGGACAGCCGGCCTGTCTAGCTTTGCCGCCAT  
CCCTTTCGCCCAGAGCATCTTCTACCGGCTGAACGGCGTG  
GGCATCACACAACAGGTGCTGAGCGAGAACCAGAAGCTG  
ATCGCCAACAAGTTTAACCAGGCACTGGGCGCCATGCAGA  
CCGGCTTACCACCACCAACGAGGCCTTCAGAAAGGTGCA  
GGACGCCGTGAACAACAACGCCAGGCTCTGAGCAAGCT  
GGCCTCCGAGCTGAGCAATACCTTCGGCGCCATCAGCGCC  
TCCATCGGCGACATCATCCAGCGGCTGGACGTGCTGGAAC  
AGGACGCCCAGATCGACCGGCTGATCAACGGCAGACTGA  
CCACCCTGAACGCCTTCGTGGCACAGCAGCTCGTGCGGAG  
CGAATCTGCCGCTCTGTCTGCTCAGCTGGCCAAGGACAAA  
GTGAACGAGTGCGTGAAGGCCAGTCCAAGCGGAGCGGC  
TTTTGTGGCCAGGGCACCCACATCGTGTCTTCGTCTGAA  
TGCCCCCAACGGCCTGTACTTTATGCACGTGGGCTATTACC  
CCAGCAACCACATCGAGGTGGTGTCCGCCTATGGCCTGTG  
CGACGCCGCAATCCTACCAACTGTATCGCCCCCGTGAAC  
GGCTACTTCATCAAGACCAACAACACCCGGATCGTGGACG  
AGTGGTCCTACACAGGCAGCAGCTTCTACGCCCCCGAGCC  
CATCACCTCCCTGAACACCAATAACGTGGCCCCCAAGTG  
ACATACCAGAACATCTCCACCAACCTGCCCCCTCCACTGC  
TGGGAAATTCCACCGGCATCGACTTCCAGGACGAGCTGGA  
CGAGTTCTTCAAGAACGTGTCCACCTCCATCCCCAACTTCG  
GCAGCCTGACCCAGATCAACACCACTCTGCTGGACCTGAC

CTACGAGATGCTGTCCCTGCAACAGGTCGTGAAAGCCCTG  
AACGAGAGCTACATCGACCTGAAAGAGCTGGGGAACTAC  
ACCTACTACAACAAGTGGCCTTGGTACATTTGGCTGGGCT  
TTATCGCCGGCCTGGTGGCCCTGGCCCTGTGCGTGTTCTTC  
ATCCTGTGCTGCACCGGCTGCGGCACCAATTGCATGGGCA  
AGCTGAAATGCAACCGGTGCTGCGACAGATACGAGGAAT  
ACGACCTGGAACCTCACAAAGTGCATGTGCAC Betacoronavirus mRNA Sequences gb|KJ156934.1|:21  
AUGAUACACUCAGUGUUUCUACUGAUGUUCUUGUUAAC 65 405-25466 Middle  
ACCUACAGAAAGUUACGUUGAUGUAGGGCCAGAUUCUG East respiratory  
UUAAGUCUGCUUGUAUUGAGGUUGAUUAACAACAGACC syndrome  
UUCUUUGAUAAAACUUGGCCUAGGCCAAUUGAUGUUUC coronavirus  
UAAGGCUGACGGUAUUUAUUAUACCCUCAAGGCCGUACAU isolate  
AUUCUAACAUAACUAUCACUUAUCAAGGUCUUUUUCCCU Riyadh\_14\_2013,  
AUCAGGGAGACCAUGGUGAUUAUGUAUGUUUACUCUGCA spike protein  
GGACAUGCUCACAGGCACAACUCCACAAAAGUUGUUUGU (nucleotide)  
AGCUAACUAUUCUCAGGACGUCAAACAGUUUUGC UAAUG  
GGUUUGUCGUCCGUAUAGGAGCAGCUGCCAAUCCACUG  
GCACUGUUAUUUAGCCCAUCUACCAGCGCUACUAUAC  
GAAAAUUUACCCUGCUUUUAUGCUGGGUUCUUCAGUU  
GGUAAUUUCUCAGAUGGUAAAUGGGCCGCUUCUUCAA  
UCAUACUCUAGUUCUUUUGCCC GAUGGAUGUGGCACUU  
UACUUAGAGCUUUUUAUUGUAUUCUAGAGCCUCGCUCU  
GGAAUCAUUGUCCUGCUGGCAAUCCUAUACUUCUUU  
UGCCACUUAUCACACUCCUGCAACAGAUUGUUCUGAUGG  
CAAUUACAAUCGUAAUGCCAGUCUGAACUCUUUUAAGG  
AGUAUUUAAUUUACGUAAUCUGCACC UUUAUGUACACU  
UAUAACAUAUACCGAAGAUGAGAUUUUAGAGUGGUUUGG  
CAUUACACAAACUGCUCUAAGGUGUUCACCUCUUCUCAUC  
UCGGUAUGUUGAUUUGUACGGCGGCAAUAUGUUUCAAU  
UUGCCACCUUGCCUGUUUAUGAUACUAUUAAGUAUUAU  
UCUAUCAUUCUCACAGUAUUCGUUCUAUCCAAAGUGAU  
AGAAAAGCUUGGGCUGCCUUCUACGUUAUUAACUUCA  
ACCGUUAACUUCUGUUGGAUUUUUCUGUUGAUGGUU  
AUUAACGCAGAGCUAUAGACUGUGGUUUUAAUGAUUUG  
UCACAACUCCACUGCUCUAUUGAAUCCUUCGAUGUUGAA  
UCUGGAGUUUAUUCAGUUUCGUCUUUCGAAGCAAACCC  
UUCUGGCUCAGUUGUGGAACAGGCUGAAGGUGUUGAAU  
GUGAUUUUUCACCUCUUCUGUCUGGCACACCUCUCAGG  
UUUAUAAUUUCAAGCGUUUGGUUUUUACCAAUUGCAAU  
UAUAAUCUUAACCAAUUGCUUUCACUUUUUUCUGUGAA  
UGAUUUUACUUGUAGUCAAAUAUCUCCAGCAGCAAUUG  
CUAGCAACUGUUAUUCUUCACUGAUUUUGGAUUUUUU  
UCAUACCCACUUAAGUAUGAAAUCCGAUCUCAGUGUUAG  
UUCUGCUGGUCCAAUAUCCAGUUUAUUUAUAAACAGU  
CCUUUUCUAAUCCCAUGUUUGAUCUUAGCGACUGUUC  
CUCUAUACCUUACUACUAUUACUAAGCCUCUUAAGUACA  
GCUAUUAUACAAGUGCUCUCGUCUUCUUUCUGAUGAU  
CGUACUGAAGUACCUCAGUUAGUGAACGCUAAUCAUA  
CUCACCCUGUGUAUCCAUUGUCCCAUCCACUGUGUGGGA  
AGACGGUGAUUAUUUAUGGAAACAACUAUCUCCACUUG  
AAGGUGGUGGCUGGCUUGUUGCUAGUGGCUCAACUGUU  
GCCAUGACUGAGCAAUUACAGAUGGGCUUUGGUUUUAC  
AGUUCAAUAUGGUACAGACACCAAUAGUGUUUGCCCA  
AGCUUGAAUUUGC UAAUGACACAAAAAUUGCCUCUCAA

UUAGGCAAUUGCGUGGAAUUAUCCUCUAUGGUGUUUC  
GGGCCGUGGUGUUUUUCAGAAUUGCACAGCUGUAGGUG  
UUCGACAGCAGCGCUUUGUUUAUGAUGCGUACCAGAAU  
UUAGUUGGCUAUUAUUCUGAUGAUGGCAACUACUACUG  
UCUGCGUGCUUGUGUUAGUGUUCUGUUUCUGUCAUCU  
AUGAUAAAGAAACUAAAACCCACGCUACUCUAUUUGGU  
AGUGUUGCAUGUGAACACAUUUCUUCUACCAUGUCUCA  
AUACUCCCGUUCUACGCGAUCAAUGCUUAAACGGCGAGA  
UUCUACAUAUGGCCCCCUUCAGACACCGUUGGUUGUGU  
CCUAGGACUUGUUAUUCUCUUCUGUUCGUAGAGGACU  
GCAAGUUGCCUCUCGGUCAAUUCUCUCUGUGCUCUCCUG  
ACACACCUAGUACUCUCACACCUCGCAGUGUGCGCUCUG  
UGCCAGGUGAAAUGCGCUUGGCAUCCAUUGCUUUUAAU  
CAUCCCAUUCAGGUUGAUCACUAAUAGUAGUUAUUU  
UAAAUAAGUAUACCCACUAAUUUUUCCUUGGUGUGA  
CUCAGGAGUACAUUCAGACAACCAUUCAGAAAGUUACU  
GUUGAUUGUAAACAGUACGUUUGCAAUGGUUCCAGAA  
GUGUGAGCAAUACUGCGCGAGUAUGGCCAGUUUUGUU  
CCAAAUAACAGGCUCUCAUGGUGCCAAUUUACGCC  
AGGAUGAUUCUGUACGUAAUUUGUUUGCGAGCGUGAAA  
AGCUCUCAAUCAUCUCCUAUCAUACCAGGUUUUGGAGGU  
GACUUUAAUUGACACUUCUAGAACCUGUUUCUAUAC  
UACUGGCAGUCGUAGUGCACGUAGUGCUAUUGAGGAUU  
UGCUAUUUGACAAGUCACUAUAGCUGAUCCUGGUUAU  
AUGCAAGGUUACGAUGAUUGUAUGCAGCAAGGUCCAGC  
AUCAGCUCGUGAUCUUAUUUGUGCUCAAUUGUGGCUG  
GUUAUAAAGUAUUACCUCCUCUUAUGGAUGUAAUUG  
GAAGCCGCGUAUACUUCUUCUUGCUUGGCAGCAUAGCA  
GGUGUUGGCUGGACUGCUGGCCUUAUCCUCCUUGCUGCU  
AUUCCAUUUGCACAGAGUAUYUUUUUAUAGGUUAAACGG  
UGUUGGCAUUACUCAACAGGUUCUUCAGAGAACCAA  
AGCUUAUUGCCAUAAGUUUAAUCAGGCUCUGGGAGCU  
AUGCAAACAGGCUUCACUACAACUAAUGAAGCUUUUCG  
GAAGGUUCAGGAUGCUGUGAACAACAUGCACAGGCUC  
UAUCCAAAUAGCUAGCGAGCUAUCUAAUACUUUUGGU  
GCUAUUUCCGCCUCUAUUGGAGACAUCAUACAACGUCUU  
GAUGUUCUCGAACAGGACGCCCAAUAGACAGACUUAU  
UAAUGGCCGUUUGACAACACUAAAUGCUUUUGUUGCAC  
AGCAGCUUGUUCGUUCCGAAUCAGCUGCUCUUCGCGCUC  
AAUUGGCUAAAGAUAAAGUCAUUGAGUGUGUCAAGGCA  
CAAUCCAAGCGUUCUGGAUUUUGCGGUCAAGGCACACAU  
AUAGUGUCCUUGUUGUAAAUGCCCCUAAUGGCCUUUA  
CUUUUUGCAUGUUGGUUAUUACCCUAGCAACCACAUUG  
AGGUUGUUUCUGCUUAUGGUCUUUGCGAUGCAGCUAAC  
CCUACUAAUUGUAUAGCCCCUGUUAUUGGCUACUUUAU  
UAAAACUAAUAACACUAGGAUUGUUGAUGAGUGGUCAU  
AUACUGGCUCGUCCUUCUAUGCACCUGAGCCCAUCACCU  
CUCUUAUACUAAGUAUGUUGCACCACAGGUGACAUAACC  
AAAACAUUUCUACUAACCUCCCUCUCCUCUUCUCGGCA  
AUUCCACCGGGAUUGACUUCUCCAAGAUGAGUUGGAUGAG  
UUUUUCAAAAAUGUUAGCACCAGUAUACCUAAUUUUGG  
UUCUCUAAACACAGAUUAAUACUACAUAUCUGAUCUUAAC  
CUACGAGAUGUUGUCUCUUCACAAGUUGUUAAGCCC  
UUAAUGAGUCUUAUCAUAGACCUUAAAGAGCUUGGCAAU

UAUACUUAUUACAACAAAUGGCCGUGGUACAUUUGGCU  
UGGUUUCAUUGCUGGGCUUGUUGCCUAGCUCUAUGCG  
UCUUCUUCAUACUGUGCUGCACUGGUUGUGGCACAAACU  
GUAUGGGAAAACUUAAGUGUAAUCGUUGUUGUAUAGA  
UACGAGGAAUACGACCUCGAGCCGCAUAAGGUUCAUGU UCACUAA MERS S FL  
AUGAUACACUCAGUGUUUCUACUGAUGUUCUUGUUAAC 66 SPIKE  
ACCUACAGAAAGUUACGUUGAUGUAGGGCCAGAUUCUG 2cEMC/2012  
UUAAGUCUGCUUGUAUUGAGGUUGAUUAACAACAGACU (XBaI change  
UUCUUUGAUAAAACUUGGCCUAGGCCAAUUGAUGUUUC (U to G))  
UAAGGCUGACGGUAUUUAUUAACCCUCAAGGCCGUACAU (nucleotide)  
AUUCUAACAUAACUAUCACUUAUCAAGGUCUUUUUCCCU  
AUCAGGGAGACCAUGGUGUAUUGUAUGUUUACUCUGCA  
GGACAUGCACAGGCACAACUCCACAAAAGUUGUUUGU  
AGCUAACUAUUCUCAGGACGUCAAACAGUUUGCUAAUG  
GGUUUGUCGUCCGUAUAGGAGCAGCUGCCAAUCCACUG  
GCACUGUUAUUUAUAGCCCAUCUACCAGCGCUACUAUAC  
GAAAAUUUACCCUGCUUUUAUGCUGGGUUCUUCAGUU  
GGUAAUUUCUCAGAUGGUAAAUGGGCCGCUUCUCAA  
UCAUACUCUAGUUCUUUUGCCCGAUGGAUGUGGCACUU  
UACUUAGAGCUUUUUAUUGUAUUCUGGAGCCUCGCUCU  
GGAAUCAUUGUCCUGCUGGCAAUCCUAUACUUCUUU  
UGCCACUUAUCACACUCCUGCAACAGAUUGUUCUGAUGG  
CAAUUACAAUCGUAAUGCCAGUCUGAACUCUUUUAAGG  
AGUAUUUUAUUUACGUAAACUGCACCUUUAUGUACACU  
UAUAACAUAUACCGAAGAUGAGAUUUUAGAGUGGUUUGG  
CAUUAACAAACUGCUCUAAAGGUGUUCACCUCUUCUCAUC  
UCGGUAUGUUGAUUUUGUACGGCGGCAAUAUGUUCAAU  
UUGCCACCUUGCCUGUUUAUGAUACUAUUAAGUAUUUAU  
UCUAUCAUUCUCACAGUAUUCGUUCUAUCCAAAGUGAU  
AGAAAAGCUUGGGCUGCCUUCUACGUUAUUAACUUCA  
ACCGUUAACUUCCUGUUGGAUUUUUCUGUUGAUGGUU  
AUUAACGCAGAGCUAUAGACUGUGGUUUUAAUGAUUUG  
UCACAACUCCACUGCUCUAUUGAAUCCUUCGAUGUUGAA  
UCUGGAGUUUAUUCAGUUUCGUCUUUCGAAGCAAACC  
UUCUGGCUCAGUUGUGGAACAGGCUGAAGGUGUUGAAU

GUGAUUUUUCACCUCUUCUGUCUGGCACACCUCUCAGG  
UUUAUAAUUUCAAGCGUUUGGUUUUUACCAAUUGCAAU  
UAUAAUCUUACCAAUUGCUUUCACUUUUUCUGUGAA  
UGAUUUUACUUGUAGUCAAAUAUCUCCAGCAGCAAUUG  
CUAGCAACUGUUAUUCUUCACUGAUUUUUGGAUUACUUU  
UCAUACCCACUUAGUAUGAAAUCCGAUCUCAGUGUUAG  
UUCUGCUGGUCAAUAUCCAGUUUAAUUAUAAACAGU  
CCUUUUCUAAUCCACAUGUUUGAUUUUAGCGACUGUUC  
CUCUAUACCUUACUACUAUUACUAAGCCUCUUAAGUACA  
GCUAUUAUAACAAGUGCUCUCGUCUUCUUCUGAUGAU  
CGUACUGAAGUACCUCAGUUAGUGAACGCUAAUCAUA  
CUCACCCUGUGUAUCCAUUGUCCAUCCACUGUGUGGGA  
AGACGGUGAUUAUUUAUAGGAAACAACUAUCUCCACUUG  
AAGGUGGUGGCUGGCUUGUUGCUAGUGGCUCAACUGUU  
GCCAUGACUGAGCAAUUACAGAUGGGCUUUGGUUUUAU  
AGUUCAAUAUGGUACAGACACCAAUAGUGUUUGCCCA  
AGCUUGAAUUUGCUAAUGACACAAAAAUUGCCUCUCAA  
UUAGGCAAUUGCGUGGAAUAUCCCUUCUAUGGUGUUUC

GGGCCGUGGUGUUUUUCAGAAUUGCACAGCUGUAGGUG  
UUCGACAGCAGCGCUUUGUUUAUGAUGCGUACCAGAAU  
UUAGUUGGCUAUUAUUCUGAUGAUGGCAACUACUACUG  
UUUGCGUGCUUGUGUUAGUGUUCUGUUUCUGUCAUCU  
AUGAUAAAGAAACUAAAACCCACGCUACUCUAAUUGGU  
AGUGUUGCAUGUGAACACAUUUCUUCUACCAUGUCUCA  
AUACUCCCCGUUCUACGCGAUCAAUGCUUAAACGGCGAGA  
UUCUACAUAUGGCCCCCUUCAGACACCUGUUGGUUGUGU  
CCUAGGACUUGUAAAUUCCUCUUGUUCGUAGAGGACU  
GCAAGUUGCCUCUUGGUCAAUCUCUCUGUGCUCUCCUG  
ACACACCUAGUACUCUCACACCUCGCGAGUGUGCGCUCUG  
UUCAGGUGAAAUGCGCUUGGCAUCCAUUGCUUUUAAU  
CAUCCUAUUCAGGUUGAUAACUAAUAGUAGUUAUUU  
UAAAUAAGUAUACCCACUAAUUUUUCCUUUGGUGUGA  
CUCAGGAGUACAUUCAGACAACCAUUCAGAAAGUUACU  
GUUGAUUGUAAACAGUACGUUUGCAAUGGUUUCAGAA  
GUGUGAGCAAUACUGCGCGAGUAUGGCCAGUUUUGU  
CCAAAUAACAGGCUCCUUGGUGCCAAUUUACGCC  
AGGAUGAUUCUGUACGUAAUUUGUUUGCGAGCGUGAAA  
AGCUCUCAAUCAUCUCCUAUCAUACCAGGUUUUGGAGGU  
GACUUUAAUUUGACACUUCUGGAACCUGUUUCUAUAUC  
UACUGGCAGUCGUAGUGCACGUAGUGCUAUUGAGGAUU  
UGCUAUUUGACAAAGUCACUAUAGCUGAUCCUGGUUAU  
AUGCAAGGUUACGAUGAUUGCAUGCAGCAAGGUCCAGC  
AUCAGCUCGUGAUCUUAUUUGUGCUCAAUUGUGGCUG  
GUUACAAAGUAUUACCUCUCUUAUGGAUGUAAUUG  
GAAGCCGCGUAUACUUCUUCUUGCUUGGCAGCAUAGCA  
GGUGUUGGCUGGACUGCUGGCCUUAUCCUCCUUGCUGCU  
AUUCCAUUUGCACAGAGUAUCUUUUUAUAGGUUAAACGG  
UGUUGGCAUUACUCAACAGGUUCUUUCAGAGAACCAA  
AGCUUAUUGCCAUAAGUUUAAUCAGGCUCUGGGAGCU  
AUGCAAACAGGCUUCACUACAACUAAUGAAGCUUUUCA  
GAAGGUUCAGGAUGCUGUGAACAACAUGCACAGGCUC  
UAUCCAAAUAGCUAGCGAGCUAUCUAAUACUUUUGGU  
GCUAUUUCGCCUCUAUUGGAGACAUCAUACAACGUCUU  
GAUGUUCUCGAACAGGACGCCCAAUAGACAGACUUUAU  
UAAUGGCCGDUUGACAACACUAAAUGCUUUUGUUGCAC  
AGCAGCUUGUUCGUUCCGAAUCAGCUGCUCUUUCCGCUC  
AAUUGGCUAAAGAUAAAGUCAUAGAGUGUGUCAAGGCA  
CAAUCCAAGCGUUCUGGAUUUUGCGGUCAAGGCACACAU  
AUAGUGUCCUUGUUGUAAAUGCCCCUAAUGGCCUUUA  
CUUCAUGCAUGUUGGUUAUUACCCUAGCAACCACAUUGA  
GGUUGUUUCUGCUUAUGGUCUUUGCGAUGCAGCUAACC  
CUACUAAUUGUAUAGCCCCUGUUAAUGGCUACUUUAUU  
AAAACUAAUAACACUAGGAUUGUUGAUGAGUGGUCAUA  
UACUGGCUCGUCCUUCU AUGCACCUGAGCCCAUUACCUC  
CCUAAUACUAAGUAUGUUGCACCACAGGUGACAUACCA  
AAACAUUUCUACUAACCUCUCCUCCUCUUCUCGGCAA  
UUCACCGGGAUUGACUCCAAGAUGAGUUGGAUGAGU  
UUUUCAAAAUGUUAGCACCAGUAUACCUAAUUUUGGU  
UCCCUAACACAGAUAAUACUACAUAUCUGAUCUUACC  
UACGAGAUGUUGUCUCUUAACAAGUUGUUAAAGCCCU  
UAAUGAGUCUUAUAUAGACCUUAAAGAGCUUGGCAAUU  
AUACUUAUUACAACAAAUGGCCGUGGUACAUUUGGCUU

GGUUUCAUUGCUGGGCUUGUUGCCUAGCUCUAUGCGU  
CUUCUUCAUACUGUGCUGCACUGGUUGUGGCACAAACUG  
UAUGGGAAAACUUAAGUGUAAUCGUUGUUGUGAUAGAU  
ACGAGGAAUACGACCUCGAGCCGCAUAAGGUUCAUGUUC ACUAA Novel\_MERS\_S2\_  
AUGAUCCACUCCGUGUUCUCCUCAUGUUCUGUUGACC 67 subunit\_trimeric  
CCCACUGAGUCAGACUGCAAGCUCGCCUGGGACAGUCC vaccine  
CUGUGUGCGCUGCCUGACACUCCUAGCACUCUGACCCCA (nucleotide)  
CGCUCGUGCGGUCGGUGCCUGGGCAAUUGCGGCUGGCC  
UCCAUCGCCUCAAUCACCCAAUCCAAGUGGAUCAGCUG  
AAUAGCUCGUUUUCAAGCUGUCCAUCCCCACGAACUUC  
UCGUUCGGGGUCACCCAGGAGUACAUCCAGACCACAAU  
CAGAAGGUCACCGUCGAUUGCAAGCAAUACGUGUGCAAC  
GGCUUCCAGAAGUGCGAGCAGCUGCUGAGAGAAUACGG  
GCAGUUUUGCAGCAAGAUAACCAGGGCGCUGCAUGGAGC  
UAACUUGCGCCAGGACGACUCCGUGCGCAACCUCUUUGC  
CUCUGUGAAGUCAUCCAGUCCUCCCCAAUCAUCCCGGG  
AUUCGGAGGGGACUUAACCUGACCCUCCUGGAGCCCGU  
GUCGAUCAGCACCGGUAGCAGAUCGGCGCGCUCAGCCAU  
UGAAGAUCUUCUGUUCGACAAGGUCACCAUCGCCGAUCC  
GGGCUACAUGCAGGGAUACGACGACUGUAUGCAGCAGG  
GACCAGCCUCCGCGAGGGACCUCAUCUGCGCGCAAUACG  
UGGCCGGGUACAAAGUGCUGCCUCCUCUGAUGGAUGUG  
AACAUUGGAGGCCGCUUAUACUUCGUCCUUGCUCGGCUCU  
AUCGCCGGCGUGGGGUGGACCGCCGGCCUGUCCUCCUUC  
GCCGCUAUCCCCUUGCACAUAUCAUUUUCUACCGGCUC  
AACGGCGUGGGCAUUAUCAACAAGUCCUGUCGGAGAAC  
CAGAAGUUGAUCGCAAACAAGUUCAAUCAGGCCUUGGG  
GGCCAUGCAGACUGGAUUCACUACGACUAACGAAGCGUU  
CCAGAAGGUCCAGGACGCUGUGAACAACAACGCCAGGC  
GCUCUCAAAAGCUGGCCUCCGAACUCAGCAACACCUUCGG  
AGCCAUCAGCGCAUCGAUCGGUGACAUAUUUCAGCGGCU  
GGACGUGCUGGAGCAGGACGCCCAGAUCCGACCGCCUCAU  
CAACGGACGGCUGACCACCUUGAAUGCCUUCGUGGCACA  
ACAGCUGGUCCGGAGCGAAUCAGCGGCACUUUCCGCCCA  
ACUCGCCAAGGACAAAGUCAACGAAUGCGUGAAGGCCCA  
GUCCAAGAGGUCCGGUUUCUGCGGUCAAGGAACCCAUAU  
UGUGUCCUUCGUCGUGAACGCGCCCAACGGUCUGUACUU  
UAUGCACGUCGGCUACUACCCGAGCAAUCAUAUCGAAGU  
GGUGUCCGCCUACGGCCUGUGCGAUGCCGCUAACCCAC  
UAACUGUAUUGCCCCUGUGAACGGAUUUUUUAUUAAGA  
CCAACAACACCCGCAUUGUGGACGAAUGGUCAUACACCG  
GUUCGUCCUUCUACGCGCCCGAGCCCAUCACUUCACUGA  
ACACCAAUACGUGGCUCGCAAGUGACCUACCAGAACA  
UCUCCACCAAUUUGCCGCCCGCCGUCGUCGAAACAGCA  
CCGGAUUUGAUUUCCAAGAUGAACUGGACGAAUUCUUC  
AAGAACGUGUCCACUCCAUUCCCAACUUCGGAAGCCUG  
ACACAGAUCAACACCACCCUUCUCGACCUGACCUACGAG  
AUGCUGAGCCUUAACAAGUGGUCAAGGCCUUGAACGAG  
AGCUACAUCGACCUGAAGGAGCUGGGCAACUAUACCUAC  
UACAACAAGUGGCCGGACAAGAUUGAGGAGAUUCUGUC  
GAAAUCUACCACAUUGAAAACGAGAUCGCCAGAAUCA AGAAGCUUAUCGGCGAAGCC  
MERS\_S0\_Full- AUGGAAACCCUGCCCAGCUGCUGUUCUGCUGCUGCUG 68 length Spike  
UGGCUGCCUGAUACCACCGGCAGCUAUGUGGACGUGGGC protein  
CCCGAUAGCGUGAAGUCCGCCUGUAUCGAAGUGGACAUC (nucleotide, codon)

CAGCAGACCUUUUUCGACAAGACCUGGCCAGACCCAUC optimized)  
GACGUGUCCAAGGCCGACGGCAUCAUCAUCCACAAGGC  
CGGACCUACAGCAACAUCACCAUACCACCAGGGCCUG  
UCCCAUAUCAAGGCGACCACGGCGAUUAGUACGUGUAC  
UCUGCCGGCCACGCCACCGGCACCACACCCAGAAACUG  
UUCGUGGCCAACUACAGCCAGGACGUGAAGCAGUUCGCC  
AACGGCUUCGUCGUGCGGAUUGGCGCCGCUGCCAAUAGC  
ACCGGCACAGUGAUCAUCAGCCCCAGCACCAGCGCCACC  
AUCCGGAAGAUCUACCCCGCCUUCAUGCUGGGCAGCUCC  
GUGGGCAAUUUCAGCGACGGCAAGAUGGGCCGGUUCUU  
CAACCACACCCUGGUGCUGCUGCCCGAUUGGCUGUGGCAC  
ACUGCUGAGAGCCUUCUACUGCAUCCUGGAACCCAGAAG  
CGGCAACCACUGCCCGCCGCAUAGCUACACCAGCUU  
CGCCACCUACCACACACCCGCCACCGAUUGCUCGACGG  
CAACUACAACCGGAACGCCAGCCUGAACAGCUUCAAGA  
GUACUUCAACCUGCGGAACUGCACCUUCAUGUACACCUA  
CAAUAUCACCGAGGACGAGAUCCUGGAAUGGUUCGGCA  
UCACCAGACCGCCAGGGCGUGCACCUGUUCAGCAGCA  
GAUACGUGGACCUGUACGGCGGCAACAUGUUCAGUUU  
GCCACCCUGCCCGUGUACGACACCAUCAAGUACUACAGC  
AUCAUCCCCACAGCAUCCGGUCCAUCAGAGCGACAGA  
AAAGCCUGGGCCGCCUUCUACGUGUACAAGCUGCAGCCC  
CUGACCUUCCUGCUGGACUUCAGCGUGGACGGCUACAUC  
AGACGGGCCAUCGACUGCGGCUUCAACGACCUGAGCCAG  
CUGCACUGCUCCUACGAGAGCUUCGACGUGGAAAGCGGC  
GUGUACAGCGUGUCCAGCUUCGAGGCCAAGCCUAGCGGC  
AGCGUGGUGGAACAGGCUGAGGGCGUGGAAUGCGACUU  
CAGCCCUCUGCUGAGCGGCACCCCUCCCCAGGUGUACAA  
CUUCAAGCGGCUGGUGUACCAACUGCAAUACAACCU  
GACCAAGCUGCUGAGCCUGUUCUCCGUGAACGACUUCAC  
CUGUAGCCAGAUACAGCCCUGCCGCCAUUGCCAGCAACUG  
CUACAGCAGCCUGAUCCUGGACUACUUCAGCUACCCCCU  
GAGCAUGAAGUCCGAUCUGAGCGUGUCCUCCGCCGGACC  
CAUCAGCCAGUUAACUACAAGCAGAGCUUCAGCAACCC  
UACCUGCCUGAUUCUGGCCACCGUGCCCCACAUCUGAC  
CACCAUCACCAAGCCCCUGAAGUACAGCUACAUCAACAA  
GUGCAGCAGACUGCUGUCCGACGACCGGACCGAAGUGCC  
CCAGCUCGUGAACGCCAACCAGUACAGCCCCUGCGUGUC  
CAUCGUGCCAGCACCGUGUGGGAGGACGGCGACUACUA  
CAGAAAGCAGCUGAGCCCCUGGAAGGCGGGCGGAUGGCU  
GGUGGCUUCUGGAAGCACAGUGGCAUGACCGAGCAGCU  
GCAGAUGGGCUUUGGCAUCACCGUGCAGUACGGCACCGA  
CACCAACAGCGUGUGCCCCAAGCUGGAAUUCGCCAAUGA  
CACCAAGAUCGCCAGCCAGCUGGGAAACUGCGUGGAAUA  
CUCCCUGUAUGGCGUGUCCGGACGGGGCGUGUCCAGAA  
UUGCACAGCAGUGGGAGUGCGGCAGCAGAGAUUCGUGU  
ACGAUGCCUACCAGAACCUCGUGGGCUACUACAGCGACG  
ACGGCAAUUAACUACUGCCUGCGGGCCUGUGUGUCCGUGC  
CCGUGUCCGUGAUCUACGACAAAGAGACAAAGACCCACG  
CCACACUGUUCGGCUCCGUGGGCCUGCGAGCACAUACAGCU  
CCACCAUGAGCCAGUACUCCCGCUCCACCCGGUCCAUGC  
UGAAGCGGAGAGAUAGCACCUACGGCCCCUGCAGACAC  
CUGUGGGAUUGUGUGCUGGGCCUCGUGAACAGCUCCUGU  
UUGUGGAAGAUUGCAAGCUGCCCCUGGGCCAGAGCCUGU



GUGCCCUGCCAGAUACCCCUAGCACCCUGACCCCUAGAA  
GCGUGGCGCUCUGUGCCCGGCGAAAUGCGGCUGGCCUCUA  
UCGCCUUCAAUCACCCCAUCCAGGUGGACCAGCUGAACU  
CCAGCUACUUCAAGCUGAGCAUCCCCACCAACUUCAGCU  
UCGGCGUGACCCAGGAGUACAUCCAGACCACAAUCCAGA  
AAGUGACCGUGGACUGCAAGCAGUACGUGUGCAACGGC  
UUUCAGAAGUGCGAACAGCUGCUGCGCGAGUACGGCCAG  
UUCUGCAGCAAGAUAACCAGGCCUGCACGGCGCCAAC  
CUGAGACAGGAUGACAGCGUGCGGAACCUUUCGCCAGC  
GUGAAAAGCAGCCAGUCCAGCCCCAUCAUCCCUGGCUUC  
GGCGGCGACUUUAACCUGACCCUGCUGGAACCUGUGUCC  
AUCAGCACCGGCUCCAGAAGCGCCAGAUCCGCCAUCGAG  
GACCUGCUGUUCGACAAAGUGACCAUUGCCGACCCCGGC  
UACAUGCAGGGCUACGACGAUUGCAUGCAGCAGGGCCCA  
GCCAGCGCCAGGGAUCUGAUCUGUGCCCAGUAUGUGGCC  
GGCUACAAGGUGCUGCCCCCCCUGAUGGACGUGAACAU  
GAAGCCGCCUACACCUCCAGCCUGCUGGGCUCUAUUGCU  
GGCGUGGGGAUGGACAGCCGGCCUGUCUAGCUUUGCCGCC  
AUCCCUUUCGCCAGAGCAUCUUCUACCGGCUGAACGGC  
GUGGGCAUCACACAACAGGUGCUGAGCGAGAACCAGAA  
GCUGAUCGCCAACAAAGUUUAACCAGGCACUGGGCGCCA  
GCAGACCGGCUUCACCACCACCAACGAGGCCUUCAGAAA  
GGUGCAGGACGCCGUGAACAAACGCCCAGGCUCUGAG  
CAAGCUGGCCUCCGAGCUGAGCAAUACCUUCGGCGCCA  
CAGCGCCUCCAUCGGCGACAUCAUCCAGCGGCUGGACGU  
GCUGGAACAGGACGCCAGAUCCGACCGGCUGAUCAACGG  
CAGACUGACCACCCUGAACGCCUUCGUGGCACAGCAGCU  
CGUGCGGAGCGAAUCUGCCGCUCUGUCUGCUCAGCUGGC  
CAAGGACAAAGUGAACGAGUGCGUGAAGGCCAGUCCA  
AGCGGAGCGGCUUUUGUGGGCCAGGGCACCCACAUCGUGU  
CCUUCGUCGUGAAUGCCCCAACGGCCUGUACUUUAUGC  
ACGUGGGCUAUUACCCAGCAACCACAUCGAGGUGGUGU  
CCGCCUAUGGCCUGUGCGACGCCGCCAAUCCUACCAACU  
GUAUCGCCCCCGUGAACGGCUACUUCAUCAAGACCAACA  
ACACCCGGAUCGUGGACGAGUGGUCCUACACAGGCAGCA  
GCUUCUACGCCCCCGAGCCAUCACCUCCUGAACACCA  
AAUACGUGGGCCCCCAAGUGACAUAACAGAACAUCCUCCA  
CCAACCUGCCCCUCCACUGCUGGGGAAAUCCACCGGCA  
UCGACUUCAGGACGAGCUGGACGAGUUCUUAAGAACG  
UGUCCACCUCCAUCCCCAACUUCGGCAGCCUGACCCAGA  
UCAACACCACUCUGCUGGACCUGACCUACGAGAUGCUGU  
CCCUGCAACAGGUCGUGAAAGCCUGAACGAGAGCUACA  
UCGACCUGAAAGAGCUGGGGAACUACACCUACUACAACA  
AGUGGCCUUGGUACAUAUUGGCUGGGCUUUAUCGCCGGCC  
UGGUGGGCCUGGCCCUGUGCGUGUUCUUAUCCUGUGCU  
GCACCGGCUGCGGCACCAAUUGCAUUGGGCAAGCUGAAAU  
GCAACCGGUGCUGCGACAGAUACGAGGAAUACGACCUGG AACCUCACAAAGUGCAUGUGCAC

TABLE-US-00012 TABLE 11 Betacoronavirus Amino Acid Sequences SEQ ID Strain Amino Acid Sequence  
NO: gb|KJ156934.1|:21 MIHSVFLLMFLLTPTESYVDVGPDSVKSACIEVDIQQTFDDKT 24 405-25466  
Middle WPRPIDVSKADGIIYPQGRITYSNITITYQGLFPYQGDHGDY East respiratory  
VYSAGHATGTTpQKLFVANYSQDVKQFANGFVVRIGAAANS syndrome  
TGTVIIISPSTSATIRKIYPFMLGSSVGNFSDGKMGRFFNHTL coronavirus  
VLLPDGCGTLLRAFYCILEPRSGNHCPAGNSYTSFATYHTPA isolate

TDCSDGNYNRNASLNSFKEYFNLRNCTFMYTYNITEDEILEW Riyadh\_14\_2013,  
FGITQTAQGVHLFSSRYVDLYGGNMFQFATLPVYDTIKYYSSII spike protein  
PHSIRSIQSDRKAWAAFYVYKQLQPLTFLLDIFSVDGYIRRAIDC (amino acid)  
GFNDLSQLHCSYESFDVESGVVSVSSFEAKPSGSVVEQAEGV  
ECDFSPLLSGTPPQVYNFKRLVFTNCNYNLTKLLSLFSVNDFT  
CSQISPAAIASNCYSSLILDYFSYPLSMKSDLSVSSAGPISQFN  
YKQSFSNPTCLILATVPHNLTTITKPLKYSYINKCSRLSDDRT  
EVPQLVNNANQYSPCVSIVPSTVWEDGDYRQKQLSPLEGGGW  
LVASGSTVAMTEQLQMGFGITVQYGTDTNSVCPKLEFANDT  
KIASQLGNCVEYSLYGVSGRGVFQNCTAVGVRQQRFFVYDA  
YQNLVGYYSDDGNYYCLRACVSVVSVIYDKETKTHATLFG  
SVACEHISSTMSQYSRSTRSMLKRRDSTYGPLQTPVGCVLGL  
VNSSLFVEDCKLPLGQSLCALPDPSTLTPRSVRSVPGEMRLA  
SIAFNHPIQVDQLNSSYFKLSIPTNFSFGVTQEYIQTTIQKVTV  
DCKQYVCNGFQKCEQLLREYGQFCSKINqALHGANLRQDDS  
VRNLFASVKSSQSSPIIPGFGGDFNLTLEPVSISTGSRARSASAI  
EDLLFDKVTIADPGYMQGYDDCMQQGPASARDLICAQYVA  
GYKVLPLMDVNMEAAYTSSLLGSIAGVGWTAGLSSFAAIPF  
AQSFYRLNGVGITQQVLSNQKLIANKFNQALGAMQTGFTT  
TNEAFrKVQDAVNNNAQALSCLASELSNTFGAISASIGDIIQR  
LDVLEQDAQIDRLINGRLTTLNAFVAQQLVRSESAALSAQLA  
KDKVNECVKAQSKRSGFCGQGTHIVSFVFNAPNGLYFMHV  
GYPSNHIEVVSAYGLCDAANPTNCIAPVNGYFIKTNNTRIV  
DEWSYTGSSFYAPEPITSLNTKYVAPQVTYQNISTNLPPPLLG  
NSTGIDFQDELDEFFKNVSTSIPTNFGSLTQINTTLLDLTYEMLS  
LQQVVKALNESYIDLKELGNYTYYNKWPWYIWLGFIAGLVA  
LALCVFFILCCTGCGTNCMGKLCNRCCDRYEEYDLEPHKV HVH MERS S FL  
MIHSVFLLMFLLTPTESYVDVGPDSVKSACIEVDIQQTFDFKT 25 SPIKE  
WPRPIDVSKADGIYPQGRYSNITITYQGLFPYQGDHGDYMY 2cEMC/2012  
VYSAGHATGTPQKLFVANYSQDVKQFANGFVVRIGAAANS (XBaI change  
TGTVIISPSTSATIRKIYPAFMLGSSVGNFSDGKMGRFFNHTL (T to G))  
VLLPDGCGTLLRAFYCILEPRSGNHCPAGNSYTSFATYHTPA (amino acid)  
TDCSDGNYNRNASLNSFKEYFNLRNCTFMYTYNITEDEILEW  
FGITQTAQGVHLFSSRYVDLYGGNMFQFATLPVYDTIKYYSSII  
PHSIRSIQSDRKAWAAFYVYKQLQPLTFLLDIFSVDGYIRRAIDC  
GFNDLSQLHCSYESFDVESGVVSVSSFEAKPSGSVVEQAEGV  
ECDFSPLLSGTPPQVYNFKRLVFTNCNYNLTKLLSLFSVNDFT  
CSQISPAAIASNCYSSLILDYFSYPLSMKSDLSVSSAGPISQFN  
YKQSFSNPTCLILATVPHNLTTITKPLKYSYINKCSRLSDDRT  
EVPQLVNNANQYSPCVSIVPSTVWEDGDYRQKQLSPLEGGGW  
LVASGSTVAMTEQLQMGFGITVQYGTDTNSVCPKLEFANDT  
KIASQLGNCVEYSLYGVSGRGVFQNCTAVGVRQQRFFVYDA  
YQNLVGYYSDDGNYYCLRACVSVVSVIYDKETKTHATLFG  
SVACEHISSTMSQYSRSTRSMLKRRDSTYGPLQTPVGCVLGL  
VNSSLFVEDCKLPLGQSLCALPDPSTLTPRSVRSVPGEMRLA  
SIAFNHPIQVDQLNSSYFKLSIPTNFSFGVTQEYIQTTIQKVTV  
DCKQYVCNGFQKCEQLLREYGQFCSKINQALHGANLRQDDS  
VRNLFASVKSSQSSPIIPGFGGDFNLTLEPVSISTGSRARSASAI  
EDLLFDKVTIADPGYMQGYDDCMQQGPASARDLICAQYVA  
GYKVLPLMDVNMEAAYTSSLLGSIAGVGWTAGLSSFAAIPF  
AQSFYRLNGVGITQQVLSNQKLIANKFNQALGAMQTGFTT  
TNEAFQKVQDAVNNNAQALSCLASELSNTFGAISASIGDIIQR  
LDVLEQDAQIDRLINGRLTTLNAFVAQQLVRSESAALSAQLA  
KDKVNECVKAQSKRSGFCGQGTHIVSFVFNAPNGLYFMHV

GYYP SNHIEVVSAYGLCDAANPTNCIAPVNGYFIKTNTRIV  
DEWSYTGSSFYAPEPITSLNTKYVAPQV TYQNISTNLPPLLG  
NSTGIDFQDELDEFFKNVST SIPNFGSLTQINTTLLDLTYEMLS  
LQQVVKALNESYIDLKELGNYTYYNKWPWYIWLGFIAGLVA  
LALCVFFILCCTGCGTNCMGKLCNRCCDRYEEYDLEPHKV HVH Novel\_MERS\_S2\_  
MIHSVFLLMFLLTPTESDCKLPLGQSLCALPDTPTSTLTPRSVR 26 subunit\_trimeric  
SVPGEMRLASIAFNHPIQVDQLNSSYFKLSIPTNFSFGVTQEYI vaccine (amino  
QTTIQKVTVDCKQYVCNGFQKCEQLLREYGQFCSKINQALH acid)  
GANLRQDDSVRNLFASVKSSQSSPIIPGFGGDFNLTLLLEPVSIS  
TGRSARSASIEDLLFDKVTIADPGYMQGYDDCMQQGPASAR  
DLICAQYVAGYKVLPLMDVNMEAAAYTSSLLGSIAGVGWTA  
GLSSFAAIPFAQSIFYRLNGVGITQQVLS ENQKLIANKFNQAL  
GAMQTGFTTTNEAFQKVQDAVN NNAQALSKLASELSNTFG  
AISASIGDIIQRLDVLEQDAQIDRLINGRLTTLNAFVAQQLVRS  
ESAALSAQLAKDKVNECVKAQSKRSGFCGQGTHIVSFVVNA  
PNGLYFMHVGYYPSNHIEVVSAYGLCDAANPTNCIAPVNGY  
FIKTNTRIVDEWSYTGSSFYAPEPITSLNTKYVAPQV TYQNI  
STNLPPLLGNSTGIDFQDELDEFFKNVST SIPNFGSLTQINTTLL  
DLTYEMLSLQQVVKALNESYIDLKELGNYTYYNKWPDKIE EILSKIYHIENEIARIKKLIGEA Isolate  
A1- MIHSVFLLMFLLTPTESYVDVGPDSVKSACIEVDIQQTFFDKT 27 Hasa\_1\_2013  
WPRPIDVSKADGHIYPQGR TYSNITITYQGLFPYQGDHGD MY (NCBI accession  
VYSAGHATGTPQKLFVANYSQDVKQFANGFVVRIGAAANS #AGN70962)  
TGTVIISPSTSATIRKIYPAFMLGSSVGNFSDGKMGRFFNHTL  
VLLPDGCGTLLRAFYCILEPRSGNHCPAGNSYTSFATYHTPA  
TDCSDGNYNRNASLNSFKEYFNLRNCTFMYTYNITEDEILEW  
FGITQTAQGVHLFSSRYVDLYGGNMFQFATLPVYDTIKYYSII  
PHSRSIQSDRKAWAAFYVYK LQPLTFLDFSVDGYIRRAIDC  
GFNDLSQLHCSYESFDVESGVYSVSSFEAKPSGSVVEQAEGV  
ECDFSPLLSGTPPQVYNFKRLVFTNCNYNLTKLLSLFSVNDFT  
CSQISPAAIASNCYSSLILDYFSYPLSMKSDLSVSSAGPISQFN  
YKQSFSNPTCLILATVPHNLTTITKPLKYSYINKCSRLSDDRT  
EVPQLVNANQYSPCVSIVPSTVWEDGDY YRKQLSPLEGGGW  
LVASGSTVAMTEQLQMFGITVQYGTDTNSVCPKLEFANDT  
KIASQLGNCVEYSLYGVSGRGVFQNTAVGVRQQR FVYDA  
YQNLVGYYSDDGNYYCLRACVSVPVSVIYDKETKTHATLFG  
SVACEHISSTMSQYSRSTRSMLKRRDSTYGPLQTPVGCVLGL  
VNSSLFVEDCKLPLGQSLCALPDTPTSTLTPRSVRSVPGEMRLA  
SIAFNHPIQVDQLNSSYFKLSIPTNFSFGVTQEYIQTTIQKVTV  
DCKQYVCNGFQKCEQLLREYGQFCSKINQALHGANLRQDDSV  
VRNLFASVKSSQSSPIIPGFGGDFNLTLLLEPVSISTGRSARSAS  
IEDLLFDKVTIADPGYMQGYDDCMQQGPASARDLICAQYVA  
GYKVLPLMDVNMEAAAYTSSLLGSIAGVGWTAGLSSFAAIPF  
AQSFYRLNGVGITQQVLS ENQKLIANKFNQALGAMQTGFTT  
TNEAFRKVQDAVN NNAQALSKLASELSNTFGAISASIGDIIQR  
LDVLEQDAQIDRLINGRLTTLNAFVAQQLVRS ESAALSAQLA  
KDKVNECVKAQSKRSGFCGQGTHIVSFVVNA PNGLYFMHV  
GYYP SNHIEVVSAYGLCDAANPTNCIAPVNGYFIKTNTRIV  
DEWSYTGSSFYAPEPITSLNTKYVAPHV TYQNISTNLPPLLG  
NSTGIDFQDELDEFFKNVST SIPNFGSLTQINTTLLDLTYEMLS  
LQQVVKALNESYIDLKELGNYTYYNKWPWYIWLGFIAGLVA  
LALCVFFILCCTGCGTNCMGKLCNRCCDRYEEYDLEPHKV HVH Middle East  
MIHSVFLLMFLLTPTESYVDVGPDSVKSACIEVDIQQTFFDKT 28 respiratory  
WPRPIDVSKADGHIYPQGR TYSNITITYQGLFPYQGDHGD MY syndrome  
VYSAGHATGTPQKLFVANYSQDVKQFANGFVVRIGAAANS coronavirus S

TGTVIISPSTSATIRKIYPAFMLGSSVGNFSDGKMGRFFNHTL protein  
VLLPDGCGTLLRAFYCILEPRSGNHCPAGNSYTSFATYHTPA UniProtKB-  
TDCSDGNYNRNASLNSFKEYFNLRNCTFMYYTNYTEDEILEW R9UQ53  
FGITQTAQGVHLFSSRYVDLYGGNMFQFATLPVYDTIKYYSII  
PHSIRSIQSDRKAWAAFYVYKLOPLTFLLDVSDGYIRRAIDC  
GFNDLSQLHCSYESFDVESGVYSVSSFEAKPSGSVVEQAEGV  
ECDFSPLLSGTPPQVYNFKRLVFTNCNYNLTKLLSLFSVNDFT  
CSQISPAAIASNCYSSLILDYFSYPLSMKSDLVSSAGPISQFN  
YKQSFNPTCLILATVPHNLTTITKPLKYSYINKCSRLLSDDRT  
EVPQLVNANQYSPCVSIVPSTVWEDGDYRQKQLSPLEGGGW  
LVASGSTVAMTEQLQMGFGITVQYGTDTNSVCPKLEFANDT  
KIASQLGNCVEYSLYGVSGRGVFNCTAVGVRQQRFFVYDA  
YQNLVGYYSDDGNYCLRACVSVPSVIYDKETKTHATLFG  
SVACEHISSTMSQYSRSTRMLKRRDSTYGPLQTPVGCVLGL  
VNSSLFVEDCKLPLGQSLCALPDTPTLTPRSVRSVPGEMRLA  
SIAFNHPIQVDQLNSSYFKLSIPTNFSFGVTQEYIQTTIQKVTV  
DCKQYVCNGFQKCEQLLREYGFQFCSKINQALHGANLRQDDS  
VRNLFASVKSSQSSPIPGFGGDFNLTLEPVSISTGSRARSASAI  
EDLLFDKVTIADPGYMQGYDDCMQQGPASARDLICAQYVA  
GYKVLPLMDVNMEAAYTSSLLGSIAGVGWTAGLSSFAAIPF  
AQSIFYRLNGVGITQQVLSNQKLIANKFNQALGAMQTGFTT  
TNEAFRKVQDAVNNAQALSKLASELSNTFGAISASIGDIIQR  
LDVLEQDAQIDRLINGRLTTLNAFVAQQLVRSESAALSAQLA  
KDKVNECVKAQSKRSGFCGQGTHIVSFVFNAPNGLYFMHV  
GYPSNHIEVVSAYGLCDAANPTNCIAPVNGYFIKTNTRIV  
DEWSYTGSSFYAPEPITSLNTKYVAPHVTYQNISTNLPPPLG  
NSTGIDFQDELDEFFKNVSTSI PNFGSLTQINTTLLDLTYEMLS  
LQQVVKALNESYIDLKELGNYTYYNKWPWYIWLGFIAGLVA  
LALCVFFILCCTGCGTNCMGKLCNRCCDRYEEYDLEPHKV HVH Human **SARS**  
MFIFLLFLTSTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYY 29 coronavirus  
PDEIFRSDTLYLTQDLFLPFYSNVTGFHTINHTFGNPVIPFKDG (**SARS-CoV**)  
IYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRAC (Severe acute  
NFELCDNPFFAVSKPMGTQHTMIFDNFNCTFEYISDAFSLD respiratory  
VSEKSGNFKHLREFVFKNKDGLYVYKGYQPIDVVRDLPSGF syndrome  
NTLKPIFKLPLGINITNFRAILTAFAQDIWGTSAAYFVGYL coronavirus)  
KPTTFMLKYDENGITIDAVDCSQNPLAELKCSVKSFEIDKGI Spike  
YQTSNFRVVPDGVVRFNITNLCPFGEVFNATKFPSVYAWE glycoprotein  
RKKISNCVADYSVLYNSTFFSTFKCYGVSATKLNLDLCSNVY UniProtKB-  
ADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAW P59594  
NTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGK  
PCTPPALNCYWPLNDYGFYTTTGIGYQPYRVVLSFELLNAP  
ATVCGPKLSTDLIKNQC VNFNFNGLTGTGVLT PSSKRFQPFQ  
QFGRDVSDFDTSVRDPKTSEILDISPCSF GGVS VITPGTNASSE  
VAVLYQDVNCTDVSTAIHADQLTPAWRIYSTGNNVFQTQAG  
CLIGAEHVDTSYECDIPIGAGICASYHTVSLLRSTSQKSIVAYT  
MSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCN  
MYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREV  
FAQVKQMYKTPTLKYFGGFNFSQILPDPLKPTKRSFIEDLLFN  
KVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLL  
TDDMIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAYR  
FNGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTSTALGKL  
QDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAE  
VQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSEC  
VLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTVVPSQER

NFTTAPAICHEGKAYFPREGVVFVNGTSWFITQRNFFSPQIITT  
DNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNH  
TSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQE  
LGKYEQYIKWPWYVWLGFIAGLIAIVMVTILLCCMTSCCSCL  
KGACSCGSCCKFDEDDSEPVLKGVKLHYT Human  
MFLILLISLPTAFVIGDLKCTSDNINDKDTGPPPISDTVDVT 30 coronavirus OC43  
NGLGTYVLDREVYLNNTLFLNGYYPTSGSTYRNMALKGSVL (HCoV-OC43)  
LSRLWFKPPFLSDFINGIFAKVKNTKVIKDRVMYSEFPAITIGS Spike  
TFVNTSYSVVVQPRINSTQDGDNKLQGLLEVSVCQYNMCE glycoprotein  
YPQTICHPNLGNHRKELWHLDTGVVVSCLYKRNFTYDVNAD UniProtKB-  
YLYFHFYQEGGTFYAYFTDTGVVTKFLFNVYLGMAISHYYV P36334  
MPLTCNSKLTLEYWVTPLTSRQYLLAFNQDGIIFNAEDCMSD  
FMSEIKCKTQSIAPPTGVYELNGYTVQPIADVRRKPNLPNC  
NIEAWLNDKSVPSPLNWERKTFSNCFNMSSLMFSIQADSFT  
CNNIDAAKIYGMCSSITIDKFAIPNGRKVDLQLGNLGYLQSF  
NYRIDTTATSCQLYYNLPAANVSVSRFNPSTWNRFGFIEDS  
VFKPRPAGVLTNHDVVYAQHCFKAPKNFCPCKLNGSCVGS  
PGKNNGIGTCPAGTNYLTCDNLCTPDPITFTGTYKCPQTKSL  
VGIGEHCGLAVKSDYCGGNSCTCRPQAFLGWSADSCLQGD  
KCNIFANFILHDVNSGLTCTDLQKANTDIILGVCVNYDLYGI  
LGQGIFVEVNATYYNSWQNLLYDSNGNLYGFRDYIINRTFMI  
RSCYSGRVSAAFHANSSEPALLFRNIKCNVVFNNSLTRQLQPI  
NYFDSYLGCVVNAYNSTAISVQTCDLTVGSGYCVDYSKNRR  
SRGAITTYRFTNFEPFTVNSVNSLEPVGGLYEIQIPSEFTIG  
NMVEFIQTSSPKVTIDCAAFVCGDYAACKSQLVEYGSFCDNI  
NAILTEVNELDDTTQLQVANSLMNGVTLSTKLKDGVNFNVD  
DINFSPVLGCLGSECSKASSRSAIEDLLFDKVKLSDVGFVEAY  
NNCTGGAEIRDLCVQSYKGIKVLPLLENQISGYTLAATSA  
SLFPPWTAAGVPFYLNQYRINGLGVTMDVLSQNQKLIAN  
AFNNALYAIQEGFDATNSALVKIQAVVNANAEALNLLQQL  
SNRFGAISASLQEILSRLEDAEAQIDRLINGRLTALNAYVS  
QQLSDSTLVKFSAAQAMEKVNCEVKSQSSRINFCGNGNHIIS  
LVQNAPYGLYFIHFSYVPTKYVTARVSPGLCIAGDRGIAPKS  
GYFVNVNNTWMYTGSYYPPEPITENNVVMSTCAVNYTK  
APYVMLNTSIPNLPDFKEELDQWFKNQTSVAPDLSLDYINVT  
FLDLQVEMNRLQEAIKVLNQSYINLKDIGTYEYVVKWPWYV  
WLLICLAGVAMVLLFFICCTGCGTSCFKKCGGCCDDYTG YQELVIKTSHDD Human  
MFLIIFILPTTLAVIGDFNCTNSFINDYNKTIPRISEDVVDVSLG 31 coronavirus  
LGTYYVLRVYLNNTLLFTGYFPKSGANFRDLALKGSIYLS HKU1 (isolate  
LWYKPPFLSDFNNGIFSKVKNTKLYVNNTLYSEFSTIVIGSVF N5) (HCoV-  
VNTSYTIVVQPHNGILEITACQYTMCEYPHTVCKSKGSIRNES HKU1) Spike  
WHIDSSEPLCLFKKNFTYNVSADWLYFHFYQERGVFYAYYA glycoprotein  
DVGMPPTFLFSLYLGTLSHYYVMPLTCNAISSNTDNETLEY UniProtKB-  
WVTPLSRRQYLLNFDEHGVITNAVDCSSFLSEIQCKTQSFAP QOZME7  
NTGVYDLSGFTVKPVATVYRRIPNLPDCDIDNWLNNVSVSP  
LNWERRIFSNCNFNLSLRLVHVDSFSCNNLDKSKIFGSCFN  
SITVDKFAIPNRRRDDLLQLGSSGFLQSSNYKIDISSSSCQLYYS  
LPLVNVNTINNFNPSSWNRRYGFSGFNLSSYDVVYSDHCFSVN  
SDFCPCADPSVVNSCAKSKPPSAICPAGTKYRHCDLDTTLYV  
KNWCRCCLPDPISYSPNTCPQKVVVVGIGEHCPLGINEE  
KCGTQLNHSSCFCSPDAFLGWSFDCISNNRCNIFSNFIFNGIN  
SGTTCSNDLLYSNTEISTGVCVNYDLYGITGQGIFKEVSAAY  
YNNWQNLLYDSNGNIIGFKDFLTNKTYTILPCYSGRVSAAFY  
QNSSSPALLYRNLKCSYVLNNISFISQPFYFDSYLGCVLNAVN

LTSYSVSSCDLRMGSGFCIDYALPSSRRKRRGISSPYRFVTFEP  
FNVSFVNDSVETVGGFLFEIQIPTNFTIAGHEEFIQTSSPKVTIDC  
SAFVCSNYAACHDLLSEYGTFCDNINSILNEVNDLLDITQLQV  
ANALMQGVTLSSNLNTNLHSDVDNIDFKSLLGCLGSQCGSSS  
RSLLEDLLFNKVKLSVDVGFVEAYNNCTGGSEIRDLLCVQSFN  
GIKVLPPILSETQISGYTTAATVAAMFPPWSAAAGVPFSLNVQ  
YRINGLGVTMDVLNKNQKLIANAFNKALLSIQNGFTATNSAL  
AKIQSVVNANAQALNSLLQQLFNKFGAISSSLQEILSRLDNLE  
AQVQIDRLINGRLTALNAYVSQQLSDITLIKAGASRAIEKVNE  
CVKSQSPRINFCGNGNHILSLVQNAPYGLLFIHFSYKPTSFKT

VLVSPGLCLSGDRGIAPKQGYFIKQND SWMFTGSSYYYPEPIS  
DKNVVMNSCSVNFTKAPFIYLNNSIPNLSDFEAE LSLWFKN  
HTSIAPNLT FN SHINATFLDLYEMNVIQESIKSLNSSFINLKEI  
GTYEMYVKWPWYIWLLIVILFIIFLMILFFICCCTGCGSACFSK CHNCCDEYGGHND FVIKASHDD  
Novel\_ **SARS** \_S2 MFIFLLFLT LTSGSDLDRALSGIAAEQDRNTREVFAQVKQMY 32

KTPTLKYFGGFNFSQILPDPLKPTKRSFIEDLLFNK VTLADAG  
FMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDDMIAAYT  
AALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQN  
VLYENQKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNA  
QALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITG  
RLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRV  
DFCGKGYHLMSFPQAAPHGVVFLHVITYVPSQERNFTTAPAIC  
HEGKAYFPREGVVFVNGT SWFITQRNFFSPQIITDNTFVSGN  
CDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLG  
DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI  
KWPWYVWLGFIAGLIAIVMTILLCCMTSCCSCLKGACSCGS CCKFDEDDSEPVLKGVKLHYT  
Novel\_ **MERS** \_S2 MIHSVFLLMFLLTPTESDCKLPLGQSLCALPDTPTSTLTPRSVR 33

SVPGEMRLASIAFNHPIQVDQLNSSYFKLSIPTNFSFGVTQEYI  
QTTIQKVTVDCKQYVCNGFQKCEQLLREYGQFCSKINQALH  
GANLRQDDSVRNLFASVKSSQSSPIIPGFGGDFNLTLLEPVSIS  
TGSRSARSAIEDLLFDKVTIADPGYMQGYDDCMQQGPASAR  
DLICAQYVAGYKVLPLMDVNMEAAAYTSSLLGSIAGVGWTA  
GLSSFAAIPFAQSIFYRLNGVGITQQVLS ENQKLIANKFNQAL  
GAMQTGFTTTNEAFQKVQDAVNNNAQALS KLASELSNTFG  
AISASIGDIIQRLDVLEQDAQIDRLINGRLTTLNAFVAQQLVRS  
ESAALSAQLAKDKVNECVKAQSKRSGFCGQGTHIVSFVVNA  
PNGLYFMHVGYYPSNHIEVVSAYGLCDAANPTNCIAPVNGY  
FIKTNNTRIVDEWSYTGSSFYAPEPITSLNTKYVAPQVITYQNI  
STNLPPLLGNSTGIDFQDELDEFFKNVST SIPNFGSLTQINTTL  
LDLTYEMLSLQVVKALNESYIDLKELGNYTYYNKWP Novel\_ **Trimeric**  
MFIFLLFLT LTSGSDLDRALSGIAAEQDRNTREVFAQVKQMY 34 **SARS** \_S2

KTPTLKYFGGFNFSQILPDPLKPTKRSFIEDLLFNK VTLADAG  
FMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDDMIAAYT  
AALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQN  
VLYENQKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNA  
QALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITG  
RLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRV  
DFCGKGYHLMSFPQAAPHGVVFLHVITYVPSQERNFTTAPAIC  
HEGKAYFPREGVVFVNGT SWFITQRNFFSPQIITDNTFVSGN  
CDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLG  
DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI  
KWPWYVWLGFIAGLIAIVMTILLCCMTSCCSCLKGACSCGS CCKFDEDDSEPVLKGVKLHYT

TABLE-US-00013 TABLE 12 Full-length Spike Glycoprotein Amino Acid Sequences (Homo sapiens strains)

GenBank Collection	Accession	Country	Date Release	Date	Virus Name
	AFY13307	United	2012 Sep. 11	2012 Dec. 5	Betacoronavirus
	AFS88936	England	2012 Jun. 13	2012 Sep. 27	Human betacoronavirus 2 c
	AGG22542	Kingdom	2012 Sep. 19	2013 Feb. 27	Human betacoronavirus 2 c
	AHY21469	England-Qatar	2012 May 04	2014 May 04	Human betacoronavirus 2 c
	AGH58717	Jordan	2012 Apr. 25	2013 Mar. 25	Human betacoronavirus 2 c
	AGV08444	Jordan-N3	2012 Sep. 17	2013 May 7	Middle East respiratory syndrome Arabia coronavirus isolate
	AGV08546	Al-Hasa	2013 May 11	2013 Sep. 17	Middle East respiratory syndrome Arabia coronavirus isolate
	AGV08535	Al-Hasa	2013 May 12	2013 Sep. 17	Middle East respiratory syndrome Arabia coronavirus isolate
	AGV08558	Al-Hasa	2013 May 15	2013 Sep. 17	Middle East respiratory syndrome Arabia coronavirus isolate
	AGV08573	Al-Hasa	2013 May 23	2013 Sep. 17	Middle East respiratory syndrome Arabia coronavirus isolate
	AGV08480	Al-Hasa	2013 May 23	2013 Sep. 17	Middle East respiratory syndrome Arabia coronavirus isolate
	AGN70962	Al-Hasa	2013 May 9	2013 Jun. 10	Middle East respiratory syndrome Arabia coronavirus isolate
	AGV08492	Al-Hasa	2013 May 30	2013 Sep. 17	Middle East respiratory syndrome Arabia coronavirus isolate
	AHI48517	Al-Hasa	2013 May 2	2014 Feb. 6	Middle East respiratory syndrome Arabia coronavirus isolate
	AGN70951	Al-Hasa	2013 Apr. 21	2013 Jun. 10	Middle East respiratory syndrome Arabia coronavirus isolate
	AGN70973	Al-Hasa	2013 Apr. 22	2013 Jun. 10	Middle East respiratory syndrome Arabia coronavirus isolate
	AGN70929	Al-Hasa	2013 May 1	2013 Jun. 10	Middle East respiratory syndrome Arabia coronavirus isolate
	AGV08408	Al-Hasa	2012 Jun. 19	2013 Sep. 17	Middle East respiratory syndrome Arabia coronavirus isolate
	AGV08467	Bisha	2012 Sep. 17	2013 May 13	Middle East respiratory syndrome Arabia coronavirus isolate
	AID50418	Buraidah	2013 Feb. 10	2014 Jun. 18	Middle East respiratory syndrome Kingdom coronavirus isolate
	AJD81451	England	2013 Feb. 10	2015 Jan. 18	Middle East respiratory syndrome Kingdom coronavirus isolate
	AJD81440	England	2013 Feb. 13	2015 Jan. 18	Middle East respiratory syndrome Kingdom coronavirus isolate
	AHB33326	England	2013 May 7	2013 Dec. 7	Middle East respiratory syndrome coronavirus isolate
	AIZ48760	FRA/UAE	2014 June	2014 Dec. 14	Middle East respiratory syndrome coronavirus isolate
	AGV08455	Florida/USA	2013 Jun. 4	2013 Sep. 17	Middle East respiratory syndrome Arabia coronavirus isolate
	AHI48561	Hafr-Al-Batin	2013 Aug. 5	2014 Feb. 6	Middle East respiratory syndrome Arabia coronavirus isolate
	AHI48539	Hafr-Al-Batin	2013 Aug. 28	2014 Feb. 6	Middle East respiratory syndrome Arabia coronavirus isolate
	AIZ74417	Hafr-Al-Batin	2013 Apr. 26	2015 Mar. 10	Middle East respiratory syndrome coronavirus isolate
	AIZ74433	Hu-France (UAE)-FRA1	2013 May 7	2015 Mar. 10	Middle East respiratory syndrome coronavirus isolate
	AIZ74439	Hu-France--FRA2	2013 May 7	2015 Mar. 10	Middle East respiratory syndrome coronavirus isolate
	AIZ74450	Hu-France--FRA2	2013 May 7	2015 Mar. 10	Middle East respiratory syndrome coronavirus isolate
	AKK52602	Hu-France--FRA2	2013 May 7	2015 Mar. 10	Middle East respiratory syndrome coronavirus isolate
	AKK52612	Hu-Riyadh_KSA	2015 Feb. 10	2015 Jun. 8	Middle East respiratory syndrome Arabia coronavirus isolate
	AHN10812	Hu-Riyadh_KSA	2015 Mar. 1	2015 Jun. 8	Middle East respiratory syndrome Arabia coronavirus isolate
	AID55071	Hu-Riyadh_KSA	2013 Nov. 6	2014 Mar. 24	Middle East respiratory syndrome Arabia coronavirus isolate
	AID55066	Jeddah	2014 Apr. 21	2014 Nov. 12	Middle East respiratory syndrome Arabia coronavirus isolate
	AID55067	Jeddah	2014 Apr. 21	2014 Nov. 12	Middle East respiratory syndrome Arabia coronavirus isolate
	AID55068	Jeddah	2014 Apr. 21	2014 Nov. 12	Middle East respiratory syndrome Arabia coronavirus isolate
	AID55069	Jeddah	2014 Apr. 7	2014 Nov. 12	Middle East respiratory syndrome Arabia coronavirus isolate
	AID55070	Jeddah	2014 Apr. 12	2014 Nov. 12	Middle East respiratory syndrome Arabia coronavirus isolate
	AID55070	Jeddah	2014 Apr. 14	2014 Nov. 12	Middle East respiratory syndrome Arabia coronavirus isolate

East respiratory syndrome Arabia coronavirus isolate Jeddah\_C9055/KSA/2014-04-14, complete genome AHE78108 Saudi 2013 Nov. 5 2014 May 1 Middle East respiratory syndrome Arabia coronavirus isolate MERS-CoV- Jeddah-human-1, complete genome AKL59401 South 2015 May 20 2015 Jun. 9 Middle East respiratory syndrome Korea coronavirus isolate MERS- CoV/KOR/KNIH/002\_05\_2015, complete genome ALD51904 Thailand 2015 Jun. 17 2015 Jul. 7 Middle East respiratory syndrome coronavirus isolate MERS-CoV/THA/CU/17\_06\_2015, complete genome AID55072 Saudi 2014 Apr. 15 2014 Nov. 12 Middle East respiratory syndrome Arabia coronavirus isolate Makkah\_C9355/KSA/Makkah/2014- 04-15, complete genome AHC74088 Qatar 2013 Oct. 13 2013 Dec. 23 Middle East respiratory syndrome coronavirus isolate Qatar3, complete genome AHC74098 Qatar 2013 Oct. 17 2013 Dec. 23 Middle East respiratory syndrome coronavirus isolate Qatar4, complete genome AHI48572 Saudi 2013 Aug. 15 2014 Feb. 6 Middle East respiratory syndrome Arabia coronavirus isolate Riyadh\_14\_2013, complete genome AGV08379 Saudi 2012 Oct. 23 2013 Sep. 17 Middle East respiratory syndrome Arabia coronavirus isolate Riyadh\_1\_2012, complete genome AID55073 Saudi 2014 Apr. 22 2014 Nov. 12 Middle East respiratory syndrome Arabia coronavirus isolate Riyadh\_2014KSA\_683/KSA/2014, complete genome AGV08584 Saudi 2012 Oct. 30 2013 Sep. 17 Middle East respiratory syndrome Arabia coronavirus isolate Riyadh\_2\_2012, complete genome AGV08390 Saudi 2013 Feb. 5 2013 Sep. 17 Middle East respiratory syndrome Arabia coronavirus isolate Riyadh\_3\_2013, complete genome AHI48605 Saudi 2013 Mar. 1 2014 Feb. 6 Middle East respiratory syndrome Arabia coronavirus isolate Riyadh\_4\_2013, complete genome AHI48583 Saudi 2013 Jul. 2 2014 Feb. 6 Middle East respiratory syndrome Arabia coronavirus isolate Riyadh\_5\_2013, complete genome AHI48528 Saudi 2013 Jul. 17 2014 Feb. 6 Middle East respiratory syndrome Arabia coronavirus isolate Riyadh\_9\_2013, complete genome AHI48594 Saudi 2013 Jun. 12 2014 Feb. 6 Middle East respiratory syndrome Arabia coronavirus isolate Taif\_1\_2013, complete genome AHI48550 Saudi 2013 Jun. 12 2014 Feb. 6 Middle East respiratory syndrome Arabia coronavirus isolate Wadi-Ad- Dawasir\_1\_2013, complete genome AIY60558 United 2014 Mar. 7 2014 Dec. 6 Middle East respiratory syndrome Arab coronavirus strain Abu Emirates Dhabi/Gayathi\_UAE\_2\_2014, complete genome AIY60538 United 2014 Apr. 10 2014 Dec. 6 Middle East respiratory syndrome Arab coronavirus strain Abu Emirates Dhabi\_UAE\_16\_2014, complete genome AIY60528 United 2014 Apr. 10 2014 Dec. 6 Middle East respiratory syndrome Arab coronavirus strain Abu Emirates Dhabi\_UAE\_18\_2014, complete genome AIY60588 United 2014 Apr. 13 2014 Dec. 6 Middle East respiratory syndrome Arab coronavirus strain Abu Emirates Dhabi\_UAE\_26\_2014, complete genome AIY60548 United 2014 Apr. 19 2014 Dec. 6 Middle East respiratory syndrome Arab coronavirus strain Abu Emirates Dhabi\_UAE\_30\_2014, complete genome AIY60568 United 2014 Apr. 17 2014 Dec. 6 Middle East respiratory syndrome Arab coronavirus strain Abu Emirates Dhabi\_UAE\_33\_2014, complete genome AIY60518 United 2014 Apr. 7 2014 Dec. 6 Middle East respiratory syndrome Arab coronavirus strain Abu Emirates Dhabi\_UAE\_8\_2014, complete genome AIY60578 United 2013 Nov. 15 2014 Dec. 6 Middle East respiratory syndrome Arab coronavirus strain Abu Emirates Dhabi\_UAE\_9\_2013, complete genome AKJ80137 China 2015 May 27 2015 Jun. 5 Middle East respiratory syndrome coronavirus strain ChinaGD01, complete genome AHZ64057 USA 2014 May 10 2014 May 14 Middle East respiratory syndrome coronavirus strain Florida/USA- 2\_Saudi Arabia\_2014, complete genome AKM76229 Oman 2013 Oct. 28 2015 Jun. 23 Middle East respiratory syndrome coronavirus strain Hu/Oman\_2285\_2013, complete genome AKM76239 Oman 2013 Dec. 28 2015 Jun. 23 Middle East respiratory syndrome coronavirus strain Hu/Oman\_2874\_2013, complete genome AKI29284 Saudi 2015 Jan. 6 2015 May 27 Middle East respiratory syndrome Arabia coronavirus strain Hu/Riyadh-KSA- 2049/2015, complete genome AKI29265 Saudi 2015 Jan. 21 2015 May 27 Middle East respiratory syndrome Arabia coronavirus strain Hu/Riyadh-KSA-

2343/2015, complete genome AKI29255 Saudi 2015 Jan. 21 2015 May 27 Middle East respiratory syndrome Arabia coronavirus strain Hu/Riyadh-KSA- 2345/2015, complete genome AKI29275 Saudi 2015 Jan. 26 2015 May 27 Middle East respiratory syndrome Arabia coronavirus strain Hu/Riyadh-KSA- 2466/2015, complete genome AKK52582 Saudi 2015 Feb. 10 2015 Jun. 8 Middle East respiratory syndrome Arabia coronavirus strain Hu/Riyadh\_KSA\_2959\_2015, complete genome AKK52592 Saudi 2015 Mar. 1 2015 Jun. 8 Middle East respiratory syndrome Arabia coronavirus strain Hu/Riyadh\_KSA\_4050\_2015, complete genome AHZ58501 USA 2014 Apr. 30 2014 May 13 Middle East respiratory syndrome coronavirus strain Indiana/USA- 1\_Saudi Arabia\_2014, complete genome AGN52936 United 2013 2013 Jun. 10 Middle East respiratory syndrome Arab coronavirus, complete genome Emirates



TABLE-US-00014 TABLE 13 SEQ ID Description Sequence NO: MeV Nucleic Acid Sequences

GC\_F\_MEASLES\_TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACT 35 B3.1

CACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAA Sequence, NT (5'

GAAATATAAGAGCCACCATGGGTCTCAAGGTGAACGTC UTR, ORF, 3'

TCTGCCGTATTCATGGCAGTACTGTAACTCTCCAAACA UTR)

CCCGCCGGTCAAATTCATTGGGGCAATCTCTCTAAGAT Sequence Length:

AGGGGTAGTAGGAATAGGAAGTGCAAGCTACAAAGTT 1864

ATGACTCGTTCAGCCATCAATCATTAGTCATAAAATT

AATGCCCAATATAACTCTCCTCAATAACTGCACGAGGG

TAGAGATTGCAGAATACAGGAGACTACTAAGAACAGTT

TTGGAACCAATTAGGGATGCACTTAATGCAATGACCCA

GAACATAAAGGCCGGTTCAGAGCGTAGCTTCAAGTAGGA

GACACAAGAGATTTGCGGGAGTAGTCCTGGCAGGTGCG

GCCCTAGGTGTTGCCACAGCTGCTCAGATAACAGCCGG

CATTGCACTTCACCGGTCCATGCTGAACTCTCAGGCCAT

CGACAATCTGAGAGCGAGCCTGGAACTACTAATCAGG

CAATTGAGGCAATCAGACAAGCAGGGCAGGAGATGAT

ATTGGCTGTTCAAGGTGTCCAAGACTACATCAATAATG

AGCTGATACCGTCTATGAACCAGCTATCTTGTGATCTA

ATCGGTCAGAAGCTCGGGCTCAAATTGCTTAGATACTA

TACAGAAATCCTGTCATTATTTGGCCCCAGCCTACGGG

ACCCCATATCTGCGGAGATATCTATCCAGGCTTTGAGTT

ATGCACTTGGAGGAGATATCAATAAGGTGTTAGAAAAG

CTCGGATACAGTGGAGGCGATTTACTAGGCATCTTAGA

GAGCAGAGGAATAAAGGCTCGGATAACTCACGTGAC

ACAGAGTCCTACTTCATAGTCCTCAGTATAGCCTATCCG

ACGCTGTCCGAGATTAAGGGGGTGATTGTCCACCGGCT

AGAGGGGGTCTCGTACAACATAGGCTCTCAAGAGTGGT

ATACCACTGTGCCCAAGTATGTTGCAACCCAAGGGTAC

CTTATCTCGAATTTTGATGAGTCATCATGTACTTTTCATG

CCAGAGGGGACTGTGTGCAGCCAAAATGCCTTGTACCC

GATGAGTCCTCTGCTCCAAGAATGCCTCCGGGGGTCCA

CCAAGTCCTGTGCTCGTACACTCGTATCCGGGTCTTTTG

GGAACCGGTTCAATTTATCACAAGGGAACCTAATAGCC

AATTGTGCATCAATTCCTTGTAAAGTGTTACACAACAGGT

ACGATTATTAATCAAGACCCTGACAAGATCCTAACATA

CATTGCTGCCGATCGCTGCCCGGTAGTCGAGGTGAACG

GCGTGACCATCAAGTCGGGAGCAGGAGGTATCCAGA

CGCTGTGTACTIONGCACAGAATTGACCTCGGTCCTCCCAT

ATCATTGGAGAGGTTGGACGTAGGGACAAATCTGGGG

AATGCAATTGCCAAATTGGAGGATGCCAAGGAATTGTT

GGAATCATCGGACCAGATATTGAGAAGTATGAAAGGTT

TATCGAGCACTAGCATAGTCTACATCCTGATTGCAGTG

TGTCTTGGAGGGTTGATAGGGATCCCCACTTTAATATGT

TGCTGCAGGGGGCGTTGTAACAAAAGGGAGAACAAG

TTGGTATGTCAAGACCAGGCCTAAAGCCTGACCTTACA

GGAACATCAAATCCTATGTAAGATCGCTTTGATGATA

ATAGGCTGGAGCCTCGGTGGCCAAGCTTCTTGCCCCTT

GGGCCTCCCCCAGCCCCTCCTCCCCTTCTGCACCCGT

ACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGGCGGC GC\_F\_MEASLES\_

ATGGGTCTCAAGGTGAACGTCTCTGCCGTATTCATGGC 36 B3.1

AGTACTGTAACTCTCCAAACACCCGCCGGTCAAATTC ORF Sequence, NT

ATTGGGGCAATCTCTCTAAGATAGGGGTAGTAGGAATA

GGAAGTGCAAGCTACAAAGTTATGACTCGTTCAGCCA

TCAATCATTAGTCATAAAATTAATGCCCAATATAACTCT  
CCTCAATAACTGCACGAGGGTAGAGATTGCAGAATACA  
GGAGACTACTAAGAACAGTTTTTGGAAACCAATTAGGGAT  
GCACTTAATGCAATGACCCAGAACATAAGGCCGGTTCA  
GAGCGTAGCTTCAAGTAGGAGACACAAGAGATTTGCG  
GGAGTAGTCCTGGCAGGTGCGGCCCTAGGTGTTGCCAC  
AGCTGCTCAGATAACAGCCGGCATTGCACTTCACCGGT  
CCATGCTGAACTCTCAGGCCATCGACAATCTGAGAGCG  
AGCCTGGAACTACTAATCAGGCAATTGAGGCAATCAG  
ACAAGCAGGGCAGGAGATGATATTGGCTGTTTCAGGGTG  
TCCAAGACTACATCAATAATGAGCTGATACCGTCTATG  
AACCAGCTATCTTGTGATCTAATCGGTCAGAAGCTCGG  
GCTCAAATTGCTTAGATACTATACAGAAATCCTGTCATT  
ATTTGGCCCCAGCCTACGGGACCCCATATCTGCGGAGA  
TATCTATCCAGGCTTTGAGTTATGCACTTGGAGGAGAT  
ATCAATAAGGTGTTAGAAAAGCTCGGATACAGTGGAG  
GCGATTTACTAGGCATCTTAGAGAGCAGAGGAATAAAG  
GCTCGGATAACTCACGTCGACACAGAGTCCTACTTCAT  
AGTCCTCAGTATAGCCTATCCGACGCTGTCCGAGATTA  
AGGGGGTGATTGTCCACCGGCTAGAGGGGGTCTCGTAC  
AACATAGGCTCTCAAGAGTGGTATACCACTGTGCCCAA  
GTATGTTGCAACCCAAGGGTACCTTATCTCGAATTTTGA  
TGAGTCATCATGTACTTTCATGCCAGAGGGGACTGTGT  
GCAGCCAAAATGCCTTGTACCCGATGAGTCCTCTGCTC  
CAAGAATGCCTCCGGGGGTCCACCAAGTCCTGTGCTCG  
TACTCTCGTATCCGGGTCTTTTGGGAACCGGTTCATTTT  
ATCACAAGGGAACCTAATAGCCAATTGTGCATCAATTC  
TTTGTAAAGTGTTACACAACAGGTACGATTATTAATCAA  
GACCCTGACAAGATCCTAACATACATTGCTGCCGATCG  
CTGCCCGGTAGTCGAGGTGAACGGCGTGACCATCCAAG  
TCGGGAGCAGGAGGTATCCAGACGCTGTGTACTTGCAC  
AGAATTGACCTCGGTCTCCATATCATTGGAGAGGTT  
GGACGTAGGGACAAATCTGGGGAATGCAATTGCCAAA  
TTGGAGGATGCCAAGGAATTGTTGGAATCATCGGACCA  
GATATTGAGAAGTATGAAAGGTTTATCGAGCACTAGCA  
TAGTCTACATCCTGATTGCAGTGTGTCTTGGAGGGTTGA  
TAGGGATCCCCACTTTAATATGTTGCTGCAGGGGGCGT  
TGTAACAAAAAGGGAGAACAAGTTGGTATGTCAAGAC  
CAGGCCTAAAGCCTGACCTTACAGGAACATCAAATCC TATGTAAGATCGCTTTGA  
GC\_F\_MEASLES\_G\*GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAAT 37 B3.1  
ATAAGAGCCACCATGGGTCTCAAGGTGAACGTCTCTGC mRNA Sequence  
CGTATTCATGGCAGTACTGTTAACTCTCCAAACACCCG (assumes T100 tail)  
CCGGTCAAATTCATTGGGGCAATCTCTCTAAGATAGGG mRNA Sequence  
GTAGTAGGAATAGGAAGTGCAAGCTACAAAGTTATGA Length: 1925  
CTCGTTCCAGCCATCAATCATTAGTCATAAAATTAATGC  
CCAATATAACTCTCCTCAATAACTGCACGAGGGTAGAG  
ATTGCAGAATACAGGAGACTACTAAGAACAGTTTTTGG  
ACCAATTAGGGATGCACTTAATGCAATGACCCAGAACA  
TAAGGCCGGTTCAGAGCGTAGCTTCAAGTAGGAGACAC  
AAGAGATTTGCGGGAGTAGTCCTGGCAGGTGCGGCCCT  
AGGTGTTGCCACAGCTGCTCAGATAACAGCCGGCATTG  
CACTTCACCGGTCCATGCTGAACTCTCAGGCCATCGAC  
AATCTGAGAGCGAGCCTGGAACTACTAATCAGGCAAT  
TGAGGCAATCAGACAAGCAGGGCAGGAGATGATATTG

GCTGTT CAGGGTGTCCAAGACTACATCAATAATGAGCT  
GATACCGTCTATGAACCAGCTATCTTGTGATCTAATCG  
GTCAGAAGCTCGGGCTCAAATTGCTTAGATACTATA  
CAAATCCTGTCATTATTTGGCCCCAGCCTACGGGACCC  
CATATCTGCGGAGATATCTATCCAGGCTTTGAGTTATGC  
ACTTGGAGGAGATATCAATAAGGTGTTAGAAAAGCTCG  
GATACAGTGGAGGCGATTTACTAGGCATCTTAGAGAGC  
AGAGGAATAAAGGCTCGGATAACTCACGTCGACACAG  
AGTCCTACTTCATAGTCCTCAGTATAGCCTATCCGACGC  
TGTCCGAGATTAAGGGGGTGATTGTCCACCGGCTAGAG  
GGGGTCTCGTACAACATAGGCTCTCAAGAGTGGTATAC  
CACTGTGCCCAAGTATGTTGCAACCCAAGGGTACCTTA  
TCTCGAATTTTGATGAGTCATCATGTACTTTCATGCCAG  
AGGGGACTGTGTGCAGCCAAAATGCCTTGTACCCGATG  
AGTCCTCTGCTCCAAGAATGCCTCCGGGGGTCCACCAA  
GTCCTGTGCTCGTACACTCGTATCCGGGTCTTTTGGGAA  
CCGGTTCATTTTATCACAAGGGAACCTAATAGCCAATT  
GTGCATCAATTCCTTTGTAAGTGTTACACAACAGGTACG  
ATTATTAATCAAGACCCTGACAAGATCCTAACATACAT  
TGCTGCCGATCGCTGCCCGGTAGTCGAGGTGAACGGCG  
TGACCATCCAAGTCGGGAGCAGGAGGTATCCAGACGCT  
GTGTACTTGCACAGAATTGACCTCGGTCTCCCATATCA  
TTGGAGAGGTTGGACGTAGGGACAAATCTGGGGAAATG  
CAATTGCCAAATTGGAGGATGCCAAGGAATTGTTGGAA  
TCATCGGACCAGATATTGAGAAGTATGAAAGGTTTATC  
GAGCACTAGCATAGTCTACATCCTGATTGCAGTGTGTC  
TTGGAGGGTTGATAGGGATCCCCACTTTAATATGTTGCT  
GCAGGGGGCGTTGTAACAAAAGGGAGAACAAGTTGG  
TATGTCAAGACCAGGCCTAAAGCCTGACCTTACAGGAA  
CATCAAAATCCTATGTAAGATCGCTTTGATGATAATAG  
GCTGGAGCCTCGGTGGCCAAGCTTCTTGCCCCTTGGGC  
CTCCCCCAGCCCCCTCCTCCCCTTCTGCACCCGTACCC  
CCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGCAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATCTAG GC\_F\_MEASLES\_  
TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACT 38 D8  
CACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAA Sequence, NT (5'  
GAAATATAAGAGCCACCATGGGTCTCAAGGTGAACGTC UTR, ORF, 3'  
TCTGTCATATTCATGGCAGTACTGTAACTCTTCAAACA UTR)  
CCCACCGGTCAAATCCATTGGGGCAATCTCTCTAAGAT Sequence Length:  
AGGGGTGGTAGGGGTAGGAAGTGCAAGCTACAAAGTT 1864  
ATGACTCGTTCCAGCCATCAATCATTAGTCATAAAGTT  
AATGCCCAATATAACTCTCCTCAACAATTGCACGAGGG  
TAGGGATTGCAGAATACAGGAGACTACTGAGAACAGTT  
CTGGAACCAATTAGAGATGCACTTAATGCAATGACCCA  
GAATATAAGACCGGTTCAAGAGTGTAGCTTCAAGTAGGA  
GACACAAGAGATTTGCGGGAGTTGTCCTGGCAGGTGCG  
GCCCTAGGCGTTGCCACAGCTGCTCAAATAACAGCCGG  
TATTGCACTTCACCAGTCCATGCTGAACTCTCAAGCCAT  
CGACAATCTGAGAGCGAGCCTAGAACTACTAATCAGG  
CAATTGAGGCAATCAGACAAGCAGGGCAGGAGATGAT  
ATTGGCTGTTCAAGGTGTCCAAGACTACATCAATAATG  
AGCTGATACCGTCTATGAATCAACTATCTTGTGATTTAA

TCGGCCAGAAGCTAGGGCTCAAATTGCTCAGATACTAT  
ACAGAAATCCTGTCATTATTTGGCCCCAGCTTACGGGA  
CCCCATATCTGCGGAGATATCTATCCAGGCTTTGAGCT  
ATGCGCTTGAGGAGATATCAATAAGGTGTTGGAAAAG  
CTCGGATACAGTGGAGGTGATCTACTGGGCATCTTAGA  
GAGCAGAGGAATAAAGGCCCGGATAACTCACGTGCAC  
ACAGAGTCCTACTTCATTGTACTCAGTATAGCCTATCCG  
ACGCTATCCGAGATTAAGGGGGTGATTGTCCACCGGCT  
AGAGGGGGTCTCGTACAACATAGGCTCTCAAGAGTGGT  
ATACCACTGTGCCCAAGTATGTTGCAACCCAAGGGTAC  
CTTATCTCGAATTTTGATGAGTCATCATGCACTTTCATG  
CCAGAGGGGACTGTGTGCAGCCAGAATGCCTTGTACCC  
GATGAGTCCTCTGCTCCAAGAATGCCTCCGGGGGTCCA  
CTAAGTCCTGTGCTCGTACACTCGTATCCGGGTCTTTCG  
GGAACCGGTTCAATTTATCACAGGGGAACCTAATAGCC  
AATTGTGCATCAATCCTTTGCAAGTGTTACACAACAGG  
ACAATCATTAAATCAAGACCCTGACAAGATCCTAACAT  
ACATTGCTGCCGATCACTGCCCCGGTGGTTCGAGGTGAAT  
GGCGTGACCATCCAAGTCGGGAGCAGGAGGTATCCGG  
ACGCTGTGTACTTGCACAGGATTGACCTCGGTCTCTCCC  
ATATCTTTGGAGAGGTTGGACGTAGGGACAAATCTGGG  
GAATGCAATTGCTAAGTTGGAGGATGCCAAGGAATTGT  
TGGAGTCATCGGACCAGATATTGAGGAGTATGAAAGGT  
TTATCGAGCACTAGTATAGTTTACATCCTGATTGCAGTG  
TGTCTTGGAGGATTGATAGGGATCCCCGCTTTAATATGT  
TGCTGCAGGGGGCGTTGTAACAAGAAGGGAGAACAAG  
TTGGTATGTCAAGACCAGGCCTAAAGCCTGATCTTACA  
GGAACATCAAATCCTATGTAAGGTCACTCTGATGATA  
ATAGGCTGGAGCCTCGGTGGCCAAGCTTCTTGCCCCTT  
GGGCCTCCCCCAGCCCCTCCTCCCCTTCTGCACCCGT  
ACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGGCGGC GC\_F\_MEASLES\_  
ATGGGTCTCAAGGTGAACGTCTCTGTCAATTCATGGC 39 D8  
AGTACTGTAACTCTTCAAACACCCACCGGTCAAATCC ORF Sequence, NT  
ATTGGGGCAATCTCTCTAAGATAGGGGTGGTAGGGGTA  
GGAAGTGCAAGCTACAAAGTTATGACTCGTTCAGCCA  
TCAATCATTAGTCATAAAGTTAATGCCCAATATAACTCT  
CCTCAACAATTGCACGAGGGTAGGGATTGCAGAATACA  
GGAGACTACTGAGAACAGTTCTGGAACCAATTAGAGAT  
GCACTTAATGCAATGACCCAGAATATAAGACCGGTTCA  
GAGTGTAGCTTCAAGTAGGAGACACAAGAGATTTGCGG  
GAGTTGTCCTGGCAGGTGCGGCCCTAGGCGTTGCCACA  
GCTGCTCAAATAACAGCCGGTATTGCACTTCACCAGTC  
CATGCTGAACTCTCAAGCCATCGACAATCTGAGAGCGA  
GCCTAGAAACTACTAATCAGGCAATTGAGGCAATCAGA  
CAAGCAGGGCAGGAGATGATATTGGCTGTTCAAGGGTGT  
CCAAGACTACATCAATAATGAGCTGATACCGTCTATGA  
ATCAACTATCTTGTGATTTAATCGGCCAGAAGCTAGGG  
CTCAAATTGCTCAGATACTATAACAGAAATCCTGTCATT  
ATTTGGCCCCAGCTTACGGGACCCCATATCTGCGGAGA  
TATCTATCCAGGCTTTGAGCTATGCGCTTGGAGGAGAT  
ATCAATAAGGTGTTGGAAAAGCTCGGATACAGTGGAG  
GTGATCTACTGGGCATCTTAGAGAGCAGAGGAATAAAG  
GCCCGGATAACTCACGTGCACACAGAGTCCTACTTCAT  
TGTAICTAGTATAGCCTATCCGACGCTATCCGAGATTA

AGGGGGTGATTGTCCACCGGCTAGAGGGGGTCTCGTAC  
AACATAGGCTCTCAAGAGTGGTATAACCACTGTGCCAA  
GTATGTTGCAACCCAAGGGTACCTTATCTCGAATTTGA  
TGAGTCATCATGCACTTTCATGCCAGAGGGGACTGTGT  
GCAGCCAGAATGCCTTGTACCCGATGAGTCCTCTGCTC  
CAAGAATGCCTCCGGGGGTCCACTAAGTCCTGTGCTCG  
TACTCTCGTATCCGGGTCTTTCGGGAACCGGTTCAATTT  
ATCACAGGGGAACCTAATAGCCAATTGTGCATCAATCC  
TTTGCAAGTGTTACACAACAGGAACAATCATTAAATCAA  
GACCCTGACAAGATCCTAACATACATTGCTGCCGATCA  
CTGCCCGGTGGTCGAGGTGAATGGCGTGACCATCCAAG  
TCGGGAGCAGGAGGTATCCGGACGCTGTGTACTTGCAC  
AGGATTGACCTCGTCTCCCATATCTTTGGAGAGGTT  
GGACGTAGGGACAAATCTGGGGAATGCAATTGCTAAGT  
TGGAGGATGCCAAGGAATTGTTGGAGTCATCGGACCAG  
ATATTGAGGAGTATGAAAGGTTTATCGAGCACTAGTAT  
AGTTTACATCCTGATTGCAGTGTGTCTTGGAGGATTGAT  
AGGGATCCCCGCTTTAATATGTTGCTGCAGGGGGCGTT  
GTAACAAGAAGGGAGAACAAGTTGGTATGTCAAGACC  
AGGCCTAAAGCCTGATCTTACAGGAACATCAAATCCT ATGTAAGGTCACTCTGA  
GC\_F\_MEASLES\_G\*GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAAT 40

D8 ATAAGAGCCACCATGGGTCTCAAGGTGAACGTCTCTGT mRNA Sequence

CATATTCATGGCAGTACTGTTAACTCTTCAAACACCCAC (assumes T100 tail)

CGGTCAAATCCATTGGGGCAATCTCTCTAAGATAGGGG Sequence Length:

TGGTAGGGGTAGGAAGTGCAAGCTACAAAGTTATGACT 1925

CGTTCCAGCCATCAATCATTAGTCATAAAGTTAATGCC  
CAATATAACTCTCCTCAACAATTGCACGAGGGTAGGGA  
TTGCAGAATACAGGAGACTACTGAGAACAGTTCTGGAA  
CCAATTAGAGATGCACTTAATGCAATGACCCAGAATAT  
AAGACCGGTTTCAGAGTGTAGCTTCAAGTAGGAGACACA  
AGAGATTTGCGGGAGTTGTCCTGGCAGGTGCGGCCCTA  
GGCGTTGCCACAGCTGCTCAAATAACAGCCGGTATTGC  
ACTTACCAGTCCATGCTGAACTCTCAAGCCATCGACA  
ATCTGAGAGCGAGCCTAGAACTACTAATCAGGCAATT  
GAGGCAATCAGACAAGCAGGGCAGGAGATGATATTGG  
CTGTTTCAGGGTGTCCAAGACTACATCAATAATGAGCTG  
ATACCGTCTATGAATCAACTATCTTGTGATTTAATCGGC  
CAGAAGCTAGGGCTCAAATTGCTCAGATACTATACAGA  
AATCCTGTCATTATTTGGCCCCAGCTTACGGGACCCCAT  
ATCTGCGGAGATATCTATCCAGGCTTTGAGCTATGCGC  
TTGGAGGAGATATCAATAAGGTGTTGGAAAAGCTCGGA  
TACAGTGGAGGTGATCTACTGGGCATCTTAGAGAGCAG  
AGGAATAAAGGCCCGGATAACTCACGTCGACACAGAG  
TCCTACTTCATTGTA CTAGTATAGCCTATCCGACGCTA  
TCCGAGATTAAGGGGGTGATTGTCCACCGGCTAGAGGG  
GGTCTCGTACAACATAGGCTCTCAAGAGTGGTATACCA  
CTGTGCCCAAGTATGTTGCAACCCAAGGGTACCTTATC  
TCGAATTTTGATGAGTCATCATGCACTTTCATGCCAGAG  
GGGACTGTGTGCAGCCAGAATGCCTTGTACCCGATGAG  
TCCTCTGCTCCAAGAATGCCTCCGGGGGTCCACTAAGT  
CCTGTGCTCGTACACTCGTATCCGGGTCTTTCGGGAACC  
GGTTCATTTTATCACAGGGGAACCTAATAGCCAATTGT  
GCATCAATCCTTTGCAAGTGTTACACAACAGGAACAAT



TCAGGGATGGACCTATACAAATCCAACCTGCAACAATGT  
GTATTGGCTGACTATTCCGCCAATGAGAAATCTAGCCT  
TAGGCGTAATCAACACATTGGAGTGGATACCGAGATTC  
AAGGTTAGTCCCAACCTCTTCACTGTCCCAATTAAGGA  
AGCAGGCGAAGACTGCCATGCCCAACATACCTACCTG  
CGGAGGTGGACGGTGATGTCAAACCTCAGTTCCAACCTG  
GTGATTCTACCTGGTCAAGATCTCCAATATGTTTTGGCA  
ACCTACGATACCTCCAGGGTTGAGCATGCTGTGGTTTA  
TTACGTTTACAGCCCAAGCCGCTCATTTTCTTACTTTTA  
TCCTTTTAGGTTGCCTATAAAGGGGGTCCCAATCGAAC  
TACAAGTGGAATGCTTCACATGGGATCAAAAACCTCTGG  
TGCCGTCACCTTCTGTGTGCTTGCGGACTCAGAATCCGGT  
GGACTTATCACTCACTCTGGGATGGTGGGCATGGGAGT  
CAGCTGCACAGCTACCCGGGAAGATGGAACCAATCGC  
AGATAATGATAATAGGCTGGAGCCTCGGTGGCCAAGCT  
TCTTGCCCCTTGGGCCTCCCCCAGCCCCTCCTCCCCTT  
CCTGCACCCGTACCCCGTGGTCTTTGAATAAAGTCTG AGTGGGCGGC GC\_H\_MEASLES\_  
ATGTCACCGCAACGAGACCGGATAAATGCCTTCTACAA 42 B3  
AGATAACCCTTATCCCAAGGGAAGTAGGATAGTTATTA ORF Sequence, NT  
ACAGAGAACATCTTATGATTGACAGACCCTATGTTCTG  
CTGGCTGTTCTGTTCTGTCATGTTTCTGAGCTTGATCGGA  
TTGCTGGCAATTGCAGGCATTAGACTTCATCGGGCAGC  
CATCTACACCGCGGAGATCCATAAAAGCCTCAGTACCA  
ATCTGGATGTGACTAACTCCATCGAGCATCAGGTCAAG  
GACGTGCTGACACCACTCTTTAAAATCATCGGGGATGA  
AGTGGGCCTGAGAACACCTCAGAGATTCAGTACCTAG  
TGAAATTCATCTCGGACAAGATTAATTCCTTAATCCG  
GATAGGGAGTACGACTTCAGAGATCTCACTTGGTGCAT  
CAACCCGCCAGAGAGGATCAAACCTAGATTATGATCAAT  
ACTGTGCAGATGTGGCTGCTGAAGAGCTCATGAATGCA  
TTGGTGAACCTCAACTCTACTGGAGACCAGAACAACCAC  
TCAGTTCCTAGCTGTCTCAAAGGGAAACTGCTCAGGGC  
CCACTACAATCAGAGGTCAATTCTCAAACATGTCGCTG  
TCCTTGTTGGACTTGTACTTAGGTCGAGGTTACAATGTG  
TCATCTATAGTCACTATGACATCCCAGGGAATGTATGG  
GGGAACCTACCTAGTTGAAAAGCCTAATCTGAACAGCA  
AAGGGTCAGAGTTGTCACAACTGAGCATGTACCGAGTG  
TTTGAAGTAGGTGTGATCAGAAACCCGGGTTTGGGGGC  
TCCGGTGTCCATATGACAAACTATTTTGAGCAACCAG  
TCAGTAATGGTCTCGGCAACTGTATGGTGGCTTTGGGG  
GAGCTCAAACCTCGCAGCCCTTTGTCACGGGGACGATTC  
TATCATAATCCCTATCAGGGATCAGGGAAAGGTGTCA  
GCTTCCAGCTCGTCAAGCTGGGTGTCTGGAAATCCCA  
ACCGACATGCAATCCTGGGTCCCCTTATCAACGGATGA  
TCCAGTGGTAGACAGGCTTTACCTCTCATCTCACAGAG  
GTGTCATCGCTGACAATCAAGCAAAATGGGCTGTCCCG  
ACAACACGAACAGATGACAAGTTGCGAATGGAGACAT  
GCTTCCAGCAGGCGTGTAAAGGTAAAATCCAAGCACTC  
TGCGAGAATCCCGAGTGGGTACCATTGAAGGATAACAG  
GATTCCTTCATACGGGGTCCCTGTCTGTTGATCTGAGTCT  
GACGGTTGAGCTTAAAATCAAATGCTTCGGGATTCG  
GGCCATTGATCACACACGGCTCAGGGATGGACCTATAC  
AAATCCAACCTGCAACAATGTGTATTGGCTGACTATTCC  
GCCAATGAGAAATCTAGCCTTAGGCGTAATCAACACAT

TGGAGTGGATACCGAGATTCAAGGTTAGTCCCAACCTC  
TTC ACTGTCCCAATTAAGGAAGCAGGCGAAGACTGCCA  
TGCCCCAACATACTACCTGCGGAGGTGGACGGTGATG  
TCAA ACTCAGTTCCAACCTGGTGATTCTACCTGGTCAA  
GATCTCCAATATGTTTTGGCAACCTACGATACCTCCAG  
GGTTGAGCATGCTGTGGTTTATTACGTTTACAGCCCAA  
GCCGCTCATTCTTACTTTTATCCTTTTAGGTTGCCTAT  
AAAGGGGGTCCCAATCGAACTACAAGTGGAATGCTTCA  
CATGGGATCAAAA ACTCTGGTGCCGTC ACTTCTGTGTG  
CTTGCGGACTCAGAATCCGGTGGACTTATCACTCACTCT  
GGGATGGTGGGCATGGGAGTCAGCTGCACAGCTACCCG GGAAGATGGAACCAATCGCAGATAA  
GC\_H\_MEASLES\_G\*GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAAT 43 B3  
ATAAGAGCCACCATGTCACCGCAACGAGACCGGATAA mRNA Sequence  
ATGCCTTCTACAAAGATAACCCTTATCCCAAGGGAAGT (assumes T100 tail)  
AGGATAGTTATTAACAGAGAACATCTTATGATTGACAG Sequence Length:  
ACCCTATGTTCTGCTGGCTGTTCTGTTTCGTCATGTTTCT 2126  
GAGCTTGATCGGATTGCTGGCAATTGCAGGCATTAGAC  
TTCATCGGGCAGCCATCTACACCGCGGAGATCCATAAA  
AGCCTCAGTACCAATCTGGATGTGACTAACTCCATCGA  
GCATCAGGTCAAGGACGTGCTGACACCACTCTTTAAAA  
TCATCGGGGATGAAGTGGGCCTGAGAACACCTCAGAG  
ATTC ACTGACCTAGTGAAATTCATCTCGGACAAGATTA  
AATTCCTTAATCCGGATAGGGAGTACGACTTCAGAGAT  
CTCACTTGGTGCATCAACCCGCCAGAGAGGATCAA ACT  
AGATTATGATCAATACTGTGCAGATGTGGCTGCTGAAG  
AGCTCATGAATGCATTGGTGA ACTCAACTCTACTGGAG  
ACCAGAACAACCACTCAGTTCCTAGCTGTCTCAAAGGG  
AAACTGCTCAGGGCCCACTACAATCAGAGGTCAATTCT  
CAAACATGTCGCTGTCTTGTGGACTTGTACTTAGGTC  
GAGGTTACAATGTGTCATCTATAGTCACTATGACATCC  
CAGGGAATGTATGGGGGAACCTACCTAGTTGAAAAGCC  
TAATCTGAACAGCAAAGGGTTCAGAGTTGTCACA ACTGA  
GCATGTACCGAGTGTTTGAAGTAGGTGTGATCAGAAAC  
CCGGGTTTGGGGGCTCCGGTGTTCATATGACAAACTA  
TTTTGAGCAACCAGTCAGTAATGGTCTCGGCAACTGTA  
TGGTGGCTTTGGGGGAGCTCAA ACTCGCAGCCCTTTGT  
CACGGGGACGATTCTATCATAATTCCCTATCAGGGATC  
AGGGAAAGGTGTCAGCTTCCAGCTCGTCAAGCTGGGTG  
TCTGGAAATCCCCAACCGACATGCAATCCTGGGTCCCC  
TTATCAACGGATGATCCAGTGGTAGACAGGCTTTACCT  
CTCATCTCACAGAGGTGTCATCGCTGACAATCAAGCAA  
AATGGGCTGTCCCGACAACACGAACAGATGACAAGTTG  
CGAATGGAGACATGCTTCCAGCAGGCGTGTAAGGTAA  
AATCCAAGCACTCTGCGAGAATCCCGAGTGGGTACCAT  
TGAAGGATAACAGGATTCCCTTCATACGGGGTCCCTGTCT  
GTTGATCTGAGTCTGACGGTTGAGCTTAAAATCAAAT  
TGCTTCGGGATTCGGGCCATTGATCACACACGGCTCAG  
GGATGGACCTATACAAATCCA ACTGCAACAATGTGTAT  
TGGCTGACTATTCCGCCAATGAGAAATCTAGCCTTAGG  
CGTAATCAACACATTGGAGTGGATACCGAGATTCAAGG  
TTAGTCCCAACCTCTTCACTGTCCCAATTAAGGAAGCA  
GGCGAAGACTGCCATGCCCCAACATACTACCTGCGGA  
GGTGGACGGTGTGTCAAACTCAGTTCCAACCTGGTGA  
TTCTACCTGGTCAAGATCTCCAATATGTTTTGGCAACCT



ACGATACCTCCAGGGTTGAGCATGCTGTGGTTTATTAC  
GTTTACAGCCCAAGCCGCTCATTTTCTTACTTTTATCCT  
TTTAGGTTGCCTATAAAGGGGGTCCCAATCGAACTACA  
AGTGAATGCTTCACATGGGATCAAAAACCTCTGGTGCC  
GTCAC TTCTGTGTGCTTGC GGACTCAGAATCCGGTGGA  
CTTATCACTCACTCTGGGATGGTGGGCATGGGAGTCAG  
CTGCACAGCTACCCGGGAAGATGGAACCAATCGCAGAT  
AATGATAATAGGCTGGAGCCTCGGTGGCCAAGCTTCTT  
GCCCC TTGGGCCTCCCCCAGCCCCCTCCTCCCCTTCCTG  
CACCCGTACCCCGTGGTCTTTGAATAAAGTCTGAGTG  
GGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACT 44 D8  
CACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAA Sequence, NT (5'  
GAAATATAAGAGCCACCATGTCAACCACAACGAGACCG UTR, ORF, 3'  
GATAAATGCCTTCTACAAAGACAACCCCATCCTAAGG UTR)  
GAAGTAGGATAGTTATTAACAGAGAACATCTTATGATT Sequence Length:  
GATAGACCTTATGTTTTGCTGGCTGTTCTATTTCGTCATG 2065  
TTTCTGAGCTTGATCGGGTTGCTAGCCATTGCAGGCATT  
AGACTTCATCGGGCAGCCATCTACACCGCAGAGATCCA  
TAAAAGCCTCAGCACC AATCTGGATGTA ACTAACTCAA  
TCGAGCATCAGGTTAAGGACGTGCTGACACCACTCTTC  
AAGATCATCGGTGATGAAGTGGGCTTGAGGACACCTCA  
GAGATTCAC TGACCTAGTGAAGTTCATCTCTGACAAGA  
TTAAATTCCTTAATCCGGACAGGGAATACGACTTCAGA  
GATCTCACTTGGTGTATCAACCCGCCAGAGAGAATCAA  
ATTGGATTATGATCAATACTGTGCAGATGTGGCTGCTG  
AAGA ACTCATGAATGCATTGGTGA ACTCAACTCTACTG  
GAGACCAGGGCAACCAATCAGTTCCTAGCTGTCTCAA  
GGGAAACTGCTCAGGGCCCACTACAATCAGAGGCCAAT  
TCTCAAACATGTCGCTGTCCCTGTTGGACTTGTATTTAA  
GTCGAGGTTACAATGTGTCATCTATAGTCACTATGACA  
TCCCAGGGAATGTACGGGGGAACTTACCTAGTGGAAAA  
GCCTAATCTGAGCAGCAAAGGGTCAGAGTTGTCACAAC  
TGAGCATGCACCGAGTGTGTTGAAGTAGGTGTTATCAGA  
AATCCGGGTTTGGGGGCTCCGGTATTCCATATGACAAA  
CTATCTTGAGCAACCAGTCAGTAATGATTTTCAGCAACT  
GCATGGTGGCTTTGGGGGAGCTCAAGTTCGCAGCCCTC  
TGTCACAGGGAAGATTCTATCACAATCCCTATCAGGG  
ATCAGGGAAAGGTGTCAGCTTCCAGCTTGTC AAGCTAG  
GTGTCTGGAAATCCCAACCGACATGCAATCCTGGGTC  
CCCCTATCAACGGATGATCCAGTGATAGACAGGCTTTA  
CCTCTCATCTCACAGAGGCGTTATCGCTGACAATCAAG  
CAAAATGGGCTGTCCCGACAACACGGACAGATGACAA  
GTTGCGAATGGAGACATGCTTCCAGCAGGCGTGTAAGG  
GTAAAATCCAAGCACTTTGCGAGAATCCCGAGTGGACA  
CCATTGAAGGATAACAGGATTCCTTCATACGGGGTCTT  
GTCTGTTGATCTGAGTCTGACAGTTGAGCTTAAAATCA

AAATTGTTTCAGGATTCGGGCCATTGATCACACACGGT  
TCAGGGATGGACCTATACAAATCCAACCACAACAATAT  
GTATTGGCTGACTATCCCGCCAATGAAGAACCTGGCCT  
TAGGTGTAATCAACACATTGGAGTGGATACCGAGATTC

AAGGTTAGTCCCAACCTCTTCACTGTTCCAATTAAGGA  
AGCAGGCGAGGACTGCCATGCCCCAACATACCTACCTG  
CGGAGGTGGATGGTGTATGTCAAACCTCAGTTCCAATCTG  
GTGATTCTACCTGGTCAAGATCTCCAATATGTTCTGGCA  
ACCTACGATACTTCCAGAGTTGAACATGCTGTAGTTTAT  
TACGTTTACAGCCCAAGCCGCTCATTTTCTTACTTTTAT  
CCTTTTAGGTTGCCTGTAAGGGGGGTCCCCATTGAATTA  
CAAGTGGAAATGCTTCACATGGGACCAAAAACCTCTGGTG  
CCGTCACTTCTGTGTGCTTGCGGACTCAGAATCTGGTGG  
ACATATCACTCACTCTGGGATGGTGGGCATGGGAGTCA  
GCTGCACAGCCACTCGGGAAGATGGAACCAGCCGCAG  
ATAGTGATAATAGGCTGGAGCCTCGGTGGCCAAGCTTC  
TTGCCCTTGGGCTCCCCCAGCCCCTCCTCCCCTTCC  
TGCACCCGTACCCCGTGGTCTTTGAATAAAGTCTGAG TGGGCGGC GC\_H\_MEASLES\_  
ATGTCACCACAACGAGACCGGATAAATGCCTTCTACAA 45 D8  
AGACAACCCCATCCTAAGGGAAGTAGGATAGTTATTA ORF Sequence, NT  
ACAGAGAACATCTTATGATTGATAGACCTTATGTTTTGC  
TGGCTGTTCTATTCGTCATGTTTCTGAGCTTGATCGGGT  
TGCTAGCCATTGCAGGCATTAGACTTCATCGGGCAGCC  
ATCTACACCGCAGAGATCCATAAAAGCCTCAGCACCAA  
TCTGGATGTAACATAACTCAATCGAGCATCAGGTTAAGG  
ACGTGCTGACACCACTCTTCAAGATCATCGGTGATGAA  
GTGGGCTTGAGGACACCTCAGAGATTCACTGACCTAGT  
GAAGTTCATCTCTGACAAGATTAAATTCCTTAATCCGG  
ACAGGGAATACGACTTCAGAGATCTCACTTGGTGTATC  
AACCCGCCAGAGAGAATCAAATTGGATTATGATCAATA  
CTGTGCAGATGTGGCTGCTGAAGAACTCATGAATGCAT  
TGGTGAACCAACTCTACTGGAGACCAGGGCAACCAAT  
CAGTTCCTAGCTGTCTCAAAGGGAAACTGCTCAGGGCC  
CACTACAATCAGAGGCCAATTCTCAAACATGTCGCTGT  
CCCTGTTGGACTTGTATTTAAGTCGAGGTTACAATGTGT  
CATCTATAGTCACTATGACATCCCAGGGAATGTACGGG  
GGAACCTACCTAGTGGAAAAGCCTAATCTGAGCAGCAA  
AGGGTCAGAGTTGTCACTGAGCATGCACCGAGTGT  
TTGAAGTAGGTGTTATCAGAAATCCGGGTTTGGGGGCT  
CCGGTATTCCATATGACAAACTATCTTGAGCAACCAGT  
CAGTAATGATTTAGCAACTGCATGGTGGCTTTGGGGG  
AGCTCAAGTTCGCAGCCCTCTGTCACAGGGAAGATTCT  
ATCACAATTCCTATCAGGGATCAGGGAAAGGTGTCAG  
CTTCCAGCTTGTCAAGCTAGGTGTCTGGAAATCCCCAA  
CCGACATGCAATCCTGGGTCCCCCTATCAACGGATGAT  
CCAGTGATAGACAGGCTTTACCTCTCATCTCACAGAGG  
CGTTATCGCTGACAATCAAGCAAAATGGGCTGTCCCGA  
CAACACGGACAGATGACAAGTTGCGAATGGAGACATG  
CTTCCAGCAGGCGTGTAAGGGTAAAATCCAAGCACTTT  
GCGAGAATCCCGAGTGGACACCATTGAAGGATAACAG  
GATTCCTTCATACGGGGTCTTGTCTGTTGATCTGAGTCT  
GACAGTTGAGCTTAAAATCAAATTTGTTTCAGGATTCG  
GGCCATTGATCACACACGGTTCAGGGATGGACCTATAC  
AAATCCAACCACAACAATATGTATTGGCTGACTATCCC  
GCCAATGAAGAACCCTGGCCTTAGGTGTAATCAACACAT  
TGGAGTGGATACCGAGATTCAAGGTTAGTCCCAACCTC  
TTCCTGTTCCAATTAAGGAAGCAGGCGAGGACTGCCA  
TGCCCCAACATACCTACCTGCGGAGGTGGATGGTGTATG

TCAAACCTCAGTTCCAATCTGGTGATTCTACCTGGTCAAG  
ATCTCCAATATGTTCTGGCAACCTACGATACTTCCAGA  
GTTGAACATGCTGTAGTTTATTACGTTTACAGCCCAAGC  
CGCTCATTTTCTTACTTTTATCCTTTTAGGTTGCCTGTAA  
GGGGGGTCCCATGAATTACAAGTGGAATGCTTCACA  
TGGGACCAAAAACCTCTGGTGCCGTCACCTTCTGTGTGCTT  
GCGGACTCAGAATCTGGTGGACATATCACTCACTCTGG  
GATGGTGGGCATGGGAGTCAGCTGCACAGCCACTCGGG AAGATGGAACCAGCCGCAGATAG  
GC\_H\_MEASLES\_G\*GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAAT 46 D8  
ATAAGAGCCACCATGTCACCACAACCGAGACCGGATAA mRNA Sequence  
ATGCCTTCTACAAAGACAACCCCCATCCTAAGGGAAGT (assumes T100 tail)  
AGGATAGTTATTAACAGAGAACATCTTATGATTGATAG Sequence Length:  
ACCTTATGTTTTGCTGGCTGTTCTATTCGTCATGTTTCTG 2126  
AGCTTGATCGGGTTGCTAGCCATTGCAGGCATTAGACT  
TCATCGGGCAGCCATCTACACCGCAGAGATCCATAAAA  
GCCTCAGCACCAATCTGGATGTAACCTCAATCGAG  
CATCAGGTTAAGGACGTGCTGACACCACTCTTCAAGAT  
CATCGGTGATGAAGTGGGCTTGAGGACACCTCAGAGAT  
TCACTGACCTAGTGAAGTTCATCTCTGACAAGATTA  
TTCCTTAATCCGGACAGGGAATACGACTTCAGAGATCT  
CACTTGGTGTATCAACCCGCCAGAGAGAATCAAATTGG  
ATTATGATCAATACTGTGCAGATGTGGCTGCTGAAGAA  
CTCATGAATGCATTGGTGAACCTCACTCTACTGGAGAC  
CAGGGCAACCAATCAGTTCCTAGCTGTCTCAAAGGGAA  
ACTGCTCAGGGCCCACTACAATCAGAGGCCAATTCTCA  
AACATGTCGCTGTCCCTGTTGGACTTGTATTTAAGTCGA  
GGTTACAATGTGTCATCTATAGTCACTATGACATCCCA  
GGGAATGTACGGGGGAACCTTACCTAGTGGAAAAGCCT  
AATCTGAGCAGCAAAGGGTCAGAGTTGTCACAACCTGAG  
CATGCACCGAGTGTGTTGAAGTAGGTGTTATCAGAAATC  
CGGGTTTGGGGGCTCCGGTATTCCATATGACAAACTAT  
CTTGAGCAACCAGTCAGTAATGATTTCAAGCAACTGCAT  
GGTGGCTTTGGGGGAGCTCAAGTTCGCAGCCCTCTGTC  
ACAGGGAAGATTCTATCACAATCCCTATCAGGGATCA  
GGGAAAGGTGTCAGCTTCCAGCTTGTCAGCTAGGTGT  
CTGGAAATCCCCAACCGACATGCAATCCTGGGTCCCC  
TATCAACGGATGATCCAGTGATAGACAGGCTTTACCTC  
TCATCTCACAGAGGCGTTATCGCTGACAATCAAGCAA  
ATGGGCTGTCCCGACAACACGGACAGATGACAAGTTGC  
GAATGGAGACATGCTTCCAGCAGGCGTGTAAGGGTAA  
AATCCAAGCACTTTGCGAGAATCCCGAGTGGACACCAT  
TGAAGGATAACAGGATTCCCTTCATACGGGGTCTTGTCT  
GTTGATCTGAGTCTGACAGTTGAGCTTAAAATCAAAT  
TGTTTCAGGATTCGGGCCATTGATCACACACGGTTCAG  
GGATGGACCTATACAAATCCAACCACAACAATATGTAT  
TGGCTGACTATCCCGCCAATGAAGAACCTGGCCTTAGG  
TGTAATCAACACATTGGAGTGGATACCGAGATTCAAGG  
TTAGTCCCAACCTCTTCACTGTTCCAATTAAGGAAGCA  
GGCGAGGACTGCCATGCCCCAACATACCTACCTGCGGA  
GGTGGATGGTGTGATGCAAACTCAGTTCCAATCTGGTGA  
TTCTACCTGGTCAAGATCTCCAATATGTTCTGGCAACCT  
ACGATACTTCCAGAGTTGAACATGCTGTAGTTTATTAC  
GTTTACAGCCCAAGCCGCTCATTTTCTTACTTTTATCCT  
TTTAGGTTGCCTGTAAGGGGGTCCCCATTGAATTACA

AGTGG AATGCTTCACATGGGACCAAAA ACTCTGGTGCC  
GTC ACTTCTGTGTGCTTGC G GACTCAGAATCTGGTGGA  
CATATCACTCACTCTGGGATGGTGGGCATGGGAGTCAG  
CTGCACAGCCACTCGGGAAGATGGAACCAGCCGCAGA  
TAGTGATAATAGGCTGGAGCCTCGGTGGCCAAGCTTCT  
TGCCCCTTGGGCCTCCCCCAGCCCCTCCTCCCCTTCCT  
GCACCCGTACCCCGTGGTCTTTGAATAAAGTCTGAGT  
GGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAT CTAG MeV mRNA Sequences  
GC\_F\_MEASLES\_UCAAGCUUUUGGACCCUCGUACAGAAGCUAAUACGAC 69 B3.1  
UCACUAUAGGGAAUAAGAGAGAAAAGAAGAGUAAG Sequence, NT (5'  
AAGAAUAUAAGAGCCACCAUGGGUCUCAAGGUGAA UTR, ORF, 3'  
CGUCUCUGCCGUAUUCAUGGCAGUACUGUUAACUCUC UTR)  
CAAACACCCGCCGGUCAAAUUCAUUGGGGCAAUCUCU Sequence Length:  
CUAAGAUAGGGGUAGUAGGAAUAGGAAGUGCAAGCU 1864  
ACAAAGUUAUGACUCGUUCCAGCCAUCAUCAUUAGU  
CAUAAAAUUAUGCCCAAUAUAACUCUCCUCAUAAC  
UGCACGAGGGUAGAGAUUGCAGAAUACAGGAGACUA  
CUAAGAACAGUUUUGGAACCAAUUAGGGAUGCACUU  
AAUGCAAUGACCCAGAACAUAAGGCCGGUUCAGAGCG  
UAGCUUCAAGUAGGAGACACAAGAGAUUUGCGGGAG  
UAGUCCUGGCAGGUGCGGCCCUAGGUGUUGCCACAGC  
UGCUCAGAUAACAGCCGGCAUUGCACUUCACCGGUCC  
AUGCUGAACUCUCAGGCCAUCGACAAUCUGAGAGCGA  
GCCUGGAAACUACUAAUCAGGCAAUUGAGGCAAUCAG  
ACAAGCAGGGCAGGAGAUGAUAUUGGCUGUUCAGGG  
UGUCCAAGACUACAUCAUAUAUGAGCUGAUACCGUCU  
AUGAACCAGCUAUCUUGUGAUCUAAUCGGUCAGAAGC  
UCGGGCUCAAUUGCUUAGAUACUUAACAGAAAUCCU  
GUCAUUAUUUGGCCCCAGCCUACGGGACCCCAUAUCU  
GCGGAGAUAUUCU AUCCAGGCUUUGAGUUAUGCACUU  
GGAGGAGAUUCAUAAGGUGUUAGAAAAGCUCGGA  
UACAGUGGAGGCGAUUUACUAGGCAUCUUAAGAGAGC  
AGAGGAAUAAGGCUCGGAUAACUCACGUCGACACAG  
AGUCCUACUUCAUAGUCCUCAGUAUAGCCUAUCCGAC  
GCUGUCCGAGAUUAAGGGGGUGAUUGUCCACCGGCUA  
GAGGGGGUCUCGUACAACAUAAGGCUCUCAAGAGUGG  
UAUACCACUGUGCCCAAGUAUGUUGCAACCCAAGGGU  
ACCUUAUCUCGAAUUUUGAUGAGUCAUCAUGUACUU  
UCAUGCCAGAGGGGACUGUGUGCAGCCAAAUGCCUU  
GUACCCGAUGAGUCCUCUGCUCCAAGAAUGCCUCCGG  
GGUCCACCAAGUCCUGUGCUCGUACACUCGUAUCCG  
GGUCUUUUGGGAACCGGUUCAUUUUAUCACAAGGGA  
ACCUAAUAGCCAAUUGUGCAUCAAUUCUUGUAAGU  
GUUACACAACAGGUACGAUUAUUAUCAAGACCCUGA  
CAAGAUCUACAUAUCAUUGCUGCCGAUCGUGCCCG  
GUAGUCGAGGUGAACGGCGUGACCAUCCAAGUCGGGA  
GCAGGAGGUAUCCAGACGCUGUGUACUUGCACAGAAU  
UGACCUCGGUCCUCCCAUAUCAUUGGAGAGGUUGGAC  
GUAGGGACAAAUCUGGGGAAUGCAAUUGCCAAAUUG  
GAGGAUGCCAAGGAAUUGUUGGAAUCAUCGGACCAG  
AUAUUGAGAAGUAUGAAAGGUUAUCGAGCACUAGC  
AUAGUCUACAUCCUGAUUGCAGUGUCUUGGAGGG

UUGAUAGGGAUCCCCACUUAAUAUGUUGCUGCAGG  
GGGCGUUGUAACAAAAAGGGAGAACAAGUUGGUAUG  
UCAAGACCAGGCCUAAAGCCUGACCUUACAGGAACAU  
CAAAUCCUAUGUAAGAUCGCUUUGAUGAUAAUAGG  
CUGGAGCCUCGGUGGCCAAGCUUCUUGCCCCUUGGGC  
CUCCCCCAGCCCCUCCUCCCCUCCUGCACCCGUACC  
CCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC GC\_F\_MEASLES\_  
AUGGGUCUCAAGGUGAACGUCUCUGCCGUAUUCAUGG 70 B3.1  
CAGUACUGUUAACUCUCUCCAAACACCCGCCGGUCAAAU ORF Sequence, NT  
UCAUUGGGGCAAUCUCUCUAAGAUAGGGGUAGUAGG  
AAUAGGAAGUGCAAGCUACAAAGUUAUGACUCGUUC  
CAGCCAUCAAUCAUUAGUCAUAAAUUAUUGCCCAAU  
AUAACUCUCCUCAUAACUGCACGAGGGUAGAGAUUG  
CAGAAUACAGGAGACUACUAAGAACAGUUUUGGAAC  
CAAUUAGGGAUGCACUAAUGCAAUGACCCAGAACAU  
AAGGCCGGUUCAGAGCGUAGCUUCAAGUAGGAGACAC  
AAGAGAUUUGCGGGAGUAGUCCUGGCAGGUGCGGCC  
UAGGUGUUGCCACAGCUGCUCAGAUAAACAGCCGGCAU  
UGCACUUCACCGGUCCAUGCUGAACUCUCAGGCCAUC  
GACAAUCUGAGAGCGAGCCUGGAAACUACUAAUCAGG  
CAAUUGAGGCAAUCAGACAAGCAGGGCAGGAGAUGA  
UAUUGGCUGUUCAGGGUGUCCAAGACUACAUCAAUA  
AUGAGCUGAUACCGUCUAUGAACAGCUAUCUUGUGA  
UCUAAUCGGUCAGAAGCUCGGGCUCAAAUUGCUUAGA  
UACUAUACAGAAUCCUGUCAUUAUUUGGCCCCAGCC  
UACGGGACCCCAUAUCUGCGGAGAUUCUAUCCAGGC  
UUUGAGUUAUGCACUUGGAGGAGAUUCAUAAGGU  
GUUAGAAAAGCUCGGAUACAGUGGAGGCGAUUUACU  
AGGCAUCUUAGAGAGCAGAGGAAUAAAGGCUCGGAU  
AACUCACGUCGACACAGAGUCCUACUUCAUAGUCCUC  
AGUAUAGCCUAUCCGACGCUGUCCGAGAUUAAGGGGG  
UGAUUGUCCACCGGCUAGAGGGGGUCUCGUACAACAU  
AGGCUCUCAAGAGUGGUUAUACCACUGUGCCCAAGUAU  
GUUGCAACCCAAGGGUACCUUAUCUCGAAUUUUGAUG  
AGUCAUCAUGUACUUAUGCCAGAGGGGACUGUGU  
GCAGCCAAAUGCCUUGUACCCGAUGAGUCCUCUGCU  
CCAAGAAUGCCUCCGGGGGUCCACCAAGUCCUGUGCU  
CGUACACUCGUAUCCGGGUCUUUUGGGAACCGGUUCA  
UUUUUAUCACAAGGGAACCUAAUAGCCAAUUGUGCAUC  
AAUUCUUUGUAAGUGUUACACAACAGGUACGAUUAU  
UAAUCAAGACCCUGACAAGAUCUUAACAUAUUGCU  
GCCGAUCGUCGCCCGGUAGUCGAGGUGAACGGCGUGA  
CCAUCCAAGUCGGGAGCAGGAGGUAUCCAGACGCUGU  
GUACUUGCACAGAAUUGACCUCGGUCCUCCAUAUCA  
UUGGAGAGGUUGGACGUAGGGACAAAUCUGGGGAAU  
GCAAUUGCCAAAUUGGAGGAUGCCAAGGAAUUGUUG  
GAAUCAUCGGACCAGAUUUGAGAAGUAUGAAAGGU  
UUAUCGAGCACUAGCAUAGUCUACAUCUGAUUGCAG  
UGUGUCUUGGAGGGUUGAUAGGGAUCCCCACUUUAA  
UAUGUUGCUGCAGGGGGCGUUGUAACAAAAAGGGAG  
ACAAGUUGGUUUGUCAAGACCAGGCCUAAAGCCUGA  
CCUACAGGAACAUCAAAUCCUAUGUAAGAUCGCUU UGA GC\_F\_MEASLES\_  
G\*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAA 71 B3.1  
UAUAAGAGCCACCAUGGGUCUCAAGGUGAACGUCUCU mRNA Sequence

GCCGUAUUCAUGGCAGUACUGUUAACUCUCCAAACAC (assumes T100 tail)

CCGCCGGUCAAAUUCUUGGGGCAAUCUCUCUAAGAU mRNA Sequence

AGGGGUAGUAGGAAUAGGAAGUGCAAGCUACAAAGU Length: 1925

UAUGACUCGUUCCAGCCAUCAUUAUAGUCAUAAAA  
UUAAUGCCCAAUAUAAACUCUCCUCAUAAACUGCACGA  
GGGUAGAGAUUGCAGAAUACAGGAGACUACUAAGAA  
CAGUUUUGGAACCAAUUAAGGGAUGCACUAAUGCAA  
UGACCCAGAACAUAAGGCCGGUUCAGAGCGUAGCUUC  
AAGUAGGAGACACAAGAGAUUUGCGGGAGUAGUCCU  
GGCAGGUGCGGCCCUAGGUGUUGCCACAGCUGCUCAG  
AUAAACAGCCGGCAUUGCACUUCACCGGUCCAUGCUGA  
ACUCUCAGGCCAUCGACAAUCUGAGAGCGAGCCUGGA  
AACUACUAAUCAGGCAAUUGAGGCAAUCAGACAAGCA  
GGGCAGGAGAUGAUUUGGCUGUUCAGGGUGUCCAA  
GACUACAUAUAAUGAGCUGAUACCGUCUAUGAACCC  
AGCUAUCUUGUGAUCUAAUCGGUCAGAAGCUCGGGCU  
CAAUUGCUUAGAUACUUAACAGAAAUCCUGUCAUU  
AUUUGGCCCCAGCCUACGGGACCCCAUAUCUGCGGAG  
AUAUCUAUCCAGGCUUUGAGUUAUGCACUUGGAGGA  
GAUAUCAUAAGGUGUUAGAAAAGCUCGGAUACAGU  
GGAGGCGAUUUACUAGGCAUCUUAGAGAGCAGAGGA

AUAAAGGCUCGGAUAAACUCACGUCGACACAGAGUCCU  
ACUUCAUAGUCCUCAGUAUAGCCUAUCCGACGCUGUC  
CGAGAUUAAGGGGGUGAUUGUCCACCGGCUAGAGGG  
GGUCUCGUACAACAUAGGCUCUCAAGAGUGGUUUAACC  
ACUGUGCCCAAGUAUGUUGCAACCCAAGGGUACCUUA  
UCUCGAAUUUUGAUGAGUCAUCAUGUACUUUCAUGCC  
AGAGGGGACUGUGUGCAGCCAAAUGCCUUGUACCCG  
AUGAGUCCUCUGCUCCAAGAAUGCCUCCGGGGGUCCA  
CCAAGUCCUGUGCUCGUACACUCGUUCCGGGUCUUU  
UGGGAACCGGUUCAUUUUAUCACAAGGGAACCUAAU  
AGCCAAUUGUGCAUCAAUUCUUUGUAAGUGUUACAC  
AACAGGUACGAUUAUUAAUCAAGACCCUGACAAGAUC  
CUAACAUACAUUGCUGCCGAUCGCUGCCCGGUAGUCG  
AGGUGAACGGCGUGACCAUCCAAGUCGGGAGCAGGAG  
GUAUCCAGACGCUGUGUACUUGCACAGAAUUGACCUC  
GGUCCUCCCAUAUCAUUGGAGAGGUUGGACGUAGGG  
ACAAAUCUGGGGAAUGCAAUUGCCAAAUUGGAGGAU  
GCCAAGGAAUUGUUGGAAUCAUCGGACCAGAUUUG  
AGAAGUAUGAAAGGUUAUCGAGCACUAGCAUAGUC  
UACAUCCUGAUUGCAGUGUGUCUUGGAGGGUUGAUA  
GGGAUCCCCACUUAAUAUGUUGCUGCAGGGGGCGUU  
GUAACAAAAGGGGAGAACAAGUUGGUAUGUCAAGAC  
CAGGCCUAAAGCCUGACCUUACAGGAACAUCAAAUC  
CUAUGUAAGAUCGCUUUGAUGAUAAUAGGCUGGAGC  
CUCGGUGGCCAAGCUUCUUGCCCCUUGGGCCUCCCC  
CAGCCCCUCCUCCCCUUCUGCACCCGUACCCCCGUGG  
UCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAUUCUAG  
GC\_F\_MEASLES\_UCAAGCUUUUGGACCCUCGUACAGAAGCUAAUACGAC 72 D8  
UCACUAUAGGGAAUUAAGAGAGAAAAGAAGAGUAAG Sequence, NT (5'  
AAGAAUUAUAAAGAGCCACCAUGGGUCUCAAGGUGAA UTR, ORF, 3'

CGUCUCUGUCAUAUUCAUGGCAGUACUGUUAACUCUU UTR)  
CAAACACCCACCGGUCAAUCCAUGGGGCAAUCUCU Sequence Length:  
CUAAGAUAGGGGUGGUAGGGGUAGGAAGUGCAAGCU 1864  
ACAAAGUUAUGACUCGUUCCAGCCAUCAUCAUUAGU  
CAUAAAGUUAUGCCCAAUAUAACUCUCCUCAACAAU  
UGCACGAGGGUAGGGAUUGCAGAAUACAGGAGACUA  
CUGAGAACAGUUCUGGAACCAAUUAGAGAUGCACUU  
AAUGCAAUGACCCAGAAUAUAAGACCGGUUCAGAGU  
GUAGCUUCAAGUAGGAGACACAAGAGAUUUGCGGGA  
GUUGUCCUGGCAGGUGCGGCCCUAGGCGUUGCCACAG  
CUGCUCAAAUAACAGCCGGUAUUGCACUUCACCAGUC  
CAUGCUGAACUCUCAAGCCAUCGACAAUCUGAGAGCG  
AGCCUAGAAACUACUAAUCAGGCAAUUGAGGCAAUCA  
GACAAGCAGGGCAGGAGAUGAUUAUUGGCUGUUCAGG  
GUGUCCAAGACUACAUCAAAUAUGAGCUGAUACCGUC  
UAUGAAUCAACUAUCUUGUGAUUUAAUCGGCCAGAA  
GCUAGGGCUCAAAUUGCUCAGAUACUAUACAGAAAUC  
CUGUCAUUAUUUGGCCCCAGCUUACGGGACCCCAUAU  
CUGCGGAGAUUCUAUCCAGGCUUUGAGCUAUGCGCU  
UGGAGGAGAUUCAAAUAAGGUGUUGGAAAAGCUCGG  
AUACAGUGGAGGUGAUCUACUGGGCAUCUUAGAGAG  
CAGAGGAAUAAAGGCCCGGAUAACUCACGUCGACACA  
GAGUCCUACUUCAUUGUACUCAGUAUAGCCUAUCCGA  
CGCUAUCCGAGAUUAAGGGGGUGAUUGUCCACCGGCU  
AGAGGGGGUCUCGUACAACAUAAGGCUCUCAAGAGUG  
GUAUACCACUGUGCCCAAGUAUGUUGCAACCCAAGGG  
UACCUUAUCUCGAAUUUUGAUGAGUCAUCAUGCACUU  
UCAUGCCAGAGGGGACUGUGUGCAGCCAGAAUGCCUU  
GUACCCGAUGAGUCCUCUGCUCCAAGAAUGCCUCCGG  
GGGUCCACUAAGUCCUGUGCUCGUACACUCGUAUCCG  
GGUCUUUCGGGAACCGGUUCAUUUUAUCACAGGGGA  
ACCUAAUAGCCAAUUGUGCAUCAAUCCUUUGCAAGUG  
UUACACAACAGGAACAAUCAUUAUCAAGACCCUGAC  
AAGAUCCUAACAUAUAUUGCUGCCGAUCACUGCCCGG  
UGGUCGAGGUGAAUGGCGUGACCAUCCAAGUCGGGA  
GCAGGAGGUAUCCGGACGCUGUGUACUUGCACAGGAU  
UGACCUCGGUCCUCCCAUAUCUUUGGAGAGGUUGGAC  
GUAGGGACAAAUCUGGGGAAUGCAAUUGCUAAGUUG  
GAGGAUGCCAAGGAAUUGUUGGAGUCAUCGGACCAG  
AUUUGAGGAGUAUGAAAGGUUUAUCGAGCACUAGU  
AUAGUUUACAUCCUGAUUGCAGUGUGUCUUGGAGGA  
UUGAUAGGGAUCCCCGCUUUAUAUGUUGCUGCAGG  
GGGCGUUGUAACAAGAAGGGAGAACAAGUUGGUAUG  
UCAAGACCAGGCCUAAAGCCUGAUCUACAGGAACAU  
CAAAAUCCUAUGUAAGGUCACUCUGAUGAUAAUAGG  
CUGGAGCCUCGGUGGCCAAGCUUCUUGCCCCUUGGGC  
CUCCCCCAGCCCCUCCUCCCCUCCUGCACCCGUACC  
CCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC GC\_F\_MEASLES\_  
AUGGGUCUCAAGGUGAACGUCUCUGUCAUAUUCAUG 73 D8  
GCAGUACUGUUAACUCUCAAACACCCACCGGUCAA ORF Sequence, NT  
UCCAUUGGGGCAAUCUCUCUAAGAUAGGGGUGGUAG  
GGUAGGAAGUGCAAGCUACAAGUUAUGACUCGUU  
CCAGCCAUCAAUCAUUGUCAUAAAGUUAUUGCCCAA  
UAUAACUCUCCUCAACAAUUGCACGAGGGUAGGGAAU

GCAGAAUACAGGAGACUACUGAGAACAGUUCUGGAA  
CCAAUUAAGAGAUAGCACUAAAUGCAAUGACCCAGAAUA  
UAAGACCGGUUCAGAGUGUAGCUUCAAGUAGGAGAC  
ACAAGAGAUUUGCGGGAGUUGUCCUGGCAGGUGCGG  
CCCUAGGCGUUGCCACAGCUGCUAAAUAACAGCCGG  
UAUUGCACUUCACCAGUCCAUGCUGAACUCUCAAGCC  
AUCGACAAUCUGAGAGCGAGCCUAGAAACUACUAAUC  
AGGCAAUUGAGGCAAUCAGACAAGCAGGGCAGGAGA  
UGAUAUUGGCUGUUCAGGGUGUCCAAGACUACAUCA  
AUAUUGAGCUGAUACCGUCUAUGAAUCAACUACUUCU  
GUGAUUUAAAUCGGCCAGAAGCUAGGGCUAAAUUGC  
UCAGAUACUUAACAGAAAUCUGUCAUUAAUUGGCC  
CAGCUUACGGGACCCCAUAUCUGCGGAGAUUCUUAUC  
CAGGCUUUGAGCUAUGCGCUUGGAGGAGAUUCAAU  
AAGGUGUUGGAAAAGCUCGGAUACAGUGGAGGUGAU  
CUACUGGGCAUCUUAGAGAGCAGAGGAAUAAAGGCC  
GGAUAACUCACGUCGACACAGAGUCCUACUUCAUUGU  
ACUCAGUAUAGCCUAUCCGACGCUAUCGAGAUUAAG  
GGGUGAUUGUCCACCGGCUAGAGGGGGUCUCGUACA  
ACAUAGGCUCUCAAGAGUGGUUAUACCACUGUGCCCAA  
GUAUGUUGCAACCCAAGGGUACCUUAUCUCGAAUUUU  
GAUGAGUCAUCAUGCACUUUCAUGCCAGAGGGGACUG  
UGUGCAGCCAGAAUGCCUUGUACCCGAUGAGUCCUCU  
GCUCCAAGAAUGCCUCCGGGGGUCCACUAAGUCCUGU  
GCUCGUACACUCGUAUCCGGGUCUUUCGGGAACCGGU  
UCAUUUUUAUCACAGGGGAACCUAAUAGCCAAUUGUGC  
AUCAAUCCUUUGCAAGUGUUACACAACAGGAACAAUC  
AUAAUCAAGACCCUGACAAGAUCCUAACAUACAUUG  
CUGCCGAUCACUGCCCGGUGGUCGAGGUGAAUGGCGU  
GACCAUCCAAGUCGGGAGCAGGAGGUUACCGGACGCU  
GUGUACUUGCACAGGAUUGACCUCGGUCCUCCCAUUA  
CUUUGGAGAGGUUGGACGUAGGGACAAAUCUGGGGA  
AUGCAAUUGCUAAGUUGGAGGAUGCCAAGGAAUUGU  
UGGAGUCAUCGGACCAGAUUAUUGAGGAGUAUGAAAG  
GUUUAUCGAGCACUAGUAUAGUUUACAUCCUGAUUG  
CAGUGUGUCUUGGAGGAUUGAUAGGGAUCCCCGCUU  
UAAUAUGUUGCUGCAGGGGGCGUUGUAACAAGAAGG  
GAGAACAAGUUGGUUUGUCAAGACCAGGCCUAAAGCC  
UGAUCUUACAGGAACAUCAAAUCCUAUGUAAGGUC ACUCUGA GC\_F\_MEASLES\_  
G\*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAA 74 D8  
UAUAAGAGCCACCAUGGGUCUCAAGGUGAACGUCUCU mRNA Sequence  
GUCAUAUUCAUGGCAGUACUGUUAACUCUCAAACAC (assumes T100 tail)  
CCACCGGUCAAUCCAUUGGGGCAAUCUCUCUAAGAU Sequence Length:  
AGGGGUGGUAGGGGUAGGAAGUGCAAGCUACAAAGU 1925  
UAUGACUCGUUCCAGCCAUCAAUCAUUAGUCAUAAAG  
UUAAUGCCCAAUAUAACUCUCCUCAACAAUUGCACGA  
GGGUAGGGAUUGCAGAAUACAGGAGACUACUGAGAA  
CAGUUCUGGAACCAAUUAGAGAUGCACUUAUUGCAA  
UGACCCAGAAUAUAAGACCGGUUCAGAGUGUAGCUUC  
AAGUAGGAGACACAAGAGAUUUGCGGGAGUUGUCCU  
GGCAGGUGCGGCCCUAGGCGUUGCCACAGCUGCUCAA  
AUAACAGCCGGUAUUGCACUUCACCAGUCCAUGCUGA  
ACUCUCAAGCCAUCGACAAUCUGAGAGCGAGCCUAGA  
AACUACUAAUCAGGCAAUUGAGGCAAUCAGACAAGCA



GGGCAGGAGAUGAUAUUGGCUGUUCAGGGUGUCCAA  
 GACUACAUCAAUAAUGAGCUGAUACCGUCUAUGAAUC  
 AACUAUCUUGUGAUUUAAUCGGCCAGAAGCUAGGGC  
 UCAAAUUGCUCAGAUACUAUACAGAAAUCCUGUCAUU  
 AUUUGGCCCCAGCUUACGGGACCCCAUAUCUGCGGAG  
 AUUUCUAUCCAGGCUUUGAGCUAUGCAGCUUGGAGGA  
 GAUAUCAAAUAAAGGUGUUGGAAAAGCUCGGAUACAGU  
 GGAGGUGAUCUACUGGGCAUCUUAAGAGAGCAGAGGA  
 AUAAAGGCCCGGAUAACUCACGUCGACACAGAGUCCU  
 ACUUCAUUGUACUCAGUAUAGCCUAUCCGACGCUAUC  
 CGAGAUUAAGGGGGUGAUUGUCCACCGGCUAGAGGG  
 GGUCUCGUACAACAUAAGGCUCUCAAGAGUGGUAUACC  
 ACUGUGCCCAAGUAUGUUGCAACCCAAGGGUACCUUA  
 UCUCGAAUUUUGAUGAGUCAUCAUGCACUUAUGCC  
 AGAGGGGACUGUGUGCAGCCAGAAUGCCUUGUACCCG  
 AUGAGUCCUCUGCUCCAAGAAUGCCUCCGGGGGUCCA  
 CUAAGUCCUGUGCUCGUACACUCGUUACCGGGUCUUU  
 CGGGAAACCGGUUCAUUUAUCACAGGGGAACCUAAUA  
 GCCAAUUGUGCAUCAUCCUUGCAAGUGUUAACCAA  
 CAGGAACAAUCAUUAUUAUCAGAACCCUGACAAGAUCU  
 AACAUACAUUGCUGCCGAUCACUGCCCGGUGGUCGAG  
 GUGAAUGGCGUGACCAUCCAAGUCGGGAGCAGGAGG  
 UAUCCGGACGCUGUGUACUUGCACAGGAUUGACCUCG  
 GUCCUCCAUAUCUUGGAGAGGUUGGACGUAGGGAC  
 AAUCUGGGGAAUGCAAUUGCUAAGUUGGAGGAUGC  
 CAAGGAAUUGUUGGAGUCAUCGGACCAGAUAUUGAG  
 GAGUAUGAAAGGUUAUCGAGCACUAGUAUAGUUA  
 CAUCCUGAUUGCAGUGUGUCUUGGAGGAUUGAUAGG  
 GAUCCCCGCUUUAUAUUGUUGCUGCAGGGGGCGUUGU  
 AACAGAAGGGAGAACAAAGUUGGUAUGUCAAGACCA  
 GGCCUAAAGCCUGAUCUUAACAGGAACAUCAAAUCU  
 AUGUAAGGUCACUCUGAUGAUAUAAGGCUGGAGCCU  
 CGGUGGCCAAGCUUCUUGCCCCUUGGGCCUCCCCCA  
 GCCCUCCUCCCUUCCUGCACC CGUACCCCGUGGGUC  
 UUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAA  
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAUCUAG  
 GC\_H\_MEASLES\_ UCAAGCUUUUGGACCCUCGUACAGAAGCUAAUACGAC 75 B3  
 UCACUAUAGGGAAUUAAGAGAGAAAAGAAGAGUAAG Sequence, NT (5'  
 AAGAAAUUAAGAGCCACCAUGUCACCGCAACGAGAC UTR, ORF, 3'  
 CGGAUAAAUGCCUUCUACAAGAUAAACCCUUAUCCCA UTR)  
 AGGGAAGUAGGAUAGUUAUUAAACAGAGAACAUUCUUA Sequence Length:  
 UGAUUGACAGACCCUUGUUCUGGCUGGCUUUCUGUU 2065  
 CGUCAUGUUCUGAGCUUGAUCGGAUUGCUGGCAAU  
 UGCAGGCAUUAAGACUUCUACGGGCAGCCAUCUACACC  
 GCGGAGAUCCAUAAGAAGCCUCAGUACCAAUCUGGAUG  
 UGACUAACUCCAUCGAGCAUCAGGUAAGGACGUGCU  
 GACACCACUCUUUAAAAUCAUCGGGGAUGAAGUGGGC  
 CUGAGAACACCUCAGAGAUUCACUGACCUAGUGAAAU  
 UCAUCUCGGACAAGAUUAAAUCCUUAAUCCGGAUAG  
 GGAGUACGACUUCAGAGAUUCACUUGGUGCAUCAAC  
 CCGCCAGAGAGGAUCAAACUAGAUUAUGAUCAAUACU  
 GUGCAGAUGUGGCUGCUGAAGAGCUCUUGAAUGCAU  
 UGGUGAACUCAACUCUACUGGAGACCAGAACAACCAC

UCAGUCCUAGCUGUCUCAAGGGAAACUGCUCAGGG  
CCCACUACAAUCAGAGGUCAAUUCUCAACAUGUCGC  
UGUCCUUGUUGGACUUGUACUUAAGGUCGAGGUACA  
AUGUGUCAUCUAUAGUCACUAUGACAUCCCAGGGAAU  
GUAUGGGGGAAACCUACCUAGUUGAAAAGCCUAAUCU  
GAACAGCAAAGGGUCAGAGUUGUCACAACUGAGCAU  
GUACCGAGUGUUUGAAGUAGGUGUGAUCAGAAACCC  
GGGUUUGGGGGCUCGCGUGUCCAUAUGACAAACUA  
UUUUGAGCAACCAGUCAGUAAUGGUCUCGGCAACUGU  
AUGGUGGCUUUGGGGGAGCUCAAACUCGCAGCCCUU  
GUCACGGGGACGAUUCUAUCAUAAUCCCUAUCAGGG  
AUCAGGGAAAGGUGUCAGCUUCCAGCUCGUCAAGCUG  
GGUGUCUGGAAAUCCCCAACCGACAUGCAAUCCUGGG  
UCCCCUUAUCAACGGAUGAUCCAGUGGUAGACAGGCU  
UUACCUCUCAUCUCACAGAGGUGUCAUCGCUGACAAU  
CAAGCAAAAUGGGCUGUCCCGACAACACGAACAGAUG  
ACAAGUUGCGAAUGGAGACAUGCUUCCAGCAGGCGUG  
UAAAGGUAAAAUCCAAGCACUCUGCGAGAAUCCCGAG  
UGGGUACCAUUGAAGGAUAACAGGAUCCUUCAUAC  
GGGUCCUGUCUGUUGAUCUGAGUCUGACGGUUGAG  
CUUAAAAUCAAAAUUGCUUCGGGAUUCGGGCCAUUG  
AUCACACACGGCUCAGGGAUGGACCUAUACAAAUCCA  
ACUGCAACAAUGUGUAUUGGCUGACUAUCCGCCAAU  
GAGAAAUCUAGCCUUAAGGCGUAAUCAACACAUUGGA  
GUGGAUACCGAGAUUCAAGGUUAGUCCCAACCUCUUC  
ACUGUCCCAAUUAAGGAAGCAGGCGAAGACUGCCAUG  
CCCCAACAUACCUACCUUGCGGAGGUGGACGGUGAUGU  
CAAACUCAGUCCAACCUGGUGAUUCUACCUGGUCAA  
GAUCUCCAUAUGUUUUGGCAACCUACGAUACCUCCA  
GGGUUGAGCAUGCUGUGGUUUUAUUACGUUUACAGCC  
CAAGCCGCUCAUUUUCUUAUUUUUUAUCCUUUUAGGUU  
GCCUAUAAAGGGGGUCCCAAUCGAACUACAAGUGGAA  
UGCUCACAUGGGAUCAAAAACUCUGGUGCCGUCACU  
UCUGUGUGCUUGCGGACUCAGAAUCCGGUGGACUUAU  
CACUCACUCUGGGAUGGUGGGCAUGGGAGUCAGCUGC  
ACAGCUACCCGGGAAGAUGGAACCAAUCGCAGAUAAU  
GAUAAUAGGCUGGAGCCUCGGUGGCCAAGCUUCUUGC  
CCCUUGGGCCUCCCCCAGCCCCUCCUCCCCUCCUGC  
ACCCGUACCCCGUGGUCUUUGAAUAAAGUCUGAGUG GGC GGC GC\_H\_MEASLES\_  
AUGUCACCGCAACGAGACCGGAUAAAUGCCUUCUACA 76 B3  
AAGAUAAACCCUUAUCCCAAGGGAAGUAGGAUAGUUA ORF Sequence, NT  
UUAACAGAGAACAUUCUUAUGAUUGACAGACCCUAUG  
UUCUGCUGGCUGUUCUGUUCGUAUGUUUCUGAGCUU  
GAUCGGAUUGCUGGCAAUUGCAGGCAUUAGACUUCA  
UCGGGCAGCCAUCUACACCGCGGAGAUCCAUAAAAGC  
CUCAGUACCAAUCUGGAUGUGACUAAUCUCCAUCGAGC  
AUCAGGUCAAGGACGUGCUGACACCACUCUUAAAAU  
CAUCGGGGAUGAAGUGGGCCUGAGAACACCUCAGAGA

UUCACUGACCUAGUGAAAUUCAUCUCGGACAAGAUUA  
AAUCCUUAUCCGGAUAGGGAGUACGACUUCAGAG  
AUCUCACUUGGUGCAUCAACCCGCCAGAGAGGAUCAA  
ACUAGAUUAUGAUCAAUACUGUGCAGAUGUGGCUGC  
UGAAGAGCUCAUGAAUGCAUUGGUGAACUCAACUCU

ACUGGAGACCAGAACAACCACUCAGUCCUAGCUGUC  
UCAAGGGAAACUGCUCAGGGCCACUACAAUCAGAG  
GUCAAUUCUCAACAUGUCGCUGUCCUUGUUGGACUU  
GUACUUAGGUCGAGGUUACAAUGUGUCAUCUAUAGU  
CACUAUGACAUCCCAGGGAAUGUAUGGGGGAACCUAC  
CUAGUUGAAAAGCCUAAUCUGAACAGCAAAGGGUCA  
GAGUUGUCACAACUGAGCAUGUACCGAGUGUUUGAA  
GUAGGUGUGAUCAGAAACCCGGGUUUGGGGGCUCCG  
GUGUCCAU AUGACAAACUAUUUUGAGCAACCAGUCA  
GUA AUGGUCUCGGCAACUGUAUGGUGGCUUUGGGGG  
AGCUCAAACUCGCAGCCCUUUGUCACGGGGACGAUUC  
UAUCAUAAUUCUUAUCAGGGGAUCAGGGAAAGGUGU  
CAGCUUCCAGCUCGUCAAGCUGGGUGUCUGGAAAUCC  
CCAACCGACAUGCAAUCCUGGGUCCCCUUAUCAACGG  
AUGAUCCAGUGGUAGACAGGCUUUACCUUCUAUCUCA  
CAGAGGUGUCAUCGCUGACAAUCAAGCAAAAUGGGCU  
GUCCCGACAACACGAACAGAUGACAAGUUGCGAAUGG  
AGACAUGCUUCCAGCAGGCGUGUAAAGGUAAAAUCCA  
AGCACUCUGCGAGAAUCCCGAGUGGGUACCAUUGAAG  
GAUAACAGGAUUCUUAUACGGGGUCCUGUCUGUUG  
AUCUGAGUCUGACGGUUGAGCUUAAAAUCAAAAUUG  
CUUCGGGAUUCGGGCCAUUGAUCACACGGGCUCAGG  
GAUGGACCUAUACAAAUCCAACUGCAACAAUGUGUAU  
UGGCUGACUAUUCGCGCAAUGAGAAAUCUAGCCUUA  
GCGUAAUCAACACAUUGGAGUGGAUACCGAGAUUCA  
AGGUUAGUCCCAACCUCUUCACUGUCCCAAUUAAGGA  
AGCAGGCGAAGACUGCCAUGCCCCAACAUACCUACCU  
GCGGAGGUGGACGGUGAUGUCAAACUCAGUCCAACC  
UGGUGAUUCUACCUUGGUCUAGAUCUCCAAUAUGUUU  
UGGCAACCUACGAUACCUCCAGGGUUGAGCAUGCUGU  
GGUUUAUUACGUUUACAGCCCAAGCCGCUCAUUUUCU  
UACUUUUUAUCUUAUAGGUUGCCUAUAAAGGGGGUC  
CCAUCGAACUACAAGUGGAAUGCUUCACAUGGGAUC  
AAAAACUCUGGUGCCGUCACUUCUGUGUCUUGCGGA  
CUCAGAAUCCGGUGGACUUAUCACUCACUCUGGGGAUG  
GUGGGCAUGGGAGUCAGCUGCACAGCUACCCGGGAAG AUGGAACCAAUCGCAGAUAA  
GC\_H\_MEASLES\_G\*GGGAAUAAGAGAGAAAAGAAGAGUAAGAAGAAA 77 B3  
UAUAAGAGCCACCAUGUCACCGCAACGAGACCGGAUA mRNA Sequence  
AAUGCCUUCUACAAAGAUAAACCUUAUCCCAAGGGAA (assumes T100  
GUAGGAUAGUUAUUAACAGAGAACAUCUUAUGAUUG Tail)  
ACAGACCCUAUGUUCUGCUGGCUGUUCUGUUCGUCAU Sequence Length:  
GUUUCUGAGCUUGAUCGGAUUGCUGGCAAUUGCAGG 2126  
CAUAGACUUAUCGGGCAGCCAUCUACACCGCGGAG  
AUCCAUAAAAGCCUCAGUACCAAUCUGGAUGUGACUA  
ACUCCAUCGAGCAUCAGGUCAAGGACGUGCUGACACC  
ACUCUUUAAAAUCAUCGGGGAUGAAGUGGGCCUGAG  
AACACCUCAGAGAUUCACUGACCUAGUGAAAUUCAUC  
UCGGACAAGAUUAAAUCCUUAUUCGGGAUAGGGAG  
UACGACUUCAGAGAUUCACUUGGUGCAUCAACCCGC  
CAGAGAGGAUCAAAACUAGAUUAUGAUCAAUACUGUG  
CAGAUUGGCUGCUGAAGAGCUCAUGAAUGCAUUGG  
UGAACUCAACUCUACUGGAGACCAGAACAACCACUCA  
GUUCCUAGCUGUCUCAAAGGGAAACUGCUCAGGGCCC  
ACUACAAUCAGAGGUCAAUUCUCAAACAUGUCGCUGU

CCUUGUUGGACUUGUACUAGGUCGAGGUUACAAUG  
UGUCAUCUAUAGUCACUAUGACAUCCCAGGGAAUGUA  
UGGGGGAACCUACCUAGUUGAAAAGCCUAAUCUGAAC  
AGCAAAGGGUCAGAGUUGUCACAACUGAGCAUGUACC  
GAGUGUUUGAAGUAGGUGUGAUCAGAAACCCGGGUU  
UGGGGGCUCCGGUGUCCAUAUGACAAACUAUUUUG  
AGCAACCAGUCAGUAAUGGUCUCGGCAACUGUAUGGU  
GGCUUUGGGGAGCUCAAACUCGCAGCCCUUUGUCAC  
GGGGACGAUUCUAUCAUAAUCCCUAUCAGGGAUCAG  
GGAAAGGUGUCAGCUUCCAGCUCGUAAGCUGGGUGU  
CUGGAAAUCCCAACCGACAUGCAAUCCUGGGUCCCC  
UUAUCAACGGAUGAUCCAGUGGUAGACAGGCUUUACC  
UCUCAUCUCACAGAGGUGUCAUCGCUGACAAUCAAGC  
AAAAUGGGCUGUCCCGACAACACGAACAGAUGACAAG  
UUGCFAAUGGAGACAUGCUUCCAGCAGGCGUGUAAA  
GGUAAAUAUCAAGCACUCUGCGAGAAUCCCGAGUGGG  
UACCAUUGAAGGAUAACAGGAUCCUUCAUACGGGG  
UCCUGUCUGUUGAUCUGAGUCUGACGGUUGAGCUUA  
AAAUCAAAAUUGCUCGGGAUUCGGGCCAUUGAUCAC  
ACACGGCUCAGGGAUGGACCUAUACAAAUCCAACUGC  
AACAAUGUGUAUUGGCUGACUAUUCCGCCAAUGAGA  
AAUCUAGCCUAGGCGUAAUCAACACAUUGGAGUGG  
AUACCGAGAUUCAAGGUUAGUCCAACCUUCUUCACUG  
UCCCAAUUAAGGAAGCAGGCGAAGACUGCCAUGCCCC  
AACAUACCUACCUAGCGGAGGUGGACGGUGAUGUCAA  
CUCAGUCCAACCUAGGUGAUUCUACCUAGGUAAGAUC  
UCCAAUAUGUUUUGGCAACCUACGAUACCUCCAGGGU  
UGAGCAUGCUGUGGUUUAUUACGUUUACAGCCCAAGC  
CGCUCAUUUUCUUAUUUAUCCUUUUAGGUUGCCUA  
UAAAGGGGGUCCCAAUCGAACUACAAGUGGAAUGCU  
UCACAUGGGAUCAAACUCUGGUGCCGUCACUUCUG  
UGUGCUUGCGGACUCAGAAUCCGGUGGACUUAUCACU  
CACUCUGGGAUGGUGGGCAUGGGAGUCAGCUGCACAG  
CUACCCGGGAAGAUGGAACCAAUCGCAGAUAAUGAUA  
AUAGGCUGGAGCCUCGGUGGCCAAGCUUCUUGCCCCU  
UGGGCCUCCCCCAGCCCCUCCUCCCCUUCUGCACCC  
GUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCG  
GCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAG GC\_H\_MEASLES\_  
UCAAGCUUUUGGACCCUCGUACAGAAGCUAAUACGAC 78 D8  
UCACUAUAGGGAAUUAAGAGAGAAAAGAAGAGUAAG Sequence, NT (5'  
AAGAAUAUAAGAGCCACCAUGUCACCACAACGAGAC UTR, ORF, 3'  
CGGAUAAAUGCCUUCUACAAAGACAACCCCAUCCUA UTR)  
AGGGAAGUAGGAUAGUUAUUAACAGAGAACAUCUUA Sequence Length:  
UGAUUGAUAGACCUUAUGUUUUGCUGGCUGUUCUAU 2065  
UCGUCAUGUUUCUGAGCUUGAUCGGGUUGCUAGCCAU  
UGCAGGCAUUAAGACUUAUCGGGCAGCCAUCUACACC  
GCAGAGAUCCAUAAAAGCCUCAGCACCAAUCUGGAUG  
UAACUAAUCUCAAUCGAGCAUCAGGUUAAGGACGUGCU  
GACACCACUCUUAAGAUAUCGGUGAUGAAGUGGGC  
UUGAGGACACCUCAGAGAUUCACUGACCUAGUGAAGU  
UCAUCUCUGACAAGAUUAAAUCCUUAUCCGGACAG  
GGAAUACGACUUCAGAGAUUCACUUGGUGUAUCAAC

CCGCCAGAGAGAAUCAAAUUGGAUUAUGAUCAAUAC  
UGUGCAGAUGUGGCUGCUGAAGAACUCAUGAAUGCA  
UUGGUGAACUCAACUCUACUGGAGACCAGGGCAACCA  
AUCAGUUCCUAGCUGUCUCAAGGGAAACUGCUCAGG  
GCCCACUACAAUCAGAGGCCAAUUCUCAACAUGUCG  
CUGUCCCUGUUGGACUUGUAUUUAAGUCGAGGUUAC  
AAUGUGUCAUCUAUAGUCACUAUGACAUCCAGGGAA  
UGUACGGGGGAACUUACCUAGUGGAAAAGCCUAAUC  
UGAGCAGCAAAGGGUCAGAGUUGUCACAACUGAGCA  
UGCACCGAGUGUUUGAAGUAGGUGUUUUCAGAAAUC  
CGGGUUUGGGGGCUCGCGUAUCCAUAUGACAAACUA  
UCUUGAGCAACCAGUCAGUAAUGAUUUCAGCAACUCG  
AUGGUGGCUUUGGGGGAGCUCAGUUCGCAGCCCUCU  
GUCACAGGGAAGAUUCUAUCACAAUCCCUAUCAGGG  
AUCAGGGAAAGGUGUCAGCUUCCAGCUUGUCAAGCUA  
GGUGUCUGGAAAUCCCCAACCGACAUGCAAUCCUGGG  
UCCCCCUAUCAACGGAUGAUCCAGUGAUAGACAGGCU  
UUACCUCUCAUCUCACAGAGGCGUUUUCGCUGACAAU  
CAAGCAAAAUGGGCUGUCCCAGACAACACGGACAGAUG  
ACAAGUUGCGAAUGGAGACAUGCUUCCAGCAGGCGUG  
UAAGGGUAAAAUCCAAGCACUUUGCGAGAAUCCCAG  
UGGACACCAUUGAAGGAUAACAGGAUCCUUCUAACG  
GGGUCUUGUCUGUUGAUCUGAGUCUGACAGUUGAGC  
UUAAAUCAAAAUUGUUUCAGGAUUCGGGCCAUUGA  
UCACACACGGUUCAGGGAUGGACCUAUACAAAUCCAA  
CCACAACAAUUGUAUUGGCUGACUAUCCCAGCAAUG  
AGAACCUGGCCUUAGGUGUAAUCAACACAUUGGAG  
UGGAUACCGAGAUUCAAGGUUAGUCCCAACCUCUUCA  
CUGUCCAAUUAAGGAAGCAGGCGAGGACUGCCAUGC  
CCCAACAUACCUACCUGCGGAGGUGGAUGGUGAUGUC  
AAACUCAGUCCAAUCUGGUGAUUCUACCUGGUCAAG  
AUCUCCAAUAUGUUCUGGCAACCUACGAUACUCCAG  
AGUUGAACAUGCUGUAGUUUAUUACGUUUACAGCCC  
AAGCCGCUCAUUUUCUACUUUUUACCUUUUAGGUUG  
CCUGUAAGGGGGGUCCCCAUUGAAUUACAAGUGGAA  
UGCUCACAUGGGACCAAAAACUCUGGUGCCGUCACU  
UCUGUGUGCUUGCGGACUCAGAAUCUGGUGGACUA  
UCACUCACUCUGGGAUGGUGGGCAUGGGAGUCAGCUG  
CACAGCCACUCGGGAAGAUGGAACCAGCCGCAGAUAG  
UGAUAAUAGGCUGGAGCCUCGGUGGCCAAGCUUCUUG  
CCCCUUGGGCCUCCCCCAGCCCCUCCUCCCCUCCUG  
CACCCGUACCCCGUGGUCUUUGAAUAAAGUCUGAGU GGGCGGC GC\_H\_MEASLES\_  
AUGUCACCACAACGAGACCGGAUAAAUGCCUUCUACA 79 D8  
AAGACAACCCCAUCCUAAGGGAAGUAGGAUAGUUUAU ORF Sequence, NT  
UAACAGAGAACAUCUUAUGAUUGAUAGACCUUAUGU  
UUUGCUGGCUGUUCUAUUCGUCAUGUUUCUGAGCUU  
GAUCGGGUUGCUAGCCAUUGCAGGCAUUAGACUUCAU  
CGGGCAGCCAUCUACACCGCAGAGAUCCAUAAAAGCC  
UCAGCACCAAUCUGGAUGUAACUAAUCUCAAUCGAGCA  
UCAGGUUAAGGACGUGCUGACACCACUCUUCAAGAUC  
AUCGGUGAUGAAGUGGGCUUGAGGACACCUCAGAGA  
UUCACUGACCUAGUGAAGUUCAUCUCUGACAAGAUUA  
AAUUCUUAUCCGGACAGGGAAUACGACUUCAGAGA  
UCUCACUUGGUGUAUCAACCCGCCAGAGAGAAUCAA

UUGGAUUAUGAUCAAUACUGUGCAGAUGUGGCUGCU  
GAAGAACUCAUGAAUGCAUUGGUGAACUCAACUCUAC  
UGGAGACCAGGGCAACCAAUCAGUUCCUAGCUGUCUC  
AAAGGGAAACUGCUCAGGGCCCACUACAAUCAGAGGC  
CAAUUCUCAAAACAUUGUCGUGUCCCUGUUGGACUUGU  
AUUUAAAGUCGAGGUUACAAUGUGUCAUCUAUAGUCA  
CUAUGACAUCCCAGGGAAUGUACGGGGGAACUUACCU  
AGUGGAAAAGCCUAAUCUGAGCAGCAAAGGGUCAGA  
GUUGUCACAACUGAGCAUGCACCGAGUGUUUGAAGU  
AGGUGUUUUCAGAAAUCCGGGUUUGGGGGCUCCGGU  
AUUCCAUAUGACAAACUAUCUUGAGCAACCAGUCAGU  
AAUGAUUUCAGCAACUGCAUGGGUGGCUUUGGGGGAG  
CUCAAGUUCGCAGCCCUCUGUCACAGGGAAGAUUCUA  
UCACAAUUCCCUAUCAGGGGAUCAGGGAAAGGUGUCAG  
CUUCCAGCUUGUCAAGCUAGGUGUCUGGAAAUCCCCA  
ACCGACAUGCAAUCCUGGGUCCCCCUAUC AACGGAUG  
AUCCAGUGAUAGACAGGCUUUACCUCUCAUCUCACAG  
AGGCGUUAUCGCUGACAAUCAAGCAAAAUGGGCUGUC  
CCGACAACACGGACAGAUGACAAGUUGCGAAUGGAGA  
CAUGC UUCAGCAGGCGUGUAAGGGUAAAAUCCAAGC  
ACUUUGCGAGAAUCCCGAGUGGACACCAUUGAAGGAU  
AACAGGAUUCUUCUAUACGGGGUCUUGUCUGUUGAUC  
UGAGUCUGACAGUUGAGCUUAAAUCAAAAUUGUUU  
CAGGAUUCGGGCCAUUGAUCACACACGGUUCAGGGAU  
GGACCUAUACAAAUCCAACCACAACAAUAUGUAUUGG  
CUGACUAUCCCGCCAUGAAGAACCUGGCCUUAAGGUG  
UAAUCAACACAUUGGAGUGGAUACCGAGAUUCAAGG  
UUAGUCCCAACCUCUUCACUGUUCCAAUUAAGGAAGC  
AGGCGAGGACUGCCAUGCCCCAACAUACCUACCUGCG  
GAGGUGGAUGGUGAUGUCAAAACUCAGUUCCAAUCUG  
GUGAUUCUACCUGGUCAAGAUCUCCAAUAUGUUCUGG  
CAACCUACGAUACUUCAGAGUUGAACAUGCUGUAGU  
UUAUUACGUUUACAGCCCAAGCCGCUCAUUUUCUAC  
UUUUAUCCUUUUAGGUUGCCUGUAAGGGGGGUCCCCA  
UUGAAUUACAAGUGGAAUGCUUCACAUGGGACCAA  
AACUCUGGUGCCGUCACUUCUGUGUGCUUGCGGACUC  
AGAAUCUGGUGGACAUUACACUCACUCUGGGAUGGU  
GGGCAUGGGAGUCAGCUGCACAGCCACUCGGGAAGAU GGAACCAGCCGCAGAUAG  
GC\_H\_MEASLES\_G\*GGGAAUAAGAGAGAAAAGAAGAGUAAGAAGAAA 80 D8  
UAUAAGAGCCACCAUGUCACCACAACGAGACCGGAUA mRNA Sequence  
AAUGCCUUCUACAAAGACAACCCCAUCCUAAAGGAA (assumes T100 tail)  
GUAGGAUAGUUUAUUAACAGAGACAUCUUAUGAUUG Sequence Length:  
AUAGACCUUAUGUUUUGCUGGCUGUUCUAUUCGUCA 2126  
UGUUUCUGAGCUUGAUCGGGUUGCUAGCCAUUGCAG  
GCAUUAGACUUCUUCGGGCAGCCAUCUACACCGCAGA  
GAUCCAUAAAAGCCUCAGCACCAAUCUGGAUGUAACU  
AACUCAUUCGAGCAUCAGGUUAAGGACGUGCUGACAC  
CACUCUUC AAGAUCAUCGGUGAUGAAGUGGGCUUGA  
GGACACCUCAGAGAUUCACUGACCUAGUGAAGUUCAU  
CUCUGACAAGAUUAAAUCCUUAUUCGGACAGGGAA  
UACGACUUCAGAGAUUCACUUGGUGUAUCAACCCGC  
CAGAGAGAAUCAAAUUGGAUUAUGAUCAAUACUGUG  
CAGAUUGGCUGCUGAAGAACUCAUGAAUGCAUUGG  
UGAACUCAACUCUACUGGAGACCAGGGCAACCAAUCA

GUUCCUAGCUGUCUCAAGGGAAACUGCUCAGGGCCC  
ACUACAAUCAGAGGCCAAUUCUCAACAUGUCGCUGU  
CCCUGUUGGACUUGUAUUUAAGUCGAGGUUACAAUG  
UGUCAUCUAUAGUCACUAUGACAUCCCAGGGAAUGUA  
CGGGGGAACUUACCUAGUGGAAAAGCCUAAUCUGAGC  
AGCAAAGGGUCAGAGUUGUCACAACUGAGCAUGCACC  
GAGUGUUUGAAGUAGGUGUUUUCAGAAAUCCGGGUU  
UGGGGGCUCCGGUUUCCAUAUGACAAACUAUCUUGA  
GCAACCAGUCAGUAAUGAUUUCAGCAACUGCAUGGUG  
GCUUUGGGGGAGUCUCAAAGUUCGCAGCCCUCUGUCACA  
GGGAAGAUUCUAUCACAAUUCUUAUCAGGGAUUCAGG  
GAAAGGUGUCAGCUUCCAGCUUGUCAAGCUAGGUGUC  
UGGAAAUCCCCAACCGACAUGCAAUCCUGGGUCCCCC  
UAUCAACGGAUGAUCCAGUGAUAGACAGGCUUUACCU  
CUCAUCUCACAGAGGGCGUUUUCGCUGACAAUCAAGCA  
AAAUGGGCUGUCCCGACAACACGGACAGAUGACAAGU  
UGCGAAUGGAGACAUGCUUCCAGCAGGCGUGUAAGG  
GUAAAUAUCAAGCACUUUGCGAGAAUCCCGAGUGGAC  
ACCAUUGAAGGAUAACAGGAUUCUUAUCACGGGGUC  
UUGUCUGUUGAUCUGAGUCUGACAGUUGAGCUUAAA  
AUCAAAAUUGUUUCAGGAUUCGGGCCAUUGAUCACAC  
ACGGUUCAGGGAUUGGACCUAUACAAAUCCAACCACAA  
CAAUAUGUAUUGGCUGACUAUCCCGCCAAUGAAGAAC

CUGGCCUUAGGUGUAAUCAACACAUUGGAGUGGAUA  
CCGAGAUUCAAGGUUAGUCCCAACCUCUUCACUGUUC  
CAAUUAAGGAAGCAGGCGAGGACUGCCAUGCCCCAAC  
AUACCUACCUGCGGAGGUGGAUGGUGAUGUCAAACUC  
AGUUCCAAUCUGGUGAUUCUACCUGGUCAAGAUCUCC  
AAUAUGUUCUGGCAACCUACGAUACUUCAGAGUUGA  
ACAUGCUGUAGUUUAUUACGUUUACAGCCCAAGCCGC  
UCAUUUUCUUAUUUAUCCUUUUAGGUUGCCUGUA  
AGGGGGGUGCCCAUUGAAUUAACAAGUGGAAUGCUUC  
ACAUGGGACCAAAAACUCUGGUGCCGUCACUUCUGUG  
UGCUUGCGGACUCAGAAUCUGGUGGACAUAUCACUCA  
CUCUGGGAUGGUGGGCAUGGGAGUCAGCUGCACAGCC  
ACUCGGGAAGAUGGAACCAGCCGCAGAUAGUGAUAA  
UAGGCUGGAGCCUCGGUGGCAAGCUUCUUGCCCCUU  
GGGCCUCCCCCAGCCCCUCCUCCCCUUCUGCACCCG  
UACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGG  
CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAG

TABLE-US-00015 TABLE 14 MeV Amino Acid Sequences De- SEQ scrip- ID tion Sequence NO: GC\_F\_  
MGLKVNVS AVFMAVLLTLQTPAGQIHWGNLSKIGVV 47 MEA-  
GIGSASYKVMTRSSHQSLVIKLMPNITLLNNTTRVEIA SLES\_  
EYRLLRRTVLEPIRDALNAMTQNIRPVQSVASSRRHK B3.1  
RFAGVVLAGAALGVATAAQITAGIALHRSMLNSQAID ORF  
NLRASLETTNQAIEAIRQAGQEMILAVQGVQDYINNE Se-  
LIPSMNQLSCDLIGQKLGLKLLRYYTEILSLFGPSLRDP quence,  
ISAEISIQALS YALGGDINKVLEKLGYSGGDLLGILES R AA  
GIKARITHVDTESYFIVLSIAYPTLSEIKGVIVHRLEGVS  
YNIGSQEWYTTVPKYVATQGYLISNFDSSCTFMPEG

TVCSQNALYPMSPLLQECLRGSTKSCARTLVSGSFGN  
RFILSQGNLIANCASILCKCYTTGTIINQDPDKILTYIAA  
DRCPVVEVNGVTIQVGSRRYPDAVYLHRIDLGPPISE  
RLDVGTNLGNIAIAKLEDAKELLESDQILRSMKGLSST  
SIVYILIAVCLGGLIGIPTLICCCRGRCNKKGEQVGMSR PGLKPDLTGTSKSYVRSL\* GC\_F\_  
MGLKVNVSIVFMAVLLTLQTPTGQIHWGNLSKIGVVG 48 MEA-  
VGSASYKVMTRSSHQSLVIKLPNITLLNNCTRVGIAE SLES\_  
YRLLRRTVLEPIRDALNAMTQNIRPVQSVASSRRHKR D8 ORF  
FAGVVLAGAALGVATAAQITAGIALHQSMNSQAIDN Se-  
LRASLETTNQAIEAIRQAGQEMILAVQGVQDYINNELI quence,  
PSMNQLSCDLIGQKLGKLLRYYTEILSLFGPSLRDPIS AA  
AEISIQALSIALGGDINKVLEKLGYSGGDLLGILESRI  
KARITHVDTESYFIVLSIAYPTLSEIKGVIVHRLEGVSY  
NIGSQEWYTTVPKYVATQGYLISNFDESSCTFMPEGT  
VCSQNALYPMSPLLQECLRGSTKSCARTLVSGSFGNR  
FILSQGNLIANCASILCKCYTTGTIINQDPDKILTYIAAD  
HCPVVEVNGVTIQVGSRRYPDAVYLHRIDLGPPISE  
LDVGTNLGNIAIAKLEDAKELLESDQILRSMKGLSSTS  
IVYILIAVCLGGLIGIPALICCCRGRCNKKGEQVGMSRP GLKPDLTGTSKSYVRSL\* GC\_H\_  
MSPQRDRINAFYKDNPPYKGSRIVINREHLMIDRPYVL 49 MEA-  
LAVLFVFMFLSLIGLLAIAGIRLHRAAIYTAEIHKSLSTN SLES\_  
LDVTNSIEHQVKDVLTPFKIIGDEVGLRTPQRFTDLV B3 ORF  
KFISDKIKFLNPDREYDFRDLTWCINPPERIKLDYDQY Se-  
CADVAAEELMNALVNSTLLETRTTTQFLAVSKGNCS quence,  
GPTTIRGQFSNMSLSLLDLYLGRGYNVSSIVTMTSQG AA  
MYGGTYLVEKPNLNSKGSELSQLSMYRVFEVGVIRNP  
GLGAPVFHMTNYFEQPVSNGLGNCMVALGELKLAAL  
CHGDDSIIPYQGSQKGVSFQLVKLGVWKSPTDMQSW  
VPLSTDDPVDRLYLSSHARGVIADNQAQWAVPTTRT  
DDKLRMETCFQACKGKIQAALCENPEWVPLKDNRIPS  
YGVLSVDLSLTVELKIKIASGFGPLITHGSGMDLYKSN  
CNNVYWLTIIPMRNLALGVINTLEWIPRFKVSPLNFTV  
PIKEAGEDCHAPTYLPAEVDGDVKLSSNLVILPGQDL  
QYVLATYDTSRVEHAVVYVYSPSRFSYFYPFRLPIK  
GVPIELQVECFTWDQKLWCRHFCVLADSESGGLITHS GMVGMGVSCATREDGTNR\* GC\_H\_  
MSPQRDRINAFYKDNPHPKGSRIVINREHLMIDRPYVL 50 MEA-  
LAVLFVFMFLSLIGLLAIAGIRLHRAAIYTAEIHKSLSTN SLES\_  
LDVTNSIEHQVKDVLTPFKIIGDEVGLRTPQRFTDLV D8 ORF  
KFISDKIKFLNPDREYDFRDLTWCINPPERIKLDYDQY Se-  
CADVAAEELMNALVNSTLLETRATNQFLAVSKGNCS quence,  
GPTTIRGQFSNMSLSLLDLYLSRGYNVSSIVTMTSQGM AA  
YGGTYLVEKPNLSSKGSELSQLSMHRVFEVGVIRNPG  
LGAPVFHMTNYLEQPVSNDFSNCMVALGELKFAALC  
HREDSITIPYQGSQKGVSFQLVKLGVWKSPTDMQSW  
VPLSTDDPVIDRLYLSSHARGVIADNQAQWAVPTTRTD  
DKLRMETCFQACKGKIQAALCENPEWTPLKDNRIPSY  
GVLSVDLSLTVELKIKIVSGFGPLITHGSGMDLYKSNH  
NNMYWLTIIPMKNLALGVINTLEWIPRFKVSPLNFTV  
PIKEAGEDCHAPTYLPAEVDGDVKLSSNLVILPGQDL  
QYVLATYDTSRVEHAVVYVYSPSRFSYFYPFRLPV  
RGVPIELQVECFTWDQKLWCRHFCVLADSESGGHITH SGMVGMGVSCATREDGTSRR\*

TABLE-US-00016 TABLE 15 MeV NCBI Accession Numbers (Amino Acid Sequences) Type Virus Name  
GenBank Accession hemagglutinin hemagglutinin [Measles virus strain Moraten] AAF85673.1 hemagglutinin



hemagglutinin [Measles virus strain Rubeovax] AAF85689.1 hemagglutinin hemagglutinin [Measles virus] AAF89824.1 hemagglutinin hemagglutinin protein [Measles virus] CAA91369.1 hemagglutinin hemagglutinin [Measles virus] BAJ23068.1 hemagglutinin hemagglutinin protein [Measles virus] BAB39848.1 hemagglutinin hemagglutinin [Measles virus] AAA50551.1 hemagglutinin RecName: Full = Hemagglutinin glycoprotein P08362.1 hemagglutinin hemagglutinin [Measles virus] AAB63802.1 hemagglutinin hemagglutinin [Measles virus] AAA56650.1 hemagglutinin hemagglutinin [Measles virus] AAA56642.1 hemagglutinin hemagglutinin [Measles virus] AAA74936.1 hemagglutinin hemagglutinin protein [Measles virus] BAH56665.1 hemagglutinin hemagglutinin [Measles virus] ACC86105.1 hemagglutinin hemagglutinin [Measles virus strain Edmonston-Zagreb] AAF85697.1 hemagglutinin hemagglutinin [Measles virus] AAR89413.1 hemagglutinin hemagglutinin [Measles virus] AAA56653.1 hemagglutinin RecName: Full = Hemagglutinin glycoprotein P35971.1 hemagglutinin Hemagglutinin [Measles virus] CAB94916.1 hemagglutinin hemagglutinin [Measles virus] AAC03036.1 hemagglutinin hemagglutinin [Measles virus] AAF85681.1 hemagglutinin Hemagglutinin [Measles virus] CAB94927.1 hemagglutinin Hemagglutinin [Measles virus] CAB94925.1 hemagglutinin hemagglutinin protein [Measles virus] BAB39835.1 hemagglutinin Hemagglutinin [Measles virus] CAB94931.1 hemagglutinin hemagglutinin [Measles virus genotype A] AFO84712.1 hemagglutinin hemagglutinin [Measles virus] AAA56639.1 hemagglutinin Hemagglutinin [Measles virus] CAB94926.1 hemagglutinin hemagglutinin protein [Measles virus] BAB39836.1 hemagglutinin Hemagglutinin [Measles virus] CAB94929.1 hemagglutinin RecName: Full = Hemagglutinin glycoprotein P06830.1 hemagglutinin Hemagglutinin [Measles virus] CAB94928.1 hemagglutinin hemagglutinin protein [Measles virus] BAB39837.1 hemagglutinin hemagglutinin [Measles virus] AAA74935.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43780.1 hemagglutinin hemagglutinin [Measles virus] BAA09952.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43815.1 hemagglutinin hemagglutinin [Measles virus] AAF28390.1 hemagglutinin Hemagglutinin [Measles virus] CAB94923.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43785.1 hemagglutinin hemagglutinin [Measles virus] ABD34001.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43782.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43781.1 hemagglutinin hemagglutinin [Measles virus] BAH22353.1 hemagglutinin hemagglutinin [Measles virus] AAC35878.2 hemagglutinin hemagglutinin protein [Measles virus] AAL86996.1 hemagglutinin hemagglutinin [Measles virus] CAA76066.2 hemagglutinin hemagglutinin [Measles virus] AAA46428.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43803.1 hemagglutinin Hemagglutinin [Measles virus] CAB94918.1 hemagglutinin hemagglutinin [Measles virus] AAF72162.1 hemagglutinin hemagglutinin [Measles virus] AAM70154.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43776.1 hemagglutinin hemagglutinin [Measles virus genotype D4] ACT78395.1 hemagglutinin hemagglutinin [Measles virus genotype D7] AAL02030.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43789.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43774.1 hemagglutinin Hemagglutinin [Measles virus] CAB94920.1 hemagglutinin Hemagglutinin [Measles virus] CAB94922.1 hemagglutinin hemagglutinin [Measles virus] ABB59491.1 hemagglutinin hemagglutinin protein [Measles virus] BAB39843.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43804.1 hemagglutinin hemagglutinin [Measles virus] AAX52048.1 hemagglutinin Hemagglutinin [Measles virus] CAB94930.1 hemagglutinin hemagglutinin [Measles virus] AAA74526.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43814.1 hemagglutinin hemagglutinin [Measles virus] ABB59493.1 hemagglutinin hemagglutinin [Measles virus genotype D4] AAL02019.1 hemagglutinin Hemagglutinin [Measles virus] CAB94919.1 hemagglutinin hemagglutinin protein [Measles virus] AAL86997.1 hemagglutinin hemagglutinin [Measles virus genotype C2] AAL02017.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43769.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43808.1 hemagglutinin hemagglutinin [Measles virus] BAO97032.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43805.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43777.1 hemagglutinin hemagglutinin [Measles virus] AAL67793.1 hemagglutinin hemagglutinin [Measles virus] AAF89816.1 hemagglutinin hemagglutinin [Measles virus genotype D4] AAL02020.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43786.1 hemagglutinin hemagglutinin protein [Measles virus strain MVi/New AEP40452.1 Jersey.USA/45.05] hemagglutinin hemagglutinin [Measles virus] AAA74531.1 hemagglutinin hemagglutinin [Measles virus] AAB63800.1 hemagglutinin hemagglutinin [Measles virus] AAO21711.1 hemagglutinin hemagglutinin [Measles virus genotype D8] ALE27189.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43810.1 hemagglutinin hemagglutinin [Measles virus] AAF89817.1 hemagglutinin hemagglutinin [Measles virus genotype D6] AAL02022.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43800.1 hemagglutinin hemagglutinin protein [Measles virus genotype B3] AGA17219.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43770.1 hemagglutinin

hemagglutinin protein [Measles virus strain AEP40444.1 MVi/Texas.USA/4.07] hemagglutinin hemagglutinin [Measles virus] AAX52047.1 hemagglutinin hemagglutinin [Measles virus] AAB63794.1 hemagglutinin hemagglutinin [Measles virus] AAB63796.1 hemagglutinin hemagglutinin [Measles virus] AAA74528.1 hemagglutinin hemagglutinin [Measles virus] AAB63774.1 hemagglutinin hemagglutinin [Measles virus] AAB63795.1 hemagglutinin hemagglutinin [Measles virus] AAA74519.1 hemagglutinin hemagglutinin protein [Measles virus] CAB43778.1 fusion protein fusion protein [Measles virus strain Moraten] AAF85672.1 fusion protein fusion protein [Measles virus] AAA56645.1 fusion protein fusion protein [Measles virus strain Rubeovax] AAF85688.1 fusion protein fusion protein [Measles virus] AAF85680.1 fusion protein fusion protein [Measles virus] AEF30359.1 fusion protein fusion protein [Measles virus] BAA09957.1 fusion protein fusion protein [Measles virus] AAV84957.1 fusion protein fusion protein [Measles virus MeV-eGFP\_Edm-tag] AII16636.1 fusion protein fusion protein [Measles virus] ABY58018.1 fusion protein fusion protein [Measles virus] BAA19838.1 fusion protein fusion protein [Measles virus] AAA56641.1 fusion protein F protein [Measles virus] ABK40529.1 fusion protein fusion protein [Measles virus] AAA56652.1 fusion protein fusion protein [Measles virus] ABY58017.1 fusion protein fusion protein [Measles virus] ABB71645.1 fusion protein fusion protein [Measles virus] NP\_056922.1 fusion protein fusion protein [Measles virus strain AIK-C] AAF85664.1 fusion protein fusion protein [Measles virus] BAB60865.1 fusion protein fusion protein [Measles virus] BAA09950.1 fusion protein fusion protein [Measles virus strain MVi/New AEP40403.1 York.USA/26.09/3] fusion protein fusion protein [Measles virus] AAA74934.1 fusion protein fusion protein [Measles virus] CAB38075.1 fusion protein fusion protein [Measles virus strain AEP40443.1 MVi/Texas.USA/4.07] fusion protein fusion protein [Measles virus] AAF02695.1 fusion protein fusion protein [Measles virus] AAF02696.1 fusion protein fusion protein [Measles virus] AAT99301.1 fusion protein fusion protein [Measles virus] ABB71661.1 fusion protein fusion protein [Measles virus] BAK08874.1 fusion protein fusion protein [Measles virus] AAF02697.1 fusion protein fusion protein [Measles virus genotype D4] AFY12704.1 fusion protein fusion protein [Measles virus strain AEP40467.1 MVi/California.USA/16.03] fusion protein fusion protein [Measles virus genotype D8] AHN07989.1 fusion protein fusion protein [Measles virus] AAA46421.1 fusion protein fusion protein [Measles virus] AAA56638.1 fusion protein fusion protein [Measles virus strain AEP40419.1 MVi/Virginia.USA/15.09] fusion protein fusion protein [Measles virus genotype D8] ALE27200.1 fusion protein fusion protein [Measles virus genotype D8] AFY12695.1 fusion protein fusion protein [Measles virus genotype D8] ALE27248.1 fusion protein fusion protein [Measles virus genotype D8] ALE27224.1 fusion protein fusion protein [Measles virus] AAT99300.1 fusion protein fusion protein [Measles virus] BAH96592.1 fusion protein fusion protein [Measles virus strain AEP40459.1 MVi/California.USA/8.04] fusion protein fusion protein [Measles virus genotype D8] AIG94081.1 fusion protein fusion protein [Measles virus] BAA09951.1 fusion protein fusion protein [Measles virus genotype D8] ALE27194.1 fusion protein fusion protein [Measles virus] BAA33871.1 fusion protein fusion protein [Measles virus strain AEP40427.1 MVi/Washington.USA/18.08/1] fusion protein fusion protein [Measles virus] ABY21182.1 fusion protein fusion protein [Measles virus genotype D8] ALE27284.1 fusion protein fusion protein [Measles virus] ACA09725.1 fusion protein fusion protein [Measles virus genotype D8] ALE27314.1 fusion protein fusion protein [Measles virus genotype G3] AFY12712.1 fusion protein fusion protein [Measles virus genotype D8] ALE27368.1 fusion protein RecName: Full = Fusion glycoprotein F0; Contains: P35973.1 RecName: Full = Fusion glycoprotein F2; Contains: RecName: Full = Fusion glycoprotein F1; Flags: Precursor fusion protein fusion protein [Measles virus genotype H1] AIG53713.1 unnamed protein product [Measles virus] CAA34588.1 fusion protein fusion protein [Measles virus] CAA76888.1 fusion protein fusion protein [Measles virus genotype B3.1] AIY55563.1 fusion protein fusion protein [Measles virus] ADO17330.1 fusion protein fusion protein [Measles virus genotype H1] AIG53703.1 fusion protein fusion protein [Measles virus genotype B3] AGA17208.1 fusion protein fusion protein [Measles virus] AAL29688.1 fusion protein fusion protein [Measles virus genotype H1] AIG53706.1 fusion protein fusion protein [Measles virus genotype H1] AIG53701.1 fusion protein fusion protein [Measles virus genotype B3] ALE27092.1 fusion protein fusion protein [Measles virus genotype H1] AIG53714.1 fusion protein fusion protein [Measles virus genotype H1] AIG53694.1 fusion protein fusion protein [Measles virus genotype H1] AIG53668.1 fusion protein fusion protein [Measles virus] ACC86094.1 fusion protein fusion protein [Measles virus genotype H1] AIG53670.1 fusion protein fusion protein [Measles virus genotype H1] AIG53707.1 fusion protein fusion protein [Measles virus genotype B3] AGA17216.1 fusion protein fusion protein [Measles virus genotype H1] AIG53671.1 fusion protein fusion protein [Measles virus strain MVi/New AEP40451.1 Jersey.USA/45.05] fusion protein fusion protein [Measles virus genotype H1] AIG53684.1 fusion protein fusion protein [Measles virus genotype H1] AIG53688.1 fusion protein fusion protein [Measles virus

genotype B3] AGA17214.1 fusion protein fusion protein [Measles virus genotype H1] AIG53683.1 fusion protein fusion protein [Measles virus genotype H1] AIG53667.1 fusion protein fusion protein [Measles virus genotype H1] AIG53686.1 fusion protein fusion protein [Measles virus genotype H1] AIG53685.1 fusion protein fusion protein [Measles virus genotype H1] AIG53681.1 unnamed protein product [Measles virus] CAA34589.1 fusion protein fusion protein [Measles virus genotype H1] AIG53678.1 fusion protein fusion protein [Measles virus genotype H1] AIG53710.1 fusion protein fusion protein [Measles virus genotype H1] AIG53669.1 fusion protein fusion protein [Measles virus genotype H1] AIG53664.1 fusion protein fusion protein [Measles virus] AAA50547.1 fusion protein fusion protein [Measles virus genotype H1] AIG53679.1 fusion protein fusion protein [Measles virus genotype H1] AIG53709.1 fusion protein fusion protein [Measles virus genotype H1] AIG53672.1 fusion protein fusion protein [Measles virus genotype H1] AIG53697.1 fusion protein fusion protein [Measles virus genotype H1] AIG53689.1 fusion protein fusion protein [Measles virus genotype H1] AIG53676.1 fusion protein fusion protein [Measles virus genotype H1] AIG53675.1 fusion protein fusion protein [Measles virus genotype H1] AIG53663.1 fusion protein fusion protein [Measles virus] BAA19841.1 fusion protein fusion protein [Measles virus] AAF02701.1 fusion protein fusion protein [Measles virus genotype H1] AIG53680.1 fusion protein fusion protein [Measles virus genotype H1] AIG53674.1 C protein C protein [Measles virus strain Moraten] AAF85670.1 C protein RecName: Full = Protein C P03424.1 C protein C protein [Measles virus] ACN54404.1 C protein C protein [Measles virus] ACN54412.1 C protein RecName: Full = Protein C P35977.1 C protein C protein [Measles virus] AAF85678.1 C protein C protein [Measles virus] ABD33998.1 C protein unnamed protein product [Measles virus] CAA34586.1 C protein C protein [Measles virus] BAJ51786.1 C protein C protein [Measles virus] BAA33869.1 C protein virulence factor [Measles virus] ABO69700.1 C protein C protein [Measles virus] NP\_056920.1 C protein C protein [Measles virus] ADO17333.1 C protein C protein [Measles virus] ACC86082.1 C protein C protein [Measles virus] BAA33875.1 C protein C protein [Measles virus] ABY21189.1 C protein C protein [Measles virus] BAE98296.1 C protein C protein [Measles virus] ADU17782.1 C protein C protein [Measles virus strain MVi/Virginia.USA/15.09] AEP40417.1 C protein C protein [Measles virus] ADU17814.1 C protein C protein [Measles virus] ADU17798.1 C protein C protein [Measles virus genotype D4] AFY12700.1 C protein C protein [Measles virus] ADU17784.1 C protein C protein [Measles virus strain AEP40465.1 MVi/California.USA/16.03] C protein C protein [Measles virus] ABB71643.1 C protein C protein [Measles virus] AEI91027.1 C protein C protein [Measles virus] ADU17874.1 C protein C protein [Measles virus] ADU17903.1

C protein C protein [Measles virus] CAA34579.1 C protein C protein [Measles virus] ADU17790.1 C protein C protein [Measles virus] ADU17800.1 C protein C protein [Measles virus] ABB71667.1 C protein unnamed protein product [Measles virus] CAA34572.1 C protein C protein [Measles virus strain AEP40433.1 MVi/Arizona.USA/11.08/2] C protein C protein [Measles virus] ADU17830.1 C protein C protein [Measles virus] ADU17947.1 C protein C protein [Measles virus] ADU17818.1 C protein C protein [Measles virus strain MVi/New Jersey.USA/45.05] C protein C protein [Measles virus strain MVi/Texas.USA/4.07] AEP40441.1 C protein C protein [Measles virus] ADU17864.1 C protein C protein [Measles virus] ADU17838.1 C protein C protein [Measles virus] ADU17881.1 C protein C protein [Measles virus strain AEP40425.1 MVi/Washington.USA/18.08/1] C protein C protein [Measles virus] ADU17927.1 C protein C protein [Measles virus] ADU17953.1 C protein C protein [Measles virus] ADU17889.1 C protein C protein [Measles virus] ADU17963.1 C protein C protein [Measles virus] ADU17893.1 C protein C protein [Measles virus] ADU17820.1 C protein C protein [Measles virus] ABB71651.1 C protein C protein [Measles virus] ADU17786.1 C protein C protein [Measles virus] ADU17862.1 C protein C protein [Measles virus] ADU17923.1 C protein C protein [Measles virus] ADU17959.1 C protein C protein [Measles virus] ADU17951.1 C protein C protein [Measles virus] ADU17916.1 C protein C protein [Measles virus] ADU17957.1 C protein C protein [Measles virus] ADU17925.1 C protein C protein [Measles virus] ADU17901.1 C protein C protein [Measles virus] ADU17887.1 C protein C protein [Measles virus] ADU17832.1 C protein C protein [Measles virus] ADU17891.1 C protein C protein [Measles virus] ADU17961.1 C protein C protein [Measles virus] ADU17872.1 C protein C protein [Measles virus] ADU17929.1 C protein C protein [Measles virus] ADU17908.1 C protein C protein [Measles virus] ADU17910.1 C protein C protein [Measles virus] ADU17921.1 C protein C protein [Measles virus] ADU17824.1 C protein C protein [Measles virus strain AEP40473.1 MVi/Pennsylvania.USA/20.09] C protein C protein [Measles virus] ADU17828.1 C protein C protein [Measles virus] ADU17812.1 C protein C protein

[Measles virus genotype D8] AFY12692.1 C protein nonstructural C protein [Measles virus] ABA59559.1 C protein RecName: Full = Protein C Q00794.1 C protein nonstructural C protein [Measles virus] AD017934.1 C protein nonstructural C protein [Measles virus] ACJ66773.1 C protein C protein [Measles virus genotype G3] AFY12708.1 C protein RecName: Full = Protein C P26035.1 C protein C protein [Measles virus] BAA84128.1 nucleoprotein RecName: Full = Nucleoprotein; AltName: Q77M43.1 Full = Nucleocapsid protein; Short = NP; Short = Protein N nucleoprotein nucleocapsid protein [Measles virus strain Rubeovax] AAF85683.1 nucleoprotein RecName: Full = Nucleoprotein; AltName: Q89933.1 Full = Nucleocapsid protein; Short = NP; Short = Protein N nucleoprotein nucleocapsid protein [Measles virus strain AIK-C] AAF85659.1 nucleoprotein nucleoprotein [Measles virus] ABI54102.1 nucleoprotein nucleoprotein [Measles virus] AAA56643.1 nucleoprotein nucleoprotein [Measles virus] AAC03050.1 nucleoprotein nucleoprotein [Measles virus] AAA18990.1 nucleoprotein nucleoprotein [Measles virus] AAA56640.1 nucleoprotein RecName: Full = Nucleoprotein; AltName: P35972.1 Full = Nucleocapsid protein; Short = NP; Short = Protein N nucleoprotein RecName: Full = Nucleoprotein; AltName: P10050.1 Full = Nucleocapsid protein; Short = NP; Short = Protein N nucleoprotein N protein [Measles virus] BAB60956.1 nucleoprotein RecName: Full = Nucleoprotein; AltName: B1AAA7.1 Full = Nucleocapsid protein; Short = NP; Short = Protein N nucleoprotein nucleoprotein [Measles virus] AAA18991.1 nucleoprotein nucleoprotein [Measles virus] CAB46894.1 nucleoprotein nucleoprotein [Measles virus] CAB46871.1 nucleoprotein nucleoprotein [Measles virus] CAB46872.1 nucleoprotein nucleoprotein [Measles virus] ABU49606.1 nucleoprotein nucleocapsid protein [Measles virus] AAA75494.1 nucleoprotein nucleoprotein [Measles virus] CAB46883.1 nucleoprotein nucleoprotein [Measles virus] CAB46892.1 nucleoprotein unnamed protein product [Measles virus] CAA34584.1 nucleoprotein nucleoprotein [Measles virus] AAA18997.1 nucleoprotein nucleoprotein [Measles virus] CAB46863.1 nucleoprotein nucleoprotein [Measles virus] AEF30352.1 nucleoprotein nucleoprotein [Measles virus] ABI54103.1 nucleoprotein nucleocapsid protein [Measles virus] AAA46433.1 nucleoprotein nucleoprotein [Measles virus] CAB46902.1 nucleoprotein nucleoprotein [Measles virus] CAB46873.1 nucleoprotein nucleoprotein [Measles virus] CAB 46906.1 nucleoprotein nucleoprotein [Measles virus] AAA74547.1 nucleoprotein nucleoprotein [Measles virus] AAA74537.1 nucleoprotein nucleoprotein [Measles virus] CAB46862.1 nucleoprotein nucleocapsid protein [Measles virus] BAA09961.1 nucleoprotein nucleoprotein [Measles virus] AA015875.1 nucleoprotein nucleoprotein [Measles virus] AA015871.1 nucleoprotein nucleoprotein [Measles virus] CAB46882.1 nucleoprotein nucleoprotein [Measles virus] CAB60124.1 nucleoprotein nucleoprotein [Measles virus] ABI54104.1 nucleoprotein nucleoprotein [Measles virus] CAB 46869.1 nucleoprotein nucleoprotein [Measles virus] CAB46880.1 nucleoprotein nucleoprotein [Measles virus] AAA74541.1 nucleoprotein nucleocapsid protein [Measles virus strain MVi/New AEP40446.1 Jersey.USA/45.05] nucleoprotein nucleoprotein [Measles virus] ABI54110.1 nucleoprotein nucleoprotein [Measles virus] CAB46903.1 nucleoprotein nucleoprotein [Measles virus] CAB46899.1 nucleoprotein nucleoprotein [Measles virus] CAB46901.1 nucleoprotein nucleocapsid protein [Measles virus] ABB71640.1 nucleoprotein nucleoprotein [Measles virus] CAB60113.1 nucleoprotein nucleoprotein [Measles virus] CAB60114.1 nucleoprotein nucleoprotein [Measles virus] CAB60116.1 nucleoprotein nucleoprotein [Measles virus] CAB46895.1 nucleoprotein nucleoprotein [Measles virus] CAB60121.1 nucleoprotein nucleoprotein [Measles virus] ABI54111.1 nucleoprotein nucleoprotein [Measles virus] CAB46889.1 nucleoprotein nucleoprotein [Measles virus] CAB46898.1 nucleoprotein nucleoprotein [Measles virus genotype B3] ALE27083.1 nucleoprotein nucleoprotein [Measles virus] CAB60118.1 tif 307 nucleoprotein nucleocapsid protein [Measles virus] CAA34570.1 nucleoprotein nucleoprotein [Measles virus] AAC29443.1 nucleoprotein nucleocapsid protein [Measles virus strain AEP40422.1 MVi/Washington.USA/18.08/1] nucleoprotein nucleoprotein [Measles virus] AAO15872.1 nucleoprotein nucleoprotein [Measles virus] CAB46874.1 nucleoprotein nucleoprotein [Measles virus] AAA74550.1 nucleoprotein nucleocapsid protein [Measles virus] ABB71648.1 nucleoprotein nucleoprotein [Measles virus] CAB46900.1 nucleoprotein nucleoprotein [Measles virus] BAH22440.1 nucleoprotein nucleocapsid protein [Measles virus] AAA46432.1 nucleoprotein nucleocapsid protein [Measles virus] BAA33867.1 nucleoprotein nucleoprotein [Measles virus] AAA74539.1 nucleoprotein nucleoprotein [Measles virus] CAB60115.1 nucleoprotein nucleoprotein [Measles virus] CAB60123.1 nucleoprotein nucleocapsid protein [Measles virus] ABB71664.1 nucleoprotein nucleoprotein [Measles virus] CAB60125.1 nucleoprotein nucleoprotein [Measles virus] AAA74546.1 nucleoprotein nucleoprotein [Measles virus] CAB46886.1 nucleoprotein nucleoprotein [Measles virus] BAH22350.1 nucleoprotein nucleoprotein [Measles virus] CAB46867.1 nucleoprotein nucleocapsid protein [Measles virus] BAA09954.1 nucleoprotein nucleoprotein [Measles virus] AAO15873.1 nucleoprotein nucleocapsid protein

[Measles virus] AEP95735.1 nucleoprotein nucleoprotein [Measles virus] AAL37726.1 nucleoprotein nucleoprotein [Measles virus] AAA74549.1 nucleoprotein RecName: Full = Nucleoprotein; AltName: P26030.1 Full = Nucleocapsid protein; Short = NP; Short = Protein N nucleoprotein nucleoprotein [Measles virus ETH55/99] AAK07777.1 nucleoprotein nucleoprotein [Measles virus genotype B3] AGA17238.1 nucleoprotein nucleoprotein [Measles virus] AEF30351.1 nucleoprotein nucleoprotein [Measles virus genotype B3] AGA17242.1 nucleoprotein nucleoprotein [Measles virus ETH54/98] AAK07776.1 nucleoprotein nucleoprotein [Measles virus] AAA74548.1 nucleoprotein nucleoprotein [Measles virus] AAA19221.1 nucleoprotein nucleoprotein [Measles virus] AAC03039.1 nucleoprotein nucleoprotein [Measles virus] AAA19223.1 nucleoprotein nucleoprotein [Measles virus genotype B3] AGA17241.1 nucleoprotein nucleoprotein [Measles virus] CAB60122.1 nucleoprotein nucleoprotein [Measles virus] CAC34599.1 nucleoprotein nucleoprotein [Measles virus] AAC03042.1 nucleoprotein nucleoprotein [Measles virus] CAC34604.1 nucleoprotein nucleoprotein [Measles virus] AAA74544.1 nucleoprotein nucleocapsid protein [Measles virus] NP\_056918.1 V Protein RecName: Full = Non-structural protein V Q9IC37.1 V Protein RecName: Full = Non-structural protein V Q9EMA9.1 V Protein V protein [Measles virus] ACN54411.1 V Protein V protein [Measles virus] ACN54403.1 V Protein V protein [Measles virus] AEP95742.1 V Protein V protein [Measles virus strain MVi/Nirginia.USA/15.09] AEP40416.1 V Protein V protein [Measles virus] ADU17801.1 V Protein V protein [Measles virus] ADU17849.1 V Protein V protein [Measles virus] ABB71642.1 V Protein V protein [Measles virus genotype D8] AFY12693.1 V Protein V protein [Measles virus] YP\_003873249.2 V Protein V protein [Measles virus strain AEP40432.1 MVi/Arizona.USA/11.08/2] V Protein RecName: Full = Non-structural protein V P26036.1 V Protein V protein [Measles virus strain AEP40464.1 MVi/California.USA/16.03] V Protein V protein [Measles virus strain AEP40456.1 MVi/California.USA/8.04] V Protein V protein [Measles virus] ABY21188.1 V Protein V protein [Measles virus strain AEP40424.1 MVi/Washington.USA/18.08/1] V Protein V protein [Measles virus] BAH96581.1 V Protein V protein [Measles virus] ABB71666.1 V Protein RecName: Full = Non-structural protein V P60168.1 V Protein V protein [Measles virus] BAH96589.1 V Protein V protein [Measles virus] ADU17954.1 V Protein V protein [Measles virus strain MVi/New AEP40400.1 York.USA/26.09/3] V Protein V protein [Measles virus] ABY21196.1 V Protein virulence factor [Measles virus] ABO69701.1 V Protein V protein [Measles virus] ABB71650.1 V Protein V protein [Measles virus] ACC86086.1 V Protein V protein [Measles virus genotype D4] AFY12702.1 V Protein V protein [Measles virus strain MVi/New AEP40448.1 Jersey.USA/45.05] V Protein V protein [Measles virus] BAE98295.1 V Protein V protein [Measles virus] ACC86083.1 V Protein V protein [Measles virus] ACU57139.1 V Protein V protein [Measles virus] ADO17334.1 V Protein V protein [Measles virus] ADU17930.1 V Protein V protein [Measles virus genotype G3] AFY12710.1 V Protein V protein [Measles virus strain AEP40472.1 MVi/Pennsylvania.US A/20.09] V Protein phosphoprotein [Measles virus] ADU17839.1 V Protein V protein [Measles virus] ADU17894.1 V Protein V protein [Measles virus] ACN50010.1 V Protein V protein [Measles virus] ADU17892.1 unnamed protein product [Measles virus] CAA34585.1 V Protein V protein [Measles virus] ABD33997.1

TABLE-US-00017 TABLE 16 SEQ ID Name Sequence NO: Flagellin Nucleic Acid Sequences NT

TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCA 51 (5'  
CTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAAT UTR,  
ATAAGAGCCACCATGGCACAAGTCATTAATACAAACAGCC ORF,  
TGTCGCTGTTGACCCAGAATAACCTGAACAAATCCCAGTC 3'  
CGCACTGGGCACTGCTATCGAGCGTTTGTCTTCCGGTCTG UTR)  
CGTATCAACAGCGCGAAAGACGATGCGGCAGGACAGGCGA  
TTGCTAACCGTTTTACCGCGAACATCAAAGGTCTGACTCA  
GGCTTCCCCTAACGCTAACGACGGTATCTCCATTGCGCAG  
ACCACTGAAGGCGCGCTGAACGAAATCAACAACAACCTGC  
AGCGTGTGCGTGAACCTGGCGGTTTCAGTCTGCGAATGGTAC  
TAACTCCCAGTCTGACCTCGACTCCATCCAGGCTGAAATC  
ACCCAGCGCCTGAACGAAATCGACCGTGTATCCGGCCAGA  
CTCAGTTCAACGGCGTGAAAGTCTGGCGCAGGACAACAC  
CCTGACCATCCAGGTTGGTGCCAACGACGGTGAACACTATC  
GATATTGATTTAAAAGAAATCAGCTCTAAAACACTGGGAC  
TTGATAAGCTTAATGTCCAAGATGCCTACACCCCGAAAGA

AACTGCTGTAACCGTTGATAAACTACCTATAAAAATGGT  
ACAGATCCTATTACAGCCCAGAGCAATACTGATATCCAAA  
CTGCAATTGGCGGTGGTGCAACGGGGGTTACTGGGGCTGA  
TATCAAATTTAAAGATGGTCAATACTATTTAGATGTTAAA  
GGCGGTGCTTCTGCTGGTGTATAAAGCCACTTATGATG  
AACTACAAAAGAAAGTTAATATTGATACGACTGATAAAC  
TCCGTTGGCAACTGCGGAAGCTACAGCTATTCGGGGAACG  
GCCACTATAACCCACAACCAAAATTGCTGAAGTAACAAAAG  
AGGGTGTGATACGACCACAGTTGCGGCTCAACTTGCTGC  
AGCAGGGGTTACTGGCGCCGATAAGGACAATACTAGCCTT  
GTAAAACCTATCGTTTGAGGATAAAAACGGTAAGGTTATTG  
ATGGTGGCTATGCAGTGAAAATGGGCGACGATTTCTATGC  
CGCTACATATGATGAGAAAACAGGTGCAATTACTGCTAAA  
ACCACTACTTATACAGATGGTACTGGCGTTGCTCAAACCTG  
GAGCTGTGAAATTTGGTGGCGCAAATGGTAAATCTGAAGT  
TGTTACTGCTACCGATGGTAAGACTTACTTAGCAAGCGAC  
CTTGACAAACATAACTTCAGAACAGGCGGTGAGCTTAAAG  
AGGTTAATACAGATAAGACTGAAAACCCACTGCAGAAAAT  
TGATGCTGCCTTGGCACAGGTTGATACTTTCGTTCTGAC  
CTGGGTGCGGTTTCCAGAACCGTTTCAACTCCGCTATCACCA  
ACCTGGGCAATACCGTAAATAACCTGTCTTCTGCCCGTAG  
CCGTATCGAAGATTCCGACTACGCAACCGAAGTCTCCAAC  
ATGTCTCGCGCGCAGATTCTGCAGCAGGCCGGTACCTCCG  
TTCTGGCGCAGGCCAACCAGGTTCCGCAAACGTCCTCTC  
TTTACTGCGTTGATAATAGGCTGGAGCCTCGGTGGCCATG  
CTTCTTGCCCCTTGGGCCTCCCCCAGCCCCTCCTCCCCT  
TCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGA GTGGGCGGC ORF  
ATGGCACAAGTCATTAATAACAAACAGCCTGTCGCTGTTGA 52 Se-  
CCCAGAATAACCTGAACAAATCCCAGTCCGCACTGGGCAC quence,  
TGCTATCGAGCGTTTGTCTTCCGGTCTGCGTATCAACAGC NT  
GCGAAAGACGATGCGGCAGGACAGGCGATTGCTAACCGTT  
TTACCGCGAACATCAAAGGTCTGACTCAGGCTTCCCCTAA  
CGCTAACGACGGTATCTCCATTGCGCAGACCACTGAAGGC  
GCGCTGAACGAAATCAACAACAACCTGCAGCGTGTGCGTG  
AACTGGCGGTTTCACTGCGAATGGTACTAACTCCCAGTC  
TGACCTCGACTCCATCCAGGCTGAAATCACCCAGCGCCTG  
AACGAAATCGACCGTGTATCCGGCCAGACTCAGTTCAACG  
GCGTGAAAGTCCTGGCGCAGGACAACACCCTGACCATCCA  
GGTTGGTGCCAACGACGGTGAACCTATCGATATTGATTAA  
AAAGAAATCAGCTCTAAAACACTGGGACTTGATAAGCTTA  
ATGTCCAAGATGCCTACACCCCGAAAGAAACTGCTGTAAC  
CGTTGATAAACTACCTATAAAAATGGTACAGATCCTATT  
ACAGCCCAGAGCAATACTGATATCCAAACTGCAATTGGCG  
GTGGTGCACACGGGGGTTACTGGGGCTGATATCAAATTTAA  
AGATGGTCAATACTATTTAGATGTTAAAGGCGGTGCTTCT  
GCTGGTGTATAAAGCCACTTATGATGAAACTACAAAGA  
AAGTTAATATTGATACGACTGATAAACTCCGTTGGCAAC  
TGCGGAAGCTACAGCTATTCGGGGAACGGCCACTATAACC  
CACAACCAAAATTGCTGAAGTAACAAAAGAGGGTGTGATA  
CGACCACAGTTGCGGCTCAACTTGCTGCAGCAGGGGTTAC  
TGGCGCCGATAAGGACAATACTAGCCTTGTAAAAACCTATCG  
TTTGAGGATAAAAACGGTAAGGTTATTGATGGTGGCTATG  
CAGTGAAAATGGGCGACGATTTCTATGCCGCTACATATGA  
TGAGAAAACAGGTGCAATTACTGCTAAAACCACTACTTAT

ACAGATGGTACTGGCGTTGCTCAAACCTGGAGCTGTGAAAT  
TTGGTGGCGCAAATGGTAAATCTGAAAGTTGTTACTGCTAC  
CGATGGTAAGACTTACTTAGCAAGCGACCTTGACAAACAT  
AACTTCAGAACAGGGCGGTGAGCTTAAAGAGGTTAATACAG  
ATAAGACTGAAAACCCACTGCAGAAAATTGATGCTGCCTT  
GGCACAGGTTGATACACTTCGTTCTGACCTGGGTGCGGTT  
CAGAACCGTTTCAACTCCGCTATACCAACCTGGGCAATA  
CCGTAATAACCTGTCTTCTGCCCGTAGCCGTATCGAAGA  
TTCCGACTACGCAACCGAAGTCTCCAACATGTCTCGCGCG  
CAGATTCTGCAGCAGGCCGGTACCTCCGTTCTGGCGCAGG  
CGAACCAGGTTCCGCAAACGTCCTCTCTTTACTGCGT mRNA  
G\*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUA 53 Se-  
AGAGCCACCAUGGCACAAGUCAUUAUACAAACAGCCUGU quence  
CGCUGUUGACCCAGAAUAACCUGAACAAAUCCCAGUCCGC (as-  
ACUGGGCACUGCUAUCGAGCGUUUGUCUUCGGUCUGCGU sumes  
AUCAACAGCGCGAAAGACGAUGCGGCAGGACAGGCGAUUG T100  
CUAACCGUUUUACCGCGAACAUCAAAGGUCUGACUCAGGC tail)  
UUCCCUGAACGCUAACGACGGUAUCUCCAUUGCGCAGACC  
ACUGAAGGCGCGCUGAACGAAAUCAACAACAACCUGCAGC  
GUGUGCGUGAACUGGGCGGUUCAGUCUGCGAAUGGUACUAA  
CUCCCAGUCUGACCUCGACUCCAUCCAGGCUGAAAUCACC  
CAGCGCCUGAACGAAAUCGACCGUGUAUCCGGCCAGACUC  
AGUUCAACGGCGUGAAAGUCCUGGCGCAGGACAACACCCU  
GACCAUCCAGGUUGGUGCCAACGACGGUGAAACUAUCGAU  
AUUGAUUUAAAAGAAAUCAGCUCUAAAACACUGGGACUUG  
AUAAGCUUAAUGUCCAAGAUGCCUACACCCCGAAAGAAAC  
UGCUGUAACCGUUGAUAAAACUACCUAUAAAAAUGGUACA  
GAUCCUAUUACAGCCCAGAGCAAUACUGAUAUCCAAACUG  
CAAUUGGCGGUGGUGCAACGGGGGUACUGGGGCUGAUUAU  
CAAUUUAAAAGAUGGUCAAUACUAAUUAGAUGUUAAAGGC  
GGUGCUUCUGCUGGUGUUUAUAAAGCCACUUAUGAUGAAA  
CUACAAAGAAAGUUAAUAUUGAUACGACUGAUAAAACUCC  
GUUGGCAACUGCGGAAGCUACAGCUAUUCGGGGAACGGCC  
ACUAUAACCCACAACCAAUUGCUGAAGUAACAAAAGAGG  
GUGUUGAUACGACCACAGUUGCGGCUCAACUUGCUGCAGC  
AGGGGUUACUGGCGCCGAUAAGGACAAUACUAGCCUUGUA  
AAACUAUCGUUUGAGGAUAAAACGGUAAGGUUAUUGAUG  
GUGGCUAUGCAGUGAAAAUGGGCGACGAUUUCUAUGCCGC  
UACAUUAUGAUGAGAAAACAGGUGCAAUUACUGCUAAAACC  
ACUACUUAUACAGAUGGUACUGGCGUUGCUCAAACUGGAG  
CUGUGAAAUUUGGUGGCGCAAUUGGUAAAUCUGAAGUUGU  
UACUGCUACCGAUGGUUAGACUUAACUAGCAAGCGACCUU  
GACAAACAUAAACUUCAGAACAGGCGGUGAGCUUAAAGAGG  
UUAAUACAGAUAAAGACUGAAAACCCACUGCAGAAAUAUGA  
UGCUGCCUUGGCACAGGUUGAUACACUUCGUUCUGACCUG  
GGUGCGGUUCAGAACCGUUUCAACUCCGCUAUCACCAACC  
UGGGCAAUACCGUAAAUAACCUGUCUUCUGCCCGUAGCCG  
UAUCGAAGAUUCCGACUACGCAACCGAAGUCUCCAACAUG  
UCUCGCGCGCAGAUUCUGCAGCAGGCCGGUACCUCGGUUC  
UGGCGCAGGCCAACCAGGUUCCGCAAACGUCCUCUCUUU  
ACUGCGUUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUU  
CUUGCCCCUUGGGCCUCCCCCAGCCCCUCCUCCCCUCC  
UGCACCCGUACCCCGUGGUCUUUGAAUAAAGUCUGAGUG  
GGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA





AACGAAAUCGACCGUGUAUCCGGCCAGACUCAGUUCAACG  
GCGUGAAAGUCCUGGCGCAGGACAACACCCUGACCAUCCA  
GGUUGGUGCCAACGACGGUGAAACUAUCGAUAUUGAUUUA  
AAAGAAAUCAGCUCUAAAACACUGGGACUUGAUAAAGCUUA  
AUGUCCAAGAUGCCUACACCCCGAAAGAAACUGCUGUAAC  
CGUUGAUAAAACUACCUAUAAAAAUGGUACAGAUCCUAUU  
ACAGCCCAGAGCAAUACUGAUAUCCAAACUGCAAUUGGCG  
GUGGUGCAACGGGGGUUACUGGGGCUGAUAUCAAUUUAA  
AGAUGGUCAAUACUAAUUAGAUGUUAAGGCGGUGCUUCU  
GCUGGUGUUUAUAAAGCCACUUAUGAUGAAACUACAAAGA  
AAGUAAAUUUGAUACGACUGAUAAAACUCCGUUGGCAAC  
UGCGGAAGCUACAGCUAUUCGGGGAACGGCCACUUAACC  
CACAACCAAUUGCUGAAGUAACAAAAGAGGGUGUUGAUA  
CGACCACAGUUGCGGCUCAACUUGCUGCAGCAGGGGUUAC  
UGGCGCCGAUAAGGACAAUACUAGCCUUGUAAAACUAUCG  
UUUGAGGAUAAAACGGUAAGGUUAUUGAUGGUGGCUAUG  
CAGUGAAAUGGGCGACGAUUUCUAUGCCGCUACAUAUGA  
UGAGAAAACAGGUGCAAUACUGCUAAAACCACUACUUAU  
ACAGAUGGUACUGGCGUUGCUCAAACUGGAGCUGUGAAAU  
UUGGUGGCGCAAUUGGUAAAUCUGAAGUUGUACUGCUAC  
CGAUGGUAAAGACUUAUCUAGCAAGCGACCUUGACAAACAU  
AACUUCAGAACAGGCGGUGAGCUUAAAGAGGUUAAUACAG  
AUAAGACUGAAAACCCACUGCAGAAAUAUGAUGCUGCCUU  
GGCACAGGUUGAUACACUUCGUUCUGACCUGGGUGCGGUU  
CAGAACCGUUCAACUCCGCUAUCACCAACCUGGGCAAUA  
CCGUAAAUAACCUGUCUUCUGCCCGUAGCCGUUUCGAAGA  
UUCGACUACGCAACCGAAGUCUCCAACAUGUCUCGCGCG  
CAGAUUCUGCAGCAGGCCGGUACCUCGCUUCUGGCGCAGG  
CGAACCAGGUUCCGCAAACGUCCUCUCUUUACUGCGU mRNA  
G\*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUA 83 Se-  
AGAGCCACCAUGGCACAAGUCAUUAUACAAACAGCCUGU quence  
CGCUGUUGACCCAGAAUAACCUGAACAAAUCCCAGUCCGC (as-  
ACUGGGCACUGCUAUCGAGCGUUUGUCUUCGGUCUGCGU sumes  
AUCAACAGCGCGAAAGACGAUGCGGCAGGACAGGCGAUUG T100  
CUAACCGUUUACCGCGAACAUCAAAGGUCUGACUCAGGC tail)  
UUCCCGUAACGCUAACGACGGUAUCUCCAUUGCGCAGACC  
ACUGAAGGCGCGCUGAACGAAAUCAACAACAACCUGCAGC  
GUGUGCGUGAACUGGCGGUUCAGUCUGCGAAUGGUACUAA  
CUCCCAGUCUGACCUCGACUCCAUCCAGGCUGAAAUCACC  
CAGCGCCUGAACGAAAUCGACCGUGUAUCCGGCCAGACUC  
AGUUCAACGGCGUGAAAGUCCUGGCGCAGGACAACACCCU  
GACCAUCCAGGUUGGUGCCAACGACGGUGAAACUAUCGAU  
AUUGAUUUAAAAGAAAUCAGCUCUAAAACACUGGGACUUG  
AUAAGCUUAAUGUCCAAGAUGCCUACACCCCGAAAGAAAC  
UGCUGUAACCGUUGAUAAAACUACCUAUAAAAAUGGUACA  
GAUCCUAUUACAGCCCAGAGCAAUACUGAUAUCCAAACUG  
CAAUUGGCGGUGGUGCAACGGGGGUUACUGGGGCUGAUAU  
CAAUUUAAAAGAUGGUCAAUACUAAUUAGAUGUUAAGGC  
GGUGCUUCUGCUGGUGUUUAUAAAGCCACUUAUGAUGAAA  
CUACAAAGAAAGUUAUUAUUGAUACGACUGAUAAAACUCC  
GUUGGCAACUGCGGAAGCUACAGCUAUUCGGGGAACGGCC  
ACUUAACCCACAACCAAUUGCUGAAGUAACAAAAGAGG  
GUGUUGAUACGACCACAGUUGC GGCUCAACUUGCUGCAGC  
AGGGGUUACUGGCGCCGAUAAGGACAAUACUAGCCUUGUA



GVTGTASVVKMSYTDNNGKTIDGGLAVKVGD DYYSATQNKDGSISINTTKYTADDGTSKTAL  
NKLGGADGKTEVVSIGGKTYAASKAEGHNFK AQPDLAEAAATTENPLQKIDAALAQVDTLR  
SDLGAVQNRFNSAITNLGNTVNNLTSARSRI EDSYATEVSNMSRAQILQQAGTSVLAQANQ  
VPQNVLSLLR

TABLE-US-00019 TABLE 18 Human Metapneumovirus Mutant Amino Acid Sequences SEQ ID Strain  
Sequence NO: HMPV\_SC\_MSWKVVIIFSLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTLEV

85 DSCAV1\_4M DVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPGSGSFVLG MV  
AIALGVAAAAAVTAGVAICKTIRLESEVTAINNALKKTNEAVSTLGNGVRV  
LAFVRELKDFVSKNLTRALNKNKCDIDDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLLENRAMVRRKGFIL  
CGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNYACLLREDQGWY  
CQNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYP  
KVSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIKQLNKGCSYITNQ  
DADTVTIDNTVYQLSKVEGEQHVIVKGRPVSSSFDPIKFPEDQFNVALDQVFE  
NIENSQALVDQSNRILSSAEKGTGFIIIVILIAVLGSSMILVSIFIIIKTKTKPTG APPELSGVTNNGFIPHN  
HMPV\_SC\_MSWKVVIIFSLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTLEV 86  
DSTRIC\_4M DVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPGSGSFVLG MV  
AIALGVAAAAAVTAGVAICKTIRLESEVTAINNALKKTNEAVSTLGNGVRV  
LATAVRELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLLENRAMVRRKGFIL  
CGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNYACLLREDQGWY  
CQNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYP  
KVSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIKQLNKGCSYITNQ  
DADTVTIDNTVYQLSKVEGEQHVIVKGRPVSSSFDPIKFPEDQFNVALDQVFE  
NIENSQALVDQSNRILSSAEKGTGFIIIVILIAVLGSSMILVSIFIIIKTKTKPTG APPELSGVTNNGFIPHN  
HMPV\_SC\_MSWKVVIIFSLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTLEV 87  
DM\_Krarup\_DVENLTCSDGPSLIKTELDLLKSALRELKTVSADQLAREEQIENPGSGSFVLG T74LD185P  
AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV  
LATAVRELKDFVSKNLTRAINKNKCDIPDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLLENRAMVRRKGFIL  
GVYGGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNYACLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCK  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIKQLNKGCSYITNQD  
ADTVTIDNTVYQLSKVEGEQHVIVKGRPVSSSFDPIKFPEDQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGTGFIIIVILIAVLGSSMILVSIFIIIKTKTKPTGA PPELSGVTNNGFIPHN  
HMPV\_SC\_T MSWKVVIIFSLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTLEV 88  
M\_Krarup\_T DVENLTCSDGPSLIKTELDLLKSALRELKTVSADQLAREEQIENPGSGSFVLG 74LD185PD4  
AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV 54N  
LATAVRELKDFVSKNLTRAINKNKCDIPDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLLENRAMVRRKGFIL  
GVYGGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNYACLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCK  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIKQLNKGCSYITNQD  
ADTVTIDNTVYQLSKVEGEQHVIVKGRPVSSSFDPIKFPENQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGTGFIIIVILIAVLGSSMILVSIFIIIKTKTKPTGA PPELSGVTNNGFIPHN  
HMPV\_SC\_4 MSWKVVIIFSLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTLEV 89  
M\_Krarup\_DVENLTCSDGPSLIKTELDLLKSALRELKTVSADQLAREEQIENPGSGSFVLG T74LS170LD  
AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV 185P  
LATAVRELKDFVLKNLTRAINKNKCDIPDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLLENRAMVRRKGFIL  
GVYGGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNYACLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCK  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIKQLNKGCSYITNQD

ADTVTIDNTVYQLSKVEGEQHVIVKGRPVSSSFDPIKFPEDQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGNMGFIIIVIIIAVLGSSMILVSIFIIIKTKTKPTGA PPELSGVTNNGFIPHN  
HMPV\_SC\_5 MSWKVVIIIFSLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVG 90  
M\_Krarup\_T DVENLTCSDGPSLIKTELDLLKSALRELKTVSADQLAREEQIENPGSGSFVLG 74LS170LD1  
AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV 85PD454N  
LATAVRELKDFVLKNLTRAINKNKCDIPDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLLENRAMVRRKGFGLI  
GVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNYA CLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCK  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQD  
ADTVTIDNTVYQLSKVEGEQHVIVKGRPVSSSFDPIKFPENQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGNMGFIIIVIIIAVLGSSMILVSIFIIIKTKTKPTGA PPELSGVTNNGFIPHN  
HMPV\_SC\_MS WKVVIIIFSLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTLPVG 91  
DM\_Krarup\_DVENLTCSDGPSLIKTELDLLKSALRELKTVSADQLAREEQIENPGSGSFVLG E51PT74L  
AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV  
LATAVRELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLLENRAMVRRKGFGLI  
GVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNYA CLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCK  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQD  
ADTVTIDNTVYQLSKVEGEQHVIVKGRPVSSSFDPIKFPEDQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGNMGFIIIVIIIAVLGSSMILVSIFIIIKTKTKPTGA PPELSGVTNNGFIPHN  
HMPV\_SC\_T MSWKVVIIIFSLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTLPVG 92  
M\_Krarup\_E DVENLTCSDGPSLIKTELDLLKSALRELKTVSADQLAREEQIENPGSGSFVLG 51PT74LD45  
AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV 4N  
LATAVRELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLLENRAMVRRKGFGLI  
GVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNYA CLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCK  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQD  
ADTVTIDNTVYQLSKVEGEQHVIVKGRPVSSSFDPIKFPENQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGNMGFIIIVIIIAVLGSSMILVSIFIIIKTKTKPTGA PPELSGVTNNGFIPHN  
HMPV\_SC\_MS WKVVIIIFSLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVG 93 Stabilize  
DVENLTCSDGPSLIKTELDLLKSALRELKTVSADQLAREEQIENPGSGSFVLG Alpha\_T74L  
AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV  
LATAVRELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLLENRAMVRRKGFGLI  
GVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNYA CLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCK  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQD  
ADTVTIDNTVYQLSKVEGEQHVIVKGRPVSSSFDPIKFPEDQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGNMGFIIIVIIIAVLGSSMILVSIFIIIKTKTKPTGA PPELSGVTNNGFIPHN  
HMPV\_MS WKVVIIIFSLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVG 94 SC\_Stabilize  
DLENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPGSGSFVLG Alpha\_V55L  
AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV  
LATAVRELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLLENRAMVRRKGFGLI  
GVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNYA CLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCK  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQD  
ADTVTIDNTVYQLSKVEGEQHVIVKGRPVSSSFDPIKFPEDQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGNMGFIIIVIIIAVLGSSMILVSIFIIIKTKTKPTGA PPELSGVTNNGFIPHN  
HMPV\_MS WKVVIIIFSLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVG 95 SC\_Stabilize  
DVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPGSGSFVLG Alpha\_S170L

AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV  
LATAVRELKDFVLKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLLENRAMVRRKGFGLI  
GVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNACLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPC  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIKQLNKGCSYITNQD  
ADTVTIDNTVYQLSKVEGEQHVIGRVPVSSSFDPIKFPEDQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGTGFIIIVILIAVLGSSMILVSIFIIIKTKTKPTGA PPELSGVTNNGFIPHN  
HMPV\_ MSWKVVIIFSLITPQHGLKESYLEESCSTITEGYLSVLRGTWYTNVFTLEVG 96 SC\_Stabilize  
DVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPGSGSFVLG Alpha\_T174  
AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV W  
LATAVRELKDFVSKNLWRANKNKCDIDDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLLENRAMVRRKGFGLI  
GVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNACLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPC  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIKQLNKGCSYITNQD  
ADTVTIDNTVYQLSKVEGEQHVIGRVPVSSSFDPIKFPEDQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGTGFIIIVILIAVLGSSMILVSIFIIIKTKTKPTGA PPELSGVTNNGFIPHN  
HMPV\_SC\_4 MSWKVVIIFSLITPQHGLKESYLEESCSTITEGYLSVLRGTWYTNVFTLEVG 97  
M\_Stabilize DLENLTCSDGPSLIKTELDLLKSALRELKTVSADQLAREEQIENPGSGSFVLG  
Alpha\_V55LT7 AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV 4LS170LT17  
LATAVRELKDFVLKNLWRANKNKCDIDDLKMAVSFSQFNRRFLNVVRQFS 4W  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLLENRAMVRRKGFGLI  
GVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNACLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPC  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIKQLNKGCSYITNQD  
ADTVTIDNTVYQLSKVEGEQHVIGRVPVSSSFDPIKFPEDQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGTGFIIIVILIAVLGSSMILVSIFIIIKTKTKPTGA PPELSGVTNNGFIPHN  
HMPV\_Proline MSWKVVIIFSLITPQHGLKESYLEESCSTITEGYLSVLRGTWYTNVFTLPVG 98  
Stab\_E51P DVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPGSGSFVLG  
AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV  
LATAVRELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLLENRAMVRRKGFGLI  
GVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNACLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPC  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIKQLNKGCSYITNQD  
ADTVTIDNTVYQLSKVEGEQHVIGRVPVSSSFDPIKFPEDQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGTGFIIIVILIAVLGSSMILVSIFIIIKTKTKPTGA PPELSGVTNNGFIPHN  
HMPV\_Proline MSWKVVIIFSLITPQHGLKESYLEESCSTITEGYLSVLRGTWYTNVFTLEVG 99  
Stab\_D185 DVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPGSGSFVLG P  
AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV  
LATAVRELKDFVSKNLTRAINKNKCDIPDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLLENRAMVRRKGFGLI  
GVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNACLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPC  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIKQLNKGCSYITNQD  
ADTVTIDNTVYQLSKVEGEQHVIGRVPVSSSFDPIKFPEDQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGTGFIIIVILIAVLGSSMILVSIFIIIKTKTKPTGA PPELSGVTNNGFIPHN  
HMPV\_Proline MSWKVVIIFSLITPQHGLKESYLEESCSTITEGYLSVLRGTWYTNVFTLEVG 100  
Stab\_D183 DVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPGSGSFVLG P  
AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV  
LATAVRELKDFVSKNLTRAINKNKCPIDDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLLENRAMVRRKGFGLI  
GVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNACLLREDQGWYC

QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCK  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIKQLNKGCSYITNQD  
ADVTIDNTVYQLSKVEGEQHVIKGRPVSSSFDPKFPEDQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGNMGFIIIVIIIAVLGSSMILVSIFIIIKKTCKPTGA PPELSGVTNNGFIPHN  
HMPV\_Proline MSWKVVIIFSLITPQHGLKESYLEESCSTITEGYLSVLRGTWYTNVFTLEVG 101  
Stab\_E131 DVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPGSGSFVLG P  
AIALGVAAAAAVTAGVAIAKTIRLPSEVTAINNALKKTNEAVSTLGNGVRV  
LATAVRELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLNENRAMVRRKGFGLI  
GVYSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNYACLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCK  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIKQLNKGCSYITNQD  
ADVTIDNTVYQLSKVEGEQHVIKGRPVSSSFDPKFPEDQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGNMGFIIIVIIIAVLGSSMILVSIFIIIKKTCKPTGA PPELSGVTNNGFIPHN  
HMPV\_Proline MSWKVVIIFSLITPQHGLKESYLEESCSTITEGYLSVLRGTWYTNVFTLEVG 102  
Stab\_D447 DVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPGSGSFVLG P  
AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV  
LATAVRELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLNENRAMVRRKGFGLI  
GVYSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNYACLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCK  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIKQLNKGCSYITNQD  
ADVTIDNTVYQLSKVEGEQHVIKGRPVSSSFPPKFPEDQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGNMGFIIIVIIIAVLGSSMILVSIFIIIKKTCKPTGA PPELSGVTNNGFIPHN  
HMPV\_Trimer MSWKVVIIFSLITPQHGLKESYLEESCSTITEGYLSVLRGTWYTNVFTLEVG 103  
RepulsionD DVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPGSGSFVLG 454N  
AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV  
LATAVRELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLNENRAMVRRKGFGLI  
GVYSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNYACLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCK  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIKQLNKGCSYITNQD  
ADVTIDNTVYQLSKVEGEQHVIKGRPVSSSFDPKFPENQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGNMGFIIIVIIIAVLGSSMILVSIFIIIKKTCKPTGA PPELSGVTNNGFIPHN  
HMPV\_Trimer MSWKVVIIFSLITPQHGLKESYLEESCSTITEGYLSVLRGTWYTNVFTLEVG 104  
RepulsionE DVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPGSGSFVLG 453N  
AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV  
LATAVRELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLNENRAMVRRKGFGLI  
GVYSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNYACLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCK  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIKQLNKGCSYITNQD  
ADVTIDNTVYQLSKVEGEQHVIKGRPVSSSFDPKFPQDQFQVALDQVFENI  
ENSQALVDQSNRILSSAEKGNMGFIIIVIIIAVLGSSMILVSIFIIIKKTCKPTGA PPELSGVTNNGFIPHN  
HMPV\_Stabilize MSWKVVIIFSLITPQHGLKESYLEESCSTITEGYLSVLRGTWYTNVFTLEVG 105  
AlphaF196 DVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPGSGSFVLG W  
AIALGVAAAAAVTAGVAIAKTIRLESEVTAINNALKKTNEAVSTLGNGVRV

LATAVRELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQWNRRFLNVVRQFS  
DNAGITPAISLDLMTDAELARAVPNMPTSAGQIKLMLNENRAMVRRKGFGLI  
GVYSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNYACLLREDQGWYC  
QNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCK  
VSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIKQLNKGCSYITNQD  
ADVTIDNTVYQLSKVEGEQHVIKGRPVSSSFDPKFPEDQFQVALDQVFENI

ENSQALVDQSNRILSSAEKNTGFIIVIIILIAVLGSSMILVSIFIIIKTKKPTGA PPELSGVTNNGFIPHN

TABLE-US-00020 TABLE 19 SEQ ID Strain Nucleic Acid Sequence NO: Human Metapneumovirus Mutant Nucleic Acid Sequences HMPV\_ ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 106

SC\_DSC CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT AV1\_ CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG 4MMV

AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC  
GACGTCGAGAATCTGACATGCTCTGATGGCCCTAGCCTGA  
TCAAGACCGAGCTGGATCTGACCAAGAGCGCCCTGAGAG  
AACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGA  
ACAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGA  
GCCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAG  
CAGGCGTGGCCATCTGCAAGACCATCAGACTGGAAAGCG  
AAGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACG  
AGGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGCTGGC  
CTTTGCCGTGCGGAGCTGAAGGACTTCGTGTCCAAGAAC  
CTGACACGGGCCCTGAACAAGAACAAGTGCGACATCGAC  
GACCTGAAGATGGCCGTGTCCTTTAGCCAGTTCAACCGGC  
GGTTTCTGAACGTCGTGCGGCAGTTTAGCGACAACGCCGG  
AATCACACCAGCCATCAGCCTGGACCTGATGACAGATGCT  
GAGCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCG  
GCCAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCG  
ACGGAAGGCTTCGGCATTCTGTGTGGCGTGTACGGCAGC  
AGCGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGA  
TCGACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTG  
TAGCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGA  
GGACCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTG  
TACTACCCTAACGAGAAGGACTGCGAGACAAGAGGGCGAC  
CACGTGTTCTGTGATAACGCCGCTGGAATCAATGTGGCCG  
AGCAGAGCAAAGAGTGCAACATCAACATCAGCACCA  
ACTATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTT  
TATGGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGT  
TATAAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGG  
GCATCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCAC  
CAACCAGGACGCCGATACCGTGACCATCGACAACACCGTG  
TATCAGCTGAGCAAGGTGGAAGGCCGAACAGCACGTGATC  
AAGGGCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGT  
TCCCTGAGGATCAGTTCAACGTGGCCCTGGACCAGGTGTT  
CGAGAACATCGAGAATTCCCAGGCTCTGGTGGACCAGTCC  
AACAGAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGC  
TTCATCATCGTGATCATCCTGATCGCCGTGCTGGGCAGCT  
CATGATCCTGGTGTCCATCTTCATCATTATCAAGAAGACC  
CAAGAAGCCCACCGGCGCTCCTCCAGAACTGAGCGGAGTG  
ACCAACAATGGCTTCATCCCTCACAAAC HMPV\_  
ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 107 SC\_DST  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT RIC\_  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG 4MMV  
AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC  
GACGTCGAGAATCTGACATGCTCTGATGGCCCTAGCCTGA  
TCAAGACCGAGCTGGATCTGACCAAGAGCGCCCTGAGAG  
AACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGA  
ACAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGA  
GCCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAG  
CAGGCGTGGCCATCTGCAAGACCATCAGACTGGAAAGCG

AAGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACG  
AGGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGCTGGC  
CACAGCCGTGCGCGAGCTGAAGGACTTCGTGTCCAAGAAC  
CTGACACGGGCCATTAACAAGAACAAGTGCGACATCGAC  
GACCTGAAGATGGCCGTGTCCTTTAGCCAGTTCAACCGGC  
GGTTTCTGAACGTCGTGCGGCAGTTTAGCGACAACGCCGG  
AATCACACCAGCCATCAGCCTGGACCTGATGACAGATGCT  
GAGCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCG  
GCCAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCG  
ACGAAAGGCTTCGGCATTCTGTGTGGCGTGTACGGCAGC  
AGCGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGA  
TCGACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTG  
TAGCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGA  
GGACCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTG  
TACTACCCTAACGAGAAGGACTGCGAGACAAGAGGCGAC  
CACGTGTTCTGTGATACCGCCGCTGGAATCAATGTGGCCG  
AGCAGAGCAAAGAGTGCAACATCAACATCAGCACCA  
ACTATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTT  
TATGGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGT  
TATAAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGG  
GCATCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCAC  
CAACCAGGACGCCGATACCGTGACCATCGACAACACCGTG  
TATCAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATC  
AAGGGCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGT  
TCCCTGAGCACCAGTGGCATGTGGCCCTGGACCAGGTGTT  
CGAGAACATCGAGAATTCCCAGGCTCTGGTGGACCAGTCC  
AACAGAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGC  
TTCATCATCGTGATCATCCTGATCGCCGTGCTGGGCAGCT  
CCATGATCCTGGTGTCCATCTTCATCATTATCAAGAAGAC  
CAAGAAGCCCACCGGCGCTCCTCCAGAACTGAGCGGAGTG  
ACCAACAATGGCTTCATCCCTCACAAAC HMPV\_  
ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 108 SC\_DM\_  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT Krar  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG up\_  
AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC T74L  
GACGTGAGAAATCTGACATGCTCTGATGGCCCTAGCCTGA D185P  
TCAAGACCGAGCTGGATCTGCTCAAGAGCGCCCTGAGAGA  
ACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGAA  
CAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGAG  
CCATTGCTCTTGAGTGGCTGCTGCTGCAGCTGTTACAGC  
AGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCGA  
AGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACGA  
GGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGCTGGCC  
ACAGCCGTGCGCGAGCTGAAGGACTTCGTGTCCAAGAACC  
TGACACGGGCCATTAACAAGAACAAGTGCGACATCCCTGA  
CCTGAAGATGGCCGTGTCCTTTAGCCAGTTCAACCGGCGG  
TTTCTGAACGTCGTGCGGCAGTTTAGCGACAACGCCGGAA  
TCACACCAGCCATCAGCCTGGACCTGATGACAGATGCTGA  
GCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCGGC  
CAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCGAC  
GGAAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGCAG  
CGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGATC  
GACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTGTA  
GCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGAGGA



CCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTGTAC  
TACCCTAACGAGAAGGACTGCGAGACAAGAGGCGACCAC  
GTGTTCTGTGATAACCGCCGCTGGAATCAATGTGGCCGAGC  
AGAGCAAAGAGTGCAACATCAACATCAGCACCAACT  
ATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTTCTAT  
GGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGTTAT  
AAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGGGCA  
TCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCACCAA  
CCAGGACGCCGATAACCGTGACCATCGACAACACCGTGTAT  
CAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATCAAGG  
GCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGTTCCC  
TGAGGATCAGTTCAGGTGGCCCTGGACCAGGTGTTTCGAG  
AACATCGAGAATTCACAGGCTCTGGTGGACCAGTCCAACA  
GAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGCTTCAT  
CATCGTGATCATCCTGATCGCCGTGCTGGGCAGCTCCATG  
ATCCTGGTGTCCATCTTCATCATTATCAAGAAGACCAAGA  
AGCCCACCGGCGCTCCTCCAGAACTGAGCGGAGTGACCAA CAATGGCTTCATCCCTCACAAC  
HMPV\_ ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 109 SC\_TM\_  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT Krar  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG up\_  
AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC T74L  
GACGTCGAGAATCTGACATGCTCTGATGGCCCTAGCCTGA D185P  
TCAAGACCGAGCTGGATCTGCTCAAGAGCGCCCTGAGAGA D454N  
ACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGAA  
CAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGAG  
CCATTGCTCTTGAGTGGCTGCTGCTGCAGCTGTTACAGC  
AGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCGA  
AGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACGA  
GGCCGTGAGCACACTCGGCAATGGCGTTAGAGTGCTGGCC  
ACAGCCGTGCGCGAGCTGAAGGACTTCGTGTCCAAGAACC  
TGACACGGGCCATTAACAAGAACAAGTGCGACATCCCTGA  
CCTGAAGATGGCCGTGTCTTTAGCCAGTTCAACCGGCGG  
TTTCTGAACGTCGTGCGGCAGTTTAGCGACAACGCCGGAA  
TCACACCAGCCATCAGCCTGGACCTGATGACAGATGCTGA  
GCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCGGC  
CAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCGAC  
GGAAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGCAG  
CGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGATC  
GACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTGTA  
GCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGAGGA  
CCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTGTAC  
TACCCTAACGAGAAGGACTGCGAGACAAGAGGCGACCAC  
GTGTTCTGTGATAACCGCCGCTGGAATCAATGTGGCCGAGC  
AGAGCAAAGAGTGCAACATCAACATCAGCACCAACT  
ATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTTCTAT  
GGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGTTAT  
AAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGGGCA  
TCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCACCAA  
CCAGGACGCCGATAACCGTGACCATCGACAACACCGTGTAT  
CAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATCAAGG  
GCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGTTCCC  
TGAGAACCAGTTCAGGTGGCCCTGGACCAGGTGTTTCGAG  
AACATCGAGAATTCACAGGCTCTGGTGGACCAGTCCAACA  
GAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGCTTCAT

CATCGTGATCATCCTGATCGCCGTGCTGGGCAGCTCCATG  
ATCCTGGTGTCCATCTTCATCATTATCAAGAAGACCAAGA  
AGCCCACCGGCGCTCCTCCAGAACTGAGCGGAGTGACCAA CAATGGCTTCATCCCTCACAAAC  
HMPV\_ ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 110 SC\_4M\_  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT Krar  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG up\_  
AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC T74L  
GACGTGAGAAATCTGACATGCTCTGATGGCCCTAGCCTGA S170L  
TCAAGACCGAGCTGGATCTGCTCAAGAGCGCCCTGAGAGA D185P  
ACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGAA  
CAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGAG  
CCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAGC  
AGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCGA  
AGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACGA  
GGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGCTGGCC  
ACAGCCGTGCGCGAGCTGAAGGACTTCGTGCTTAAGAACC  
TGACACGGGCCATTAACAAGAACAAGTGCGACATCCCTGA  
CCTGAAGATGGCCGTGTCTTTAGCCAGTTCAACCGGCGG  
TTTCTGAACGTCGTGCGGCAGTTTAGCGACAACGCCGAA  
TCACACCAGCCATCAGCCTGGACCTGATGACAGATGCTGA  
GCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCGGC  
CAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCGAC  
GGAAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGCAG  
CGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGATC  
GACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTGTA  
GCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGAGGA  
CCAAGGCTGGTATTGTGTCAGAACGCCGGCAGCACCGTGTAC  
TACCCTAACGAGAAGGACTGCGAGACAAGAGGGCGACCAC  
GTGTTCTGTGATAACCGCCGCTGGAATCAATGTGGCCGAGC  
AGAGCAAAGAGTGCAACATCAACATCAGCACCACCAACT  
ATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTTCTAT  
GGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGTTAT  
AAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGGGCA  
TCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCACCAA  
CCAGGACGCCGATAACCGTGACCATCGACAACACCGTGTAT  
CAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATCAAGG  
GCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGTTCCC  
TGAGGATCAGTTCCAGGTGGCCCTGGACCAGGTGTTTCGAG  
AACATCGAGAATTCACAGGCTCTGGTGGACCAGTCCAACA  
GAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGCTTCAT  
CATCGTGATCATCCTGATCGCCGTGCTGGGCAGCTCCATG  
ATCCTGGTGTCCATCTTCATCATTATCAAGAAGACCAAGA  
AGCCCACCGGCGCTCCTCCAGAACTGAGCGGAGTGACCAA CAATGGCTTCATCCCTCACAAAC  
HMPV\_ ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 111 SC\_5M\_  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT Krar  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG up\_  
AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC T74L  
GACGTGAGAAATCTGACATGCTCTGATGGCCCTAGCCTGA S170L  
TCAAGACCGAGCTGGATCTGCTCAAGAGCGCCCTGAGAGA D185P  
ACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGAA D454N  
CAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGAG  
CCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAGC  
AGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCGA  
AGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACGA

GGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGCTGGCC  
ACAGCCGTGCGCGAGCTGAAGGACTTCGTGCTTAAGAACC  
TGACACGGGCCATTAACAAGAACAAGTGCGACATCCCTGA  
CCTGAAGATGGCCGTGTCCTTTAGCCAGTTCAACCGGCGG  
TTTCTGAACGTCGTGCGGCAGTTTAGCGACAACGCCGGAA  
TCACACCAGCCATCAGCCTGGACCTGATGACAGATGCTGA  
GCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCGGC  
CAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCGAC  
GGAAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGCAG  
CGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGATC  
GACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTGTA  
GCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGAGGA  
CCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTGTAC  
TACCCTAACGAGAAGGACTGCGAGACAAGAGGCGACCAC  
GTGTTCTGTGATAACGCCGCTGGAATCAATGTGGCCGAGC  
AGAGCAAAGAGTGCAACATCAACATCAGCACCACCAACT  
ATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTTCTAT  
GGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGTTAT  
AAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGGGCA  
TCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCACAA

CCAGGACGCCGATAACCGTGACCATCGACAACACCGTGTAT  
CAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATCAAGG  
GCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGTTCCC  
TGAGAACCAGTTCCAGGTGGCCCTGGACCAGGTGTTTCGAG  
AACATCGAGAATTTCCAGGCTCTGGTGGACCAGTCCAACA  
GAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGCTTCAT  
CATCGTGATCATCCTGATCGCCGTGCTGGGCAGCTCCATG  
ATCCTGGTGTCCATCTTCATCATTATCAAGAAGACCAAGA  
AGCCCACCGGCGCTCCTCCAGAACTGAGCGGAGTGACCAA CAATGGCTTCATCCCTCACAAC  
HMPV\_ ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 112 SC\_DM\_  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT Krar  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG up\_  
AACCGGCTGGTACACCAACGTGTTCACTGCCTGTGGGC E51P  
GACGTGAGAAATCTGACATGCTCTGATGGCCCTAGCCTGA T74L  
TCAAGACCGAGCTGGATCTGCTCAAGAGCGCCCTGAGAGA  
ACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGAA  
CAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGAG  
CCATTGCTCTTGAGTGGCTGCTGCTGCAGCTGTTACAGC  
AGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCGA  
AGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACGA  
GGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGCTGGCC  
ACAGCCGTGCGCGAGCTGAAGGACTTCGTGTCCAAGAACC  
TGACACGGGCCATTAACAAGAACAAGTGCGACATCGACG  
ACCTGAAGATGGCCGTGTCCTTTAGCCAGTTCAACCGGCG  
GTTTCTGAACGTCGTGCGGCAGTTTAGCGACAACGCCGGAA  
ATCACACCAGCCATCAGCCTGGACCTGATGACAGATGCTG  
AGCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCGG  
CCAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCGA  
CGGAAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGCA  
GCGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGAT  
CGACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTGT  
AGCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGAGG  
ACCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTGTGA

CTACCCTAACGAGAAGGACTGCGAGACAAGAGGCGACCA  
CGTGTCTGTGATAACCGCCGCTGGAATCAATGTGGCCGAG  
CAGAGCAAAGAGTGCAACATCAACATCAGCACCACCAAC  
TATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTTCTA  
TGGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGTTA  
TAAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGGGC  
ATCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCACCA  
ACCAGGACGCCGATAACCGTGACCATCGACAACACCGTGTA  
TCAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATCAAG  
GGCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGTTCC  
CTGAGGATCAGTTCCAGGTGGCCCTGGACCAGGTGTTCTGA  
GAACATCGAGAATTCCCAGGCTCTGGTGGACCAGTCCAAC  
AGAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGCTTCA  
TCATCGTGATCATCCTGATCGCCGTGCTGGGCAGCTCCAT  
GATCCTGGTGTCCATCTTCATCATTATCAAGAAGACCAAG  
AAGCCCACCGGCGCTCCTCCAGAAGTGAAGGAGTGACCA ACAATGGCTTCATCCCTCACAAC  
HMPV\_ ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 113 SC\_TM\_  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT Krar  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG up\_  
AACCGGCTGGTACACCAACGTGTTCACTGCCTGTGGGC E51P  
GACGTGAGAAATCTGACATGCTCTGATGGCCCTAGCCTGA T74L  
TCAAGACCGAGCTGGATCTGCTCAAGAGCGCCCTGAGAGA D454N  
ACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGAA  
CAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGAG  
CCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAGC  
AGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCGA  
AGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACGA  
GGCCGTGAGCACACTCGGCAATGGCGTTAGAGTGCTGGCC  
ACAGCCGTGCGCGAGCTGAAGGACTTCGTGTCCAAGAACC  
TGACACGGGCCATTAACAAGAACAAGTGCGACATCGACG  
ACCTGAAGATGGCCGTGTCTTTAGCCAGTTCAACCGGCG  
GTTTCTGAACGTCGTGCGGCAGTTTAGCGACAACGCCGGA  
ATCACACCAGCCATCAGCCTGGACCTGATGACAGATGCTG  
AGCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCGG  
CCAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCGA  
CGGAAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGCA  
GCGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGAT  
CGACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTGT  
AGCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGAGG  
ACCAAGGCTGGTATTGTGAGAACGCCGGCAGCACCGTGTA  
CTACCCTAACGAGAAGGACTGCGAGACAAGAGGCGACCA  
CGTGTCTGTGATAACCGCCGCTGGAATCAATGTGGCCGAG  
CAGAGCAAAGAGTGCAACATCAACATCAGCACCACCAAC  
TATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTTCTA  
TGGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGTTA  
TAAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGGGC  
ATCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCACCA  
ACCAGGACGCCGATAACCGTGACCATCGACAACACCGTGTA  
TCAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATCAAG  
GGCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGTTCC  
CTGAGAACCAGTTCCAGGTGGCCCTGGACCAGGTGTTCTGA  
GAACATCGAGAATTCCCAGGCTCTGGTGGACCAGTCCAAC  
AGAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGCTTCA  
TCATCGTGATCATCCTGATCGCCGTGCTGGGCAGCTCCAT

GATCCTGGTGTCCATCTTCATCATTATCAAGAAGACCAAG  
AAGCCCACCGGCGCTCCTCCAGAAGTGGAGTGACCA ACAATGGCTTCATCCCTCACAAC  
HMPV\_ ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 114 SC\_  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT Stabi-  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG lize  
AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC Alpha\_  
GACGTGAGAATCTGACATGCTCTGATGGCCCTAGCCTGA T74L\_  
TCAAGACCGAGCTGGATCTGCTCAAGAGCGCCCTGAGAGA  
ACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGAA  
CAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGAG  
CCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAGC  
AGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCGA  
AGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACGA  
GGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGCTGGCC  
ACAGCCGTGCGCGAGCTGAAGGACTTCGTGTCCAAGAACC  
TGACACGGGCCATTAACAAGAACAAGTGCGACATCGACG  
ACCTGAAGATGGCCGTGTCCTTTAGCCAGTTCAACCGGCG  
GTTTCTGAACGTCGTGCGGCAGTTTAGCGACAACGCCGGA  
ATCACACCAGCCATCAGCCTGGACCTGATGACAGATGCTG  
AGCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCGG  
CCAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCGA  
CGGAAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGCA  
GCGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGAT  
CGACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTGT  
AGCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGAGG  
ACCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTGTA  
CTACCCTAACGAGAAGGACTGCGAGACAAGAGGCGACCA  
CGTGTCTGTGATACCGCCGCTGGAATCAATGTGGCCGAG  
CAGAGCAAAGAGTGCAACATCAACATCAGCACCAACCAAC  
TATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTTCTA  
TGGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGTTA  
TAAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGGGC  
ATCATCAAGCAGCTGAACAAGGGCTGCAGCTACATACCA  
ACCAGGACGCCGATACCGTGACCATCGACAACACCGTGTA  
TCAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATCAAG  
GGCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGTTCC  
CTGAGGATCAGTTCCAGGTGGCCCTGGACCAGGTGTTCTGA  
GAACATCGAGAATTCCCAGGCTCTGGTGGACCAGTCCAAC  
AGAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGCTTCA  
TCATCGTGATCATCCTGATCGCCGTGCTGGGCAGCTCCAT  
GATCCTGGTGTCCATCTTCATCATTATCAAGAAGACCAAG  
AAGCCCACCGGCGCTCCTCCAGAAGTGGAGTGACCA ACAATGGCTTCATCCCTCACAAC  
HMPV\_ ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 115 SC\_  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT Stabi-  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG lize  
AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC Alpha\_  
GACCTCGAGAATCTGACATGCTCTGATGGCCCTAGCCTGA V55L\_  
TCAAGACCGAGCTGGATCTGACCAAGAGCGCCCTGAGAG  
AACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGA  
ACAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGA  
GCCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAG  
CAGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCG  
AAGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACG  
AGGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGCTGGC

CACAGCCGTGCGCGAGCTGAAGGACTTCGTGTCCAAGAAC  
CTGACACGGGCCATTAACAAGAACAAGTGCGACATCGAC  
GACCTGAAGATGGCCGTGTCCTTTAGCCAGTTCAACCGGC  
GGTTTCTGAACGTCGTGCGGCAGTTTACGCGACAACGCCGG  
AATCACACCAGCCATCAGCCTGGACCTGATGACAGATGCT  
GAGCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCG  
GCCAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCG  
ACGGAAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGC  
AGCGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGA  
TCGACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTG  
TAGCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGA  
GGACCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTG  
TACTACCCTAACGAGAAGGACTGCGAGACAAGAGGCGAC  
CACGTGTTCTGTGATAACGCCGCTGGAATCAATGTGGCCG  
AGCAGAGCAAAGAGTGCAACATCAACATCAGCACCACCA  
ACTATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTT  
TATGGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGT  
TATAAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGG  
GCATCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCAC  
CAACCAGGACGCCGATACCGTGACCATCGACAACACCGTG  
TATCAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATC  
AAGGGCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGT  
TCCCTGAGGATCAGTTCAGGTGGCCCTGGACCAGGTGTT  
CGAGAACATCGAGAATCCCAGGCTCTGGTGGACCAGTCC  
AACAGAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGC  
TTCATCATCGTGATCATCCTGATCGCCGTGCTGGGCAGCT  
CCATGATCCTGGTGTCCATCTTCATCATTATCAAGAAGAC  
CAAGAAGCCCACCGGCGCTCCTCCAGAAGTGAAGCGGAGTG  
ACCAACAATGGCTTCATCCCTCACAAAC HMPV\_  
ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 116 SC\_  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT Stabi-  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG lize  
AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC Alpha\_  
GACGTCGAGAATCTGACATGCTCTGATGGCCCTAGCCTGA S170L\_  
TCAAGACCGAGCTGGATCTGACCAAGAGCGCCCTGAGAG  
AACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGA  
ACAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGA  
GCCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAG  
CAGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCG  
AAGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACG  
AGGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGCTGGC  
CACAGCCGTGCGCGAGCTGAAGGACTTCGTGCTTAAGAAC  
CTGACACGGGCCATTAACAAGAACAAGTGCGACATCGAC  
GACCTGAAGATGGCCGTGTCCTTTAGCCAGTTCAACCGGC  
GGTTTCTGAACGTCGTGCGGCAGTTTACGCGACAACGCCGG  
AATCACACCAGCCATCAGCCTGGACCTGATGACAGATGCT  
GAGCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCG  
GCCAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCG  
ACGGAAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGC  
AGCGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGA  
TCGACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTG  
TAGCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGA  
GGACCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTG  
TACTACCCTAACGAGAAGGACTGCGAGACAAGAGGCGAC

CACGTGTTCTGTGATACCGCCGCTGGAATCAATGTGGCCG  
AGCAGAGCAAAGAGTGCAACATCAACATCAGCACCACCA  
ACTATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTTT  
TATGGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGT  
TATAAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGG  
GCATCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCAC  
CAACCAGGACGCCGATACCGTGACCATCGACAACACCGTG  
TATCAGCTGAGCAAGGTGGAAGGCCGAACAGCACGTGATC  
AAGGGCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGT  
TCCCTGAGGATCAGTTCAGGTGGCCCTGGACCAGGTGTT  
CGAGAACATCGAGAATTCCCAGGCTCTGGTGGACCAGTCC  
AACAGAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGC  
TTCATCATCGTGATCATCCTGATCGCCGTGCTGGGCAGCT  
CCATGATCCTGGTGTCCATCTTCATCATTATCAAGAAGAC  
CAAGAAGCCACCGGCGCTCCTCCAGAACTGAGCGGAGTG  
ACCAACAATGGCTTCATCCCTCACAAAC HMPV\_  
ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 117 SC\_  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT Stabi\_  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG lize  
AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC Alpha\_  
GACGTGAGAATCTGACATGCTCTGATGGCCCTAGCCTGA T174W\_  
TCAAGACCGAGCTGGATCTGACCAAGAGCGCCCTGAGAG  
AACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGA  
ACAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGA  
GCCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAG  
CAGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCG  
AAGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACG  
AGGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGCTGGC  
CACAGCCGTGCGCGAGCTGAAGGACTTCGTGTCCAAGAAC  
CTGTGGCGGGCCATTAACAAGAACAAGTGCAGCATCGAC  
GACCTGAAGATGGCCGTGTCCTTTAGCCAGTTCAACCGGC  
GGTTTCTGAACGTCGTGCGGCAGTTTAGCGACAACGCCGG  
AATCACACCAGCCATCAGCCTGGACCTGATGACAGATGCT  
GAGCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCG  
GCCAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCG  
ACGGAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGC  
AGCGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGA  
TCGACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTG  
TAGCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGA  
GGACCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTG  
TACTACCCTAACGAGAAGGACTGCGAGACAAGAGGCGAC  
CACGTGTTCTGTGATACCGCCGCTGGAATCAATGTGGCCG  
AGCAGAGCAAAGAGTGCAACATCAACATCAGCACCACCA  
ACTATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTTT  
TATGGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGT  
TATAAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGG

GCATCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCAC  
CAACCAGGACGCCGATACCGTGACCATCGACAACACCGTG  
TATCAGCTGAGCAAGGTGGAAGGCCGAACAGCACGTGATC  
AAGGGCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGT  
TCCCTGAGGATCAGTTCAGGTGGCCCTGGACCAGGTGTT  
CGAGAACATCGAGAATTCCCAGGCTCTGGTGGACCAGTCC  
AACAGAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGC

TTCATCATCGTGATCATCCTGATCGCCGTGCTGGGCAGCT  
CCATGATCCTGGTGTCCATCTTCATCATTATCAAGAAGAC  
CAAGAAGCCACCGGCGCTCCTCCAGAAGTGGAGCGGAGTG  
ACCAACAATGGCTTCATCCCTCACAAC HMPV\_  
ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 118 SC\_4M\_  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT Stabi-  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG lize  
AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC Alpha\_  
GACCTCGAGAATCTGACATGCTCTGATGGCCCTAGCCTGA V55L\_  
TCAAGACCGAGCTGGATCTGCTCAAGAGCGCCCTGAGAGA T74L  
ACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGAA S170L  
CAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGAG T174W  
CCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAGC  
AGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCGA  
AGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACGA  
GGCCGTGAGCACACTCGGCAATGGCGTTAGAGTGCTGGCC  
ACAGCCGTGCGCGAGCTGAAGGACTTCGTGCTTAAGAACC  
TGTGGCGGGCCATTAACAAGAACAAGTGGCAGCATCGACG  
ACCTGAAGATGGCCGTGCTCTTAGCCAGTTCAACCGGCG  
GTTTCTGAACGTCGTGCGGCAGTTTAGCGACAACGCCGGA  
ATCACACCAGCCATCAGCCTGGACCTGATGACAGATGCTG  
AGCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCGG  
CCAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCGA  
CGGAAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGCA  
GCGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGAT  
CGACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTGT  
AGCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGAGG  
ACCAAGGCTGGTATTGTGAGAACGCCGGCAGCACCGTGTA  
CTACCCTAACGAGAAGGACTGCGAGACAAGAGGGCGACCA  
CGTGTCTGTGATAACCGCCGCTGGAATCAATGTGGCCGAG  
CAGAGCAAAGAGTGCAACATCAACATCAGCACCAACCAAC  
TATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTTCTA  
TGGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGTTA  
TAAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGGGC  
ATCATCAAGCAGCTGAACAAGGGCTGCAGCTACATACCA  
ACCAGGACGCCGATAACCGTGACCATCGACAACACCGTGTA  
TCAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATCAAG  
GGCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGTTCC  
CTGAGGATCAGTTCCAGGTGGCCCTGGACCAGGTGTTTCA  
GAACATCGAGAATTCCCAGGCTCTGGTGGACCAGTCCAAC  
AGAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGCTTCA  
TCATCGTGATCATCCTGATCGCCGTGCTGGGCAGCTCCAT  
GATCCTGGTGTCCATCTTCATCATTATCAAGAAGACCAAG  
AAGCCCACCGGCGCTCCTCCAGAAGTGGAGCGGAGTGACCA ACAATGGCTTCATCCCTCACAAC  
HMPV\_ ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 119 Pro-  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT line  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG Stab\_  
AACCGGCTGGTACACCAACGTGTTCACTGCCTGTGGGC E51P\_  
GACGTCGAGAATCTGACATGCTCTGATGGCCCTAGCCTGA  
TCAAGACCGAGCTGGATCTGACCAAGAGCGCCCTGAGAG  
AACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGA  
ACAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGA  
GCCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAG  
CAGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCG



AAGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACG  
AGGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGCTGGC  
CACAGCCGTGCGCGAGCTGAAGGACTTCGTGTCCAAGAAC  
CTGACACGGGCCATTAACAAGAACAAGTGCGACATCGAC  
GACCTGAAGATGGCCGTGTCCTTTAGCCAGTTCAACCGGC  
GGTTTCTGAACGTCGTGCGGCAGTTTAGCGACAACGCCGG  
AATCACACCAGCCATCAGCCTGGACCTGATGACAGATGCT  
GAGCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCG  
GCCAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCG  
ACGGAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGC  
AGCGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGA  
TCGACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTG  
TAGCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGA  
GGACCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTG  
TACTACCCTAACGAGAAGGACTGCGAGACAAGAGGCGAC  
CACGTGTTCTGTGATACCGCCGCTGGAATCAATGTGGCCG  
AGCAGAGCAAAGAGTGCAACATCAACATCAGCACCA  
ACTATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTT  
TATGGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGT  
TATAAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGG  
GCATCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCAC  
CAACCAGGACGCCGATACCGTGACCATCGACAACACCGTG  
TATCAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATC  
AAGGGCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGT  
TCCCTGAGGATCAGTTCCAGGTGGCCCTGGACCAGGTGTT  
CGAGAACATCGAGAATTCCCAGGCTCTGGTGGACCAGTCC  
AACAGAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGC  
TTCATCATCGTGATCATCCTGATCGCCGTGCTGGGCAGCT  
CCATGATCCTGGTGTCCATCTTCATCATTATCAAGAAGAC  
CAAGAAGCCCACCGGCGCTCCTCCAGAACTGAGCGGAGTG  
ACCAACAATGGCTTCATCCCTCACAAAC HMPV\_  
ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 120 Pro-  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT line  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG Stab\_  
AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC D185P  
GACGTGAGAAATCTGACATGCTCTGATGGCCCTAGCCTGA  
TCAAGACCGAGCTGGATCTGACCAAGAGCGCCCTGAGAG  
AACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGA  
ACAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGA  
GCCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAG  
CAGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCG  
AAGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACG  
AGGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGCTGGC  
CACAGCCGTGCGCGAGCTGAAGGACTTCGTGTCCAAGAAC  
CTGACACGGGCCATTAACAAGAACAAGTGCGACATCCCTG  
ACCTGAAGATGGCCGTGTCCTTTAGCCAGTTCAACCGGCG  
GTTTCTGAACGTCGTGCGGCAGTTTAGCGACAACGCCGGA  
ATCACACCAGCCATCAGCCTGGACCTGATGACAGATGCTG  
AGCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCGG  
CCAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCGA  
CGGAAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGCA  
GCGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGT  
CGACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTGT  
AGCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGAGG

ACCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTGTA  
CTACCCTAACGAGAAGGACTGCGAGACAAGAGGCGACCA  
CGTGTCTGTGATACCGCCGCTGGAATCAATGTGGCCGAG  
CAGAGCAAAGAGTGAACATCAACATCAGCACCAACCAAC  
TATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTTCTA  
TGGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGTTA  
TAAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGGGC  
ATCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCACCA  
ACCAGGACGCCGATACCGTGACCATCGACAACACCGTGTA  
TCAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATCAAG  
GGCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGTTCC  
CTGAGGATCAGTTCCAGGTGGCCCTGGACCAGGTGTTCGA  
GAACATCGAGAATTCCCAGGCTCTGGTGGACCAGTCCAAC  
AGAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGCTTCA  
TCATCGTGATCATCCTGATCGCCGTGCTGGGCAGCTCCAT  
GATCCTGGTGTCCATCTTCATCATTATCAAGAAGACCAAG  
AAGCCCACCGGCGCTCCTCCAGAAGTGGAGTGACCA ACAATGGCTTCATCCCTCACAAC  
HMPV\_ ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 121 Pro-  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT line  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG Stab\_  
AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC D183P  
GACGTCGAGAATCTGACATGCTCTGATGGCCCTAGCCTGA  
TCAAGACCGAGCTGGATCTGACCAAGAGCGCCCTGAGAG  
AACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGA  
ACAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGA  
GCCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAG  
CAGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCG  
AAGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACG  
AGGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGCTGGC  
CACAGCCGTGCGCGAGCTGAAGGACTTCGTGTCCAAGAAC  
CTGACACGGGCCATTAACAAGAACAAGTGCCCTATCGACG  
ACCTGAAGATGGCCGTGTCTTTAGCCAGTTCAACCGGCG  
GTTTCTGAACGTCGTGCGGCAGTTTAGCGACAACGCCGGA  
ATCACACCAGCCATCAGCCTGGACCTGATGACAGATGCTG  
AGCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCGG  
CCAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCGA  
CGGAAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGCA  
GCGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGAT  
CGACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTGT  
AGCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGAGG  
ACCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTGTA  
CTACCCTAACGAGAAGGACTGCGAGACAAGAGGCGACCA  
CGTGTCTGTGATACCGCCGCTGGAATCAATGTGGCCGAG  
CAGAGCAAAGAGTGAACATCAACATCAGCACCAACCAAC  
TATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTTCTA  
TGGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGTTA  
TAAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGGGC  
ATCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCACCA  
ACCAGGACGCCGATACCGTGACCATCGACAACACCGTGTA  
TCAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATCAAG  
GGCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGTTCC  
CTGAGGATCAGTTCCAGGTGGCCCTGGACCAGGTGTTCGA  
GAACATCGAGAATTCCCAGGCTCTGGTGGACCAGTCCAAC  
AGAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGCTTCA

TCATCGTGATCATCCTGATCGCCGTGCTGGGCAGCTCCAT  
GATCCTGGTGTCCATCTTCATCATTATCAAGAAGACCAAG  
AAGCCCACCGGCGCTCCTCCAGAAGTGAAGCGGAGTGACCA ACAATGGCTTCATCCCTCACAAC  
HMPV\_ ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 122 Pro-  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT line  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG Stab\_  
AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC E131P  
GACGTGAGAAATCTGACATGCTCTGATGGCCCTAGCCTGA  
TCAAGACCGAGCTGGATCTGACCAAGAGCGCCCTGAGAG  
AACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGA  
ACAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGA  
GCCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAG  
CAGGCGTGGCCATCGCTAAGACCATCAGACTGCCTAGCGA  
AGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACGA  
GGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGTGGCC  
ACAGCCGTGCGCGAGCTGAAGGACTTCGTGTCCAAGAACC  
TGACACGGGCCATTAACAAGAACAAGTGCGACATCGACG  
ACCTGAAGATGGCCGTGTCCTTTAGCCAGTTCAACCGGCG  
GTTTCTGAACGTCGTGCGGCAGTTTAGCGACAACGCCGGA  
ATCACACCAGCCATCAGCCTGGACCTGATGACAGATGCTG  
AGCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCGG  
CCAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCGA  
CGGAAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGCA  
GCGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGAT  
CGACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTGT  
AGCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGAGG  
ACCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTGTA  
CTACCCTAACGAGAAGGACTGCGAGACAAGAGGGCGACCA  
CGTGTCTGTGATAACCGCCGCTGGAATCAATGTGGCCGAG  
CAGAGCAAAGAGTGCAACATCAACATCAGCACCAACCAAC  
TATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTTCTA  
TGGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGTTA  
TAAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGGGC  
ATCATCAAGCAGCTGAACAAGGGCTGCAGCTACATACCA  
ACCAGGACGCCGATACCGTGACCATCGACAACACCGTGTA  
TCAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATCAAG  
GGCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGTTCC  
CTGAGGATCAGTTCCAGGTGGCCCTGGACCAGGTGTTTCA  
GAACATCGAGAATTCCCAGGCTCTGGTGGACCAGTCCAAC  
AGAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGCTTCA  
TCATCGTGATCATCCTGATCGCCGTGCTGGGCAGCTCCAT  
GATCCTGGTGTCCATCTTCATCATTATCAAGAAGACCAAG  
AAGCCCACCGGCGCTCCTCCAGAAGTGAAGCGGAGTGACCA ACAATGGCTTCATCCCTCACAAC  
HMPV\_ ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 123 Pro-  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT line  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG Stab\_  
AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC D447P  
GACGTGAGAAATCTGACATGCTCTGATGGCCCTAGCCTGA  
TCAAGACCGAGCTGGATCTGACCAAGAGCGCCCTGAGAG  
AACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGA  
ACAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGA  
GCCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAG  
CAGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCG  
AAGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACG

AGGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGCTGGC  
CACAGCCGTGCGCGAGCTGAAGGACTTCGTGTCCAAGAAC  
CTGACACGGGCCATTAACAAGAACAAGTGCGACATCGAC  
GACCTGAAGATGGCCGTGTCCTTTAGCCAGTTCAACCGGC  
GGTTTCTGAACGTCGTGCGGCAGTTTtagCGACAACGCCGG  
AATCACACCAGCCATCAGCCTGGACCTGATGACAGATGCT  
GAGCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCG  
GCCAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCG  
ACGGAAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGC  
AGCGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGA  
TCGACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTG  
TAGCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGA  
GGACCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTG  
TACTACCCTAACGAGAAGGACTGCGAGACAAGAGGCGAC  
CACGTGTTCTGTGATAACGCCGCTGGAATCAATGTGGCCG  
AGCAGAGCAAAGAGTGCAACATCAACATCAGCACCA  
ACTATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTT  
TATGGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGT

TATAAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGG  
GCATCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCAC  
CAACCAGGACGCCGATACCGTGACCATCGACAACACCGTG  
TATCAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATC  
AAGGGCAGACCTGTGTCCAGCAGCTTCCCACCTATCAAGT  
TCCCTGAGGATCAGTTCCAGGTGGCCCTGGACCAGGTGTT  
CGAGAACATCGAGAATTCCCAGGCTCTGGTGGACCAGTCC  
AACAGAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGC  
TTCATCATCGTGATCATCCTGATCGCCGTGCTGGGCAGCT  
CCATGATCCTGGTGTCCATCTTCATCATTATCAAGAAGAC  
CAAGAAGCCCACCGGCGCTCCTCCAGAACTGAGCGGAGTG  
ACCAACAATGGCTTCATCCCTCACAAAC HMPV  
ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 124 Trimer  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT Repul-  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG sion  
AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC D454N  
GACGTGAGAAATCTGACATGCTCTGATGGCCCTAGCCTGA  
TCAAGACCGAGCTGGATCTGACCAAGAGCGCCCTGAGAG  
AACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGA  
ACAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGA  
GCCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAG  
CAGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCG  
AAGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACG  
AGGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGCTGGC  
CACAGCCGTGCGCGAGCTGAAGGACTTCGTGTCCAAGAAC  
CTGACACGGGCCATTAACAAGAACAAGTGCGACATCGAC  
GACCTGAAGATGGCCGTGTCCTTTAGCCAGTTCAACCGGC  
GGTTTCTGAACGTCGTGCGGCAGTTTtagCGACAACGCCGG  
AATCACACCAGCCATCAGCCTGGACCTGATGACAGATGCT  
GAGCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCG  
GCCAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCG  
ACGGAAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGC  
AGCGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGA  
TCGACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTG  
TAGCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGA

GGACCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTG  
TACTACCCTAACGAGAAGGACTGCGAGACAAGAGGCGAC  
CACGTGTTCTGTGATAACCGCCGCTGGAATCAATGTGGCCG  
AGCAGAGCAAAGAGTGCAACATCAACATCAGCACCACCA  
ACTATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTTT  
TATGGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGT  
TATAAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGG  
GCATCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCAC  
CAACCAGGACGCCGATACCGTGACCATCGACAACACCGTG  
TATCAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATC  
AAGGGCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGT  
TCCCTGAGAACCAGTTCAGGTGGCCCTGGACCAGGTGTT  
CGAGAACATCGAGAATTCCCAGGCTCTGGTGGACCAGTCC  
AACAGAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGC  
TTCATCATCGTGATCATCCTGATCGCCGTGCTGGGCAGCT  
CCATGATCCTGGTGTCCATCTTCATCATTATCAAGAAGAC  
CAAGAAGCCCACCGGCGCTCCTCCAGAACTGAGCGGAGTG  
ACCAACAATGGCTTCATCCCTCACAAAC HMPV\_  
ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 125 Trimer  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT Repul-  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG sion  
AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC E453N  
GACGTGAGAAATCTGACATGCTCTGATGGCCCTAGCCTGA  
TCAAGACCGAGCTGGATCTGACCAAGAGCGCCCTGAGAG  
AACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGA  
ACAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGA  
GCCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAG  
CAGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCG  
AAGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACG  
AGGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGCTGGC  
CACAGCCGTGCGCGAGCTGAAGGACTTCGTGTCCAAGAAC  
CTGACACGGGCCATTAACAAGAACAAGTGCGACATCGAC  
GACCTGAAGATGGCCGTGTCCTTTAGCCAGTTCAACCGGC  
GGTTTCTGAACGTCGTGCGGCAGTTTAGCGACAACGCCGG  
AATCACACCAGCCATCAGCCTGGACCTGATGACAGATGCT  
GAGCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCG  
GCCAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCG  
ACGGAAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGC  
AGCGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGA  
TCGACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTG  
TAGCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGA  
GGACCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTG  
TACTACCCTAACGAGAAGGACTGCGAGACAAGAGGCGAC  
CACGTGTTCTGTGATAACCGCCGCTGGAATCAATGTGGCCG  
AGCAGAGCAAAGAGTGCAACATCAACATCAGCACCACCA  
ACTATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTTT  
TATGGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGT  
TATAAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGG  
GCATCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCAC  
CAACCAGGACGCCGATACCGTGACCATCGACAACACCGTG  
TATCAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATC  
AAGGGCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGT  
TCCCTCAGGATCAGTTCAGGTGGCCCTGGACCAGGTGTT  
CGAGAACATCGAGAATTCCCAGGCTCTGGTGGACCAGTCC

AACAGAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGC  
TTCATCATCGTGATCATCCTGATCGCCGTGCTGGGCAGCT  
CCATGATCCTGGTGTCCATCTTCATCATTATCAAGAAGAC  
CAAGAAGCCCACCGGCGCTCCTCCAGAACTGAGCGGAGTG  
ACCAACAATGGCTTCATCCCTCACAAAC HMPV\_  
ATGAGCTGGAAGGTGGTCATCATCTTCAGCCTGCTGATCA 126 Stabi-  
CACCTCAGCACGGCCTGAAAGAGAGCTACCTGGAAGAGT lize  
CCTGCAGCACCATCACAGAGGGCTACCTGTCTGTGCTGAG Alpha  
AACCGGCTGGTACACCAACGTGTTCACTGGAAGTGGGC F196W  
GACGTCGAGAATCTGACATGCTCTGATGGCCCTAGCCTGA  
TCAAGACCGAGCTGGATCTGACCAAGAGCGCCCTGAGAG  
AACTCAAGACCGTGTCTGCCGATCAGCTGGCCAGAGAGGA  
ACAGATCGAGAATCCTGGCAGCGGCAGCTTTGTGCTGGGA  
GCCATTGCTCTTGGAGTGGCTGCTGCTGCAGCTGTTACAG  
CAGGCGTGGCCATCGCTAAGACCATCAGACTGGAAAGCG  
AAGTGACCGCCATCAACAACGCCCTGAAGAAGACAAACG  
AGGCCGTCAGCACACTCGGCAATGGCGTTAGAGTGCTGGC  
CACAGCCGTGCGCGAGCTGAAGGACTTCGTGTCCAAGAAC  
CTGACACGGGCCATTAACAAGAACAAGTGCGACATCGAC  
GACCTGAAGATGGCCGTGTCTTTAGCCAGTGGAACCGGC  
GGTTTCTGAACGTCGTGCGGCAGTTTAGCGACAACGCCGG  
AATCACACCAGCCATCAGCCTGGACCTGATGACAGATGCT  
GAGCTGGCTAGAGCCGTGCCTAACATGCCTACATCTGCCG  
GCCAGATCAAGCTGATGCTCGAGAATAGAGCCATGGTCCG  
ACGGAAAGGCTTCGGCATTCTGATTGGCGTGTACGGCAGC  
AGCGTGATCTATATGGTGCAGCTGCCTATCTTCGGCGTGA  
TCGACACACCCTGCTGGATTGTGAAGGCCGCTCCTAGCTG  
TAGCGAGAAGAAGGGCAATTACGCCTGCCTGCTGAGAGA  
GGACCAAGGCTGGTATTGTCAGAACGCCGGCAGCACCGTG  
TACTACCCTAACGAGAAGGACTGCGAGACAAGAGGCGAC  
CACGTGTTCTGTGATAACCGCCGCTGGAATCAATGTGGCCG  
AGCAGAGCAAAGAGTGCAACATCAACATCAGCACCA  
ACTATCCCTGCAAGGTGTCCACCGGCAGGCACCCTATTT  
TATGGTGGCTCTGTCTCCTCTGGGAGCCCTGGTGGCTTGT  
TATAAGGGCGTGTCTGTAGCATCGGCAGCAACAGAGTGG  
GCATCATCAAGCAGCTGAACAAGGGCTGCAGCTACATCAC  
CAACCAGGACGCCGATACCGTGACCATCGACAACACCGTG  
TATCAGCTGAGCAAGGTGGAAGGCGAACAGCACGTGATC  
AAGGGCAGACCTGTGTCCAGCAGCTTCGACCCTATCAAGT  
TCCCTGAGGATCAGTTCAGGTGGCCCTGGACCAGGTGTT  
CGAGAACATCGAGAATTCCCAGGCTCTGGTGGACCAGTCC  
AACAGAATCCTGTCTAGCGCCGAGAAGGGAAACACCGGC  
TTCATCATCGTGATCATCCTGATCGCCGTGCTGGGCAGCT  
CCATGATCCTGGTGTCCATCTTCATCATTATCAAGAAGAC  
CAAGAAGCCCACCGGCGCTCCTCCAGAACTGAGCGGAGTG  
ACCAACAATGGCTTCATCCCTCACAAAC Human Metapneumovirus mRNA Sequences HMPV\_  
AUGAGCUGGAAGGUGGUCAUCAUCUUCAGCCUGCUGAU 127 SC\_DSC  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA AV1\_  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU 4MMV  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG  
CCUGAUC AAGACCGAGCUGGAUCUGACCAAGAGCGCCCU  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG

UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCCAUCUGCAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCUUUGCCGUGCGCGAGCUGAAGGACUUC  
GUGUCCAAGAACCUGACACGGGCCUGAACAAGAACAAG  
UGCGACAUCGACGACCUGAAGAUGGCCGUGUCCUUUAGC  
CAGUUCAACCGGCGGUUUCUGAACGUCGUGCGGCAGUUU  
AGCGACAACGCCGGAUACACACCAGCCAUCAGCCUGGAC  
CUGAUGACAGAUGCUGAGCUGGCUAGAGCCGUGCCU AAC  
AUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGAG  
AAUAGAGCCAUGGUCCGACGGAAAGGCUUCGGCAUUCU  
GUGUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUGC  
AGCUGCCUAUCUUCGGCGUGAUCGACACACCUGCUGGA  
UUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGGC  
AAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGGCAGCACCGUGUACUACCCU AACGA  
GAAGGACUGCGAGACAAGAGGGCACCACGUGUUCUGUG  
AUACCGCCGUGGAAUCA AUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUCAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGU UCCC  
UGAGGAUCAGUUCAACGUGGCCCUUGGACCAGGUGUUCG  
AGAACAUCGAGAAU UCCCAGGCUCUGGUGGACCAGUCCA  
ACAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCU  
UCAUCAUCGUGAUCAUCCUGAUCGCCGUGCUGGGCAGCU  
CCAUGAUCCUGGUGUCCAUCUUCAUCAUUAUCAAGAAGA  
CCAAGAAGCCCACCGGCGCUCCUCCAGAACUGAGCGGAG  
UGACCAACA AUGGCUUCAUCCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUCAUCAUCUUCAGCCUGCUGAU 128 SC\_DSU  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA RIC\_  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU 4MMV  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG  
CCUGAUCAAGACCGAGCUGGAUCUGACCAAGAGCGCCCU  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCCAUCUGCAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGCGAGCUGAAGGACUUC  
GUGUCCAAGAACCUGACACGGGCCAUUAACAAGAACAAG  
UGCGACAUCGACGACCUGAAGAUGGCCGUGUCCUUUAGC  
CAGUUCAACCGGCGGUUUCUGAACGUCGUGCGGCAGUUU  
AGCGACAACGCCGGAUACACACCAGCCAUCAGCCUGGAC  
CUGAUGACAGAUGCUGAGCUGGCUAGAGCCGUGCCU AAC  
AUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGAG  
AAUAGAGCCAUGGUCCGACGGAAAGGCUUCGGCAUUCU

GUGUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUGC  
AGCUGCCUAUCUUCGGCGUGAUCGACACACCCUGCUGGA  
UUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGGC  
AAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGGCAGCACCGUGUACUACCCUAACGA  
GAAGGACUGCGAGACAAGAGGGCACCACGUGUUCUGUG  
AUACCGCCGUGGAAUCAUAUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGUCCC  
UGAGCACAGUGGCAUGUGGCCUCUGGACCAGGUGUUCGA  
GAACAUCGAGAAUCCCAGGCUCUGGUGGACCAGUCCAA  
CAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCUU  
CAUCAUCGUGAUAUCCUGAUCGCCGUGCUGGGCAGCUC  
CAUGAUCCUGGUGUCCAUCUUCAUCAUUAUCAAGAAGAC  
CAAGAAGCCCACCGGCGCUCCUCCAGAACUGAGCGGAGU  
GACCAACAAUGGCUUCAUCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUAUCAUCUUCAGCCUGCUGAU 129 SC\_DM\_  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA Krar  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU up\_  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU U74L  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG D185P  
CCUGAUCAAGACCGAGCUGGAUCUGCUCAAGAGCGCCCU  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCCAUCGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCCUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGGAGCUGAAGGACUUC  
GUGUCCAAGAACCUGACACGGGCCAUUAACAAGAACAAG  
UGCACAUCCCUGACCUGAAGAUGGCCGUGUCCUUUAGC  
CAGUUCAACCGGCGGUUUCUGAACGUCGUGCGGCAGUUU  
AGCGACAACGCCGGAUUCACACCAGCCAUCAGCCUGGAC  
CUGAUGACAGAUUGCUGAGCUGGCUAGAGCCGUGCCUAC  
AUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGAG  
AAUAGAGCAUUGGUCCGACGGAAAGGCUUCGGCAUUCU  
GAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUGC  
AGCUGCCUAUCUUCGGCGUGAUCGACACACCCUGCUGGA  
UUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGGC  
AAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGGCAGCACCGUGUACUACCCUAACGA

GAAGGACUGCGAGACAAGAGGGCACCACGUGUUCUGUG  
AUACCGCCGUGGAAUCAUAUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC



AAGCAGCUGAACAAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGUUCCC  
UGAGGAUCAGUUCAGGUGGCCUGGACCAGGUGUUCG  
AGAACAUCGAGAAUUCCCAGGCUCUGGUGGACCAGUCCA  
ACAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCU  
UCAUCAUCGUGAUAUCCUGAUCGCCGUGCUGGGCAGCU  
CCAUGAUCCUGGUGUCCAUCUUCAUCAUUAUCAAGAAGA  
CCAAGAAGCCCACCGGCGCUCCUCCAGAACUGAGCGGAG  
UGACCAACAAUGGCUUCAUCCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUCAUCAUCUUCAGCCUGCUGAU 130 SC\_UM\_  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA Krar  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU up\_  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU U74L  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG D185P  
CCUGAUAAGACCGAGCUGGAUCUGCUCAAGAGCGCCCU D454N  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCCAUCGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCCUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGGAGCUGAAGGACUUC  
GUGUCCAAGAACCUGACACGGGCAUUAACAAGAACAAG  
UGCAGAUCCCUGACCUGAAGAUGGCCGUGUCCUUUAGC  
CAGUUCAACCGGCGGUUUCUGAACGUCGUGCGGCAGUUU  
AGCGACAACGCCGGAUCACACCAGCCAUCAGCCUGGAC  
CUGAUGACAGAUUGCUGAGCUGGCUAGAGCCGUGCCU AAC  
AUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGAG  
AAUAGAGCCAUGGUCCGACGGAAAGGCUUCGGCAUUCU  
GAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUGC  
AGCUGCCUAUCUUCGGCGUGAUCGACACACCUGCUGGA  
UUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGGC  
AAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGGCAGCACCGUGUACUACCCU AACGA  
GAAGGACUGCGAGACAAGAGGGCACCACGUGUUCUGUG  
AUACCGCCGUGGAAUCAUUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGUUCCC  
UGAGAACCAGUUCAGGUGGCCUGGACCAGGUGUUCGA  
GAACAUCGAGAAUUCCCAGGCUCUGGUGGACCAGUCCAA  
CAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCUU  
CAUCAUCGUGAUAUCCUGAUCGCCGUGCUGGGCAGCUC  
CAUGAUCCUGGUGUCCAUCUUCAUCAUUAUCAAGAAGAC  
CAAGAAGCCCACCGGCGCUCCUCCAGAACUGAGCGGAGU  
GACCAACAAUGGCUUCAUCCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUCAUCAUCUUCAGCCUGCUGAU 131 SC\_4M\_

CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA Krar  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU up\_  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU U74L  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG S170L  
CCUGAUCAAGACCGAGCUGGAUCUGCUCAAGAGCGCCCU D185P  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCAUCGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGCGAGCUGAAGGACUUC  
GUGCUUAAGAACCUGACACGGGCAUUAACAAGAACA  
GUGCGACAUCCCUGACCUGAAGAUGGCCGUGUCCUUUAG  
CCAGUUCAACCGGCGGUUUCUGAACGUCGUGCGGCAGUU  
UAGCGACAACGCCGGAUACACACCAGCCAUCAGCCUGGA  
CCUGAUGACAGAUGCUGAGCUGGCUAGAGCCGUGCCUAA  
CAUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGA  
GAUAGAGCCAUGGUCCGACGGAAAGGCUUCGGCAUUC  
UGAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUG  
CAGCUGCCUAUCUUCGGCGUGAUCGACACACCUGCUGG  
AUUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGG  
CAAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGCGCAGCACCGUGUACUACCCUACGA  
GAAGGACUGCGAGACAAGAGGCGACCACGUGUUCUGUG  
AUACCGCCGCUUGAAUCAUUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUCAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGUCCC  
UGAGGAUCAGUCCAGGUGGCCCUUGACCAGGUGUUCG  
AGAACAUCGAGAAUCCCAGGCUCUGGUGGACCAGUCCA  
ACAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCU  
UCAUCAUCGUGAUCAUCCUGAUCGCCGUGCUGGGCAGCU  
CCAUGAUCUGGUGUCCAUCUUCAUCAUUAUCAAGAAGA  
CCAAGAAGCCCACCGGCGCUCCUCCAGAACUGAGCGGAG  
UGACCAACA AUGGCUUCAUCCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUAUCAUCUUCAGCCUGCUGAU 132 SC\_5M\_  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA Krar  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU up\_  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU U74L  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG S170L  
CCUGAUCAAGACCGAGCUGGAUCUGCUCAAGAGCGCCCU D185P  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG D454N  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCAUCGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGCGAGCUGAAGGACUUC

GUGCUUAAGAACCUGACACGGGCCAUAACAAGAACAA  
GUGCGACAUCCCUGACCUGAAGAUGGCCGUGUCCUUUAG  
CCAGUUCAACCGGCGGUUCUGAACGUCGUGCGGCAGUU  
UAGCGACAACGCCGGAUACACACCAGCCAUCAGCCUGGA  
CCUGAUGACAGAUGCUGAGCUGGCUAGAGCCGUGCCUAA  
CAUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGA  
GAAUAGAGCCAUGGUCCGACGGAAAGGCUUCGGCAUUC  
UGAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUG  
CAGCUGCCUAUCUUCGGCGUGAUCGACACACCUGCUGG  
AUUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGG  
CAAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGCGCAGCACCGUGUACUACCCUAAACGA  
GAAGGACUGCGAGACAAGAGGGCGACCACGUGUUCUGUG  
AUACCGCCGUGGAAUCAUUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGGCGAACAGCACGUGAUCAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGUCCC  
UGAGAACCAGUUCAGGUGGCCUUGGACCAGGUGUUCGA  
GAACAUCGAGAAUUCAGGCUCUGGUGGACCAGUCCAA  
CAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCUU  
CAUCAUCGUGAUCAUCCUGAUCGCCGUGCUGGGCAGCUC  
CAUGAUCCUGGUGUCCAUCUUCAUCAUUAUCAAGAAGAC  
CAAGAAGCCCACCGGCGCUCUCCAGAACUGAGCGGAGU  
GACCAACAAUGGCUUCAUCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUCAUCAUCUUCAGCCUGCUGAU 133 SC\_DM\_  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA Krar  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU up\_  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGCCUGU E51P  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG U74L  
CCUGAUCAAGACCGAGCUGGAUCUGCUCAAGAGCGCCCU  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCCAUCGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCUUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGCGAGCUGAAGGACUUC  
GUGUCCAAGAACCUGACACGGGCCAUUAACAAGAACAAG  
UGCACAUUCGACGACCUGAAGAUGGCCGUGUCCUUUAGC  
CAGUUCAACCGGCGGUUCUGAACGUCGUGCGGCAGUUU  
AGCGACAACGCCGGAUACACACCAGCCAUCAGCCUGGAC  
CUGAUGACAGAUGCUGAGCUGGCUAGAGCCGUGCCUAAAC  
AUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGAG  
AAUAGAGCCAUGGUCCGACGGAAAGGCUUCGGCAUUCU  
GAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUGC  
AGCUGCCUAUCUUCGGCGUGAUCGACACACCUGCUGGA  
UUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGGC  
AAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGCGCAGCACCGUGUACUACCCUAAACGA

GAAGGACUGCGAGACAAGAGGGCGACCACGUGUUCUGUG  
AUACCGCCGCUGGAAUCA AUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUC AAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGU UCCC  
UGAGGAUCAGU UCCAGGUGGCCUCUGGACCAGGUGUUCG  
AGAACAUCGAGAAU UCCCAGGCUCUGGUGGACCAGUCCA  
ACAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCU  
UCAUCAUCGUGAUCAUCCUGAUCGCCGUGCUGGGCAGCU  
CCAUGAUCCUGGUGUCCAUCUUCAUCAUUAUCAAGAAGA  
CCAAGAAGCCCACCGGCGCUCCUCCAGAACUGAGCGGAG  
UGACCAACA AUGGCUUCAUCCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUCAUCAUCUUCAGCCUGCUGAU 134 SC\_UM\_  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA Krar  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU up\_  
GAGAACC GGCUGGUACACCAACGUGUUCACACUGCCUGU E51P  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG U74L  
CCUGAUCAAGACCGAGCUGGAUCUGCUCAAGAGCGCCCU D454N  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCCAU CGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCCUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGCGAGCUGAAGGACUUC  
GUGUCCAAGAACCUGACACGGGCCAUUAACAAGAACAAG  
UGC GACAUCGACGACCUGAAGAUGGCCGUGUCCUUUAGC  
CAGUUCAACCGGCGGUUCUGAACGUCGUGCGGCAGUUU  
AGCGACAACGCCGGAUCACACCAGCCAUCAGCCUGGAC  
CUGAUGACAGAU GCUGAGCUGGCUAGAGCCGUGCCU AAC  
AUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGAG  
AAUAGAGCCAUGGUCCGACGGAAAGGCUUCGGAUUCU  
GAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUGC  
AGCUGCCUAUCUUCGGCGUGAUCGACACACCUCUGCUGGA  
UUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGGC  
AAUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGGCAGCACCGUGUACUACCCUAACGA  
GAAGGACUGCGAGACAAGAGGCGACCACGUGUUCUGUG  
AUACCGCCGCUGGAAUCA AUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUC AAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGU UCCC  
UGAGAACCAGU UCCAGGUGGCCUCUGGACCAGGUGUUCGA  
GAACAUCGAGAAU UCCCAGGCUCUGGUGGACCAGUCCAA

CAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCUU  
CAUCAUCGUGAUCAUCCUGAUCGCCGUGCUGGGCAGCUC  
CAUGAUCCUGGUGUCCAUCUUCAUCAUUAUCAAGAAGAC  
CAAGAAGCCCACCGGCGCUCUCCAGAACUGAGCGGAGU  
GACCAACAAUGGCUUCAUCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUCAUCAUCUUCAGCCUGCUGAU 135 SC\_  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA SUabi-  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU lize  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU Alpha\_  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG U74L\_  
CCUGAUCAAGACCGAGCUGGAUCUGCUCAAGAGCGCCCU  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCCAUCGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGCGAGCUGAAGGACUUC  
GUGUCCAAGAACCUGACACGGGCCAUUAACAAGAACAAG  
UGCACAUUCGACGACCUGAAGAUGGCCGUGUCCUUUAGC  
CAGUUCAACCGGCGGUUUCUGAACGUCGUGCGGCAGUUU  
AGCGACAACGCCGGAUACACACCAGCCAUCAGCCUGGAC  
CUGAUGACAGAUGCUGAGCUGGCUAGAGCCGUGCCU AAC

AUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGAG  
AAUAGAGCCAUGGUCCGACGGAAAGGCUUCGGCAUUCU  
GAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUGC  
AGCUGCCUAUCUUCGGCGUGAUCGACACACCUCUGGGA  
UUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGGC  
AAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGGCAGCACCGUGUACUACCCUAACGA  
GAAGGACUGCGAGACAAGAGGCGACCACGUGUUCUGUG  
AUACCGCCGCUGGAAUCA AUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUCAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGUCCC  
UGAGGAUCAGUCCAGGUGGCCUUGGACCAGGUGUUCG  
AGAACAUCGAGAAUCCCAGGCUCUGGUGGACCAGUCCA  
ACAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCU  
UCAUCAUCGUGAUCAUCCUGAUCGCCGUGCUGGGCAGCU  
CCAUGAUCCUGGUGUCCAUCUUCAUCAUUAUCAAGAAGA  
CCAAGAAGCCCACCGGCGCUCUCCAGAACUGAGCGGAG  
UGACCAACAAUGGCUUCAUCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUCAUCAUCUUCAGCCUGCUGAU 136 SC\_  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA SUabi-  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU lize  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU Alpha\_  
GGGCGACCUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG V55L\_  
CCUGAUCAAGACCGAGCUGGAUCUGACCAAGAGCGCCCU

GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCCAUUCGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGCGAGCUGAAGGACUUC  
GUGUCCAAGAACCUGACACGGGCCAUUAACAAGAACAAG  
UGCGACAUCGACGACCUGAAGAUGGCCGUGUCCUUUAGC  
CAGUUCAACCGGCGGUUUCUGAACGUCGUGCGGCAGUUU  
AGCGACAACGCCGGAUUCACACCAGCCAUCAGCCUGGAC  
CUGAUGACAGAUGCUGAGCUGGCUAGAGCCGUGCCU AAC  
AUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGAG  
AAUAGAGCCAUGGUCCGACGGAAAGGCUUCGGCAUUCU  
GAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUGC  
AGCUGCCUAUCUUCGGCGUGAUCGACACACCUCUGCUGGA  
UUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGGC  
AAUACGCCUGCCUGCUGAGAGAGGACCAAGGCUUGGUA  
UUGUCAGAACGCCGGCAGCACCGUGUACUACCCUAACGA  
GAAGGACUGCGAGACAAGAGGCGACCACGUGUUCUGUG  
AUACCGCCGUGGAAUCA AUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCUGGUGGCUUGUUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUCAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGUCCC  
UGAGGAUCAGUUCAGGUGGCCUGGACCAGGUGUUCG  
AGAACAUCGAGAAUUCACAGGCUCUGGUGGACCAGUCCA  
ACAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCU  
UCAUCAUCGUGAUCAUCCUGAUCGCCGUGCUGGGCAGCU  
CCAUGAUCCUGGUGUCCAUCUUAUCAUUAUCAAGAAGA  
CCAAGAAGCCCACCGGCGCUCCUCCAGAACUGAGCGGAG  
UGACCAACA AUGGCUUCAUCCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUC AUCAUCUUCAGCCUGCUGAU 137 SC\_  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA SUabi-  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU lize  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU Alpha\_  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG S170L\_  
CCUGAUCAAGACCGAGCUGGAUCUGACCAAGAGCGCCCU  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCCAUUCGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGCGAGCUGAAGGACUUC  
GUGCUUAAGAACCUGACACGGGCCAUUAACAAGAACA  
GUGCGACAUCGACGACCUGAAGAUGGCCGUGUCCUUUAG  
CCAGUUCAACCGGCGGUUUCUGAACGUCGUGCGGCAGUU  
UAGCGACAACGCCGGAUUCACACCAGCCAUCAGCCUGGA  
CCUGAUGACAGAUGCUGAGCUGGCUAGAGCCGUGCCUAA

CAUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGA  
GAAUAGAGCCAUGGUCCGACGGAAAGGCUUCGGCAUUC  
UGAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUG  
CAGCUGCCUAUCUUCGGCGUGAUCGACACACCCUGCUGG  
AUUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGG  
CAAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGGCAGCACCGUGUACUACCCUAACGA  
GAAGGACUGCGAGACAAGAGGCGACCACGUGUUCUGUG  
AUACCGCCGCUGGAAUCA AUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUCAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGUCCC  
UGAGGAUCAGUCCAGGUGGCCUUGGACCAGGUGUUCG  
AGAACAUCGAGAAUCCCAGGCUCUGGUGGACCAGUCCA  
ACAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCU  
UCAUCAUCGUGAUCAUCCUGAUCGCCGUGCUGGGCAGCU  
CCAUGAUCCUGGUGUCCAUCUUAUCAUUAUCAAGAAGA  
CCAAGAAGCCCACCGGCGCUCCUCCAGAACUGAGCGGAG  
UGACCAACA AUGGCUUCAUCCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUCAUCAUCUUCAGCCUGCUGAU 138 SC\_  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA SUabi\_  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU lize  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU Alpha\_  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG U174W  
CCUGAUCAAGACCGAGCUGGAUCUGACCAAGAGCGCCCU  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCCAUCGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCCUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGCGAGCUGAAGGACUUC  
GUGUCCAAGAACCUGUGGGCGGGCCAUAACAAGAACA  
GUGCGACAUCGACGACCUGAAGAUGGCCGUGUCCUUUAG  
CCAGUUCAACCGGCGGUUUCUGAACGUCGUGCGGCAGUU  
UAGCGACAACGCCGGAUACACCAGCCAUCAGCCUGGA  
CCUGAUGACAGAUGCUGAGCUGGCUAGAGCCGUGCCUAA  
CAUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGA  
GAAUAGAGCCAUGGUCCGACGGAAAGGCUUCGGCAUUC  
UGAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUG  
CAGCUGCCUAUCUUCGGCGUGAUCGACACACCCUGCUGG  
AUUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGG  
CAAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGGCAGCACCGUGUACUACCCUAACGA  
GAAGGACUGCGAGACAAGAGGCGACCACGUGUUCUGUG  
AUACCGCCGCUGGAAUCA AUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC

GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGUUCCC  
UGAGGAUCAGUUCAGGUGGGCCUGGACCAGGUGUUCG  
AGAACAUCGAGAAUUCCCAGGCUCUGGUGGACCAGUCCA  
ACAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCU  
UCAUCAUCGUGAUAUCCUGAUCGCCGUGCUGGGCAGCU  
CCAUGAUCCUGGUGUCCAUCUUAUCAUUAUCAAGAAGA  
CCAAGAAGCCCACCGGCGCUCCUCCAGAACUGAGCGGAG  
UGACCAACAAUGGCUUCAUCCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUCAUCAUCUUCAGCCUGCUGAU 139 SC\_4M\_  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA SUabi-  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU lize  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU Alpha\_  
GGGCGACCUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG V55L  
CCUGAUAAGACCGAGCUGGAUCUGCUCAAGAGCGCCCU U74L  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG S170L  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG U174W  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCCAUCGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCCUAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGCGAGCUGAAGGACUUC  
GUGCUUAAGAACCUGUGGGCGGGCCAUAACAAGAACA  
GUGCGACAUCGACGACCUGAAGAUGGCCGUGUCCUUUAG  
CCAGUUCAACCGGCGGUUUCUGAACGUCGUGCGGCAGUU  
UAGCGACAACGCCGGAUACACACCAGCCAUCAGCCUGGA  
CCUGAUGACAGAUGCUGAGCUGGCUAGAGCCGUGCCUAA  
CAUGCCUACAUCUGCCGGCCAGAUAAGCUGAUGCUCGA  
GAAUAGAGCCAUGGUCCGACGGAAGGCUUCGGCAUUC  
UGAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUG  
CAGCUGCCUAUCUUCGGCGUGAUCGACACACCCUGCUGG  
AUUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGG  
CAAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGGCAGCACCGUGUACUACCCUAAACGA  
GAAGGACUGCGAGACAAGAGGCGACCACGUGUUCUGUG  
AUACCGCCGUGGAAUCAUUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCAACCUAUCUCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGUUCCC  
UGAGGAUCAGUUCAGGUGGGCCUGGACCAGGUGUUCG  
AGAACAUCGAGAAUUCCCAGGCUCUGGUGGACCAGUCCA  
ACAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCU  
UCAUCAUCGUGAUAUCCUGAUCGCCGUGCUGGGCAGCU  
CCAUGAUCCUGGUGUCCAUCUUAUCAUUAUCAAGAAGA  
CCAAGAAGCCCACCGGCGCUCCUCCAGAACUGAGCGGAG  
UGACCAACAAUGGCUUCAUCCCUCACAAC HMPV\_



AUGAGCUGGAAGGUGGUCAUCAUCUUCAGCCUGCUGAU 140 Pro-  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA line  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU SUab\_  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGCCUGU E51P  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG  
CCUGAUCAAGACCGAGCUGGAUCUGACCAAGAGCGCCCU  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCCAUCGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGCGAGCUGAAGGACUUC  
GUGUCCAAGAACCUGACACGGGCCAUUAACAAGAACAAG  
UGCAGCAUCGACGACCUGAAGAUGGCCGUGUCCUUUAGC  
CAGUUCAACCGGCGGUUUCUGAACGUCGUGCGGCAGUUU  
AGCGACAACGCCGGAUACACACCAGCCAUCAGCCUGGAC  
CUGAUGACAGAUGCUGAGCUGGCUAGAGCCGUGCCU AAC  
AUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGAG  
AAUAGAGCCAUGGUCCGACGGAAAGGCUUCGGCAUUCU  
GAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUGC  
AGCUGCCU AUCUUCGGCGUGAUCGACACACCUCUGCUGGA  
UUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGGC  
AAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGGCAGCACCGUGUACUACCCU AACGA  
GAAGGACUGCGAGACAAGAGGGCACCACGUGUUCUGUG  
AUACCGCCGUGGAAUCA AUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUCAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGU UCCC  
UGAGGAUCAGU UCCAGGUGGCCCUGGACCAGGUGUUCG  
AGAACAUCGAGAAU UCCCAGGCUCUGGUGGACCAGUCCA  
ACAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCU  
UCAUCAUCGUGAUCAUCCUGAUCGCCGUGCUGGGCAGCU  
CCAUGAUCUGGUGUCCAUCUUCAUCAUUAUCAAGAAGA  
CCAAGAAGCCCACCGGCGCUCCUCCAGAACUGAGCGGAG  
UGACCAACA AUGGCUUCAUCCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUCAUCAUCUUCAGCCUGCUGAU 141 Pro-  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA line  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU SUab\_  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU D185P  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG  
CCUGAUCAAGACCGAGCUGGAUCUGACCAAGAGCGCCCU  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCCAUCGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCUGAAG

AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGCGAGCUGAAGGACUUC  
GUGUCCAAGAACCUGACACGGGCCAUUAACAAGAACAAG  
UGCGACAUCCUGACCUGAAGAUGGCCGUGUCCUUUAGC  
CAGUUCAACCGGCGGUUUCUGAACGUCGUGCGGCAGUUU  
AGCGACAACGCCGGAUACACACCAGCCAUCAGCCUGGAC  
CUGAUGACAGAUGCUGAGCUGGCUAGAGCCGUGCCU AAC  
AUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGAG  
AAUAGAGCCAUGGUCCGACGGAAAGGCUUCGGCAUUCU  
GAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUGC  
AGCUGCCUAUCUUCGGCGUGAUCGACACACCUGCUGGA  
UUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGGC  
AAUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGGCAGCACCGUGUACUACCCUAACGA  
GAAGGACUGCGAGACAAGAGGCGACCACGUGUUCUGUG  
AUACCGCCGCUGGAAUCA AUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCAGUGAUCAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGUCCC  
UGAGGAUCAGUCCAGGUGGCCUUGGACCAGGUGUUCG  
AGAAUCAUCGAGAAUCCCAGGCUCUGGUGGACCAGUCCA  
ACAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCU  
UCAUCAUCGUGAUCAUCCUGAUCGCCGUGCUGGGCAGCU  
CCAUGAUCUGGUGUCCAUCUUCAUCAUUAUCAAGAAGA  
CCAAGAAGCCCACCGGCGCUCCUCCAGAACUGAGCGGAG  
UGACCAACA AUGGCUUCAUCCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUC AUCAUCUUCAGCCUGCUGAU 142 Pro-  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA line  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU SUab\_  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU D183P  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG  
CCUGAUCAAGACCGAGCUGGAUCUGACCAAGAGCGCCCU  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUACAGCAGGCGUGGCCAU CGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCCU GAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGCGAGCUGAAGGACUUC  
GUGUCCAAGAACCUGACACGGGCCAUUAACAAGAACAAG  
UGCCCUAUCGACGACCUGAAGAUGGCCGUGUCCUUUAGC  
CAGUUCAACCGGCGGUUUCUGAACGUCGUGCGGCAGUUU  
AGCGACAACGCCGGAUACACACCAGCCAUCAGCCUGGAC  
CUGAUGACAGAUGCUGAGCUGGCUAGAGCCGUGCCU AAC  
AUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGAG  
AAUAGAGCCAUGGUCCGACGGAAAGGCUUCGGCAUUCU  
GAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUGC  
AGCUGCCUAUCUUCGGCGUGAUCGACACACCUGCUGGA  
UUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGGC

AAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGGCAGCACCGUGUACUACCCUAACGA  
GAAGGACUGCGAGACAAGAGGCGACCACGUGUUCUGUG  
AUACCGCCGCUGGAAUCA AUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGUUCCC  
UGAGGAUCAGUCCAGGUGGCCUGGACCAGGUGUUCG  
AGAACAUCGAGAAUCCCAGGCUCUGGUGGACCAGUCCA  
ACAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCU  
UCAUCAUCGUGAUAUCCUGAUCGCCGUGCUGGGCAGCU  
CCAUGAUCCUGGUGUCCAUCUUAUCAUUAUCAAGAAGA  
CCAAGAAGCCCACCGGCGCUCCUCCAGAACUGAGCGGAG  
UGACCAACA AUGGCUUCAUCCCUCACAAC HMPV  
AUGAGCUGGAAGGUGGUCAUCAUCUUCAGCCUGCUGAU 143 Pro-  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA line  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU SUab  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU E131P  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG  
CCUGAUAAGACCGAGCUGGAUCUGACCAAGAGCGCCCU  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCCAUCGCUAAGACCAUCAGA  
CUGCCUAGCGAAGUGACCGCCAUCAACAACGCCCUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGCGAGCUGAAGGACUUC  
GUGUCCAAGAACCUGACACGGGCCAUUAACAAGAACAAG  
UGCAGAUUCGACGACCUGAAGAUGGCCGUGUCCUUUAGC  
CAGUUCAACCGGCGGUUUCUGAACGUCGUGCGGCAGUUU  
AGCGACAACGCCGGAUCACACCAGCCAUCAGCCUGGAC  
CUGAUGACAGAUUCUGAGCUGGCUAGAGCCGUGCCU AAC  
AUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGAG  
AAUAGAGCCAUGGUCCGACGGAAGGCUUCGGCAUUCU  
GAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUGC  
AGCUGCCUAUCUUCGGCGUGAUCGACACACCUGCUGGA  
UUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGGC  
AAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGGCAGCACCGUGUACUACCCUAACGA  
GAAGGACUGCGAGACAAGAGGCGACCACGUGUUCUGUG  
AUACCGCCGCUGGAAUCA AUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGUUCCC

UGAGGAUCAGUCCAGGUGGCCUGGACCAGGUGUUCG  
AGAACAUCGAGAAUCCCCAGGCUCUGGUGGACCAGUCCA  
ACAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCU  
UCAUCAUCGUGAUCAUCCUGAUCGCCGUGCUGGGCAGCU  
CCAUGAUCCUGGUGUCCAUCUUAUCAUUAUCAAGAAGA  
CCAAGAAGCCCACCGGCGCUCCUCCAGAACUGAGCGGAG  
UGACCAACAAUGGCUUCAUCCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUCAUCAUCUUCAGCCUGCUGAU 144 Pro-  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA line  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU SUab\_  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU D447P  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG  
CCUGAUCAAGACCGAGCUGGAUCUGACCAAGAGCGCCCU  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUACAGCAGGCGUGGCAUCGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGCGAGCUGAAGGACUUC  
GUGUCCAAGAACCUGACACGGGCAUUAACAAGAACAAG  
UGCAGAUUCGACGACCUGAAGAUGGCCGUGUCCUUUAGC  
CAGUUCAACCGGCGGUUUCUGAACGUCGUGCGGCAGUUU  
AGCGACAACGCCGGAUCACACCAGCCAUCAGCCUGGAC  
CUGAUGACAGAUUGCUGAGCUGGCUAGAGCCGUGCCUAC  
AUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGAG  
AAUAGAGCCAUGGUCCGACGGAAGGCUUCGGCAUUCU  
GAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUGC  
AGCUGCCUAUCUUCGGCGUGAUCGACACCCUGCUGGA  
UUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGGC  
AAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGCGCAGCACCCGUGUACUACCCUACGA  
GAAGGACUGCGAGACAAGAGGCGACCACGUGUUCUGUG  
AUACCGCCGUGGAAUCAUUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUCAAGGG  
CAGACCUGUGUCCAGCAGCUUCCCACCUAUAAGUCCC  
UGAGGAUCAGUCCAGGUGGCCUGGACCAGGUGUUCG  
AGAACAUCGAGAAUCCCCAGGCUCUGGUGGACCAGUCCA  
ACAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCU  
UCAUCAUCGUGAUCAUCCUGAUCGCCGUGCUGGGCAGCU  
CCAUGAUCCUGGUGUCCAUCUUAUCAUUAUCAAGAAGA  
CCAAGAAGCCCACCGGCGCUCCUCCAGAACUGAGCGGAG  
UGACCAACAAUGGCUUCAUCCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUCAUCAUCUUCAGCCUGCUGAU 145 Urimer  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA Repul-  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU sion  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU D454N  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG

CCUGAUCAAGACCGAGCUGGAUCUGACCAAGAGCGCCCU  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCCAUCGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGCGAGCUGAAGGACUUC  
GUGUCCAAGAACCUGACACGGGCCAUUAACAAGAACAAG  
UGCGACAUCGACGACCUGAAGAUGGCCGUGUCCUUUAGC  
CAGUUCAACCGGCGGUUUCUGAACGUCGUGCGGCAGUUU  
AGCGACAACGCCGGAUUCACACCAGCCAUCAGCCUGGAC  
CUGAUGACAGAUUCUGAGCUGGCCUAGAGCCGUGCCU AAC  
AUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGAG  
AAUAGAGCCAUGGUCCGACGGAAAGGCUUCGGCAUUCU  
GAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUGC  
AGCUGCCUAUCUUCGGCGUGAUCGACACACCUGCUGGA  
UUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGGC  
AAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGCGCAGCACCCGUGUACUACCCU AACGA  
GAAGGACUGCGAGACAAGAGGCGACCACGUGUUCUGUG  
AUACCGCCGUGGAAUCA AUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAACAUCAGCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUCAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGUCCC  
UGAGAACCAGUUCAGGUGGCCUUGGACCAGGUGUUCGA  
GAACAUCGAGAAUUCAGGCUCUGGUGGACCAGUCCAA  
CAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCUU  
CAUCAUCGUGAUCAUCCUGAUCGCCGUGCUGGGCAGCUC  
CAUGAUCCUGGUGUCCAUCUUCAUCAUUAUCAAGAAGAC  
CAAGAAGCCCACCGGCGCUCUCCAGAACUGAGCGGAGU  
GACCAACAAUGGCUUCAUCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUAUCAUCUUCAGCCUGCUGAU 146 Urimer  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA Repul-  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU sion  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU E453N  
GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG  
CCUGAUCAAGACCGAGCUGGAUCUGACCAAGAGCGCCCU  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCCAUCGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGCGAGCUGAAGGACUUC  
GUGUCCAAGAACCUGACACGGGCCAUUAACAAGAACAAG  
UGCGACAUCGACGACCUGAAGAUGGCCGUGUCCUUUAGC  
CAGUUCAACCGGCGGUUUCUGAACGUCGUGCGGCAGUUU  
AGCGACAACGCCGGAUUCACACCAGCCAUCAGCCUGGAC

CUGAUGACAGAUGCUGAGCUGGCUAGAGCCGUGCCU AAC  
AUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGAG  
AAUAGAGCCAUGGUCCGACGGAAAGGCUUCGGCAUUCU  
GAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUGC  
AGCUGCCUAUCUUCGGCGUGAUCGACACACCUGCUGGA  
UUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGGC  
AAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGGCAGCACCGUGUACUACCCUAACGA  
GAAGGACUGCGAGACAAGAGGGCGACCACGUGUUCUGUG  
AUACCGCCGCUGGAAUCA AUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAUCAUCAGCACCAACUAUCCCUGCA  
AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUCAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGUCCC  
UCAGGAUCAGUUCAGGUGGCCUUGGACCAGGUGUUCGA  
GAACAUCGAGAAUUCAGGCUCUGGUGGACCAGUCCAA  
CAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCUU  
CAUCAUCGUGAUCAUCCUGAUCGCCGUGCUGGGCAGCUC  
CAUGAUCCUGGUGUCCAUCUUCAUCAUUAUCAAGAAGAC  
CAAGAAGCCCACCGGCGCUCUCCAGAACUGAGCGGAGU  
GACCAACA AUGGCUUCAUCCUCACAAC HMPV\_  
AUGAGCUGGAAGGUGGUCAUCAUCUUCAGCCUGCUGAU 147 SU  
CACACCUCAGCACGGCCUGAAAGAGAGCUACCUGGAAGA abi-  
GUCCUGCAGCACCAUCACAGAGGGCUACCUGUCUGUGCU lize  
GAGAACCGGCUGGUACACCAACGUGUUCACACUGGAAGU

Alpha GGGCGACGUCGAGAAUCUGACAUGCUCUGAUGGCCCUAG F196W  
CCUGAUCAAGACCGAGCUGGAUCUGACCAAGAGCGCCCU  
GAGAGAACUCAAGACCGUGUCUGCCGAUCAGCUGGCCAG  
AGAGGAACAGAUUCGAGAAUCCUGGCAGCGGCAGCUUUG  
UGCUGGGAGCCAUUGCUCUUGGAGUGGCUGCUGCUGCA  
GCUGUUACAGCAGGCGUGGCCAUCGCUAAGACCAUCAGA  
CUGGAAAGCGAAGUGACCGCCAUCAACAACGCCCUGAAG  
AAGACAAACGAGGCCGUCAGCACACUCGGCAAUGGCGUU  
AGAGUGCUGGCCACAGCCGUGCGGAGCUGAAGGACUUC  
GUGUCCAAGAACCUGACACGGGCCAUUAACAAGAACAAG  
UGCGACAUCGACGACCUGAAGAUGGCCGUGUCCUUUAGC  
CAGUGGAACC GGCGGUUCUGAACGUCGUGCGGCAGUU  
UAGCGACAACGCCGGAUACACACCAGCCAUCAGCCUGGA  
CCUGAUGACAGAUGCUGAGCUGGCUAGAGCCGUGCCUAA  
CAUGCCUACAUCUGCCGGCCAGAUCAAGCUGAUGCUCGA  
GAAUAGAGCCAUGGUCCGACGGAAAGGCUUCGGCAUUC  
UGAUUGGCGUGUACGGCAGCAGCGUGAUCUAUAUGGUG  
CAGCUGCCUAUCUUCGGCGUGAUCGACACACCUGCUGG  
AUUGUGAAGGCCGCUCCUAGCUGUAGCGAGAAGAAGGG  
CAAUUACGCCUGCCUGCUGAGAGAGGACCAAGGCUGGUA  
UUGUCAGAACGCCGGCAGCACCGUGUACUACCCUAACGA  
GAAGGACUGCGAGACAAGAGGGCGACCACGUGUUCUGUG  
AUACCGCCGCUGGAAUCA AUGUGGCCGAGCAGAGCAAAG  
AGUGCAACAUCAUCAUCAGCACCAACUAUCCCUGCA

AGGUGUCCACCGGCAGGCACCCUAUUUCUAUGGUGGCUC  
UGUCUCCUCUGGGAGCCCUGGUGGCUUGUUAUAAGGGC  
GUGUCCUGUAGCAUCGGCAGCAACAGAGUGGGCAUCAUC  
AAGCAGCUGAACAAAGGGCUGCAGCUACAUCACCAACCAG  
GACGCCGAUACCGUGACCAUCGACAACACCGUGUAUCAG  
CUGAGCAAGGUGGAAGGCGAACAGCACGUGAUAAGGG  
CAGACCUGUGUCCAGCAGCUUCGACCCUAUCAAGUUCCC  
UGAGGAUCAGUCCAGGUGGCCUCUGGACCAGGUGUUCG  
AGAACAUCGAGAAUUCCCAGGCUCUGGUGGACCAGUCCA  
ACAGAAUCCUGUCUAGCGCCGAGAAGGGAAACACCGGCU  
UCAUCAUCGUGAUAUCCUGAUCGCCGUGCUGGGCAGCU  
CCAUGAUCUGGUGUCCAUCUUAUCAUUAUCAAGAAGA  
CCAAGAAGCCCACCGGCGCUCCUCCAGAACUGAGCGGAG  
UGACCAACAAUGGCUUCAUCCCUCACAAC

## EQUIVALENTS

[0838] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the disclosure described herein. Such equivalents are intended to be encompassed by the following claims.

[0839] All references, including patent documents, disclosed herein are incorporated by reference in their entirety.

## Sequence CWU 1

1

14711620DNA Human metapneumovirus 1atgagctgga aggtggtgat tatcttcagc ctgctgatta cacctcaaca cggcctgaag  
60gagagctacc tggaagagag ctgctccacc atcaccgagg gctacctgag cgtgctgceg 120accggctggt acaccaacgt gttcacctg  
gaggtggcg acgtggagaa cctgacctgc 180agcgacggcc ctgacctgat caagaccgag ctggacctga ccaagagcgc tctgagagag  
240ctgaagaccg tgccgccga ccagctggcc agagaggaac agatcgagaa cctcggcgag 300agcagattcg tgctgggegc catcgtctg  
ggagtgcgg ctgccgtgc agtgacagct 360ggagtggcca ttgctaagac catcagactg gaaagcgagg tgacagccat caacaatgcc  
420ctgaagaaga ccaacgagc cgtgagcacc ctgggcaatg gagtgagagt gctggccaca 480gccgtgctgg agctgaagga ctctgtgagc  
aagaacctga ccagagccat caacaagaac 540aagtgcgaca tcatgacct gaagatggcc gtgagcttct cccagttcaa cagacggttc  
600ctgaacgtgg tgagacagtt ctccgacaac gctggaatca cacctgccat tagcctggac 660ctgatgaccg acgccgagct ggctagagcc  
gtgccaaca tgcccaccag cgctggccag 720atcaagctga tgctggagaa cagagccatg gtgcggagaa agggcttcgg catcctgatt  
780gggggtgatg gaagctccgt gatctacatg gtgcagctgc ccatcttcgg cgtgatcgac 840acacctgct ggatcgtgaa ggcgctct  
agctgctccg agaagaaagg aaactatgcc 900tgtctgctga gagaggacca ggctggttac tgccagaacg ccggaagcag agtgtactat  
960ccaacgaga aggactgcga gaccagagc gaccactgt tctgcgacac cgctgccgga 1020atcaacgtgg ccgagcagag  
caaggagtgc aacatcaaca tcagcacaac caactacccc 1080tgcaaggtga gcaccggagc gcacccatc agcatggtgg ctctgagccc  
tctggcgct 1140ctggtggcct gctataaggc cgtgtctgt agcatggca gcaatcgggt gggcatcctc 1200aagcagctga acaagggatg  
ctctacatc accaaccagg acgccgacac cgtgaccatc 1260gacaacaccg tgtaccagct gagcaaggtg gagggcgagc agcagctgat  
caaggcaga 1320cccgtgagct ccagcttcga ccccatcaag ttccctgagg accagtcaa cgtggccctg 1380gaccaggtg ttgagaacat  
cgagaacagc caggccctgg tggaccagag caacagaatc 1440ctgtccagc ctgagaaggg caacaccggc tcatcattg tgatcattt  
gatgcctg 1500ctgggcagct ccatgatcct ggtgagcctc tcatcatta tcaagaagac caagaaacc 1560accggagccc ctctgagct  
gagcggcgtg accaacaatg gcttcattcc ccacaactga 162021620DNA Human metapneumovirus 2atgtcttgg aagtgatgat  
catcatttcg ttactcataa caccagca cgggctaaag 60gagagtatt tggaagaatc atgtagtact ataactgagg gatacctcag tgtttaaga  
120acaggctggt aactaatgt cttcacatta gaagttggtg atgtgaaaa tcttacatgt 180actgatggac ctgcttaac caaacagaa  
ctgatctaa caaaaagtc ttaagggaa 240ctcaaaacag tctctgctga tcagtggcg agagaggagc aaattgaaaa tccagacaa  
300tcaagatttg tctaggtgc gatagctctc ggagttgcta cagcagcagc agtcacagca 360ggcattgcaa tagccaaaac cataaggtt  
gagagtgagg tgaatcaat taaaggtgct 420ctcaaaaaa ctaatgaagc agtatccaca ttagggaatg gtgtgcgggt cctagccact  
480gcagtgagag agctaaaaga atgtgagc aaaaactga ctagtgaat caacaggaac 540aatgtgaca ttgctgatct gaagatggct  
gtcagcttca gtcaatcaa cagaagattt 600ctaaatgttg tgccgagtt ttacagcaat gcagggataa caccagcaat atcattggac

660ctgatgactg atgctgagtt ggccagagct gtatcataca tgccaacatc tgcagggcag 720ataaaaactga tgttgagaa ccgcgcaatg  
gtaaggagaa aaggatttgg aatcctgata 780ggggctctacg gaagctctgt gatttcatg gttcaattgc cgatcttgg tgcatagat  
840acaccttgtt ggatcatcaa ggcagctccc tctgtctcag aaaaaaacgg gaattatgct 900tgcctcctaa gagaggatca aggggtggtat  
tgtaaaaatg caggatctac tgtttactac 960ccaaatgaaa aagactgcga aacaagaggt gatcatgttt tttgtgacac agcagcaggg  
1020atcaatgttg ctgagcaate aagagaatgc aacatcaaca tatctactac caactacca 1080tgcaaagta gacaggaag acaccctata  
agcatggttg cactatcacc tctcgggtgct 1140ttgggtgctt gctataaagg ggtaagctgc tgcattggca gcaattgggt tggatcatc  
1200aaacaattac ccaaaggctg ctacataca accaaccagg atgcagacac tgaacaatt 1260gacaataccg tgcataact aagcaaagt  
gaagtgaaac agcatgtaat aaaagggaga 1320ccagtttcaa gcagtttga tccaatcaag ttcctgagg atcagttaa tgttgcgctt  
1380gatcaagtct tgcgaagcat tgagaacagt caggcactag tggaccagtc aaaaaaatt 1440ctaaacagtg cagaaaaagg aacactggt  
ttcattatcg tagtaatttt ggttgcgtt 1500cttgggtctaa ccatgatttc agtgagcacc atcatcataa tcaagaaaac aaggaagccc  
1560acaggagcac ctccagagct gaatggtgct accaacggcg gtttcatacc acatagttag 162031620DNAHuman  
metapneumovirus 3atgtcttggga aagtgatgat tatcatttcg ttactcataa cacctcagca tggactaaaa 60gaaagtatt tagaagaatc  
atgtagtact ataactgaag gatattcag tgttttaaga 120acaggttgg acaccaatgt cttacatta gaagttggg atgttgaaaa tcttactgt  
180actgatggac ctgacttaac caaaacagaa cttgacctaa caaaagtgc ttaagagaa 240ctcaaaacag tttctgctga tcatgtagc  
agagaagaac aaattgaaaa tcccagacaa 300tcaaggttgg tctaggtgct aatagctctt ggagttgcca cagcagcagc agtcacagca  
360ggcattgcaa tagccaaaac tataaggctt gagagtgaag tgaatgcaat caaaggtgct 420ctcaaaacaa ccaatgaggc agtatcaaca  
ctaggaaatg gagtgcgggt cctagccact 480gcagtaagag agctgaaaga atttgtgagc aaaaacctga ctagtgcgat caacaagaac  
540aagtgtgaca ttgctgatt gaagatggct gtcagctca gtcagtcaa cagaagattc 600ctaaatgttg tgcggcagtt ttcagacaat  
gcagggataa caccagcaat atcattggac 660ctgatgaatg atgctgagct ggccagagct gtatcataca tgccaacatc tgcaggacag  
720ataaaaactaa tggtagagaa ccgtgcaatg gtgaggagaa aaggatttgg aatcttgata 780ggggctctacg gaagctctgt gatttcatg  
gtccagctgc cgatcttgg tgcataaat 840acaccttgtt ggataatcaa ggcagctccc tctgttctcag aaaaagatgg aattatgct  
900tgcctcctaa gagaggatca aggggtggtat tgtaaaaatg caggatccac tgtttactac 960ccaaatgaaa aagactgcga aacaagaggt  
gatcatgttt tttgtgacac agcagcaggg 1020atcaatgttg ctgagcaate aagagaatgc aacatcaaca tatctaccac caactacca  
1080tgcaaagta gacaggaag acaccctatc agcatggttg cactatcacc tctcgggtgct 1140ttggtagctt gctacaaagg ggttagctgc  
tgcactggca gtaatcaggt tggataatc 1200aaacaactac ctaaaggctg ctacataca actaaccagg acgcagacac tgaacaatt  
1260gacaactag tgcataact aagcaaagt gaggggtgaa agcatgtaat aaaagggaga 1320ccagtttcaa gcagtttga tccaatcagg  
ttcctgagg atcagttaa tgttgcgctt 1380gatcaagtct tgaagcat tgaaaacagt caagcactag tggaccagtc aaaaaaatt  
1440ctgaacagtg cagaaaaagg aacactggt ttcattatg taataatttt gattgctgtt 1500cttgggttaa ccatgatttc agtgagcacc  
atcatcataa tcaaaaaaac aaggaagccc 1560acaggggac ctccggagct gaatggtgct accaacggcg gtttcatacc gcatagttag  
162041725DNAHuman respiratory syncytial virus 4atggagttgc caatctcaa acaaatgca attaccacaa tcttctgctg  
agtcacactc 60tgttctgctt ccagtcacaa catcactgaa gaattttatc aatcaacatg cagtgcagtt 120agcaaaggct atcttagtgc tcaagaact  
ggttggata ctagtgttat aactatagaa 180ttaagtaata tcaaggaaaa taagttaat ggaacagatg ctaaggtaaa atgataaaa  
240caagaattag ataatataa aatgctgta acagaattgc agttgctcat gcaaaagcaca 300ccagcagcca acaatcgagc cagaagagaa  
ctaccaaggt ttatgaatta tacactcaat 360aatacaaaa ataccaatgt aacattaagc aagaaaagga aaagaagatt tcttggcttt  
420ttgttaggtg ttgatctgc aatgccagct ggcattgctg tatctaaagt cctgcaccta 480gaaggggaag tgaacaaaat caaaagtct  
ctactatcca caacaaggc ttagtctcagc 540ttatcaaatg gatttagtct ctaaccagc aaagtgttag acctcaaaaa ctatagat  
600aaacagttgt tacctattgt gaacaagca agctgcagca tatcaaacat tgaactgtg 660atagagtcc acaaaaagaa caacagacta  
ctagagatta ccaggaatt tagtgttaat 720gcaggtgtaa ctacacctgt aagcacttat atgttaacta atagtgaatt attatcatta 780atcaatgata  
tgcctataac aatgatcag aaaaagttaa tgcacaaca tgttcaata 840gtagacagc aaagtactc tatcatgtcc ataataaagg aggaagtctt  
agcatatgta 900gtacaattac cactataggg tgtaatagat acacctgtt ggaaactgca cacatccct 960ctatgtacaa ccaacacaaa  
ggaagggcc aacatctgct taacaagaac cgacagagga 1020tggtattgtg acaatgcagg atcagtatct ttctccac aagctgaaac  
atgtaaagt 1080caatcgaatc ggttatttg tgacacaatg aacagtttaa cattaccaag tgaagtaaat 1140ctctgcaaca ttgacatatt  
caaccccaaa tatgattgca aaattatgac tcaaaaaaca 1200gatgtaagca gctccgttat cacatctcta ggagccattg tgcattgta tggcaaaact  
1260aaatgtacag catcaataa aatctgtggg atcataaaga cattttctaa cgggtgtgat 1320tatgtatcaa ataagggggg ggatactgtg  
tctgtaggta atacattata ttatgtaaat 1380aagcaagaag gcaaaagtct ctatgtaaaa ggtgaacaa taataaatt ctatgacca  
1440ttagtgtcc cctctgatga atttgatgca tcaatatctc aagtcaatga gaagattaac 1500cagagcctag catttattcg taaatccgat  
gaattattc ataagttaa tgcgtgtaaa 1560tccaccacaa atatcatgat aactactata attatagta ttatagtaatt attgtatca  
1620ttaattgcag ttgactgct cctactctg aaggccagaa gacaccagc cacactaagt 1680aaggatcaac tgaatggtat aaataatatt  
gcattagta actga 1725539PRTHuman metapneumovirus isolate 5Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu  
Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu  
Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35 40 45Thr Leu Glu Val Gly Asp Val Glu Asn  
Leu Thr Cys Ser Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu Asp Leu Thr Lys Ser Ala Leu Arg Glu65 70  
75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu 85 90 95Asn Pro Arg Gln Ser Arg Phe  
Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Ala Ala Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr



Ile 115 120 125Arg Leu Glu Ser Glu Val Thr Ala Ile Asn Asn Ala Leu Lys Lys Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155 160Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Thr Arg Ala 165 170 175Ile Asn Lys Asn Lys Cys Asp Ile Asp Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210 215 220Ala Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile385 390 395 400Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410 415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Lys Phe Pro Glu Asp Gln Phe Asn Val Ala Leu Asp Gln Val Phe 450 455 460Glu Asn Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile 485 490 495Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu Val Ser Ile Phe Ile 500 505 510Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser 515 520 525Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn 530 535539PRTHuman metapneumovirus 6Met Ser Trp Lys Val Met Ile Ile Ile Ser Leu Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35 40 45Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Thr Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu Asp Leu Thr Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu 85 90 95Asn Pro Arg Gln Ser Arg Phe Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Thr Ala Ala Ala Val Thr Ala Gly Ile Ala Ile Ala Lys Thr Ile 115 120 125Arg Leu Glu Ser Glu Val Asn Ala Ile Lys Gly Ala Leu Lys Gln Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155 160Ala Val Arg Glu Leu Lys Glu Phe Val Ser Lys Asn Leu Thr Ser Ala 165 170 175Ile Asn Arg Asn Lys Cys Asp Ile Ala Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210 215 220Ala Glu Leu Ala Arg Ala Val Ser Tyr Met Pro Thr Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Ile Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys Asn Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn Trp Val Gly Ile Ile385 390 395 400Lys Gln Leu Pro Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410 415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Lys Phe Pro Glu Asp Gln Phe Asn Val Ala Leu Asp Gln Val Phe 450 455 460Glu Ser Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Lys Ile465 470 475 480Leu Asn Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Val Ile 485 490 495Leu Val Ala Val Leu Gly Leu Thr Met Ile Ser Val Ser Ile Ile Ile 500 505 510Ile Ile Lys Lys Thr Arg Lys Pro Thr Gly Ala Pro Pro Glu Leu Asn 515 520 525Gly Val Thr Asn Gly Gly Phe Ile Pro His Ser 530 535539PRTHuman metapneumovirus 7Met Ser Trp Lys Val Met Ile Ile Ile Ser Leu Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35 40 45Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Thr Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu Asp Leu Thr Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu 85 90 95Asn Pro Arg Gln Ser Arg Phe Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Thr Ala Ala Ala Val Thr Ala Gly Ile Ala Ile Ala Lys Thr Ile 115 120 125Arg Leu Glu Ser Glu Val Asn Ala Ile Lys Gly Ala Leu Lys Thr Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155 160Ala Val Arg Glu Leu Lys Glu Phe Val Ser Lys Asn Leu Thr Ser Ala 165 170 175Ile Asn Lys Asn Lys Cys Asp Ile Ala Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Asn Asp 210 215 220Ala Glu Leu Ala Arg Ala Val Ser Tyr

Met Pro Thr Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly  
Phe 245 250 255Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln 260 265 270Leu Pro Ile Phe  
Gly Val Ile Asn Thr Pro Cys Trp Ile Ile Lys Ala

275 280 285Ala Pro Ser Cys Ser Glu Lys Asp Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu Asp Gln Gly  
Trp Tyr Cys Lys Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly  
Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Arg Glu Cys Asn Ile 340  
345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser Met Val Ala  
Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Thr Gly Ser Asn Gln Val  
Gly Ile Ile385 390 395 400Lys Gln Leu Pro Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410 415Thr  
Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly Arg Pro  
Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Arg Phe Pro Glu Asp Gln Phe Asn Val Ala Leu Asp Gln Val Phe  
450 455 460Glu Ser Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Lys Ile465 470 475 480Leu Asn Ser Ala  
Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile 485 490 495Leu Ile Ala Val Leu Gly Leu Thr Met Ile Ser Val Ser  
Ile Ile Ile 500 505 510Ile Ile Lys Lys Thr Arg Lys Pro Thr Gly Ala Pro Pro Glu Leu Asn 515 520 525Gly Val  
Thr Asn Gly Gly Phe Ile Pro His Ser 530 535574PRTHuman respiratory syncytial virus 8Met Glu Leu Pro Ile  
Leu Lys Thr Asn Ala Ile Thr Thr Ile Leu Ala1 5 10 15Ala Val Thr Leu Cys Phe Ala Ser Ser Gln Asn Ile Thr Glu  
Glu Phe 20 25 30Tyr Gln Ser Thr Cys Ser Ala Val Ser Lys Gly Tyr Leu Ser Ala Leu 35 40 45Arg Thr Gly Trp  
Tyr Thr Ser Val Ile Thr Ile Glu Leu Ser Asn Ile 50 55 60Lys Glu Asn Lys Cys Asn Gly Thr Asp Ala Lys Val Lys  
Leu Ile Lys65 70 75 80Gln Glu Leu Asp Lys Tyr Lys Asn Ala Val Thr Glu Leu Gln Leu Leu 85 90 95Met Gln  
Ser Thr Pro Ala Ala Asn Asn Arg Ala Arg Arg Glu Leu Pro 100 105 110Arg Phe Met Asn Tyr Thr Leu Asn Asn  
Thr Lys Asn Thr Asn Val Thr 115 120 125Leu Ser Lys Lys Arg Lys Arg Arg Phe Leu Gly Phe Leu Leu Gly Val  
130 135 140Gly Ser Ala Ile Ala Ser Gly Ile Ala Val Ser Lys Val Leu His Leu145 150 155 160Glu Gly Glu Val  
Asn Lys Ile Lys Ser Ala Leu Leu Ser Thr Asn Lys 165 170 175Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu  
Thr Ser Lys Val 180 185 190Leu Asp Leu Lys Asn Tyr Ile Asp Lys Gln Leu Leu Pro Ile Val Asn 195 200  
205Lys Gln Ser Cys Ser Ile Ser Asn Ile Glu Thr Val Ile Glu Phe Gln 210 215 220Gln Lys Asn Asn Arg Leu Leu  
Glu Ile Thr Arg Glu Phe Ser Val Asn225 230 235 240Ala Gly Val Thr Thr Pro Val Ser Thr Tyr Met Leu Thr Asn  
Ser Glu 245 250 255Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Thr Asn Asp Gln Lys Lys 260 265 270Leu Met  
Ser Asn Asn Val Gln Ile Val Arg Gln Gln Ser Tyr Ser Ile 275 280 285Met Ser Ile Ile Lys Glu Glu Val Leu Ala  
Tyr Val Val Gln Leu Pro 290 295 300Leu Tyr Gly Val Ile Asp Thr Pro Cys Trp Lys Leu His Thr Ser Pro305 310  
315 320Leu Cys Thr Thr Asn Thr Lys Glu Gly Ser Asn Ile Cys Leu Thr Arg 325 330 335Thr Asp Arg Gly Trp  
Tyr Cys Asp Asn Ala Gly Ser Val Ser Phe Phe 340 345 350Pro Gln Ala Glu Thr Cys Lys Val Gln Ser Asn Arg  
Val Phe Cys Asp 355 360 365Thr Met Asn Ser Leu Thr Leu Pro Ser Glu Val Asn Leu Cys Asn Ile 370 375  
380Asp Ile Phe Asn Pro Lys Tyr Asp Cys Lys Ile Met Thr Ser Lys Thr385 390 395 400Asp Val Ser Ser Ser Val  
Ile Thr Ser Leu Gly Ala Ile Val Ser Cys 405 410 415Tyr Gly Lys Thr Lys Cys Thr Ala Ser Asn Lys Asn Arg Gly  
Ile Ile 420 425 430Lys Thr Phe Ser Asn Gly Cys Asp Tyr Val Ser Asn Lys Gly Val Asp 435 440 445Thr Val Ser  
Val Gly Asn Thr Leu Tyr Tyr Val Asn Lys Gln Glu Gly 450 455 460Lys Ser Leu Tyr Val Lys Gly Glu Pro Ile Ile  
Asn Phe Tyr Asp Pro465 470 475 480Leu Val Phe Pro Ser Asp Glu Phe Asp Ala Ser Ile Ser Gln Val Asn 485  
490 495Glu Lys Ile Asn Gln Ser Leu Ala Phe Ile Arg Lys Ser Asp Glu Leu 500 505 510Leu His Asn Val Asn  
Ala Gly Lys Ser Thr Thr Asn Ile Met Ile Thr 515 520 525Thr Ile Ile Ile Val Ile Ile Val Ile Leu Leu Ser Leu Ile  
Ala Val 530 535 540Gly Leu Leu Leu Tyr Cys Lys Ala Arg Ser Thr Pro Val Thr Leu Ser545 550 555 560Lys  
Asp Gln Leu Ser Gly Ile Asn Asn Ile Ala Phe Ser Asn 565 57091617DNAHuman parainfluenza virus 3  
9atgccaattt caactactgtt aattattaca accatgatca tggcatcaca ctgccaata 60gacatcaca aactacagca ttaggtgtg tttgtcaaca  
gtccaaagg gatgaagata 120tcacaaaact tcgaacaag atatctaact ctgagtctca taccaaaaat agaagattct 180aactctgtg  
gtgaccaaca gatcaagcaa tacaagagg tattggatag actgatcatt 240cctttatag atggactaag attacagaag gatgtgatag tgactaatca  
agaatccaat 300gaaaacactg atcccagaac agaacgattc tttggagggg taattggaac tattgctcta 360ggagtagca cctcagcaca  
aattacagca gcagttgctc tgggtgaagc caagcaggca 420agatcagaca tgaaaaact caaggaagca atcagggaca caataaagc  
agtgcagtca 480gttcagagct ctgtaggaaa ttgatagta gcaattaaat cagtcaggga ttatgtcaac 540aaagaaatcg tgccatcgat  
tgcgagacta ggtgtggaag cagcaggact tcagttaggg 600attgcattaa cacagcatta ctcagaatta acaaatatat ttggtgataa cataggatcg  
660ttacaagaaa aaggaataaa attacaaggt atagcatcat tataccgtac aaatcaca 720gaaatattca caacatcaac agttgacaaa  
tatgatattt atgatctatt atttacagaa 780tcaataaagg tgagagttat agatgttgat tgaatgatt actcaataac cctccaagtc 840agactccctt  
tattgaccag actgtgaac actcaatct acaagtaga ttccatata 900tacaatatcc aaatagaga atggtatata cctcttccca gccatatac  
gacgaaaggg 960gcatttctag gtggagcaga tgtcaagaa tgcatagaag cattcagcag ttatatatgc 1020cctctgatac caggattgt  
actaaacat gaaatggaga gctgtctatac aggaacata 1080tccaatgctc caagaaccac agtcaatca gacatagttc ctaggatgc

attgtcaat 1140ggaggagtgg ttgcaattg tataacaact acatgtacat gcaatggat cgtaataga 1200atcaaccaac cacctgatca  
aggagtcaaa attatacac ataaagaatg taatacaata 1260ggatcaacg gaatgctatt caacacaaa aaagaaggaa ccttgcatt  
ctacacacca 1320gacgacataa cattaacaa ttctgttca cttgatccga ttgacatata aatcgagctc 1380aacaaggcca aatcagatct  
tgaggatca aaagaatgga taagaagtc aatcaaaag 1440ctagattcta ttggaagtg gcatcaatct agcactaca tcatagtat tttgataatg  
1500atgattat tgtttataa taatataca ataattaca ttgcaattaa gtattacaga 1560attcaaaaga gaaatcgagt gcatcaaaa  
gataagccgt atgtattaac aaacaag 1617101716DNAHuman parainfluenza virus 3 10atggaatact ggaagcacac  
caaccacgga aaggatgctg gtaatgagct ggagacatcc 60acagccactc atggcaacaa gtcaccaac aagataacat atatattgtg  
gacgataacc 120ctggtgttat tatcaatagt cttcatcata gtgctaacta attccatcaa aagtgaaaag 180gcccgcgaat cattgctaca  
agacataaat aatgagttta tggagttac agaaaagatc 240caagtggcat cggataatac taatgatcta atacagtacg gagtgaatac aaggcttct  
300acaattcaga gtcattgcca gaattatata ccaatatac tgacacaaca aatatcggat 360cttaggaaat tcattagtga aattacaatt  
agaaatgata atcaagaagt gccaccacaa 420agaataacac atgatgtggg tataaaacct ttaatccag atgatttctg gagatgcacg  
480ctgtgtctc catctttgat gaaaactcca aaaataagat taatcccgg accaggatta 540ttagctatgc caagactgt tgatggctgt  
gtcagaacc cgtccttagt gataaatgat 600ctgatttat cttacacctc aatctaatt actcgaggtt gccaggatat agggaaatca  
660tatcaatgat tacagatagg gataataact gtaaactcag actgtgtacc tgaactaaat 720cctaggatct ctacacctt caacataaat  
gacaatagaa agtcatgttc tctagcactc 780ctaaatacag atgtatatca actgtgttca acccaaaaag ttgatgaaag atcagattat  
840gcatcatcag gcatagaaga tattgtactt gatattgtca attatgatgg ctcaatctcg 900acaacaagat ttaagaataa taatataagt tttgatcaac  
catatgccc attataccca 960ctgttggac caggatata ctacaaaggc aaaataat tctcgggta tggaggtctt 1020gaacatcaa  
taaatgagaa tgcaatctgc aacacaactg ggtgtctcgg gaaaacacag 1080agagactgta atcaagcctc tcatagtcca tggttttcag  
atagaaggat ggtaactct 1140ataattgtt ttgacaaggg cttgaactca gtccaaaat tgaaggatg gacgatatct 1200atgagacaaa  
attactgggg gtcagaagga agattactc tactaggtaa caagatctac 1260atatacaca gatctacaag ttggcacagc aagttaaat  
taggaataat tgacattact 1320gactacagt atataaggat aaaatggaca tggcataatg tctatcaag accaggaaac 1380aatgaatgc  
catggggaca tcatgtccg gatgatgta taacgggagt atataccgat 1440gcatatccac tcaatccac aggaagcatt gtatcatctg  
tcatattgga ctacaaaaa 1500ctgagagtca accagctcat aacttactca acagcaaccg aaagggtaaa cgagctggct 1560atccgaaaca  
aaactctc agctgggtac acaacaaca gctgcattac aactataac 1620aaagggtatt gtttcatat agtagaaata aatcataaaa  
gctaaacac atttaaccc 1680atgttgttca aacagagat tcaaaaagc tgcagt 1716111716DNAArtificial SequenceSynthetic  
Polynucleotide 11atggaatact ggaagcacac caaccacggc aaggacggc gcaacgagct gaaaccacg 60acagccacac  
acggcaacaa gctgaccaac aagatcacct acatctgtg gaccatcacc 120ctggtgctgc tgagcatcgt gttcatcctc gtgctgacca  
atagcatcaa gagcgaag 180gccagagaga gctgtgca ggacatcaac aacgagtca tggagtgac cgagaagatc 240caggtggcca  
gcaacaac caacgactg atccagagc gctggaac cggtgtgctg 300accatccaga gccactgca gaactacatc ccatcagcc  
tgaccagca gatcagcagc 360ctgaggagt tcatcagcga gatcaccatc cggaacgaca accaggaagt gccccccag 420agaatcacc  
acgactggg catcaagccc ctgaacccc acgatttctg gcggtgtaca 480ageggcctgc ccagcctgat gaagacccc aagatccgce  
tgatgctgg cctggactg 540ctggccatgc ctaccacagt ggatggctgt gtgcggacc ccagcctctg gatcaacgat 600ctgatctacg  
ctacaccag caacctgat acccggggt gccaggatat cggcaagagc 660taccaggtgc tgcagatcgg catcaccac gtgaactccg  
acctggtgcc cgacctgaac 720cctcgatca gccacacctt caacatcaac gacaacagaa agagctgcag cctggctctg 780ctgaacaccg  
acgtgtacca gctgtgcagc accccaagg tggacgagag aagcactac 840gccagcagc gcatcagga tatctgctg gatcctgga  
actacgacgg cagcatcagc 900accaccgggt tcaagaaca caacatcagc ttcgaccagc cctacgccg cctgtacct 960ctgtgggcc  
ctgcatccta ctacaaggc aagatcatct tctgggcta cggcgctg 1020gaacaccca tcaacgagaa cgcctctgc aacaccaccg  
gctgccctg caagaccag 1080agagactgca atcagccag ccacagcccc tggttcagc accgcagaat ggtaactct 1140atcctggtg  
tggacaagg cctgaacagc gtgccaaagc taaaagtgt gacaatcagc 1200atgcgccaga actactgggg cagcagggc agacttctg  
tgctgggaaa caagatctac 1260atctacacc ggtccaccag ctggcacagc aaactgcagc tgggaatcat cgatcacc 1320gactacagc  
acatccgat caagtggacc tggcaaacg tctgagcag accggcaac 1380aatgagtcc ctggggcca cagctcccc gatgatgta  
tcaccggct gtacaccag 1440gcctacccc tgaatctac cgctccatc gtgtccagc tgatcttga cagccagaaa 1500agcagagtga  
accctgat cacatacagc accgccacc agagagtga cgaactggcc 1560atcagaaca agacctgag cgccggctac accaccacaa  
gctgcatc aactacaac 1620aagggtact gttccatc cgtggaate aaccacaagt cctgaacac ctccagccc 1680atgctgttca  
agaccgat cccaagagc tctcc 1716121617DNAArtificial SequenceSynthetic Polynucleotide 12atgccatca  
gcatctgct gatcaccac acaatgatca tggccagcca ctgccagatc 60gatcaccac agctgcagca cgtggcgctg ctctgtaaca  
gccccagg catgaagatc 120agccagaact tgcagacag ctactgatc ctgagcctga tccccaat cgaggacagc 180aacagctgcg  
gcaacagca gatcaagc tacaagcggc tctggacag actgatcct 240ccctgtacg accgctgcg gctgcagaaa gactgatc  
tgaccaaca ggaagcaac 300gagaacacc acccggac cgagagatc ttcggcgcg tgatccgac aatccctg 360ggagtggcca  
caagcgcga gattacagc gctgtggccc tgggtgaagc caagcagcc 420agaagcagca tgcagaagct gaaagagcc atccgggaca  
ccaacaaggc cgtgcagagc 480gtgcagtcca gctgggcaa tctgatcgt gccatcaagt cctgcagga ctactgtaac 540aaagaaatg  
tccctctat cccccgctg gctgtgaag ctgccgact gcagctggc 600attgcctga cacagacta cagcagctg accaacatct  
tcggcgaca catcggcagc 660ctgcagaaa agggcattaa gctgcagga atcggcagc tgcagcag caacatcacc 720gatcttca  
ccaccagcag cgtggataag tacgatct acgactgct gttaccag 780agatcaag tgcgctgat cgactggac ctgaacgat

acagcatcac cctgcaagtg 840cgggtgcccc tgctgaccag actgctgaac accagatct acaagtgga cagcatctcc 900tacaacatcc  
agaaccgca gtggtacatc cctctgcccc gccacattat gaccaagggc 960gcctttctgg gggagccga cgtgaaagag tgcctgagg  
ccttcagcag ctacatctgc 1020cccagcgacc ctggtctctg getgaaccac gagatggaaa gctgcctgag cggcaacatc 1080agccagtgc  
ccagaaccac cgtgacctcc gacatctgc ccagatacgc cttctgtaat 1140ggcggcgtgg tggccaactg catcaccacc acctgtacct  
gcaacggcat cggcaaccgg 1200atcaaccagc ctccgatca gggcgtgaag attatcacc acaagagtg taacaccatc 1260ggcatcaacg  
gcatgctgtt caataccaac aaagagggca ccttgacct ctacaccccc 1320gacgatatca cctgaaaca cctcgtgct ctggaccca  
tcgacatctc catcgagctg 1380aacaaggcca agagcgacct ggaagagtcc aaagagtga tccggcggag caaccagaag  
1440ctggactta tggcagctg gcaccagagc agcaccacca tcatctgat cctgattatg 1500atgattatc tgttcatcat caacattacc  
atcatcacta tggcattaa gtactaccgg 1560atccagaaac ggaaccgggt ggaccagaat gacaagcct acctgctgac aaacaag  
161713539PRTHuman parainfluenza virus 3 13Met Pro Ile Ser Ile Leu Leu Ile Ile Thr Thr Met Ile Met Ala Ser1  
5 10 15His Cys Gln Ile Asp Ile Thr Lys Leu Gln His Val Gly Val Leu Val 20 25 30Asn Ser Pro Lys Gly Met Lys  
Ile Ser Gln Asn Phe Glu Thr Arg Tyr 35 40 45Leu Ile Leu Ser Leu Ile Pro Lys Ile Glu Asp Ser Asn Ser Cys Gly  
50 55 60Asp Gln Gln Ile Lys Gln Tyr Lys Arg Leu Leu Asp Arg Leu Ile Ile65 70 75 80Pro Leu Tyr Asp Gly Leu  
Arg Leu Gln Lys Asp Val Ile Val Thr Asn 85 90 95Gln Glu Ser Asn Glu Asn Thr Asp Pro Arg Thr Glu Arg Phe  
Phe Gly 100 105 110Gly Val Ile Gly Thr Ile Ala Leu Gly Val Ala Thr Ser Ala Gln Ile 115 120 125Thr Ala Ala  
Val Ala Leu Val Glu Ala Lys Gln Ala Arg Ser Asp Ile 130 135 140Glu Lys Leu Lys Glu Ala Ile Arg Asp Thr  
Asn Lys Ala Val Gln Ser145 150 155 160Val Gln Ser Ser Val Gly Asn Leu Ile Val Ala Ile Lys Ser Val Gln 165  
170 175Asp Tyr Val Asn Lys Glu Ile Val Pro Ser Ile Ala Arg Leu Gly Cys 180 185 190Glu Ala Ala Gly Leu Gln  
Leu Gly Ile Ala Leu Thr Gln His Tyr Ser 195 200 205Glu Leu Thr Asn Ile Phe Gly Asp Asn Ile Gly Ser Leu Gln  
Glu Lys 210 215 220Gly Ile Lys Leu Gln Gly Ile Ala Ser Leu Tyr Arg Thr Asn Ile Thr225 230 235 240Glu Ile  
Phe Thr Thr Ser Thr Val Asp Lys Tyr Asp Ile Tyr Asp Leu 245 250 255Leu Phe Thr Glu Ser Ile Lys Val Arg Val  
Ile Asp Val Asp Leu Asn 260 265 270Asp Tyr Ser Ile Thr Leu Gln Val Arg Leu Pro Leu Leu Thr Arg Leu 275  
280 285Leu Asn Thr Gln Ile Tyr Lys Val Asp Ser Ile Ser Tyr Asn Ile Gln 290 295 300Asn Arg Glu Trp Tyr Ile  
Pro Leu Pro Ser His Ile Met Thr Lys Gly305 310 315 320Ala Phe Leu Gly Gly Ala Asp Val Lys Glu Cys Ile Glu  
Ala Phe Ser 325 330 335Ser Tyr Ile Cys Pro Ser Asp Pro Gly Phe Val Leu Asn His Glu Met 340 345 350Glu Ser  
Cys Leu Ser Gly Asn Ile Ser Gln Cys Pro Arg Thr Thr Val 355 360 365Thr Ser Asp Ile Val Pro Arg Tyr Ala Phe  
Val Asn Gly Gly Val Val 370 375 380Ala Asn Cys Ile Thr Thr Thr Cys Thr Cys Asn Gly Ile Gly Asn Arg385  
390 395 400Ile Asn Gln Pro Pro Asp Gln Gly Val Lys Ile Ile Thr His Lys Glu 405 410 415Cys Asn Thr Ile Gly  
Ile Asn Gly Met Leu Phe Asn Thr Asn Lys Glu 420 425 430Gly Thr Leu Ala Phe Tyr Thr Pro Asp Asp Ile Thr  
Leu Asn Asn Ser 435 440 445Val Ala Leu Asp Pro Ile Asp Ile Ser Ile Glu Leu Asn Lys Ala Lys 450 455 460Ser  
Asp Leu Glu Glu Ser Lys Glu Trp Ile Arg Arg Ser Asn Gln Lys465 470 475 480Leu Asp Ser Ile Gly Ser Trp His  
Gln Ser Ser Thr Thr Ile Ile Val 485 490 495Ile Leu Ile Met

Met Ile Ile Leu Phe Ile Ile Asn Ile Thr Ile Ile 500 505 510Thr Ile Ala Ile Lys Tyr Tyr Arg Ile Gln Lys Arg Asn  
Arg Val Asp 515 520 525Gln Asn Asp Lys Pro Tyr Val Leu Thr Asn Lys 530 53514572PRTHuman  
parainfluenza virus 3 14Met Glu Tyr Trp Lys His Thr Asn His Gly Lys Asp Ala Gly Asn Glu1 5 10 15Leu Glu  
Thr Ser Thr Ala Thr His Gly Asn Lys Leu Thr Asn Lys Ile 20 25 30Thr Tyr Ile Leu Trp Thr Ile Thr Leu Val Leu  
Leu Ser Ile Val Phe 35 40 45Ile Ile Val Leu Thr Asn Ser Ile Lys Ser Glu Lys Ala Arg Glu Ser 50 55 60Leu Leu  
Gln Asp Ile Asn Asn Glu Phe Met Glu Val Thr Glu Lys Ile65 70 75 80Gln Val Ala Ser Asp Asn Thr Asn Asp  
Leu Ile Gln Ser Gly Val Asn 85 90 95Thr Arg Leu Leu Thr Ile Gln Ser His Val Gln Asn Tyr Ile Pro Ile 100 105  
110Ser Leu Thr Gln Gln Ile Ser Asp Leu Arg Lys Phe Ile Ser Glu Ile 115 120 125Thr Ile Arg Asn Asp Asn Gln  
Glu Val Pro Pro Gln Arg Ile Thr His 130 135 140Asp Val Gly Ile Lys Pro Leu Asn Pro Asp Asp Phe Trp Arg  
Cys Thr145 150 155 160Ser Gly Leu Pro Ser Leu Met Lys Thr Pro Lys Ile Arg Leu Met Pro 165 170 175Gly  
Pro Gly Leu Leu Ala Met Pro Thr Thr Val Asp Gly Cys Val Arg 180 185 190Thr Pro Ser Leu Val Ile Asn Asp  
Leu Ile Tyr Ala Tyr Thr Ser Asn 195 200 205Leu Ile Thr Arg Gly Cys Gln Asp Ile Gly Lys Ser Tyr Gln Val Leu  
210 215 220Gln Ile Gly Ile Ile Thr Val Asn Ser Asp Leu Val Pro Asp Leu Asn225 230 235 240Pro Arg Ile Ser  
His Thr Phe Asn Ile Asn Asp Asn Arg Lys Ser Cys 245 250 255Ser Leu Ala Leu Leu Asn Thr Asp Val Tyr Gln  
Leu Cys Ser Thr Pro 260 265 270Lys Val Asp Glu Arg Ser Asp Tyr Ala Ser Ser Gly Ile Glu Asp Ile 275 280  
285Val Leu Asp Ile Val Asn Tyr Asp Gly Ser Ile Ser Thr Thr Arg Phe 290 295 300Lys Asn Asn Asn Ile Ser Phe  
Asp Gln Pro Tyr Ala Ala Leu Tyr Pro305 310 315 320Ser Val Gly Pro Gly Ile Tyr Tyr Lys Gly Lys Ile Ile Phe  
Leu Gly 325 330 335Tyr Gly Gly Leu Glu His Pro Ile Asn Glu Asn Ala Ile Cys Asn Thr 340 345 350Thr Gly  
Cys Pro Gly Lys Thr Gln Arg Asp Cys Asn Gln Ala Ser His 355 360 365Ser Pro Trp Phe Ser Asp Arg Arg Met  
Val Asn Ser Ile Ile Val Val 370 375 380Asp Lys Gly Leu Asn Ser Val Pro Lys Leu Lys Val Trp Thr Ile Ser385  
390 395 400Met Arg Gln Asn Tyr Trp Gly Ser Glu Gly Arg Leu Leu Leu Leu Gly 405 410 415Asn Lys Ile Tyr

Ile Tyr Thr Arg Ser Thr Ser Trp His Ser Lys Leu 420 425 430Gln Leu Gly Ile Ile Asp Ile Thr Asp Tyr Ser Asp  
Ile Arg Ile Lys 435 440 445Trp Thr Trp His Asn Val Leu Ser Arg Pro Gly Asn Asn Glu Cys Pro 450 455 460Trp  
Gly His Ser Cys Pro Asp Gly Cys Ile Thr Gly Val Tyr Thr Asp465 470 475 480Ala Tyr Pro Leu Asn Pro Thr  
Gly Ser Ile Val Ser Ser Val Ile Leu 485 490 495Asp Ser Gln Lys Ser Arg Val Asn Pro Val Ile Thr Tyr Ser Thr  
Ala 500 505 510Thr Glu Arg Val Asn Glu Leu Ala Ile Arg Asn Lys Thr Leu Ser Ala 515 520 525Gly Tyr Thr  
Thr Thr Ser Cys Ile Thr His Tyr Asn Lys Gly Tyr Cys 530 535 540Phe His Ile Val Glu Ile Asn His Lys Ser Leu  
Asn Thr Phe Gln Pro545 550 555 560Met Leu Phe Lys Thr Glu Ile Pro Lys Ser Cys Ser 565  
5701520PRTArtificial SequenceSynthetic Polypeptide 15Met Glu Thr Pro Ala Gln Leu Leu Phe Leu Leu Leu  
Leu Trp Leu Pro1 5 10 15Asp Thr Thr Gly 201618PRTArtificial SequenceSynthetic Polypeptide 16Met Asp Trp  
Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val1 5 10 15His Ser1724PRTArtificial SequenceSynthetic  
Polypeptide 17Met Leu Gly Ser Asn Ser Gly Gln Arg Val Val Phe Thr Ile Leu Leu1 5 10 15Leu Leu Val Ala Pro  
Ala Tyr Ser 201817PRTArtificial SequenceSynthetic Polypeptide 18Met Lys Cys Leu Leu Tyr Leu Ala Phe Leu  
Phe Ile Gly Val Asn Cys1 5 10 15Ala1915PRTArtificial SequenceSynthetic Polypeptide 19Met Trp Leu Val Ser  
Leu Ala Ile Val Thr Ala Cys Ala Gly Ala1 5 10 15204062DNAMiddle East respiratory syndrome coronavirus  
20atgatacact cagtgttct actgatgttc ttgtaaacac ctacagaaag ttacgttgat 60gtaggccag attctgttaa gctcgttgt attgaggtg  
atatacaaca gacctcttt 120gataaaactt ggctaggcc aattgatgtt tctaaggctg acggtattat atacctcaa 180ggccgtacat  
attctaacat aactatact tatcaaggc ttttcccta tcaggagac 240catggtgata tgtatgttta ctctgcagga catgtacag gcaaacctc  
acaaaagtg 300ttttagcta actatttca ggacgtcaaa cagtttctca atgggttctg ctctcgata 360ggagcagctg ccaattccac  
tgccactgtt attattagcc catctaccag cgctactata 420cgaaaaattt accctgcttt tatgctgggt tcttcagttg gtaatttctc agatggtaa  
480atgggcccgt tcttcaatca tactctagtt ctttgcctg atggatgtgg cactttact 540agagctttt attgtattct agagcctcgc tctggaatc  
attgtcctgc tggcaattcc 600tatacttct ttgccactta tcacactct gcaacagatt gttctgatgg caattacaat 660cgtaatgcca gctgaactc  
tttaaggag tatttaatt tacgtaactg cactttatg 720tacactata acattaccga agatgagatt ttagagtgtt ttggcattac acaactgct  
780caaggtgttc accttctc atctcggtat gttgattgt acggcgcaa tatgttcaa 840tttgccact tgcctgttta tgatactatt aagtattat  
ctatcattcc tcacagtatt 900cgttctatcc aaagtgatag aaaagcttgg gctgccttct acgtataaa actcaaccg 960ttaactttcc tgttgatt  
ttctgttgat ggttatatac gcagagctat agactgtgt 1020tttaagtatt tgcacaact cactgctca tatgaatct tcgatgttga atctggagt  
1080tattcagtt cgtcttctga agcaaaacct tctggctcag ttgtggaaca ggctgaagt 1140gttgaatgtg attttcacc tctctgtct  
ggcacacctc ctcaggttta taattcaag 1200cgtttgttt ttaccaattg caattataat ctaccacaaat tctttcact ttttctgtg 1260aatgattta  
ctttagtca aatatctcca gcagcaattg ctagcaactg ttattctca 1320ctgattttgg attattttc ataccactt agtatgaaat cegatctcag  
tgttagttct 1380gctgttccaa tatccagtt taattataaa cagtccttt ctaatccac atgtttgatc 1440ttagcgactg ttctcataa ccttactact  
attactaagc ctcttaagta cagctatatt 1500aacaagtgtc ctctcttct ttctgatgat cgtactgaag tacctcagtt agtgaacgt  
1560aatcaact caccctgtgt atccattgtc ccatccactg tgtgggaaga cggtgattat 1620tataggaaac aactatctcc acttgaaggt  
ggtgctgctg tttgtctag tggctcaact 1680gttccatga ctgagcaatt acagatgggc ttggatta cagttcaata tggtagac  
1740accaatagtg tttgcccga gttgaattt gtaatgaca caaaaattgc ctctcaatta 1800ggcaattgct tggaaattc cctctatggt  
gtttcgggcc gtggtgttt tcagaattgc 1860acagctgtag gtgttcgaca gcagccttt gtttatgatg cgtaccagaa ttagttggc  
1920tattattctg atgatggcaa ctactactgt ctgcgtgctt gtgttagtgt tctgtttct 1980gtcatctatg ataaagaac taaaccac  
gctactctat ttgtagtgt tgcattgtaa 2040cacatttct ctaccatgtc tcaatactcc cgttctacgc gatcaatgt taaacggcga  
2100gattctacat atggccccct tcagacacct gttggtgtg tctaggact ttttaattcc 2160ctttgtctg tagaggactg caagttgct  
ctcggtaat ctctctgtgc tctctctgac 2220acacctagta ctctcacacc tgcagtggtg cgctctgtgc caggtgaaat gcgcttggca  
2280ccattgctt ttaatctcc cattcagtt gatcaactta atagtagtta ttttaatta 2340agtataccca ctaattttc ctttgggtg actcaggagt  
acattcagac aaccattcag 2400aaagtactg ttgattgtaa acagtactgt tgcaatggtt tcagaagtg tgagcaatta 2460ctgcgcgagt  
atggccagtt ttgtccaaa ataaaccagg ctctccatgg tgccaattta 2520cgccaggatg atctgtacg taattgttt gcgagcgtga aaagctctca  
atcatctct 2580atcataccag gttttggagg tgactttaa ttgacactc tagaacctgt ttctatatct 2640actggcagtc gtagtgacg  
tagtgctatt gaggattgct tatttgaaa agtcactata 2700gctgatctct gttatatgca aggttacgat gattgtatgc agcaaggctc agcatcagct  
2760cgtgatctta tttgtctca atagtggct ggttataag tattactcc tttatggat 2820gttaatatgg aagccgcgta tacttcatct  
ttgcttggca gcatagcagg ttttgctg 2880actgctgctt tctctctt tctgtctatt ccattgcac agagtatytt ttataggtta  
2940aacggtgttg gcattactca acaggttctt tcagagaacc aaaagcttat tgccaataag 3000tttaatcagg ctctgggagc tatgcaaca  
ggcttcaact caactaatga agctttcgg 3060aaggttcagg atgctgtgaa caaatgca caggtctat ccaattagc tagcgagct  
3120tctaactt ttgtgctat tccgctct attggagaca tcatacaacg tctgtatgt 3180ctcgaacagg acgcccacaa agacagact  
attaatggcc gtttgacaac actaaatgt 3240tttggcagc agcagctgt tcttccgaa tcagctctc tttccgctca attggctaaa  
3300gataaagtca atgagtgtgt caaggcaaa tccaagegtt ctggattttg cgttcaaggc 3360acacatatag tctctttgtg ttaaatgcc  
cctaattggcc ttactttat gcatgttgg 3420tattacccta gcaaccacat tgaggttgtt tctgcttatg gcttttgcga tgcagctaac  
3480cctactaatt gtagagccc ttttaattgg tactttata aaactaataa cactaggatt 3540gtttagtgat ggtcatatac tggctcgtcc  
ttctatgcac ctgagccat cactctctt 3600aactaactag atgttgcacc acaggtgaca taccaaaaca tttctactaa cctccctct  
3660cctctctctg gcaattccac cgggattgac ttcaagatg agttggatga gttttcaaa 3720aatgttagca ccagtatacc taattttgt

tcttaacac agattaatac tacattactc 3780gatcttacct acgagatggt gctcttcaa caagttgta aagcccttaa tgagtctac  
3840atagacctta aagagcttgg caattatact tattacaaca aatggccgtg gtacatttgg 3900cttggttca ttgctgggct tgtgcctta  
gctctatgcg tcttctcat actgtgctgc 3960actgggtgtg gcacaaactg tatgggaaaa ctaagtgt atcgttgtg tgatagatac  
4020gaggaatacg acctcgagcc gcataaggt catgttcaact aa 4062214062DNAArtificial SequenceSynthetic  
Polynucleotide 21atgatacact cagtgtttct actgatgttc ttgtaaacac ctacagaaag ttacgttgat 60gtagggccag attctgttaa  
gtctgcttgt attgaggtg atatacaaca gactttctt 120gataaaactt ggcctaggcc aattgatgt tctaaggctg acggtattat atacctcaa  
180ggccgtacat attctaacat aactatact tacaaggtc ttttcctta tcaggagac 240catggtgata tgatgttta ctctgcagga  
catgctacag gcacaactcc aaaaagtgt 300ttttagtca actattctca ggacgtcaaa cagtttgta atgggttgt cgtccgtata  
360ggagcagctg ccaattccac tggcactgtt attattagcc catctaccag cgtactata 420cgaaaaattt acctgcttt tatgctgggt  
tcttcagttg gtaattctc agatggtaaa 480atgggcccgt tctcaatca tacttagtt ctttggccc atggatgtg cactttact 540agagctttt  
attgtattct ggagcctcgc tctggaaatc attgtcctgc tggcaattcc 600tatactctt ttgccactta tcacactcct gcaacagatt gtctgatgg  
caattacaat 660cgtaatgcca gtctgaactc tttaaggag tatttaatt tacgtaactg cacctttatg 720tacacttata acattaccga agatgagatt  
ttagatgggt ttggcattac acaaactgct 780caaggtgtc acctctctc atctcggtat gttgattgt acggcggcaa tatgttcaa 840tttggcact  
tgctgttta tgatactatt aagtattat ctatctcc tcacagtatt 900cgttctatcc aaagtatag aaaagcttgg gctgcctct acgtataaa  
actcaaccg 960ttaactttc tgttgattt tctgttga gttatatac gcagagctat agactgtgtg 1020ttaatgatt tgcacaact cactgctca  
tatgaatcct tcgatgtga atctggagtt 1080tattcagtt cgtcttctga agcaaaacct tctggctcag ttgtggaaca ggctgaaggt  
1140gttgaatgtg attttccacc tctctgtct ggacacctc ctcaagttta taattcaag 1200cgttgggtt ttaccaattg caattataat ctaccaaat  
tgcttctact ttttctgtg 1260aatgatttta ctgtagtc aatatctca gcagcaattg ctageaactg ttattctca 1320ctgattttgg attactttc  
ataccactt agtatgaaat ccgatctcag tgttagttct 1380gctggtccaa taccactt taattataaa cagtccttt ctaatccac atgttgatt  
1440ttagcagctg ttctcataa cttactact attactaagc ctcttaagta cagctatatt 1500aacaagtgt cctgctctct tctgatgat  
cgtactgaag tacctcagtt agtgaacgt 1560aatcaatact cacctgtgt atccattgc ccatccactg tgtggaaga cggtgattat  
1620tataggaac aactatctc acttgaaggt ggtgctgctg ttgttctag ttgctcaact 1680gttccatga ctgagcaatt acagatgggc  
tttggtatta cagttcaata tggtagacac 1740accaatagt tttgcccaca gcttgaatt gctaagaca caaaaattgc ctctcaata  
1800ggcaattgc tggaaatct cctctatgtt gttcggggc gtggtgttt tcagaattgc 1860acagctgtag gtgttcgaca gcagcgtt  
gtttatgatg cgtaccagaa tttagttggc 1920tattattctg atgatggcaa ctactactgt ttgcgtgctt gtgttagtgt tctgtttct 1980gtcatctatg  
ataaagaac taaaaccac gctactctat ttgtagtgt tgcagtgtga 2040cacattctt ctaccatgc tcaatactc cgttctacgc gatcaatgt  
taaacggcga 2100gattctacat atggccccct tcagacacct gttggtgtg tcttaggact tgttaattcc 2160tcttgttcg tagaggactg  
caagttgctt cttggtcaat ctctctgtgc tcttctgac 2220acacctagta ctctcacacc tcgacgtgtg cgtctgttc cagtgaaat gcgcttgcca  
2280tcattgctt ttaatctcc tattcaggtt gatcaacta atagtagtta tttaaaatta 2340agtatacca ctaattttc ctttgggtg actcaggagt  
acattcagac aaccattcag 2400aaagttactg ttgattgta acagtactgt tgcaatggt tccagaagtg tgagcaatta 2460ctgcgcgagt  
atggccagtt ttgtccaaa ataaaccag cctccatgg tgccaattta 2520cgccaggatg attctgtacg taattgttt gcgagcgtga aaagctctca  
atcatctct 2580atcataccag gtttggagg tgacttfaat ttgacactc tggaaactgt tctatattct 2640actggcagtc gtagtgcacg  
tagtctatt gaggattgc tatttgaca agtcactata 2700gctgatcctg gttatagca aggttacgat gattgcacg agcaaggtcc agcatcagct  
2760cgtgatctta tttgtctca atatgtggt gttacaaaag tattacctc tctatggat 2820gttaatatgg aagcccgcta tacttcatc  
ttgcttgcca gcatagcagg tttggtgctg 2880actgctggt tctctctt tctgctatt ccaattgcac agagtatctt ttataggta  
2940aacggtgtg gcattactca acagttctt tcagagaacc aaaagcttat tgccaataag 3000ttaatcagg ctctgggagc tatgcaaca  
ggcttacta caactaatga agctttcag 3060aaggttcagg atctgtgaa caaatgca caggtctat ccaattagc tagcgagcta  
3120tctaactt ttgtgctat ttccgctct attggagaca tcatacaacg tcttgatgt 3180ctcgaacagg acgcccacat agacagact  
attaatggcc gttgacaac actaaatgt 3240tttgtgcac agcagctgt tcttccga tcagctgctc ttccgctca attgctaaa  
3300gataaagtca atgagtgtg caaggcaca tccaagctt ctggatttg cgtcaaggc 3360acacatatag tctctttgt tgtaaatgcc  
cctaatggcc ttacttcat gcatgttgg 3420tattaccct gcaaccacat ttgaggtgt tctgcttatg gtctttgca tgcagctaac  
3480cctactaatt gtagagccc tgtaatggc tactttata aactaataa cactaggatt 3540gttgatgagt ggtcatatac ttgctcgtcc  
ttctatgcac ctgagccat tacctcctt 3600aactaactg atgtgcacc acagtgaca taccacaaa ttctactaa cctcctct  
3660cctctctc gcaattccac cgggattgac ttcaagatg agttggatga gttttcaaa 3720aatgttagca ccagtatacc taatttgg  
tcctaacac agattaatac tacattactc 3780gatcttacct acgagatggt gctcttcaa caagttgta aagcccttaa tgagtctac  
3840atagacctta aagagcttgg caattatact tattacaaca aatggccgtg gtacatttgg 3900cttggttca ttgctgggct tgtgcctta  
gctctatgcg tcttctcat actgtgctgc 3960actgggtgtg gcacaaactg tatgggaaaa ctaagtgt atcgttgtg tgatagatac  
4020gaggaatacg acctcgagcc gcataaggt catgttcaact aa 4062221845DNAArtificial SequenceSynthetic  
Polynucleotide 22atgatccact cgtgttct cctcatgtc ctgtgacc cactgagtc agactgcaag 60ctcccgtgg gacagtcct  
gtgtgcgtg cctgacactc ctgactct gaccccagc 120ctcgtgctg cgtgctctg cgaaatggc ctggcctca tgccttcaa  
tcaccaatc 180caagtggatc agctgaatg cctgtattc aagctgcca tccccagaa cttctgctc 240ggggtcacc aggagatcat  
ccagaccaca atcagaagg tcaccgtca ttgcaagcaa 300tacgtgtgca acggttcca gaagtgcgag cagctgctga gagaatcgg  
gcagtttgc 360agcaagatca accagcgtc gcatggagct aactgcgcc aggacgactc cgtgcgcaac 420ctcttgct cgtgaaagt  
atcccagtc tcccacata tcccgggatt cggaggggac 480ttcaacctga cctctctgga gccctgtctg atcagaccg gtagcagatc

ggcgcgctca 540gccattgaag atcttctgtt cgacaaggtc accatgccc atccgggcta catgcaggga 600tacgacgact gtatgcagca  
gggaccagcc tccgcgaggg acctcatctg cgcgcaatac 660gtggccgggt acaaagtct gcctcctctg atggatgtga acatggagge  
cgcttatact 720tcgtccctgc tccgctctat cgcggcgtg ggggtggaccg ccggcctgtc ctctctgcc 780gctatccct ttgcacaatc  
cattttctac cggctcaac gcgtgggcat tactcaaca 840gtcctgtcgg agaaccagaa gttgatcgca aacaagtca atcaggccct  
gggggcatg 900cagactgat tcaactacg taacgaagc ttccagaag tccaggacgc tgtgaacaac 960aacgcccagg cgctctcaaa  
gctggcctcc gaactcagca acacctcgg agccatcagc 1020gcatcgtg gtagacataat tcagcggctg gacgtgctgg agcaggacgc  
ccagatcgac 1080cgcctcatca acggacggct gaccacctg aatgccttcg tggcacaaca gctgtccgg 1140agegaatcag cggcacttc  
cgcccaactc gccaaaggaca aagtcaacga atgcgtgaag 1200gcccagcca agaggtccgg tttctgcggt caaggaacc atattgtgc  
ctctcgtg 1260aacgcgcca acggctgtg ctttatgcac gtcggctact acccgagca tcatatcga 1320gtggtgccc cctacggcct  
gtgcgatcc gtaaccca ctaactgtat tgcctctg 1380aacggatatt ttattaagac caacaacacc cgattgtgg acgaatggtc  
atacaccggt 1440tcgtcctct acgcgccga gccatcact tcaactgaaca ccaatacgt ggctccgca 1500gtgacctacc agaactctc  
cacaattg ccgcccgcgc tgcctggaaa cagcaccgga 1560attgattcc aagatgaact ggacgaattc tcaagaac tgtccactc  
cattccaac 1620ttcgggaagc tgacacagat caacaccacc ctctcgacc tgacctcga gatgctgagc 1680ctcaacaag tggtaagc  
cctgaacgag agctacatc acctgaagga gctgggcaac 1740tatactact acaacaagt gcccggacaag attgaggaga ttctgtcga  
aatctaccac 1800attgaaaac agatcgccag aatcaagaag ctatcggcg aagcc 1845234071DNAArtificial  
SequenceSynthetic Polynucleotide 23atggaaacc ctgccagct gctgttctg ctgctgctg ggctgctga taccaccgc  
60agctatgtg acgtggccc cgatagcgtg aagtcgcct gtaggaagt ggacatccag 120cagaccttt tcgacaagac ctggcccaga  
cccacgacg tgcacaagc cgacggcacc 180atctatccac aaggccggac ctacagcaac ataccatta cctaccaggc cctgttcca  
240tatcaaggcg accacggcga tatgtactg tactctgcg gccacgccac cggcaccaca 300cccagaaac

tgtctgtggc caactacagc caggacgtga agcagttgc caacggctc 360gtcgtgaggga ttggcgcgc tgccaatagc accggcacg  
tgatcatcag cccagcacc 420agegccacca tccggaagat ctaccgcc tctatgctgg gcagctccgt gggcaattc 480agcagcggca  
agatgggccc gttctcaac cacacctgg tctgctgccc cgatggctg 540ggcacactgc tgagaccct ctactgac ctggaacca  
gaagcggca cactgcct 600gcccgaata gtagaccag ctccgccacc taccacac ccgcccaga ttgtccgac 660ggcaactaca  
accggaacgc cagctgaac agctcaaac agtactcaa cctcgggaa 720tgacctca tgacaccta caatcacc gaggacgaga  
tctggaatg gttcggcacc 780accagaccg ccaggcgtg gcacctg agcagcagat acgtggacct gtagggcggc 840aacatgttc  
agttgccac cctgcccgtg tagcacca tcaagtact cagcatc 900ccccacagca tccggtccat ccagagcagc agaaagcct  
ggcgcgctt ctactgtac 960aagctcagc cctgacct cctgctggac ttagcgtgg accgctacat cagacggcc 1020atcactgctg  
gctcaacga cctgagccag ctgactgct cctacgagag ctccgacgtg 1080gaaagcggc ttagacagc gttcagctt gaggccaagc  
ctagcggcag cgtggtgga 1140caggctgagg gcgtggaat gcactcagc cctctgctga gggcacc cccaggtg 1200tacaactca  
agcggctggt gttaccaac tgcaattaca acctgacca gctgctgagc 1260ctgttctcc gtagcactt cactgtagc cagatcagc  
ctggcccat tgccagcaac 1320tgctacagca gctgatct ggactctt agtaccccc tgagatgaa gtcgatctg 1380agcgtgctt  
ccgcccagc catcagccag tcaactaca agcagactt cagcaacct 1440acctgctga ttctggccac cgtgcccac aatctgacca  
ccatcaccac gccctgag 1500tacagctaca tcaacaagt cagcagact ctgcccagc accggaccga agtccccag 1560ctctgaaac  
ccaaccagta cagcccctgc gttccatc tgcccagc cgtgtgggag 1620gacggcgact actacagaaa gcagctgagc ccctggaag  
gcccgggat gctggtggct 1680tctggaagca cagtggccat gaccgagcag ctgcagatgg gctttggcat caccgtgag 1740tacggcaccg  
acaccaacag cgtgtgccc aagctggaat tcccaatga cacaagatc 1800gcccagcagc tgggaaact cgtggaatc tctctgatg  
gcgtgtccg acggggcgtg 1860ttcagaat gcacagcagc gggagtgagg cagcagatg tctgtacg tgcctaccag 1920aacctcgtg  
gctactacag cgacagcgc aattactact gctcggggc ctgtgtgccc 1980gtgcccgtg cctgatcta cgacaagag acaagacc  
acgccact gttcgctcc 2040gtgcccgtgc agcatcag ctccacct agccagct cccgtccac ccggtccatg 2100ctgaaagcga  
gagatagc ctacggccc ctgcagac ctgtgggatg tgtgtgggc 2160ctctgaaac gctcctgtt tgggaagat tgaagctgc  
cctgggcca gagctgtg 2220gcccgtccag ataccctag caccctgacc cctagaagc tgcgtctgt gcccggcga 2280atcggctg  
cctctatgc ctcaatcacc ccatccagc tggaccagc gaactcagc 2340tactcaagc tgagatccc cacaactt agctcgggc  
tgaccagga gtacatccag 2400accacaatc agaaagtgc cgtgactgc aagcagtag tgtgcaacgg ctccagaag 2460tgcaacagc  
tctcgcgca gtacggccag ttctgagca agatcaaca gcccctgac 2520ggcgaacc tgagacagga tgacagcgt cggaacctg  
tcccagcgt gaaaagcagc 2580cagtcagcc ccatcacc tggctcggc ggcactta acctgacct gctggaacct 2640gttccatc  
gcaccgctc cagaagcgc agatccgca ttaggacct gctgtgac 2700aaagtgaaca ttgcccacc cggctacat cagggtacg  
acgattgat gcagcagggc 2760ccagccagc ccaggatct gatctgtccc cagtatggt ccggtaca ggtgctccc 2820cccctgatgg  
acgtgaacat ggaagccc tacacctca gctgctggg ctctattgt 2880ggcgtgggag ggacagccg cctgtctagc ttgcccga  
tcccttgc ccagacatc 2940ttctaccggc tgaacggcgt gggcatcaca caacaggtg tgagcagaa ccagaagctg 3000atcgcaca  
agttaacca ggcactggc gccatcaga cggcttcc caccaccaac 3060gaggcctca gaaagtgca ggaccccgtg acaacaac  
cccagctct gagcaagctg 3120gctccgagc tgagcaatac ctccggccc atcagcct ccatcggcga catcatccag 3180cggctggagc  
tctggaaca ggaccccag atcagccgc ttagcaacgg cagactgacc 3240acctgaac cctcgtggc acagcagct gtcggagc  
aatctccgc tctgtctg 3300cagctggcca aggacaaagt gaacagctg gtgaagccc agtcaagc gagcggctt 3360tggccagc

gcaccacat cgtgtccttc gtcgtgaatg cccccaacgg cctgtacttt 3420atgcacgtgg gtattacc cagcaaccac atcgaggtgg  
tgtccgceta tggcctgtgc 3480gacgccgcca atctaccaaa ctgtatcgcc cccgtgaacg gtacttcat caagaccaac 3540aacaccggga  
tcgtggacga gtggctctac acaggcagca gttctacgc ccccgagccc 3600atcacctccc tgaacacaaa atacgtggcc ccccaagta  
cataccagaa catctccacc 3660aacctgcccc ctccactgt gggaaattcc accggcatcg acttccagga cgagctggac 3720gagttctca  
agaacgtgc cacctccatc cccaacttgc gcagcctgac ccagatcaac 3780accactctgc tggacctgac ctacgagatg ctgtcctgc  
aacaggtcgt gaaagccctg 3840aacgagagct acatcgacct gaaagagctg gggaactaca cctactacaa caagtggcct 3900tggctacatt  
ggctgggctt tatcgccggc ctggtggccc tggcctgtg cgtgttcttc 3960atcctgtgct gcaccggctg cggcaccaat tgcattggga  
agctgaaatg caaccggtgc 4020tgcgacagat acgaggaata cgacctgga cctcaciaag tgcattgtgca c 4071241353PRTMiddle  
East respiratory syndrome coronavirus 24Met Ile His Ser Val Phe Leu Leu Met Phe Leu Leu Thr Pro Thr Glu1 5  
10 15Ser Tyr Val Asp Val Gly Pro Asp Ser Val Lys Ser Ala Cys Ile Glu 20 25 30Val Asp Ile Gln Gln Thr Phe  
Phe Asp Lys Thr Trp Pro Arg Pro Ile 35 40 45Asp Val Ser Lys Ala Asp Gly Ile Ile Tyr Pro Gln Gly Arg Thr Tyr  
50 55 60Ser Asn Ile Thr Ile Thr Tyr Gln Gly Leu Phe Pro Tyr Gln Gly Asp65 70 75 80His Gly Asp Met Tyr Val  
Tyr Ser Ala Gly His Ala Thr Gly Thr Thr 85 90 95Pro Gln Lys Leu Phe Val Ala Asn Tyr Ser Gln Asp Val Lys  
Gln Phe 100 105 110Ala Asn Gly Phe Val Val Arg Ile Gly Ala Ala Ala Asn Ser Thr Gly 115 120 125Thr Val Ile  
Ile Ser Pro Ser Thr Ser Ala Thr Ile Arg Lys Ile Tyr 130 135 140Pro Ala Phe Met Leu Gly Ser Ser Val Gly Asn  
Phe Ser Asp Gly Lys145 150 155 160Met Gly Arg Phe Phe Asn His Thr Leu Val Leu Leu Pro Asp Gly Cys 165  
170 175Gly Thr Leu Leu Arg Ala Phe Tyr Cys Ile Leu Glu Pro Arg Ser Gly 180 185 190Asn His Cys Pro Ala  
Gly Asn Ser Tyr Thr Ser Phe Ala Thr Tyr His 195 200 205Thr Pro Ala Thr Asp Cys Ser Asp Gly Asn Tyr Asn  
Arg Asn Ala Ser 210 215 220Leu Asn Ser Phe Lys Glu Tyr Phe Asn Leu Arg Asn Cys Thr Phe Met225 230 235  
240Tyr Thr Tyr Asn Ile Thr Glu Asp Glu Ile Leu Glu Trp Phe Gly Ile 245 250 255Thr Gln Thr Ala Gln Gly Val  
His Leu Phe Ser Ser Arg Tyr Val Asp 260 265 270Leu Tyr Gly Gly Asn Met Phe Gln Phe Ala Thr Leu Pro Val  
Tyr Asp 275 280 285Thr Ile Lys Tyr Tyr Ser Ile Ile Pro His Ser Ile Arg Ser Ile Gln 290 295 300Ser Asp Arg Lys  
Ala Trp Ala Ala Phe Tyr Val Tyr Lys Leu Gln Pro305 310 315 320Leu Thr Phe Leu Leu Asp Phe Ser Val Asp  
Gly Tyr Ile Arg Arg Ala 325 330 335Ile Asp Cys Gly Phe Asn Asp Leu Ser Gln Leu His Cys Ser Tyr Glu 340  
345 350Ser Phe Asp Val Glu Ser Gly Val Tyr Ser Val Ser Ser Phe Glu Ala 355 360 365Lys Pro Ser Gly Ser Val  
Val Glu Gln Ala Glu Gly Val Glu Cys Asp 370 375 380Phe Ser Pro Leu Leu Ser Gly Thr Pro Pro Gln Val Tyr  
Asn Phe Lys385 390 395 400Arg Leu Val Phe Thr Asn Cys Asn Tyr Asn Leu Thr Lys Leu Leu Ser 405 410  
415Leu Phe Ser Val Asn Asp Phe Thr Cys Ser Gln Ile Ser Pro Ala Ala 420 425 430Ile Ala Ser Asn Cys Tyr Ser  
Ser Leu Ile Leu Asp Tyr Phe Ser Tyr 435 440 445Pro Leu Ser Met Lys Ser Asp Leu Ser Val Ser Ser Ala Gly Pro  
Ile 450 455 460Ser Gln Phe Asn Tyr Lys Gln Ser Phe Ser Asn Pro Thr Cys Leu Ile465 470 475 480Leu Ala Thr  
Val Pro His Asn Leu Thr Thr Ile Thr Lys Pro Leu Lys 485 490 495Tyr Ser Tyr Ile Asn Lys Cys Ser Arg Leu Leu  
Ser Asp Asp Arg Thr 500 505 510Glu Val Pro Gln Leu Val Asn Ala Asn Gln Tyr Ser Pro Cys Val Ser 515 520  
525Ile Val Pro Ser Thr Val Trp Glu Asp Gly Asp Tyr Tyr Arg Lys Gln 530 535 540Leu Ser Pro Leu Glu Gly Gly  
Gly Trp Leu Val Ala Ser Gly Ser Thr545 550 555 560Val Ala Met Thr Glu Gln Leu Gln Met Gly Phe Gly Ile  
Thr Val Gln 565 570 575Tyr Gly Thr Asp Thr Asn Ser Val Cys Pro Lys Leu Glu Phe Ala Asn 580 585 590Asp  
Thr Lys Ile Ala Ser Gln Leu Gly Asn Cys Val Glu Tyr Ser Leu 595 600 605Tyr Gly Val Ser Gly Arg Gly Val Phe  
Gln Asn Cys Thr Ala Val Gly 610 615 620Val Arg Gln Gln Arg Phe Val Tyr Asp Ala Tyr Gln Asn Leu Val  
Gly625 630 635 640Tyr Tyr Ser Asp Asp Gly Asn Tyr Tyr Cys Leu Arg Ala Cys Val Ser 645 650 655Val Pro  
Val Ser Val Ile Tyr Asp Lys Glu Thr Lys Thr His Ala Thr 660 665 670Leu Phe Gly Ser Val Ala Cys Glu His Ile  
Ser Ser Thr Met Ser Gln 675 680 685Tyr Ser Arg Ser Thr Arg Ser Met Leu Lys Arg Arg Asp Ser Thr Tyr 690  
695 700Gly Pro Leu Gln Thr Pro Val Gly Cys Val Leu Gly Leu Val Asn Ser705 710 715 720Ser Leu Phe Val  
Glu Asp Cys Lys Leu Pro Leu Gly Gln Ser Leu Cys 725 730 735Ala Leu Pro Asp Thr Pro Ser Thr Leu Thr Pro  
Arg Ser Val Arg Ser 740 745 750Val Pro Gly Glu Met Arg Leu Ala Ser Ile Ala Phe Asn His Pro Ile 755 760  
765Gln Val Asp Gln Leu Asn Ser Ser Tyr Phe Lys Leu Ser Ile Pro Thr 770 775 780Asn Phe Ser Phe Gly Val Thr  
Gln Glu Tyr Ile Gln Thr Thr Ile Gln785 790 795 800Lys Val Thr Val Asp Cys Lys Gln Tyr Val Cys Asn Gly Phe  
Gln Lys 805 810 815Cys Glu Gln Leu Leu Arg Glu Tyr Gly Gln Phe Cys Ser Lys Ile Asn 820 825 830Gln Ala  
Leu His Gly Ala Asn Leu Arg Gln Asp Asp Ser Val Arg Asn 835 840 845Leu Phe Ala Ser Val Lys Ser Ser Gln  
Ser Ser Pro Ile Ile Pro Gly 850 855 860Phe Gly Gly Asp Phe Asn Leu Thr Leu Leu Glu Pro Val Ser Ile Ser865  
870 875 880Thr Gly Ser Arg Ser Ala Arg Ser Ala Ile Glu Asp Leu Leu Phe Asp 885 890 895Lys Val Thr Ile Ala  
Asp Pro Gly Tyr Met Gln Gly Tyr Asp Asp Cys 900 905 910Met Gln Gln Gly Pro Ala Ser Ala Arg Asp Leu Ile  
Cys Ala Gln Tyr 915 920 925Val Ala Gly Tyr Lys Val Leu Pro Pro Leu Met Asp Val Asn Met Glu 930 935  
940Ala Ala Tyr Thr Ser Ser Leu Leu Gly Ser Ile Ala Gly Val Gly Trp945 950 955 960Thr Ala Gly Leu Ser Ser  
Phe Ala Ala Ile Pro Phe Ala Gln Ser Ile 965 970 975Phe Tyr Arg Leu Asn Gly Val Gly Ile Thr Gln Gln Val Leu  
Ser Glu 980 985 990Asn Gln Lys Leu Ile Ala Asn Lys Phe Asn Gln Ala Leu Gly Ala Met 995 1000 1005Gln



Thr Gly Phe Thr Thr Thr Asn Glu Ala Phe Arg Lys Val Gln 1010 1015 1020 Asp Ala Val Asn Asn Asn Ala Gln  
Ala Leu Ser Lys Leu Ala Ser 1025 1030 1035 Glu Leu Ser Asn Thr Phe Gly Ala Ile Ser Ala Ser Ile Gly Asp  
1040 1045 1050 Ile Ile Gln Arg Leu Asp Val Leu Glu Gln Asp Ala Gln Ile Asp 1055 1060 1065 Arg Leu Ile Asn  
Gly Arg Leu Thr Thr Leu Asn Ala Phe Val Ala 1070 1075 1080 Gln Gln Leu Val Arg Ser Glu Ser Ala Ala Leu  
Ser Ala Gln Leu 1085 1090 1095 Ala Lys Asp Lys Val Asn Glu Cys Val Lys Ala Gln Ser Lys Arg 1100 1105  
1110 Ser Gly Phe Cys Gly Gln Gly Thr His Ile Val Ser Phe Val Val 1115 1120 1125 Asn Ala Pro Asn Gly Leu Tyr  
Phe Met His Val Gly Tyr Tyr Pro 1130 1135 1140 Ser Asn His Ile Glu Val Val Ser Ala Tyr Gly Leu Cys Asp Ala  
1145 1150 1155 Ala Asn Pro Thr Asn Cys Ile Ala Pro Val Asn Gly Tyr Phe Ile 1160 1165 1170 Lys Thr Asn Asn  
Thr Arg Ile Val Asp Glu Trp Ser Tyr Thr Gly 1175 1180 1185 Ser Ser Phe Tyr Ala Pro Glu Pro Ile Thr Ser Leu  
Asn Thr Lys 1190 1195 1200 Tyr Val Ala Pro Gln Val Thr Tyr Gln Asn Ile Ser Thr Asn Leu 1205 1210 1215 Pro  
Pro Pro Leu Leu Gly Asn Ser Thr Gly Ile Asp Phe Gln Asp 1220 1225 1230 Glu Leu Asp Glu Phe Phe Lys Asn  
Val Ser Thr Ser Ile Pro Asn 1235 1240 1245 Phe Gly Ser Leu Thr Gln Ile Asn Thr Thr Leu Leu Asp Leu Thr  
1250 1255 1260 Tyr Glu Met Leu Ser Leu Gln Gln Val Val Lys Ala Leu Asn Glu 1265 1270 1275 Ser Tyr Ile Asp  
Leu Lys Glu Leu Gly Asn Tyr Thr Tyr Tyr Asn 1280 1285 1290 Lys Trp Pro Trp Tyr Ile Trp Leu Gly Phe Ile Ala  
Gly Leu Val 1295 1300 1305 Ala Leu Ala Leu Cys Val Phe Phe Ile Leu Cys Cys Thr Gly Cys 1310 1315  
1320 Gly Thr Asn Cys Met Gly Lys Leu Lys Cys Asn Arg Cys Cys Asp 1325 1330 1335 Arg Tyr Glu Glu Tyr  
Asp Leu Glu Pro His Lys Val His Val His 1340 1345 1350 251353 PRT Artificial Sequence Synthetic Polypeptide  
25 Met Ile His Ser Val Phe Leu Leu Met Phe Leu Leu Thr Pro Thr Glu 1 5 10 15 Ser Tyr Val Asp Val Gly Pro Asp  
Ser Val Lys Ser Ala Cys Ile Glu 20 25 30 Val Asp Ile Gln Gln Thr Phe Phe Asp Lys Thr Trp Pro Arg Pro Ile 35  
40 45 Asp Val Ser Lys Ala Asp Gly Ile Ile Tyr Pro Gln Gly Arg Thr Tyr 50 55 60 Ser Asn Ile Thr Ile Thr Tyr Gln  
Gly Leu Phe Pro Tyr Gln Gly Asp 65 70 75 80 His Gly Asp Met Tyr Val Tyr Ser Ala Gly His Ala Thr Gly Thr  
Thr 85 90 95 Pro Gln Lys Leu Phe Val Ala Asn Tyr Ser Gln Asp Val Lys Gln Phe 100 105 110 Ala Asn Gly Phe  
Val Val Arg Ile Gly Ala Ala Ala Asn Ser Thr Gly 115 120 125 Thr Val Ile Ile Ser Pro Ser Thr Ser Ala Thr Ile Arg  
Lys Ile Tyr 130 135 140 Pro Ala Phe Met Leu Gly Ser Ser Val Gly Asn Phe Ser Asp Gly Lys 145 150 155 160 Met  
Gly Arg Phe Phe Asn His Thr Leu Val Leu Leu Pro Asp Gly Cys 165 170 175 Gly Thr Leu Leu Arg Ala Phe Tyr  
Cys Ile Leu Glu Pro Arg Ser Gly 180 185 190 Asn His Cys Pro Ala Gly Asn Ser Tyr Thr Ser Phe Ala Thr Tyr  
His 195 200 205 Thr Pro Ala Thr Asp Cys Ser Asp Gly Asn Tyr Asn Arg Asn Ala Ser 210 215 220 Leu Asn Ser  
Phe Lys Glu Tyr Phe Asn Leu Arg Asn Cys Thr Phe Met 225 230 235 240 Tyr Thr Tyr Asn Ile Thr Glu Asp Glu  
Ile Leu Glu Trp Phe Gly Ile 245 250 255 Thr Gln Thr Ala Gln Gly Val His Leu Phe Ser Ser Arg Tyr Val Asp 260  
265 270 Leu Tyr Gly Gly Asn Met Phe Gln Phe Ala Thr Leu Pro Val Tyr Asp 275 280 285 Thr Ile Lys Tyr Tyr  
Ser Ile Ile Pro His Ser Ile Arg Ser Ile Gln 290 295 300 Ser Asp Arg Lys Ala Trp Ala Ala Phe Tyr Val Tyr Lys  
Leu Gln Pro 305 310 315 320 Leu Thr Phe Leu Leu Asp Phe Ser Val Asp Gly Tyr Ile Arg Arg Ala 325 330 335 Ile  
Asp Cys Gly Phe Asn Asp Leu Ser Gln Leu His Cys Ser Tyr Glu 340 345 350 Ser Phe Asp Val Glu Ser Gly Val  
Tyr Ser Val Ser Ser Phe Glu Ala 355 360 365 Lys Pro Ser Gly Ser Val Val Glu Gln Ala Glu Gly Val Glu Cys Asp  
370 375 380 Phe Ser Pro Leu Leu Ser Gly Thr Pro Pro Gln Val Tyr Asn Phe Lys 385 390 395 400 Arg Leu Val  
Phe Thr Asn Cys Asn Tyr Asn Leu Thr Lys Leu Leu Ser 405 410 415 Leu Phe Ser Val Asn Asp Phe Thr Cys Ser  
Gln Ile Ser Pro Ala Ala 420 425 430 Ile Ala Ser Asn Cys Tyr Ser Ser Leu Ile Leu Asp Tyr Phe Ser Tyr 435 440  
445 Pro Leu Ser Met Lys Ser Asp Leu Ser Val Ser Ser Ala Gly Pro Ile 450 455 460 Ser Gln Phe Asn Tyr Lys Gln  
Ser Phe Ser Asn Pro Thr Cys Leu Ile 465 470 475

480 Leu Ala Thr Val Pro His Asn Leu Thr Thr Ile Thr Lys Pro Leu Lys 485 490 495 Tyr Ser Tyr Ile Asn Lys Cys  
Ser Arg Leu Leu Ser Asp Asp Arg Thr 500 505 510 Glu Val Pro Gln Leu Val Asn Ala Asn Gln Tyr Ser Pro Cys  
Val Ser 515 520 525 Ile Val Pro Ser Thr Val Trp Glu Asp Gly Asp Tyr Tyr Arg Lys Gln 530 535 540 Leu Ser Pro  
Leu Glu Gly Gly Gly Trp Leu Val Ala Ser Gly Ser Thr 545 550 555 560 Val Ala Met Thr Glu Gln Leu Gln Met  
Gly Phe Gly Ile Thr Val Gln 565 570 575 Tyr Gly Thr Asp Thr Asn Ser Val Cys Pro Lys Leu Glu Phe Ala Asn  
580 585 590 Asp Thr Lys Ile Ala Ser Gln Leu Gly Asn Cys Val Glu Tyr Ser Leu 595 600 605 Tyr Gly Val Ser Gly  
Arg Gly Val Phe Gln Asn Cys Thr Ala Val Gly 610 615 620 Val Arg Gln Gln Arg Phe Val Tyr Asp Ala Tyr Gln  
Asn Leu Val Gly 625 630 635 640 Tyr Tyr Ser Asp Asp Gly Asn Tyr Tyr Cys Leu Arg Ala Cys Val Ser 645 650  
655 Val Pro Val Ser Val Ile Tyr Asp Lys Glu Thr Lys Thr His Ala Thr 660 665 670 Leu Phe Gly Ser Val Ala Cys  
Glu His Ile Ser Ser Thr Met Ser Gln 675 680 685 Tyr Ser Arg Ser Thr Arg Ser Met Leu Lys Arg Arg Asp Ser Thr  
Tyr 690 695 700 Gly Pro Leu Gln Thr Pro Val Gly Cys Val Leu Gly Leu Val Asn Ser 705 710 715 720 Ser Leu  
Phe Val Glu Asp Cys Lys Leu Pro Leu Gly Gln Ser Leu Cys 725 730 735 Ala Leu Pro Asp Thr Pro Ser Thr Leu  
Thr Pro Arg Ser Val Arg Ser 740 745 750 Val Pro Gly Glu Met Arg Leu Ala Ser Ile Ala Phe Asn His Pro Ile 755  
760 765 Gln Val Asp Gln Leu Asn Ser Ser Tyr Phe Lys Leu Ser Ile Pro Thr 770 775 780 Asn Phe Ser Phe Gly Val

Thr Gln Glu Tyr Ile Gln Thr Thr Ile Gln785 790 795 800Lys Val Thr Val Asp Cys Lys Gln Tyr Val Cys Asn Gly  
Phe Gln Lys 805 810 815Cys Glu Gln Leu Leu Arg Glu Tyr Gly Gln Phe Cys Ser Lys Ile Asn 820 825 830Gln  
Ala Leu His Gly Ala Asn Leu Arg Gln Asp Asp Ser Val Arg Asn 835 840 845Leu Phe Ala Ser Val Lys Ser Ser  
Gln Ser Ser Pro Ile Ile Pro Gly 850 855 860Phe Gly Gly Asp Phe Asn Leu Thr Leu Leu Glu Pro Val Ser Ile  
Ser865 870 875 880Thr Gly Ser Arg Ser Ala Arg Ser Ala Ile Glu Asp Leu Leu Phe Asp 885 890 895Lys Val Thr  
Ile Ala Asp Pro Gly Tyr Met Gln Gly Tyr Asp Asp Cys 900 905 910Met Gln Gln Gly Pro Ala Ser Ala Arg Asp  
Leu Ile Cys Ala Gln Tyr 915 920 925Val Ala Gly Tyr Lys Val Leu Pro Pro Leu Met Asp Val Asn Met Glu 930  
935 940Ala Ala Tyr Thr Ser Ser Leu Leu Gly Ser Ile Ala Gly Val Gly Trp945 950 955 960Thr Ala Gly Leu Ser  
Ser Phe Ala Ala Ile Pro Phe Ala Gln Ser Ile 965 970 975Phe Tyr Arg Leu Asn Gly Val Gly Ile Thr Gln Gln Val  
Leu Ser Glu 980 985 990Asn Gln Lys Leu Ile Ala Asn Lys Phe Asn Gln Ala Leu Gly Ala Met 995 1000  
1005Gln Thr Gly Phe Thr Thr Thr Asn Glu Ala Phe Gln Lys Val Gln 1010 1015 1020Asp Ala Val Asn Asn Asn  
Ala Gln Ala Leu Ser Lys Leu Ala Ser 1025 1030 1035Glu Leu Ser Asn Thr Phe Gly Ala Ile Ser Ala Ser Ile Gly  
Asp 1040 1045 1050Ile Ile Gln Arg Leu Asp Val Leu Glu Gln Asp Ala Gln Ile Asp 1055 1060 1065Arg Leu Ile  
Asn Gly Arg Leu Thr Thr Leu Asn Ala Phe Val Ala 1070 1075 1080Gln Gln Leu Val Arg Ser Glu Ser Ala Ala  
Leu Ser Ala Gln Leu 1085 1090 1095Ala Lys Asp Lys Val Asn Glu Cys Val Lys Ala Gln Ser Lys Arg 1100 1105  
1110Ser Gly Phe Cys Gly Gln Gly Thr His Ile Val Ser Phe Val Val 1115 1120 1125Asn Ala Pro Asn Gly Leu Tyr  
Phe Met His Val Gly Tyr Tyr Pro 1130 1135 1140Ser Asn His Ile Glu Val Val Ser Ala Tyr Gly Leu Cys Asp Ala  
1145 1150 1155Ala Asn Pro Thr Asn Cys Ile Ala Pro Val Asn Gly Tyr Phe Ile 1160 1165 1170Lys Thr Asn Asn  
Thr Arg Ile Val Asp Glu Trp Ser Tyr Thr Gly 1175 1180 1185Ser Ser Phe Tyr Ala Pro Glu Pro Ile Thr Ser Leu  
Asn Thr Lys 1190 1195 1200Tyr Val Ala Pro Gln Val Thr Tyr Gln Asn Ile Ser Thr Asn Leu 1205 1210 1215Pro  
Pro Pro Leu Leu Gly Asn Ser Thr Gly Ile Asp Phe Gln Asp 1220 1225 1230Glu Leu Asp Glu Phe Phe Lys Asn  
Val Ser Thr Ser Ile Pro Asn 1235 1240 1245Phe Gly Ser Leu Thr Gln Ile Asn Thr Thr Leu Leu Asp Leu Thr  
1250 1255 1260Tyr Glu Met Leu Ser Leu Gln Gln Val Val Lys Ala Leu Asn Glu 1265 1270 1275Ser Tyr Ile Asp  
Leu Lys Glu Leu Gly Asn Tyr Thr Tyr Tyr Asn 1280 1285 1290Lys Trp Pro Trp Tyr Ile Trp Leu Gly Phe Ile Ala  
Gly Leu Val 1295 1300 1305Ala Leu Ala Leu Cys Val Phe Phe Ile Leu Cys Cys Thr Gly Cys 1310 1315  
1320Gly Thr Asn Cys Met Gly Lys Leu Lys Cys Asn Arg Cys Cys Asp 1325 1330 1335Arg Tyr Glu Glu Tyr  
Asp Leu Glu Pro His Lys Val His Val His 1340 1345 135026615PRTArtificial SequenceSynthetic Polypeptide  
26Met Ile His Ser Val Phe Leu Leu Met Phe Leu Leu Thr Pro Thr Glu1 5 10 15Ser Asp Cys Lys Leu Pro Leu  
Gly Gln Ser Leu Cys Ala Leu Pro Asp 20 25 30Thr Pro Ser Thr Leu Thr Pro Arg Ser Val Arg Ser Val Pro Gly  
Glu 35 40 45Met Arg Leu Ala Ser Ile Ala Phe Asn His Pro Ile Gln Val Asp Gln 50 55 60Leu Asn Ser Ser Tyr  
Phe Lys Leu Ser Ile Pro Thr Asn Phe Ser Phe65 70 75 80Gly Val Thr Gln Glu Tyr Ile Gln Thr Thr Ile Gln Lys  
Val Thr Val 85 90 95Asp Cys Lys Gln Tyr Val Cys Asn Gly Phe Gln Lys Cys Glu Gln Leu 100 105 110Leu Arg  
Glu Tyr Gly Gln Phe Cys Ser Lys Ile Asn Gln Ala Leu His 115 120 125Gly Ala Asn Leu Arg Gln Asp Asp Ser  
Val Arg Asn Leu Phe Ala Ser 130 135 140Val Lys Ser Ser Gln Ser Ser Pro Ile Ile Pro Gly Phe Gly Gly Asp145  
150 155 160Phe Asn Leu Thr Leu Leu Glu Pro Val Ser Ile Ser Thr Gly Ser Arg 165 170 175Ser Ala Arg Ser Ala  
Ile Glu Asp Leu Leu Phe Asp Lys Val Thr Ile 180 185 190Ala Asp Pro Gly Tyr Met Gln Gly Tyr Asp Asp Cys  
Met Gln Gln Gly 195 200 205Pro Ala Ser Ala Arg Asp Leu Ile Cys Ala Gln Tyr Val Ala Gly Tyr 210 215  
220Lys Val Leu Pro Pro Leu Met Asp Val Asn Met Glu Ala Ala Tyr Thr225 230 235 240Ser Ser Leu Leu Gly  
Ser Ile Ala Gly Val Gly Trp Thr Ala Gly Leu 245 250 255Ser Ser Phe Ala Ala Ile Pro Phe Ala Gln Ser Ile Phe  
Tyr Arg Leu 260 265 270Asn Gly Val Gly Ile Thr Gln Gln Val Leu Ser Glu Asn Gln Lys Leu 275 280 285Ile Ala  
Asn Lys Phe Asn Gln Ala Leu Gly Ala Met Gln Thr Gly Phe 290 295 300Thr Thr Thr Asn Glu Ala Phe Gln Lys  
Val Gln Asp Ala Val Asn Asn305 310 315 320Asn Ala Gln Ala Leu Ser Lys Leu Ala Ser Glu Leu Ser Asn Thr  
Phe 325 330 335Gly Ala Ile Ser Ala Ser Ile Gly Asp Ile Ile Gln Arg Leu Asp Val 340 345 350Leu Glu Gln Asp  
Ala Gln Ile Asp Arg Leu Ile Asn Gly Arg Leu Thr 355 360 365Thr Leu Asn Ala Phe Val Ala Gln Gln Leu Val  
Arg Ser Glu Ser Ala 370 375 380Ala Leu Ser Ala Gln Leu Ala Lys Asp Lys Val Asn Glu Cys Val Lys385 390  
395 400Ala Gln Ser Lys Arg Ser Gly Phe Cys Gly Gln Gly Thr His Ile Val 405 410 415Ser Phe Val Val Asn Ala  
Pro Asn Gly Leu Tyr Phe Met His Val Gly 420 425 430Tyr Tyr Pro Ser Asn His Ile Glu Val Val Ser Ala Tyr Gly  
Leu Cys 435 440 445Asp Ala Ala Asn Pro Thr Asn Cys Ile Ala Pro Val Asn Gly Tyr Phe 450 455 460Ile Lys  
Thr Asn Asn Thr Arg Ile Val Asp Glu Trp Ser Tyr Thr Gly465 470 475 480Ser Ser Phe Tyr Ala Pro Glu Pro Ile  
Thr Ser Leu Asn Thr Lys Tyr 485 490 495Val Ala Pro Gln Val Thr Tyr Gln Asn Ile Ser Thr Asn Leu Pro Pro 500  
505 510Pro Leu Leu Gly Asn Ser Thr Gly Ile Asp Phe Gln Asp Glu Leu Asp 515 520 525Glu Phe Phe Lys Asn  
Val Ser Thr Ser Ile Pro Asn Phe Gly Ser Leu 530 535 540Thr Gln Ile Asn Thr Thr Leu Leu Asp Leu Thr Tyr Glu  
Met Leu Ser545 550 555 560Leu Gln Gln Val Val Lys Ala Leu Asn Glu Ser Tyr Ile Asp Leu Lys 565 570  
575Glu Leu Gly Asn Tyr Thr Tyr Tyr Asn Lys Trp Pro Asp Lys Ile Glu 580 585 590Glu Ile Leu Ser Lys Ile Tyr

His Ile Glu Asn Glu Ile Ala Arg Ile 595 600 605Lys Lys Leu Ile Gly Glu Ala 610 615271353PRTMiddle East  
respiratory syndrome coronavirus 27Met Ile His Ser Val Phe Leu Leu Met Phe Leu Leu Thr Pro Thr Glu1 5 10  
15Ser Tyr Val Asp Val Gly Pro Asp Ser Val Lys Ser Ala Cys Ile Glu 20 25 30Val Asp Ile Gln Gln Thr Phe Phe  
Asp Lys Thr Trp Pro Arg Pro Ile 35 40 45Asp Val Ser Lys Ala Asp Gly Ile Ile Tyr Pro Gln Gly Arg Thr Tyr 50  
55 60Ser Asn Ile Thr Ile Thr Tyr Gln Gly Leu Phe Pro Tyr Gln Gly Asp65 70 75 80His Gly Asp Met Tyr Val Tyr  
Ser Ala Gly His Ala Thr Gly Thr Thr 85 90 95Pro Gln Lys Leu Phe Val Ala Asn Tyr Ser Gln Asp Val Lys Gln  
Phe 100 105 110Ala Asn Gly Phe Val Val Arg Ile Gly Ala Ala Ala Asn Ser Thr Gly 115 120 125Thr Val Ile Ile  
Ser Pro Ser Thr Ser Ala Thr Ile Arg Lys Ile Tyr 130 135 140Pro Ala Phe Met Leu Gly Ser Ser Val Gly Asn Phe  
Ser Asp Gly Lys145 150 155 160Met Gly Arg Phe Phe Asn His Thr Leu Val Leu Leu Pro Asp Gly Cys 165 170  
175Gly Thr Leu Leu Arg Ala Phe Tyr Cys Ile Leu Glu Pro Arg Ser Gly 180 185 190Asn His Cys Pro Ala Gly  
Asn Ser Tyr Thr Ser Phe Ala Thr Tyr His 195 200 205Thr Pro Ala Thr Asp Cys Ser Asp Gly Asn Tyr Asn Arg  
Asn Ala Ser 210 215 220Leu Asn Ser Phe Lys Glu Tyr Phe Asn Leu Arg Asn Cys Thr Phe Met225 230 235  
240Tyr Thr Tyr Asn Ile Thr Glu Asp Glu Ile Leu Glu Trp Phe Gly Ile 245 250 255Thr Gln Thr Ala Gln Gly Val  
His Leu Phe Ser Ser Arg Tyr Val Asp 260 265 270Leu Tyr Gly Gly Asn Met Phe Gln Phe Ala Thr Leu Pro Val  
Tyr Asp 275 280 285Thr Ile Lys Tyr Tyr Ser Ile Ile Pro His Ser Ile Arg Ser Ile Gln 290 295 300Ser Asp Arg Lys  
Ala Trp Ala Ala Phe Tyr Val Tyr Lys Leu Gln Pro305 310 315 320Leu Thr Phe Leu Leu Asp Phe Ser Val Asp  
Gly Tyr Ile Arg Arg Ala 325 330 335Ile Asp Cys Gly Phe Asn Asp Leu Ser Gln Leu His Cys Ser Tyr Glu 340  
345 350Ser Phe Asp Val Glu Ser Gly Val Tyr Ser Val Ser Ser Phe Glu Ala 355 360 365Lys Pro Ser Gly Ser Val  
Val Glu Gln Ala Glu Gly Val Glu Cys Asp 370 375 380Phe Ser Pro Leu Leu Ser Gly Thr Pro Pro Gln Val Tyr  
Asn Phe Lys385 390 395 400Arg Leu Val Phe Thr Asn Cys Asn Tyr Asn Leu Thr Lys Leu Leu Ser 405 410  
415Leu Phe Ser Val Asn Asp Phe Thr Cys Ser Gln Ile Ser Pro Ala Ala 420 425 430Ile Ala Ser Asn Cys Tyr Ser  
Ser Leu Ile Leu Asp Tyr Phe Ser Tyr 435 440 445Pro Leu Ser Met Lys Ser Asp Leu Ser Val Ser Ser Ala Gly Pro  
Ile 450 455 460Ser Gln Phe Asn Tyr Lys Gln Ser Phe Ser Asn Pro Thr Cys Leu Ile465 470 475 480Leu Ala Thr  
Val Pro His Asn Leu Thr Thr Ile Thr Lys Pro Leu Lys 485 490 495Tyr Ser Tyr Ile Asn Lys Cys Ser Arg Leu Leu  
Ser Asp Asp Arg Thr 500 505 510Glu Val Pro Gln Leu Val Asn Ala Asn Gln Tyr Ser Pro Cys Val Ser 515 520  
525Ile Val Pro Ser Thr Val Trp Glu Asp Gly Asp Tyr Tyr Arg Lys Gln 530 535 540Leu Ser Pro Leu Glu Gly Gly  
Gly Trp Leu Val Ala Ser Gly Ser Thr545 550 555 560Val Ala Met Thr Glu Gln Leu Gln Met Gly Phe Gly Ile  
Thr Val Gln 565 570 575Tyr Gly Thr Asp Thr Asn Ser Val Cys Pro Lys Leu Glu Phe Ala Asn 580 585 590Asp  
Thr Lys Ile Ala Ser Gln Leu Gly Asn Cys Val Glu Tyr Ser Leu 595 600 605Tyr Gly Val Ser Gly Arg Gly Val Phe  
Gln Asn Cys Thr Ala Val Gly 610 615 620Val Arg Gln Gln Arg Phe Val Tyr Asp Ala Tyr Gln Asn Leu Val  
Gly625 630 635 640Tyr Tyr Ser Asp Asp Gly Asn Tyr Tyr Cys Leu Arg Ala Cys Val Ser 645 650 655Val Pro  
Val Ser Val Ile Tyr Asp Lys Glu Thr Lys Thr His Ala Thr 660 665 670Leu Phe Gly Ser Val Ala Cys Glu His Ile  
Ser Ser Thr Met Ser Gln 675 680 685Tyr Ser Arg Ser Thr Arg Ser Met Leu Lys Arg Arg Asp Ser Thr Tyr 690  
695 700Gly Pro Leu Gln Thr Pro Val Gly Cys Val Leu Gly Leu Val Asn Ser705 710 715 720Ser Leu Phe Val  
Glu Asp Cys Lys Leu Pro Leu Gly Gln Ser Leu Cys 725 730 735Ala Leu Pro Asp Thr Pro Ser Thr Leu Thr Pro  
Arg Ser Val Arg Ser 740 745 750Val Pro Gly Glu Met Arg Leu Ala Ser Ile Ala Phe Asn His Pro Ile 755 760  
765Gln Val Asp Gln Leu Asn Ser Ser Tyr Phe Lys Leu Ser Ile Pro Thr 770 775 780Asn Phe Ser Phe Gly Val Thr  
Gln Glu Tyr Ile Gln Thr Thr Ile Gln785 790 795 800Lys Val Thr Val Asp Cys Lys Gln Tyr Val Cys Asn Gly Phe  
Gln Lys 805 810 815Cys Glu Gln Leu Leu Arg Glu Tyr Gly Gln Phe Cys Ser Lys Ile Asn 820 825 830Gln Ala  
Leu His Gly Ala Asn Leu Arg Gln Asp Asp Ser Val Arg Asn 835 840 845Leu Phe Ala Ser Val Lys Ser Ser Gln  
Ser Ser Pro Ile Ile Pro Gly 850 855 860Phe Gly Gly Asp Phe Asn Leu Thr Leu Leu Glu Pro Val Ser Ile Ser865  
870 875 880Thr Gly Ser Arg Ser Ala Arg Ser Ala Ile Glu Asp Leu Leu Phe Asp 885 890 895Lys Val Thr Ile Ala  
Asp Pro Gly Tyr Met Gln Gly Tyr Asp Asp Cys 900 905 910Met Gln Gln Gly Pro Ala Ser Ala Arg Asp Leu Ile  
Cys Ala Gln Tyr 915 920 925Val Ala Gly Tyr Lys Val Leu Pro Pro Leu Met Asp Val Asn Met Glu 930 935  
940Ala Ala Tyr Thr Ser Ser Leu Leu Gly Ser Ile Ala Gly Val Gly Trp945 950 955 960Thr Ala Gly Leu Ser Ser  
Phe

Ala Ala Ile Pro Phe Ala Gln Ser Ile 965 970 975Phe Tyr Arg Leu Asn Gly Val Gly Ile Thr Gln Gln Val Leu Ser  
Glu 980 985 990Asn Gln Lys Leu Ile Ala Asn Lys Phe Asn Gln Ala Leu Gly Ala Met 995 1000 1005Gln Thr  
Gly Phe Thr Thr Thr Asn Glu Ala Phe Arg Lys Val Gln 1010 1015 1020Asp Ala Val Asn Asn Asn Ala Gln Ala  
Leu Ser Lys Leu Ala Ser 1025 1030 1035Glu Leu Ser Asn Thr Phe Gly Ala Ile Ser Ala Ser Ile Gly Asp 1040  
1045 1050Ile Ile Gln Arg Leu Asp Val Leu Glu Gln Asp Ala Gln Ile Asp 1055 1060 1065Arg Leu Ile Asn Gly  
Arg Leu Thr Thr Leu Asn Ala Phe Val Ala 1070 1075 1080Gln Gln Leu Val Arg Ser Glu Ser Ala Ala Leu Ser  
Ala Gln Leu 1085 1090 1095Ala Lys Asp Lys Val Asn Glu Cys Val Lys Ala Gln Ser Lys Arg 1100 1105 1110Ser

Gly Phe Cys Gly Gln Gly Thr His Ile Val Ser Phe Val Val 1115 1120 1125Asn Ala Pro Asn Gly Leu Tyr Phe Met  
His Val Gly Tyr Tyr Pro 1130 1135 1140Ser Asn His Ile Glu Val Val Ser Ala Tyr Gly Leu Cys Asp Ala 1145  
1150 1155Ala Asn Pro Thr Asn Cys Ile Ala Pro Val Asn Gly Tyr Phe Ile 1160 1165 1170Lys Thr Asn Asn Thr  
Arg Ile Val Asp Glu Trp Ser Tyr Thr Gly 1175 1180 1185Ser Ser Phe Tyr Ala Pro Glu Pro Ile Thr Ser Leu Asn  
Thr Lys 1190 1195 1200Tyr Val Ala Pro His Val Thr Tyr Gln Asn Ile Ser Thr Asn Leu 1205 1210 1215Pro Pro  
Pro Leu Leu Gly Asn Ser Thr Gly Ile Asp Phe Gln Asp 1220 1225 1230Glu Leu Asp Glu Phe Phe Lys Asn Val  
Ser Thr Ser Ile Pro Asn 1235 1240 1245Phe Gly Ser Leu Thr Gln Ile Asn Thr Thr Leu Leu Asp Leu Thr 1250  
1255 1260Tyr Glu Met Leu Ser Leu Gln Gln Val Val Lys Ala Leu Asn Glu 1265 1270 1275Ser Tyr Ile Asp Leu  
Lys Glu Leu Gly Asn Tyr Thr Tyr Tyr Asn 1280 1285 1290Lys Trp Pro Trp Tyr Ile Trp Leu Gly Phe Ile Ala Gly  
Leu Val 1295 1300 1305Ala Leu Ala Leu Cys Val Phe Phe Ile Leu Cys Cys Thr Gly Cys 1310 1315 1320Gly  
Thr Asn Cys Met Gly Lys Leu Lys Cys Asn Arg Cys Cys Asp 1325 1330 1335Arg Tyr Glu Glu Tyr Asp Leu  
Glu Pro His Lys Val His Val His 1340 1345 1350281353PRTMiddle East respiratory syndrome coronavirus  
28Met Ile His Ser Val Phe Leu Leu Met Phe Leu Leu Thr Pro Thr Glu1 5 10 15Ser Tyr Val Asp Val Gly Pro Asp  
Ser Val Lys Ser Ala Cys Ile Glu 20 25 30Val Asp Ile Gln Gln Thr Phe Phe Asp Lys Thr Trp Pro Arg Pro Ile 35  
40 45Asp Val Ser Lys Ala Asp Gly Ile Ile Tyr Pro Gln Gly Arg Thr Tyr 50 55 60Ser Asn Ile Thr Ile Thr Tyr Gln  
Gly Leu Phe Pro Tyr Gln Gly Asp65 70 75 80His Gly Asp Met Tyr Val Tyr Ser Ala Gly His Ala Thr Gly Thr  
Thr 85 90 95Pro Gln Lys Leu Phe Val Ala Asn Tyr Ser Gln Asp Val Lys Gln Phe 100 105 110Ala Asn Gly Phe  
Val Val Arg Ile Gly Ala Ala Ala Asn Ser Thr Gly 115 120 125Thr Val Ile Ile Ser Pro Ser Thr Ser Ala Thr Ile Arg  
Lys Ile Tyr 130 135 140Pro Ala Phe Met Leu Gly Ser Ser Val Gly Asn Phe Ser Asp Gly Lys145 150 155 160Met  
Gly Arg Phe Phe Asn His Thr Leu Val Leu Leu Pro Asp Gly Cys 165 170 175Gly Thr Leu Leu Arg Ala Phe Tyr  
Cys Ile Leu Glu Pro Arg Ser Gly 180 185 190Asn His Cys Pro Ala Gly Asn Ser Tyr Thr Ser Phe Ala Thr Tyr  
His 195 200 205Thr Pro Ala Thr Asp Cys Ser Asp Gly Asn Tyr Asn Arg Asn Ala Ser 210 215 220Leu Asn Ser  
Phe Lys Glu Tyr Phe Asn Leu Arg Asn Cys Thr Phe Met225 230 235 240Tyr Thr Tyr Asn Ile Thr Glu Asp Glu  
Ile Leu Glu Trp Phe Gly Ile 245 250 255Thr Gln Thr Ala Gln Gly Val His Leu Phe Ser Ser Arg Tyr Val Asp 260  
265 270Leu Tyr Gly Gly Asn Met Phe Gln Phe Ala Thr Leu Pro Val Tyr Asp 275 280 285Thr Ile Lys Tyr Tyr  
Ser Ile Ile Pro His Ser Ile Arg Ser Ile Gln 290 295 300Ser Asp Arg Lys Ala Trp Ala Ala Phe Tyr Val Tyr Lys  
Leu Gln Pro305 310 315 320Leu Thr Phe Leu Leu Asp Phe Ser Val Asp Gly Tyr Ile Arg Arg Ala 325 330 335Ile  
Asp Cys Gly Phe Asn Asp Leu Ser Gln Leu His Cys Ser Tyr Glu 340 345 350Ser Phe Asp Val Glu Ser Gly Val  
Tyr Ser Val Ser Ser Phe Glu Ala 355 360 365Lys Pro Ser Gly Ser Val Val Glu Gln Ala Glu Gly Val Glu Cys Asp  
370 375 380Phe Ser Pro Leu Leu Ser Gly Thr Pro Pro Gln Val Tyr Asn Phe Lys385 390 395 400Arg Leu Val  
Phe Thr Asn Cys Asn Tyr Asn Leu Thr Lys Leu Leu Ser 405 410 415Leu Phe Ser Val Asn Asp Phe Thr Cys Ser  
Gln Ile Ser Pro Ala Ala 420 425 430Ile Ala Ser Asn Cys Tyr Ser Ser Leu Ile Leu Asp Tyr Phe Ser Tyr 435 440  
445Pro Leu Ser Met Lys Ser Asp Leu Ser Val Ser Ser Ala Gly Pro Ile 450 455 460Ser Gln Phe Asn Tyr Lys Gln  
Ser Phe Ser Asn Pro Thr Cys Leu Ile465 470 475 480Leu Ala Thr Val Pro His Asn Leu Thr Thr Ile Thr Lys Pro  
Leu Lys 485 490 495Tyr Ser Tyr Ile Asn Lys Cys Ser Arg Leu Leu Ser Asp Asp Arg Thr 500 505 510Glu Val  
Pro Gln Leu Val Asn Ala Asn Gln Tyr Ser Pro Cys Val Ser 515 520 525Ile Val Pro Ser Thr Val Trp Glu Asp Gly  
Asp Tyr Tyr Arg Lys Gln 530 535 540Leu Ser Pro Leu Glu Gly Gly Gly Trp Leu Val Ala Ser Gly Ser Thr545  
550 555 560Val Ala Met Thr Glu Gln Leu Gln Met Gly Phe Gly Ile Thr Val Gln 565 570 575Tyr Gly Thr Asp  
Thr Asn Ser Val Cys Pro Lys Leu Glu Phe Ala Asn 580 585 590Asp Thr Lys Ile Ala Ser Gln Leu Gly Asn Cys  
Val Glu Tyr Ser Leu 595 600 605Tyr Gly Val Ser Gly Arg Gly Val Phe Gln Asn Cys Thr Ala Val Gly 610 615  
620Val Arg Gln Gln Arg Phe Val Tyr Asp Ala Tyr Gln Asn Leu Val Gly625 630 635 640Tyr Tyr Ser Asp Asp  
Gly Asn Tyr Tyr Cys Leu Arg Ala Cys Val Ser 645 650 655Val Pro Val Ser Val Ile Tyr Asp Lys Glu Thr Lys Thr  
His Ala Thr 660 665 670Leu Phe Gly Ser Val Ala Cys Glu His Ile Ser Ser Thr Met Ser Gln 675 680 685Tyr Ser  
Arg Ser Thr Arg Ser Met Leu Lys Arg Arg Asp Ser Thr Tyr 690 695 700Gly Pro Leu Gln Thr Pro Val Gly Cys  
Val Leu Gly Leu Val Asn Ser705 710 715 720Ser Leu Phe Val Glu Asp Cys Lys Leu Pro Leu Gly Gln Ser Leu  
Cys 725 730 735Ala Leu Pro Asp Thr Pro Ser Thr Leu Thr Pro Arg Ser Val Arg Ser 740 745 750Val Pro Gly  
Glu Met Arg Leu Ala Ser Ile Ala Phe Asn His Pro Ile 755 760 765Gln Val Asp Gln Leu Asn Ser Ser Tyr Phe  
Lys Leu Ser Ile Pro Thr 770 775 780Asn Phe Ser Phe Gly Val Thr Gln Glu Tyr Ile Gln Thr Thr Ile Gln785 790  
795 800Lys Val Thr Val Asp Cys Lys Gln Tyr Val Cys Asn Gly Phe Gln Lys 805 810 815Cys Glu Gln Leu Leu  
Arg Glu Tyr Gly Gln Phe Cys Ser Lys Ile Asn 820 825 830Gln Ala Leu His Gly Ala Asn Leu Arg Gln Asp Asp  
Ser Val Arg Asn 835 840 845Leu Phe Ala Ser Val Lys Ser Ser Gln Ser Ser Pro Ile Ile Pro Gly 850 855 860Phe  
Gly Gly Asp Phe Asn Leu Thr Leu Leu Glu Pro Val Ser Ile Ser865 870 875 880Thr Gly Ser Arg Ser Ala Arg Ser  
Ala Ile Glu Asp Leu Leu Phe Asp 885 890 895Lys Val Thr Ile Ala Asp Pro Gly Tyr Met Gln Gly Tyr Asp Asp  
Cys 900 905 910Met Gln Gln Gly Pro Ala Ser Ala Arg Asp Leu Ile Cys Ala Gln Tyr 915 920 925Val Ala Gly

Tyr Lys Val Leu Pro Pro Leu Met Asp Val Asn Met Glu 930 935 940Ala Ala Tyr Thr Ser Ser Leu Leu Gly Ser  
Ile Ala Gly Val Gly Trp945 950 955 960Thr Ala Gly Leu Ser Ser Phe Ala Ala Ile Pro Phe Ala Gln Ser Ile 965  
970 975Phe Tyr Arg Leu Asn Gly Val Gly Ile Thr Gln Gln Val Leu Ser Glu 980 985 990Asn Gln Lys Leu Ile Ala  
Asn Lys Phe Asn Gln Ala Leu Gly Ala Met 995 1000 1005Gln Thr Gly Phe Thr Thr Thr Asn Glu Ala Phe Arg  
Lys Val Gln 1010 1015 1020Asp Ala Val Asn Asn Asn Ala Gln Ala Leu Ser Lys Leu Ala Ser 1025 1030  
1035Glu Leu Ser Asn Thr Phe Gly Ala Ile Ser Ala Ser Ile Gly Asp 1040 1045 1050Ile Ile Gln Arg Leu Asp Val  
Leu Glu Gln Asp Ala Gln Ile Asp 1055 1060 1065Arg Leu Ile Asn Gly Arg Leu Thr Thr Leu Asn Ala Phe Val  
Ala 1070 1075 1080Gln Gln Leu Val Arg Ser Glu Ser Ala Ala Leu Ser Ala Gln Leu 1085 1090 1095Ala Lys  
Asp Lys Val Asn Glu Cys Val Lys Ala Gln Ser Lys Arg 1100 1105 1110Ser Gly Phe Cys Gly Gln Gly Thr His Ile  
Val Ser Phe Val Val 1115 1120 1125Asn Ala Pro Asn Gly Leu Tyr Phe Met His Val Gly Tyr Tyr Pro 1130 1135  
1140Ser Asn His Ile Glu Val Val Ser Ala Tyr Gly Leu Cys Asp Ala 1145 1150 1155Ala Asn Pro Thr Asn Cys Ile  
Ala Pro Val Asn Gly Tyr Phe Ile 1160 1165 1170Lys Thr Asn Asn Thr Arg Ile Val Asp Glu Trp Ser Tyr Thr Gly  
1175 1180 1185Ser Ser Phe Tyr Ala Pro Glu Pro Ile Thr Ser Leu Asn Thr Lys 1190 1195 1200Tyr Val Ala Pro  
His Val Thr Tyr Gln Asn Ile Ser Thr Asn Leu 1205 1210 1215Pro Pro Pro Leu Leu Gly Asn Ser Thr Gly Ile Asp  
Phe Gln Asp 1220 1225 1230Glu Leu Asp Glu Phe Phe Lys Asn Val Ser Thr Ser Ile Pro Asn 1235 1240  
1245Phe Gly Ser Leu Thr Gln Ile Asn Thr Thr Leu Leu Asp Leu Thr 1250 1255 1260Tyr Glu Met Leu Ser Leu  
Gln Gln Val Val Lys Ala Leu Asn Glu 1265 1270 1275Ser Tyr Ile Asp Leu Lys Glu Leu Gly Asn Tyr Thr Tyr  
Tyr Asn 1280 1285 1290Lys Trp Pro Trp Tyr Ile Trp Leu Gly Phe Ile Ala Gly Leu Val 1295 1300 1305Ala Leu  
Ala Leu Cys Val Phe Phe Ile Leu Cys Cys Thr Gly Cys 1310 1315 1320Gly Thr Asn Cys Met Gly Lys Leu Lys  
Cys Asn Arg Cys Cys Asp 1325 1330 1335Arg Tyr Glu Glu Tyr Asp Leu Glu Pro His Lys Val His Val His 1340  
1345 1350291255PRTHuman SARS coronavirus 29Met Phe Ile Phe Leu Leu Phe Leu Thr Leu Thr Ser Gly Ser  
Asp Leu1 5 10 15Asp Arg Cys Thr Thr Phe Asp Asp Val Gln Ala Pro Asn Tyr Thr Gln 20 25 30His Thr Ser Ser  
Met Arg Gly Val Tyr Tyr Pro Asp Glu Ile Phe Arg 35 40 45Ser Asp Thr Leu Tyr Leu Thr Gln Asp Leu Phe Leu  
Pro Phe Tyr Ser 50 55 60Asn Val Thr Gly Phe His Thr Ile Asn His Thr Phe Gly Asn Pro Val65 70 75 80Ile Pro  
Phe Lys Asp Gly Ile Tyr Phe Ala Ala Thr Glu Lys Ser Asn 85 90 95Val Val Arg Gly Trp Val Phe Gly Ser Thr  
Met Asn Asn Lys Ser Gln 100 105 110Ser Val Ile Ile Ile Asn Asn Ser Thr Asn Val Val Ile Arg Ala Cys 115 120  
125Asn Phe Glu Leu Cys Asp Asn Pro Phe Phe Ala Val Ser Lys Pro Met 130 135 140Gly Thr Gln Thr His Thr  
Met Ile Phe Asp Asn Ala Phe Asn Cys Thr145 150 155 160Phe Glu Tyr Ile Ser Asp Ala Phe Ser Leu Asp Val  
Ser Glu Lys Ser 165 170 175Gly Asn Phe Lys His Leu Arg Glu Phe Val Phe Lys Asn Lys Asp Gly 180 185  
190Phe Leu Tyr Val Tyr Lys Gly Tyr Gln Pro Ile Asp Val Val Arg Asp 195 200 205Leu Pro Ser Gly Phe Asn Thr  
Leu Lys Pro Ile Phe Lys Leu Pro Leu 210 215 220Gly Ile Asn Ile Thr Asn Phe Arg Ala Ile Leu Thr Ala Phe Ser  
Pro225 230 235 240Ala Gln Asp Ile Trp Gly Thr Ser Ala Ala Ala Tyr Phe Val Gly Tyr 245 250 255Leu Lys Pro  
Thr Thr Phe Met Leu Lys Tyr Asp Glu Asn Gly Thr Ile 260 265 270Thr Asp Ala Val Asp Cys Ser Gln Asn Pro  
Leu Ala Glu Leu Lys Cys 275 280 285Ser Val Lys Ser Phe Glu Ile Asp Lys Gly Ile Tyr Gln Thr Ser Asn 290 295  
300Phe Arg Val Val Pro Ser Gly Asp Val Val Arg Phe Pro Asn Ile Thr305 310 315 320Asn Leu Cys Pro Phe Gly  
Glu Val Phe Asn Ala Thr Lys Phe Pro Ser 325 330 335Val Tyr Ala Trp Glu Arg Lys Lys Ile Ser Asn Cys Val Ala  
Asp Tyr 340 345 350Ser Val Leu Tyr Asn Ser Thr Phe Phe Ser Thr Phe Lys Cys Tyr Gly 355 360 365Val Ser Ala  
Thr Lys Leu Asn Asp Leu Cys Phe Ser Asn Val Tyr Ala 370 375 380Asp Ser Phe Val Val Lys Gly Asp Asp Val  
Arg Gln Ile Ala Pro Gly385 390 395 400Gln Thr Gly Val Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe  
405 410 415Met Gly Cys Val Leu Ala Trp Asn Thr Arg Asn Ile Asp Ala Thr Ser 420 425 430Thr Gly Asn Tyr  
Asn Tyr Lys Tyr Arg Tyr Leu Arg His Gly Lys Leu 435 440 445Arg Pro Phe Glu Arg Asp Ile Ser Asn Val Pro  
Phe Ser Pro Asp Gly 450 455 460Lys Pro Cys Thr Pro Pro Ala Leu Asn Cys Tyr Trp Pro Leu Asn Asp465 470  
475 480Tyr Gly Phe Tyr Thr Thr Thr Gly Ile Gly Tyr Gln Pro Tyr Arg Val 485 490 495Val Val Leu Ser Phe Glu  
Leu Leu Asn Ala Pro Ala Thr Val Cys Gly 500 505 510Pro Lys Leu Ser Thr Asp Leu Ile Lys Asn Gln Cys Val  
Asn Phe Asn 515 520 525Phe Asn Gly Leu Thr Gly Thr Gly Val Leu Thr Pro Ser Ser Lys Arg 530 535 540Phe  
Gln Pro Phe Gln Gln Phe Gly Arg Asp Val Ser Asp Phe Thr Asp545 550 555 560Ser Val Arg Asp Pro Lys Thr  
Ser Glu Ile Leu Asp Ile Ser Pro Cys 565 570 575Ser Phe Gly Gly Val Ser Val Ile Thr Pro Gly Thr Asn Ala Ser  
Ser 580 585 590Glu Val Ala Val Leu Tyr Gln Asp Val Asn Cys Thr Asp Val Ser Thr 595 600 605Ala Ile His Ala  
Asp Gln Leu Thr Pro Ala Trp Arg Ile Tyr Ser Thr 610 615 620Gly Asn Asn Val Phe Gln Thr Gln Ala Gly Cys  
Leu Ile Gly Ala Glu625 630 635 640His Val Asp Thr Ser Tyr Glu Cys Asp Ile Pro Ile Gly Ala Gly Ile 645 650  
655Cys Ala Ser Tyr His Thr Val Ser Leu Leu Arg Ser Thr Ser Gln Lys 660 665 670Ser Ile Val Ala Tyr Thr Met  
Ser Leu Gly Ala Asp Ser Ser Ile Ala 675 680 685Tyr Ser Asn Asn Thr Ile Ala Ile Pro Thr Asn Phe Ser Ile Ser  
Ile 690 695 700Thr Thr Glu Val Met Pro Val Ser Met Ala

Lys Thr Ser Val Asp Cys705 710 715 720Asn Met Tyr Ile Cys Gly Asp Ser Thr Glu Cys Ala Asn Leu Leu Leu  
725 730 735Gln Tyr Gly Ser Phe Cys Thr Gln Leu Asn Arg Ala Leu Ser Gly Ile 740 745 750Ala Ala Glu Gln  
Asp Arg Asn Thr Arg Glu Val Phe Ala Gln Val Lys 755 760 765Gln Met Tyr Lys Thr Pro Thr Leu Lys Tyr Phe  
Gly Gly Phe Asn Phe 770 775 780Ser Gln Ile Leu Pro Asp Pro Leu Lys Pro Thr Lys Arg Ser Phe Ile785 790 795  
800Glu Asp Leu Leu Phe Asn Lys Val Thr Leu Ala Asp Ala Gly Phe Met 805 810 815Lys Gln Tyr Gly Glu Cys  
Leu Gly Asp Ile Asn Ala Arg Asp Leu Ile 820 825 830Cys Ala Gln Lys Phe Asn Gly Leu Thr Val Leu Pro Pro  
Leu Leu Thr 835 840 845Asp Asp Met Ile Ala Ala Tyr Thr Ala Ala Leu Val Ser Gly Thr Ala 850 855 860Thr  
Ala Gly Trp Thr Phe Gly Ala Gly Ala Ala Leu Gln Ile Pro Phe865 870 875 880Ala Met Gln Met Ala Tyr Arg  
Phe Asn Gly Ile Gly Val Thr Gln Asn 885 890 895Val Leu Tyr Glu Asn Gln Lys Gln Ile Ala Asn Gln Phe Asn  
Lys Ala 900 905 910Ile Ser Gln Ile Gln Glu Ser Leu Thr Thr Thr Ser Thr Ala Leu Gly 915 920 925Lys Leu Gln  
Asp Val Val Asn Gln Asn Ala Gln Ala Leu Asn Thr Leu 930 935 940Val Lys Gln Leu Ser Ser Asn Phe Gly Ala  
Ile Ser Ser Val Leu Asn945 950 955 960Asp Ile Leu Ser Arg Leu Asp Lys Val Glu Ala Glu Val Gln Ile Asp 965  
970 975Arg Leu Ile Thr Gly Arg Leu Gln Ser Leu Gln Thr Tyr Val Thr Gln 980 985 990Gln Leu Ile Arg Ala Ala  
Glu Ile Arg Ala Ser Ala Asn Leu Ala Ala 995 1000 1005Thr Lys Met Ser Glu Cys Val Leu Gly Gln Ser Lys Arg  
Val Asp 1010 1015 1020Phe Cys Gly Lys Gly Tyr His Leu Met Ser Phe Pro Gln Ala Ala 1025 1030 1035Pro  
His Gly Val Val Phe Leu His Val Thr Tyr Val Pro Ser Gln 1040 1045 1050Glu Arg Asn Phe Thr Thr Ala Pro Ala  
Ile Cys His Glu Gly Lys 1055 1060 1065Ala Tyr Phe Pro Arg Glu Gly Val Phe Val Phe Asn Gly Thr Ser 1070  
1075 1080Trp Phe Ile Thr Gln Arg Asn Phe Phe Ser Pro Gln Ile Ile Thr 1085 1090 1095Thr Asp Asn Thr Phe  
Val Ser Gly Asn Cys Asp Val Val Ile Gly 1100 1105 1110Ile Ile Asn Asn Thr Val Tyr Asp Pro Leu Gln Pro Glu  
Leu Asp 1115 1120 1125Ser Phe Lys Glu Glu Leu Asp Lys Tyr Phe Lys Asn His Thr Ser 1130 1135 1140Pro  
Asp Val Asp Leu Gly Asp Ile Ser Gly Ile Asn Ala Ser Val 1145 1150 1155Val Asn Ile Gln Lys Glu Ile Asp Arg  
Leu Asn Glu Val Ala Lys 1160 1165 1170Asn Leu Asn Glu Ser Leu Ile Asp Leu Gln Glu Leu Gly Lys Tyr 1175  
1180 1185Glu Gln Tyr Ile Lys Trp Pro Trp Tyr Val Trp Leu Gly Phe Ile 1190 1195 1200Ala Gly Leu Ile Ala Ile  
Val Met Val Thr Ile Leu Leu Cys Cys 1205 1210 1215Met Thr Ser Cys Cys Ser Cys Leu Lys Gly Ala Cys Ser  
Cys Gly 1220 1225 1230Ser Cys Cys Lys Phe Asp Glu Asp Asp Ser Glu Pro Val Leu Lys 1235 1240 1245Gly  
Val Lys Leu His Tyr Thr 1250 1255301353PRTHuman coronavirus 30Met Phe Leu Ile Leu Leu Ile Ser Leu Pro  
Thr Ala Phe Ala Val Ile1 5 10 15Gly Asp Leu Lys Cys Thr Ser Asp Asn Ile Asn Asp Lys Asp Thr Gly 20 25  
30Pro Pro Pro Ile Ser Thr Asp Thr Val Asp Val Thr Asn Gly Leu Gly 35 40 45Thr Tyr Tyr Val Leu Asp Arg Val  
Tyr Leu Asn Thr Thr Leu Phe Leu 50 55 60Asn Gly Tyr Tyr Pro Thr Ser Gly Ser Thr Tyr Arg Asn Met Ala  
Leu65 70 75 80Lys Gly Ser Val Leu Leu Ser Arg Leu Trp Phe Lys Pro Pro Phe Leu 85 90 95Ser Asp Phe Ile Asn  
Gly Ile Phe Ala Lys Val Lys Asn Thr Lys Val 100 105 110Ile Lys Asp Arg Val Met Tyr Ser Glu Phe Pro Ala Ile  
Thr Ile Gly 115 120 125Ser Thr Phe Val Asn Thr Ser Tyr Ser Val Val Val Gln Pro Arg Thr 130 135 140Ile Asn  
Ser Thr Gln Asp Gly Asp Asn Lys Leu Gln Gly Leu Leu Glu145 150 155 160Val Ser Val Cys Gln Tyr Asn Met  
Cys Glu Tyr Pro Gln Thr Ile Cys 165 170 175His Pro Asn Leu Gly Asn His Arg Lys Glu Leu Trp His Leu Asp  
Thr 180 185 190Gly Val Val Ser Cys Leu Tyr Lys Arg Asn Phe Thr Tyr Asp Val Asn 195 200 205Ala Asp Tyr  
Leu Tyr Phe His Phe Tyr Gln Glu Gly Gly Thr Phe Tyr 210 215 220Ala Tyr Phe Thr Asp Thr Gly Val Val Thr  
Lys Phe Leu Phe Asn Val225 230 235 240Tyr Leu Gly Met Ala Leu Ser His Tyr Tyr Val Met Pro Leu Thr Cys  
245 250 255Asn Ser Lys Leu Thr Leu Glu Tyr Trp Val Thr Pro Leu Thr Ser Arg 260 265 270Gln Tyr Leu Leu  
Ala Phe Asn Gln Asp Gly Ile Ile Phe Asn Ala Glu 275 280 285Asp Cys Met Ser Asp Phe Met Ser Glu Ile Lys  
Cys Lys Thr Gln Ser 290 295 300Ile Ala Pro Pro Thr Gly Val Tyr Glu Leu Asn Gly Tyr Thr Val Gln305 310 315  
320Pro Ile Ala Asp Val Tyr Arg Arg Lys Pro Asn Leu Pro Asn Cys Asn 325 330 335Ile Glu Ala Trp Leu Asn  
Asp Lys Ser Val Pro Ser Pro Leu Asn Trp 340 345 350Glu Arg Lys Thr Phe Ser Asn Cys Asn Phe Asn Met Ser  
Ser Leu Met 355 360 365Ser Phe Ile Gln Ala Asp Ser Phe Thr Cys Asn Asn Ile Asp Ala Ala 370 375 380Lys Ile  
Tyr Gly Met Cys Phe Ser Ser Ile Thr Ile Asp Lys Phe Ala385 390 395 400Ile Pro Asn Gly Arg Lys Val Asp Leu  
Gln Leu Gly Asn Leu Gly Tyr 405 410 415Leu Gln Ser Phe Asn Tyr Arg Ile Asp Thr Thr Ala Thr Ser Cys Gln  
420 425 430Leu Tyr Tyr Asn Leu Pro Ala Ala Asn Val Ser Val Ser Arg Phe Asn 435 440 445Pro Ser Thr Trp  
Asn Lys Arg Phe Gly Phe Ile Glu Asp Ser Val Phe 450 455 460Lys Pro Arg Pro Ala Gly Val Leu Thr Asn His  
Asp Val Val Tyr Ala465 470 475 480Gln His Cys Phe Lys Ala Pro Lys Asn Phe Cys Pro Cys Lys Leu Asn 485  
490 495Gly Ser Cys Val Gly Ser Gly Pro Gly Lys Asn Asn Gly Ile Gly Thr 500 505 510Cys Pro Ala Gly Thr  
Asn Tyr Leu Thr Cys Asp Asn Leu Cys Thr Pro 515 520 525Asp Pro Ile Thr Phe Thr Gly Thr Tyr Lys Cys Pro  
Gln Thr Lys Ser 530 535 540Leu Val Gly Ile Gly Glu His Cys Ser Gly Leu Ala Val Lys Ser Asp545 550 555  
560Tyr Cys Gly Gly Asn Ser Cys Thr Cys Arg Pro Gln Ala Phe Leu Gly 565 570 575Trp Ser Ala Asp Ser Cys  
Leu Gln Gly Asp Lys Cys Asn Ile Phe Ala 580 585 590Asn Phe Ile Leu His Asp Val Asn Ser Gly Leu Thr Cys  
Ser Thr Asp 595 600 605Leu Gln Lys Ala Asn Thr Asp Ile Ile Leu Gly Val Cys Val Asn Tyr 610 615 620Asp

Leu Tyr Gly Ile Leu Gly Gln Gly Ile Phe Val Glu Val Asn Ala625 630 635 640Thr Tyr Tyr Asn Ser Trp Gln Asn  
Leu Leu Tyr Asp Ser Asn Gly Asn 645 650 655Leu Tyr Gly Phe Arg Asp Tyr Ile Ile Asn Arg Thr Phe Met Ile  
Arg 660 665 670Ser Cys Tyr Ser Gly Arg Val Ser Ala Ala Phe His Ala Asn Ser Ser 675 680 685Glu Pro Ala Leu  
Leu Phe Arg Asn Ile Lys Cys Asn Tyr Val Phe Asn 690 695 700Asn Ser Leu Thr Arg Gln Leu Gln Pro Ile Asn  
Tyr Phe Asp Ser Tyr705 710 715 720Leu Gly Cys Val Val Asn Ala Tyr Asn Ser Thr Ala Ile Ser Val Gln 725 730  
735Thr Cys Asp Leu Thr Val Gly Ser Gly Tyr Cys Val Asp Tyr Ser Lys 740 745 750Asn Arg Arg Ser Arg Gly  
Ala Ile Thr Thr Gly Tyr Arg Phe Thr Asn 755 760 765Phe Glu Pro Phe Thr Val Asn Ser Val Asn Asp Ser Leu  
Glu Pro Val 770 775 780Gly Gly Leu Tyr Glu Ile Gln Ile Pro Ser Glu Phe Thr Ile Gly Asn785 790 795 800Met  
Val Glu Phe Ile Gln Thr Ser Ser Pro Lys Val Thr Ile Asp Cys 805 810 815Ala Ala Phe Val Cys Gly Asp Tyr Ala  
Ala Cys Lys Ser Gln Leu Val 820 825 830Glu Tyr Gly Ser Phe Cys Asp Asn Ile Asn Ala Ile Leu Thr Glu Val  
835 840 845Asn Glu Leu Leu Asp Thr Thr Gln Leu Gln Val Ala Asn Ser Leu Met 850 855 860Asn Gly Val Thr  
Leu Ser Thr Lys Leu Lys Asp Gly Val Asn Phe Asn865 870 875 880Val Asp Asp Ile Asn Phe Ser Pro Val Leu  
Gly Cys Leu Gly Ser Glu 885 890 895Cys Ser Lys Ala Ser Ser Arg Ser Ala Ile Glu Asp Leu Leu Phe Asp 900  
905 910Lys Val Lys Leu Ser Asp Val Gly Phe Val Glu Ala Tyr Asn Asn Cys 915 920 925Thr Gly Gly Ala Glu  
Ile Arg Asp Leu Ile Cys Val Gln Ser Tyr Lys 930 935 940Gly Ile Lys Val Leu Pro Pro Leu Leu Ser Glu Asn Gln  
Ile Ser Gly945 950 955 960Tyr Thr Leu Ala Ala Thr Ser Ala Ser Leu Phe Pro Pro Trp Thr Ala 965 970 975Ala  
Ala Gly Val Pro Phe Tyr Leu Asn Val Gln Tyr Arg Ile Asn Gly 980 985 990Leu Gly Val Thr Met Asp Val Leu  
Ser Gln Asn Gln Lys Leu Ile Ala 995 1000 1005Asn Ala Phe Asn Asn Ala Leu Tyr Ala Ile Gln Glu Gly Phe Asp  
1010 1015 1020Ala Thr Asn Ser Ala Leu Val Lys Ile Gln Ala Val Val Asn Ala 1025 1030 1035Asn Ala Glu Ala  
Leu Asn Asn Leu Leu Gln Gln Leu Ser Asn Arg 1040 1045 1050Phe Gly Ala Ile Ser Ala Ser Leu Gln Glu Ile  
Leu Ser Arg Leu 1055 1060 1065Asp Ala Leu Glu Ala Glu Ala Gln Ile Asp Arg Leu Ile Asn Gly 1070 1075  
1080Arg Leu Thr Ala Leu Asn Ala Tyr Val Ser Gln Gln Leu Ser Asp 1085 1090 1095Ser Thr Leu Val Lys Phe  
Ser Ala Ala Gln Ala Met Glu Lys Val 1100 1105 1110Asn Glu Cys Val Lys Ser Gln Ser Ser Arg Ile Asn Phe Cys  
Gly 1115 1120 1125Asn Gly Asn His Ile Ile Ser Leu Val Gln Asn Ala Pro Tyr Gly 1130 1135 1140Leu Tyr Phe  
Ile His Phe Ser Tyr Val Pro Thr Lys Tyr Val Thr 1145 1150 1155Ala Arg Val Ser Pro Gly Leu Cys Ile Ala Gly  
Asp Arg Gly Ile 1160 1165 1170Ala Pro Lys Ser Gly Tyr Phe Val Asn Val Asn Asn Thr Trp Met 1175 1180  
1185Tyr Thr Gly Ser Gly Tyr Tyr Tyr Pro Glu Pro Ile Thr Glu Asn 1190 1195 1200Asn Val Val Val Met Ser Thr  
Cys Ala Val Asn Tyr Thr Lys Ala 1205 1210 1215Pro Tyr Val Met Leu Asn Thr Ser Ile Pro Asn Leu Pro Asp  
Phe 1220 1225 1230Lys Glu Glu Leu Asp Gln Trp Phe Lys Asn Gln Thr Ser Val Ala 1235 1240 1245Pro Asp  
Leu Ser Leu Asp Tyr Ile Asn Val Thr Phe Leu Asp Leu 1250 1255 1260Gln Val Glu Met Asn Arg Leu Gln Glu  
Ala Ile Lys Val Leu Asn 1265 1270 1275Gln Ser Tyr Ile Asn Leu Lys Asp Ile Gly Thr Tyr Glu Tyr Tyr 1280  
1285 1290Val Lys Trp Pro Trp Tyr Val Trp Leu Leu Ile Cys Leu Ala Gly 1295 1300 1305Val Ala Met Leu Val  
Leu Leu Phe Phe Ile Cys Cys Cys Thr Gly 1310 1315 1320Cys Gly Thr Ser Cys Phe Lys Lys Cys Gly Gly Cys  
Cys Asp Asp 1325 1330 1335Tyr Thr Gly Tyr Gln Glu Leu Val Ile Lys Thr Ser His Asp Asp 1340 1345  
1350311351PRTHuman coronavirus 31Met Phe Leu Ile Ile Phe Ile Leu Pro Thr Thr Leu Ala Val Ile Gly1 5 10  
15Asp Phe Asn Cys Thr Asn Ser Phe Ile Asn Asp Tyr Asn Lys Thr Ile 20 25 30Pro Arg Ile Ser Glu Asp Val Val  
Asp Val Ser Leu Gly Leu Gly Thr 35 40 45Tyr Tyr Val Leu Asn Arg Val Tyr Leu Asn Thr Thr Leu Leu Phe Thr  
50 55 60Gly Tyr Phe Pro Lys Ser Gly Ala Asn Phe Arg Asp Leu Ala Leu Lys65 70 75 80Gly Ser Ile Tyr Leu Ser  
Thr Leu Trp Tyr Lys Pro Pro Phe Leu Ser 85 90 95Asp Phe Asn Asn Gly Ile Phe Ser Lys Val Lys Asn Thr Lys  
Leu Tyr 100 105 110Val Asn Asn Thr Leu Tyr Ser Glu Phe Ser Thr Ile Val Ile Gly Ser 115 120 125Val Phe Val  
Asn Thr Ser Tyr Thr Ile Val Val Gln Pro His Asn Gly 130 135 140Ile Leu Glu Ile Thr Ala Cys Gln Tyr Thr Met  
Cys Glu Tyr Pro His145 150 155 160Thr Val Cys Lys Ser Lys Gly Ser Ile Arg Asn Glu Ser Trp His Ile 165 170  
175Asp Ser Ser Glu Pro Leu Cys Leu Phe Lys Lys Asn Phe Thr Tyr Asn 180 185 190Val Ser Ala Asp Trp Leu  
Tyr Phe His Phe Tyr Gln Glu Arg Gly Val 195 200 205Phe Tyr Ala Tyr Tyr Ala Asp Val Gly Met Pro Thr Thr  
Phe Leu Phe 210 215 220Ser Leu Tyr Leu Gly Thr Ile Leu Ser His Tyr Tyr Val Met Pro Leu225 230 235 240Thr  
Cys Asn Ala Ile Ser Ser Asn Thr Asp Asn Glu Thr Leu Glu Tyr 245 250 255Trp Val Thr Pro Leu Ser Arg Arg  
Gln Tyr Leu Leu Asn Phe Asp Glu 260 265 270His Gly Val Ile Thr Asn Ala Val Asp Cys Ser Ser Ser Phe Leu  
Ser 275 280 285Glu Ile Gln Cys Lys Thr Gln Ser Phe Ala Pro Asn Thr Gly Val Tyr 290 295 300Asp Leu Ser  
Gly Phe Thr Val Lys Pro Val Ala Thr Val Tyr Arg Arg305 310 315 320Ile Pro Asn Leu Pro Asp Cys Asp Ile Asp  
Asn Trp Leu Asn Asn Val 325 330 335Ser Val Pro Ser Pro Leu Asn Trp Glu Arg Arg Ile Phe Ser Asn Cys 340  
345 350Asn Phe Asn Leu Ser Thr Leu Leu Arg Leu Val His Val Asp Ser Phe 355 360 365Ser Cys Asn Asn Leu  
Asp Lys Ser Lys Ile Phe Gly Ser Cys Phe Asn 370 375 380Ser Ile Thr Val Asp Lys Phe Ala Ile Pro Asn Arg Arg  
Arg Asp Asp385 390 395 400Leu Gln Leu Gly Ser Ser Gly Phe Leu Gln Ser Ser Asn Tyr Lys Ile 405 410  
415Asp Ile Ser Ser Ser Ser Cys Gln Leu Tyr Tyr Ser Leu Pro Leu Val 420 425 430Asn Val Thr Ile Asn Asn Phe

Asn Pro Ser Ser Trp Asn Arg Arg Tyr 435 440 445Gly Phe Gly Ser Phe Asn Leu Ser Ser Tyr Asp Val Val Tyr  
Ser Asp 450 455 460His Cys Phe Ser Val Asn Ser Asp Phe Cys Pro Cys Ala Asp Pro Ser465 470 475 480Val  
Val Asn Ser Cys Ala Lys Ser Lys Pro Pro Ser Ala Ile Cys Pro 485 490 495Ala Gly Thr Lys Tyr Arg His Cys Asp  
Leu Asp Thr Thr Leu Tyr Val 500 505 510Lys Asn Trp Cys Arg Cys Ser Cys Leu Pro Asp Pro Ile Ser Thr Tyr  
515 520 525Ser Pro Asn Thr Cys Pro Gln Lys Lys Val Val Val Gly Ile Gly Glu 530 535 540His Cys Pro Gly Leu  
Gly Ile Asn Glu Glu Lys Cys Gly Thr Gln Leu545 550

555 560Asn His Ser Ser Cys Phe Cys Ser Pro Asp Ala Phe Leu Gly Trp Ser 565 570 575Phe Asp Ser Cys Ile Ser  
Asn Asn Arg Cys Asn Ile Phe Ser Asn Phe 580 585 590Ile Phe Asn Gly Ile Asn Ser Gly Thr Thr Cys Ser Asn  
Asp Leu Leu 595 600 605Tyr Ser Asn Thr Glu Ile Ser Thr Gly Val Cys Val Asn Tyr Asp Leu 610 615 620Tyr  
Gly Ile Thr Gly Gln Gly Ile Phe Lys Glu Val Ser Ala Ala Tyr625 630 635 640Tyr Asn Asn Trp Gln Asn Leu Leu  
Tyr Asp Ser Asn Gly Asn Ile Ile 645 650 655Gly Phe Lys Asp Phe Leu Thr Asn Lys Thr Tyr Thr Ile Leu Pro  
Cys 660 665 670Tyr Ser Gly Arg Val Ser Ala Ala Phe Tyr Gln Asn Ser Ser Ser Pro 675 680 685Ala Leu Leu Tyr  
Arg Asn Leu Lys Cys Ser Tyr Val Leu Asn Asn Ile 690 695 700Ser Phe Ile Ser Gln Pro Phe Tyr Phe Asp Ser Tyr  
Leu Gly Cys Val705 710 715 720Leu Asn Ala Val Asn Leu Thr Ser Tyr Ser Val Ser Ser Cys Asp Leu 725 730  
735Arg Met Gly Ser Gly Phe Cys Ile Asp Tyr Ala Leu Pro Ser Ser Arg 740 745 750Arg Lys Arg Arg Gly Ile Ser  
Ser Pro Tyr Arg Phe Val Thr Phe Glu 755 760 765Pro Phe Asn Val Ser Phe Val Asn Asp Ser Val Glu Thr Val  
Gly Gly 770 775 780Leu Phe Glu Ile Gln Ile Pro Thr Asn Phe Thr Ile Ala Gly His Glu785 790 795 800Glu Phe  
Ile Gln Thr Ser Ser Pro Lys Val Thr Ile Asp Cys Ser Ala 805 810 815Phe Val Cys Ser Asn Tyr Ala Ala Cys His  
Asp Leu Leu Ser Glu Tyr 820 825 830Gly Thr Phe Cys Asp Asn Ile Asn Ser Ile Leu Asn Glu Val Asn Asp 835  
840 845Leu Leu Asp Ile Thr Gln Leu Gln Val Ala Asn Ala Leu Met Gln Gly 850 855 860Val Thr Leu Ser Ser  
Asn Leu Asn Thr Asn Leu His Ser Asp Val Asp865 870 875 880Asn Ile Asp Phe Lys Ser Leu Leu Gly Cys Leu  
Gly Ser Gln Cys Gly 885 890 895Ser Ser Ser Arg Ser Leu Leu Glu Asp Leu Leu Phe Asn Lys Val Lys 900 905  
910Leu Ser Asp Val Gly Phe Val Glu Ala Tyr Asn Asn Cys Thr Gly Gly 915 920 925Ser Glu Ile Arg Asp Leu  
Leu Cys Val Gln Ser Phe Asn Gly Ile Lys 930 935 940Val Leu Pro Pro Ile Leu Ser Glu Thr Gln Ile Ser Gly Tyr  
Thr Thr945 950 955 960Ala Ala Thr Val Ala Ala Met Phe Pro Pro Trp Ser Ala Ala Ala Gly 965 970 975Val Pro  
Phe Ser Leu Asn Val Gln Tyr Arg Ile Asn Gly Leu Gly Val 980 985 990Thr Met Asp Val Leu Asn Lys Asn Gln  
Lys Leu Ile Ala Asn Ala Phe 995 1000 1005Asn Lys Ala Leu Leu Ser Ile Gln Asn Gly Phe Thr Ala Thr Asn  
1010 1015 1020Ser Ala Leu Ala Lys Ile Gln Ser Val Val Asn Ala Asn Ala Gln 1025 1030 1035Ala Leu Asn Ser  
Leu Leu Gln Gln Leu Phe Asn Lys Phe Gly Ala 1040 1045 1050Ile Ser Ser Ser Leu Gln Glu Ile Leu Ser Arg  
Leu Asp Asn Leu 1055 1060 1065Glu Ala Gln Val Gln Ile Asp Arg Leu Ile Asn Gly Arg Leu Thr 1070 1075  
1080Ala Leu Asn Ala Tyr Val Ser Gln Gln Leu Ser Asp Ile Thr Leu 1085 1090 1095Ile Lys Ala Gly Ala Ser Arg  
Ala Ile Glu Lys Val Asn Glu Cys 1100 1105 1110Val Lys Ser Gln Ser Pro Arg Ile Asn Phe Cys Gly Asn Gly Asn  
1115 1120 1125His Ile Leu Ser Leu Val Gln Asn Ala Pro Tyr Gly Leu Leu Phe 1130 1135 1140Ile His Phe Ser  
Tyr Lys Pro Thr Ser Phe Lys Thr Val Leu Val 1145 1150 1155Ser Pro Gly Leu Cys Leu Ser Gly Asp Arg Gly Ile  
Ala Pro Lys 1160 1165 1170Gln Gly Tyr Phe Ile Lys Gln Asn Asp Ser Trp Met Phe Thr Gly 1175 1180 1185Ser  
Ser Tyr Tyr Tyr Pro Glu Pro Ile Ser Asp Lys Asn Val Val 1190 1195 1200Phe Met Asn Ser Cys Ser Val Asn Phe  
Thr Lys Ala Pro Phe Ile 1205 1210 1215Tyr Leu Asn Asn Ser Ile Pro Asn Leu Ser Asp Phe Glu Ala Glu 1220  
1225 1230Leu Ser Leu Trp Phe Lys Asn His Thr Ser Ile Ala Pro Asn Leu 1235 1240 1245Thr Phe Asn Ser His  
Ile Asn Ala Thr Phe Leu Asp Leu Tyr Tyr 1250 1255 1260Glu Met Asn Val Ile Gln Glu Ser Ile Lys Ser Leu Asn  
Ser Ser 1265 1270 1275Phe Ile Asn Leu Lys Glu Ile Gly Thr Tyr Glu Met Tyr Val Lys 1280 1285 1290Trp Pro  
Trp Tyr Ile Trp Leu Leu Ile Val Ile Leu Phe Ile Ile 1295 1300 1305Phe Leu Met Ile Leu Phe Phe Ile Cys Cys Cys  
Thr Gly Cys Gly 1310 1315 1320Ser Ala Cys Phe Ser Lys Cys His Asn Cys Cys Asp Glu Tyr Gly 1325 1330  
1335Gly His Asn Asp Phe Val Ile Lys Ala Ser His Asp Asp 1340 1345 135032526PRTArtificial  
SequenceSynthetic Polypeptide 32Met Phe Ile Phe Leu Leu Phe Leu Thr Leu Thr Ser Gly Ser Asp Leu1 5 10  
15Asp Arg Ala Leu Ser Gly Ile Ala Ala Glu Gln Asp Arg Asn Thr Arg 20 25 30Glu Val Phe Ala Gln Val Lys  
Gln Met Tyr Lys Thr Pro Thr Leu Lys 35 40 45Tyr Phe Gly Gly Phe Asn Phe Ser Gln Ile Leu Pro Asp Pro Leu  
Lys 50 55 60Pro Thr Lys Arg Ser Phe Ile Glu Asp Leu Leu Phe Asn Lys Val Thr65 70 75 80Leu Ala Asp Ala  
Gly Phe Met Lys Gln Tyr Gly Glu Cys Leu Gly Asp 85 90 95Ile Asn Ala Arg Asp Leu Ile Cys Ala Gln Lys Phe  
Asn Gly Leu Thr 100 105 110Val Leu Pro Pro Leu Leu Thr Asp Asp Met Ile Ala Ala Tyr Thr Ala 115 120  
125Ala Leu Val Ser Gly Thr Ala Thr Ala Gly Trp Thr Phe Gly Ala Gly 130 135 140Ala Ala Leu Gln Ile Pro Phe  
Ala Met Gln Met Ala Tyr Arg Phe Asn145 150 155 160Gly Ile Gly Val Thr Gln Asn Val Leu Tyr Glu Asn Gln  
Lys Gln Ile 165 170 175Ala Asn Gln Phe Asn Lys Ala Ile Ser Gln Ile Gln Glu Ser Leu Thr 180 185 190Thr Thr  
Ser Thr Ala Leu Gly Lys Leu Gln Asp Val Val Asn Gln Asn 195 200 205Ala Gln Ala Leu Asn Thr Leu Val Lys



Gln Leu Ser Ser Asn Phe Gly 210 215 220Ala Ile Ser Ser Val Leu Asn Asp Ile Leu Ser Arg Leu Asp Lys Val225  
230 235 240Glu Ala Glu Val Gln Ile Asp Arg Leu Ile Thr Gly Arg Leu Gln Ser 245 250 255Leu Gln Thr Tyr Val  
Thr Gln Gln Leu Ile Arg Ala Ala Glu Ile Arg 260 265 270Ala Ser Ala Asn Leu Ala Ala Thr Lys Met Ser Glu  
Cys Val Leu Gly 275 280 285Gln Ser Lys Arg Val Asp Phe Cys Gly Lys Gly Tyr His Leu Met Ser 290 295  
300Phe Pro Gln Ala Ala Pro His Gly Val Val Phe Leu His Val Thr Tyr305 310 315 320Val Pro Ser Gln Glu Arg  
Asn Phe Thr Thr Ala Pro Ala Ile Cys His 325 330 335Glu Gly Lys Ala Tyr Phe Pro Arg Glu Gly Val Phe Val  
Phe Asn Gly 340 345 350Thr Ser Trp Phe Ile Thr Gln Arg Asn Phe Phe Ser Pro Gln Ile Ile 355 360 365Thr Thr  
Asp Asn Thr Phe Val Ser Gly Asn Cys Asp Val Val Ile Gly 370 375 380Ile Ile Asn Asn Thr Val Tyr Asp Pro Leu  
Gln Pro Glu Leu Asp Ser385 390 395 400Phe Lys Glu Glu Leu Asp Lys Tyr Phe Lys Asn His Thr Ser Pro Asp  
405 410 415Val Asp Leu Gly Asp Ile Ser Gly Ile Asn Ala Ser Val Val Asn Ile 420 425 430Gln Lys Glu Ile Asp  
Arg Leu Asn Glu Val Ala Lys Asn Leu Asn Glu 435 440 445Ser Leu Ile Asp Leu Gln Glu Leu Gly Lys Tyr Glu  
Gln Tyr Ile Lys 450 455 460Trp Pro Trp Tyr Val Trp Leu Gly Phe Ile Ala Gly Leu Ile Ala Ile465 470 475 480Val  
Met Val Thr Ile Leu Leu Cys Cys Met Thr Ser Cys Cys Ser Cys 485 490 495Leu Lys Gly Ala Cys Ser Cys Gly  
Ser Cys Cys Lys Phe Asp Glu Asp 500 505 510Asp Ser Glu Pro Val Leu Lys Gly Val Lys Leu His Tyr Thr 515  
520 52533588PRTArtificial SequenceSynthetic Polypeptide 33Met Ile His Ser Val Phe Leu Leu Met Phe Leu  
Leu Thr Pro Thr Glu1 5 10 15Ser Asp Cys Lys Leu Pro Leu Gly Gln Ser Leu Cys Ala Leu Pro Asp 20 25 30Thr  
Pro Ser Thr Leu Thr Pro Arg Ser Val Arg Ser Val Pro Gly Glu 35 40 45Met Arg Leu Ala Ser Ile Ala Phe Asn  
His Pro Ile Gln Val Asp Gln 50 55 60Leu Asn Ser Ser Tyr Phe Lys Leu Ser Ile Pro Thr Asn Phe Ser Phe65 70 75  
80Gly Val Thr Gln Glu Tyr Ile Gln Thr Thr Ile Gln Lys Val Thr Val 85 90 95Asp Cys Lys Gln Tyr Val Cys Asn  
Gly Phe Gln Lys Cys Glu Gln Leu 100 105 110Leu Arg Glu Tyr Gly Gln Phe Cys Ser Lys Ile Asn Gln Ala Leu  
His 115 120 125Gly Ala Asn Leu Arg Gln Asp Asp Ser Val Arg Asn Leu Phe Ala Ser 130 135 140Val Lys Ser  
Ser Gln Ser Ser Pro Ile Ile Pro Gly Phe Gly Gly Asp145 150 155 160Phe Asn Leu Thr Leu Leu Glu Pro Val Ser  
Ile Ser Thr Gly Ser Arg 165 170 175Ser Ala Arg Ser Ala Ile Glu Asp Leu Leu Phe Asp Lys Val Thr Ile 180 185  
190Ala Asp Pro Gly Tyr Met Gln Gly Tyr Asp Asp Cys Met Gln Gln Gly 195 200 205Pro Ala Ser Ala Arg Asp  
Leu Ile Cys Ala Gln Tyr Val Ala Gly Tyr 210 215 220Lys Val Leu Pro Pro Leu Met Asp Val Asn Met Glu Ala  
Ala Tyr Thr225 230 235 240Ser Ser Leu Leu Gly Ser Ile Ala Gly Val Gly Trp Thr Ala Gly Leu 245 250 255Ser  
Ser Phe Ala Ala Ile Pro Phe Ala Gln Ser Ile Phe Tyr Arg Leu 260 265 270Asn Gly Val Gly Ile Thr Gln Gln Val  
Leu Ser Glu Asn Gln Lys Leu 275 280 285Ile Ala Asn Lys Phe Asn Gln Ala Leu Gly Ala Met Gln Thr Gly Phe  
290 295 300Thr Thr Thr Asn Glu Ala Phe Gln Lys Val Gln Asp Ala Val Asn Asn305 310 315 320Asn Ala Gln  
Ala Leu Ser Lys Leu Ala Ser Glu Leu Ser Asn Thr Phe 325 330 335Gly Ala Ile Ser Ala Ser Ile Gly Asp Ile Ile  
Gln Arg Leu Asp Val 340 345 350Leu Glu Gln Asp Ala Gln Ile Asp Arg Leu Ile Asn Gly Arg Leu Thr 355 360  
365Thr Leu Asn Ala Phe Val Ala Gln Gln Leu Val Arg Ser Glu Ser Ala 370 375 380Ala Leu Ser Ala Gln Leu  
Ala Lys Asp Lys Val Asn Glu Cys Val Lys385 390 395 400Ala Gln Ser Lys Arg Ser Gly Phe Cys Gly Gln Gly  
Thr His Ile Val 405 410 415Ser Phe Val Val Asn Ala Pro Asn Gly Leu Tyr Phe Met His Val Gly 420 425 430Tyr  
Tyr Pro Ser Asn His Ile Glu Val Val Ser Ala Tyr Gly Leu Cys 435 440 445Asp Ala Ala Asn Pro Thr Asn Cys Ile  
Ala Pro Val Asn Gly Tyr Phe 450 455 460Ile Lys Thr Asn Asn Thr Arg Ile Val Asp Glu Trp Ser Tyr Thr Gly465  
470 475 480Ser Ser Phe Tyr Ala Pro Glu Pro Ile Thr Ser Leu Asn Thr Lys Tyr 485 490 495Val Ala Pro Gln Val  
Thr Tyr Gln Asn Ile Ser Thr Asn Leu Pro Pro 500 505 510Pro Leu Leu Gly Asn Ser Thr Gly Ile Asp Phe Gln  
Asp Glu Leu Asp 515 520 525Glu Phe Phe Lys Asn Val Ser Thr Ser Ile Pro Asn Phe Gly Ser Leu 530 535  
540Thr Gln Ile Asn Thr Thr Leu Leu Asp Leu Thr Tyr Glu Met Leu Ser545 550 555 560Leu Gln Gln Val Val  
Lys Ala Leu Asn Glu Ser Tyr Ile Asp Leu Lys 565 570 575Glu Leu Gly Asn Tyr Thr Tyr Tyr Asn Lys Trp Pro  
580 58534526PRTArtificial SequenceSynthetic Polypeptide 34Met Phe Ile Phe Leu Leu Phe Leu Thr Leu Thr  
Ser Gly Ser Asp Leu1 5 10 15Asp Arg Ala Leu Ser Gly Ile Ala Ala Glu Gln Asp Arg Asn Thr Arg 20 25 30Glu  
Val Phe Ala Gln Val Lys Gln Met Tyr Lys Thr Pro Thr Leu Lys 35 40 45Tyr Phe Gly Gly Phe Asn Phe Ser Gln  
Ile Leu Pro Asp Pro Leu Lys 50 55 60Pro Thr Lys Arg Ser Phe Ile Glu Asp Leu Leu Phe Asn Lys Val Thr65 70  
75 80Leu Ala Asp Ala Gly Phe Met Lys Gln Tyr Gly Glu Cys Leu Gly Asp 85 90 95Ile Asn Ala Arg Asp Leu  
Ile Cys Ala Gln Lys Phe Asn Gly Leu Thr 100 105 110Val Leu Pro Pro Leu Leu Thr Asp Asp Met Ile Ala Ala  
Tyr Thr Ala 115 120 125Ala Leu Val Ser Gly Thr Ala Thr Ala Gly Trp Thr Phe Gly Ala Gly 130 135 140Ala  
Ala Leu Gln Ile Pro Phe Ala Met Gln Met Ala Tyr Arg Phe Asn145 150 155 160Gly Ile Gly Val Thr Gln Asn  
Val Leu Tyr Glu Asn Gln Lys Gln Ile 165 170 175Ala Asn Gln Phe Asn Lys Ala Ile Ser Gln Ile Gln Glu Ser Leu  
Thr 180 185 190Thr Thr Ser Thr Ala Leu Gly Lys Leu Gln Asp Val Val Asn Gln Asn 195 200 205Ala Gln Ala  
Leu Asn Thr Leu Val Lys Gln Leu Ser Ser Asn Phe Gly 210 215 220Ala Ile Ser Ser Val Leu Asn Asp Ile Leu Ser  
Arg Leu Asp Lys Val225 230 235 240Glu Ala Glu Val Gln Ile Asp Arg Leu Ile Thr Gly Arg Leu Gln Ser 245  
250 255Leu Gln Thr Tyr Val Thr Gln Gln Leu Ile Arg Ala Ala Glu Ile Arg 260 265 270Ala Ser Ala Asn Leu Ala

Ala Thr Lys Met Ser Glu Cys Val Leu Gly 275 280 285Gln Ser Lys Arg Val Asp Phe Cys Gly Lys Gly Tyr His  
Leu Met Ser 290 295 300Phe Pro Gln Ala Ala Pro His Gly Val Val Phe Leu His Val Thr Tyr305 310 315 320Val  
Pro Ser Gln Glu Arg Asn Phe Thr Thr Ala Pro Ala Ile Cys His 325 330 335Glu Gly Lys Ala Tyr Phe Pro Arg  
Glu Gly Val Phe Val Phe Asn Gly 340 345 350Thr Ser Trp Phe Ile Thr Gln Arg Asn Phe Phe Ser Pro Gln Ile Ile  
355 360 365Thr Thr Asp Asn Thr Phe Val Ser Gly Asn Cys Asp Val Val Ile Gly 370 375 380Ile Ile Asn Asn Thr  
Val Tyr Asp Pro Leu Gln Pro Glu Leu Asp Ser385 390 395 400Phe Lys Glu Glu Leu Asp Lys Tyr Phe Lys Asn  
His Thr Ser Pro Asp 405 410 415Val Asp Leu Gly Asp Ile Ser Gly Ile Asn Ala Ser Val Val Asn Ile 420 425  
430Gln Lys Glu Ile Asp Arg Leu Asn Glu Val Ala Lys Asn Leu Asn Glu 435 440 445Ser Leu Ile Asp Leu Gln  
Glu Leu Gly Lys Tyr Glu Gln Tyr Ile Lys 450 455 460Trp Pro Trp Tyr Val Trp Leu Gly Phe Ile Ala Gly Leu Ile  
Ala Ile465 470 475 480Val Met Val Thr Ile Leu Leu Cys Cys Met Thr Ser Cys Cys Ser Cys 485 490 495Leu Lys  
Gly Ala Cys Ser Cys Gly Ser Cys Cys Lys Phe Asp Glu Asp 500 505 510Asp Ser Glu Pro Val Leu Lys Gly Val  
Lys Leu His Tyr Thr 515 520 525351864DNAArtificial SequenceSynthetic Polynucleotide 35tcaagctttt

ggacctcgt acagaagcta atacgactca ctatagggaa ataagagaga 60aagaagagt aagaagaaat ataagagcca ccatgggtct  
caaggtgaac gtctctgccg 120tattcatggc agtactgtta actctccaaa caccgcggc tcaaatcat tggggcaatc 180tctctaagat  
aggggtagta ggaataggaa gtgcaagcta caaagttatg actcgttcca 240gccatcaatc attagtcata aaattaatgc ccaataaac tctcctcaat  
aactgcacga 300gggtagatg tgcagaatac aggagactac taagaacagt ttggaacca attagggatg 360cacttaatgc aatgaccag  
aacataaggc cgggtcagag cgtagcttca agtaggagac 420acaagagatt tgcgggagta gtctggcag gtgcggcct aggtgttgc  
acagctgctc 480agataacagc cggcattgca cttaccggc ccatgctgaa ctctcagcgc atcgacaatc 540tgagagcagc cctgaaact  
actaatcagg caattgaggc aatcagacaa gcagggcagg 600agatgatatt ggctgttcag ggtgtccaag actacatcaa taatgagctg  
atacctgcta 660tgaaccagct atctgtgat ctaatcggc agaagctcgg gctcaaatg cttagatact 720atacagaaat cctgtcatta  
tttgcccca gcctacggga cccatatact gcgagatg 780ctatccagc tttgagttat gcactggag gagatataca taaggtgta  
gaaaagctc 840gatacagtg aggegatta ctaggcatct tagagagcag aggaataaag gctcggataa 900ctcacgctca cacagatcc  
tactcatag tctcagat agcctatcc acgctgtccg 960agattaagg ggtgattgc caccggctag aggggtctc gtacaacata  
ggctctcaag 1020agtgtatc cactgtccc aagtatgtg caaccaagg gtacattc tgaatttg 1080atgagtcac atgtacttc  
atgccagagg ggactgtg cagccaaaat gcctgtacc 1140cgtatgctc tctgtccaa gaatgcctc ggggtccac caagtctgt  
gctcgtacac 1200cgtatccg gtcttttggg aaccggttca tttatcaca agggaacct aatagccaat 1260gtgcatcaat tctttgtaag  
tgttacaca caggtacgat tattaatcaa gacctgaca 1320agatcctaac atacattgct gccgatcgt ccccgtagt cgaggtgaac  
ggcgtgaca 1380tccaagtcgg gacgaggagg tatccagac ctgtgtact gcacagaat gacctcggc 1440ctccatatac attggagagg  
ttgacgtag ggacaaatc ggggaatgca attgccaat 1500tgaggatgc caaggaattg ttggaatcat cggaccagat attgagaagt  
atgaaaggt 1560atcagacac tagcatagtc tacatcctga ttgcagtgt tcttgaggg ttgatagga 1620ccccacttt aatatgttc  
tgcaggggc gttgtaaca aaaggagaa caagttgta 1680gtcaagacc aggcctaaag cctgacctta caggaacac aaaatcctat  
gtaagatgc 1740ttgatgata ataggctgga gctcgggtg ccaagcttct tgccttgg gctcccc 1800agcctcct cccctctc  
caccgtacc cccgtgtt tgaataaag tctgagtg 1860cggc 1864361653DNAArtificial SequenceSynthetic  
Polynucleotide 36atgggtctca aggtgaactc ctctgccgta tcatggcag tactgttaac tctccaaaca 60cccgcggc aaattcattg  
ggcaatctc tctaagatag gggtagtagg aataggaagt 120gcaagctaca aagttatgac tegtccagc catcaatcat tagtcataaa attaagccc  
180aatataact tctcaataa ctgcacgagg gtagagattg cagaatacag gagactacta 240agaacagttt tggaaacat tagggatgca  
cttaatgcaa tgaccagaa cataaggccc 300gttcagagcg tagcttcaag taggagacac aagagattg cgggagtagt cctggcaggt  
360gcggccctag gtgttccac agctgctcag ataacagccg gcattgact taccggctc 420atgctgaact ctcaggcct cgacaatc  
agagcgagcc tggaaactac taatcaggca 480attgaggcaa tcagacaagc agggcaggag atgatattgg ctgtcaggg tgccaagac  
540tacatcaata atgagctgat accgtctatg aaccagctat cttgtgatc aatcggtcag 600aagctcggc tcaattgct tagatactat  
acagaaatcc tgcattatt tgccccagc 660ctacgggacc ccatatctgc ggagatatct atccaggctt tgagttatgc acttgaggga  
720gatataata aggtgttaga aaagctcggg tacagtggag gcgattact aggcattta 780gagagcagag gaataaaggc tcggataact  
cacgtcaca cagagtcta cttcatagtc 840ctcagatag cctatccgac gctgtccgag attaagggg tgattgtcca cggctagag  
900ggggtctcgt acaacatagg ctctcaagag tggatacca ctgtccca gtagttgca 960accaagggt acctatctc gaattttag  
gagtcacat gactttcat gccagagggg 1020actgtgtgca gcaaaatgc cttgtaccg atgagctc tctccaaga atgcctcgg  
1080gggtccaca agtctgtgc tctacact gatacgggt ctttgggaa cgggtcatt 1140ttatcacaag ggaacctaat agccaattg  
gcatcaatc tttgtaagt ttacacaaca 1200ggtacgatta ttaataaga cctgacaag atcctaaca acattgctc cgatectgc  
1260ccgtagtc aggtgaacgg cgtgaccac caagtcggga gcaggagta tccagacgt 1320gtgtacttc acagaattga cctcgtcct  
cccatatcat tggagaggt ggacgtagg 1380acaatctgg ggaatgcaat tgccaaattg gaggatgcca aggaattgt ggaatcatg  
1440gaccagatag tgagaagtat gaaaggtta tcgagcacta gcatagtcta catcctgatt 1500gcagtgtgct ttggagggt gatagggat  
cccacttaa tatgtgctg cagggggcgt 1560tgaacaaaa agggagaaca agttggtatg tcaagaccag gcctaaagcc tgacctta  
1620ggaacatcaa aatcctatg aagatcgtt tga 1653371925DNAArtificial SequenceSynthetic Polynucleotide  
37ggggaataa gagagaaag aagagtaaga agaaataa gagccaccat ggtctcaag 60gtgaactct ctgccgtatt catggcagta

ctgttaactc tccaaacacc cgccgggtcaa 120attcattggg gcaatctctc taagataggg gtagtaggaa taggaagtgc aagctacaaa  
180gttatgactc gttccagcca tcaatcatta gtcataaaat taatgcccaa tataactctc 240ctcaataact gcacgagggt agagattgca  
gaatacagga gactactaag aacagtttg 300gaaccaatta gggatgactc taatgcaatg acccagaaca taaggccggg tcagagcgta  
360gcttcaagta ggagacacaa gagatttgcg ggagtagtcc tggcaggtgc ggcctaggt 420gttgccacag ctgctcagat aacagccggc  
attgcacttc accgggtccat gctgaactct 480caggccatcg acaatctgag agcgagcctg gaaactacta atcaggcaat tgaggcaatc  
540agacaagcag ggcaggagat gatattggct gttcagggtg tccaagacta catcaataat 600gagctgatac cgtctatgaa ccagctatct  
tgtgatctaa tcggtcagaa gtcggggctc 660aaattgctta gatactatac agaaatcctg tcattatttg gccccagcct acgggacccc  
720atatctgcgg agatatctat ccaggcttg agttatgcac ttggaggaga tatcaataag 780gtgttagaaa agctcggata cagtggaggc  
gatttactag gcactctaga gagcagagga 840ataaaggctc ggataactca cgtcgacaca gactcctact tcatagtctc cagtatagcc  
900tatccgacgc tgtccgagat taaggggggtg attgtccacc ggctagaggg ggtctctgac 960aacataggtc tcaagagtg gtataccact  
gtgcccagt atgttgaac ccaagggtac 1020cttatctcga attttgatga gtcacatgt actttcatgc cagagggggac tgtgtgcagc  
1080caaatgcct tgtaccgat gactcctctg ctccaagaat gctcggggg gtcaccaag 1140tctctgtctc gtacactcgt atccgggtct  
tttgggaacc ggttcatttt atcacaaggg 1200aacctaataag ccaattgtgc atcaattctt tgtaagtgtt acacaacagg tacgattatt  
1260aatcaagacc ctgacaagat ctaacatac attgtctgcc atcgtctccc ggtagctcag 1320gtgaacggcg tgaccatcca agtcggggagc  
aggaggtatc cagacgtgt gactctgcac 1380agaattgacc tcggctctcc catatcattg gagaggttg acgtagggac aaatctgggg  
1440aatgcaattg ccaattgga ggatgccaag gaattgttg aatcatcgga ccagatattg 1500agaagtatga aagtttacc gagcactagc  
atagtctaca tctgattgc agtgtgtctt 1560ggaggggtga tagggatccc cactttaata tgtgtctgca gggggcggtg taacaaaaag  
1620ggagaacaag ttggtatgc aagaccagc ctaaagcctg acctacagg aacatcaaaa 1680tctatgtaa gatcgtttg atgataatag  
gctggagcct cgggtggcaa gcttctgcc 1740ccttgggct cccccagcc cctctccc tctctgacc cgtaccccc gggtcttga  
1800ataaagtctg agtggggcg aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1860aaaaaaaaa aaaaaaaaaa  
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1920tctag 1925381864DNAArtificial SequenceSynthetic  
Polynucleotide 38tcaagctttt ggaccctctg acagaagcta atacgactca ctatagggaa ataagagaga 60aaagaagagt aagaagaat  
ataagagcca ccatgggtct caaggtgaac gtctctgca 120tattcatggc agtactgta actctcaaa caccaccgg tcaatccat tggggcaatc  
180tctctaagat aggggtgta ggggtaggaa gtgcaagcta caaagtatg actcgtcca 240gcatcaatc attagtcata aagttatgc  
ccaatataac tctctcaac aattgcagga 300gggtagggat tgcagaatac aggagactac tgagaacagt tctggaacca attagagatg  
360cacttaatgc aatgaccag aatataagac cgggtcagag ttagcttca agtaggagac 420acaagagatt tgcgggagt gctctggcag  
gtcgggacct aggcgttgc acagctgctc 480aaataacagc cggattgca cttaccagt ccatgctgaa ctctcaagcc atcgacaatc  
540tgagagcgag ctagaaact actaatcagg caattgagc aatcagacaa gcagggcagg 600agatgatatt gctgttcag ggtgtccaag  
actacatca taatgagctg ataccgtctc 660tgaatcaact atcttgtgac ttaatcgcc agaagctagg gctcaattg ctgatact  
720atacagaaat cctgtcatta tttgcccga gttaccggga ccccatatct gggagatat 780ctatccagc tttgagctat gcgcttggag  
gagatatcaa taaggtgtt gaaaagctc 840gatacagtgg aggtgatcta ctgggcatct tagagagcag aggaataag gcccgataa  
900ctcacgtcga cacagagtc tacttcatg tactcagat agcctatcc agctatcc 960agattaagg ggtgattgc caccggtag  
agggggtctc gtacaacata ggctctcaag 1020agtgttatac cactgtccc aagtattg caaccaagg gtacctatc tgaattttg  
1080atgagtcac atgcacttc atgccagag ggactgtgt cagccagaat gcctgtacc 1140cagtagtc tctgtccaa gaatgcctc  
gggggtccac taagtctgt gctctgacac 1200ctgatccgg gctttcggg aaccggttca tttatcaca ggggaacct atagccaatt  
1260gtgcatcaat ctttgcaag tttacaca caggaacaat cattaatca gacctgaca 1320agatcctaac atacattgct gccgatcact  
gcccgtgtg cgaggtgaat ggcgtgacca 1380tcaagtcgg gagcaggagg tatccggac ctgtgtact gcacaggatt gacctggctc  
1440ctccatatac tttggagag ttggacgtag ggacaaatct ggggaatgca attgctaagt 1500tgaggatgc caaggaattg ttgagtcac  
cggaccagat attgaggagt atgaaaggt 1560tatcgagcac tagtatagt tacatctga ttgagctgt tcttgagga ttgataggga  
1620tccccgttt aatattgtc tgcagggggc gttgtaaca gaaggagaa caagttgta 1680tgtaagacc aggcctaaag cctgatctta  
caggaacac aaaaactat gtaagtcac 1740tctgatgata ataggctgga gctcgggtg ccaagcttct tccccgtg gctcccc  
1800agccccctc cccctctc caccgtacc cccgtgtct tgaataaag tctgagtg 1860cggc 1864391653DNAArtificial  
SequenceSynthetic Polynucleotide 39atgggtctca aggtgaactc ctctgcata tcatggcag tactgttaac tctcaaca  
60cccaccgctc aatccattg ggcgaatctc tcaagatag gggtgtagg gtaggaagt 120gcaagctaca aagttatgac tcttccagc  
catcaatcat tagcataaa gtaattgcc 180aatataact tctcaaca ttgcagagg gtagggattg cagaatacag gagactactg  
240agaacagttc tgaaccaat tagagatgca cttaatgca tgaccagaa tataagaccg 300gttcagagtg tagcttcaag taggagacac  
aagagattg cgggagttg cctggcaggt 360cggccctag gcgttgcac agctgctca ataacagccg gtattgact tcaccagtc  
420atgctgaact ctcaagccat cgacaatctg agagcgagcc tagaaactac taatcaggca 480attgaggcaa tcagacaagc agggcaggag  
atgatattg ctgtcaggg tgccaagac 540tatatcaata atgagctgat accgtctat aatcaatct cttgtgatt aatcggccag  
600aagctagggc tcaattgct cagatactat acagaatcc tgcattatt tggccccagc 660ttaccgggacc ccatatctgc ggagatatct  
atccaggctt tgagctatgc gttggagga 720gatataata aggtgttga aaagctcggg tacagtggag gtgatctact gggcatctta  
780gagagcagag gaataaaggc ccgataact cactcgaca cagagtctc cttcattgta 840ctcagtatag cctatccgac gctatccgag  
attaaggggg tgattgcca ccggctagag 900ggggtctctg acaacatagg ctctcaagag ttgtatacca ctgtgcccga gtatgtgca  
960accaagggg acctatctc gaattttgat gactcctat gccagaggg 1020actgtgtgca gccagaatgc cttgtacccg

atgagtctc tgc tccaaga atgcctccgg 1080gggtccacta agtctctgtc tcttacactc gtatccgggt ctttcgggaa cgggttcatt  
1140ttatcacagg ggaacctaat agccaattgt gcataatcc tttgcaagt ttacacaaca 1200ggaacaatca ttaatcaaga ccctgacaag  
atcctaaca acattgctgc cgtactcgc 1260ccgggtggtc aggtgaatgg cgtgaccatc caagtcggga gcaggaggta tccggacgct  
1320gtgtacttgc acaggattga cctcggctct cccatatctt tggagaggtt ggacgtaggg 1380acaaatctgg ggaatgcaat tgctaagttg  
gaggatgcca aggaattgtt ggagtcacg 1440gaccagatat tgaggagat gaaaggttta tgcagcacta gtatagtta catctgtatt  
1500gcagtgtgct ttggaggatt gatagggatc cccgctttaa tatgttgcg cagggggcgt 1560tgtaacaaga agggagaaca agttggtatg  
tcaagaccag gcctaaagcc tgatcttaca 1620ggaacatcaa aatcctatgt aaggtcactc tga 1653401925DNAArtificial  
SequenceSynthetic Polynucleotide 40ggggaaataa gagagaaaag aagagtaaga agaataataa gagccaccat gggctcaag  
60gtgaacgtct ctgcatatt catggcagta ctgtaactc tcaaacacc caccggta 120atccattggg gcaatctctc taagataggg  
gtggtagggg taggaagtgc aagctacaaa 180gttatgactc gtccagcca tcaatcatta gtcataaagt taatgccc aaataactc  
240ctcaacaatt gcacgagggt agggattgca gaatacagga gactactgag aacagttctg 300gaaccaata gagatgcact taatgcaatg  
accagaata taagaccggt tcagagtga 360gcttcaagta ggagacacaa gagatttgcg ggagtgtcc tggcagggtc ggcctaggc  
420gttgccacag ctgctcaat aacagccggt atgcaactc accagttcat gctgaactc 480caagccatc acaatctgag agcagccta  
gaaactacta atcaggcaat tgaggcaatc 540agacaagcag ggcaggagat gatattggct gttcagggtg tccaagacta catcaataat  
600gagctgatac cgtctatgaa tcaactatct tgtgattaa tggccagaa gctagggtc 660aaattgctca gatactatac agaaatctg  
tcattattg gcccagctt acgggacccc 720atctctcgg agatatctat ccaggctttg agctatgctc ttggaggaga tatcaataag  
780gtgttgaaa agctcggata cagtggaggt gatctactgg gcatctaga gagcagagga 840ataaaggccc ggataactca cgtcgacaca  
gagctctact ctattgtact cagtatagc 900tatccgacgc tatccgagat taaggggggtg attgtccacc ggctagaggg ggtctcgtac  
960aacataggct ctcaagagtg gtatacactc gtgcccaggt atgttgaac ccaagggtac 1020cttatctega attttgatga gtcacatgc  
acttctatgc cagaggggac tgtgtgcagc 1080cagaatgctc tctaccgat gagtctctc ctccaagaat gcctccgggg gtccactaag  
1140tctgtgctc gtacactcgt atccgggtc ttcgggaacc ggttcatttt atcacagggg 1200aacctaag ccaattgtgc atcaatcct  
tgcaagtgt acacaacagg acaatcatt 1260aatcaagacc ctgacaagat ctaacatac attgtctccg atcactgccc ggtggtcgag  
1320gtgaatggcg tgaccatca agtcggggagc agggagtatc cggacgtgt gacttgcac 1380aggattgacc tggctctcc catatctttg  
gagaggttg acgtagggac aaatctgggg 1440aatgcaattg ctaagtggga ggatgccaag gaattgttg agtcacgga ccagatattg  
1500aggagtatga aaggtttatc gagcactagt atagttaca tctgattgc agtgtgctt 1560ggaggattga taggatccc cgtttaata  
tgttctgca gggggcgttg taacaagaag 1620ggagaacaag ttgtatgct aagaccaggc ctaaagcctg atctacagg aacatcaaaa  
1680tctatgtaa ggtcactctg atgataatag gctggagcct cgggtggcaa gcttctgccc 1740ccttgggct cccccagcc cctctcccc  
ttctgcacc cgtaccccc tggtctttga 1800ataaagctc agtggggcgc aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa  
1860aaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa 1920tctag 1925412065DNAArtificial  
SequenceSynthetic Polynucleotide 41tcaagctttt ggaccctcgt acagaagta atcagactca ctataggga ataagagaga  
60aaagaagagt aagaagaat ataagagcca ccatgtcacc gcaacgagac cggataaatg 120cctctaca agataaccct tatccaagg  
gaagtaggat agttattaac agagaacatc 180ttatgattga cagacctat gttctgctg ctgttctgtt cgtcatgttt ctgagcttga 240tcggattgct  
ggcaattgca ggcatagac ttcacgggc agccatctac acccgggaga 300tcataaaag cctcagttac aatctggatg tgactaactc  
catcgagcat caggtaagg 360acgtgctgac accactcttt aaaatcatc gggatgaagt ggcctgaga acacccaga 420gattcactga  
cctagtgaat tcatctcgg acaagattaa atctctaat cccgataggg 480agtacgactc cagagatctc acttggtgca tcaaccgccc  
agagaggatc aaactagatt 540atgatcaata ctgtcagat gtggtgctg aagagctcat gaatgcattg gtgaactca 600ctctactgga  
gaccagaaca accactcagt tctagctgt ctcaaaggga aactgctcag 660ggcccactac aatcagaggt caattctca acatgctct  
gtcctgttg gactgtact 720taggtcgagg ttcaatgtg tcatctatg tcaactatg atccaggga atgtatgggg 780gaacctactc  
agttgaaaag ctaactgta acagcaaagg gtcagagttg tcacaactga 840gcatgtaccg agtgtttgaa gtggtgtg taagaacc  
gggtttgggg gctccggtgt 900tccatagc aaactatctt gagcaaccag tcagtaatgg tctcggcaac tgatgttg 960cttggggga  
gtcaaacctc gcagccctt gtcaggggga cgttctatc ataattcct 1020atcagggatc agggaaagt gtcagcttcc agctcgtca  
gtgggtgct tggaaatccc 1080caaccgacat gcaatctggt gtcctctat caacggatga tccagtggtg gacaggttt 1140acctctac  
tcacagaggt gcatcgtc acaatcaagc aaaatgggt gtcctgaca 1200cacgaacaga tgacaagt gcaatggaga catgcttca  
gcaggcgtg aaaggtaaaa 1260tccaagcact ctgcgagaat cccagtggtg taccattgaa ggataacagg atctctcat 1320acgggtcct  
gtctgtgat ctgagctga cgttgagct taaaatcaaa attgctcgg 1380gattcgggcc atgatcaca caggtctcag ggatggacct  
atacaaatcc aactgcaaca 1440atgtgtattg gctgactatt ccccaatga gaaatctagc cttaggcgta atcaacacat 1500tgagtggtg  
accgagattc aaggttagtc ccaactctt cactgtcca ataaaggaag 1560caggcgaaga ctgcatgccc ccaacatacc tacctgagga  
ggtggacggt gatgcaaac 1620tcagttcaa cctggtgatt ctacctggtc aagatctca atagttttg gcaacctacg 1680atacctccag  
ggtgagcat gctgtggtt attagttta cagcccagc cgtcatttt 1740ctactttta tcttttagg ttgctataa aggggtccc aatgcaacta  
caagtggaat 1800gcttcatg ggatcaaaaa ctctggtgccc gtcactctg tgtgcttgc gactcagaat 1860ccggtggact tactctac  
tctgggatg tggcatggg agtcagctgc acagctacc 1920gggaagatg aaccaatcgc agataatgat aataggctg agcctcggtg  
gccaagctc 1980ttgcccctt ggctcccc cagccctcc tccctctc gaccctac cccgtggtc 2040ttgataaa gctgagtg  
gccc 2065421854DNAArtificial SequenceSynthetic Polynucleotide 42atgtaccgc aacgagaccg gataatgccc  
ttctacaag ataaccctta tccaaggga 60agtaggatag ttattaacag agaactctt atgattgaca gacctatgt tctgctgct 120gttctgctg

tcatgtttct gagcttgatc ggattgctgg caattgcagg cattagactt 180catcgggcag ccatctacac cgcggagatc cataaaagcc  
tcagtaccaa tctggatgtg 240actaactcca tcgagcatca ggtcaaggac gtgctgacac cactctttaa aatcatcggg 300gatgaagtgg  
gcctgagaac acctcagaga ttcactgacc tagtgaaatt catctcggac 360aagattaaat tecttaatcc ggatagggag tacgacttca  
gagatctcac ttggtgcatc 420aacccgccag agaggatcaa actagattat gatcaatact gtgcagatgt ggctgctgaa 480gagctcatga  
atgcattggt gaactcaact ctactggaga ccagaacaac cactcagttc 540ctagctgtct caaagggaaa ctgctcaggg cccactacaa  
tcagaggtca attctcaaac 600atgctgctgt ccttgttga cttgtactta ggctcaggtt acaatgtgct atctatagtc 660actatgacat  
cccagggaaat gtatggggga acctacatg ttgaaaagcc taatctgaac 720agcaaagggt cagagttgct acaactgagc atgtaccgag  
tgttgaagt aggtgtgac 780agaaccccg gtttgggggc tccggtgctc catatgacaa actattttga gcaaccagtc 840agtaatggct  
tcggcaactg tatggtggct ttgggggagc tcaaactgc agcccttct 900cacggggcag attctatcat aattcctat cagggatcag  
ggaaaggtgt cagcttcag 960ctcgtcaagc tgggtgtctg gaaatccca accgacatgc aatcctgggt cccctatca 1020acggatgac  
cagtggtaga caggcttac ctctcatctc acagaggtgt catcgtgac 1080aatcaagcaa aatgggctgt cccgacaaca cgaacagatg  
acaagttgcg aatggagaca 1140tgcttcagc aggcgtgtaa aggtaaaac caagcactct gcgagaatcc cgagtgggta 1200ccattgaagg  
ataacagat tctctacac ggggtcctgt ctgtgatct gactctgac 1260gttgagctta aatcaaaat tgcttcggga ttcgggccat tgatcacaca  
cggtcaggg 1320atggacctat acaaatccaa ctgcaacaat gtgtattgac tgactattcc gcaatgaga 1380aatctagctt

taggcgtaat caacacattg gactggatc cgagattcaa ggtagtccc 1440aacctcttca ctgtcccaat taaggaagca ggcaagact  
gccatgccc aacataccta 1500cctgcggagg tggacggtga tctcaaac agttccaacc tgggtattct acctggtcaa 1560gatctccaat  
atgttttggc aacctagat acctcaggg ttgagcatgc tgtgtttat 1620tacgtttaca gccaagccg ctcttttct tacttttct ctttaggt  
gcctataaag 1680gggggtccaa tcgaactaca agtgaatgc tccatggg atcaaaaact ctggtgccgt 1740cactctctgt tcttgcgga  
ctcagaatcc ggtgactta tcaactc tgggatggt 1800ggcatgggag tcagctgcac agctaccgg gaagatggaa ccaatcgcag ataa  
1854432126DNAArtificial SequenceSynthetic Polynucleotide 43ggggaaataa gagagaaaag aagagtaaga agaaatataa  
gagccaccat gtcaccgaa 60cgagaccgga taaatgcctt ctacaagat aaccttacc ccaagggag taggatagtt 120attaacagag  
aacatctat gattgacaga ccctatgct tctgtgctc 180atgttttga gcttgcagc attgctggca attgcaggca ttagacttca  
tcgggcagcc 240atctacacc cggagatcca taaaagcctc agtaccatc tggatgtgac taactcacc 300gagcatcagg tcaaggacgt  
gctgacacca ctcttataa tcatcgggga tgaagtggc 360ctgagaacac ctacagatc cactgaccta gtgaaattca tctcggacaa  
gattaaattc 420cttaatccgg atagggagta cacttcaga gatctcact ggtgacatca cccgccagag 480aggatcaaac tagattatga  
tcaactgtg gcagatgtg ctgctgaaga gctcatgaa 540gcattggtga actcaactct actggagacc agaacaacca ctacttct agctgtctca  
600aagggaaact gctcaggcc cactacaac agaggtcaat tctcaaacat gctgctgccc 660ttgtggact tgacttagg tcgaggttac  
aatgtgcat ctatagtcac tatgacatc 720cagggatgt atgggggaa ctacctagt gaaaagccta atctgaacag caaagggtca  
780gagttgtcac aactgagcat gtaccgagtg tttgaagtag gtgtgacag aaacccgggt 840ttgggggctc cgggttcca tatgacaac  
tatttgagc aaccagtcg taatgctc 900ggcaactgta tgggtgctt gggggagctc aaactcgcag cctttgtca cggggacgat  
960tctatcataa ttcctatca gggatcagg aaaggtgca gcttcagct cgtcaagctg 1020gggtgctgga aatcccaac cgacatgcaa  
tctgggtcc cctatcaac gcatgaccca 1080gtgtagaca gctttacct ctatctcac agaggtgca tctgacaaa tcaagcaaaa  
1140tgggctgtcc cgacaacag aacagatgac aagtgcgaa tggagacatg ctccagcag 1200gcgtgtaaa gtaaaatcca agcactctg  
gagaatccc agtgggtacc attgaagat 1260aacaggatc ctctacagc ggtcctgct gttgatctga gtctgacggt tgactttaa  
1320atcaaaattg ctccgggatt cgggccattg atcacacag gctcaggat ggacctatc 1380aaatccaact gcaacaatgt gtattggctg  
actattccgc caatgagaaa tctagcctta 1440ggcgtaatca acacattgga tggataccg agattcaagg ttactccaa cctcttact  
1500gtcccaatta aggaagcagg cgaagactgc catgccccaa catacctacc tgcggaggtg 1560gacggtgatg tcaaacctag ttcaacctg  
gtattctac ctggtcaaga tctcaaat 1620gttttgcaa cctacgatac ctccagggtt gagcatgctg tggttatta cgtttacagc  
1680ccaagccgct cattttcta cttttact ttaggttgc ctataaagg ggtccaatc 1740gaactacaag tggatgctt cacatgggat  
caaaaactct ggtgctgca ctctgtgtg 1800cttgcggact cagaatccgg tggacttacc actcactctg gtaggtggg catgggagtc  
1860agctgacag ctaccgggga agatggaacc aatcgcagat aatgataata ggctggagcc 1920tcggtggcca agcttcttgc ccttgggccc  
tccccccag cctctctccc ctctctgac 1980ccgtaccccc gtggtctttg aataaagtct gactgggccc caaaaaaaaa aaaaaaaaa  
2040aaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa 2100aaaaaaaa aaaaaaaaa atctag  
2126442065DNAArtificial SequenceSynthetic Polynucleotide 44tcaagcttt ggacctctg acagaagcta atcagactca  
ctatagggaa ataagagaga 60aaagaagat aagaagaaat ataagagcca ccatgtcacc acaacgagac cggataaatg 120ccttctaca  
agacaacccc catcctaagg gaagtaggat agttattaac agagaacac 180ttatgattga tagaccttat gtttctgctg ctgtctatt cgtcatggt  
ctgagcttga 240tcgggtgct agccattgca ggcattagac tcatcgggc agccatctac accgcagaga 300tcataaaag cctcagcacc  
aatctggatg taactaact aatcagcat caggttaagg 360actgctgac accactctc aagatcagc gtgatgaagt gggcttgagg  
acacctcaga 420gattcactga ctagtgaag tcatctctg acaagattaa attccttaac cggacaggg 480aatacagact cagagatctc  
actggtgta tcaacccgc agagagaac aattggatt 540atgatcaata ctgtcagat gtggctgctg aagaactcat gaatgattg gtgaactca  
600ctctactgga gaccagggca accaatcagt tctagctgt ctcaaaggga aactgctcag 660ggcccactac aatcagagcc caattctca  
acatgctgct gctcctgtg gactgtatt 720taagtcaggg ttacaatgt tcatctatag tcaatgac atcccagga atgtacggg  
780gaacttacct agtggaaaag ctaactctga gcagcaagg gtcagagttg tcacaactga 840gcatgcacc agtgtttgaa gtaggtgta

tcagaaatcc gggtttgggg gctccggtat 900tccatgatgac aaactatctt gagcaaccag tcagtaatga ttcagcaac tgcattggtg  
960ctttggggga gctcaagttc gcagccctct gtcacaggga agattctatc acaattccct 1020atcagggatc agggaaaggt gtcagttcc  
agcttgcaa gctaggtgct tggaaatccc 1080caaccgacat gcaatctggt gtcacctat caacggatga tccagtata gacaggctt  
1140acctctc tccagaggc gttatcgctg acaatcaagc aaaatgggct gtcggacaa 1200cacggacaga tgacaagttg cgaatggaga  
catgctcca gcaggcgtg aagggtaaaa 1260tcaagcact ttgcgagaat cccgagtga caccattgaa ggataacagg attcctcat  
1320acggggctt gtctgtgat ctgagtctga cagttgagct taaaatcaaa attgtttcag 1380gattcgggcc attgatcaca cacggttcag  
ggatggacct atacaaatcc aaccacaaca 1440atatgtattg gctgactatc ccgcaatga agaactggc ctaggtgta atcaacacat  
1500tgagtgat accgagattc aaggttagtc ccaacctct cactgttcca attaaggaag 1560caggcgagga ctgcatgccc ccaacatacc  
tactgcgga ggtggatggt gatgtcaaac 1620tcagtcca tctgggtatt ctacctggtc aagatctcca atattgtctg gcaacctagc  
1680atactccag agttgaacat gctgtagttt attagttta cagcccaagc cgctcattt 1740cttacttta tcttttagg ttgctgttaa  
ggggggctcc cattgaatta caagtgaat 1800gcttcacatg ggacaaaaaa ctctggtgccc gtcacttctg tgtgcttgcg gactcagaat  
1860ctggtggaca tactactcac tctgggatgg tgggcatggg agtcagctgc acagccactc 1920gggaagatgg aaccagccgc agatagtgat  
aataggctgg agcctcggtg gccaagcttc 1980ttgccccctg ggctcccccc cagccctccc tccccctct gcaccctgac cccctggctc  
2040tttgaataaa gtctgagtgg gcggc 2065451854DNAArtificial SequenceSynthetic Polynucleotide 45atgtcaccac  
aacgagaccg gataaatgcc tttacaaaag acaacccccca tctaaggga 60agtaggatag ttataacag agaacatctt atgattgata gacctatgt  
tttctggct 120gttctattcg tcatgtttct gagcttgatc ggggtgctag ccattgcagg cattagactt 180catcgggcag ccatctacac  
cgcagagatc cataaaagcc tcagaccaa tctggatgta 240actaactcaa tcgagcatca ggttaaggac gtgctgacac cactcttcaa  
gatcatcgg 300gatgaagtgg gcttgaggac acctcagaga ttcactgacc tagtgaagtt catctctgac 360aagattaat tcttaatcc  
ggacagggaa tacgacttca gagatctcac ttggtgtatc 420aacccgccag agagaatcaa attggattat gatcaatact gtgcagatgt  
ggctgctgaa 480gaactcatga atgcattggt gaactcaact ctactggaga ccagggcaac caatcagttc 540ctagctgtct caaagggaaa  
ctgctcagg ccactacaa tcagaggcca attctcaaac 600atgtcgtgt cctgttggga ctgtattta agtcgaggtt acaatgtgc atctatagtc  
660actatgacat cccagggaa gtacggggga acttacctag tggaaaagcc taactgagc 720agcaagggt cagagttgac acaactgagc  
atgcaccgag tgtttgaagt aggtgtatc 780agaaatccgg gttgggggc tccggtatc catatgacaa actatcttga gcaaccagtc  
840agtaatgatt tcagcaactg catggtggt tggggggagc tcaagttgc agcctctgt 900cacagggaag attctatcac aattccctat  
cagggatcag ggaaaggtg cagctccag 960ctgtcaagc taggtgtctg gaaatcccc accgacatgc aatcctgggt cccctatca  
1020acggatgac cagtgataga caggctttac ctctatctc acagagcgt tategtgac 1080aatcaagcaa aatgggctgt cccgacaaca  
cggacagatg acaagttgcg aatggagaca 1140gtctccagc agcgtgtaa ggttaaaatc caagcacttt gcgagaatcc cgagtggaca  
1200ccattgaagg ataacaggat tcttcatac ggggtctgt ctgtgtatct gactctgaca 1260gttgagctta aatcaaaaat tgttcagga  
ttcgggcat tgatcacaca cggttcagg 1320atggacctat acaaatccaa ccacaacaat atgtattgag tgactatccc gccaatgaag  
1380aacctggcct taggtgtaat caacacattg gagtggatc cgagattcaa ggttagtccc 1440aacctcttca ctgttcaat taaggaagca  
ggcgaggact gccatgcccc aacataccta 1500cctgcggagg tggatggtga tgcaaaact agttcaatc tgggtattct acctggtcaa  
1560gatctcaat atgttctgac aacctagat actccagag ttgaacatgc ttagtttat 1620tacgtttaca gccaagccg ctctttct  
tactttatc cttttaggt gctgtaaag 1680gggggtcccc tgaattaca agtggatgc ttcacatggg accaaaaact ctgggtccgt  
1740cactctgtg tcttgcgga ctcagaatc ggtggacata tcaactcact tgggatggtg 1800ggcatgggag tcagctgac agccactcg  
gaagatggaa ccagccgag atag 1854462126DNAArtificial SequenceSynthetic Polynucleotide 46gggggaaataa  
gagagaaaag aagagtaaga agaaataa gagccacct gtcaccacaa 60cgagaccgga taaatgctt ctacaagac aacccccatc  
ctaagggaag taggatagt 120attaacagag aacatctt gattgataga cctatgtt tctgtgctgt tctatctgc 180atgtttctga gcttgatcgg  
gttctagcc attgcaggca ttgacttca tccggcagcc 240atctacacc cagagatcca taaaagcctc agcacaate tggatgtaac  
taactcaatc 300gagcatcagg ttaaggactg gctgacacca ctctcaaga tcatcgttga tgaagtggg 360ttgaggacac ctcagagatt  
cactgaccta tgaagtcca tctctgacaa gattaaattc 420ctaatccgg acaggaata cgactcaga gatctcactt ggtgatcaa cccgacagag  
480agaatcaaat tggattatga tcaactgtg gcagatgtgg ctgctgaaga actcatgaa 540gcattggtga actcaactc actggagacc  
agggcaacca atcattctc agctgtctca 600aagggaact gtcagggcc cactacaatc agaggccaat tctcaaacat gtcgtctgccc  
660ctgttgact tgtattaaag tcgaggttac aatgtgcat ctatagtcac tatgacatcc 720cagggaatgt acgggggaaac ttacctagt  
gaaaagccta atctgagcag caaagggtca 780gagttgctac aactgagcat gcaccagtg tttgaagtag gtgtatcag aatccgggt  
840ttgggggctc cgtattcca tatgacaaac tctctgagc aaccagtcag taatgattc 900agcaactgca tgggtgcttt gggggagctc  
aagttcgag cctctgtca cagggaagat 960tctatcacia tccctatca gggatcagg aaaggtgca gcttccagct tgtaagcta  
1020ggtgtctgga aatccccaac cgacatgcaa tctgggtccc cctatcaac ggatgatcca 1080gtgatagaca gctttacct ctatctcac  
agaggctta tctgacaaa tcaagcaaaa 1140tgggtgtccc cgacaacacg gacagatgac aagttcgaa tggagacatg ctccagcag  
1200cgtgtaagg gtaaatcca agcactttgc gagaatccc agtgagacc attgaagat 1260aacaggattc ctctacagg ggtctgtct  
gttgatctga gctgacagt tgagcttaaa 1320atcaaaattg ttcaggatt cgggccattg atcacacacg gtcagggat ggacctatac  
1380aaatcaacc acaacaat atgttgctg actatcccc caatgaagaa cctggcctta 1440ggtgtaatca acacattgga tggataccg  
agattcaagg ttagtccaa cctcttact 1500gttcaatga aggaagcagg cgaggactgc catgccccaa catacctacc tgcggaggtg  
1560gatggtgatg tcaactcag ttcaatctg gtgattctac ctgtcaaga tctcaaat 1620gttctggcaa ctacgatac ttccagatt  
gaacatgctg tagttatta cgtttacagc 1680ccaagccgct cattttctta ctttatct ttaggttgc ctgtaagggg ggtccccatt

1740gaattacaag tggatgctt cacatgggac caaaaactct ggtgccgtca cttctgtgtg 1800cttgccgact cagaatctgg tggacatc  
actcactctg ggatggtggg catgggagtc 1860agctgcacag ccactcggga agatggaacc agccgcagat agtgataata ggctggagcc  
1920tcggtggcca agcttcttgc cccttgggcc tccccccagc cctctctccc ctctctgcac 1980ccgtaccccc gtggtctttg aataaagtct  
gagtgggccc caaaaaaaaa aaaaaaaaaa 2040aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa  
2100aaaaaaaaa aaaaaaaaaa atctag 212647550PRTArtificial SequenceSynthetic Polypeptide 47Met Gly Leu Lys  
Val Asn Val Ser Ala Val Phe Met Ala Val Leu Leu1 5 10 15Thr Leu Gln Thr Pro Ala Gly Gln Ile His Trp Gly  
Asn Leu Ser Lys 20 25 30Ile Gly Val Val Gly Ile Gly Ser Ala Ser Tyr Lys Val Met Thr Arg 35 40 45Ser Ser His  
Gln Ser Leu Val Ile Lys Leu Met Pro Asn Ile Thr Leu 50 55 60Leu Asn Asn Cys Thr Arg Val Glu Ile Ala Glu  
Tyr Arg Arg Leu Leu65 70 75 80Arg Thr Val Leu Glu Pro Ile Arg Asp Ala Leu Asn Ala Met Thr Gln 85 90  
95Asn Ile Arg Pro Val Gln Ser Val Ala Ser Ser Arg Arg His Lys Arg 100 105 110Phe Ala Gly Val Val Leu Ala  
Gly Ala Ala Leu Gly Val Ala Thr Ala 115 120 125Ala Gln Ile Thr Ala Gly Ile Ala Leu His Arg Ser Met Leu  
Asn Ser 130 135 140Gln Ala Ile Asp Asn Leu Arg Ala Ser Leu Glu Thr Thr Asn Gln Ala145 150 155 160Ile  
Glu Ala Ile Arg Gln Ala Gly Gln Glu Met Ile Leu Ala Val Gln 165 170 175Gly Val Gln Asp Tyr Ile Asn Asn  
Glu Leu Ile Pro Ser Met Asn Gln 180 185 190Leu Ser Cys Asp Leu Ile Gly Gln Lys Leu Gly Leu Lys Leu Leu  
Arg 195 200 205Tyr Tyr Thr Glu Ile Leu Ser Leu Phe Gly Pro Ser Leu Arg Asp Pro 210 215 220Ile Ser Ala Glu  
Ile Ser Ile Gln Ala Leu Ser Tyr Ala Leu Gly Gly225 230 235 240Asp Ile Asn Lys Val Leu Glu Lys Leu Gly Tyr  
Ser Gly Gly Asp Leu 245 250 255Leu Gly Ile Leu Glu Ser Arg Gly Ile Lys Ala Arg Ile Thr His Val 260 265  
270Asp Thr Glu Ser Tyr Phe Ile Val Leu Ser Ile Ala Tyr Pro Thr Leu 275 280 285Ser Glu Ile Lys Gly Val Ile Val  
His Arg Leu Glu Gly Val Ser Tyr 290 295 300Asn Ile Gly Ser Gln Glu Trp Tyr Thr Thr Val Pro Lys Tyr Val  
Ala305 310 315 320Thr Gln Gly Tyr Leu Ile Ser Asn Phe Asp Glu Ser Ser Cys Thr Phe 325 330 335Met Pro  
Glu Gly Thr Val Cys Ser Gln Asn Ala Leu Tyr Pro Met Ser 340 345 350Pro Leu Leu Gln Glu Cys Leu Arg Gly  
Ser Thr Lys Ser Cys Ala Arg 355 360 365Thr Leu Val Ser Gly Ser Phe Gly Asn Arg Phe Ile Leu Ser Gln Gly  
370 375 380Asn Leu Ile Ala Asn Cys Ala Ser Ile Leu Cys Lys Cys Tyr Thr Thr385 390 395 400Gly Thr Ile Ile  
Asn Gln Asp Pro Asp Lys Ile Leu Thr Tyr Ile Ala 405 410 415Ala Asp Arg Cys Pro Val Val Glu Val Asn Gly  
Val Thr Ile Gln Val 420 425 430Gly Ser Arg Arg Tyr Pro Asp Ala Val Tyr Leu His Arg Ile Asp Leu 435 440  
445Gly Pro Pro Ile Ser Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly 450 455 460Asn Ala Ile Ala Lys Leu  
Glu Asp Ala Lys Glu Leu Leu Glu Ser Ser465 470 475 480Asp Gln Ile Leu Arg Ser Met Lys Gly Leu Ser Ser  
Thr Ser Ile Val 485 490 495Tyr Ile Leu Ile Ala Val Cys Leu Gly Gly Leu Ile Gly Ile Pro Thr 500 505 510Leu Ile  
Cys Cys Cys Arg Gly Arg Cys Asn Lys Lys Gly Glu Gln Val 515 520 525Gly Met Ser Arg Pro Gly Leu Lys Pro  
Asp Leu Thr Gly Thr Ser Lys 530 535 540Ser Tyr Val Arg Ser Leu545 55048550PRTArtificial  
SequenceSynthetic Polypeptide 48Met Gly Leu Lys Val Asn Val Ser Val Ile Phe Met Ala Val Leu Leu1 5 10  
15Thr Leu Gln Thr Pro Thr Gly Gln Ile His Trp Gly Asn Leu Ser Lys 20 25 30Ile Gly Val Val Gly Val Gly Ser  
Ala Ser Tyr Lys Val Met Thr Arg 35 40 45Ser Ser His Gln Ser Leu Val Ile Lys Leu Met Pro Asn Ile Thr Leu 50  
55 60Leu Asn Asn Cys Thr Arg Val Gly Ile Ala Glu Tyr Arg Arg Leu Leu65 70 75 80Arg Thr Val Leu Glu Pro  
Ile Arg Asp Ala Leu Asn Ala Met Thr Gln 85 90 95Asn Ile Arg Pro Val Gln Ser Val Ala Ser Ser Arg Arg His  
Lys Arg 100 105 110Phe Ala Gly Val Val Leu Ala Gly Ala Ala Leu Gly Val Ala Thr Ala 115 120 125Ala Gln Ile  
Thr Ala Gly Ile Ala Leu His Gln Ser Met Leu Asn Ser 130 135 140Gln Ala Ile Asp Asn Leu Arg Ala Ser Leu  
Glu Thr Thr Asn Gln Ala145 150 155 160Ile Glu Ala Ile Arg Gln Ala Gly Gln Glu Met Ile Leu Ala Val Gln 165  
170 175Gly Val Gln Asp Tyr Ile Asn Asn Glu Leu Ile Pro Ser Met Asn Gln 180 185 190Leu Ser Cys Asp Leu  
Ile Gly Gln Lys Leu Gly Leu Lys Leu Leu Arg 195 200 205Tyr Tyr Thr Glu Ile Leu Ser Leu Phe Gly Pro Ser  
Leu Arg Asp Pro 210 215 220Ile Ser Ala Glu Ile Ser Ile Gln Ala Leu Ser Tyr Ala Leu Gly Gly225 230 235  
240Asp Ile Asn Lys Val Leu Glu Lys Leu Gly Tyr Ser Gly Gly Asp Leu 245 250 255Leu Gly Ile Leu Glu Ser  
Arg Gly Ile Lys Ala Arg Ile Thr His Val 260 265 270Asp Thr Glu Ser Tyr Phe Ile Val Leu Ser Ile Ala Tyr Pro  
Thr Leu 275 280 285Ser Glu Ile Lys Gly Val Ile Val His Arg Leu Glu Gly Val Ser Tyr 290 295 300Asn Ile Gly  
Ser Gln Glu Trp Tyr Thr Thr Val Pro Lys Tyr Val Ala305 310 315 320Thr Gln Gly Tyr Leu Ile Ser Asn Phe Asp  
Glu Ser Ser Cys Thr Phe 325 330 335Met Pro Glu Gly Thr Val Cys Ser Gln Asn Ala Leu Tyr Pro Met Ser 340  
345 350Pro Leu Leu Gln Glu Cys Leu Arg Gly Ser Thr Lys Ser Cys Ala Arg 355 360 365Thr Leu Val Ser Gly  
Ser Phe Gly Asn Arg Phe Ile Leu Ser Gln Gly 370 375 380Asn Leu Ile Ala Asn Cys Ala Ser Ile Leu Cys Lys  
Cys Tyr Thr Thr385 390 395 400Gly Thr Ile Ile Asn Gln Asp Pro Asp Lys Ile Leu Thr Tyr Ile Ala 405 410  
415Ala Asp His Cys Pro Val Val Glu Val Asn Gly Val Thr Ile Gln Val 420 425

430Gly Ser Arg Arg Tyr Pro Asp Ala Val Tyr Leu His Arg Ile Asp Leu 435 440 445Gly Pro Pro Ile Ser Leu Glu  
Arg Leu Asp Val Gly Thr Asn Leu Gly 450 455 460Asn Ala Ile Ala Lys Leu Glu Asp Ala Lys Glu Leu Leu Glu  
Ser Ser465 470 475 480Asp Gln Ile Leu Arg Ser Met Lys Gly Leu Ser Ser Thr Ser Ile Val 485 490 495Tyr Ile

Leu Ile Ala Val Cys Leu Gly Gly Leu Ile Gly Ile Pro Ala 500 505 510Leu Ile Cys Cys Cys Arg Gly Arg Cys  
Asn Lys Lys Gly Glu Gln Val 515 520 525Gly Met Ser Arg Pro Gly Leu Lys Pro Asp Leu Thr Gly Thr Ser Lys  
530 535 540Ser Tyr Val Arg Ser Leu545 55049617PRTArtificial SequenceSynthetic Polypeptide 49Met Ser Pro  
Gln Arg Asp Arg Ile Asn Ala Phe Tyr Lys Asp Asn Pro1 5 10 15Tyr Pro Lys Gly Ser Arg Ile Val Ile Asn Arg  
Glu His Leu Met Ile 20 25 30Asp Arg Pro Tyr Val Leu Leu Ala Val Leu Phe Val Met Phe Leu Ser 35 40 45Leu  
Ile Gly Leu Leu Ala Ile Ala Gly Ile Arg Leu His Arg Ala Ala 50 55 60Ile Tyr Thr Ala Glu Ile His Lys Ser Leu  
Ser Thr Asn Leu Asp Val65 70 75 80Thr Asn Ser Ile Glu His Gln Val Lys Asp Val Leu Thr Pro Leu Phe 85 90  
95Lys Ile Ile Gly Asp Glu Val Gly Leu Arg Thr Pro Gln Arg Phe Thr 100 105 110Asp Leu Val Lys Phe Ile Ser  
Asp Lys Ile Lys Phe Leu Asn Pro Asp 115 120 125Arg Glu Tyr Asp Phe Arg Asp Leu Thr Trp Cys Ile Asn Pro  
Pro Glu 130 135 140Arg Ile Lys Leu Asp Tyr Asp Gln Tyr Cys Ala Asp Val Ala Ala Glu145 150 155 160Glu  
Leu Met Asn Ala Leu Val Asn Ser Thr Leu Leu Glu Thr Arg Thr 165 170 175Thr Thr Gln Phe Leu Ala Val Ser  
Lys Gly Asn Cys Ser Gly Pro Thr 180 185 190Thr Ile Arg Gly Gln Phe Ser Asn Met Ser Leu Ser Leu Leu Asp  
Leu 195 200 205Tyr Leu Gly Arg Gly Tyr Asn Val Ser Ser Ile Val Thr Met Thr Ser 210 215 220Gln Gly Met Tyr  
Gly Gly Thr Tyr Leu Val Glu Lys Pro Asn Leu Asn225 230 235 240Ser Lys Gly Ser Glu Leu Ser Gln Leu Ser  
Met Tyr Arg Val Phe Glu 245 250 255Val Gly Val Ile Arg Asn Pro Gly Leu Gly Ala Pro Val Phe His Met 260  
265 270Thr Asn Tyr Phe Glu Gln Pro Val Ser Asn Gly Leu Gly Asn Cys Met 275 280 285Val Ala Leu Gly Glu  
Leu Lys Leu Ala Ala Leu Cys His Gly Asp Asp 290 295 300Ser Ile Ile Ile Pro Tyr Gln Gly Ser Gly Lys Gly Val  
Ser Phe Gln305 310 315 320Leu Val Lys Leu Gly Val Trp Lys Ser Pro Thr Asp Met Gln Ser Trp 325 330 335Val  
Pro Leu Ser Thr Asp Asp Pro Val Val Asp Arg Leu Tyr Leu Ser 340 345 350Ser His Arg Gly Val Ile Ala Asp  
Asn Gln Ala Lys Trp Ala Val Pro 355 360 365Thr Thr Arg Thr Asp Asp Lys Leu Arg Met Glu Thr Cys Phe Gln  
Gln 370 375 380Ala Cys Lys Gly Lys Ile Gln Ala Leu Cys Glu Asn Pro Glu Trp Val385 390 395 400Pro Leu  
Lys Asp Asn Arg Ile Pro Ser Tyr Gly Val Leu Ser Val Asp 405 410 415Leu Ser Leu Thr Val Glu Leu Lys Ile Lys  
Ile Ala Ser Gly Phe Gly 420 425 430Pro Leu Ile Thr His Gly Ser Gly Met Asp Leu Tyr Lys Ser Asn Cys 435  
440 445Asn Asn Val Tyr Trp Leu Thr Ile Pro Pro Met Arg Asn Leu Ala Leu 450 455 460Gly Val Ile Asn Thr  
Leu Glu Trp Ile Pro Arg Phe Lys Val Ser Pro465 470 475 480Asn Leu Phe Thr Val Pro Ile Lys Glu Ala Gly Glu  
Asp Cys His Ala 485 490 495Pro Thr Tyr Leu Pro Ala Glu Val Asp Gly Asp Val Lys Leu Ser Ser 500 505  
510Asn Leu Val Ile Leu Pro Gly Gln Asp Leu Gln Tyr Val Leu Ala Thr 515 520 525Tyr Asp Thr Ser Arg Val  
Glu His Ala Val Val Tyr Tyr Val Tyr Ser 530 535 540Pro Ser Arg Ser Phe Ser Tyr Phe Tyr Pro Phe Arg Leu Pro  
Ile Lys545 550 555 560Gly Val Pro Ile Glu Leu Gln Val Glu Cys Phe Thr Trp Asp Gln Lys 565 570 575Leu Trp  
Cys Arg His Phe Cys Val Leu Ala Asp Ser Glu Ser Gly Gly 580 585 590Leu Ile Thr His Ser Gly Met Val Gly  
Met Gly Val Ser Cys Thr Ala 595 600 605Thr Arg Glu Asp Gly Thr Asn Arg Arg 610 61550617PRTArtificial  
SequenceSynthetic Polypeptide 50Met Ser Pro Gln Arg Asp Arg Ile Asn Ala Phe Tyr Lys Asp Asn Pro1 5 10  
15His Pro Lys Gly Ser Arg Ile Val Ile Asn Arg Glu His Leu Met Ile 20 25 30Asp Arg Pro Tyr Val Leu Leu Ala  
Val Leu Phe Val Met Phe Leu Ser 35 40 45Leu Ile Gly Leu Leu Ala Ile Ala Gly Ile Arg Leu His Arg Ala Ala 50  
55 60Ile Tyr Thr Ala Glu Ile His Lys Ser Leu Ser Thr Asn Leu Asp Val65 70 75 80Thr Asn Ser Ile Glu His Gln  
Val Lys Asp Val Leu Thr Pro Leu Phe 85 90 95Lys Ile Ile Gly Asp Glu Val Gly Leu Arg Thr Pro Gln Arg Phe  
Thr 100 105 110Asp Leu Val Lys Phe Ile Ser Asp Lys Ile Lys Phe Leu Asn Pro Asp 115 120 125Arg Glu Tyr  
Asp Phe Arg Asp Leu Thr Trp Cys Ile Asn Pro Pro Glu 130 135 140Arg Ile Lys Leu Asp Tyr Asp Gln Tyr Cys  
Ala Asp Val Ala Ala Glu145 150 155 160Glu Leu Met Asn Ala Leu Val Asn Ser Thr Leu Leu Glu Thr Arg Ala  
165 170 175Thr Asn Gln Phe Leu Ala Val Ser Lys Gly Asn Cys Ser Gly Pro Thr 180 185 190Thr Ile Arg Gly  
Gln Phe Ser Asn Met Ser Leu Ser Leu Leu Asp Leu 195 200 205Tyr Leu Ser Arg Gly Tyr Asn Val Ser Ser Ile  
Val Thr Met Thr Ser 210 215 220Gln Gly Met Tyr Gly Gly Thr Tyr Leu Val Glu Lys Pro Asn Leu Ser225 230  
235 240Ser Lys Gly Ser Glu Leu Ser Gln Leu Ser Met His Arg Val Phe Glu 245 250 255Val Gly Val Ile Arg Asn  
Pro Gly Leu Gly Ala Pro Val Phe His Met 260 265 270Thr Asn Tyr Leu Glu Gln Pro Val Ser Asn Asp Phe Ser  
Asn Cys Met 275 280 285Val Ala Leu Gly Glu Leu Lys Phe Ala Ala Leu Cys His Arg Glu Asp 290 295 300Ser  
Ile Thr Ile Pro Tyr Gln Gly Ser Gly Lys Gly Val Ser Phe Gln305 310 315 320Leu Val Lys Leu Gly Val Trp Lys  
Ser Pro Thr Asp Met Gln Ser Trp 325 330 335Val Pro Leu Ser Thr Asp Asp Pro Val Ile Asp Arg Leu Tyr Leu  
Ser 340 345 350Ser His Arg Gly Val Ile Ala Asp Asn Gln Ala Lys Trp Ala Val Pro 355 360 365Thr Thr Arg Thr  
Asp Asp Lys Leu Arg Met Glu Thr Cys Phe Gln Gln 370 375 380Ala Cys Lys Gly Lys Ile Gln Ala Leu Cys Glu  
Asn Pro Glu Trp Thr385 390 395 400Pro Leu Lys Asp Asn Arg Ile Pro Ser Tyr Gly Val Leu Ser Val Asp 405  
410 415Leu Ser Leu Thr Val Glu Leu Lys Ile Lys Ile Val Ser Gly Phe Gly 420 425 430Pro Leu Ile Thr His Gly  
Ser Gly Met Asp Leu Tyr Lys Ser Asn His 435 440 445Asn Asn Met Tyr Trp Leu Thr Ile Pro Pro Met Lys Asn  
Leu Ala Leu 450 455 460Gly Val Ile Asn Thr Leu Glu Trp Ile Pro Arg Phe Lys Val Ser Pro465 470 475 480Asn  
Leu Phe Thr Val Pro Ile Lys Glu Ala Gly Glu Asp Cys His Ala 485 490 495Pro Thr Tyr Leu Pro Ala Glu Val



Asp Gly Asp Val Lys Leu Ser Ser 500 505 510Asn Leu Val Ile Leu Pro Gly Gln Asp Leu Gln Tyr Val Leu Ala  
Thr 515 520 525Tyr Asp Thr Ser Arg Val Glu His Ala Val Val Tyr Tyr Val Tyr Ser 530 535 540Pro Ser Arg Ser  
Phe Ser Tyr Phe Tyr Pro Phe Arg Leu Pro Val Arg545 550 555 560Gly Val Pro Ile Glu Leu Gln Val Glu Cys Phe  
Thr Trp Asp Gln Lys 565 570 575Leu Trp Cys Arg His Phe Cys Val Leu Ala Asp Ser Glu Ser Gly Gly 580 585  
590His Ile Thr His Ser Gly Met Val Gly Met Gly Val Ser Cys Thr Ala 595 600 605Thr Arg Glu Asp Gly Thr Ser  
Arg Arg 610 615511729DNAArtificial SequenceSynthetic Polynucleotide 51tcaagctttt ggaccctcgt acagaagcta  
atacgactca ctataggaa ataagagaga 60aaagaagagt aagaagaaat ataagagcca ccatggcaca agtcattaat acaaacagcc  
120tgtcgtgtt gaccagaat aacctgaaca aatcccagtc cgcactgggc actgctatcg 180agcgtttgtc ttcgggtctg cgtatcaaca  
gcgcgaaaga cgatgcggca ggacaggcga 240ttgctaaccg tttaccgcg aacatcaaag gtctgactca ggctcccgt aacgctaacg  
300acggtatctc cattgcgcag accactgaag gcgcgctgaa cgaaatcaac aacaacctgc 360agcgtgtgcg tgaactggcg gttcagtctg  
cgaatgtac taactccag tctgacctcg 420actccatcca ggctgaaatc acccagcgcc tgaacgaaat cgacctgta tccggccaga  
480ctcagttcaa cggcgtgaaa gtctggcgc aggacaacac cctgaccatc caggttggtg 540ccaacgacgg tgaactatc gatattgatt  
taaaagaaat cagctctaaa acactgggac 600ttgataagct taatgtccaa gatgcctaca ccccgaaaga aactgtgta accgttgata  
660aaactaccta taaaaatggt acagatccta ttacagcca gagcaatact gatatccaaa 720ctgcaattgg cgggtgtgca acgggggta  
ctggggtga tatcaaat tt aaagatggtc 780aatactatt agatgttaa ggcggtgctt ctgctggtgt ttataagcc acttatgatg  
840aaactacaaa gaaagttaat atgatacga ctgataaac tccgttgca actgcggaag 900ctacagctat tcggggaacg gccactataa  
cccacaacca aattgctgaa gtaacaaaag 960agggtgtgta tacgaccaca gttgcggcgc aactgtctgc agcaggggtt actggcgccg  
1020ataaggacaa tactagcctt gtaaaactat cgtttgagga taaaacggt aaggtattg 1080atggtggcta tgcagtgaaa atggcgacg  
attctatgc cgtacatat gatgaaaa 1140caggtgcaat tactgctaaa accactactt atacagatgg tactggcggt gctcaaactg  
1200gagctgtgaa atttggtggc gcaaatgta aatctgaagt tgtactgct accgatgta 1260agacttactt agcaagcgac ctgacaaa  
ataactcag aacaggcggg gagctaaag 1320aggtaatac agataagact gaaaaccac tgcagaaaat tgatgctgc ttggcacagg  
1380ttgatacact tcgttctgac ctgggtgcgg ttcagaaccg ttcaactcc gctatcacca 1440acctgggcaa taccgtaaat aactgtctt  
ctgccgtag ccgatcgaa gattccgact 1500acgcaaccga agtctccaac atgtctcgcg cgcagattct gcagcaggcc ggtacctccg  
1560ttctggcgca ggcgaaccag gttccgcaaa acgtctctc tttactgctg tgataatagg 1620ctggagcctc ggtggccatg cttctgccc  
cttgggctc cccccagccc ctctcccct 1680tctgcaacc gtaccccct ggtctttgaa taaagtctga gtgggcggc  
1729521518DNAArtificial SequenceSynthetic Polynucleotide 52atggcacaag tcattaatac aaacagcctg tcgctgtgta  
cccagaataa cctgaacaaa 60tccagtcgc cactgggcaac tgctatcgag cgtttgtctt ccggtctcgc tatcaacagc 120gcgaaagacg  
atgcggcagg acaggcgatt gtaaccgtt ttaccgcgaa catcaaaggt 180ctgactcagg ctcccgtaa cgtaacgac ggtatctcca  
ttgcgcgac cactgaaggc 240gcgctgaacg aatcaacaa caacctgcag cgtgtgcgtg aactggcggt tcagtctcgc 300aatggtaacta  
actcccagtc tgacctgac tccatccagg ctgaaatcac ccagcgctg 360aacgaaatcg accgtgtatc cgccagact cagttaacg  
gcgtgaaagt cctggcgag 420gacaacacc tgaccatcca ggttggtgcc aacgacggtg aaactatcga tattgatta 480aaagaaatca  
gctctaaaac actgggactt gataagctta atgtccaaga tgctacacc 540ccgaaagaaa ctgctgtaac cgttgataaa actacctata  
aaaatggtac agatcctatt 600acagcccaga gcaatactga tatccaaact gcaattggcg gtggtgcaac gggggttact 660ggggctgata  
tcaaatltaa agatggta tactatttag atgttaaagg cgggtcttct 720gctggtgtt ataaagccac ttatgatgaa actacaaaga aagtaaat  
tgatacgact 780gataaaactc cgttggaac tgcggaagct acagctattc ggggaacggc cactataacc 840cacaacaaa ttgctgaagt  
aacaaaagag ggtgttgata cgaccacagt tgcggctcaa 900cttctcgcag caggggttac tggcgccgat aaggacaata ctagcctgt  
aaaactatcg 960ttgaggata aaaacgtaa ggttattgat ggtgctatg cagtgaaat gggcgacgat 1020ttctatgccg ctacatgta  
tgagaaaaca ggtgcaatta ctgctaaaac cactacttat 1080acagatgta ctggcggtgc tcaaactgga gctgtgaaat ttggtggcgc  
aaatggtaaa 1140tctgaagttg ttactgctac cgatgtaag acttacttag caagcgacct tgacaaacat 1200aactcagaa caggcggtga  
gcttaaagag gtaatacag ataagactga aaaccactg 1260cagaaaattg atgctgcctt ggcacaggtt gatacctc gttctgacct  
gggtgcggtt 1320cagaaccgtt tcaactcgc taccacaaac ctgggcaata ccgtaataa cctgtcttct 1380gcccgtagcc gtatcgaaga  
ttccgactac gcaaccgag tctccaat gctcgcgcg 1440cagattctgc agcagggcgg tactctcgtt ctggcgacg cgaaccaggt  
tccgcaaac 1500gtctctctt tactgctg 1518531790RNAArtificial SequenceSynthetic Polynucleotide 53ggggaauaa  
gagagaaaag aagaguaaga agaaauauaa gagccaccau ggcacaaguc 60auuaauacaa acagccuguc gcuguugacc cagaauaacc  
ugaacaaauc ccaguccga 120cugggacug cuaucgagcg uuugucuucc ggucugcgu ucaacagcgc gaaagacgau  
180gcggcaggac aggcgauugc uaaccguuuu accgcgaaca ucaaaggucu gacucaggu 240uccguaacg cuaacgacgg  
uauuccauu gcgcagacca cugaaggcgc gcugaacgaa 300aucaacaaca accugcagcg ugugcgugaa cuggcgguuu  
agucugcga ugguaauaac 360uccagucug accucgacuc cauccaggu gaaucacc agcgcugaa cgaaucgac  
420cguguaucg gccagacua guucaacggc gugaagucc uggcgagga caacaccug 480accuaccag uuggugccaa  
cgacggugaa acuaucgau uugauuuuuu agaaucagc 540ucuaaaacac ugguacuuga uaagcuuuu guccaagaug  
ccuacacccc gaaagaaacu 600gcuguaaccg uugauuuuac uaccuauuuu aaugguacag auccuuuuac agcccagagc  
660aaucugua uccaacugc aauggcggu ggugcaacgg gguuuacug ggcugauuac 720aaauuuuag auggucauu  
cuuuuuagau guuuuaggcg gugcuucugc ugguguuuuu 780aaagccacu augaugaaac uacaaagaaa guuuuuuug  
auacgacuga uaaaacuccg 840uuggcaacug cggaagcuac agcuuuucgg ggaacggcca cuuaaccca caacaaaau

900gcugaagua caaaagaggg uguugauacg accacaguug cggcucaacu ugcugcagca 960gggguuacug ggcgccgaa  
ggacaauacu agccuuguaa aacuaucguu ugaggauaaa 1020aacgguaagg uuaauauggg uggcuauca gugaauaugg  
gagcaguuu cuaugccgc 1080acauaugaug agaaaacagg ugcauuuacu gcuaaaacca cuacuauac agaugguacu  
1140ggcguugcuc aaacuggagc ugugaaauuu gguggcgcaa augguaauac ugaaguuguu 1200acugcuaccg augguaagac  
uuacuuagca agcgaccuug acaacauaa cuucagaaca 1260ggcggugagc uuaaagaggu uauacagau aagacugaaa  
accacugca gaaaauugau 1320gugccuugg cacagguuga uacacuucgu ucugaccugg gugcgguuca gaaccguuuc  
1380aacuccgeua ucaccaaccu gggcauacc guaaauaacc ugucuucugc ccguagccgu 1440aucgaagauu ccgacuacgc  
aaccgaaguc uccaacaugu cucgcgcgca gauucugcag 1500caggccggua ccuccguucu ggcgaggcg aaccagguuc  
cgcaaacgu ccucuuuu 1560cugcguugau auuaggcugg agccucggug gccaugcuuc uugcccuug ggccuccc  
1620cagccuccc ucccuuccu gcaccguac ccccgugguc uuugaauaaa gucugagugg 1680gcgcaaaaa aaaaaaaaa  
aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa 1740aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaucug  
179054506PRTArtificial SequenceSynthetic Polypeptide 54Met Ala Gln Val Ile Asn Thr Asn Ser Leu Ser Leu  
Leu Thr Gln Asn1 5 10 15Asn Leu Asn Lys Ser Gln Ser Ala Leu Gly Thr Ala Ile Glu Arg Leu 20 25 30Ser Ser  
Gly Leu Arg Ile Asn Ser Ala Lys Asp Asp Ala Ala Gly Gln 35 40 45Ala Ile Ala Asn Arg Phe Thr Ala Asn Ile  
Lys Gly Leu Thr Gln Ala 50 55 60Ser Arg Asn Ala Asn Asp Gly Ile Ser Ile Ala Gln Thr Thr Glu Gly65 70 75  
80Ala Leu Asn Glu Ile Asn Asn Asn Leu Gln Arg Val Arg Glu Leu Ala 85 90 95Val Gln Ser Ala Asn Gly Thr  
Asn Ser Gln Ser Asp Leu Asp Ser Ile 100 105 110Gln Ala Glu Ile Thr Gln Arg Leu Asn Glu Ile Asp Arg Val Ser  
Gly 115 120 125Gln Thr Gln Phe Asn Gly Val Lys Val Leu Ala Gln Asp Asn Thr Leu 130 135 140Thr Ile Gln  
Val Gly Ala Asn Asp Gly Glu Thr Ile Asp Ile Asp Leu145 150 155 160Lys Glu Ile Ser Ser Lys Thr Leu Gly Leu  
Asp Lys Leu Asn Val Gln 165 170 175Asp Ala Tyr Thr Pro Lys Glu Thr Ala Val Thr Val Asp Lys Thr Thr 180  
185 190Tyr Lys Asn Gly Thr Asp Pro Ile Thr Ala Gln Ser Asn Thr Asp Ile 195 200 205Gln Thr Ala Ile Gly Gly  
Gly Ala Thr Gly Val Thr Gly Ala Asp Ile 210 215 220Lys Phe Lys Asp Gly Gln Tyr Tyr Leu Asp Val Lys Gly  
Gly Ala Ser225 230 235

240Ala Gly Val Tyr Lys Ala Thr Tyr Asp Glu Thr Thr Lys Lys Val Asn 245 250 255Ile Asp Thr Thr Asp Lys Thr  
Pro Leu Ala Thr Ala Glu Ala Thr Ala 260 265 270Ile Arg Gly Thr Ala Thr Ile Thr His Asn Gln Ile Ala Glu Val  
Thr 275 280 285Lys Glu Gly Val Asp Thr Thr Thr Val Ala Ala Gln Leu Ala Ala Ala 290 295 300Gly Val Thr  
Gly Ala Asp Lys Asp Asn Thr Ser Leu Val Lys Leu Ser305 310 315 320Phe Glu Asp Lys Asn Gly Lys Val Ile  
Asp Gly Gly Tyr Ala Val Lys 325 330 335Met Gly Asp Asp Phe Tyr Ala Ala Thr Tyr Asp Glu Lys Thr Gly Ala  
340 345 350Ile Thr Ala Lys Thr Thr Tyr Thr Asp Gly Thr Gly Val Ala Gln 355 360 365Thr Gly Ala Val Lys  
Phe Gly Gly Ala Asn Gly Lys Ser Glu Val Val 370 375 380Thr Ala Thr Asp Gly Lys Thr Tyr Leu Ala Ser Asp  
Leu Asp Lys His385 390 395 400Asn Phe Arg Thr Gly Gly Glu Leu Lys Glu Val Asn Thr Asp Lys Thr 405 410  
415Glu Asn Pro Leu Gln Lys Ile Asp Ala Ala Leu Ala Gln Val Asp Thr 420 425 430Leu Arg Ser Asp Leu Gly  
Ala Val Gln Asn Arg Phe Asn Ser Ala Ile 435 440 445Thr Asn Leu Gly Asn Thr Val Asn Asn Leu Ser Ser Ala  
Arg Ser Arg 450 455 460Ile Glu Asp Ser Asp Tyr Ala Thr Glu Val Ser Asn Met Ser Arg Ala465 470 475 480Gln  
Ile Leu Gln Gln Ala Gly Thr Ser Val Leu Ala Gln Ala Asn Gln 485 490 495Val Pro Gln Asn Val Leu Ser Leu  
Leu Arg 500 50555698PRTArtificial SequenceSynthetic Polypeptide 55Met Ala Gln Val Ile Asn Thr Asn Ser  
Leu Ser Leu Leu Thr Gln Asn1 5 10 15Asn Leu Asn Lys Ser Gln Ser Ala Leu Gly Thr Ala Ile Glu Arg Leu 20  
25 30Ser Ser Gly Leu Arg Ile Asn Ser Ala Lys Asp Asp Ala Ala Gly Gln 35 40 45Ala Ile Ala Asn Arg Phe Thr  
Ala Asn Ile Lys Gly Leu Thr Gln Ala 50 55 60Ser Arg Asn Ala Asn Asp Gly Ile Ser Ile Ala Gln Thr Thr Glu  
Gly65 70 75 80Ala Leu Asn Glu Ile Asn Asn Asn Leu Gln Arg Val Arg Glu Leu Ala 85 90 95Val Gln Ser Ala  
Asn Ser Thr Asn Ser Gln Ser Asp Leu Asp Ser Ile 100 105 110Gln Ala Glu Ile Thr Gln Arg Leu Asn Glu Ile  
Asp Arg Val Ser Gly 115 120 125Gln Thr Gln Phe Asn Gly Val Lys Val Leu Ala Gln Asp Asn Thr Leu 130 135  
140Thr Ile Gln Val Gly Ala Asn Asp Gly Glu Thr Ile Asp Ile Asp Leu145 150 155 160Lys Gln Ile Asn Ser Gln  
Thr Leu Gly Leu Asp Thr Leu Asn Val Gln 165 170 175Gln Lys Tyr Lys Val Ser Asp Thr Ala Ala Thr Val Thr  
Gly Tyr Ala 180 185 190Asp Thr Thr Ile Ala Leu Asp Asn Ser Thr Phe Lys Ala Ser Ala Thr 195 200 205Gly  
Leu Gly Gly Thr Asp Gln Lys Ile Asp Gly Asp Leu Lys Phe Asp 210 215 220Asp Thr Thr Gly Lys Tyr Tyr Ala  
Lys Val Thr Val Thr Gly Gly Thr225 230 235 240Gly Lys Asp Gly Tyr Tyr Glu Val Ser Val Asp Lys Thr Asn  
Gly Glu 245 250 255Val Thr Leu Ala Gly Gly Ala Thr Ser Pro Leu Thr Gly Gly Leu Pro 260 265 270Ala Thr  
Ala Thr Glu Asp Val Lys Asn Val Gln Val Ala Asn Ala Asp 275 280 285Leu Thr Glu Ala Lys Ala Ala Leu Thr  
Ala Ala Gly Val Thr Gly Thr 290 295 300Ala Ser Val Val Lys Met Ser Tyr Thr Asp Asn Asn Gly Lys Thr Ile305  
310 315 320Asp Gly Gly Leu Ala Val Lys Val Gly Asp Asp Tyr Tyr Ser Ala Thr 325 330 335Gln Asn Lys Asp  
Gly Ser Ile Ser Ile Asn Thr Thr Lys Tyr Thr Ala 340 345 350Asp Asp Gly Thr Ser Lys Thr Ala Leu Asn Lys Leu  
Gly Gly Ala Asp 355 360 365Gly Lys Thr Glu Val Val Ser Ile Gly Gly Lys Thr Tyr Ala Ala Ser 370 375 380Lys

Ala Glu Gly His Asn Phe Lys Ala Gln Pro Asp Leu Ala Glu Ala385 390 395 400Ala Ala Thr Thr Thr Glu Asn  
Pro Leu Gln Lys Ile Asp Ala Ala Leu 405 410 415Ala Gln Val Asp Thr Leu Arg Ser Asp Leu Gly Ala Val Gln  
Asn Arg 420 425 430Phe Asn Ser Ala Ile Thr Asn Leu Gly Asn Thr Val Asn Asn Leu Thr 435 440 445Ser Ala  
Arg Ser Arg Ile Glu Asp Ser Asp Tyr Ala Thr Glu Val Ser 450 455 460Asn Met Ser Arg Ala Gln Ile Leu Gln  
Gln Ala Gly Thr Ser Val Leu465 470 475 480Ala Gln Ala Asn Gln Val Pro Gln Asn Val Leu Ser Leu Leu Arg  
Gly 485 490 495Gly Gly Gly Ser Gly Gly Gly Gly Ser Met Met Ala Pro Asp Pro Asn 500 505 510Ala Asn Pro  
Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn 515 520 525Ala Asn Pro Asn Ala Asn Pro Asn Ala  
Asn Pro Asn Ala Asn Pro Asn 530 535 540Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro  
Asn545 550 555 560Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn 565 570 575Ala Asn  
Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Lys Asn Asn Gln 580 585 590Gly Asn Gly Gln Gly His Asn Met  
Pro Asn Asp Pro Asn Arg Asn Val 595 600 605Asp Glu Asn Ala Asn Ala Asn Asn Ala Val Lys Asn Asn Asn  
Asn Glu 610 615 620Glu Pro Ser Asp Lys His Ile Glu Gln Tyr Leu Lys Lys Ile Lys Asn625 630 635 640Ser Ile  
Ser Thr Glu Trp Ser Pro Cys Ser Val Thr Cys Gly Asn Gly 645 650 655Ile Gln Val Arg Ile Lys Pro Gly Ser Ala  
Asn Lys Pro Lys Asp Glu 660 665 670Leu Asp Tyr Glu Asn Asp Ile Glu Lys Lys Ile Cys Lys Met Glu Lys 675  
680 685Cys Ser Ser Val Phe Asn Val Val Asn Ser 690 69556692PRTArtificial SequenceSynthetic Polypeptide  
56Met Met Ala Pro Asp Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala1 5 10 15Asn Pro Asn Ala Asn Pro Asn  
Ala Asn Pro Asn Ala Asn Pro Asn Ala 20 25 30Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro  
Asn Ala 35 40 45Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala 50 55 60Asn Pro Asn  
Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala65 70 75 80Asn Pro Asn Lys Asn Asn Gln Gly Asn Gly  
Gln Gly His Asn Met Pro 85 90 95Asn Asp Pro Asn Arg Asn Val Asp Glu Asn Ala Asn Ala Asn Asn Ala 100  
105 110Val Lys Asn Asn Asn Asn Glu Glu Pro Ser Asp Lys His Ile Glu Gln 115 120 125Tyr Leu Lys Lys Ile Lys  
Asn Ser Ile Ser Thr Glu Trp Ser Pro Cys 130 135 140Ser Val Thr Cys Gly Asn Gly Ile Gln Val Arg Ile Lys Pro  
Gly Ser145 150 155 160Ala Asn Lys Pro Lys Asp Glu Leu Asp Tyr Glu Asn Asp Ile Glu Lys 165 170 175Lys  
Ile Cys Lys Met Glu Lys Cys Ser Ser Val Phe Asn Val Val Asn 180 185 190Ser Arg Pro Val Thr Met Ala Gln Val  
Ile Asn Thr Asn Ser Leu Ser 195 200 205Leu Leu Thr Gln Asn Asn Leu Asn Lys Ser Gln Ser Ala Leu Gly Thr  
210 215 220Ala Ile Glu Arg Leu Ser Ser Gly Leu Arg Ile Asn Ser Ala Lys Asp225 230 235 240Asp Ala Ala Gly  
Gln Ala Ile Ala Asn Arg Phe Thr Ala Asn Ile Lys 245 250 255Gly Leu Thr Gln Ala Ser Arg Asn Ala Asn Asp  
Gly Ile Ser Ile Ala 260 265 270Gln Thr Thr Glu Gly Ala Leu Asn Glu Ile Asn Asn Asn Leu Gln Arg 275 280  
285Val Arg Glu Leu Ala Val Gln Ser Ala Asn Ser Thr Asn Ser Gln Ser 290 295 300Asp Leu Asp Ser Ile Gln  
Ala Glu Ile Thr Gln Arg Leu Asn Glu Ile305 310 315 320Asp Arg Val Ser Gly Gln Thr Gln Phe Asn Gly Val  
Lys Val Leu Ala 325 330 335Gln Asp Asn Thr Leu Thr Ile Gln Val Gly Ala Asn Asp Gly Glu Thr 340 345  
350Ile Asp Ile Asp Leu Lys Gln Ile Asn Ser Gln Thr Leu Gly Leu Asp 355 360 365Thr Leu Asn Val Gln Gln  
Lys Tyr Lys Val Ser Asp Thr Ala Ala Thr 370 375 380Val Thr Gly Tyr Ala Asp Thr Thr Ile Ala Leu Asp Asn  
Ser Thr Phe385 390 395 400Lys Ala Ser Ala Thr Gly Leu Gly Gly Thr Asp Gln Lys Ile Asp Gly 405 410  
415Asp Leu Lys Phe Asp Asp Thr Thr Gly Lys Tyr Tyr Ala Lys Val Thr 420 425 430Val Thr Gly Gly Thr Gly  
Lys Asp Gly Tyr Tyr Glu Val Ser Val Asp 435 440 445Lys Thr Asn Gly Glu Val Thr Leu Ala Gly Gly Ala Thr  
Ser Pro Leu 450 455 460Thr Gly Gly Leu Pro Ala Thr Ala Thr Glu Asp Val Lys Asn Val Gln465 470 475  
480Val Ala Asn Ala Asp Leu Thr Glu Ala Lys Ala Ala Leu Thr Ala Ala 485 490 495Gly Val Thr Gly Thr Ala  
Ser Val Val Lys Met Ser Tyr Thr Asp Asn 500 505 510Asn Gly Lys Thr Ile Asp Gly Gly Leu Ala Val Lys Val  
Gly Asp Asp 515 520 525Tyr Tyr Ser Ala Thr Gln Asn Lys Asp Gly Ser Ile Ser Ile Asn Thr 530 535 540Thr Lys  
Tyr Thr Ala Asp Asp Gly Thr Ser Lys Thr Ala Leu Asn Lys545 550 555 560Leu Gly Gly Ala Asp Gly Lys Thr  
Glu Val Val Ser Ile Gly Gly Lys 565 570 575Thr Tyr Ala Ala Ser Lys Ala Glu Gly His Asn Phe Lys Ala Gln Pro  
580 585 590Asp Leu Ala Glu Ala Ala Ala Thr Thr Thr Glu Asn Pro Leu Gln Lys 595 600 605Ile Asp Ala Ala  
Leu Ala Gln Val Asp Thr Leu Arg Ser Asp Leu Gly 610 615 620Ala Val Gln Asn Arg Phe Asn Ser Ala Ile Thr  
Asn Leu Gly Asn Thr625 630 635 640Val Asn Asn Leu Thr Ser Ala Arg Ser Arg Ile Glu Asp Ser Asp Tyr 645  
650 655Ala Thr Glu Val Ser Asn Met Ser Arg Ala Gln Ile Leu Gln Gln Ala 660 665 670Gly Thr Ser Val Leu Ala  
Gln Ala Asn Gln Val Pro Gln Asn Val Leu 675 680 685Ser Leu Leu Arg 690571620RNAHuman  
metapneumovirus 57augagcugga agguggugau uaucuucagc cugcugauua caccucaaca cgccugaag 60gagagcuacc  
uggaagagag cugcuccacc aucaccgagg gcuaccugag cgugcugcgg 120accggcuggu acaccaacgu guucaccug  
gaggugggcg acguggagaa ccugaccugc 180agcgacggcc cuagccugau caagaccgag cuggaccuga ccaagagcgc  
ucugagagag 240cugaagaccg uguccgccga ccagcuggcc agagaggaac agaucgagaa cccucggcag 300agcagauucg  
ugcuggggcg caucgcucug ggagucgccc cugccgcugc agugacagcu 360ggaguggcca uugcuaagac caucagacug  
gaaagcgagg ugacagccau caacaugcc 420cugaagaaga ccaacgagcc cgugagcacc cugggcaaug gagugagagu  
gcuggccaca 480gccgugcggg agcugaagga cuucgugagc aagaaccuga ccagagccau caacaagaac 540aagucgcaca

ucgaugaccu gaagauggcc gugagcuucu cccaguuca cagacgguuc 600cugaacgugg ugagacaguu cuccgacaac  
gcuggaauca caccugccau uagccuggac 660cugaugaccg acgccgagcu ggcuagagcc gugcccaaca ugcccaccag  
cgcuggccag 720aucaagcuga ugcuggagaa cagagccaug gugcggagaa agggcuucgg cauccugauu 780gggguguau  
gaagcuccgu gaucaucaug gugcagcug ccaucuucgg cgugaucgac 840acaccugcu ggaucgugaa ggccgcuccu  
agcugcuccg agaagaaagg aaacuaugcc 900ugucugcuga gagaggacca gggcugguac ugccagaacg ccggaagcac  
aguguacuau 960cccaacgaga aggacugcga gaccagaggc gaccagugu ucugcgacac cgcugccgga 1020aucaacgugg  
ccgagcagag caaggagugc aacaucaca ucagcacaac caacuacccc 1080ugcaagguga gcaccggagc gcacccauc  
agcauggugg cucugagccc ucuggcgcu 1140cugguggccu gcuauaagg cguguccugu agcaucggca gcaaucgggu  
gggcaucauc 1200aagcagcuga acaagggaug cuccuacauc accaaccagg acgccgacac cgugaccauc 1260gacaacaccg  
uguaccagcu gagcaaggug gagggcgagc agcacugau caaggcaga 1320cccugagcu ccagcuucga cccaucag  
uuccugagg accaguuca cugggccug 1380gaccaggugu uugagaacau cgagaacagc caggcccugg uggaccagag  
caacagauc 1440cuguccagcg cugagaaggg caacaccggc uucaucauug ugaucuuu gaucgccgug 1500cugggcagcu  
ccaugauccu ggugagcauc uucaucauu ucaagaagac caagaaacc 1560accggagccc cuccugagcu gagcggcgug  
accaacaug gcucauucc ccacaucuga 1620581620RNAHuman metapneumovirus 58augucuugga aagugaugau  
caucauuucg uuacucaua caccagca cgggcuaaag 60gagaguuuu ugaagaau auguaguacu auaucugagg  
gauaccucag uguuuuaaga 120acaggcuggu acacuaugu cuucacauua gaaguuggug auguugaaaa ucuuacaugu  
180acugauggac cuagcuuaa caaacagaa cuugaucua caaaaagugc uuuaaggga 240cucaaacag ucucugcuga  
ucaguuggcg agagaggagc aaauugaaaa uccagacaa 300ucaaguuug ucuuaggugc gauagcucuc ggaguugcua  
cagcagcagc agucacagca 360ggcauugcaa uagccaaac cauaaggcu gagagugagg ugaauagcau uaaaggugcu  
420cucaaaaaa cuuaugaagc aguaucaca uuagggaug gugugcgggu ccuagccacu 480gcagugagag agcuuaaaga  
uuugugagc aaaaaccuga cuagugcau caacaggaac 540aaaugugaca uugcugaucu gaagauggcu gucagcuca  
gucauuuca cagaaguuu 600cuuauguug ugcggcaguu uucagacaau gcagggaaua caccagcau aucauuggac  
660cugaugacug augcugaguu ggccagagcu guaucuaca ugccaacauc ugcagggcag 720auaaaacuga uguuggagaa  
ccgcgcaaug guaaggagaa aaggauuugg auccugaua 780ggggucucag gaagcucugu gauuacaug gucauuugc  
cgauuuugg ugucuaugau 840acaccuuguu ggaucauca ggcagcucc ucuugcucag aaaaaacgg gaauuugcu  
900ugccuccua gagaggauca agggugguau uguaaaaaug caggaucuac uguuuacuac 960ccaaaugaaa aagacugcga  
aacaagaggu gaucauguu uuugugacac agcagcaggg 1020aucaauguug cugagcauc aagagaugc aacaucaca  
uaucuacuac caacuacca 1080ugcaaaugca gcacagggaag acaccuaua agcaugguug cacuauacc ucucggugcu  
1140uugguggcu gcuauaagg gguaagcugc ucgauggca gcauugggu uggaaucauc 1200aaacaauuac ccaaaggcug  
cucaucaua accaaccagg augcagacac uuaacaauu 1260gacaauaccg uguaucaacu aagcaaguu gaaggugaac  
agcauguaa aaaagggaga 1320ccaguuuca gcaguuuuga uccaaucaag uuuccugagg aucaguuca uguugcgcu  
1380gaucaagucu ucgaagcau ugagaacagu caggcacuag uggaccaguc aaacaaaau 1440cuaacagug cagaaaagg  
aaacaguggu uucauuucg uaguauuuu gguugcugu 1500cuuggucua ccaugauuuc agugagcauc aucaucaua  
ucaagaaaac aaggaagccc 1560acaggagcac cuccagagcu gaugguguc accaacggcg guucauacc acauaguug  
1620591620RNAHuman metapneumovirus 59augucuugga aagugaugau uaucauuucg uuacucaua caccucagca  
uggacuaaaa 60gaaaguuuu uagaagauc auguaguacu auaucugaag gauaucucag uguuuuaaga 120acagguuggu  
acaccaugu cuuuacaaua gaaguuggug auguugaaaa ucuuacaugu 180acugauggac cuagcuuaa caaacagaa  
cuugaccua ccaaaagugc uuuaagagaa 240cucaaacag uuucugcuga ucaguugcg agagaagaac aaauugaaaa  
uccagacaa 300ucaagguuug ucuaggugc auagcucuu ggaguugcca cagcagcagc agucacagca 360ggcauugcaa  
uagccaaac uuaaggcu gagagugaag ugaauagcau caaaggugcu 420cucaaaaaca ccaugaggc aguaucaca  
cuaggaaug gagugcgggu ccuagccacu 480gcaguaagag agcugaaaga uuugugagc aaaaaccuga cuagugcga  
caacaagaac 540aagugugaca uugcuguuu gaagauggcu gucagcuca gucaguuca cagaagauuc 600cuuauguug  
ugcggcaguu uucagacaau gcagggaaua caccagcau aucauuggac 660cugaugaug augcugagcu ggccagagcu  
guaucuaca ugccaacauc ugcaggacag 720auaaaacuaa uguuagagaa ccgugcaaug gugaggagaa aaggauuugg  
aaucuuugau 780ggggucucag gaagcucugu gauuacaug guccagcugc cgauuuugg ugucuaauu 840acaccuuguu  
ggauaauc ggcagcucc ucuugucag aaaaagauug aaauuugcu 900ugccuccua gagaggauca agggugguau  
uguaaaaug caggauccac uguuuacuac 960ccaaaugaaa aagacugcga aacaagaggu gaucauguu uuugugacac  
agcagcaggg 1020aucaauguug cugagcauc aagagaugc aacaucaca uaucuaccac caacuacca 1080ugcaaaugca  
gcacagggaag acaccuauc agcaugguug cacuauacc ucucggugcu 1140uugguagcu gcuacaaggg gguuagcugc  
ucgacuggca guaacaggu uggaauaau 1200aaacaucac cuaaaggcug cucaucaua acuaaccagg acgagacac  
uguacaauu 1260gacaacacug uguaucaacu aagcaaguu gagggugaac agcauguaa aaaagggaga 1320ccaguuuca  
gcaguuuuga uccaucagg uuuccugagg aucaguuca uguugcgcu 1380gaucaagucu uugaaagcau ugaaaacagu  
caagcucag uggaccaguc aaacaaaau 1440cugaacagug cagaaaagg aaacaguggu uucauuuug uauuuuuu  
gauugcugu 1500cuuggguua ccaugauuuc agugagcauc aucaucaua ucaaaaaac aaggaagccc 1560acaggggc

cuccggagcu

gaugguguu accaacggcg guuucuuacc gcuuuuuag 1620601725RNAHuman respiratory syncytial virus  
60auggaguugc cauccucaa aacaaugca auuaccacaa uccuugcugc agucacacuc 60uguuuugcuu ccagucacaa  
caucacugaa gaauuuuauc aucaacaug cagugcaguu 120agcaaaggcu aucuuagugc ucuaagaacu gguugguua  
cuaguguuau aacuuuagaa 180uuuaguuua ucaaggaaaa uaaguguaau ggaacagaug cuaagguaaa auugauaaaa  
240caagaauuag auuuuuuuu aaugcugua acagaauugc aguugcucuu gcaaagcaca 300ccagcagcca acaucgagc  
cagaagagaa cuaccaaggu uuuaaauua uacacucuu 360auuacaaaa auaccaaugu acauuuagc aagaaaagga aaagaaguu  
ucuuugcuuu 420uuguuaggug uuggaucugc aaucgccagu ggcauugcug uaucaaggu ccugcaccua 480gaaggggaag  
ugaacaaaau caaaagugcu cuacuaucca caacaaggc uguagucagc 540uuuacaaug gaguuagugu cuuaccagc  
aauguguuag accuacaaaa cuuuuuuaguu 600aaacaguugu uaccuuuugu gaacaagcaa agcugcagca uaucaacuu  
ugaacugug 660auagaguucc acaaaagaa caacagacua cuagaguuu ccagggaauu uaguguuuu 720gcaggugua  
cuacaccugu aagcucuau auguuuacua auaguguuuu auuuuacuuu 780aucaaugua ugccuuuac aaugaucag  
aaaaaguuua uguccaacaa uguuuuuuu 840guuagacagc aaaguuuacuc uaucaugucc auuuuuuagg aggauguuu  
agcauuuua 900guacuuuuac cacuuuuagg uguuuuuuu acaccuuuu ggaaucugca cacuuuuuu 960cuuuuuuacaa  
ccaaacacaaa ggaagggucc acaucugcu uaaagaagc cgacagagga 1020uuguuuuug acauugcagg aucaguuuu  
uuuuuuucc aagcugaaac auguuuuuu 1080cauucgaauc gguuuuuuu ugacacaaug aacaguuuuu cuuuuaccag  
ugaaguuuuu 1140cucugcaaa uugacuuuu caaccccaaa uauuuuuuagc aaauuuuagc uucaaaaaa 1200gauguaagca  
gcuccuuuu cacuuuuuu ggagccuuug uguuuuuuu uggcauuuu 1260aaauuuuagc cauccuuuu aaucguggg  
aucauuuuu cuuuuuuuu cggguguguu 1320uuuuuuuuu auuuuuuuuu ggauuuuuuu ucuuuuuuuu auuuuuuuu  
uuuuuuuuu 1380aagcaagaag gcauuuuuu cuuuuuuuuu ggugaacaa uuuuuuuuuu cuuuuuuuuu 1440uuuuuuuuu  
ccuuuuuuuu auuuuuuuuu ucauuuuuu aaguuuuuuu gaaguuuuuu 1500cagagccuuu cuuuuuuuuu uuuuuuuuu  
gauuuuuuuu auuuuuuuuu uuuuuuuuu 1560uccacacaa auuuuuuuuu aauuuuuuu auuuuuuuuu uuuuuuuuuu  
uuuuuuuuuu 1620uuuuuuuuu uuuuuuuuu uuuuuuuuu aagccuuuu gcacacuuuu 1680aaggaucuuu  
uuguuuuuu auuuuuuuuu gcauuuuuuu acuuuuuuuu 1725611617RNAHuman parainfluenza virus 61augccuuuu  
cauuuuuuuu auuuuuuuuu accuuuuuuu uuuuuuuuu uuuuuuuuu 60gacuuuuuu aauuuuuuu uguuuuuuu  
uuuuuuuuuu guuuuuuuuu 120ucuuuuuuu uuuuuuuuu auuuuuuuuu cuuuuuuuuu uuuuuuuuu  
uuuuuuuuuu 180aacuuuuuuu guuuuuuuuu guuuuuuuuu uuuuuuuuu auuuuuuuuu 240ccuuuuuuuu uuuuuuuuu  
uuuuuuuuuu auuuuuuuuu uuuuuuuuu uuuuuuuuu 300gaaauuuuu auuuuuuuuu uuuuuuuuu uuuuuuuuuu  
uuuuuuuuuu uuuuuuuuu 360gguuuuuuuu cuuuuuuuuu cuuuuuuuuu auuuuuuuuu gcuuuuuuuu uuuuuuuuu  
420aguuuuuuuu uuuuuuuuuu cauuuuuuuu auuuuuuuuu cauuuuuuuu aguuuuuuuu 480guuuuuuuuu cuuuuuuuuu  
uuuuuuuuuu gcauuuuuuuu cuuuuuuuuu uuuuuuuuu 540aaauuuuuuu uuuuuuuuu uuuuuuuuu gcuuuuuuuu  
uuuuuuuuuu cagcagcagc 600auuuuuuuuu cuuuuuuuuu cuuuuuuuuu acauuuuuuuu uuuuuuuuuu cuuuuuuuuu  
660uuuuuuuuuu aaguuuuuuuu auuuuuuuuu auuuuuuuuu 780uuuuuuuuuu uuuuuuuuuu uuuuuuuuu  
uuuuuuuuuu cuuuuuuuuu 840aguuuuuuuu uuuuuuuuuu auuuuuuuuu auuuuuuuuu acauuuuuuuu uuuuuuuuu  
900uuuuuuuuuu auuuuuuuuu auuuuuuuuu auuuuuuuuu 780uuuuuuuuuu uuuuuuuuuu uuuuuuuuu  
uuuuuuuuuu cuuuuuuuuu 960gcuuuuuuuuu uuuuuuuuuu uuuuuuuuu uuuuuuuuu  
uuuuuuuuuu 1020ccuuuuuuuu cuuuuuuuuu cuuuuuuuuu auuuuuuuuu 1080uuuuuuuuuu uuuuuuuuuu  
uuuuuuuuuu uuuuuuuuuu 1140gguuuuuuuu uuuuuuuuuu uuuuuuuuu uuuuuuuuu 1200uuuuuuuuuu  
uuuuuuuuuu uuuuuuuuuu uuuuuuuuuu 1260uuuuuuuuuu uuuuuuuuuu uuuuuuuuu uuuuuuuuu  
uuuuuuuuuu cuuuuuuuuu 1320uuuuuuuuuu uuuuuuuuuu uuuuuuuuu uuuuuuuuu 1380uuuuuuuuuu  
uuuuuuuuuu uuuuuuuuuu uuuuuuuuu uuuuuuuuu 1440uuuuuuuuuu uuuuuuuuuu uuuuuuuuu  
uuuuuuuuuu gcauuuuuuuu uuuuuuuuuu uuuuuuuuu 1500uuuuuuuuuu uuuuuuuuuu uuuuuuuuu  
uuuuuuuuuu uuuuuuuuuu 1560uuuuuuuuuu uuuuuuuuuu uuuuuuuuu uuuuuuuuu  
1617621716RNAHuman parainfluenza virus 3 62augguuuuuu ggaagcagc caaccagga aaggaugcug guuuuuuuuu  
ggagacuuuu 60acagccacuc auggcaacaa gcuuuuuuuu aaguuuuuuu auuuuuuuuu gcuuuuuuuu 120cuuuuuuuuu  
uuuuuuuuuu uuuuuuuuuu uuuuuuuuuu uuuuuuuuuu aaguuuuuuu 180gcccgcgaa cuuuuuuuuu agacuuuuuu  
aaguuuuuuu uuuuuuuuuu uuuuuuuuuu 240cauuuuuuuu uuuuuuuuuu uuuuuuuuu uuuuuuuuu  
aagcuuuuuu 300uuuuuuuuuu uuuuuuuuuu uuuuuuuuu uuuuuuuuu 360uuuuuuuuuu uuuuuuuuuu  
uuuuuuuuuu uuuuuuuuuu uuuuuuuuuu uuuuuuuuuu 420uuuuuuuuuu uuuuuuuuuu uuuuuuuuu  
uuuuuuuuuu uuuuuuuuuu uuuuuuuuuu uuuuuuuuuu 480uuuuuuuuuu uuuuuuuuuu uuuuuuuuu  
uuuuuuuuuu uuuuuuuuuu 600uuuuuuuuuu uuuuuuuuuu uuuuuuuuu uuuuuuuuu  
uuuuuuuuuu uuuuuuuuuu uuuuuuuuuu uuuuuuuuuu 660uuuuuuuuuu uuuuuuuuuu uuuuuuuuu  
uuuuuuuuuu

guaaacucag acuugguacc ugacuuaaa 720ccuaggaucu cucuacuu caacuaaaau gacaauagaa agucauguuc  
ucuagcacuc 780cuuaauacag auguauauca acuguguuca accccaaaag uugaugaaag aucagauuau 840gcaucaucag  
gcaugaaga uauuguacuu gauauuguca auuauauggg cucaaucucg 900acaacaagau uuaagaauaa uauauaagu  
uuugaucac cauaucggc auuauacca 960ucuguuggac cagggauua cuacaaaggc aaaauauau uucucgggua  
uggaggucuu 1020gaacaucua uaaugagaa ugcaaucugc aacacaacug gguguccugg gaaaacacag 1080agagacugua  
aucaagcauc ucauagucca ugguuuucag auagaaggau ggucaacucu 1140auuuuuugug uugacaaggc cuugaacua  
guccaaaaau ugaagguaug gacgauaucu 1200augagacaaa auuacugggg gucagaagga agauuacuu uacuagguua  
caagaucuac 1260auauacacaa gaucaaacag uuggcacagc aaguuaacuu uaggaauuu ugacuuacu 1320gacuacagug  
auuaaaggau aaauggaca uggcauauug ugcuaucac accaggaaac 1380aaugauguc cauggggaca uucauguccg  
gauggaugua uacgggagu auauaccgau 1440gcauuccac ucauuccac aggaagcauu guaucaucug ucauuugga  
cucacaaaa 1500ucgagaguca acccagucuu aacuuacua acagcaaccg aaaggguaaa cgagcuggcu 1560auccgaaaca  
aaacacucuc agcuggguac acaacaaca gcugcauuac acacuuaac 1620aaaggguuu guuuucauu aguagaaau  
aucauaaaa gcuuaaac auuuaacc 1680auguuguuca aaacagagau uccaaaaagc ugcagu 1716631716RNAArtificial  
SequenceSynthetic Polynucleotide 63auggaauacu ggaagcacac caaccaggc aaggacgccc gcaacgagcu ggaaccaggc  
60acagccacac acggcaaca gcugaccaac aagaucaccu acauccugug gaccaucac 120cuggugcugc ugagcaucgu  
guucauacug gucgucaca auagcauca gagcgagaag 180gccagagaga gccugcugca ggacaucac aacgaguca  
uggaagugac cgagaaguc 240cagguggcca gcgacaacac caacgaccug auccagagcg gcgugaacac ccggcugcug  
300accauccaga gccacgucga gaacuacuc ccaucagcc ugaccagca gaucagcgc 360cugcggaagu ucaucagcga  
gaucaccauc cggaacgaca accaggaagu gccccccag 420agaucaccc acgacguggg caucaagccc cugaacccc acgauuucg  
gcgguuaca 480agcggcugc ccagccugau gaagacccc aagaucggc ugaugccugg ccuggacug 540cuggccaugc  
cuaccacagu ggauggcugu gucgggacc ccagccucgu gaucaacgau 600cugaucuac ccuacaccag caaccugac  
accggggcu gccaggauau cggcaagagc 660uaccaggugc ugcagaucgg caucaucac gugaucucc accugguc  
cgaccugaac 720ccucggauca gccacacuu caacuaaac gacaacagaa agagcugcag ccuggcucug 780cugaacaccg  
acguuacca gcugucagc accccaagg uggacgagag aagcgacuac 840gccagcagc gcaucgagga uaucgucug  
gacaucguga acucagcgg cagcaucagc 900accaccggg ucaagaaca caacucagc uucgaccagc cuacgccc ccuguaccu  
960ucugugggc cuggcaucua cuacaaggc aagaucuu uccugggcu cggcgccug 1020gaacaccca ucaacgagaa  
cgcaucugc aacaccaccg gcugcccugg caagaccag 1080agagacugca aucaggccag ccacagccc ugguucagc  
accgagaau ggucaacucu 1140aucaucgugg uggacaaggc cuugaacagc guggccaagc ugaagugug gacaucagc  
1200augcgccaga acucugggg cagcgaggc agacuucugc ugcugggaaa caagaucuac 1260aucuacacc gguccaccag  
cuggcacagc aaucgucagc ugggaucuu cgacaucac 1320gacuacagc acauccggau caaguggacc uggcacaacg  
ugcugagcag accggcaac 1380aaugagugcc cuuggggcca cagcugccc gauggaugua ucaccggcu guacaccgac  
1440gcuacccc ugaucuuac cggcucauc guguccagc ugaucugga cagccagaaa 1500agcagaguga acccgugau  
cacuacagc accgccag agagagugaa cgaucuggc 1560aucagaaaca agaccugag cgccggcuac accaccaca  
gcugcaucac acacuacaac 1620aaaggguacu gcuuccacuu cguggaauc aaccacaagu ccugaacac cuuccagccc  
1680augcuguuca agaccagau cccaagagc ugcucc 1716641617RNAArtificial SequenceSynthetic Polynucleotide  
64augcccauca gcauccugcu gaucaucac acaugauca uggccagcca cuggcagac 60gacaucacca agcugcagca  
cgugggcug cucgugaaca gcccaggc caugaaguc 120agccagaacu ucgagacagc cuaccugac cugagccuga  
ucccaagau cgaggacagc 180aacagcugc gcgaccagca gaucaagcag ucaagcggc ugcuggacag acugaucauc  
240cccuguaac acggcugcgc gcugcagaaa gacgugaucg ugaccaaca ggaaagcaac 300gagaacaccg accccggc  
cgagagauuc uucggggcgc ugaucggc aaucgcccug 360ggaguggcca caagcggcca gauuacagcc gcuguggccc  
ugguggaagc caagcaggc 420agaagcagc ucgagaagcu gaaagaggc auccgggaca ccaacaaggc cgugcagagc  
480gucgagucca gcgugggcaa ucgaucugug gcaucaagu ccgucagga cuacgugaac 540aaagaaucg ugcccucuu  
cgccggcug ggcugugaag cugccggacu gcagcuggc 600auugcccuga cacagcacia cagegagcug accaacauc  
ucggcgaca caucggcagc 660cugcagaaa agggcauuu gcugcaggga aucgcccagc uguaccgac caacucac  
720gagaucuuca ccaccagc cguggauaag uacgacauc acgaccugcu guucaccag 780agcaucaag ugcgugau  
cgaguggac cugaacgacu acagcaucac ccugcaagug 840cgucgccc ugcugaccag acugcugaac acccagau  
acaaggugga cagcaucucc 900uacaacauc agaaccgca gugguacuu ccucgccc gccacuuuu gaccaaggc  
960gcuuuucug gcggagccga cgugaaagag ugcaucgagg ccuucagcag cuacucugc 1020cccagcagc cuggcuucg  
gcugaaccac gaguggaaa gcugccugag cggcaacuc 1080agccagugcc ccagaaccac cgugaccucc gacucguc  
ccagauacgc cuucgugaau 1140ggcgcgugg uggcaacug caucaccac accuguccu gcaacggcau cggcaaccg  
1200aucaaccagc cuccgauca gggcgugaag auuacacc acaagagug uacaccauc 1260ggcaucaacg gcaucuguu  
cauaccaac aaagaggcca ccuggccuu cuaccccc 1320gacgauuca ccugaaca cuccguggcu cuggaccca  
ucgacauc caucgagcug 1380aaaggcca agagcagcu ggaagagucc aaagagugga uccggcgag caaccagaag  
1440cuggacua ucggcagcgc gaccagagc agcaccaca uaucgugau ccuguuuug 1500auguuuauc uguucauau

caacauuacc aucaucacua ucgccauuaa guacuaccgg 1560auccagaaac ggaaccgggu ggaccagaau gacaagccu  
acgugcugac aacaag 1617654062RNAMiddle East respiratory syndrome coronavirus 65augauacacu caguguuuu  
acugauguuc uuguuaacac cuacagaaag uuacguugau 60guagggccag auuciguuaa gucugcuugu auugagguug  
auauacaaca gaccuucuuu 120gauaaaacuu ggccuaggcc aaugauguu ucuaggcug acgguuuuu auaccuca  
180ggccguacau auucuaacau aacuaucacu uaucaagguc uuuuuccua ucagggagac 240cauggugaua uguauguuu  
cucugcagga caugcuacag gcacaacucc acaaaaguug 300uuuguagcua acuaucuca ggacgucaaa caguuuugua  
auggguuuugu cguccguaua 360ggagcagcug ccaauuccac uggcacuguu auuuuagcc caucuaccag cguacuaua  
420cgaaaauuu accugcuuu uaugcugggu ucuucaguug guuuuuucuc agaugguaaa 480auggggccgcu ucuucaua  
uacucuaguu cuuuugccc auggaugugg cacuuuacuu 540agagcuuuuu auuguuuuu agagccucgc ucuggaauc  
auuguccugc uggcaauucc 600uauacuucuu uggccacuua ucacacuccu gcaacagauu guucugaugg cauuuacau  
660cguaaugcca gucugaacuc uuuuaaggag uuuuuuuuu uacguaacug caccuuuug 720uacacuuuaa acuuuaccga  
agaugagauu uuagaguggu uggcauuac acaaacugcu 780caagguguuc accucucuc aucucggauu guuguuuugu  
acggcggcaa uauguuuca 840uuugccaccu ugccuguuuu ugauacuauu aaguuuuuu cuacuauucc ucacaguauu  
900cguucuauc aaagugauag aaaagcuugg gcugccuuc acguuuuuu acuucaaccg 960uuuacuuucc uguugguuu  
uucuguugau gguuuuuuac gcagagcuau agacuguggu 1020uuuuuugauu ugucacaacu ccacugcuca uaugaauccu  
ucgauguuga aucuggagu 1080uauucaguuu cgucuuucga agcaaacuu ucuggcucag uuguggaaca ggcugaaggu  
1140guugaaugug auuuuucc ucuucugucu ggcacaccuc cucagguuuu uauuuucaag 1200cguuuguuu uuaccauug  
cauuuuuuu cuuacaaau ugcuuucacu uuuuucugug 1260aauuuuuu cuuguaguc aauaucucca gcagcaauug  
cuagcaacug uuauucua 1320cuguuuuug auuuuuuuu auaccacu aguaugaaau ccgacucag uguuaguuc  
1380gcugguccaa uauccagu uuuuuuuuu caguccuuu cuauccac auguuugau 1440uuagcgacug uuccucaua  
ccuuacuacu auuacuagc cucuaagua cagcuuuuu 1500aacaagugcu cucgucuuu uucugaugu cguacugaag  
uaccucagu agugaacgc 1560aaucauacu caccugugu auccauugc ccauccacug ugugggaaga cgguguuuu  
1620uauaggaac aacuauucc acugaaggu ggugcuggc uuguugcuag uggcucaacu 1680guugcauga cugagcauu  
acagaugggc uuuguuuuu caguucauu uggucagac 1740accaauagug uuugcccaa gcuugaauu gcuauagaca  
cauuuuuugc cucucauuu 1800ggcauuugc uggauuuu ccucuuuggu guuucgggc gugguuuuu ucagaauugc  
1860acagcugug guuucgaca gcagcguuu guuuuugaug cguaccagaa uuuuuugc 1920uuuuuuuug augauggca  
cuacuacug cucgugcuu guuuuugug uccuuuuu 1980gucaucuau auuuuuuuu uuuuuuuuu gcuacuauu  
uuuuuuuuu ugcauguga 2040cacuuuuu cuaccaugc ucauacucc cguucucgc gaucauugc uaaacggcga  
2100gauucuaacu auugccccc ucagaccu guugguugug uccuaggacu uguuuuuu 2160ucuuuuugc uagaggacug  
cauuuuuuu cucgucuuu cucucuguc ucuuccug 2220acaccuagua cucucacacc ucgagugug cgcucuguc  
caggugaaau gcguuugca 2280uccuuugcu uuuuuuuu cauucaggu gaucauuu auuuuuuuu uuuuuuuuu  
2340aguauacca cuuuuuuuu cuuuugugug acucaggagu acuuucagc aaccuuucag 2400aaaguucug ugauguaa  
acaguucgu ugcauuggu uccagaagug ugagcauuu 2460cugcgcgagu auugccagu uuuuuuuu auuuuuuuu  
cucuccaug ugcauuuuu 2520cgccaggaug auucugucg uuuuuuuu gcgagcguu aaagcucua aucaucuccu  
2580aucauaccg guuuuugag ugacuuuuu uugacacuu uagaaccug ucuuuuuu 2640acuggcagc guagucagc  
uagugcuuu gagguuuugc uuuuuuuu agucacuuu 2700gcugaucug guuuuuuu agguuacgu guuuuuuu  
agcaaguc agcaucagc 2760cugugauuu uuugucua auuuuuuuu gguuuuuu uuuuuuuu uuuuuuuu  
2820guuuuuuu aagcccgua ucuuucuu uugcuuugca gcuaucagc uguuuuuu 2880acugcugcu uauccuuu  
ugcugcuuu cuuuuuugc agauuuuu uuuuuuuu 2940aacggguug gcuuuuuu acagguuuu ucagagaac  
uuuuuuuu ugcauuuu 3000uuuuuuu cucugggagc uuuuuuuu gcuucacua cauuuuuuu agcuuuuuu  
3060aagguucagc augcuguga cauuuuuu caggcucuu ccauuuuu uagcagcua 3120ucuuuuuu uugugcuuu  
uuuuuuuu auuggagca uuuuuuuu ucuuuguu 3180cucgaacagc agcccauu agacagacu uuuuuuuu  
guuugaca acuuuuuu 3240uuuuuuugc agcagcuuu ucguuccgaa ucagcugc uuuuuuuu auuuuuuu  
3300gauuuuuu auagugug caagcaca uuuuuuuu cuuuuuuuu cggucaagc 3360acacuuuuu ugucuuuuu  
uuuuuuuu cuuuuuuuu gcuuuuuu 3420uuuuuuu gcauuuuu uuuuuuuu uuuuuuuu uuuuuuuu  
gcuuuuuu uuuuuuuu 3480cuuuuuuu guuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu  
3540guuuuuuu gcuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu  
acagguuuga uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu  
3660cuuuuuu gcuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu  
3720uuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu  
3780uuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu  
3840uuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu  
3900uuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu  
3960uuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu  
4020uuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu uuuuuuuu  
4062664062RNAArtificial SequenceSynthetic Polynucleotide 66augauacacu caguguuuu  
acugauguu uuguuaacac cuacagaaag uuacguugau 60guagggccag

auuciguuaa gucugcuugu auugagguug auauacaaca gacuucuuu 120gauaaaacuu ggccuaggcc aaugauguu  
ucuaaggcug acggauuuau auaccuca 180ggccguacau auucuaacau aacuaucacu uaucaagguc uuuuuccua  
ucagggagac 240cauggugaua ugauguuuu cucugcagga caugcuacag gcacaacucc aaaaaguug 300uuuguagcua  
acuauucua ggacgucaa caguugcua auggguuuu cguccguua 360ggagcagcug ccaauuccac uggcacuguu  
uuuuuagcc caucuaccag cguacuua 420cgaaaauuu accugcuuu uaugcugggu ucuucaguug guuuuuc  
agaugguaa 480augggccgc ucuucaua uacuaguu cuuuugccc auggauggg cacuuuacuu 540agagcuuuu  
auuguuuu ggagccugc ucuggaauc auuguccugc uggcauuucc 600uauacuucu uggcacuuu ucacacuccu  
gcaacagauu guucugaugg cauuuacau 660cguaaugcca gucugaacuc uuuuaggag uuuuuuuu uacguaacug  
caccuuuug 720uacacuua acuuaccga agaugagauu uuagaguggu uggcauuac acaaacugcu 780caagguguuc  
accucuucuc aucucggauu guugauuuu acggcgcaa uauguuua 840uuugccaccu ugccguuuu ugauacuau  
aaguuuuu cuacuaucc ucacaguau 900cguucuauc aaagugauag aaaagcuugg gcugccuuc acguauua  
acuucaccg 960uuacuucc uguugguuu uucuguugau gguuuuac gcagagcuu agacuguggu 1020uuuauugau  
ugucacaacu ccacugcu uaugaauc ucgauguuga aucuggagu 1080uauucaguuu cgucuuucga agcaaacu  
ucuggcucag uuguggaaca ggcugaaggu 1140guugaugug auuuuucc ucuucugucu ggcacaccuc cucagguuu  
uauuucaag 1200cguuugguuu uuaccauug cauuuuuu cuuaccuuu ugcuuucacu uuuuucugug 1260aauguuuu  
cuuguagca auuauucca gcagcaauug cuagcaacug uuauucua 1320cuguuuugg auuacuuuc auaccacu  
aguauuuuu cgaucucag uguuaguuc 1380gcuggucca uauccaguu uuuuuuuu caguccuuu cuauccac  
auguuugau 1440uuagcaguc uuccucaua ccuacuacu auuacuaagc cucuuuagca cagcuuuuu 1500aacagugcu  
cucgucuuc uucugaugau cguacugaag uaccucagu agugaacgc 1560aucauuacu caccugugu uccauuguc  
ccaucacug uguuggaaga cgguguuuu 1620uauaggaac aacuaucucc acuugaaggu gguggcuggc uuguucug  
uggcuacu 1680guugcauga cugagcauu acagugggc uuuguuuu caguucuuu uggucagac 1740accauugug  
uuugccca gcuugaauu gcuauugca caaaaauugc cucucauuu 1800ggcauuugc uggauuuu ccucuauggu  
guuucgggc gugguuuu ucagaauugc 1860acagcuguag guuucgaca gcagcguuu guuuuugaug cguaccaga  
uuuugggc 1920uuuuuucug augauggca cuacuacug uugcugucu guuuuugug uccuuuuu 1980guacuauug  
auaaagaaac uaaaccac gcuacuau uugguugug ugauguga 2040cacuuuuu cuaccuguc ucauacucc  
cguucacgc gaucauugc uaaacggcg 2100gauucacau augggcccu ucagaccu guugguugug uccuagacu

uguuuuu 2160ucuuuuguc uagaggacug caaguugcu cuuggucau cucucuguc ucuuccugac 2220acaccuagua  
cucucacacc ucgagugug cgcucuguc cagguaau gcgcuuggca 2280uccauugcu uuaucucc uauucaggu  
gaucaacu uaguuguu uuuuuuuu 2340aguauacca cuuuuuuu cuuuggugug acucaggagu acuuacagc  
aaccauucag 2400aauguuacug uugauuuu acaguacgu ugaauuggu uccagaugug ugagcauuu 2460cucgagc  
augccaguu uguuccaa auuaccag cucuccaug ugcauuuu 2520cgccaggug auucuguc uuuuuuuu  
gcgagcuga aagcucua auuacucc 2580aucauaccg guuuuggag ugacuuuu uugacacuc uggaaccug  
uucuauuc 2640acuggcagc guagucacg uagucuuu gaggauugc uuuuugaca agucacuua 2700gcugaucug  
guuuuugc agguuacgu gauugcugc agcaagucc agcaucagc 2760cugaucuuu uuugucua auuugggcu  
gguuacaag uuuuuccc ucuuugau 2820guuuuuug aagccgcu ucuuacuc uugcuuggc gcauagcag  
uguuggcug 2880acugcuggc uauccuuu ugcugcuuu cuuuugcag agaguauuu uuauuguu 2940aacgguguug  
gcuuacua acagguuu ucagagaacc aaaagcuuu ugcauuuag 3000uuuuuacag cucugggagc uaugcaaca  
ggcuacua caacuaua gcuuuucag 3060aagguucagc augcuguga caacuugc caggcucu ccauuuagc  
uagcagcua 3120ucuuuuuu uuggucuu uuccgcucu auuggagca ucauacacg ucuuguuu 3180cucgacagc  
acgccaa agacagacu auuauuggc guuugaca acuuuugcu 3240uuuuugc agcagcuug ucguccga  
ucagcugc uuccgcua auuggcuuu 3300gauuuuagc augagugug caagcaca uccaagcu cugguuuu  
cggucaagc 3360acacuuuug ugcuuuuu uguuuuugc cuuuuugc uuuuucuu gcauuuug 3420uuuuuccu  
gcaaccacu ugagguuu ucuguuuug guuuuugc ugcagcua 3480ccuacuuuu guuuuuugc uuuuuugc  
uacuuuuu auacuaua cacuagguu 3540guuugagug gucuuuuac uggcuguc ucuuugcagc cugagccu  
uaccuccu 3600auuacuuu auguugcacc acaggugca uaccuuuac uuucuuua cuuccuccu 3660ccucuucug  
gcauuuccc cggguugc uccaagugc aguuugau guuuuuuu 3720aauguuagc ccaguaucc uuuuuuug  
uccuuacac aguuuuuac uacuucuc 3780gcuuuuac agaguuu gucuuuua caaguuuu aagccuuu  
ugaguuuac 3840auagcuuu aagagcuug cauuuuuac uuuuacaa auuggccug guuuuuug 3900cuuguuu  
uugcuggcu uguugcuuu gcuuuugc ucuuuuac acugucugc 3960acugguug gcauuuac uauggaa  
cuuuuugc auuuuuug ugauuugc 4020gagguuac accucagcc gcauuuugc uuuuuuac aa  
4062671845RNA Artificial Sequence Synthetic Polynucleotide 67augauccu ceguuuuu cuuauuuu  
cuguugacc ccacugagc agacugca 60cucccugc gacaguccu gugucguc cugacacuc cuagcucuc gacccacg  
120uccgucgcu cggugcugc gaaauugc cuggccucc ucgcuuua ucaccau 180caugugc agcuuuu



cucguuuuc aagcugucca uccccacgaa cuucucguuc 240ggggucaccc aggaguacau ccagaccaca auucagaagg  
ucaccgucga uugcaagcaa 300uacgugugca acggcuucca gaagugcgag cagcugcuga gagaauacgg gcaguuuugc  
360agcaagauca accaggcgcu gcauggagcu aacuugcgcc aggacgacuc cgugcgcaac 420cucuuuugccu cugugaaguc  
aucccagucc ucccacauca ucccggggauc cggaggggac 480uucaaccuga ccucucugga gcccugugc aucagaccg  
guagcagauc ggcgcgcuca 540gccauugaag auuucuguu cgacaagguc accaucgccc auccgggcuca caugcaggga  
600uacgacgacu guaucgagca gggaccagcc uccgagggg accucaucug cgcgcaauac 660gugggccgggu acaagugcu  
gccuccucug auggauguga acauggaggc cguuuuacu 720ucguccucg ucggcucua cggcgugug ggguggaccg  
cggccuguc cuccuucgccc 780gcuauccccc uugcacauc cauuuucua cggcucaacg gcgugggcau uacuacaa  
840guccugucgg agaaccagaa guugaucgca aacaaguca aucaggcccu gggggccaug 900cagacuggau ucacuacgac  
uaacgaagcg uuccagaagg uccaggagcg ugugaacaac 960aacgcccagg cgcucuaaa gcuggccucc gaacucagca  
acaccuucgg agccaucagc 1020gcaucgauc gugacauau ucagcggcug gacgugcugg agcaggagcg ccagaucgac  
1080cgccucauca acggacggcu gaccaccuug aaugccuucg uggcacaaca gcugguccgg 1140agcgaucag cggcacuuuc  
cgcccauc gccaaggaca aagucaacga augcgugaag 1200gcccagucca agagguccgg uuucugcggu caaggaacc  
auuuuguguc cuucgucgug 1260aacgcccga acggucugua cuuuugcac gucggcuacu acccgagca ucauucgaa  
1320guggugucgg ccuacggccu gugcgaucc gcuacccca cuaacugua ugcuccugug 1380aacggauuu uuuuuagac  
caacaaccc cgcauugugg acgaugguc auacaccggu 1440ucguccuuc acgcgccga gcccaucacu ucacugaaca  
ccaaauacgu ggcuccgca 1500gugaccuacc agaacauc caccuuuug cggccgccc ugcucggaaa cagcaccgga  
1560auugauuucc aagaugaau ggacgaauuc uucaagaacg uguccacuuc cauuccaac 1620uucggaagcc ugacacagau  
caaccacc cuucucgacc ugaccuacga gaugcugagc 1680cuucaacaag uggucaagcc ccugaacgag agcuacaucg  
accugaagga gcugggcaac 1740uuuacuuacu acaacaagug gccggacaag auugaggaga uucugucgaa auuacacc  
1800auugaaaacg agaucgccc auucaagaag cuuacggcg aagcc 1845684071RNAArtificial SequenceSynthetic  
Polynucleotide 68auggaaacc cugcccagcu gcuguuccug cugcugcugu ggucgucgca uaccaccggc 60agcuauuggg  
acgugggccc cgauagcgug aaguccgcu guaucgaagu ggacaucag 120cagaccuuuu ucgacaagac cuggccaga  
cccucgacg uguccaaggc cgacggcauc 180aucuauccac aaggccggac cuacagcaac aucaccuuu ccuaccaggg ccuguucca  
240uaucaaggcg accacggcga uauguacgug uacucugccc gccacgccac cggcaccaca 300cccagaaa ucuucguggc  
caacuacagc caggacguga agcaguucgc caacggcuuc 360gucgucggga uggcgcccgc ugccaauagc accggcagc  
ugaucaucag cccagcacc 420agcgccacca uccggaagau cuaccccgc uucaugcugg gcagucuccu gggcauuuc  
480agcgacggca agaugggcgg guucuucaac cacaccugg ugcugcugcc cgauggcugu 540ggcacacugc ugagagccuu  
cuacugcauc cuggaacca gaagcggca ccacugcccu 600gccggcaua gcuacaccag cuucgccacc uaccacacac cggccaccga  
uugcuccgac 660ggcaacuaca accggaagc cagccugaac agcuucaag aguacuuaa ccugcggaac 720ugcaccuua  
uguacaccua cauuuacacc gaggacgaga uccuggaug guucggcauc 780accagaccg cccaggcgcu gcaccuugc  
agcagcagau acguggaccu guacggcggc 840aacauguucc aguuugccac ccugcccug uacgacacca ucaaguacua  
cagcauac 900cccacagca uccgguccau ccagagcgac agaaaagccu gggccgccc cuacgugua 960aagcugcagc  
cccugaccuu ccugcuggac uucagcgugg acggcuacu cagacggccc 1020aucgacugcg gcuucaacga ccugagccag  
cugcacugcu ccuacgagag cuucgacgug 1080gaaagcggcg uguacagecu guccagcuuc gagccaagc cuagcggcag  
cgugguggaa 1140caggcugagg gcguggaag cgacuucagc ccucugcuga gggcaccccc ucccaggug 1200uacaacuua  
agcggcuggu guuacaaac ugcauuuaca accugacca gcugcugagc 1260cuguuucgg ugaacgacu caccugagc  
cagauacgccc cugccgcau ugccagcaac 1320ugcuacagca gccuaguccu ggacuacuuc agcuacccc ugagcauga  
guccgucug 1380agcguguccu cggccggacc caucagccag uucaacuaca agcagagcu cagcaaccu 1440accugccuga  
uucuggccac cgugcccac auucugacca ccauaccaa gcccugaag 1500uacagcuaca ucaacaagug cagcagacug  
cuguccgac accggaccga agugcccag 1560ucgugaacg ccaaccagua cagcccugc guguccaucg ugcccagc  
cgugugggag 1620gacggcgacu acuacagaaa gcagcugagc cccuggaag gcggcggaug gcuggugcu 1680ucuggaagca  
caguggccau gaccgagcag cugcagaugg gcuuugcau caccgucag 1740uacggcaccg acaccaacag cgugugcccc  
aagcuggaa ucgcaauga cacaagauc 1800gccagccagc ugggaaacug cguggaauac uccuguaug gcguguccg  
acggggcgug 1860uuccagaauu gcacagcagu gggagugcgg cagcagagau ucguguacga ugccuaccag 1920aacucgugg  
gcuacuacag cgacgagcgc auuacuacu gccugcgggc cugugugucc 1980gugcccgugu ccgugauca cgacaagag  
acaaagacc acgccacacu guucggcucc 2040guggccugcg agcauacag cuccaccaug agccaguacu cccguccac  
ccgguccaug 2100cugaagcggga gagauagcac cuacggcccc cugcagacac cuguggaug ugugcugggc 2160ucgugaaca  
gcuccuguu uguggaagau ugcaagcugc ccugggcca gagccugugu 2220gcccugccag auaccuuag caccugacc  
ccuagaagcg ugcgucug gcccggcgaa 2280augcggcug ccuacuagc cuucauac ccauccagc uggaccagcu  
gaaccagc 2340uacuuaagc ugageauccc cacaacuuc agcuucggcg ugaccagga guacauccag 2400accacauc  
agaaugagc cguggacugc aagcaguac ugugcaacgg cuuucagaag 2460ugcgaacagc ugcugcgca guacggccag  
uucugcagca agauaccca gcccugcagc 2520ggcgccaacc ugagacagga ugacagcug cggaaccugu ucgcccagcu  
gaaaagcagc 2580caguccagc ccauauccc uggcuucggc ggcgacuuu accugaccu gcuggaaccu 2640guguccauca

gcaccggcuc cagaagcgcc agauccgcc a ucgaggaccu gcuguucgac 2700aaagugacca uugccgaccc cggcuacaug  
cagggcuacg acgauugcau gcagcagggc 2760ccagccagcg ccaggggaucu gaucugugcc caguauuggg cggcuacaa  
ggugcugccc 2820ccccugaugg acgugaacau ggaagcggc uacaccucca gccugcuggg cucuauugcu 2880ggcgugggau  
ggacagccgg ccugucuagc uuugccgcca uccuuucgc ccagagcauc 2940uucuaaccggc ugaacggcgu gggcaucaca  
caacaggugc ugagcgagaa ccagaagcug 3000aucgccaaca aguuuaacca ggcacugggc gccaugcaga cggcuucac  
caccaccaac 3060gagggccuua gaaaggugca ggacgccgug aacaacaacg cccagggcucu gagcaagcug 3120gccuccgagc  
ugagcaauac cuucggcgcc aucagegccu ccaucggcga caucauccag 3180cggcuggagc ugcuggaaca ggacgccag  
aucgaccggc ugaucacgg cagacugacc 3240accugaacg ccuucguggc acagcagcuc gucgggagcg aaucugccc  
ucugucugcu 3300cagcuggcca aggacaaagu gaacgagugc gugaaggccc aguccaagcg gagcggcuuu 3360uguggccagg  
gcaccacau cguguccuuc gucgugaau ccccaacgg ccuguacuuu 3420augcagugg gcuaauacc cagcaaccac  
aucgaggugg uguccgccua uggccugugc 3480gacgccgcca auccuacaa cuguauccg cccgugaacg gcuaucuu  
caagaccaac 3540aacaccggga ucguggacga gugguccuac acaggcagca gcuuuacgc ccccgagccc 3600aucaccucc  
ugaacacaa auacguggcc cccaaguga cauaccagaa caucuccacc 3660aaccugccc cuccacugcu gggaaauuc  
accggcaucg acuuccagga cgagcuggac 3720gaguucuuca agaacguguc caccucca cccaacuucg gcagccugac  
ccagaucac 3780accacucugc uggaccugac cuacgagaug cuguccucg aacaggucgu gaaagcccug 3840aacgagagcu  
acaucgaccu gaaagagcug gggaacuaca ccuacuaca caaguggccu 3900ugguacuuu ggcugggcuu uaucgcccg  
cugguggccc uggccugug cguguucuu 3960auccugugc gcaccggcug cggcaccuu ugcaugggca agcugaaug  
caaccggugc 4020ugcgacagau acgaggaaua cgaccuggaa ccucacaaag ugcaugugca c 4071691864RNAArtificial  
SequenceSynthetic Polynucleotide 69ucaagcuuuu ggaccucug acagaagcua auacgacua cuauagggaa auaagagaga  
60aaagaagagu aagaagaaau auaagagcca ccaugggucu caaggugaac gucucugcc 120uaucgaggc aguacugua  
acucuccaaa caccgcccgg ucauuuau uggggcauc 180ucucuaagau agggguagua ggaauaggaa gugcaagcua  
caaaguuuug acucguuca 240gccaucauc auuagucua aaauuaugc ccauuuaac ucuccuau aaucgcagc  
300ggguagagau ugcagaauac aggagacuac uaagaacagu uuuggaaca auuagggau 360cacuuauugc auagaccag  
aacauaaggc cggucagag cguagcuca aguaggagac 420acaagagau ugccgggagua guccuggcag gucggccu  
aggguuugc acagcugc 480agauaacagc cggcauugca cuucaccggc ccaugcugaa cucucaggcc aucgacauc  
540ugagagcgag ccuggaaacu acuaucagg caauugaggc aaucagaca gcagggcagg 600agaugauuu ggcuguucag  
gguguccaag acuaucuaa uauagagcug auaccgucua 660ugaaccagcu auuugugau cuaucgguc agaagcugg  
gcuaaaauug cuuagauacu 720auacagaaau ccugucuuu uuuggccca gccuacggga ccccauau cuccgagauu  
780cuauccaggc uuugauuuu gcacuuggag gagauaaca uaagguguua gaaagcugc 840gauacagugg agcgauuuu  
cuaggcaucu uagagagcag aggaauaaag gcucggaua 900cucacgucga cacagagucc uacuucuaug uccucaguu  
agcuauccg acgucugcc 960agauuaagg ggugauugc caccggcuag aggggguc guacaacua ggcucuaag  
1020agugguauac cacugugcc aaguauug caaccaagg guaccuuac ucgaauuuug 1080augagucac auguacuuuc  
augccagagg ggacugugug cagccaaaau gccuuguaac 1140cgaugagucc ucuguccaa gaauccucc ggggguccac  
caaguccug gcucguacac 1200ucguauccgg gucuuuugg aaccggucua uuuuauca agggaaucua auagccauu  
1260gugcaucau ucuuuguaag uguuacaca cagguacgau uuuuaucua gaccugaca 1320agaucuaac auacauugc  
gccgaucgc gccgguaug cagggugaac ggcgugacca 1380uccaagucgg gagcaggagg uauccagacg cugugucuu  
gcacagaau gaccucggc 1440cuccaua auuggagagg uuggagcug ggacaauc ggggaugca auugccaa  
1500uggaggauug caaggauuug uuggaucau cggaccagau auugagaagu augaaaggu 1560uauagcagc uagcauag  
uacauccuga uugcagugug ucuuggagg uugauaggga 1620ucccacu uauauguugc ugcagggggc guuguaaca  
aaaggagaa caaguuggua 1680ugucaagacc aggccuaaag ccugaccua caggaacac auaucuuu gaaagucg  
1740uuugauua auaggcugga gccucggugg ccaagcuuc ugcccug gccucucc 1800agccuccu cccuuccg  
caccguacc cccguguc uugaauaaug ucugagugg 1860cggc 1864701653RNAArtificial SequenceSynthetic  
Polynucleotide 70augggucua aggugaacg cucugccgua ucauggcag uacuguaac ucuccaaca 60cccggcggc  
aaaucauug gggcaucuc ucuaagauag ggguaugagg auuaggaug 120gcaagcua aaguuaugc ucguccagc  
caucauau uagucuaaa auuaugccc 180auuaaac uccuauuaa cugcagagg guagagauug cagaucag  
gagacuacua 240agaacaguu uggaaacau uagggaugca cuuaugca ugaccagaa cauaaggccg 300guucagagc  
uagcuucaag uaggagac aagagauug cgggaguug ccuggcag 360gcggccuag guguugccac agcugcag  
auaacagcc gcuuugcuc ucaccguc 420augcugaacu cucaggccau cgacaucug agagcagcc uggaacuac  
uaucagga 480auugaggca ucagacaagc agggcaggag augauuuug cuguucagg uguccaagc 540uacaucaua  
augagcugau accgucuaug aaccagcuau cuugugau cuucggucag 600aagcucggc ucauuuugc uagauacu  
acagaauc ugucuuuu uggcccagc 660cuacgggacc ccauucugc ggagauacu aaccagguu ugauuuugc  
acuuggagga 720gauucaua agguuuuga aaagcucgga uacaguggag gcgaaucuu aggcuuua 780gagagcag  
gaauaaaggc ucggauacu cagucgaca cagagucca cuucaugc 840cucaguuu ccauuccgac gcuguccg  
auuaagggg ugaauugca cggcuagag 900ggggucucg acaacuagc cucucaagag uggauuac cuugccca

guauguugca 960accaagggg accuuuucuc gaauuuugau gagucaucau guacuuucau gccagagggg 1020acugugugca  
gccaaaauugc cuuguaccg augaguccuc ugcuccaaga augccuccg 1080ggguccacca aguccuguc ucguacacuc  
guaucgggu cuuuugggaa ccgguucauu 1140uuaucaaac ggaaccuaau agccaauugu gcaucaauuc uuuguuagug  
uuacacaaca 1200gguacgauua uuaaucaaga ccugacaag auccuaacau acuuugcugc cgauccugc 1260ccgguagucg  
aggugaacgg cgugaccauc caagucggga gaggaggua uccagacgcu 1320guguacuugc acagaauuga ccucgguccu  
cccuaucuu uggagagguu ggacguagg 1380acaaucugg ggaugcauu ugccaauug gaggaugcca aggaauuguu  
ggaaucaucg 1440gaccagauu ugagaaguau gaaagguuu ucgagcacua gcauagucua cauccugau 1500gcaguguguc  
uuggaggguu gauagggauc cccacuuuaa uauguugcug cagggggcgu 1560uguaacaaa agggagaaca aguugguag  
ucaagaccg gccuaagcc ugaccuuaca 1620ggaacauca aauccuaugu aagaucgcu uga 1653711925RNAArtificial  
SequenceSynthetic Polynucleotide 71ggggaaauaa gagagaaaag aagauaaga agaaauuaa gagccaccu gggucuaag  
60gugaacgucu cugccguuu cauggcagua cuguuaacuc uccaaacacc cgccgguaa 120auucauuggg gcaucucuc  
uaagauagg guaguaggaa uaggaaguc aagcuacaa 180guuauagac guuccagcca ucaucauuu gucauuuuu  
uaaugccaa uuaaacucuc 240cucauuacu gcagagggu agagauugca gaauacagga gacuacuaag aacaguuuu  
300gaaccauuu gggaugcacu uauugcauug accagaaca uaaggccggu ucagagcgu 360gcuucaagua ggagacaca  
gagauuugc ggaguagucc uggcagguc ggccuaggu 420guugccacag cugcucagau aacagccgc auugcacuuc  
accgguccu gcugaacuc 480caggccauc acaucugag agcagccug gaaacuacua aucaggcau ugaggcauc  
540agacaagcag ggcaggagau gauuuuggcu guucagggu uccaagacua caucauuuu 600gagcugauac gcuaugaa  
ccagcuauc ugugaucua ucggucagaa gcucggguc 660aaauugcuu gauacuauac agaaucug ucauuuuu  
gccccagcc acgggaccc 720auaucugcg agauaucuau ccaggcuuug aguuaugcag uuggaggaga uaucauuag  
780guguuagaa agcucggua caguggagg gauuuacuag gcauuuaga gagcagagga 840auaaaggcuc ggauaacua  
cgucgacaca gaguccuacu ucauaguccu caguauagcc 900uauccgacg ucuccagau uaaggggug auugccacc  
ggcuagagg gguccguac 960aacauagcu cucaagagug guauaccacu guggccaaugu auugcaac ccaagggua  
1020cuuauucg auuuugauga gucaucau acuuuacugc cagaggggac ugugcagc 1080caaaugccu uguaccgcu  
gaguccucug cuccaagaau gccuccggg guccaccaag 1140uccugucuc guacacucg auccgggcu uuugggaacc  
gguucauuu aucacaagg 1200aacuaauag ccauuuguc ucauuucuu uguuaguuu acacaacagg uacgaauuu  
1260aacuaagacc cugacaagau ccuaacauac auugcuccg aucgucucc gguagucgag 1320gugaacggc ugaccauca  
agucgggagc aggagguauc cagacgugu guacuugc 1380agaauugacc ucgguccc caucauuug gagagguug  
acgagggac aaucugggg 1440aauugcauu ccauuugga ggaugccaag gaauuguug aaucaucgga ccagauuu  
1500agaaguauga aaguuuuac gagcacuagc auagucua uccugauugc agugugucu 1560ggaggguuga uagggauc  
cucuuaaua uguugcugc gggggcguug uaacaaaag 1620ggagaacaag uugguaguc aagaccagc cuaaagccg  
accuacagg aacaucuaa 1680uccuaugua gaucgcuuug augauuuag gcuggagccu cgugggcua gcuucugc  
1740ccuugggcu cccccagcc ccuccuccc uuccugcacc cguaccccg uggucuuuga 1800auaaagucug aguggggc  
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1860aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa  
aaaaaaaaa 1920cuuag 1925721864RNAArtificial SequenceSynthetic Polynucleotide 72ucaagcuuuu ggaccucg  
acagaagcua auacgacua cuauaggga auuagagaga 60aaagaagagu aagaagaa auuagagcca cauggguc caaggua  
gucucugua 120uauucaugc aguacuuu acuuucaaa caccaccg ucauuucau uggggcauc 180ucucuaagau  
agggguggua gggguaggaa gugcaagcua caaaguuaug acucguuca 240gcaucau auuagucua aaguuuagc  
ccaauuaac ucuccuaac auuugcagc 300ggguaggau ugcagaauac aggagacuac ugagaacagu ucggaa  
auuagagau 360cacuuuagc auuagaccg auuuaagc cgguucagag uguagcuuca aguaggagc 420acaagagau  
ugcgggagu guccggcag gugcgccu aggcguugc acagcucuc 480aaauaacagc cgguuuugc cuuaccag  
ccaugcugaa cucuaagcc aucgacauc 540ugagagcag ccuagaacu acuaucagg cauuugaggc auucagaca  
gcaggcagc 600agaugauuu ggcuguucag gguguccaag acuaucuaa uauugcug auaccgucua 660ugaaucau  
auuuugau uuaucggc agaagcuagg gcuaauug cucagauu 720auacagaa cuugcauuu uuugccca  
gcuuacggga cccauauc gcggagauu 780cuauccaggc uuugagcuu gcgcuuggag gagauuca uauugguu  
gaaaagcug 840gucagagagg agguagucua cugggcauc uagagagc aggaauuag gccggaua 900cucagcug  
cacagaguc uacuucuuug uacucagau agccuucg acgcuucg 960aguuuagg gguuuguc caccggcu  
aggggguc guacaacua ggcucuaag 1020agugguauac cacuguccc aaguauuug caaccaag guaccuau  
ucgaauuuug 1080augaguc auccacuuc auccagagg gcagugugc agccagaa gccuuuagc 1140cgaugaguc  
ucucuccaa gaugccucc ggggguccac uauugcug gcucguac 1200ucguuaccg gucuuucgg aaccgguu  
uuuauca ggggaaccua auagccaau 1260gugcauau

ccuuugcaag uguuacaca caggaaca auuauca gaccugaca 1320agaucuaac aucauugc gccgaucac  
gcccgggugc agagguaau ggcgugacca 1380uccaagucg gagcaggagg uauccggagc cugugacu gcacagga  
gaccucguc 1440cuccauauc uuugagagg uggacguag ggacaauc ggggaugca auugcuuag 1500uggagguc

caaggaaug uuggagucac cggaccagau auugaggagu augaaagguu 1560uauucgagcac uaguauaguu uacauccuga  
uugcagugug ucuuggagga uugauagggga 1620ucggcgcuu auauguugc ugcagggggc guuguaaca gaagggagaa  
caaguuggua 1680ugucaagacc aggccuaag ccugaucua caggaacac aaauccuau gaaaggucac 1740ucugaugau  
auaggcugga gccucggugg ccaagcuuc ucggcuugg gccucggc 1800agggccucc cccuuccug caccguacc  
cccgggucu uugaauaag ucugagugg 1860cggc 1864731653RNAArtificial SequenceSynthetic Polynucleotide  
73augggucuca aggugaacgu cucugucua ucauggcag uacuguaac ucucaaca 60cccaccggc aaauccauug  
gggcaaucuc ucaagauag gggugguagg gguaggaagu 120gcaagcuaca aaguuaugac ucguuccag caucauacau  
uagucuaaaa guuaaugccc 180aaauaacuc uccucaaca ugcacgagg guagggauug cagaauacag gagacuacug  
240agaacaguuc uggaaccau uagagaugca cuuaugca ugaccagaa uuaagaccg 300guucagagug uagcucaag  
uaggagacac aagagauug cgggaguugu ccuggcaggu 360gcgggccuag gcguugccac agcugcuaa auaacagccg  
guauugcacu ucaccagucc 420aucgugaacu cucaagccau cgacaucug agagcgagcc uagaacuac uaucaggca  
480auugaggca ucagacaagc agggcaggag augauauugg cuguucagg uguccaagac 540uacaucaua augagcugau  
accgucuaug aaucaacuau cuugugauuu aaucggccag 600aagcuaggc ucaauugcu cagauacuau acagaauc  
ugucuuuuu ugccccagc 660uuacgggacc ccauucugc ggagauacu auccaggcu ugagcuugc gcuuggagga  
720gauaucaua agguuugga aaagcucgga uacaguggag gugaucuacu gggcaucuua 780gagagcagag gaauaaaggc  
ccggauaacu cagcugcaca cagagucca cucauugua 840cucaguauag ccuauccgac gcuauccgag auuaaggggg  
ugauugucca ccggcuagag 900ggggucucgu acaacuagg cucucaagag ugguauacca cugugccca guauguuga  
960accaagggu accuuaucuc gaauuuugau gagucauac gcacuucac gccagagggg 1020acugugugca gccagaugc  
cuugucccg augaguccuc ugcuccaaga augccuccg 1080ggguccacua aguccuguc ucguacacuc guauccgggu  
cuucgggaa ccggucuuu 1140uuauacagg ggaaccuaa agccauuugu gcaucauucc uuugcaagug uuacaca  
1200ggaacaaua uuaaucaaga ccugacaag auccuaacu acauugcug cgaucacugc 1260ccgguggucg aggugaugg  
cgugaccau caagucggga gcaggaggua uccggacgcu 1320guguacuugc acaggauuga ccucgguccu ccauaucuu  
uggagagguu ggacguaggg 1380acaaucugg ggaugcau ugcuaaguug gaggaugcca aggaauuguu ggagucacug  
1440gaccagauu ugaggaguu gaaagguuu ucgagcaca guauaguuu cauccaguu 1500gcaguguguc uuggagguu  
gauagggac ccgcuuuua uaguugcug cagggggcgu 1560uguaacaaga agggagaaca aguugguug ucaagaccg  
gccaaagcc ugauuuaca 1620ggaacaaua auuccuauu aaggucacuc uga 1653741925RNAArtificial  
SequenceSynthetic Polynucleotide 74ggggaaaua gagagaaaag aagauaaga agaaauuaa gagccaccu gggucuaag  
60gugaacguc cucucauuu cauggcagua cuguuauc ucaaacacc caccgguaa 120auccauugg gcaucucuc  
uaagauagg gugguagggg uaggaaguc aagcuacaaa 180guuaugacuc guuccagca ucauacuuu gucauaagu  
uaugccca uuaucucuc 240cucaacaau gcacgagggu agggauugca gaauacagga gacuacugag aacaguucug  
300gaaccauuu gagaugcacu uaaugcau acccagaaua uaagaccggu ucagagugua 360gcuucaagua ggagacaca  
gagauuugc ggaguugucc uggcagguc ggccuaggc 420guugccacag cugcucauu aacagccggu auugcacuuc  
accaguccu gcugaacuc 480caagccauc acaucugag agcgagccu gaaacuacua aucaggcau ugaggcauc  
540agacaagcag ggcaggagau gauauuggcu guucaggug uccaagacua caucauuuu 600gagcugauac gcucuaugaa  
ucauacuc ucuguuuu ucggccaga gcuaggcuc 660aaauugcu gauacuauac agaaucucg ucauuuuug  
gcccagcu acgggaccc 720auaucugcgg agauacuau ccaggcuug agcuugcgc uuggaggaga uaucauuag  
780guguuggaa agcucggau caguggaggu gacuacugg gcauuuaga gagcagagga 840auaaaggccc ggauaacua  
cgucgacaca gaguccuacu ucauuuacu caguauagcc 900uauccgagc uauccgagau uaagggggug auuguccac  
ggcuagagg gguucguac 960aacauaggcu cucaagagug guauaccu gugcccaagu auguugcaac ccaaggguac  
1020cuuauucg auuuuuga gucauugc acuuuugc cagaggggac ugugucagc 1080cagaugccu uguaccgag  
gaguccuc cuccaaga gcuuccgggg guccauaag 1140uccugucuc guacacucgu auccggguc uucgggaacc  
ggucauuuu aucacagggg 1200aacuauag ccauuguc aucauuccu ugcaaguguu acacaagc aacaucuu  
1260aaucaagacc cugacaagau cuuacauac auugcugcc aucacugccc gguggucgag 1320gugaauggc ugaccauca  
agucgggagc agaggauac cggacgcu guacuugc 1380aggauugacc ucgguccuc cauauuuug gagagguug  
acguagggac aaucugggg 1440aaucauuug cuuauugga ggaugccaag gaauuuug agucaucgga ccagauuuug  
1500aggagaua aagguuuu gagcacuagu auaguuuu uccugauugc agugugucuu 1560ggaggauuga uagggauc  
cguuuuu uguugcugca gggggcguug uaacaaga 1620ggagaacaag uugguugc aagaccagc cuaaagccug  
auuuuacag acauacaaa 1680uccuauuaa ggucacucug augauuuag gcuggagccu cgguggcca gcuucugcc  
1740ccuugggcu ccccccagc ccuccccc uuccugcacc cguaccccg ugucuuuga 1800auaaaguc aguggggc  
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1860aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa  
aaaaaaaaa 1920ucug 1925752065RNAArtificial SequenceSynthetic Polynucleotide 75ucaagcuuuu ggaccucgu  
acagaagcua auacgacua cuauaggga auaagagaga 60aaagaagagu aagaagaa uuaagagcca caugucacc gcaacgagc  
cggauuuuug 120ccuucuaaca agauaacccu uauccaaag gaaguaggau aguuuuuac agagaacuc 180uuuauuga  
cagaccuau guucugcug cuguucuguu gcuauguuu cugagcuuga 240ucggauugc ggcauuugc ggcauuagc

uucaucgggc agccaucac accgcggaga 300uccauaaaag ccucaguacc aaucuggaug ugacuaacuc caucgagcau  
caggucaagg 360acgugcugac accacucuuu aaaaucaucg gggauagaagu gggccugaga acaccucaga 420gauucacuga  
ccuagugaaa uucaucucgg acaagauuaa auuccuuaa ccgauaggg 480aguacgacuu cagagaucuc acuuggugca  
ucaaccgcc agagaggauc aaacuagau 540augaucaua cugugcagau guggcugcug aagagcucac gaaugcaug  
gugaacucua 600cucucugga gaccagaaca accacucagu ucuagcugu cuaaaaggga aacugcucag 660ggcccacuc  
aaucagaggu cauuucua acaugucgu guccuuguug gacuuguacu 720uaggucgagg uuacaugug ucaucuauag  
ucacuauag aucccaggga auguagggg 780gaaccuaccu aguugaaaag ccuaucuga acagcaaagg gucagaguug  
ucacaacuga 840gcaugaccg aguguuugaa guagguguga ucagaaacc ggguuugggg gcuccggugu 900uccauaugac  
aaacuauuu gagcaaccag ucaguaaug ucucggcaac ugauggugg 960cuuuggggga gcuaaacuc gcagccuuu  
gucacgggga cgauucuauc auuuuuuu 1020aucagggauc agggaaaggu gucagcuucc agcucgucua gcuggguguc  
uggaaaaucc 1080caaccgacau gcauuccugg gucccuuuu caacggaua uccaguggua gacaggcuu 1140accucucac  
ucacagaggu gucaucguc acaucaagc aaaugggcu gucccgaca 1200cacgaacaga ugacaaguug cgauggaga  
caugcuuca gcaggcugu aaagguaaa 1260uccaagcucugcugagaau cccgaguggg uaccuugaa ggauaacagg  
auuccuuc 1320acgggguccu gucuguugau cugagucuga cggugagcu uaaaaucaaa auugcuucgg 1380gauucggggc  
auugaucaca cacggcucag ggauggaccu aucaaauc aacugcaaca 1440auguguauug gcugacuau cgcacauga  
gaaucucagc cuuaggcgua aucaacac 1500uggaguggau accgagauuc aagguuaguc ccaaccuuu cacugucca  
auuaaggag 1560caggcgaaga cugcaugcc caacauacc uaccugcga gguggacggu gaugucuaac 1620ucaguucca  
ccuggugau cuaccugguc aagauucua auuuuuug gcaaccuac 1680auaccuccag gguugagcau gcugugguu  
auuacguua cagccaagc gcucuuuu 1740cuuuuuuu ucuuuuagg uugcuuaaa aggggguccc aaucgaacua  
caugggaa 1800gcuucacug ggaucuaaaa cucuggguc gucauucug ugucucugc gacucagaau 1860ccgguggacu  
uauacucac ucugggagg ugggcaugg agucagcuc acagcuaacc 1920gggaagagg aaccaucgc agauaugau  
aauggcug agccucgug gcaagcuuc 1980uugcccuug ggcucuccc cagccuccc ucccuuccu gcaccguc  
cccugug 2040uuugaauaaa gucugagugg gcgcc 2065761854RNAArtificial SequenceSynthetic Polynucleotide  
76augucaccgc aacgagaccg gaaauugcc ucuuacaag auaacuuu uccaaggga 60aguaggauag uuuuuacag  
agaacucuu augauugaca gaccuauug ucugcugcu 120guucugucg ucauguuuc gagcuugac ggauugcug  
cauugcagg cauugacuu 180caucgggag ccaucucac cgcggagac cauaaaagcc ucaguacca ucuggaug  
240acuacucca ucgagcaua ggucaaggac gucugacac cacuuuuu aucaucggg 300gaugaagugg gccugagaac  
accucagaga uucacugacc uagugaaau caucucggc 360aagauuaau ucuuaaucc ggauaggag uacgacuua  
gagaucac ucugggcauc 420aacccgag agaggauca acuauguuu gaucauacu gucgagaug ggcugcugaa  
480gagcucauga augcauugga gaacuaacu cuacuggaga ccagaaca cacucaguuc 540cuagcuguc caaaggaaa  
cugcucaggg ccacuaca ucagagguca auucuaaac 600augucgucg ccuuguugga cuuguacuua ggucgaggu  
acauguguc aucauaguc 660acuauagcau cccagggaau gaauggggga accuaccuag uugaaaagcc uauucgaa  
720agcaagggu cagauuguc acaucgagc auguaccgag uguuugaagu agguugauc 780agaaaccgg guuuggggg  
uccgguguuc cauugaca acuauuuga gcaaccaguc 840agaaugguc ucggcaacug uauugggcu ugggggagc  
ucaaucgc agccuuugu 900cacggggagc auucuauc auuuccuau cagggaucag gaaaggugu cagcuuccag  
960cucgucagc ugggugucg gaaucucca accgacugc auccugggu cccuuuauca 1020acggaugac caguggua  
caggcuuuc cucucuc acagaggugu caucgucag 1080aucaagca auugggcu cccgacaaca cgaacagug  
acaauugc auuggagca 1140ugcuuccagc aggcuguaa agguaaaauc caagcucuc gcgagaaucc cagugggua  
1200ccauugaagg auacaggau ucuuauac ggggucugcugcuugacu gagucgagc 1260guugagcuua aucaaaa  
ugcuucggga uucgggcau ugaucacaca cggcucaggg 1320auggaccuau acaauccaa cugcaacu guguuugc  
ugacuaucc gcaaugaga 1380aucuagcu uaggcuaau caacauug gaguggauac cgaguuca gguuagucc  
1440aaccuucua cuguccau uaggaagca ggcaagacu gcaugccc acauaccua 1500ccugcggagg uggacggua  
uguaaacuc aguuccaacc uggugauuc accugucua 1560gucuccau auguuugc aaccuacg accuccagg  
uugagcugc uguguuuu 1620uacguuua gccaagcc cuuuuuu uacuuuuu cuuuuaggu gccuuaaag  
1680gggguccaa ucgaucua aguggaagc uucacuggg aucaaaauc cugggucg 1740cacuucugug ucuugcga  
cucagaaucc gguggacuua ucucucac ugggagug 1800ggcaugggag ucagcucac agcuaccgg gaaguggaa  
ccaucgag auua 1854772126RNAArtificial SequenceSynthetic Polynucleotide 77gggaaaua gagagaaa  
aagauaaga agaaauua gagccacau gucaccgca 60cgagaccgga uaaugccu cuacaagau aaccuuu ccaagggaag  
uaggauuu 120auaacagag acaucuuu gauugacaga ccuauuguc ucugcugc 180auguuucg  
gcuugaucg auugcuggca auugcaggca uuagacuua cgggagcc 240aucuacacc cggagauca uaaaagcc  
aguaccauc uggugugac uauccuac 300gagcaucagg ucaaggcug gcugacaca cuuuuuuu ucaucggga  
ugaugggg 360cugagaac cucagagau cacugaccua gaaauua ucucggaca gauuuuuu 420cuuaauccg  
auagggag cagcuucaga gacucacu ggugcaua cccgagag 480aggaucaac uaguuuuga ucauucug  
gcagugugcugcugaaga gcuaugau 540gcauuggg acuaacuc acuggagacc agaacaaca cucaguuc

agcugucuca 600aagggaacu gcucagggcc cacuacauc agaggucaau ucucacaau gucgugucc 660uuguuggacu  
uguacuuagg ucgagguuac aaugugucau cuauagucac uaugacauc 720cagggaaugu augggggaac cuaccuaguu  
gaaaagccua aucugaacag caaaggguca 780gaguugucac aacugagcau guaccgagug uuugaaguag gugugaucag  
aaaccgggu 840uuggggguc cgguguucca uaugacaac uuuuuagagc aaccagucag uauuggucuc 900ggcaacugua  
ugguggcuuu gggggagcuc aaacucgag ccuuuguca cggggacgau 960ucuaucuaa uuccuauca gggaucaggg  
aaagguguca gcuuccagcu cgucaagcug 1020ggugucugga auucccaac cgacaugca uccuggguc ccuuaucac  
ggauauca 1080gugguagaca ggcuuuaccu cucaucucac agagguguca ucgugacaa ucaagcaaaa 1140ugggcugucc  
cgacaacacg aacagaugac aaguugcga uggagacaug cuuccagcag 1200gcguguaag guaaaauca agcacucg  
gagaauccc aguggguacc auugaaggau 1260aacaggauuc cuucaucgg gguccuguc guugaucuga gucugacgg  
ugagcuuaa 1320aucaaaaug cuucgggauu cgggccauug aucacacag gcucagggau ggaccuauac 1380aaaaccau  
gcaacaau guauuggcug acuaucgc caaugagaaa ucuagccua 1440ggcguaa acacauugga guggauaccg  
agauucaagg uuaguccaa ccucucacu 1500guccaaaua aggaagcagg cgaagacugc caugcccau cauaccuacc  
ugcggaggug 1560gacggugaug ucaaacucag uuccaaccug gugauucuc cuggucaaga uuccaauau 1620guuuuggca  
ccuacgauac cuccaggguu gagcaugcug ugguuuaua cguuuacagc 1680ccaagccgcu cauuuucua cuuuuauccu  
uuuagguugc cuuaaagg ggucacauc 1740gaacuacaag uggaugcuu cacaugggau caaaaacuc ggugccguca  
cuucugugug 1800cuugcggacu cagaauccgg uggacuuauc acucacucug ggauggugg caugggaguc 1860agcugcacag  
cuaccggga agauggaacc aaucgagau auugaaua ggcuggagcc 1920ucgguggcca agcuucugc ccuugggccc  
ucccccagc ccuccucc cuuccgac 1980ccguacccc guggucuuug auaaaguc gagugggccc caaaaaaaaa  
aaaaaaaaa 2040aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2100aaaaaaaaa  
aaaaaaaaa aucuag 2126782065RNAArtificial SequenceSynthetic Polynucleotide 78ucaagcuuu ggaccucg  
acagaagcu auacgacuca cuauaggga auaagagaga 60aaagaagagu aagaagaa auaaagagcca caugucacc acaagagac  
cggauaaaug 120ccuucuaaca agacaacccc cauccaagg gaaguaggau aguuuuuac agagaacuc 180uuuagauuga  
uagaccuuu guuuugcugg cuguucuuu cgucauuuu cugagcuuga 240ucggguugcu agccauugca ggcauugac  
uucaucgggc agccauuc accgcagaga 300uccauaaaag ccucagcacc aaucuggaug uacuaacuc aaucgagcau  
cagguaaagg 360acgucgac accacucuc aagaucuc gugaugagu gggcuugagg acaccucaga 420gauucacuga  
ccuagugaag ucaucucug acaaguuua auuccuuuu ccggacaggg 480aaucgacuu cagagaucuc auuggugua  
ucaacccg agagagauc aaauuggau 540augaucaua cugugcagau guggcugcug aagaacuc auugcauug  
gugaacuca 600cucucagga gaccagggca accaaucagu ucuagcugu cucaaggga aacugcucag 660ggcccacuc  
aaucagagc cauuucua acaugucguc guccuguuu gacuuguuu 720uaagucgagg uuacaauug ucaucuaug  
ucacuaugac auccaggga auguacgggg 780gaacuaccu aguggaaaag ccuaucuga gcagcaagg gucagaguug  
ucacaucuga 840gcaugcacc aguuuuuga guagguguu ucagaaaucc ggguuuuggg gcuccgguu 900uccauaugc  
aaucuaucuu gagcaaccag ucaguauga uuucagcaac ugcauggugg 960cuuuggggga gcuaaguuc gcagccuc  
gucacagga agauucua acauuuccu 1020aucagggauc agggaaaggu gucagcuucc agcuuguca gcuagguguc  
uggaaaaucc 1080caaccgacu gcauuccg gucccccua caacggaua uccagugua gcagggcuu 1140accucucac  
ucacagagc guuucguc acaucaagc aaauugggu guccgaca 1200cacggacaga ugacaaguug cgauggaga  
cugcuuca gcagcgugu aaggguaaa 1260uccaagcuc uugcgagaau ccgagugga caccuuga ggauaacag  
auuccuuc 1320acggggucuu gucuguugau cugagucuga caguugagcu uaaaauca auuguucag 1380gauucgggccc  
auugaucaca caggguucag ggauggacu auacaaucc aaccacaaca 1440auauguauug gcugacuauc ccgcaauga  
agaaccugc cuuagguga aucaacacu 1500uggaguggau accgagauuc aagguuagc ccaaccucuu cacugucca  
auuaaggag 1560caggcgagga cugcaugcc caacauacc uaccugcgga gguggauggu gaugucaac 1620ucaguucca  
ucuggugau cuaccuguc aagaucua auauguuc gcaaccuag 1680auacuucc aguuagaau gcuguuuu  
auuacguua cagccaagc gcucuuuuu 1740cuuacuuuu uccuuuagg uugccugua ggggggucc cauuuuuu  
caaguggau 1800gcuucacug ggacaaaaa cucuggguc gucacucug ugugcuugc gacucagaau 1860cuggggaca  
uacucucac ucugggagg ugggcaugg agucagcuc acagccac 1920gggaagagg aaccagccgc agauagugau  
aauggcug agccugcug gcaagcuu 1980uugcccuug ggccuccccc cagccucc ucccuuccu gaccguc  
ccccgug 2040uuugaauaaa gucugagugg gcggc 2065791854RNAArtificial SequenceSynthetic Polynucleotide  
79augucaccac aacgagacc gauaaaugc uucuaaaag acaacccca uccuaggga 60aguaggauag uuuuuacag  
agaacucuu augauugau gaccuuuuu uuugcggcu 120guucuuucg ucauuuuu gagcuugau ggguuugcug  
ccauugcagg cauuagacu 180caucgggag caucucac cgcagagau cauuuuagc ucagacca ucuggaugua  
240acuacuca ucgagcau gguuaaggac gucugacac cacucucua gaucaucgg 300gaugaagugg gcuaggagc  
accucagaga uucacugac uagugaagu caucucgac 360aaguuuuuu uccuuuuu ggacaggga uacgacuca  
gagucucac uugguuauc 420aacccgag agagaauca auugguuuu gaucauacu gucagauug ggcugcugaa  
480gaucucaga augcauuggu gaucuaacu cuucggaga ccagggcaac caucaguuc 540cuagcuguc caaaggga  
cugcucagg cccucuaa ucagaggca auucuaaac 600augucgucg cccuuugga cuuuuuuu agucagguu

acaauguguc aucuauaguc 660acuauagacau cccaggggaau guacggggga acuuaccuag uggaaaagcc uaaucugagc  
720agcaaaagggg cagaguuguc acaacugagc augcaccgag uguuugaagu agguuuuau 780agaaaucgg guuuggggggc  
uccgguauuc cauaugacaa acuaucuga gcaaccaguc 840aguauagauu ucagcaacug caugguggcu uuggggggagc  
ucaaguucgc agcccucugu 900cacaggggaag auucuaucac aaucuccuau cagggaucag ggaaaggugu cagcuuccag  
960cuugucaagc uaggugucug gaaucacca accgacugc aaucugggu ccccuauca 1020acggaugauc cagugauaga  
caggcuuuac cucucaucuc acagaggcgu uaucgcugac 1080aaucaagcaa aaugggcugu cccgacaaca cggacagaug  
acaaguucg aauggagaca 1140ugcuuccagc aggcguguaa ggguaaaauc caagcacuuu gcgagaaucc cgaguggaca  
1200ccauugaagg auaacaggau uccuucacac ggggucuuu cuguugaucu gagucugaca 1260guugagcuua aaucacuuu  
uguuucagga uucgggccau ugaucacaca cggucaggg 1320auggaccuau acaaucaaa ccacaacau auguauuggc  
ugacuauccc gccauugaag 1380aaccuggccu uagguguaau caacacauug gaguggauac cgagauuca gguuagucc  
1440aaccucuua cuguuccau uaaggaagca ggcgaggacu gccaugcccc aacauaccua 1500ccugcggagg uggaugguga  
ugucacacuc aguuccaac uggugauucu accugguca 1560gaucuccau auguucuggc aaccuacgau acuccagag  
uugaacugc uguaguuuu 1620uacguuuaca gcccaagccg cucuuuuu uacuuuuu cuuuuagguu gccuguaagg  
1680gggguccca uugaauuaca aguggaagc uucacuggg accaaaaacu cuggugccgu 1740cacuucugug ugcucggcga  
cucagaauuc gguggacaua ucacucacuc ugggauggug 1800ggcauggggag ucagcugcag agccacucgg gaagauggaa  
ccagccgag auag 1854802126RNAArtificial SequenceSynthetic Polynucleotide 80ggggaaaua gagagaaaag  
aagauaaga agaaauuaa gagccaccu gucaccaca 60cgagaccgga uaaaugccu cuacaagac aaccuccau cuaagggaag  
uaggauugu 120auaacagag acaucuuu gauugauaga ccuuuuuu ugcuggcugu ucuauucguc 180auguuucuga

gcuugaucgg guugcuagcc auugcaggca uuagacuua ucgggcagcc 240aucuacaccg cagagaacca uaaaagccuc  
agcaccauc uggauguaac uaacuauc 300gagcaucagg uuaaggacgu gcugacacca cucuuaaga ucaucgguga  
ugaagugggc 360uugaggacac cucagagau cacugaccua gugauguua ucucugacaa gauuuuuu 420cuuuuucgg  
acagggaauc cgacuucaga gaucucacu gguguauc cccgccagag 480agaaucaau uggaauuga ucauucug  
gcagauuggcugcugaaga acuaugaa 540gcauugguga acuaucuc acuggagacc agggcaacca aucaguuccu  
agcugucua 600aagggaacu gcucagggcc cacuacauc agaggccau ucuaacau gucgcugucc 660cuguuggacu  
uguuuuuuag ucgagguuac aaugugau cuauagucac uaugacucc 720cagggaauu acgggggaac uuaccuagug  
gaaaagccua aucugagcag caaaggguca 780gaguugucac aacugagcau gcaccgagug uuugaaguag guguuuacag  
aaaucgggu 840uuggggguc cgguauuca uaugacaac uauucugagc aaccagucag uauuguuu 900agcaucgca  
ugguggcuuu gggggagcuc aaguucgag ccucuguca cagggaagau 960ucuaucaca uuccuauca gggaucaggg  
aaaggugua gcuuccagcu ucucaagcu 1020ggugucugga aaucacca cgaucgaa uccuggguc ccuaucaac  
ggauuauca 1080gugauagaca ggcuuuacu cucucucac agaggcguu ucgucgaca ucaagcaaa 1140ugggcugucc  
cgacaacag gacagaugac aaguugcga uggagacug cuuccagcag 1200gcguguaagg guuuuuuca agcacuucg  
gagaucgg aguggacac auugaaggau 1260aacaggau cuucaucgg ggucuuuguc guugaucuga gucugacagu  
ugagcuuaa 1320aucauuuug uuucaggaau cgggccauug aucacacag guucagggau ggaccuauac 1380aaucacac  
acaacauu guauuggcug acuaucggc caugaagaa ccuggccuu 1440gguguauc acacauugga guggauaccg  
agauucaagg uuaguccaa ccuucacu 1500guuccaaua aggaagcagg cgaggacugc caugcccau cauaccuacc  
ugcggaggug 1560gauggugaug ucaaacucag uucaucug gugauucac cuggucaaga ucucauuu 1620guucggca  
ccuacgauac uccagaguu gaacugcug uaguuuuuu cguuuacagc 1680ccaagccgcu cauuuuuuu cuuuuauccu  
uuuagguugc cguuaagggg ggucuccuu 1740gaauuacaag uggaugcuu cacauuggc caaaacucu ggugccguca  
cuucugugug 1800cuucggacu cagaucugg uggacauuc acucacucug ggaugguggg caugggaguc 1860agcugcagc  
ccacucggga agauugaacc agccgagau agugauuaa ggucggagcc 1920ucgguggcca agcuucugc ccuugggccc  
ucccccagc ccuucccc cuuccgac 1980ccguacccc guggucuuu auaaaguc gaguggccg caaaaaaaaa  
aaaaaaaa 2040aaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa 2100aaaaaaaa  
aaaaaaaa aucuag 2126811729RNAArtificial SequenceSynthetic Polynucleotide 81ucaagcuuu ggaccucg  
acagaagcu auacgacua cuauaggga auaagagaga 60aaagaagagu aagaagaa uuaagagcca cauggcaca agucuuuu  
acaacagcc 120ugucguguu gaccagaau aaccugaaca auuccaguc gcacugggc acugcuuagc 180agcguuugc  
uuccggucg cguaucaaca gcgcgaaaga cgaucggca ggacaggcga 240uugcuuaccg uuuuaccg cacaucuaag  
gucugacua ggcuuccgu aacgcuuacg 300acgguauc cuuugcgcag accacugaag gcgcgugaa cgaaucaac  
acaaccugc 360agcugugcug ugaacuggc guucagucug cgaugguac uacuccag ucugaccug 420acuccaaca  
ggcugaauc acccagcgc ugaacgaa cuaccgugua uccggccaga 480cucaguua cggcgugaaa guccggcgc  
aggacaacac ccugacca cagguuggug 540ccaacgagc ugaacuauc gauuuuuu uaaaagaa cagcuuaaa  
acacugggac 600uuguaagcu uauugcaaa gaugccuaca cccgaaaga aacugcugua accguugua 660aaucacua  
uuuuuaggu acagaucua uuacagcca gagcauacu gauuucuaa 720cugcauuugg cgguggugca cggggguua  
cuggggcuga uaucauuuu aaagauggc 780aaucuuuuu agauuuuuu ggcggugcu ucuguggu uuuuuagcc

acuuauaug 840aaacuacaaa gaaaguuaau auugauacga cugauaaaac uccguuggca acugcggaag 900cuacagcuau  
ucggggaacg gccacuauaa cccacaacca auugcugaa guacaaaaag 960aggguguuga uacgaccaca guugcggcuc  
aacuugcugc agcagggguu acuggcgccg 1020auaaggaca uacuagccuu guaaaacuau cguuugagga uaaaaacggu  
aagguuuuug 1080augguggcua ugcagugaaa augggcgacg auuucuaugc cguacauau gaugagaaa 1140caggugcau  
uacugcuaaa accacuacu auacagaugg uacugcgguu gcuaaacug 1200gagcugugaa auuuggggc gcaaauggua  
aacugagaug uguuacugcu accgauggua 1260agacuuaacu agcaagcgac cuugacaaac auaacuucag aacaggcggu  
gagcuuaaag 1320agguuaauac agauaagacu gaaaaccac ugcagaaaau ugaugcugcc uggcacag 1380uugauacacu  
ucguucugac cugggugcgg uucagaaccg uuuaacucc gcuaucacca 1440accugggcaa uaccguaaa aaccugucuu  
cugcccguag ccguaucgaa gauuccgacu 1500acgcaaccga agucuccaac augucugcg cgagauucu gcagcaggcc  
gguaaccug 1560uucuggcgca ggcaaccag guuccgcaa acgucucuc uuacugcgu ugauuuuag 1620cuggagccuc  
gguggccaug cuucugccc cuugggccc ccccagccc cuccucccu 1680uccugcacc guaccccgu ggucuuugaa  
uaaagucuga gugggccc 1729821518RNAArtificial SequenceSynthetic Polynucleotide 82auggcacaag  
ucauuauac aaacagccug ugcuguuuga cccagaaua ccugaacaaa 60uccagucg cacugggac ugcuaucgag cguuugucuu  
ccgugucg uaucaacag 120gcgaaagac augcgcgagg acaggcgauu gcuaaccguu uuaccgcaa cauaaaggu  
180cugacucagg cuuccgaa cgcuaacgac gguaucucca ugcgcagac cacugaaggc 240gcgcugaacg aaaucaaca  
caaccugcag cgugugcgug aacuggcggu ucagucugcg 300aaugguacua acuccaguc ugaccugc uccaaccag  
cugaaucac ccagcggc 360aacgaaucg accguguauc cggccagacu caguucaac gcgugaaagu ccuggcgag  
420gacaacacc ugaccauca gguuggugcc aacgacggug aaacuucga uauuguuuu 480aaagaaa gcuuaaaa  
acugggacu gauaagcuu auguccaaga ugccuacacc 540ccgaaagaaa cugcuguaac cguugauaaa acuaccuaua  
aaaugguac agauccuau 600acagcccaga gcauacuga uaucaaacu gcauuggcg guggugcaac ggggguuacu  
660ggggcugau ucauuuuua agaugguca uacuauuag auguuuaggg cggugcuucu 720gcugguguuu auaagccac  
uuauaugaa acuacaaaga aaguuaauu ugauacgacu 780gauaaaacuc cguuggcaac ugcggaagcu acagcuauuc  
ggggaacggc cacuaaacc 840cacaacaaa ugcugaagu acaaaagag gguguugaua cgaccacagu ugcggcuca  
900cuugcugcag cagggguuac uggcgccgau aaggacaaua cuagccuugu aaaacuucg 960uuugaggaua aaaacggua  
gguuuugau gguggcuau cagugaaaau gggcgagcu 1020uucuaugccg cuacauuga ugagaaaaca ggugcauuu  
cugcuuaaac cacuacuau 1080acagauggua cuggcguugc ucaaacugga gcugugaaa uuggggcgc aaugguaa  
1140ucugaaguug uuacugcuac cgaugguaag acuuacuau caagcaccu ugacaaacu 1200aacuucagaa caggcggu  
gcuuaaagag guuaauacag auaacagcu aaaccacug 1260cagaaaauug augcugccuu ggcacagguu gauacacuuc  
guucugaccu gggugcggu 1320cagaaccgu ucaacuccg uaucaccaac cugggcaua ccguaaaaua ccugucuuu  
1380gcccguagcc guaucgaaga uccgacuac gcaaccga ucuccaacu gucugcgcg 1440cagauucg agcaggccg  
uaccuccuu cuggcgagg cgaaccaggu uccgaaaac 1500gucucucuu uacugcgu 1518831790RNAArtificial  
SequenceSynthetic Polynucleotide 83gggaaaua gagagaaaag aagauaaga agaaauuaa gagccacau ggcacaugc  
60auuaauaca acagccugc gcuguugacc cagaauaacc ugaacaauc ccaguccgca 120cugggacug cuucgagcg  
uuugucucc ggucugcgu ucaacagcg gaaagacgau 180gcggcaggac agcgauugc uaaccguuuu accgcaaca  
ucaagguc gacucagcu 240uccguaacg cuaacgacgg uaucuauu ggcagacca cugaaggcg gcugaacgaa  
300aucaaca accugcagc ugugcgugaa cuggcgguuc agucugcga ugguaacuac 360uccagucug accugcuc  
cauccagcu gaaucacc agcgccgaa cgaaucgac 420cguguaucg gccagacu guucaacggc gugaagucc  
uggcgagg caacaccug 480accuaccag uuggugcaa cgacggugaa acuucgaa uuguuuuu agaaucagc  
540ucuaaaacac ugggacuuga uaagcuuuu gucaagaug ccuacacc gaaagaaacu 600gcuguaaccg uugauaaa  
uaccuauaaa auugguacag auccuauuac agcccagc 660aaucugua uccaacugc auuuggcggu ggugcaacgg  
ggguuacug ggugauau 720aaauuuuag auggucaua cuuuuugau guuaaggcg gugcuucugc ugguuuuu  
780aaagccacu augaugaac ucaaaagaa guuaauuug auacgacuga uaaaacucc 840uuggcaacug cggaagcuac  
agcuauucgg ggaacggca cuuaaccca caacaaaau 900gcugaagaa caaaagagg uguugauac accacaguug  
cggcuacu ugcugcagca 960gggguuacug ggcggaua ggacaauacu agccuugua aacuucgu ugaggauaaa  
1020aacgguaagg uuauaugg uggcuagca gugaauugg gcgaguuu cuaugccgu 1080acauaugaug agaaacag  
ugcauuacu gcuaaaaca cuacuauac agauguacu 1140ggcguugc aaacuggagc ugugaaaau gguggcgca  
augguaaauc ugaaguugu 1200acugcuacc augguagac uuacuugca agcaccuug acaacaua cuucagaaca  
1260ggcgugagc uuaagaggu uauacagau aagacugaa acccagc gaaaauugau 1320gcugccuugg cacagguu  
uacacuucgu ucugaccug gucgguuca gaaccguu 1380aacuccgcu uaccaaccu gggcauacc guaaauacc  
ugucucugc ccuagccgu 1440aucgaagau ccgacuacg aaccgaugc uccaacau cuugcgcgca gauucgag  
1500caggccggu cuuccguuc ggcgaggcg aaccagguuc cgaaaacgu ccucuuuu 1560cugcguugau auaggcug  
agccuggu gcaugcuu uggccuug ggccuccc 1620cagcccucc ucccuuccu gaccgcuac cccgugguc  
uuugaauaa gucugagug 1680gcggcaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa  
1740aaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaucug 17908413PRTSalmonella typhimurium 84Leu



Gln Arg Val Arg Glu Leu Ala Val Gln Ser Ala Asn1 5 1085539PRTArtificial SequenceSynthetic Polypeptide  
85Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu  
Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35  
40 45Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Ser Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu  
Asp Leu Thr Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln  
Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Ala Ala Ala  
Ala Val Thr Ala Gly Val Ala Ile Cys Lys Thr Ile 115 120 125Arg Leu Glu Ser Glu Val Thr Ala Ile Asn Asn Ala  
Leu Lys Lys Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Phe145 150 155  
160Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Thr Arg Ala 165 170 175Leu Asn Lys Asn Lys Cys  
Asp Ile Asp Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg  
Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210 215 220Ala  
Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn  
Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Cys Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val  
Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala 275 280 285Ala Pro Ser Cys  
Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly  
Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp 325  
330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn  
Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val  
Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile385 390 395 400Lys Gln  
Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410 415Thr Val Thr Ile Asp Asn Thr Val Tyr  
Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro 435  
440 445Ile Lys Phe Pro Glu Asp Gln Phe Asn Val Ala Leu Asp Gln Val Phe 450 455 460Glu Asn Ile Glu Asn  
Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile  
Ile Val Ile Ile 485 490 495Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu Val Ser Ile Phe Ile 500 505 510Ile Ile Lys  
Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser 515 520 525Gly Val Thr Asn Asn Gly Phe Ile Pro His  
Asn 530 53586539PRTArtificial SequenceSynthetic Polypeptide 86Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu  
Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu  
Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35 40 45Thr Leu Glu Val Gly Asp Val Glu Asn  
Leu Thr Cys Ser Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu Asp Leu Thr Lys Ser Ala Leu Arg Glu65 70  
75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe  
Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Ala Ala Ala Ala Val Thr Ala Gly Val Ala Ile Cys Lys Thr  
Ile 115 120 125Arg Leu Glu Ser Glu Val Thr Ala Ile Asn Asn Ala Leu Lys Lys Thr 130 135 140Asn Glu Ala Val  
Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155 160Ala Val Arg Glu Leu Lys Asp Phe Val Ser  
Lys Asn Leu Thr Arg Ala 165 170 175Ile Asn Lys Asn Lys Cys Asp Ile Asp Asp Leu Lys Met Ala Val Ser 180  
185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile  
Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210 215 220Ala Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr  
Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe 245 250  
255Gly Ile Leu Cys Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln 260 265 270Leu Pro Ile Phe Gly Val Ile  
Asp Thr Pro Cys Trp Ile Val Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu  
Leu Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315 320Pro  
Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn Val Ala  
Glu Gln Ser Lys Glu Cys Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His  
355 360 365Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly Val Ser  
Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile385 390 395 400Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn  
Gln Asp Ala Asp 405 410 415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420 425  
430Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Lys Phe Pro Glu His Gln  
Trp His Val Ala Leu Asp Gln Val Phe 450 455 460Glu Asn Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn  
Arg Ile465 470 475 480Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile 485 490 495Leu Ile Ala  
Val Leu Gly Ser Ser Met Ile Leu Val Ser Ile Phe Ile 500 505 510Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala Pro  
Pro Glu Leu Ser 515 520 525Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn 530 53587539PRTArtificial  
SequenceSynthetic Polypeptide 87Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln1 5 10 15His  
Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr  
Gly Trp Tyr Thr Asn Val Phe 35 40 45Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Ser Asp Gly Pro 50  
55 60Ser Leu Ile Lys Thr Glu Leu Asp Leu Leu Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala

Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe Val Leu Gly Ala Ile Ala Leu  
Gly Val 100 105 110Ala Ala Ala Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile 115 120 125Arg Leu Glu  
Ser Glu Val Thr Ala Ile Asn Asn Ala Leu Lys Lys Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly  
Val Arg Val Leu Ala Thr145 150 155 160Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Thr Arg Ala

165 170 175Ile Asn Lys Asn Lys Cys Asp Ile Pro Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe  
Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu  
Asp Leu Met Thr Asp 210 215 220Ala Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr Ser Ala Gly Gln225 230  
235 240Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Ile Gly  
Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile  
Val Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu  
Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu  
Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys  
Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser  
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn  
Arg Val Gly Ile Ile385 390 395 400Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410  
415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly  
Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Lys Phe Pro Glu Asp Gln Phe Gln Val Ala Leu Asp Gln  
Val Phe 450 455 460Glu Asn Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser  
Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile 485 490 495Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu  
Val Ser Ile Phe Ile 500 505 510Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser 515 520  
525Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn 530 53588539PRTArtificial SequenceSynthetic Polypeptide  
88Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu  
Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35  
40 45Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Ser Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu  
Asp Leu Leu Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln  
Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Ala Ala Ala  
Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile 115 120 125Arg Leu Glu Ser Glu Val Thr Ala Ile Asn Asn Ala  
Leu Lys Lys Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155  
160Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Thr Arg Ala 165 170 175Ile Asn Lys Asn Lys Cys  
Asp Ile Pro Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg  
Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210 215 220Ala  
Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn  
Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val  
Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala 275 280 285Ala Pro Ser Cys  
Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly  
Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp 325  
330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn  
Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val  
Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile385 390 395 400Lys Gln  
Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410 415Thr Val Thr Ile Asp Asn Thr Val Tyr  
Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro 435  
440 445Ile Lys Phe Pro Glu Asn Gln Phe Gln Val Ala Leu Asp Gln Val Phe 450 455 460Glu Asn Ile Glu Asn  
Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile  
Ile Val Ile Ile 485 490 495Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu Val Ser Ile Phe Ile 500 505 510Ile Ile Lys  
Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser 515 520 525Gly Val Thr Asn Asn Gly Phe Ile Pro His  
Asn 530 53589539PRTArtificial SequenceSynthetic Polypeptide 89Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu  
Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu  
Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35 40 45Thr Leu Glu Val Gly Asp Val Glu Asn  
Leu Thr Cys Ser Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu Asp Leu Leu Lys Ser Ala Leu Arg Glu65 70  
75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe  
Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Ala Ala Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr  
Ile 115 120 125Arg Leu Glu Ser Glu Val Thr Ala Ile Asn Asn Ala Leu Lys Lys Thr 130 135 140Asn Glu Ala Val  
Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155 160Ala Val Arg Glu Leu Lys Asp Phe Val Leu

Lys Asn Leu Thr Arg Ala 165 170 175Ile Asn Lys Asn Lys Cys Asp Ile Pro Asp Leu Lys Met Ala Val Ser 180  
185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile  
Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210 215 220Ala Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr  
Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe 245 250  
255Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp  
Thr Pro Cys Trp Ile Val Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu  
Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315 320Pro Asn  
Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn Val Ala Glu  
Gln Ser Lys Glu Cys Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355  
360 365Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys  
Ser Ile Gly Ser Asn Arg Val Gly Ile Ile385 390 395 400Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln  
Asp Ala Asp 405 410 415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420 425 430Glu  
Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Lys Phe Pro Glu Asp Gln Phe Gln  
Val Ala Leu Asp Gln Val Phe 450 455 460Glu Asn Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Arg  
Ile465 470 475 480Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile 485 490 495Leu Ile Ala Val  
Leu Gly Ser Ser Met Ile Leu Val Ser Ile Phe Ile 500 505 510Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro  
Glu Leu Ser 515 520 525Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn 530 53590539PRTArtificial  
SequenceSynthetic Polypeptide 90Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln1 5 10 15His  
Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr  
Gly Trp Tyr Thr Asn Val Phe 35 40 45Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Ser Asp Gly Pro 50  
55 60Ser Leu Ile Lys Thr Glu Leu Asp Leu Leu Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala  
Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe Val Leu Gly Ala Ile Ala Leu  
Gly Val 100 105 110Ala Ala Ala Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile 115 120 125Arg Leu Glu  
Ser Glu Val Thr Ala Ile Asn Asn Ala Leu Lys Lys Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly  
Val Arg Val Leu Ala Thr145 150 155 160Ala Val Arg Glu Leu Lys Asp Phe Val Leu Lys Asn Leu Thr Arg Ala  
165 170 175Ile Asn Lys Asn Lys Cys Asp Ile Pro Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe  
Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu  
Asp Leu Met Thr Asp 210 215 220Ala Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr Ser Ala Gly Gln225 230  
235 240Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Ile Gly  
Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile  
Val Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu  
Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu  
Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys  
Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser  
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn  
Arg Val Gly Ile Ile385 390 395 400Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410  
415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly  
Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Lys Phe Pro Glu Asn Gln Phe Gln Val Ala Leu Asp Gln  
Val Phe 450 455 460Glu Asn Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser  
Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile 485 490 495Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu  
Val Ser Ile Phe Ile 500 505 510Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser 515 520  
525Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn 530 53591539PRTArtificial SequenceSynthetic Polypeptide  
91Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu  
Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35  
40 45Thr Leu Pro Val Gly Asp Val Glu Asn Leu Thr Cys Ser Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu  
Asp Leu Leu Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln  
Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Ala Ala Ala  
Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile 115 120 125Arg Leu Glu Ser Glu Val Thr Ala Ile Asn Asn Ala  
Leu Lys Lys Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155  
160Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Thr Arg Ala 165 170 175Ile Asn Lys Asn Lys Cys  
Asp Ile Asp Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg  
Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210 215 220Ala  
Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn  
Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val

Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile385 390 395 400Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410 415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Lys Phe Pro Glu Asp Gln Phe Gln Val Ala Leu Asp Gln Val Phe 450 455 460Glu Asn Ile Glu Asn Ser Gln Ala

Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile 485 490 495Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu Val Ser Ile Phe Ile 500 505 510Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser 515 520 525Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn 530 53592539PRTArtificial SequenceSynthetic Polypeptide 92Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35 40 45Thr Leu Pro Val Gly Asp Val Glu Asn Leu Thr Cys Ser Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu Asp Leu Leu Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Ala Ala Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile 115 120 125Arg Leu Glu Ser Glu Val Thr Ala Ile Asn Asn Ala Leu Lys Lys Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155 160Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Thr Arg Ala 165 170 175Ile Asn Lys Asn Lys Cys Asp Ile Asp Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210 215 220Ala Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile385 390 395 400Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410 415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Lys Phe Pro Glu Asn Gln Phe Gln Val Ala Leu Asp Gln Val Phe 450 455 460Glu Asn Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile 485 490 495Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu Val Ser Ile Phe Ile 500 505 510Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser 515 520 525Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn 530 53593539PRTArtificial SequenceSynthetic Polypeptide 93Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35 40 45Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Ser Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu Asp Leu Leu Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Ala Ala Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile 115 120 125Arg Leu Glu Ser Glu Val Thr Ala Ile Asn Asn Ala Leu Lys Lys Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155 160Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Thr Arg Ala 165 170 175Ile Asn Lys Asn Lys Cys Asp Ile Asp Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210 215 220Ala Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu

Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys  
Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser  
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn  
Arg Val Gly Ile Ile385 390 395 400Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410  
415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly  
Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Lys Phe Pro Glu Asp Gln Phe Gln Val Ala Leu Asp Gln  
Val Phe 450 455 460Glu Asn Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser  
Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile 485 490 495Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu  
Val Ser Ile Phe Ile 500 505 510Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser 515 520  
525Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn 530 53594539PRTArtificial SequenceSynthetic Polypeptide  
94Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu  
Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35  
40 45Thr Leu Glu Val Gly Asp Leu Glu Asn Leu Thr Cys Ser Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu  
Asp Leu Thr Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln  
Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Ala Ala Ala  
Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile 115 120 125Arg Leu Glu Ser Glu Val Thr Ala Ile Asn Asn Ala  
Leu Lys Lys Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155  
160Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Thr Arg Ala 165 170 175Ile Asn Lys Asn Lys Cys  
Asp Ile Asp Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg  
Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210 215 220Ala  
Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn  
Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val  
Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala 275 280 285Ala Pro Ser Cys  
Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly  
Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp 325  
330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn  
Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val  
Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile385 390 395 400Lys Gln  
Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410 415Thr Val Thr Ile Asp Asn Thr Val Tyr  
Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro 435  
440 445Ile Lys Phe Pro Glu Asp Gln Phe Gln Val Ala Leu Asp Gln Val Phe 450 455 460Glu Asn Ile Glu Asn  
Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile  
Ile Val Ile Ile 485 490 495Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu Val Ser Ile Phe Ile 500 505 510Ile Ile Lys  
Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser 515 520 525Gly Val Thr Asn Asn Gly Phe Ile Pro His  
Asn 530 53595539PRTArtificial SequenceSynthetic Polypeptide 95Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu  
Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu  
Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35 40 45Thr Leu Glu Val Gly Asp Val Glu Asn  
Leu Thr Cys Ser Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu Asp Leu Thr Lys Ser Ala Leu Arg Glu65 70  
75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe  
Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Ala Ala Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr  
Ile 115 120 125Arg Leu Glu Ser Glu Val Thr Ala Ile Asn Asn Ala Leu Lys Lys Thr 130 135 140Asn Glu Ala Val  
Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155 160Ala Val Arg Glu Leu Lys Asp Phe Val Leu  
Lys Asn Leu Thr Arg Ala 165 170 175Ile Asn Lys Asn Lys Cys Asp Ile Asp Asp Leu Lys Met Ala Val Ser 180  
185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile  
Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210 215 220Ala Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr  
Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe 245 250  
255Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp  
Thr Pro Cys Trp Ile Val Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu  
Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315 320Pro Asn  
Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn Val Ala Glu  
Gln Ser Lys Glu Cys Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355  
360 365Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys  
Ser Ile Gly Ser Asn Arg Val Gly Ile Ile385 390 395 400Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln  
Asp Ala Asp 405 410 415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420 425 430Glu

Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Lys Phe Pro Glu Asp Gln Phe Gln Val Ala Leu Asp Gln Val Phe 450 455 460Glu Asn Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile 485 490 495Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu Val Ser Ile Phe Ile 500 505 510Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser 515 520 525Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn 530 53596539PRTArtificial SequenceSynthetic Polypeptide 96Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35 40 45Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Ser Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu Asp Leu Thr Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Ala Ala Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile 115 120 125Arg Leu Glu Ser Glu Val Thr Ala Ile Asn Asn Ala Leu Lys Lys Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155 160Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Trp Arg Ala 165 170 175Ile Asn Lys Asn Lys Cys Asp Ile Asp Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210

215 220Ala Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile385 390 395 400Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410 415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Lys Phe Pro Glu Asp Gln Phe Gln Val Ala Leu Asp Gln Val Phe 450 455 460Glu Asn Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile 485 490 495Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu Val Ser Ile Phe Ile 500 505 510Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser 515 520 525Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn 530 53597539PRTArtificial SequenceSynthetic Polypeptide 97Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35 40 45Thr Leu Glu Val Gly Asp Leu Glu Asn Leu Thr Cys Ser Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu Asp Leu Leu Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Ala Ala Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile 115 120 125Arg Leu Glu Ser Glu Val Thr Ala Ile Asn Asn Ala Leu Lys Lys Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155 160Ala Val Arg Glu Leu Lys Asp Phe Val Leu Lys Asn Leu Trp Arg Ala 165 170 175Ile Asn Lys Asn Lys Cys Asp Ile Asp Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210 215 220Ala Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile385 390 395 400Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410 415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Lys Phe Pro Glu Asp Gln Phe Gln Val Ala Leu Asp Gln Val Phe 450 455 460Glu Asn Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile 485 490 495Leu Ile

Ala Val Leu Gly Ser Ser Met Ile Leu Val Ser Ile Phe Ile 500 505 510Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala  
Pro Pro Glu Leu Ser 515 520 525Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn 530 53598539PRTArtificial  
SequenceSynthetic Polypeptide 98Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln1 5 10 15His  
Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr  
Gly Trp Tyr Thr Asn Val Phe 35 40 45Thr Leu Pro Val Gly Asp Val Glu Asn Leu Thr Cys Ser Asp Gly Pro 50  
55 60Ser Leu Ile Lys Thr Glu Leu Asp Leu Thr Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala  
Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe Val Leu Gly Ala Ile Ala Leu  
Gly Val 100 105 110Ala Ala Ala Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile 115 120 125Arg Leu Glu  
Ser Glu Val Thr Ala Ile Asn Asn Ala Leu Lys Lys Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly  
Val Arg Val Leu Ala Thr145 150 155 160Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Thr Arg Ala  
165 170 175Ile Asn Lys Asn Lys Cys Asp Ile Asp Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe  
Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu  
Asp Leu Met Thr Asp 210 215 220Ala Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr Ser Ala Gly Gln225 230  
235 240Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Ile Gly  
Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile  
Val Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu  
Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu  
Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys  
Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser  
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn  
Arg Val Gly Ile Ile385 390 395 400Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410  
415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly  
Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Lys Phe Pro Glu Asp Gln Phe Gln Val Ala Leu Asp Gln  
Val Phe 450 455 460Glu Asn Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser  
Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile 485 490 495Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu  
Val Ser Ile Phe Ile 500 505 510Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser 515 520  
525Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn 530 53599539PRTArtificial SequenceSynthetic Polypeptide  
99Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu  
Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35  
40 45Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Ser Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu  
Asp Leu Thr Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln  
Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Ala Ala Ala  
Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile 115 120 125Arg Leu Glu Ser Glu Val Thr Ala Ile Asn Asn Ala  
Leu Lys Lys Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155  
160Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Thr Arg Ala 165 170 175Ile Asn Lys Asn Lys Cys  
Asp Ile Pro Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg  
Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210 215 220Ala  
Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn  
Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val  
Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala 275 280 285Ala Pro Ser Cys  
Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly  
Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp 325  
330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn  
Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val  
Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile385 390 395 400Lys Gln  
Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410 415Thr Val Thr Ile Asp Asn Thr Val Tyr  
Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro 435  
440 445Ile Lys Phe Pro Glu Asp Gln Phe Gln Val Ala Leu Asp Gln Val Phe 450 455 460Glu Asn Ile Glu Asn  
Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile  
Ile Val Ile Ile 485 490 495Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu Val Ser Ile Phe Ile 500 505 510Ile Ile Lys  
Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser 515 520 525Gly Val Thr Asn Asn Gly Phe Ile Pro His  
Asn 530 535100539PRTArtificial SequenceSynthetic Polypeptide 100Met Ser Trp Lys Val Val Ile Ile Phe Ser  
Leu Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr 20 25  
30Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35 40 45Thr Leu Glu Val Gly Asp Val

Glu Asn Leu Thr Cys Ser Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu Asp Leu Thr Lys Ser Ala Leu Arg  
Glu65 70 75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu 85 90 95Asn Pro Gly Ser  
Gly Ser Phe Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Ala Ala Ala Ala Val Thr Ala Gly Val Ala Ile  
Ala Lys Thr Ile 115 120 125Arg Leu Glu Ser Glu Val Thr Ala Ile Asn Asn Ala Leu Lys Lys Thr 130 135 140Asn  
Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155 160Ala Val Arg Glu Leu Lys Asp  
Phe Val Ser Lys Asn Leu Thr Arg Ala 165 170 175Ile Asn Lys Asn Lys Cys Pro Ile Asp Asp Leu Lys Met Ala  
Val Ser 180 185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser 195 200 205Asp Asn  
Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210 215 220Ala Glu Leu Ala Arg Ala Val Pro Asn  
Met Pro Thr Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly  
Phe 245 250 255Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln 260 265 270Leu Pro Ile Phe  
Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys Lys Gly Asn Tyr Ala  
Cys Leu Leu Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315  
320Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn  
Val Ala Glu Gln Ser Lys Glu Cys Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly  
Arg His 355 360 365Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly  
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile385 390 395 400Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile  
Thr Asn Gln Asp Ala Asp 405 410 415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420  
425 430Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Lys Phe Pro Glu Asp  
Gln Phe Gln Val Ala Leu Asp Gln Val Phe 450 455 460Glu Asn Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser  
Asn Arg Ile465 470 475 480Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile 485 490 495Leu Ile  
Ala Val Leu Gly Ser Ser Met Ile Leu Val Ser Ile Phe Ile 500 505 510Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala

Pro Pro Glu Leu Ser 515 520 525Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn 530 535101539PRTArtificial  
SequenceSynthetic Polypeptide 101Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln1 5 10 15His  
Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr  
Gly Trp Tyr Thr Asn Val Phe 35 40 45Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Ser Asp Gly Pro 50  
55 60Ser Leu Ile Lys Thr Glu Leu Asp Leu Thr Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala  
Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe Val Leu Gly Ala Ile Ala Leu  
Gly Val 100 105 110Ala Ala Ala Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile 115 120 125Arg Leu Pro  
Ser Glu Val Thr Ala Ile Asn Asn Ala Leu Lys Lys Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly  
Val Arg Val Leu Ala Thr145 150 155 160Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Thr Arg Ala  
165 170 175Ile Asn Lys Asn Lys Cys Asp Ile Asp Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe  
Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu  
Asp Leu Met Thr Asp 210 215 220Ala Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr Ser Ala Gly Gln225 230  
235 240Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Ile Gly  
Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile  
Val Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu  
Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu  
Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys  
Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser  
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn  
Arg Val Gly Ile Ile385 390 395 400Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410  
415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly  
Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Lys Phe Pro Glu Asp Gln Phe Gln Val Ala Leu Asp Gln  
Val Phe 450 455 460Glu Asn Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser  
Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile 485 490 495Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu  
Val Ser Ile Phe Ile 500 505 510Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser 515 520  
525Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn 530 535102539PRTArtificial SequenceSynthetic Polypeptide  
102Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu  
Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35  
40 45Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Ser Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu  
Asp Leu Thr Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln  
Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Ala Ala Ala  
Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile 115 120 125Arg Leu Glu Ser Glu Val Thr Ala Ile Asn Asn Ala



Leu Lys Lys Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155  
160Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Thr Arg Ala 165 170 175Ile Asn Lys Asn Lys Cys  
Asp Ile Asp Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg  
Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210 215 220Ala  
Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn  
Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val  
Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala 275 280 285Ala Pro Ser Cys  
Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly  
Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp 325  
330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn  
Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val  
Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile385 390 395 400Lys Gln  
Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410 415Thr Val Thr Ile Asp Asn Thr Val Tyr  
Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Pro Pro 435  
440 445Ile Lys Phe Pro Glu Asp Gln Phe Gln Val Ala Leu Asp Gln Val Phe 450 455 460Glu Asn Ile Glu Asn  
Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile  
Ile Val Ile Ile 485 490 495Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu Val Ser Ile Phe Ile 500 505 510Ile Ile Lys  
Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser 515 520 525Gly Val Thr Asn Asn Gly Phe Ile Pro His  
Asn 530 535103539PRTArtificial SequenceSynthetic Polypeptide 103Met Ser Trp Lys Val Val Ile Ile Phe Ser  
Leu Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr 20 25  
30Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35 40 45Thr Leu Glu Val Gly Asp Val  
Glu Asn Leu Thr Cys Ser Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu Asp Leu Thr Lys Ser Ala Leu Arg  
Glu65 70 75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu 85 90 95Asn Pro Gly Ser  
Gly Ser Phe Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Ala Ala Ala Ala Val Thr Ala Gly Val Ala Ile  
Ala Lys Thr Ile 115 120 125Arg Leu Glu Ser Glu Val Thr Ala Ile Asn Asn Ala Leu Lys Lys Thr 130 135 140Asn  
Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155 160Ala Val Arg Glu Leu Lys Asp  
Phe Val Ser Lys Asn Leu Thr Arg Ala 165 170 175Ile Asn Lys Asn Lys Cys Asp Ile Asp Asp Leu Lys Met Ala  
Val Ser 180 185 190Phe Ser Gln Phe Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser 195 200 205Asp Asn  
Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210 215 220Ala Glu Leu Ala Arg Ala Val Pro Asn  
Met Pro Thr Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly  
Phe 245 250 255Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln 260 265 270Leu Pro Ile Phe  
Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys Lys Gly Asn Tyr Ala  
Cys Leu Leu Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315  
320Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn  
Val Ala Glu Gln Ser Lys Glu Cys Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly  
Arg His 355 360 365Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly  
Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile385 390 395 400Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile  
Thr Asn Gln Asp Ala Asp 405 410 415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420  
425 430Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Lys Phe Pro Glu Asn  
Gln Phe Gln Val Ala Leu Asp Gln Val Phe 450 455 460Glu Asn Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser  
Asn Arg Ile465 470 475 480Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile 485 490 495Leu Ile  
Ala Val Leu Gly Ser Ser Met Ile Leu Val Ser Ile Phe Ile 500 505 510Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala  
Pro Pro Glu Leu Ser 515 520 525Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn 530 535104539PRTArtificial  
SequenceSynthetic Polypeptide 104Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln1 5 10 15His  
Gly Leu Lys Glu Ser Tyr Leu Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr  
Gly Trp Tyr Thr Asn Val Phe 35 40 45Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Ser Asp Gly Pro 50  
55 60Ser Leu Ile Lys Thr Glu Leu Asp Leu Thr Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala  
Asp Gln Leu Ala Arg Glu Glu Gln Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe Val Leu Gly Ala Ile Ala Leu  
Gly Val 100 105 110Ala Ala Ala Ala Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile 115 120 125Arg Leu Glu  
Ser Glu Val Thr Ala Ile Asn Asn Ala Leu Lys Lys Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly  
Val Arg Val Leu Ala Thr145 150 155 160Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Thr Arg Ala  
165 170 175Ile Asn Lys Asn Lys Cys Asp Ile Asp Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Phe  
Asn Arg Arg Phe Leu Asn Val Val Arg Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu  
Asp Leu Met Thr Asp 210 215 220Ala Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr Ser Ala Gly Gln225 230

235 240Ile Lys Leu Met Leu Glu Asn Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Ile Gly  
Val Tyr Gly Ser Ser Val Ile Tyr Met Val Gln 260 265 270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile  
Val Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys Lys Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu  
Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu  
Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys  
Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser  
Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370 375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn  
Arg Val Gly Ile Ile385 390 395 400Lys Gln Leu Asn Lys Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410  
415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly  
Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile Lys Phe Pro Gln Asp Gln Phe Gln Val Ala Leu Asp Gln  
Val Phe 450 455 460Glu Asn Ile Glu Asn Ser Gln Ala Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser  
Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile Ile 485 490 495Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu  
Val Ser Ile Phe Ile 500 505 510Ile Ile Lys Lys Thr Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser 515 520  
525Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn 530 535105539PRTArtificial SequenceSynthetic Polypeptide  
105Met Ser Trp Lys Val Val Ile Ile Phe Ser Leu Leu Ile Thr Pro Gln1 5 10 15His Gly Leu Lys Glu Ser Tyr Leu  
Glu Glu Ser Cys Ser Thr Ile Thr 20 25 30Glu Gly Tyr Leu Ser Val Leu Arg Thr Gly Trp Tyr Thr Asn Val Phe 35  
40 45Thr Leu Glu Val Gly Asp Val Glu Asn Leu Thr Cys Ser Asp Gly Pro 50 55 60Ser Leu Ile Lys Thr Glu Leu  
Asp Leu Thr Lys Ser Ala Leu Arg Glu65 70 75 80Leu Lys Thr Val Ser Ala Asp Gln Leu Ala Arg Glu Glu Gln  
Ile Glu 85 90 95Asn Pro Gly Ser Gly Ser Phe Val Leu Gly Ala Ile Ala Leu Gly Val 100 105 110Ala Ala Ala Ala  
Ala Val Thr Ala Gly Val Ala Ile Ala Lys Thr Ile 115 120 125Arg Leu Glu Ser Glu Val Thr Ala Ile Asn Asn Ala  
Leu Lys Lys Thr 130 135 140Asn Glu Ala Val Ser Thr Leu Gly Asn Gly Val Arg Val Leu Ala Thr145 150 155  
160Ala Val Arg Glu Leu Lys Asp Phe Val Ser Lys Asn Leu Thr Arg Ala 165 170 175Ile Asn Lys Asn Lys Cys  
Asp Ile Asp Asp Leu Lys Met Ala Val Ser 180 185 190Phe Ser Gln Trp Asn Arg Arg Phe Leu Asn Val Val Arg  
Gln Phe Ser 195 200 205Asp Asn Ala Gly Ile Thr Pro Ala Ile Ser Leu Asp Leu Met Thr Asp 210 215 220Ala  
Glu Leu Ala Arg Ala Val Pro Asn Met Pro Thr Ser Ala Gly Gln225 230 235 240Ile Lys Leu Met Leu Glu Asn  
Arg Ala Met Val Arg Arg Lys Gly Phe 245 250 255Gly Ile Leu Ile Gly Val Tyr Gly Ser Ser Val Ile Tyr Met Val  
Gln 260 265

270Leu Pro Ile Phe Gly Val Ile Asp Thr Pro Cys Trp Ile Val Lys Ala 275 280 285Ala Pro Ser Cys Ser Glu Lys  
Lys Gly Asn Tyr Ala Cys Leu Leu Arg 290 295 300Glu Asp Gln Gly Trp Tyr Cys Gln Asn Ala Gly Ser Thr Val  
Tyr Tyr305 310 315 320Pro Asn Glu Lys Asp Cys Glu Thr Arg Gly Asp His Val Phe Cys Asp 325 330 335Thr  
Ala Ala Gly Ile Asn Val Ala Glu Gln Ser Lys Glu Cys Asn Ile 340 345 350Asn Ile Ser Thr Thr Asn Tyr Pro Cys  
Lys Val Ser Thr Gly Arg His 355 360 365Pro Ile Ser Met Val Ala Leu Ser Pro Leu Gly Ala Leu Val Ala Cys 370  
375 380Tyr Lys Gly Val Ser Cys Ser Ile Gly Ser Asn Arg Val Gly Ile Ile385 390 395 400Lys Gln Leu Asn Lys  
Gly Cys Ser Tyr Ile Thr Asn Gln Asp Ala Asp 405 410 415Thr Val Thr Ile Asp Asn Thr Val Tyr Gln Leu Ser  
Lys Val Glu Gly 420 425 430Glu Gln His Val Ile Lys Gly Arg Pro Val Ser Ser Ser Phe Asp Pro 435 440 445Ile  
Lys Phe Pro Glu Asp Gln Phe Gln Val Ala Leu Asp Gln Val Phe 450 455 460Glu Asn Ile Glu Asn Ser Gln Ala  
Leu Val Asp Gln Ser Asn Arg Ile465 470 475 480Leu Ser Ser Ala Glu Lys Gly Asn Thr Gly Phe Ile Ile Val Ile  
Ile 485 490 495Leu Ile Ala Val Leu Gly Ser Ser Met Ile Leu Val Ser Ile Phe Ile 500 505 510Ile Ile Lys Lys Thr  
Lys Lys Pro Thr Gly Ala Pro Pro Glu Leu Ser 515 520 525Gly Val Thr Asn Asn Gly Phe Ile Pro His Asn 530  
5351061617DNAArtificial SequenceSynthetic Polynucleotide 106atgagctgga aggtggtcat catcttcagc ctgctgatca  
cacctcagca cggcctgaaa 60gagagctacc tggaagagtc ctgcagcacc atcacagagg gctacctgtc tgtgctgaga 120accgctggt  
acaccaactg gttcacactg gaagtgggagc acgtcgagaa tctgacatgc 180tctgatggcc ctgacctgat caagaccgag ctggatctga  
ccaagagcgc cctgagagaa 240ctcaagaccg tgctgccga tcagctggcc agagaggaac agatcgagaa tctggcagc 300ggcagctttg  
tgctgggagc cattgctctt ggagtggctg ctgctgcagc tgttacagca 360ggcgtggcca tctgcaagac catcagactg gaaagcgaag  
tgaccgcat caacaagcc 420ctgaagaaga caaacgagc cgtcagcaca ctggcaatg gcgttagagt gctggccttt 480gccgtgagc  
agctgaagga ctctgtctcc aagaacctga cacgggcct gaacaagaac 540aagtgcgaca tcgacacct gaagatggcc gtgtcctta  
gccagtcaa cggcggttt 600ctgaactgc tgccgagct tagcgacaac gccggaatca caccagccat cagcctggac 660ctgatgacag  
atgctgagct ggctagagcc gtgctaaca tgctacatc tgccggccag 720atcaagctga tgctcgagaa tagagccatg gtccgacgga  
aaggctcgg cattctgtgt 780ggcgtgtacg gcagcagcgt gatctatag gtgcagctgc ctatctcgg cgtgatgac 840acacctgct  
ggattgtgaa ggccctcct agctgtagcg agaagaagg caattacgcc 900tgctctgta gagaggacca aggtggtat tgcagaac  
cggcagcac cgtgtactac 960cctaacgaga aggactgca gacaagagc gaccagctgt tctgtgatac cgccgtgga 1020atcaatgtgg  
ccgagcagag caaagagtgc aacatcaaca tcagcaccac caactatccc 1080tgcaggtgt ccaccggcag gcacctatt tctatgtgg  
ctctgtctcc tctgggagcc 1140ctgtgtgctt gttataaggc cgtgtctgt agcatggca gcaacagagt gggcatcacc 1200aagcagctga

acaagggctg cagctacatc accaaccagg acgccgatac cgtgaccatc 1260gacaacaccg tgtatcagct gagcaaggtg gaaggcgaac  
agcacgtgat caagggcaga 1320cctgtgtcca gcagcttcca ccctatcaag ttcctgagg atcagttcaa cgtggccctg 1380gaccaggtgt  
tcgagaacat cgagaattcc caggctctgg tggaccagtc caacagaatc 1440ctgtctagcg ccgagaaggg aacaccggc tcatcatcg  
tgatcatcct gatgccctg 1500ctgggcagct ccatgatcct ggtgtccatc tcatcatta tcaagaagac caagaagccc 1560accggcgctc  
ctccagaact gageggagtg accaacaatg gcttcatccc tcacaac 16171071617DNAArtificial SequenceSynthetic  
Polynucleotide 107atgagctgga aggtggtcat catcttcagc ctgctgatca cacctcagca cggcctgaaa 60gagagctacc tgaagagtc  
ctgcagcacc atcacagagg gctacctgc tgtgctgaga 120accggctggt acaccaactg gttcacactg gaagtgggcg acgtcgagaa  
tctgacatgc 180tctgatggcc ctaccctgat caagaccgag ctggatctga ccaagagcgc cctgagagaa 240ctcaagaccg tgtctgccga  
tcagctggcc agagaggaac agatcgagaa tcttggcagc 300ggcagctttg tctggggagc cattgctctt ggagtggctg ctgctgcagc  
tgttacagca 360ggcgtggcca tctgcaagac catcagactg gaaagcgaag tgaccgccc caacaagccc 420ctgaagaaga caaacgaggg  
cgtcagcaca ctggcaatg gcgtagagt gctggccaca 480gccgtgccc agctgaagga cttcgtgtcc aagaacctga cacgggccc  
taacaagaac 540aagtgcgaca tcgacacct gaagatggcc gtgtcctta gccagttcaa ccggcggtt 600ctgaacgtcg tgcggcagtt  
tagcgacaac gccggaatca caccagccat cagcctggac 660ctgatgacag atgctgagct ggctagagcc gtgcctaaca tgctacatc  
tgccggccag 720atcaagctga tctcagagaa tagagccatg gtccgacgga aaggcttcgg cattctgtgt 780ggcgtgtacg gcagcagct  
gatctatatg gtgcagctgc ctatcttcgg cgtgatcgac 840acacctgct ggattgtgaa ggccgctcct agctgtagcg agaagaagg  
caattacgcc 900tgctgtctga gagaggacca aggtggtat tgcagaacg ccggcagcac cgtgtactac 960cctaacgaga aggactgca  
gacaagaggc gaccacgtgt tctgtgatac cggcgtgga 1020atcaatgtgg ccgagcagag caaagagtc aacatcaaca tcagcaccac  
caactatccc 1080tgcaaggtgt ccaccggcag gcacctatt tctatggtgg ctctgtctcc tctgggagcc 1140ctggtggctt gttataagg  
cgtgtcctgt agcatcgcca gcaacagagt gggcatcatc 1200aagcagctga acaagggctg cagctacatc accaaccagg acgccgatac  
cgtgaccatc 1260gacaacaccg tgtatcagct gagcaaggtg gaaggcgaac agcacgtgat caagggcaga 1320cctgtgtcca gcagcttcca  
ccctatcaag ttcctgagc accagtggca tgtggccctg 1380gaccaggtgt tcgagaacat cgagaattcc caggctctgg tggaccagtc  
caacagaatc 1440ctgtctagcg ccgagaaggg aacaccggc tcatcatcg tgatcatcct gatgccctg 1500ctgggcagct ccatgatcct  
ggtgtccatc tcatcatta tcaagaagac caagaagccc 1560accggcgctc ctccagaact gageggagtg accaacaatg gcttcatccc  
tcacaac 16171081617DNAArtificial SequenceSynthetic Polynucleotide 108atgagctgga aggtggtcat catcttcagc  
ctgctgatca cacctcagca cggcctgaaa 60gagagctacc tgaagagtc ctgcagcacc atcacagagg gctacctgc tgtgctgaga  
120accggctggt acaccaactg gttcacactg gaagtgggcg acgtcgagaa tctgacatgc 180tctgatggcc ctaccctgat caagaccgag  
ctggatctgc tcaagagcgc cctgagagaa 240ctcaagaccg tgtctgccga tcagctggcc agagaggaac agatcgagaa tcttggcagc  
300ggcagctttg tctggggagc cattgctctt ggagtggctg ctgctgcagc tgttacagca 360ggcgtggcca tcgtaagac catcagactg  
gaaagcgaag tgaccgccc caacaagccc 420ctgaagaaga caaacgaggg cgtcagcaca ctggcaatg gcgtagagt gctggccaca  
480gccgtgccc agctgaagga cttcgtgtcc aagaacctga cacgggccc taacaagaac 540aagtgcgaca tcctgacct gaagatggcc  
gtgtcctta gccagttcaa ccggcggtt 600ctgaacgtcg tgcggcagtt tagcgacaac gccggaatca caccagccat cagcctggac  
660ctgatgacag atgctgagct ggctagagcc gtgcctaaca tgctacatc tgccggccag 720atcaagctga tctcagagaa tagagccatg  
gtccgacgga aaggcttcgg cattctgatt 780ggcgtgtacg gcagcagct gatctatatg gtgcagctgc ctatcttcgg cgtgatcgac  
840acacctgct ggattgtgaa ggccgctcct agctgtagcg agaagaagg caattacgcc 900tgctgtctga gagaggacca aggtggtat  
tgcagaacg ccggcagcac cgtgtactac 960cctaacgaga aggactgca gacaagaggc gaccacgtgt tctgtgatac cggcgtgga  
1020atcaatgtgg ccgagcagag caaagagtc aacatcaaca tcagcaccac caactatccc 1080tgcaaggtgt ccaccggcag gcacctatt  
tctatggtgg ctctgtctcc tctgggagcc 1140ctggtggctt gttataagg cgtgtcctgt agcatcgcca gcaacagagt gggcatcatc  
1200aagcagctga acaagggctg cagctacatc accaaccagg acgccgatac cgtgaccatc 1260gacaacaccg tgtatcagct gagcaaggtg  
gaaggcgaac agcacgtgat caagggcaga 1320cctgtgtcca gcagcttcca ccctatcaag ttcctgagg atcagttcca ggtggccctg  
1380gaccaggtgt tcgagaacat cgagaattcc caggctctgg tggaccagtc caacagaatc 1440ctgtctagcg ccgagaaggg aacaccggc  
tcatcatcg tgatcatcct gatgccctg 1500ctgggcagct ccatgatcct ggtgtccatc tcatcatta tcaagaagac caagaagccc  
1560accggcgctc ctccagaact gageggagtg accaacaatg gcttcatccc tcacaac 16171091617DNAArtificial  
SequenceSynthetic Polynucleotide 109atgagctgga aggtggtcat catcttcagc ctgctgatca cacctcagca cggcctgaaa  
60gagagctacc tgaagagtc ctgcagcacc atcacagagg gctacctgc tgtgctgaga 120accggctggt acaccaactg gttcacactg  
gaagtgggcg acgtcgagaa tctgacatgc 180tctgatggcc ctaccctgat caagaccgag ctggatctgc tcaagagcgc cctgagagaa  
240ctcaagaccg tgtctgccga tcagctggcc agagaggaac agatcgagaa tcttggcagc 300ggcagctttg tctggggagc cattgctctt  
ggagtggctg ctgctgcagc tgttacagca 360ggcgtggcca tcgtaagac catcagactg gaaagcgaag tgaccgccc caacaagccc  
420ctgaagaaga caaacgaggg cgtcagcaca ctggcaatg gcgtagagt gctggccaca 480gccgtgccc agctgaagga cttcgtgtcc  
aagaacctga cacgggccc taacaagaac 540aagtgcgaca tcctgacct gaagatggcc gtgtcctta gccagttcaa ccggcggtt  
600ctgaacgtcg tgcggcagtt tagcgacaac gccggaatca caccagccat cagcctggac 660ctgatgacag atgctgagct ggctagagcc  
gtgcctaaca tgctacatc tgccggccag 720atcaagctga tctcagagaa tagagccatg gtccgacgga aaggcttcgg cattctgatt  
780ggcgtgtacg gcagcagct gatctatatg gtgcagctgc ctatcttcgg cgtgatcgac 840acacctgct ggattgtgaa ggccgctcct  
agctgtagcg agaagaagg caattacgcc 900tgctgtctga gagaggacca aggtggtat tgcagaacg ccggcagcac cgtgtactac  
960cctaacgaga aggactgca gacaagaggc gaccacgtgt tctgtgatac cggcgtgga 1020atcaatgtgg ccgagcagag caaagagtc

aacatcaaca tcagcaccac caactatccc 1080tgcaaggtgt ccaccggcag gcaccctatt tctatggtgg ctctgtctcc tctgggagcc  
1140ctggtggcct gttataaggg cgtgtcctgt agcatcggca gcaacagagt gggcatcadc 1200aagcagctga acaagggctg cagctacac  
accaaccagg acgccgatac cgtgaccate 1260gacaacaccg tgtatcagct gagcaaggtg gaaggcgaac agcacgtgat caagggcaga  
1320cctgtgtcca gcagcttcca cctatcaag ttcctgaga accagttcca ggtggccctg 1380gaccaggtgt tcgagaacat cgagaattcc  
caggtctgg tggaccagtc caacagaate 1440ctgtctagcg ccgagaaggg aacaccggc tcatcatcg tgatcatcct gatcgccctg  
1500ctgggcagct ccatgatcct ggtgtccate tcatcatta tcaagaagac caagaagccc 1560accggcgctc ctccagaact gagcggagtg  
accaacaatg gttcatccc tcacaac 16171101617DNAArtificial SequenceSynthetic Polynucleotide 110atgagctgga  
agtggtcat catcttcagc ctgtgatca cacctcagca cggcctgaaa 60gagagctacc tggagagtc ctgcagcacc atcacagagg  
gctacctgct tgtgtgaga 120accggctggt acaccaactg gttcacactg gaagtgggag acgtcgagaa tctgacatgc 180tctgatggcc  
ctagcctgat caagaccgag ctggatctgc tcaagagegc cctgagagaa 240ctcaagaccg tgtctgccga tcagctggcc agagaggaac  
agatcgagaa tctggcagc 300ggcagcttg tctgggagc cattgctctt ggagtggctg ctgtgcagc tgttacagca 360ggcgtggcca  
tcgctaagac catcagactg gaaagcgaag tgaccgcat caacaagcc 420ctgaagaaga caaacgaggc cgtcagcaca ctggcaatg  
gcgttagagt gctggccaca 480gccgtgcgcg agctgaagga ctctgtctt aagaacctga cacgggcat taacaagaac 540aagtgcgaca  
tcctgacct gaagatggcc gtgtcttta gccagtcaa ccggcggtt 600ctgaacgtcg tgcggcagtt tagcgacaac gccggaatca  
caccagccat cagcctggac 660ctgatgacag atgtgagct ggctagagcc gtgcctaaca tgctacatc tgccggccag 720atcaagctga  
tgctcgagaa tagagccatg gtccgacgga aaggcttcgg cattctgatt 780ggcgtgtacg gcagcagctg gatctatag gtgcagctgc  
ctatcttcgg cgtgatcgc 840acaccctgct ggatttgtaa ggccgctcct agctgtagcg agaagaaggg caattacgcc 900tgctgtctga  
gagaggacca aggtctgtat tgcagaacg ccggcagcag cgtgtactac 960cctaacgaga aggactgcga gacaagaggc gaccacgtg  
tctgtgatac cggcctgga 1020atcaatgtgg ccgagcagag caaagagtgc aacatcaaca tcagcaccac caactatccc 1080tgcaaggtgt  
ccaccggcag gcaccctatt tctatggtgg ctctgtctcc tctgggagcc 1140ctggtggcct gttataaggg cgtgtcctgt agcatcggca  
gcaacagagt gggcatcadc 1200aagcagctga acaagggctg cagctacac accaaccagg acgccgatac cgtgaccate  
1260gacaacaccg tgtatcagct gagcaaggtg gaaggcgaac agcacgtgat caagggcaga 1320cctgtgtcca gcagcttcca cctatcaag  
ttcctgagg atcagttcca ggtggccctg 1380gaccaggtgt tcgagaacat cgagaattcc caggtctgg tggaccagtc caacagaate  
1440ctgtctagcg ccgagaaggg aacaccggc tcatcatcg tgatcatcct gatcgccctg 1500ctgggcagct ccatgatcct ggtgtccate  
tcatcatta tcaagaagac caagaagccc 1560accggcgctc ctccagaact gagcggagtg accaacaatg gttcatccc tcacaac  
16171111617DNAArtificial SequenceSynthetic Polynucleotide 111atgagctgga agtggtcat catcttcagc ctgtgatca  
cacctcagca cggcctgaaa 60gagagctacc tggagagtc ctgcagcacc atcacagagg gctacctgct tgtgtgaga 120accggctggt  
acaccaactg gttcacactg gaagtgggag acgtcgagaa tctgacatgc 180tctgatggcc ctagcctgat caagaccgag ctggatctgc  
tcaagagegc cctgagagaa 240ctcaagaccg tgtctgccga tcagctggcc agagaggaac agatcgagaa tctggcagc 300ggcagcttg  
tctgggagc cattgctctt ggagtggctg ctgtgcagc tgttacagca 360ggcgtggcca tcgctaagac catcagactg gaaagcgaag  
tgaccgcat caacaagcc 420ctgaagaaga caaacgaggc cgtcagcaca ctggcaatg gcgttagagt gctggccaca 480gccgtgcgcg  
agctgaagga ctctgtctt aagaacctga cacgggcat taacaagaac 540aagtgcgaca tcctgacct gaagatggcc gtgtcttta  
gccagtcaa ccggcggtt 600ctgaacgtcg tgcggcagtt tagcgacaac gccggaatca caccagccat cagcctggac 660ctgatgacag  
atgtgagct ggctagagcc gtgcctaaca tgctacatc tgccggccag 720atcaagctga tgctcgagaa tagagccatg gtccgacgga  
aaggcttcgg cattctgatt 780ggcgtgtacg gcagcagctg gatctatag gtgcagctgc ctatcttcgg cgtgatcgc 840acaccctgct  
ggatttgtaa ggccgctcct agctgtagcg agaagaaggg caattacgcc 900tgctgtctga gagaggacca aggtctgtat tgcagaacg  
ccggcagcag cgtgtactac 960cctaacgaga aggactgcga gacaagaggc gaccacgtg tctgtgatac cggcctgga 1020atcaatgtgg  
ccgagcagag caaagagtgc aacatcaaca tcagcaccac caactatccc 1080tgcaaggtgt ccaccggcag gcaccctatt tctatggtgg  
ctctgtctcc tctgggagcc 1140ctggtggcct gttataaggg cgtgtcctgt agcatcggca gcaacagagt gggcatcadc 1200aagcagctga  
acaagggctg cagctacac accaaccagg acgccgatac cgtgaccate 1260gacaacaccg tgtatcagct gagcaaggtg gaaggcgaac  
agcacgtgat caagggcaga 1320cctgtgtcca gcagcttcca cctatcaag ttcctgaga accagttcca ggtggccctg 1380gaccaggtgt  
tcgagaacat cgagaattcc caggtctgg tggaccagtc caacagaate 1440ctgtctagcg ccgagaaggg aacaccggc tcatcatcg  
tgatcatcct gatcgccctg 1500ctgggcagct ccatgatcct ggtgtccate tcatcatta tcaagaagac caagaagccc 1560accggcgctc  
ctccagaact gagcggagtg accaacaatg gttcatccc tcacaac 16171121617DNAArtificial SequenceSynthetic  
Polynucleotide 112atgagctgga agtggtcat catcttcagc ctgtgatca cacctcagca cggcctgaaa 60gagagctacc tggagagtc  
ctgcagcacc atcacagagg gctacctgct tgtgtgaga 120accggctggt acaccaactg gttcacactg cctgtgggag acgtcgagaa  
tctgacatgc 180tctgatggcc ctagcctgat caagaccgag ctggatctgc tcaagagegc cctgagagaa 240ctcaagaccg tgtctgccga  
tcagctggcc agagaggaac agatcgagaa tctggcagc 300ggcagcttg tctgggagc cattgctctt ggagtggctg ctgtgcagc  
tgttacagca 360ggcgtggcca tcgctaagac catcagactg gaaagcgaag tgaccgcat caacaagcc 420ctgaagaaga caaacgaggc  
cgtcagcaca ctggcaatg gcgttagagt gctggccaca 480gccgtgcgcg agctgaagga ctctgtctt aagaacctga cacgggcat  
taacaagaac 540aagtgcgaca tcgacgacct gaagatggcc gtgtcttta gccagtcaa ccggcggtt 600ctgaacgtcg tgcggcagtt  
tagcgacaac gccggaatca caccagccat cagcctggac 660ctgatgacag atgtgagct ggctagagcc gtgcctaaca tgctacatc  
tgccggccag 720atcaagctga tgctcgagaa tagagccatg gtccgacgga aaggcttcgg cattctgatt 780ggcgtgtacg gcagcagctg  
gatctatag gtgcagctgc ctatcttcgg cgtgatcgc 840acaccctgct ggatttgtaa ggccgctcct agctgtagcg agaagaaggg

caattacgcc 900tgccctgctga gagaggacca aggctggtat tgcagaacg cggcagcac cgtgtactac 960cctaacgaga aggactgcga gacaagaggc gaccacgtgt tctgtgatac cgccgctgga 1020atcaatgtgg ccgagcagag caaagagtgc aacatcaaca tcagcaccac caactatccc 1080tgcaaggtgt ccaccggcag gcacctatt tctatggtgg ctctgtctcc tctgggagcc 1140ctggtggctt gttataaggg cgtgtcctgt agcatcggca gcaacagagt gggcatcacc 1200aagcagctga acaagggctg cagctacatc accaaccagg acgccgatac cgtgaccatc 1260gacaacaccg tgtatcagct gagcaaggtg gaaggcgaac agcacgtgat caagggcaga 1320cctgtgtcca gcagcttcca ccctatcaag ttcctgagg atcagttcca ggtggccctg 1380gaccaggtgt tcgagaacat cgagaattcc caggctctgg tggaccagtc caacagaatc 1440ctgtctagcg ccgagaaggg aacaccggc tcatcatcg tgatcatcct gatcgccctg 1500ctgggcagct ccatgatcct ggtgtccatc tcatcatta tcaagaagac caagaagccc 1560accggcgctc ctccagaact gagcggagt accaacaatg gttcatccc tcacaac 16171131617DNAArtificial SequenceSynthetic Polynucleotide 113atgagctgga aggtggtcat catcttcagc ctgctgatca cacctcagca cggcctgaaa 60gagagctacc tggaaagatc ctgcagcacc atcacagagg gctacctgic tgtgtgaga 120accggctggt acaccaactg gttcacactg cctgtgggag acgtcgagaa tctgacatgc 180tctgatggcc ctgacctgat caagaccgag ctggatctgc tcaagagcgc cctgagagaa 240ctcaagaccg tgtctgccga tcagctggcc agagaggaac agatcgagaa tcttggcagc 300ggcagctttg tgctgggagc cattgctctt ggagtggctg ctgtctcagc tgttacagca 360ggcgtggcca tcgctaagac catcagactg gaaagcgaag tgaccgcat caacaacgcc 420ctgaagaaga caaacgagc cgtcagcaca ctgggcaatg gcgttagagt gctggccaca 480gccgtgagcg agctgaagga ctctgtctcc aagaacctga cacgggcat taacaagaac 540aagtgcgaca tcgacgacct gaagatggcc gtgtccttta gccagtcaa ccggcggttt 600ctgaacgtcg tgcggcagtt tagcgacaac gccggaatca caccagccat cagcctggac 660ctgatgacag atgctgagct ggctagagcc gtgcctaaca tgctacatc tgccggccag 720atcaagctga tgctcgagaa tagagccatg gtccgacgga aaggcttcgg cattctgatt 780ggcgtgtacg gcagcagcgt gatctatatg gtgcagctgc ctatcttcgg cgtgatcagc 840acacctgct ggattgtgaa ggccgctcct agctgtagcg agaagaaggg caattacgcc 900tgccctgctga gagaggacca aggctggtat tgcagaacg cggcagcac cgtgtactac 960cctaacgaga aggactgcga gacaagaggc gaccacgtgt tctgtgatac cgccgctgga 1020atcaatgtgg ccgagcagag caaagagtgc aacatcaaca tcagcaccac caactatccc 1080tgcaaggtgt ccaccggcag gcacctatt tctatggtgg ctctgtctcc tctgggagcc 1140ctggtggctt gttataaggg cgtgtcctgt agcatcggca gcaacagagt gggcatcacc 1200aagcagctga acaagggctg cagctacatc accaaccagg acgccgatac cgtgaccatc 1260gacaacaccg tgtatcagct gagcaaggtg gaaggcgaac agcacgtgat caagggcaga 1320cctgtgtcca gcagcttcca ccctatcaag ttcctgaga accagttcca ggtggccctg 1380gaccaggtgt tcgagaacat cgagaattcc caggctctgg tggaccagtc caacagaatc 1440ctgtctagcg ccgagaaggg aacaccggc tcatcatcg tgatcatcct gatcgccctg 1500ctgggcagct ccatgatcct ggtgtccatc tcatcatta tcaagaagac caagaagccc 1560accggcgctc ctccagaact gagcggagt accaacaatg gttcatccc tcacaac

16171141617DNAArtificial SequenceSynthetic Polynucleotide 114atgagctgga aggtggtcat catcttcagc ctgctgatca cacctcagca cggcctgaaa 60gagagctacc tggaaagatc ctgcagcacc atcacagagg gctacctgic tgtgtgaga 120accggctggt acaccaactg gttcacactg gaagtgggag acgtcgagaa tctgacatgc 180tctgatggcc ctgacctgat caagaccgag ctggatctgc tcaagagcgc cctgagagaa 240ctcaagaccg tgtctgccga tcagctggcc agagaggaac agatcgagaa tcttggcagc 300ggcagctttg tgctgggagc cattgctctt ggagtggctg ctgtctcagc tgttacagca 360ggcgtggcca tcgctaagac catcagactg gaaagcgaag tgaccgcat caacaacgcc 420ctgaagaaga caaacgagc cgtcagcaca ctgggcaatg gcgttagagt gctggccaca 480gccgtgagcg agctgaagga ctctgtctcc aagaacctga cacgggcat taacaagaac 540aagtgcgaca tcgacgacct gaagatggcc gtgtccttta gccagtcaa ccggcggttt 600ctgaacgtcg tgcggcagtt tagcgacaac gccggaatca caccagccat cagcctggac 660ctgatgacag atgctgagct ggctagagcc gtgcctaaca tgctacatc tgccggccag 720atcaagctga tgctcgagaa tagagccatg gtccgacgga aaggcttcgg cattctgatt 780ggcgtgtacg gcagcagcgt gatctatatg gtgcagctgc ctatcttcgg cgtgatcagc 840acacctgct ggattgtgaa ggccgctcct agctgtagcg agaagaaggg caattacgcc 900tgccctgctga gagaggacca aggctggtat tgcagaacg cggcagcac cgtgtactac 960cctaacgaga aggactgcga gacaagaggc gaccacgtgt tctgtgatac cgccgctgga 1020atcaatgtgg ccgagcagag caaagagtgc aacatcaaca tcagcaccac caactatccc 1080tgcaaggtgt ccaccggcag gcacctatt tctatggtgg ctctgtctcc tctgggagcc 1140ctggtggctt gttataaggg cgtgtcctgt agcatcggca gcaacagagt gggcatcacc 1200aagcagctga acaagggctg cagctacatc accaaccagg acgccgatac cgtgaccatc 1260gacaacaccg tgtatcagct gagcaaggtg gaaggcgaac agcacgtgat caagggcaga 1320cctgtgtcca gcagcttcca ccctatcaag ttcctgagg atcagttcca ggtggccctg 1380gaccaggtgt tcgagaacat cgagaattcc caggctctgg tggaccagtc caacagaatc 1440ctgtctagcg ccgagaaggg aacaccggc tcatcatcg tgatcatcct gatcgccctg 1500ctgggcagct ccatgatcct ggtgtccatc tcatcatta tcaagaagac caagaagccc 1560accggcgctc ctccagaact gagcggagt accaacaatg gttcatccc tcacaac 16171151617DNAArtificial SequenceSynthetic Polynucleotide 115atgagctgga aggtggtcat catcttcagc ctgctgatca cacctcagca cggcctgaaa 60gagagctacc tggaaagatc ctgcagcacc atcacagagg gctacctgic tgtgtgaga 120accggctggt acaccaactg gttcacactg gaagtgggag acctcgagaa tctgacatgc 180tctgatggcc ctgacctgat caagaccgag ctggatctga ccaagagcgc cctgagagaa 240ctcaagaccg tgtctgccga tcagctggcc agagaggaac agatcgagaa tcttggcagc 300ggcagctttg tgctgggagc cattgctctt ggagtggctg ctgtctcagc tgttacagca 360ggcgtggcca tcgctaagac catcagactg gaaagcgaag tgaccgcat caacaacgcc 420ctgaagaaga caaacgagc cgtcagcaca ctgggcaatg gcgttagagt gctggccaca 480gccgtgagcg agctgaagga ctctgtctcc aagaacctga cacgggcat taacaagaac 540aagtgcgaca tcgacgacct gaagatggcc gtgtccttta gccagtcaa ccggcggttt 600ctgaacgtcg tgcggcagtt tagcgacaac gccggaatca caccagccat cagcctggac

tagcgacaac gccggaatca caccagccat cagcctggac 660ctgatgacag atgctgagct ggctagagcc gtcctaaca tgctacatc  
tgccggccag 720atcaagctga tgctcgagaa tagagccatg gtccgacgga aaggcttcgg cattctgatt 780ggcgtgtacg gcagcagcgt  
gatctatatg gtgcagctgc ctatcttcgg cgtgatcgac 840acaccctgct ggattgtgaa ggccgctcct agctgtagcg agaagaaggg  
caattacgcc 900tgctgctga gagaggacca aggctggtat tgcagaacg ccggcagcac cgtgtactac 960cctaacgaga aggactgcca  
gacaagagc gaccacgtgt tctgtgatac cgccgctgga 1020atcaatgtgg ccgagcagag caaagagtgc aacatcaaca tcagcaccac  
caactatccc 1080tgcaaggtgt ccaccggcag gcacctatt tctatggtgg ctctgtctcc tctgggagcc 1140ctggtggcct gttataaggg  
cgtgtcctgt agcatcgcca gcaacagagt gggcatcacc 1200aagcagctga acaagggctg cagctacatc accaaccagg acgccgatac  
cgtgaccatc 1260gacaacaccg tgtatcagct gagcaaggtg gaaggcgaac agcacgtgat caagggcaga 1320cctgtgtcca gcagcttcca  
ccctatcaag ttcctgagg atcagttcca ggtggccctg 1380gaccaggtgt tcgagaacat cgagaattcc caggctctgg tggaccagtc  
caacagaatc 1440ctgtctagcg ccgagaaggg aacaccggc tcatcatcg tgatcatcct gatcgccctg 1500ctgggcagct ccatgatcct  
ggtgtccatc tcatcatta tcaagaagac caagaagccc 1560accggcgctc ctccagaact gageggagt accaacaatg gcttcatccc  
tcacaac 16171161617DNAArtificial SequenceSynthetic Polynucleotide 116atgagctgga agtggtcat catcttcagc  
ctgctgatca cacctcagca cggcctgaaa 60gagagctacc tgaagagtc ctgcagcacc atcacagagg gctacctgc tgtgctgaga  
120accggctggt acaccaactg gttcacactg gaagtggcg acgtcgagaa tctgacatgc 180tctgatggcc ctaccctgat caagaccgag  
ctggatctga ccaagagcgc cctgagagaa 240ctcaagaccg tgtctgccga tcagctggcc agagaggaac agatcgagaa tcttggcagc  
300ggcagctttg tcttgggagc cattgctctt ggagtggctg ctgctgcagc tttacagca 360ggcgtggcca tcgtaagac catcagactg  
gaaagcgaag tgaccgccat caacaacgcc 420ctgaagaaga caaacgaggc cgtcagcaca ctggcgaatg gcgtagagt gctggccaca  
480gccgtgctgc agctgaagga ctctgtctt aagaacctga cagggccat taacaagaac 540aagtgcgaca tcagcaccat gaagatggcc  
gtgtcctta gccagttcaa ccggcggtt 600ctgaacgtcg tgcggcagtt tagcgacaac gccggaatca caccagccat cagcctggac  
660ctgatgacag atgctgagct ggctagagcc gtcctaaca tgctacatc tgccggccag 720atcaagctga tgctcgagaa tagagccatg  
gtccgacgga aaggcttcgg cattctgatt 780ggcgtgtacg gcagcagcgt gatctatatg gtgcagctgc ctatcttcgg cgtgatcgac  
840acaccctgct ggattgtgaa ggccgctcct agctgtagcg agaagaaggg caattacgcc 900tgctgctga gagaggacca aggctggtat  
tgcagaacg ccggcagcac cgtgtactac 960cctaacgaga aggactgcca gacaagagc gaccacgtgt tctgtgatac cgccgctgga  
1020atcaatgtgg ccgagcagag caaagagtgc aacatcaaca tcagcaccac caactatccc 1080tgcaaggtgt ccaccggcag gcacctatt  
tctatggtgg ctctgtctcc tctgggagcc 1140ctggtggcct gttataaggg cgtgtcctgt agcatcgcca gcaacagagt gggcatcacc  
1200aagcagctga acaagggctg cagctacatc accaaccagg acgccgatac cgtgaccatc 1260gacaacaccg tgtatcagct gagcaaggtg  
gaaggcgaac agcacgtgat caagggcaga 1320cctgtgtcca gcagcttcca ccctatcaag ttcctgagg atcagttcca ggtggccctg  
1380gaccaggtgt tcgagaacat cgagaattcc caggctctgg tggaccagtc caacagaatc 1440ctgtctagcg ccgagaaggg aacaccggc  
tcatcatcg tgatcatcct gatcgccctg 1500ctgggcagct ccatgatcct ggtgtccatc tcatcatta tcaagaagac caagaagccc  
1560accggcgctc ctccagaact gageggagt accaacaatg gcttcatccc tcacaac 16171171617DNAArtificial  
SequenceSynthetic Polynucleotide 117atgagctgga agtggtcat catcttcagc ctgctgatca cacctcagca cggcctgaaa  
60gagagctacc tgaagagtc ctgcagcacc atcacagagg gctacctgc tgtgctgaga 120accggctggt acaccaactg gttcacactg  
gaagtggcg acgtcgagaa tctgacatgc 180tctgatggcc ctaccctgat caagaccgag ctggatctga ccaagagcgc cctgagagaa  
240ctcaagaccg tgtctgccga tcagctggcc agagaggaac agatcgagaa tcttggcagc 300ggcagctttg tcttgggagc cattgctctt  
ggagtggctg ctgctgcagc tttacagca 360ggcgtggcca tcgtaagac catcagactg gaaagcgaag tgaccgccat caacaacgcc  
420ctgaagaaga caaacgaggc cgtcagcaca ctggcgaatg gcgtagagt gctggccaca 480gccgtgctgc agctgaagga ctctgtctc  
aagaacctgt gggggccat taacaagaac 540aagtgcgaca tcagcaccat gaagatggcc gtgtcctta gccagttcaa ccggcggtt  
600ctgaacgtcg tgcggcagtt tagcgacaac gccggaatca caccagccat cagcctggac 660ctgatgacag atgctgagct ggctagagcc  
gtcctaaca tgctacatc tgccggccag 720atcaagctga tgctcgagaa tagagccatg gtccgacgga aaggcttcgg cattctgatt  
780ggcgtgtacg gcagcagcgt gatctatatg gtgcagctgc ctatcttcgg cgtgatcgac 840acaccctgct ggattgtgaa ggccgctcct  
agctgtagcg agaagaaggg caattacgcc 900tgctgctga gagaggacca aggctggtat tgcagaacg ccggcagcac cgtgtactac  
960cctaacgaga aggactgcca gacaagagc gaccacgtgt tctgtgatac cgccgctgga 1020atcaatgtgg ccgagcagag caaagagtgc  
aacatcaaca tcagcaccac caactatccc 1080tgcaaggtgt ccaccggcag gcacctatt tctatggtgg ctctgtctcc tctgggagcc  
1140ctggtggcct gttataaggg cgtgtcctgt agcatcgcca gcaacagagt gggcatcacc 1200aagcagctga acaagggctg cagctacatc  
accaaccagg acgccgatac cgtgaccatc 1260gacaacaccg tgtatcagct gagcaaggtg gaaggcgaac agcacgtgat caagggcaga  
1320cctgtgtcca gcagcttcca ccctatcaag ttcctgagg atcagttcca ggtggccctg 1380gaccaggtgt tcgagaacat cgagaattcc  
caggctctgg tggaccagtc caacagaatc 1440ctgtctagcg ccgagaaggg aacaccggc tcatcatcg tgatcatcct gatcgccctg  
1500ctgggcagct ccatgatcct ggtgtccatc tcatcatta tcaagaagac caagaagccc 1560accggcgctc ctccagaact gageggagt  
accaacaatg gcttcatccc tcacaac 16171181617DNAArtificial SequenceSynthetic Polynucleotide 118atgagctgga  
agtggtcat catcttcagc ctgctgatca cacctcagca cggcctgaaa 60gagagctacc tgaagagtc ctgcagcacc atcacagagg  
gctacctgc tgtgctgaga 120accggctggt acaccaactg gttcacactg gaagtggcg acctcgagaa tctgacatgc 180tctgatggcc  
ctaccctgat caagaccgag ctggatctgc tcaagagcgc cctgagagaa 240ctcaagaccg tgtctgccga tcagctggcc agagaggaac  
agatcgagaa tcttggcagc 300ggcagctttg tcttgggagc cattgctctt ggagtggctg ctgctgcagc tttacagca 360ggcgtggcca  
tcgtaagac catcagactg gaaagcgaag tgaccgccat caacaacgcc 420ctgaagaaga caaacgaggc cgtcagcaca ctggcgaatg

gcgtagagt gctggccaca 480gccgtgcgcg agctgaagga cttcgtgctt aagaacctgt ggcgggcat taacaagaac 540aagtgcgaca  
tcgacgacct gaagatggcc gtgtcctta gccagttca cggcggtt 600ctgaacgtcg tgcggcagtt tagcgacaac gccggaatca  
caccagccat cagcctggac 660ctgatgacag atgctgagct ggctagagcc gtgcctaaca tgctacatc tgccggccag 720atcaagctga  
tgctcgagaa tagagccatg gtccgacgga aaggctcgg cattctgatt 780ggcgtgtacg gcagcagcgt gatctatag gtgcagctgc  
ctatctcgg cgtgatcgac 840acacctgct ggattgtgaa ggccgctct agctgtagcg agaagaagg caattacgcc 900tgctgctga  
gagaggacca aggctggtat tgcagaacg ccggcagcac cgtgtactac 960cctaacgaga aggactgcca gacaagaggc gaccacgtg  
tctgtgatac cgccgtgga 1020atcaatgtgg ccgagcagag caaagagtgc aacatcaaca tcagcaccac caactatccc 1080tgcaaggtg  
ccaccggcag gcacctatt tctatggtgg ctctgtctcc tctgggagcc 1140ctggtggctt gttataaggg cgtgtctgt agcatcggca  
gcaacagagt gggcatc 1200aagcagctga acaaggctg cagctacatc accaaccagg acgccgatac cgtgaccatc  
1260gacaacaccg tttatcagct gagcaaggtg gaaggcgaac agcagctgat caaggcaga 1320cctgtgtcca gcagcttcca cctatcaag  
ttcctgagg atcagttcca ggtggcctg 1380gaccaggtg tcgagaacat cgagaattcc caggctctgg tggaccagtc caacagaatc  
1440ctgtctagcg ccgagaaggg aacaccggc tcatcatcg tgatcatct gatcgccgtg 1500ctgggcagct ccatgatct ggtgtccatc  
ttatcatta tcaagaagac caagaagccc 1560accggcgctc ctccagaact gaggcgagt accaacaatg gttcatccc tcacaac  
16171191617DNAArtificial SequenceSynthetic Polynucleotide 119atgagctgga aggtggtcat catcttcagc ctgctgatca  
cacctcagca cggcctgaaa 60gagagctacc tggagagtc ctgcagcacc atcacagagg gctacctgtc tgtgctgaga 120accggctggt  
acaccaactg gttcactg cctgtggcg acgtcgagaa tctgacatgc 180tctgatggcc ctgacctgat caagaccgag ctggatctga  
ccaagagcgc cctgagagaa 240ctcaagaccg tctgtccga tcagctggcc agagaggaac agatcgagaa tctggcagc 300ggcagcttg  
tgctgggagc cattgtctt ggagtggctg ctgctgcagc tttacagca 360ggcgtggcca tcgctaagac catcagactg gaaagcgaag  
tgaccgcat caacaacgcc 420ctgaagaaga caaacgaggc cgtcagcaca ctggcaatg gcgtagagt gctggccaca 480gccgtgcgcg  
agctgaagga cttcgtgctc aagaacctga cacgggcat taacaagaac 540aagtgcgaca tcgacgacct gaagatggcc gtgtcctta  
gccagttca cggcggtt 600ctgaacgtcg tgcggcagtt tagcgacaac gccggaatca caccagccat cagcctggac 660ctgatgacag  
atgctgagct ggctagagcc gtgcctaaca tgctacatc tgccggccag 720atcaagctga tgctcgagaa tagagccatg gtccgacgga  
aaggctcgg cattctgatt 780ggcgtgtacg gcagcagcgt gatctatag gtgcagctgc ctatctcgg cgtgatcgac 840acacctgct  
ggattgtgaa ggccgctct agctgtagcg agaagaagg caattacgcc 900tgctgctga gagaggacca aggctggtat tgcagaacg  
ccggcagcac cgtgtactac 960cctaacgaga aggactgcca gacaagaggc gaccacgtg tctgtgatac cgccgtgga 1020atcaatgtgg  
ccgagcagag caaagagtgc aacatcaaca tcagcaccac caactatccc 1080tgcaaggtg ccaccggcag gcacctatt tctatggtg  
ctctgtctcc tctgggagcc 1140ctggtggctt gttataaggg cgtgtctgt agcatcggca gcaacagagt gggcatc 1200aagcagctga  
acaaggctg cagctacatc accaaccagg acgccgatac cgtgaccatc 1260gacaacaccg tttatcagct gagcaaggtg gaaggcgaac  
agcagctgat caaggcaga 1320cctgtgtcca gcagcttcca cctatcaag ttcctgagg atcagttcca ggtggcctg 1380gaccaggtg  
tcgagaacat cgagaattcc caggctctgg tggaccagtc caacagaatc 1440ctgtctagcg ccgagaaggg aacaccggc tcatcatcg  
tgatcatct gatcgccgtg 1500ctgggcagct ccatgatct ggtgtccatc ttatcatta tcaagaagac caagaagccc 1560accggcgctc  
ctccagaact gaggcgagt accaacaatg gttcatccc tcacaac 16171201617DNAArtificial SequenceSynthetic  
Polynucleotide 120atgagctgga aggtggtcat catcttcagc ctgctgatca cacctcagca cggcctgaaa 60gagagctacc tggagagtc  
ctgcagcacc atcacagagg gctacctgtc tgtgctgaga 120accggctggt acaccaactg gaagtggcg acgtcgagaa  
tctgacatgc 180tctgatggcc ctgacctgat caagaccgag ctggatctga ccaagagcgc cctgagagaa 240ctcaagaccg tctgtccga  
tcagctggcc agagaggaac agatcgagaa tctggcagc 300ggcagcttg tgctgggagc cattgtctt ggagtggctg ctgctgcagc  
tgttacagca 360ggcgtggcca tcgctaagac catcagactg gaaagcgaag tgaccgcat caacaacgcc 420ctgaagaaga caaacgaggc  
cgtcagcaca ctggcaatg gcgtagagt gctggccaca 480gccgtgcgcg agctgaagga cttcgtgtc aagaacctga cacgggcat  
taacaagaac 540aagtgcgaca tcctgacct gaagatggcc gtgtcctta gccagttca cggcggtt 600ctgaacgtcg tgcggcagtt  
tagcgacaac gccggaatca caccagccat cagcctggac 660ctgatgacag atgctgagct ggctagagcc gtgcctaaca tgctacatc  
tgccggccag 720atcaagctga tgctcgagaa tagagccatg gtccgacgga aaggctcgg cattctgatt 780ggcgtgtacg gcagcagcgt  
gatctatag gtgcagctgc ctatctcgg cgtgatcgac 840acacctgct ggattgtgaa ggccgctct agctgtagcg agaagaagg  
caattacgcc 900tgctgctga gagaggacca aggctggtat tgcagaacg ccggcagcac cgtgtactac 960cctaacgaga aggactgcca  
gacaagaggc gaccacgtg tctgtgatac cgccgtgga 1020atcaatgtgg ccgagcagag caaagagtgc aacatcaaca tcagcaccac  
caactatccc 1080tgcaaggtg ccaccggcag gcacctatt tctatggtg ctctgtctcc tctgggagcc 1140ctggtggctt gttataaggg  
cgtgtctgt agcatcggca gcaacagagt gggcatc 1200aagcagctga acaaggctg cagctacatc accaaccagg acgccgatac  
cgtgaccatc 1260gacaacaccg tttatcagct gagcaaggtg gaaggcgaac agcagctgat caaggcaga 1320cctgtgtcca gcagcttcca  
cctatcaag ttcctgagg atcagttcca ggtggcctg 1380gaccaggtg tcgagaacat cgagaattcc caggctctgg tggaccagtc  
caacagaatc 1440ctgtctagcg ccgagaaggg aacaccggc tcatcatcg tgatcatct gatcgccgtg 1500ctgggcagct ccatgatct  
ggtgtccatc ttatcatta tcaagaagac caagaagccc 1560accggcgctc ctccagaact gaggcgagt accaacaatg gttcatccc  
tcacaac 16171211617DNAArtificial SequenceSynthetic Polynucleotide 121atgagctgga aggtggtcat catcttcagc  
ctgctgatca cacctcagca cggcctgaaa 60gagagctacc tggagagtc ctgcagcacc atcacagagg gctacctgtc tgtgctgaga  
120accggctggt acaccaactg gttcactg gaagtggcg acgtcgagaa tctgacatgc 180tctgatggcc ctgacctgat caagaccgag  
ctggatctga ccaagagcgc cctgagagaa 240ctcaagaccg tctgtccga tcagctggcc agagaggaac agatcgagaa tctggcagc

300ggcagctttg tgctgggagc cattgctctt ggagtggctg ctgctgcagc tgttacagca 360ggcgtggcca tcgctaagac catcagactg  
gaaagcgaag tgaccgcat caacaacgcc 420ctgaagaaga caaacgagge cgtcagcaca ctgggcaatg gcgtagagt gctggccaca  
480gccgtgctg agctgaagga ctctgtctcc aagaacctga cacgggcat taacaagaac 540aagtgccta tcgacgacct gaagatggcc  
gtgtccttta gccagtcaa ccggcggttt 600ctgaacgtcg tgcggcagtt tagcgacaac gccggaatca caccagccat cagcctggac  
660ctgatgacag atgctgagct ggctagagcc gtgcctaaca tgctacatc tgccggccag 720atcaagctga tgctcgagaa tagagccatg  
gtccgacgga aaggcttcgg cattctgatt 780ggcgtgtacg gcagcagcgt gatctatatg gtgcagctgc ctatctcgg cgtgatcgac  
840acacctgct ggattgtgaa ggccgctcct agctgtagcg agaagaaggg caattacgcc 900tgctgctga gagaggacca aggtggtat  
tgtcagaacg ccggcagcac cgtgtactac 960cctaacgaga aggactgcga gacaagagge gaccacgtgt tctgtgatac cgccgctgga  
1020atcaatgtgg ccgagcagag caaagagtgc aacatcaaca tcagcaccac caactatccc 1080tgcaaggtgt ccaccggcag gcacctatt  
tctatggtgg ctctgtctcc tctgggagcc 1140ctggtgctt gttataaggg cgtgtcctgt agcatcgcca gcaacagagt gggcatcacc  
1200aagcagctga acaagggctg cagctacatc accaaccagg acgcccagatc cgtgaccatc 1260gacaacaccg tgtatcagct gagcaaggtg  
gaaggcgaac agcacgtgat caagggcaga 1320cctgtgtcca gcagcttcca cctatcaag tccctgagg atcagttcca ggtggccctg  
1380gaccaggtgt tcgagaacat cgagaattcc caggctctgg tggaccagtc caacagaatc 1440ctgtctagcg ccgagaaggg aacaccggc  
tcatcatcg tgatcatcct gatcgccgtg 1500ctgggcagct ccatgatcct ggtgtccatc tcatcatta tcaagaagac caagaagccc  
1560accggcgtc

ctccagaact gagcggagtg accaacaatg gttcatccc tcacaac 16171231617DNAArtificial SequenceSynthetic  
Polynucleotide 123atgagctgga aggtggtcat catcttcagc ctgctgatca cacctcagca cggcctgaaa 60gagagctacc tggaagagtc  
ctgcagcacc atcacagagg gctacctgct tgtgtgaga 120accggctggt acaccaactg gttcacactg gaagtgggagc acgtcgagaa  
tctgacatgc 180tctgatggcc ctgacctgat caagaccgag ctggatctga ccaagagcgc cctgagagaa 240ctcaagaccg tgtctgccga  
tcagctggcc agagaggaac agatcgagaa tctggcagc 300ggcagctttg tgctgggagc cattgctctt ggagtggctg ctgctgcagc  
tgttacagca 360ggcgtggcca tcgctaagac catcagactg gaaagcgaag tgaccgcat caacaacgcc 420ctgaagaaga caaacgagge  
cgtcagcaca ctggcaatg gcgtagagt gctggccaca 480gccgtgctg agctgaagga ctctgtctcc aagaacctga cacgggcat  
taacaagaac 540aagtgcgaca tcgacgacct gaagatggcc gtgtccttta gccagtcaa ccggcggttt 600ctgaacgtcg tgcggcagtt  
tagcgacaac gccggaatca caccagccat cagcctggac 660ctgatgacag atgctgagct ggctagagcc gtgcctaaca tgctacatc  
tgccggccag 720atcaagctga tgctcgagaa tagagccatg gtccgacgga aaggcttcgg cattctgatt 780ggcgtgtacg gcagcagcgt  
gatctatatg gtgcagctgc ctatctcgg cgtgatcgac 840acacctgct ggattgtgaa ggccgctcct agctgtagcg agaagaaggg  
caattacgcc 900tgctgctga gagaggacca aggtggtat tgtcagaacg ccggcagcac cgtgtactac 960cctaacgaga aggactgcga  
gacaagagge gaccacgtgt tctgtgatac cgccgctgga 1020atcaatgtgg ccgagcagag caaagagtgc aacatcaaca tcagcaccac  
caactatccc 1080tgcaaggtgt ccaccggcag gcacctatt tctatggtgg ctctgtctcc tctgggagcc 1140ctggtgctt gttataaggg  
cgtgtcctgt agcatcgcca gcaacagagt gggcatcacc 1200aagcagctga acaagggctg cagctacatc accaaccagg acgcccagatc  
cgtgaccatc 1260gacaacaccg tgtatcagct gagcaaggtg gaaggcgaac agcacgtgat caagggcaga 1320cctgtgtcca gcagcttcca  
acatcaag tccctgagg atcagttcca ggtggccctg 1380gaccaggtgt tcgagaacat cgagaattcc caggctctgg tggaccagtc  
caacagaatc 1440ctgtctagcg ccgagaaggg aacaccggc tcatcatcg tgatcatcct gatcgccgtg 1500ctgggcagct ccatgatcct  
ggtgtccatc tcatcatta tcaagaagac caagaagccc 1560accggcgtc ctccagaact gagcggagtg accaacaatg gttcatccc  
tcacaac 16171241617DNAArtificial SequenceSynthetic Polynucleotide 124atgagctgga aggtggtcat catcttcagc



ctgctgatca cacctcagca cggcctgaaa 60gagagctacc tggaagagtc ctgcagcacc atcacagagg gctacctgtc tgtgctgaga  
120accggctggt acaccaactg gttcacactg gaagtgggcg acgtcgagaa tctgacatgc 180tctgatggcc ctgacctgat caagaccgag  
ctggatctga ccaagagcgc cctgagagaa 240ctcaagaccg tgtctgccga tcagctggcc agagaggaac agatcgagaa tcttggcagc  
300ggcagctttg tcttgggagc cattgctctt ggagtggctg ctgctgcagc tgttacagca 360ggcgtggcca tcgctaagac catcagactg  
gaaagcgaag tgaccgcat caacaacgcc 420ctgaagaaga caaacgaggc cgtcagcaca ctggcaatg gcgtagagt gctggccaca  
480gccgtgcgag agctgaagga ctctgttcc aagaacctga cacgggcat taacaagaac 540aagtgcgaca tcgacgacct gaagatggcc  
gtgtcctta gccagtcaa cggcggttt 600ctgaacgtcg tgcggcagtt tagcgacaac gccggaatca caccagccat cagcctggac  
660ctgatgacag atgctgagct ggctagagcc gtgcctaaca tgctacatc tgccggccag 720atcaagctga tgctcgagaa tagagccatg  
gtccgacgga aaggctcgg cattctgatt 780ggcgtgtacg gcagcagcgt gatctatatg gtgcagctgc ctatctcgg cgtgatcgac  
840acacctgct ggattgtgaa ggccgctct agctgtagcg agaagaaggg caattacgcc 900tgctgtgta gagaggacca aggtggtat  
tgtcagaacg cggcagcac cgtgtactac 960cctaacgaga aggactgcga gacaagaggc gaccacgtgt tctgtgatac cgccgctgga  
1020atcaatgtgg ccgagcagag caaagagtgc aacatcaaca tcagcaccac caactatccc 1080tgcaaggtgt ccaccggcag gcaccctatt  
tctatggtgg ctctgtctcc tctgggagcc 1140ctggtggtt gttataaggg cgtgtcctgt agcatcggca gcaacagagt gggcatcacc  
1200aagcagctga acaagggctg cagctacatc accaaccagg acgccgatac cgtgaccatc 1260gacaacaccg tttatcagct gagcaaggtg  
gaaggcgaac agcacgtgat caagggcaga 1320cctgtgtcca gcagcttcca ccctatcaag ttcctgaga accagttcca ggtggccctg  
1380gaccaggtgt tcgagaacat cgagaattcc caggctctgg tggaccagtc caacagaatc 1440ctgtctagcg ccgagaaggg aacaccggc  
ttcatcctg tgatcctct gatcgccgtg 1500ctgggcagct ccatgatcct ggtgtccatc ttcatcatta tcaagaagac caagaagccc  
1560accggcgtc ctccagaact gageggagtg accaacaatg gtttcatccc tcacaac 16171251617DNAArtificial  
SequenceSynthetic Polynucleotide 125atgagctgga aggtggtcat catcttcagc ctgctgatca cacctcagca cggcctgaaa  
60gagagctacc tggaagagtc ctgcagcacc atcacagagg gctacctgtc tgtgctgaga 120accggctggt acaccaactg gttcacactg  
gaagtgggcg acgtcgagaa tctgacatgc 180tctgatggcc ctgacctgat caagaccgag ctggatctga ccaagagcgc cctgagagaa  
240ctcaagaccg tgtctgccga tcagctggcc agagaggaac agatcgagaa tcttggcagc 300ggcagctttg tcttgggagc cattgctctt  
ggagtggctg ctgctgcagc tgttacagca 360ggcgtggcca tcgctaagac catcagactg gaaagcgaag tgaccgcat caacaacgcc  
420ctgaagaaga caaacgaggc cgtcagcaca ctggcaatg gcgtagagt gctggccaca 480gccgtgcgag agctgaagga ctctgttcc  
aagaacctga cacgggcat taacaagaac 540aagtgcgaca tcgacgacct gaagatggcc gtgtcctta gccagtcaa cggcggttt  
600ctgaacgtcg tgcggcagtt tagcgacaac gccggaatca caccagccat cagcctggac 660ctgatgacag atgctgagct ggctagagcc  
gtgcctaaca tgctacatc tgccggccag 720atcaagctga tgctcgagaa tagagccatg gtccgacgga aaggctcgg cattctgatt  
780ggcgtgtacg gcagcagcgt gatctatatg gtgcagctgc ctatctcgg cgtgatcgac 840acacctgct ggattgtgaa ggccgctct  
agctgtagcg agaagaaggg caattacgcc 900tgctgtgta gagaggacca aggtggtat tgtcagaacg cggcagcac cgtgtactac  
960cctaacgaga aggactgcga gacaagaggc gaccacgtgt tctgtgatac cgccgctgga 1020atcaatgtgg ccgagcagag caaagagtgc  
aacatcaaca tcagcaccac caactatccc 1080tgcaaggtgt ccaccggcag gcaccctatt tctatggtgg ctctgtctcc tctgggagcc  
1140ctggtggtt gttataaggg cgtgtcctgt agcatcggca gcaacagagt gggcatcacc 1200aagcagctga acaagggctg cagctacatc  
accaaccagg acgccgatac cgtgaccatc 1260gacaacaccg tttatcagct gagcaaggtg gaaggcgaac agcacgtgat caagggcaga  
1320cctgtgtcca gcagcttcca ccctatcaag ttcctcagg atcagttcca ggtggccctg 1380gaccaggtgt tcgagaacat cgagaattcc  
caggctctgg tggaccagtc caacagaatc 1440ctgtctagcg ccgagaaggg aacaccggc ttcatcctg tgatcctct gatcgccgtg  
1500ctgggcagct ccatgatcct ggtgtccatc ttcatcatta tcaagaagac caagaagccc 1560accggcgtc ctccagaact gageggagtg  
accaacaatg gtttcatccc tcacaac 16171261617DNAArtificial SequenceSynthetic Polynucleotide 126atgagctgga  
aggtggtcat catcttcagc ctgctgatca cacctcagca cggcctgaaa 60gagagctacc tggaagagtc ctgcagcacc atcacagagg  
gctacctgtc tgtgctgaga 120accggctggt acaccaactg gttcacactg gaagtgggcg acgtcgagaa tctgacatgc 180tctgatggcc  
ctgacctgat caagaccgag ctggatctga ccaagagcgc cctgagagaa 240ctcaagaccg tgtctgccga tcagctggcc agagaggaac  
agatcgagaa tcttggcagc 300ggcagctttg tcttgggagc cattgctctt ggagtggctg ctgctgcagc tgttacagca 360ggcgtggcca  
tcgctaagac catcagactg gaaagcgaag tgaccgcat caacaacgcc 420ctgaagaaga caaacgaggc cgtcagcaca ctggcaatg  
gcgtagagt gctggccaca 480gccgtgcgag agctgaagga ctctgttcc aagaacctga cacgggcat taacaagaac 540aagtgcgaca  
tcgacgacct gaagatggcc gtgtcctta gccagtggaa cggcggttt 600ctgaacgtcg tgcggcagtt tagcgacaac gccggaatca  
caccagccat cagcctggac 660ctgatgacag atgctgagct ggctagagcc gtgcctaaca tgctacatc tgccggccag 720atcaagctga  
tgctcgagaa tagagccatg gtccgacgga aaggctcgg cattctgatt 780ggcgtgtacg gcagcagcgt gatctatatg gtgcagctgc  
ctatctcgg cgtgatcgac 840acacctgct ggattgtgaa ggccgctct agctgtagcg agaagaaggg caattacgcc 900tgctgtgta  
gagaggacca aggtggtat tgtcagaacg cggcagcac cgtgtactac 960cctaacgaga aggactgcga gacaagaggc gaccacgtgt  
tctgtgatac cgccgctgga 1020atcaatgtgg ccgagcagag caaagagtgc aacatcaaca tcagcaccac caactatccc 1080tgcaaggtgt  
ccaccggcag gcaccctatt tctatggtgg ctctgtctcc tctgggagcc 1140ctggtggtt gttataaggg cgtgtcctgt agcatcggca  
gcaacagagt gggcatcacc 1200aagcagctga acaagggctg cagctacatc accaaccagg acgccgatac cgtgaccatc  
1260gacaacaccg tttatcagct gagcaaggtg gaaggcgaac agcacgtgat caagggcaga 1320cctgtgtcca gcagcttcca ccctatcaag  
ttcctgagg atcagttcca ggtggccctg 1380gaccaggtgt tcgagaacat cgagaattcc caggctctgg tggaccagtc caacagaatc  
1440ctgtctagcg ccgagaaggg aacaccggc ttcatcctg tgatcctct gatcgccgtg 1500ctgggcagct ccatgatcct ggtgtccatc

ttcatcatta tcaagaagac caagaagccc 1560accggcgctc ctccagaact gageggagtg accaacaatg gttcatccc tcacaac  
16171271617RNAArtificial SequenceSynthetic Polynucleotide 127augagcugga agguggucau caucuucagc  
cugcugauca caccucagca cgccugaaa 60gagagcuacc uggaagaguc cugcagcacc aucacagagg gcuaccuguc ugugcugaga  
120accggcuggu acaccaacgu guucacacug gaagugggcg acgucgagaa ucugacaugc 180ucugauggcc cuagccugau  
caagaccgag cuggaucuga ccaagagcgc ccugagagaa 240cucaagaccg ugucugcccga ucagcuggcc agagaggaac  
agaucgagaa uccuggcagc 300ggcagcuuug ugcugggagc cauugcucu gtaguggcug cugcugcagc uguuacagca  
360ggcguggcca ucugcaagac caucagacug gaaagcgaag ugaccgccau caacaacgcc 420cugaagaaga caaacgaggc  
cgucagcaca cucggcaaug gcguuagagu gcuggccuuu 480gccgugcgcg agcugaagga cuucgugucc aagaaccuga  
cacgggccu gaacaagaac 540aagugcgaca ucgacgaccu gaagauggcc guguccuuua gccaguuaa ccggcgguuu  
600cugaacgucg ugcggcaguu uagcgacaac gccggaauca caccagccau cagccuggac 660cugaugacag augcugagcu  
ggcuagagcc gugccuaaca ugccuacauc ugccggccag 720aucaagcuga ugcucgagaa uagagccaug guccgacgga  
aaggcuucgg cauucugugu 780ggcguguacg gcagcagcgu gaucuaauaug gucgagcugc cuaucucgg cgugaucgac  
840acaccugcu ggauugugaa ggccgucucu agcuguagcg agaagaagg cauuacgcc 900ugccugcuga gagaggacca  
aggcugguau ugucagaacg ccggcagcac cguguacuac 960ccuaacgaga aggacugcga gacaagaggc gaccacgugu  
ucugugauac cgccgucugga 1020aucaaugugg ccgagcagag caaagagucg aacaucaca ucagcaccac caucuauc  
1080ugcaaggugu ccaccggcag gcaccuauu ucuauggugg cucugucucc ucugggagcc 1140cugguggcuu guuuaagg  
cguguccugu agcaucggca gcaacagagu gggcaucauc 1200aagcagcuga acaaggcgug cagcuacauc accaaccagg  
acgccgauac cgugaccauc 1260gacaacaccg uguaucagcu gagcaaggug gaaggcgaac agcacgugau caaggcgaga  
1320ccugugucca gcagcuucga ccuaucuaag uuccugagc aucaguuaa cguggccug 1380gaccaggugu ucgagaacau  
cgagaauucc caggcucugg uggaccaguc caacagauc 1440cugucuagcg ccgagaagg aaacaccggc uucaucaucg  
ugaucauccu gaucgccgug 1500cugggcagcu ccaugauccu gguguccauc uucaucaua ucaagaagac caagaagccc  
1560accggcguc cuccagaacu gageggagug accaacaug gcuucaucc ucacaac 16171281617RNAArtificial  
SequenceSynthetic Polynucleotide 128augagcugga agguggucau caucuucagc cugcugauca caccucagca cgccugaaa  
60gagagcuacc uggaagaguc cugcagcacc aucacagagg gcuaccuguc ugugcugaga 120accggcuggu acaccaacgu  
guucacacug gaagugggcg acgucgagaa ucugacaugc 180ucugauggcc cuagccugau caagaccgag cuggaucuga  
ccaagagcgc ccugagagaa 240cucaagaccg ugucugcccga ucagcuggcc agagaggaac agaucgagaa uccuggcagc  
300ggcagcuuug ugcugggagc cauugcucu gtaguggcug cugcugcagc uguuacagca 360ggcguggcca ucugcaagac  
caucagacug gaaagcgaag ugaccgccau caacaacgcc 420cugaagaaga caaacgaggc cgucagcaca cucggcaaug  
gcguuagagu gcuggccaca 480gccgugcgcg agcugaagga cuucgugucc aagaaccuga cacgggccau uaacaagaac  
540aagugcgaca ucgacgaccu gaagauggcc guguccuuua gccaguuaa ccggcgguuu 600cugaacgucg ugcggcaguu  
uagcgacaac gccggaauca caccagccau cagccuggac 660cugaugacag augcugagcu ggcuagagcc gugccuaaca  
ugccuacauc ugccggccag 720aucaagcuga ugcucgagaa uagagccaug guccgacgga aaggcuucgg cauucugugu  
780ggcguguacg gcagcagcgu gaucuaauaug gucgagcugc cuaucucgg cgugaucgac 840acaccugcu ggauugugaa  
ggccgucucu agcuguagcg agaagaagg cauuacgcc 900ugccugcuga gagaggacca aggcugguau ugucagaacg  
ccggcagcac cguguacuac 960ccuaacgaga aggacugcga gacaagaggc gaccacgugu ucugugauac cgccgucugga  
1020aucaaugugg ccgagcagag caaagagucg aacaucaca ucagcaccac caucuauc 1080ugcaaggugu ccaccggcag  
gcaccuauu ucuauggugg cucugucucc ucugggagcc 1140cugguggcuu guuuaagg cguguccugu agcaucggca  
gcaacagagu gggcaucauc 1200aagcagcuga acaaggcgug cagcuacauc accaaccagg acgccgauac cgugaccauc  
1260gacaacaccg uguaucagcu gagcaaggug gaaggcgaac agcacgugau caaggcgaga 1320ccugugucca gcagcuucga  
ccuaucuaag uuccugagc accaguggca uguggccug 1380gaccaggugu ucgagaacau cgagaauucc caggcucugg  
uggaccaguc caacagauc 1440cugucuagcg ccgagaagg aaacaccggc uucaucaucg ugaucauccu gaucgccgug  
1500cugggcagcu ccaugauccu gguguccauc uucaucaua ucaagaagac caagaagccc 1560accggcguc cuccagaacu  
gagcggagug accaacaug gcuucaucc ucacaac 16171291617RNAArtificial SequenceSynthetic Polynucleotide  
129augagcugga agguggucau caucuucagc cugcugauca caccucagca cgccugaaa 60gagagcuacc uggaagaguc  
cugcagcacc aucacagagg gcuaccuguc ugugcugaga 120accggcuggu acaccaacgu guucacacug gaagugggcg  
acgucgagaa ucugacaugc 180ucugauggcc cuagccugau caagaccgag cuggaucugc ucaagagcgc ccugagagaa  
240cucaagaccg ugucugcccga ucagcuggcc agagaggaac agaucgagaa uccuggcagc 300ggcagcuuug ugcugggagc  
cauugcucu gtaguggcug cugcugcagc uguuacagca 360ggcguggcca ucgcaagac caucagacug gaaagcgaag  
ugaccgccau caacaacgcc 420cugaagaaga caaacgaggc cgucagcaca cucggcaaug gcguuagagu gcuggccaca  
480gccgugcgcg agcugaagga cuucgugucc aagaaccuga cacgggccau uaacaagaac 540aagugcgaca uccugaccu  
gaagauggcc guguccuuua gccaguuaa ccggcgguuu 600cugaacgucg ugcggcaguu uagcgacaac gccggaauca  
caccagccau cagccuggac 660cugaugacag augcugagcu ggcuagagcc gugccuaaca ugccuacauc ugccggccag  
720aucaagcuga ugcucgagaa uagagccaug guccgacgga aaggcuucgg cauucuguu 780ggcguguacg gcagcagcgu  
gaucuaauaug gucgagcugc cuaucucgg cgugaucgac 840acaccugcu ggauugugaa ggccgucucu agcuguagcg

agaagaaggg cauuuacgcc 900ugccugcuga gagaggacca aggcugguau ugucagaacg ccggcagcac cguguacuac  
960ccuaacgaga aggacugcga gacaagaggc gaccacgugu ucugugauac cgccgcugga 1020aucaaugugg ccgagcagag  
caaagagugc acaucaaca ucagcaccac caacuauc 1080ugcaaggugu ccaccggcag gcaccuauu ucuauggugg  
cucugucucc ucugggagcc 1140cuggugguu guuauaaggg cguguccugu agcaucggca gcaacagagu gggcaucauc  
1200aagcagcuga acaagggcug cagcuacauc accaaccagg acgccgauac cgugaccauc 1260gacaacaccg uguaucagcu  
gagcaaggug gaaggcgaac agcacgugau caagggcaga 1320ccugugucca gcagcuucga ccuaucaag uuccugagg  
aucaguucca gguggcccug 1380gaccaggugu ucgagaacau cgagaauucc caggcucugg uggaccaguc caacagauc  
1440cugucuagcg ccgagaaggg aaacaccggc uucaucaucg ugaucuccu gaucgccgug 1500cugggcagcu ccaugauccu  
gguguccauc uucaucauu ucaagaagac caagaagccc 1560accggcgcuc cuccagaacu gagcggagug accaacaug  
gcuucaucc ucacaac 16171301617RNAArtificial SequenceSynthetic Polynucleotide 130augagcugga  
aggugguau caucuucagc cugcugauca caccucagca cggccugaaa 60gagagcuacc uggaagaguc cugcagcacc aucacagagg  
gcuaccuguc ugucugaga 120accggcuggu acaccaacgu guucacacug gaagugggagc agucgagaa ucugacaugc  
180ucugauggcc cuagccugau caagaccgag cuggaucugc ucaagagcgc ccugagagaa 240cucaagaccg ugucugccga  
ucagcuggcc agagaggaac agaucgagaa uccuggcagc 300ggcagcuuug ugcugggagc cauugcucu ggaguggcug  
cugcugcagc uguuacagca 360ggcguggcca ucgcuagac caucagacug gaaagcgaag ugaccgccau caacaacgcc  
420cugaagaaga caaacgagc cgucagcaca cucggcaaug gcguuagagu gcuggccaca 480gccgucgagc agcugaagga  
cuucgugucc aagaaccuga cacgggccau uacaagaac 540aagugcgaca uccugaccu gaagauggcc guguccuuu  
gccaguucca ccggcgguu 600cugaacgucg ugcggcaguu uagcgacaac gccggaauca caccagccau cagccuggac  
660cugaugacag augcugagcu ggcuagagcc gugccuaaca ugccuacauc ugccggccag 720aucaagcuga ugcucgagaa  
uagagccaug guccgacgga aagguucgg cauucugauu 780ggcguguacg gcagcagcgu gaucauauug gucgagcugc  
cuauucgg cgugaucgac 840acaccugcu ggauugugaa ggccguccu agcuguagcg agaagaaggg cauuacgcc  
900ugccugcuga gagaggacca aggcugguau ugucagaacg ccggcagcac cguguacuac 960ccuaacgaga aggacugcga  
gacaagaggc gaccacgugu ucugugauac cgccgcugga 1020aucaaugugg ccgagcagag caaagagugc acaucaaca  
ucagcaccac caacuauc 1080ugcaaggugu ccaccggcag gcaccuauu ucuauggugg cucugucucc ucugggagcc  
1140cuggugguu guuauaaggg cguguccugu agcaucggca gcaacagagu gggcaucauc 1200aagcagcuga acaagggcug  
cagcuacauc accaaccagg acgccgauac cgugaccauc 1260gacaacaccg uguaucagcu gagcaaggug gaaggcgaac  
agcacgugau caagggcaga 1320ccugugucca gcagcuucga ccuaucaag uuccugaga accaguucca gguggcccug  
1380gaccaggugu ucgagaacau cgagaauucc caggcucugg uggaccaguc caacagauc 1440cugucuagcg ccgagaaggg  
aaacaccggc uucaucaucg ugaucuccu gaucgccgug 1500cugggcagcu ccaugauccu gguguccauc uucaucauu  
ucaagaagac caagaagccc 1560accggcgcuc cuccagaacu gagcggagug accaacaug gcuucaucc ucacaac  
16171311617RNAArtificial SequenceSynthetic Polynucleotide 131augagcugga aggugguau caucuucagc  
cugcugauca caccucagca cggccugaaa 60gagagcuacc uggaagaguc cugcagcacc aucacagagg gcuaccuguc ugucugaga  
120accggcuggu acaccaacgu guucacacug gaagugggagc agucgagaa ucugacaugc 180ucugauggcc cuagccugau  
caagaccgag cuggaucugc ucaagagcgc ccugagagaa 240cucaagaccg ugucugccga ucagcuggcc agagaggaac  
agaucgagaa uccuggcagc 300ggcagcuuug ugcugggagc cauugcucu ggaguggcug cugcugcagc uguuacagca  
360ggcguggcca ucgcuagac caucagacug gaaagcgaag ugaccgccau caacaacgcc 420cugaagaaga caaacgagc  
cgucagcaca cucggcaaug gcguuagagu gcuggccaca 480gccgucgagc agcugaagga cuucgugcuu aagaaccuga  
cacgggccau uacaagaac 540aagugcgaca uccugaccu gaagauggcc guguccuuu gccaguucca ccggcgguu  
600cugaacgucg ugcggcaguu uagcgacaac gccggaauca caccagccau cagccuggac 660cugaugacag augcugagcu  
ggcuagagcc gugccuaaca ugccuacauc ugccggccag 720aucaagcuga ugcucgagaa uagagccaug guccgacgga  
aagguucgg cauucugauu 780ggcguguacg gcagcagcgu gaucauauug gucgagcugc cuauucgg cgugaucgac  
840acaccugcu ggauugugaa ggccguccu agcuguagcg agaagaaggg cauuacgcc 900ugccugcuga gagaggacca  
aggcugguau ugucagaacg ccggcagcac cguguacuac 960ccuaacgaga aggacugcga gacaagaggc gaccacgugu  
ucugugauac cgccgcugga 1020aucaaugugg ccgagcagag caaagagugc acaucaaca ucagcaccac caacuauc  
1080ugcaaggugu ccaccggcag gcaccuauu ucuauggugg cucugucucc ucugggagcc 1140cuggugguu guuauaaggg  
cguguccugu agcaucggca gcaacagagu gggcaucauc 1200aagcagcuga acaagggcug cagcuacauc accaaccagg  
acgccgauac cgugaccauc 1260gacaacaccg uguaucagcu gagcaaggug gaaggcgaac agcacgugau caagggcaga  
1320ccugugucca gcagcuucga ccuaucaag uuccugagg aucaguucca gguggcccug 1380gaccaggugu ucgagaacau  
cgagaauucc caggcucugg uggaccaguc caacagauc 1440cugucuagcg ccgagaaggg aaacaccggc uucaucaucg  
ugaucuccu gaucgccgug 1500cugggcagcu

ccaugauccu gguguccauc uucaucauu ucaagaagac caagaagccc 1560accggcgcuc cuccagaacu gagcggagug  
accaacaug gcuucaucc ucacaac 16171321617RNAArtificial SequenceSynthetic Polynucleotide 132augagcugga  
aggugguau caucuucagc cugcugauca caccucagca cggccugaaa 60gagagcuacc uggaagaguc cugcagcacc aucacagagg

gcuaccuguc ugugcugaga 120accggcuggu acaccaacgu guacacacug gaagugggagc acgucgagaa ucugacaugc  
180ucugauggcc cuagccugau caagaccgag cuggaucugc ucaagagcgc ccugagagaa 240cucaagaccg ugucugccga  
ucagcuggcc agagaggaac agaucgagaa uccuggcagc 300ggcagcuuug ugcugggagc cauugcucu gtaguggcug  
cugcugcagc uguuacagca 360ggcguggcca ucgcuagac caucagacug gaaagcgaag ugaccgccau caacaacgcc  
420cugaagaaga caaacgagc cgucagcaca cucggcaaug gcguuagagu gcuggccaca 480gccgugcgcg agcugaagga  
cuucgugcuu aagaaccuga cacgggccau uaacaagaac 540aagugcgaca ucccugaccu gaagauggcc guguccuuua  
gccaguuaa ccggcgguuu 600cugaacgucg ugcggcaguu uagcgacaac gccggaauca caccagccau cagccuggac  
660cugaugacag augcugagcu ggcuagagcc gugccuaaca ugccuacauc ugccggccag 720aucaagcuga ugcucgagaa  
uagagccaug guccgacgga aagguucgg cauucugauu 780ggcguguacg gcagcagcgu gaucauauug gucgagcugc  
cuauucgg cgugaucgac 840acaccugcu ggauugugaa ggccgucucu agcuguagcg agaagaaggg cauuacgcc  
900ugccugcuga gagaggacca aggcugguau ugucagaacg ccggcagcac cguguacuac 960ccuaacgaga aggacugcga  
gacaagaggc gaccagugu ucugugauac cgccgucgga 1020aucaaugugg ccgagcagag caaagaguc aacaaca  
ucagcaccac caacuaucc 1080ugcaaggugu ccaccggcag gcaccuauu ucuauuggg cucugucucc ucugggagcc  
1140cuggugcucu guuauaaggg cguguccugu agcaucggca gcaacagagu gggcauauc 1200aagcagcuga acaaggcug  
cagcuacauc accaaccagg acgccgauac cgugaccauc 1260gacaacaccg uguauacgcu gagcaaggug gaaggcgaac  
agcagugau caagggcaga 1320ccugugucca gcagcuucga ccuaucaag ucccugaga accaguucca gguggccug  
1380gaccaggugu ucgagaacau cgagaaucc caggcucugg ugaccaguc caacagauc 1440cugucuagcg ccgagaaggg  
aaacaccggc uucauauugc ugaucuccu gaucgcccug 1500cugggagcu ccaugauccu gguguccauc uucauauua  
ucaagaagac caagaagccc 1560accggcgcuc succagaacu gaggcgagug accaacaug gcuuaucc ucacaac  
16171331617RNAArtificial SequenceSynthetic Polynucleotide 133augagcugga agguggucau cauucagc  
cugcugauca caccucagca cggccugaaa 60gagagcuacc uggaagaguc cugcagcacc aucacagagg gcuaccuguc ugugcugaga  
120accggcuggu acaccaacgu guacacacug ccugugggagc acgucgagaa ucugacaugc 180ucugauggcc cuagccugau  
caagaccgag cuggaucugc ucaagagcgc ccugagagaa 240cucaagaccg ugucugccga ucagcuggcc agagaggaac  
agaucgagaa uccuggcagc 300ggcagcuuug ugcugggagc cauugcucu gtaguggcug cugcugcagc uguuacagca  
360ggcguggcca ucgcuagac caucagacug gaaagcgaag ugaccgccau caacaacgcc 420cugaagaaga caaacgagc  
cgucagcaca cucggcaaug gcguuagagu gcuggccaca 480gccgugcgcg agcugaagga cuucgugucc aagaaccuga  
cacgggccau uaacaagaac 540aagugcgaca ucgacgaccu gaagauggcc guguccuuua gccaguuaa ccggcgguuu  
600cugaacgucg ugcggcaguu uagcgacaac gccggaauca caccagccau cagccuggac 660cugaugacag augcugagcu  
ggcuagagcc gugccuaaca ugccuacauc ugccggccag 720aucaagcuga ugcucgagaa uagagccaug guccgacgga  
aagguucgg cauucugauu 780ggcguguacg gcagcagcgu gaucauauug gucgagcugc cuauucgg cgugaucgac  
840acaccugcu ggauugugaa ggccgucucu agcuguagcg agaagaaggg cauuacgcc 900ugccugcuga gagaggacca  
aggcugguau ugucagaacg ccggcagcac cguguacuac 960ccuaacgaga aggacugcga gacaagaggc gaccagugu  
ucugugauac cgccgucgga 1020aucaaugugg ccgagcagag caaagaguc aacaaca ucagcaccac caacuaucc  
1080ugcaaggugu ccaccggcag gcaccuauu ucuauuggg cucugucucc ucugggagcc 1140cuggugcucu guuauaaggg  
cguguccugu agcaucggca gcaacagagu gggcauauc 1200aagcagcuga acaaggcug cagcuacauc accaaccagg  
acgccgauac cgugaccauc 1260gacaacaccg uguauacgcu gagcaaggug gaaggcgaac agcagugau caagggcaga  
1320ccugugucca gcagcuucga ccuaucaag ucccugagg aucaguucca gguggccug 1380gaccaggugu ucgagaacau  
cgagaaucc caggcucugg ugaccaguc caacagauc 1440cugucuagcg ccgagaaggg aaacaccggc uucauauugc  
ugaucuccu gaucgcccug 1500cugggagcu ccaugauccu gguguccauc uucauauua ucaagaagac caagaagccc  
1560accggcgcuc succagaacu gaggcgagug accaacaug gcuuaucc ucacaac 16171341617RNAArtificial  
SequenceSynthetic Polynucleotide 134augagcugga agguggucau cauucagc cugcugauca caccucagca cggccugaaa  
60gagagcuacc uggaagaguc cugcagcacc aucacagagg gcuaccuguc ugugcugaga 120accggcuggu acaccaacgu  
guacacacug ccugugggagc acgucgagaa ucugacaugc 180ucugauggcc cuagccugau caagaccgag cuggaucugc  
ucaagagcgc ccugagagaa 240cucaagaccg ugucugccga ucagcuggcc agagaggaac agaucgagaa uccuggcagc  
300ggcagcuuug ugcugggagc cauugcucu gtaguggcug cugcugcagc uguuacagca 360ggcguggcca ucgcuagac  
caucagacug gaaagcgaag ugaccgccau caacaacgcc 420cugaagaaga caaacgagc cgucagcaca cucggcaaug  
gcguuagagu gcuggccaca 480gccgugcgcg agcugaagga cuucgugucc aagaaccuga cacgggccau uaacaagaac  
540aagugcgaca ucgacgaccu gaagauggcc guguccuuua gccaguuaa ccggcgguuu 600cugaacgucg ugcggcaguu  
uagcgacaac gccggaauca caccagccau cagccuggac 660cugaugacag augcugagcu ggcuagagcc gugccuaaca  
ugccuacauc ugccggccag 720aucaagcuga ugcucgagaa uagagccaug guccgacgga aagguucgg cauucugauu  
780ggcguguacg gcagcagcgu gaucauauug gucgagcugc cuauucgg cgugaucgac 840acaccugcu ggauugugaa  
ggccgucucu agcuguagcg agaagaaggg cauuacgcc 900ugccugcuga gagaggacca aggcugguau ugucagaacg  
ccggcagcac cguguacuac 960ccuaacgaga aggacugcga gacaagaggc gaccagugu ucugugauac cgccgucgga  
1020aucaaugugg ccgagcagag caaagaguc aacaaca ucagcaccac caacuaucc 1080ugcaaggugu ccaccggcag

gcaccuauu ucuauggugg cucugucucc ucugggagcc 1140cugguggcuu guuauaaggg cguguccugu agcaucggca  
gcaacagagu gggcaucauc 1200aagcagcuga acaagggcug cagcuacauc accaaccagg acgccgauac cgugaccauc  
1260gacaacaccg uguaucagcu gagcaaggug gaaggcgaac agcacgugau caagggcaga 1320ccugugucca gcagcuucga  
ccuaucaag uuccugaga accaguucca gguggccug 1380gaccaggugu ucgagaacau cgagaauucc caggcucugg  
uggaccaguc caacagauc 1440cugucuagcg ccgagaaggg aaacaccggc uucaucaucg ugaucuccu gaucgccgug  
1500cugggcagcu ccaugaucuu gguguccauc uucaucauu ucaagaagac caagaagccc 1560accggcgcuc cuccagaacu  
gagcggagug accaacaug gcuucaucc ucacaac 16171351617RNAArtificial SequenceSynthetic Polynucleotide  
135augagcugga agguggucau caucuucagc cugcugauca caccucagca cggccugaaa 60gagagcuacc uggaagaguc  
cugcagcacc aucacagagg gcuaccuguc ugugcugaga 120accggcuggu acaccaacgu guucacacug gaagugggcg  
acgucgagaa ucugacaugc 180ucugauggcc cuagccugau caagaccgag cuggaucugc ucaagagcgc ccugagagaa  
240cucaagaccg ugucugccga ucagcuggcc agagaggaac agaucgagaa uccuggcagc 300ggcagcuuug ugcugggagc  
cauugcucuu ggaguggcug cugcugcagc uguuacagca 360ggcugggcca ucgcuaagac caucagacug gaaagcgaag  
ugaccgccau caacaacgcc 420cugaagaaga caaacgaggc cgucagcaca cucggcaaug gcguuagagu gcuggccaca  
480gccgugcgcg agcugaagga cuucgugucc aagaaccuga cacgggccau uaacaagaac 540aagugcgaca ucgacgaccu  
gaagauggcc guguccuuu gccaguucua ccggcgguuu 600cugaacgucg ugcggcaguu uagcgacaac gccggaauca  
caccagccau cagccuggac 660cugaugacag augcugagcu ggcuagagcc gugccuaaca ugccuacauc ugccggccag  
720aucaagcuga ugcucgagaa uagagccaug guccgacgga aagguucgg cauucugauu 780ggcguguacg gcagcagcgu  
gaucuauaug gugcagcugc cuauucgg cgugaucgac 840acaccugcu ggauugugaa ggccgucuu agcuguagcg  
agaagaaggg cauuacgcc 900ugccugcuga gagaggacca aggcugguau ugucagaacg ccggcagcac cguguacuac  
960ccuaacgaga aggacugcga gacaagaggc gaccagugu ucugugauac cgccgucgga 1020aucaaugugg ccgagcagag  
caaagaguc aacaucaca ucagcaccac caacuauccc 1080ugcaaggugu ccaccggcag gcaccuauu ucuauggugg  
cucugucucc ucugggagcc 1140cugguggcuu guuauaaggg cguguccugu agcaucggca gcaacagagu gggcaucauc  
1200aagcagcuga acaagggcug cagcuacauc accaaccagg acgccgauac cgugaccauc 1260gacaacaccg uguaucagcu  
gagcaaggug gaaggcgaac agcacgugau caagggcaga 1320ccugugucca gcagcuucga ccuaucaag uuccugagg  
aucaguucca gguggccug 1380gaccaggugu ucgagaacau cgagaauucc caggcucugg uggaccaguc caacagauc  
1440cugucuagcg ccgagaaggg aaacaccggc uucaucaucg ugaucuccu gaucgccgug 1500cugggcagcu ccaugaucuu  
gguguccauc uucaucauu ucaagaagac caagaagccc 1560accggcgcuc cuccagaacu gagcggagug accaacaug  
gcuucaucc ucacaac 16171361617RNAArtificial SequenceSynthetic Polynucleotide 136augagcugga  
agguggucau caucuucagc cugcugauca caccucagca cggccugaaa 60gagagcuacc uggaagaguc cugcagcacc aucacagagg  
gcuaccuguc ugugcugaga 120accggcuggu acaccaacgu guucacacug gaagugggcg accucgagaa ucugacaugc  
180ucugauggcc cuagccugau caagaccgag cuggaucuga ccaagagcgc ccugagagaa 240cucaagaccg ugucugccga  
ucagcuggcc agagaggaac agaucgagaa uccuggcagc 300ggcagcuuug ugcugggagc cauugcucuu ggaguggcug  
cugcugcagc uguuacagca 360ggcugggcca ucgcuaagac caucagacug gaaagcgaag ugaccgccau caacaacgcc  
420cugaagaaga caaacgaggc cgucagcaca cucggcaaug gcguuagagu gcuggccaca 480gccgugcgcg agcugaagga  
cuucgugucc aagaaccuga cacgggccau uaacaagaac 540aagugcgaca ucgacgaccu gaagauggcc guguccuuu  
gccaguucua ccggcgguuu 600cugaacgucg ugcggcaguu uagcgacaac gccggaauca caccagccau cagccuggac  
660cugaugacag augcugagcu ggcuagagcc gugccuaaca ugccuacauc ugccggccag 720aucaagcuga ugcucgagaa  
uagagccaug guccgacgga aagguucgg cauucugauu 780ggcguguacg gcagcagcgu gaucuauaug gugcagcugc  
cuauucgg cgugaucgac 840acaccugcu ggauugugaa ggccgucuu agcuguagcg agaagaaggg cauuacgcc  
900ugccugcuga gagaggacca aggcugguau ugucagaacg ccggcagcac cguguacuac 960ccuaacgaga aggacugcga  
gacaagaggc gaccagugu ucugugauac cgccgucgga 1020aucaaugugg ccgagcagag caaagaguc aacaucaca  
ucagcaccac caacuauccc 1080ugcaaggugu ccaccggcag gcaccuauu ucuauggugg cucugucucc ucugggagcc  
1140cugguggcuu guuauaaggg cguguccugu agcaucggca gcaacagagu gggcaucauc 1200aagcagcuga acaagggcug  
cagcuacauc accaaccagg acgccgauac cgugaccauc 1260gacaacaccg uguaucagcu gagcaaggug gaaggcgaac  
agcacgugau caagggcaga 1320ccugugucca gcagcuucga ccuaucaag uuccugagg aucaguucca gguggccug  
1380gaccaggugu ucgagaacau cgagaauucc caggcucugg uggaccaguc caacagauc 1440cugucuagcg ccgagaaggg  
aaacaccggc uucaucaucg ugaucuccu gaucgccgug 1500cugggcagcu ccaugaucuu gguguccauc uucaucauu  
ucaagaagac caagaagccc 1560accggcgcuc cuccagaacu gagcggagug accaacaug gcuucaucc ucacaac  
16171371617RNAArtificial SequenceSynthetic Polynucleotide 137augagcugga agguggucau caucuucagc  
cugcugauca caccucagca cggccugaaa 60gagagcuacc uggaagaguc cugcagcacc aucacagagg gcuaccuguc ugugcugaga  
120accggcuggu acaccaacgu guucacacug gaagugggcg acgucgagaa ucugacaugc 180ucugauggcc cuagccugau  
caagaccgag cuggaucuga ccaagagcgc ccugagagaa 240cucaagaccg ugucugccga ucagcuggcc agagaggaac  
agaucgagaa uccuggcagc 300ggcagcuuug ugcugggagc cauugcucuu ggaguggcug cugcugcagc uguuacagca  
360ggcugggcca ucgcuaagac caucagacug gaaagcgaag ugaccgccau caacaacgcc 420cugaagaaga caaacgagc

cgucagcaca cucggcaaug gCGUuagagu gcuggccaca 480gccgugcgcg agcugaagga cuucgugcuu aagaaccuga  
cacgggccaau uaacaagaac 540aagugcgaca ucgacgaccu gaagauggcc guguccuuua gccaguuaa cggcgguuu  
600cugaacgucg ugcggcaguu uagcgacaac gccggaauca caccagccau cagccuggac 660cugaugacag augcugagcu  
ggcuagagcc gugccuaaca ugccuacauc ugccggccag 720aucaagcuga ugcucgagaa uagagccaug guccgacgga  
aaggcuucgg cauucugauu 780ggcguguacg gcagcagcgu gaucauauug gucgagcugc cuaucuucgg cgugaucgac  
840acaccugcu ggauugugaa ggccgcuccu agcuguagcg agaagaaggg cauuuacgcc 900ugccugcuga gagaggacca  
aggcugguau ugucagaacg cggcgagcac cguguacuac 960ccuaacgaga aggacugcga gacaagaggc gaccacgugu  
ucugugauac cgccgcugga 1020aucaaugugg ccgagcagag caaagagugc aacaucaca ucagcaccac caacuaucc  
1080ugcaaggugu ccaccggcag gcaccuauu ucuauuggug cucugucucc ucugggagcc 1140cugguggcuu guuuaaggg  
cguguccugu agcaucggca gcaacagagu gggcaucauc 1200aagcagcuga acaagggcug cagcuacauc accaaccagg  
acgccgauac cgugaccauc 1260gacaacaccg uguaucagcu gagcaaggug gaaggcgaac agcacugau caagggcaga  
1320ccugugucca gcagcuucga ccuaucaag uuccugagg aucaguucca gguggccug 1380gaccaggugu ucgagaacau  
cgagaauucc caggcucugg uggaccaguc caacagauc 1440cugucuagcg ccgagaaggg aaacaccggc uucaucaucg  
ugaucauccu gaucgccgug 1500cugggcagcu ccaugauccu gguguccauc uucaucaua ucaagaagac caagaagccc  
1560accggcgcuc cuccagaacu gageggagug accaacaug gcuucaucc ucacaac 16171381617RNAArtificial  
SequenceSynthetic Polynucleotide 138augagcugga aggugguau caucuucagc cugcugauca caccucagca cggccugaaa  
60gagagcuacc uggaagaguc cugcagcacc aucacagagg gcuaccuguc ugugcugaga 120accggcuggu acaccaacgu  
guacacacug gaaguggcg agcugcagaa ucugacaugc 180ucugauggcc cuagccugau caagaccgag cuggaucuga  
ccaagagegc ccugagagaa 240cucaagaccg ugucugcccga ucagcuggcc agagaggaac agaucgagaa uccuggcagc  
300ggcagcuuug ugcugggagc cauugcucu ggaguggcug cugcugcagc uguuacagca 360ggcguggcca ucgcuagac  
caucagacug gaaagcgaag ugaccgccau caacaacgcc 420cugaagaaga caaacgaggc cgucagcaca cucggcaaug  
gCGUuagagu gcuggccaca 480gccgugcgcg agcugaagga cuucgugucc aagaaccugu ggcgggccaau uaacaagaac  
540aagugcgaca ucgacgaccu gaagauggcc guguccuuua gccaguuaa cggcgguuu 600cugaacgucg ugcggcaguu  
uagcgacaac gccggaauca caccagccau cagccuggac 660cugaugacag augcugagcu ggcuagagcc gugccuaaca  
ugccuacauc ugccggccag 720aucaagcuga ugcucgagaa uagagccaug guccgacgga aaggcuucgg cauucugauu  
780ggcguguacg gcagcagcgu gaucauauug gucgagcugc cuaucuucgg cgugaucgac 840acaccugcu ggauugugaa  
ggccgcuccu agcuguagcg agaagaaggg cauuuacgcc 900ugccugcuga gagaggacca aggcugguau ugucagaacg  
cggcgagcac cguguacuac 960ccuaacgaga aggacugcga gacaagaggc gaccacgugu ucugugauac cgccgcugga  
1020aucaaugugg ccgagcagag caaagagugc aacaucaca ucagcaccac caacuaucc 1080ugcaaggugu ccaccggcag  
gcaccuauu ucuauuggug cucugucucc ucugggagcc 1140cugguggcuu guuuaaggg cguguccugu agcaucggca  
gcaacagagu gggcaucauc 1200aagcagcuga acaagggcug cagcuacauc accaaccagg acgccgauac cgugaccauc  
1260gacaacaccg uguaucagcu gagcaaggug gaaggcgaac agcacugau caagggcaga 1320ccugugucca gcagcuucga  
ccuaucaag uuccugagg aucaguucca gguggccug 1380gaccaggugu ucgagaacau cgagaauucc caggcucugg  
uggaccaguc caacagauc 1440cugucuagcg ccgagaaggg aaacaccggc uucaucaucg ugaucauccu gaucgccgug  
1500cugggcagcu ccaugauccu gguguccauc uucaucaua ucaagaagac caagaagccc 1560accggcgcuc cuccagaacu  
gagcggagug accaacaug gcuucaucc ucacaac 16171391617RNAArtificial SequenceSynthetic Polynucleotide  
139augagcugga aggugguau caucuucagc cugcugauca caccucagca cggccugaaa 60gagagcuacc uggaagaguc  
cugcagcacc aucacagagg gcuaccuguc ugugcugaga 120accggcuggu acaccaacgu guacacacug gaaguggcg  
accucgagaa ucugacaugc 180ucugauggcc cuagccugau caagaccgag cuggaucugc ucaagagcgc ccugagagaa  
240cucaagaccg ugucugcccga ucagcuggcc agagaggaac agaucgagaa uccuggcagc 300ggcagcuuug ugcugggagc  
cauugcucu ggaguggcug cugcugcagc uguuacagca 360ggcguggcca ucgcuagac caucagacug gaaagcgaag  
ugaccgccau caacaacgcc 420cugaagaaga caaacgaggc cgucagcaca cucggcaaug gCGUuagagu gcuggccaca  
480gccgugcgcg agcugaagga cuucgugcuu aagaaccugu ggcgggccaau uaacaagaac 540aagugcgaca ucgacgaccu  
gaagauggcc guguccuuua gccaguuaa cggcgguuu 600cugaacgucg ugcggcaguu uagcgacaac gccggaauca  
caccagccau cagccuggac 660cugaugacag augcugagcu ggcuagagcc gugccuaaca ugccuacauc ugccggccag  
720aucaagcuga ugcucgagaa uagagccaug guccgacgga aaggcuucgg cauucugauu 780ggcguguacg gcagcagcgu  
gaucauauug gucgagcugc cuaucuucgg cgugaucgac 840acaccugcu ggauugugaa ggccgcuccu agcuguagcg  
agaagaaggg cauuuacgcc 900ugccugcuga gagaggacca aggcugguau ugucagaacg cggcgagcac cguguacuac  
960ccuaacgaga aggacugcga gacaagaggc gaccacgugu ucugugauac cgccgcugga 1020aucaaugugg ccgagcagag  
caaagagugc aacaucaca ucagcaccac caacuaucc 1080ugcaaggugu ccaccggcag gcaccuauu ucuauuggug  
cucugucucc ucugggagcc 1140cugguggcuu guuuaaggg cguguccugu agcaucggca gcaacagagu gggcaucauc  
1200aagcagcuga acaagggcug cagcuacauc accaaccagg acgccgauac cgugaccauc 1260gacaacaccg uguaucagcu  
gagcaaggug gaaggcgaac agcacugau caagggcaga 1320ccugugucca gcagcuucga ccuaucaag uuccugagg  
aucaguucca gguggccug 1380gaccaggugu ucgagaacau cgagaauucc caggcucugg uggaccaguc caacagauc

1440cugucuagcg ccgagaaggg aaacaccggc uucaucaucg ugaucauccu gaucgccgug 1500cugggcagcu ccaugauccu gguguccauc uucaucauu ucaagaagac caagaagccc 1560accggcgcuc cuccagaacu gagcggagug accaacaug gcuucaucc ucacaac 16171401617RNAArtificial SequenceSynthetic Polynucleotide 140augagcugga agguggucau caucuucagc cugcugauca caccucagca cggccugaaa 60gagagcuacc uggaagaguc cugcagcacc aucacagagg gcuaccuguc ugugcugaga 120accggcuggu acaccaacgu guucacacug ccugugggcg acgucgagaa ucugacaugc 180ucugauggcc cuagccugau caagaccgag cuggaucuga ccaagagcgc ccugagagaa 240cucaagaccg ugucugccga ucagcuggcc agagaggaac agaucgagaa uccuggcagc 300ggcagcuuug ugcugggagc cauugcucu gtaguggcug cugcugcagc uguuacagca 360ggcguggcca ucgcuagac caucagacug gaaagcgaag ugaccgccau caacaacgcc 420cugaagaaga caaacgagc cgucagcaca cucggcaaug gcguuagagu gcuggccaca 480gccgugcgcg agcugaagga cuucgugucc aagaaccuga cacgggccau uaacaagaac 540aagugcgaca ucgacgaccu gaagauggcc guguccuuua gccaguuaa cggcgguuu 600cugaacgucg ugcggcaguu uagcgacaac gccggaauca caccagccau cagccuggac 660cugaugacag augcugagcu ggcuagagcc gugccuaaca ugccuacauc ugccggccag 720aucaagcuga ugcucgagaa uagagccaug guccgacgga aagguucgg cauucugauu 780ggcguguacg gcagcagcgu gaucuaauug gucgagcugc cuauucgg cgugaucgac 840acaccugcu ggauugugaa ggccguccu agcuguagcg agaagaaggc cauuacgcc 900ugccugcuga gagaggacca aggcuuguau ugucagaacg ccggcagcac cguguacuac 960ccuaacgaga aggacugcga gacaagaggc gaccagugu ucugugauac cgccgcugga 1020aucaaugugg ccgagcagag caaagaguc aacaaca ucagcaccac caacuaucc 1080ugcaaggugu ccaccggcag gcaccuauu ucuauuggug cucugucucc ucugggagcc 1140cugguggcuu guuaaaggc cguguccugu agcaucggca gcaacagagu gggcaucauc 1200aagcagcuga acaaggcgug cagcuacauc accaaccagg acgccgauac cgugaccauc 1260gacaacaccg uguauagcu gagcaaggug gaaggcgaac agcagugau caagggcaga 1320ccugugucca gcagcuucga ccuaaucaag uuccugagg aucaguucca gguggccug 1380gaccaggugu ucgagaacau cgagaauucc caggcucugg ugaccaguc caacagauc 1440cugucuagcg

ccgagaaggg aaacaccggc uucaucaucg ugaucauccu gaucgccgug 1500cugggcagcu ccaugauccu gguguccauc uucaucauu ucaagaagac caagaagccc 1560accggcgcuc cuccagaacu gagcggagug accaacaug gcuucaucc ucacaac 16171411617RNAArtificial SequenceSynthetic Polynucleotide 141augagcugga agguggucau caucuucagc cugcugauca caccucagca cggccugaaa 60gagagcuacc uggaagaguc cugcagcacc aucacagagg gcuaccuguc ugugcugaga 120accggcuggu acaccaacgu guucacacug gaagugggcg acgucgagaa ucugacaugc 180ucugauggcc cuagccugau caagaccgag cuggaucuga ccaagagcgc ccugagagaa 240cucaagaccg ugucugccga ucagcuggcc agagaggaac agaucgagaa uccuggcagc 300ggcagcuuug ugcugggagc cauugcucu gtaguggcug cugcugcagc uguuacagca 360ggcguggcca ucgcuagac caucagacug gaaagcgaag ugaccgccau caacaacgcc 420cugaagaaga caaacgagc cgucagcaca cucggcaaug gcguuagagu gcuggccaca 480gccgugcgcg agcugaagga cuucgugucc aagaaccuga cacgggccau uaacaagaac 540aagugcgaca uccugaccu gaagauggcc guguccuuua gccaguuaa cggcgguuu 600cugaacgucg ugcggcaguu uagcgacaac gccggaauca caccagccau cagccuggac 660cugaugacag augcugagcu ggcuagagcc gugccuaaca ugccggccag 720aucaagcuga ugcucgagaa uagagccaug guccgacgga aagguucgg cauucugauu 780ggcguguacg gcagcagcgu gaucuaauug gucgagcugc cuauucgg cgugaucgac 840acaccugcu ggauugugaa ggccguccu agcuguagcg agaagaaggc cauuacgcc 900ugccugcuga gagaggacca aggcuuguau ugucagaacg ccggcagcac cguguacuac 960ccuaacgaga aggacugcga gacaagaggc gaccagugu ucugugauac cgccgcugga 1020aucaaugugg ccgagcagag caaagaguc aacaaca ucagcaccac caacuaucc 1080ugcaaggugu ccaccggcag gcaccuauu ucuauuggug cucugucucc ucugggagcc 1140cugguggcuu guuaaaggc cguguccugu agcaucggca gcaacagagu gggcaucauc 1200aagcagcuga acaaggcgug cagcuacauc accaaccagg acgccgauac cgugaccauc 1260gacaacaccg uguauagcu gagcaaggug gaaggcgaac agcagugau caagggcaga 1320ccugugucca gcagcuucga ccuaaucaag uuccugagg aucaguucca gguggccug 1380gaccaggugu ucgagaacau cgagaauucc caggcucugg ugaccaguc caacagauc 1440cugucuagcg ccgagaaggg aaacaccggc uucaucaucg ugaucauccu gaucgccgug 1500cugggcagcu ccaugauccu gguguccauc uucaucauu ucaagaagac caagaagccc 1560accggcgcuc cuccagaacu gagcggagug accaacaug gcuucaucc ucacaac 16171421617RNAArtificial SequenceSynthetic Polynucleotide 142augagcugga agguggucau caucuucagc cugcugauca caccucagca cggccugaaa 60gagagcuacc uggaagaguc cugcagcacc aucacagagg gcuaccuguc ugugcugaga 120accggcuggu acaccaacgu guucacacug gaagugggcg acgucgagaa ucugacaugc 180ucugauggcc cuagccugau caagaccgag cuggaucuga ccaagagcgc ccugagagaa 240cucaagaccg ugucugccga ucagcuggcc agagaggaac agaucgagaa uccuggcagc 300ggcagcuuug ugcugggagc cauugcucu gtaguggcug cugcugcagc uguuacagca 360ggcguggcca ucgcuagac caucagacug gaaagcgaag ugaccgccau caacaacgcc 420cugaagaaga caaacgagc cgucagcaca cucggcaaug gcguuagagu gcuggccaca 480gccgugcgcg agcugaagga cuucgugucc aagaaccuga cacgggccau uaacaagaac 540aagugccua ucgacgaccu gaagauggcc guguccuuua gccaguuaa cggcgguuu 600cugaacgucg ugcggcaguu uagcgacaac gccggaauca caccagccau cagccuggac 660cugaugacag augcugagcu ggcuagagcc gugccuaaca

ugccuacauc ugccggccag 720aucaagcuga ugcucgagaa uagagccaug guccgacgga aaggcuucgg cauucugauu  
780ggcguguacg gcagcagcgu gaucuauaug gugcagcugc cuaucuucgg cgugaucgac 840acaccugcu ggauugugaa  
ggccgucucc agcuguagcg agaagaaggg cauuacgcc 900ugccugcuga gagaggacca aggcugguau ugucagaacg  
ccggcagcac cguguacuac 960ccuaacgaga aggacugcga gacaagaggc gaccacgugu ucugugauac cgccgcugga  
1020aucaaugugg ccgagcagag caaagagugc aacaucaca ucagcaccac caacuauccc 1080ugcaaggugu ccaccggcag  
gcaccuauu ucuauuggug cucugucucc ucugggagcc 1140cugguggcuu guuauaaggg cguguccugu agcaucggca  
gcaacagagu gggcaucauc 1200aagcagcuga acaagggcug cagcuacauc accaaccagg acgccgauac cgugaccauc  
1260gacaacaccg uguaucagcu gagcaaggug gaaggcgaac agcacgugau caagggcaga 1320ccugugucca gcagcuucga  
ccuaucaag uuccugagg aucaguucca gguggcccug 1380gaccaggugu ucgagaacau cgagaauucc caggcucugg  
uggaccaguc caacagauc 1440cugucuagcg ccgagaaggg aaacaccggc uucaucaucg ugaucuccu gaucgccgug  
1500cugggcagcu ccaugauccu gguguccauc uucaucaua ucaagaagac caagaagccc 1560accggcguc cuccagaacu  
gagcggagug accaacaug gcuucaucc ucacaac 16171431617RNAArtificial SequenceSynthetic Polynucleotide  
143augagcugga agguggucau caucuucagc cugcugauca caccucagca cggccugaaa 60gagagcuacc uggaagaguc  
cugcagcacc aucacagagg gcuaccuguc ugugcugaga 120accggcuggu acaccaacgu guucacacug gaagugggcg  
acgucgagaa ucugacaugc 180ucugauggcc cuagccugau caagaccgag cuggaucuga ccaagagcgc ccugagagaa  
240cucaagaccg ugucugccga ucagcuggcc agagaggaac agaucgagaa uccuggcagc 300ggcagcuuug ugcugggagc  
cauugcucu ggaguggcug cugcugcagc uguuacagca 360ggcguggcca ucgcuagac caucagacug ccuagcgaag  
ugaccgccau caacaagcc 420cugaagaaga caaacgaggc cgucagcaca cucggcaaug gcguuagagu gcuggccaca  
480gccgugcgcg agcugaagga cuucgugucc aagaaccuga cacgggccau uaacaagaac 540aagugcgaca ucgacgaccu  
gaagauggcc guguccuuua gccaguucac ccggcgguuu 600cugaacgucg ugcggcaguu uagcgacaac gccggaauca  
caccagccau cagccuggac 660cugaugacag augcugagcu ggcuagagcc gugccuaaca ugccuacauc ugccggccag  
720aucaagcuga ugcucgagaa uagagccaug guccgacgga aaggcuucgg cauucugauu 780ggcguguacg gcagcagcgu  
gaucuauaug gugcagcugc cuaucuucgg cgugaucgac 840acaccugcu ggauugugaa ggccgucucc agcuguagcg  
agaagaaggg cauuacgcc 900ugccugcuga gagaggacca aggcugguau ugucagaacg ccggcagcac cguguacuac  
960ccuaacgaga aggacugcga gacaagaggc gaccacgugu ucugugauac cgccgcugga 1020aucaaugugg ccgagcagag  
caaagagugc aacaucaca ucagcaccac caacuauccc 1080ugcaaggugu ccaccggcag gcaccuauu ucuauuggug  
cucugucucc ucugggagcc 1140cugguggcuu guuauaaggg cguguccugu agcaucggca gcaacagagu gggcaucauc  
1200aagcagcuga acaagggcug cagcuacauc accaaccagg acgccgauac cgugaccauc 1260gacaacaccg uguaucagcu  
gagcaaggug gaaggcgaac agcacgugau caagggcaga 1320ccugugucca gcagcuucga ccuaucaag uuccugagg  
aucaguucca gguggcccug 1380gaccaggugu ucgagaacau cgagaauucc caggcucugg uggaccaguc caacagauc  
1440cugucuagcg ccgagaaggg aaacaccggc uucaucaucg ugaucuccu gaucgccgug 1500cugggcagcu ccaugauccu  
gguguccauc uucaucaua ucaagaagac caagaagccc 1560accggcguc cuccagaacu gagcggagug accaacaug  
gcuucaucc ucacaac 16171441617RNAArtificial SequenceSynthetic Polynucleotide 144augagcugga  
agguggucau caucuucagc cugcugauca caccucagca cggccugaaa 60gagagcuacc uggaagaguc cugcagcacc aucacagagg  
gcuaccuguc ugugcugaga 120accggcuggu acaccaacgu guucacacug gaagugggcg acgucgagaa ucugacaugc  
180ucugauggcc cuagccugau caagaccgag cuggaucuga ccaagagcgc ccugagagaa 240cucaagaccg ugucugccga  
ucagcuggcc agagaggaac agaucgagaa uccuggcagc 300ggcagcuuug ugcugggagc cauugcucu ggaguggcug  
cugcugcagc uguuacagca 360ggcguggcca ucgcuagac caucagacug gaaagcgaag ugaccgccau caacaagcc  
420cugaagaaga caaacgaggc cgucagcaca cucggcaaug gcguuagagu gcuggccaca 480gccgugcgcg agcugaagga  
cuucgugucc aagaaccuga cacgggccau uaacaagaac 540aagugcgaca ucgacgaccu gaagauggcc guguccuuua  
gccaguucac ccggcgguuu 600cugaacgucg ugcggcaguu uagcgacaac gccggaauca caccagccau cagccuggac  
660cugaugacag augcugagcu ggcuagagcc gugccuaaca ugccuacauc ugccggccag 720aucaagcuga ugcucgagaa  
uagagccaug guccgacgga aaggcuucgg cauucugauu 780ggcguguacg gcagcagcgu gaucuauaug gugcagcugc  
cuaucuucgg cgugaucgac 840acaccugcu ggauugugaa ggccgucucc agcuguagcg agaagaaggg cauuacgcc  
900ugccugcuga gagaggacca aggcugguau ugucagaacg ccggcagcac cguguacuac 960ccuaacgaga aggacugcga  
gacaagaggc gaccacgugu ucugugauac cgccgcugga 1020aucaaugugg ccgagcagag caaagagugc aacaucaca  
ucagcaccac caacuauccc 1080ugcaaggugu ccaccggcag gcaccuauu ucuauuggug cucugucucc ucugggagcc  
1140cugguggcuu guuauaaggg cguguccugu agcaucggca gcaacagagu gggcaucauc 1200aagcagcuga acaagggcug  
cagcuacauc accaaccagg acgccgauac cgugaccauc 1260gacaacaccg uguaucagcu gagcaaggug gaaggcgaac  
agcacgugau caagggcaga 1320ccugugucca gcagcuucc accuaucaag uuccugagg aucaguucca gguggcccug  
1380gaccaggugu ucgagaacau cgagaauucc caggcucugg uggaccaguc caacagauc 1440cugucuagcg ccgagaaggg  
aaacaccggc uucaucaucg ugaucuccu gaucgccgug 1500cugggcagcu ccaugauccu gguguccauc uucaucaua  
ucaagaagac caagaagccc 1560accggcguc cuccagaacu gagcggagug accaacaug gcuucaucc ucacaac  
16171451617RNAArtificial SequenceSynthetic Polynucleotide 145augagcugga agguggucau caucuucagc



cugcugauca caccucagca cggccugaaa 60gagagcuacc uggaagaguc cugcagcacc aucacagagg gcuaccuguc ugugcugaga  
120accggcuggu acaccaacgu guucacacug gaaguggggcg acgucgagaa ucugacaugc 180ucugauggcc cuagccugau  
caagaccgag cuggaucuga ccaagagcgc ccugagagaa 240cucaagaccg ugucugcccga ucagcuggcc agagaggaac  
agaucgagaa uccuggcagc 300ggcagcuuug ugcuggggagc cauugcucuu ggaguggcug cugcugcagc uguuacagca  
360ggcguggcca ucgcuaagac caucagacug gaaagcgaag ugaccgccau caacaacgcc 420cugaagaaga caaacgagge  
cgucagcaca cucggcaaug gcguuagagu gcuggccaca 480gccgugcgcg agcugaagga cuucgugucc aagaaccuga  
cacgggccau uaacaagaac 540aagugcgaca ucgacgaccu gaagauggcc guguccuuua gccaguuaa cggcgguuu  
600cugaacgucg ugcggcaguu uagcgacaac gccggaauca caccagccau cagccuggac 660cugaugacag augcugagcu  
ggcuagagcc gugccuaaca ugccuacauc ugccggccag 720aucaagcuga ugcucgagaa uagagccaug guccgacgga  
aaggcuucgg cauucugauu 780ggcguguacg gcagcagcgu gaucauauug gugcagcugc cuauucgg cgugaucgac  
840acaccugcu ggauugugaa ggccgucuccu agcuguagcg agaagaaggc cauuuacgcc 900ugccugcuga gagaggacca  
aggcugguau ugucagaacg cggcgagcac cguguacuac 960ccuaacgaga aggacugcga gacaagaggc gaccacgugu  
ucugugauac cgccgucgga 1020aucaaugugg ccgagcagag caaagagugc aacaucaca ucagcaccac caacuaucc  
1080ugcaaggugu ccaccggcag gcaccuauu ucuauuggug cucugucucc ucugggagcc 1140cugguggcuu guuauaaggg  
cguguccugu agcaucggca gcaacagagu gggcaucauc 1200aagcagcuga acaagggcug cagcuacauc accaaccagg  
acggcgauac cgugaccauc 1260gacaacaccg uguaucagcu gagcaaggug gaaggcgaac agcacugau caagggcaga  
1320ccugugucca gcagcuucga ccuaucaag uuccucgaga accaguucca gguggccug 1380gaccaggugu ucgagaacau  
cgagaauucc caggcucugg uggaccaguc caacagauc 1440cugucuagcg ccgagaaggg aaacaccggc ucaucaucg  
ugaucauccu gaucgcccug 1500cugggagcgu ccaugaucuu gguguccauc ucaucauuu ucaagaagac caagaagccc  
1560accggcguc succagaacu gagcggagug accaacaug gcuucaucc ucacaac 16171461617RNAArtificial  
SequenceSynthetic Polynucleotide 146augagcugga agguggucau caucuacg cugcugauca caccucagca cggccugaaa  
60gagagcuacc uggaagaguc cugcagcacc aucacagagg gcuaccuguc ugugcugaga 120accggcuggu acaccaacgu  
guucacacug gaaguggggcg acgucgagaa ucugacaugc 180ucugauggcc cuagccugau caagaccgag cuggaucuga  
ccaagagcgc ccugagagaa 240cucaagaccg ugucugcccga ucagcuggcc agagaggaac agaucgagaa uccuggcagc  
300ggcagcuuug ugcuggggagc cauugcucuu ggaguggcug cugcugcagc uguuacagca 360ggcguggcca ucgcuaagac  
caucagacug gaaagcgaag ugaccgccau caacaacgcc 420cugaagaaga caaacgagge cgucagcaca cucggcaaug  
gcguuagagu gcuggccaca 480gccgugcgcg agcugaagga cuucgugucc aagaaccuga cacgggccau uaacaagaac  
540aagugcgaca ucgacgaccu gaagauggcc guguccuuua gccaguuaa cggcgguuu 600cugaacgucg ugcggcaguu  
uagcgacaac gccggaauca caccagccau cagccuggac 660cugaugacag augcugagcu ggcuagagcc gugccuaaca  
ugccuacauc ugccggccag 720aucaagcuga ugcucgagaa uagagccaug guccgacgga aaggcuucgg cauucugauu  
780ggcguguacg gcagcagcgu gaucauauug gugcagcugc cuauucgg cgugaucgac 840acaccugcu ggauugugaa  
ggccgucuccu agcuguagcg agaagaaggc cauuuacgcc 900ugccugcuga gagaggacca aggcugguau ugucagaacg  
cggcgagcac cguguacuac 960ccuaacgaga aggacugcga gacaagaggc gaccacgugu ucugugauac cgccgucgga  
1020aucaaugugg ccgagcagag caaagagugc aacaucaca ucagcaccac caacuaucc 1080ugcaaggugu ccaccggcag  
gcaccuauu ucuauuggug cucugucucc ucugggagcc 1140cugguggcuu guuauaaggg cguguccugu agcaucggca  
gcaacagagu gggcaucauc 1200aagcagcuga acaagggcug cagcuacauc accaaccagg acggcgauac cgugaccauc  
1260gacaacaccg uguaucagcu gagcaaggug gaaggcgaac agcacugau caagggcaga 1320ccugugucca gcagcuucga  
ccuaucaag uuccucagc aucaguucca gguggccug 1380gaccaggugu ucgagaacau cgagaauucc caggcucugg  
uggaccaguc caacagauc 1440cugucuagcg ccgagaaggg aaacaccggc ucaucaucg ugaucauccu gaucgcccug  
1500cugggagcgu ccaugaucuu gguguccauc ucaucauuu ucaagaagac caagaagccc 1560accggcguc succagaacu  
gagcggagug accaacaug gcuucaucc ucacaac 16171471617RNAArtificial SequenceSynthetic Polynucleotide  
147augagcugga agguggucau caucuacg cugcugauca caccucagca cggccugaaa 60gagagcuacc uggaagaguc  
cugcagcacc aucacagagg gcuaccuguc ugugcugaga 120accggcuggu acaccaacgu guucacacug gaaguggggcg  
acgucgagaa ucugacaugc 180ucugauggcc cuagccugau caagaccgag cuggaucuga ccaagagcgc ccugagagaa  
240cucaagaccg ugucugcccga ucagcuggcc agagaggaac agaucgagaa uccuggcagc 300ggcagcuuug ugcuggggagc  
cauugcucuu ggaguggcug cugcugcagc uguuacagca 360ggcguggcca ucgcuaagac caucagacug gaaagcgaag  
ugaccgccau caacaacgcc 420cugaagaaga caaacgagge cgucagcaca cucggcaaug gcguuagagu gcuggccaca  
480gccgugcgcg agcugaagga cuucgugucc aagaaccuga cacgggccau uaacaagaac 540aagugcgaca ucgacgaccu  
gaagauggcc guguccuuua gccaguggaa cggcgguuu 600cugaacgucg ugcggcaguu uagcgacaac gccggaauca  
caccagccau cagccuggac 660cugaugacag augcugagcu ggcuagagcc gugccuaaca ugccuacauc ugccggccag  
720aucaagcuga ugcucgagaa uagagccaug guccgacgga aaggcuucgg cauucugauu 780ggcguguacg gcagcagcgu  
gaucauauug gugcagcugc cuauucgg cgugaucgac 840acaccugcu ggauugugaa ggccgucuccu agcuguagcg  
agaagaaggc cauuuacgcc 900ugccugcuga gagaggacca aggcugguau ugucagaacg cggcgagcac cguguacuac  
960ccuaacgaga aggacugcga gacaagaggc gaccacgugu ucugugauac cgccgucgga 1020aucaaugugg ccgagcagag

caaagagugc aacaucaaca ucagcaccac caacuaucce 1080ugcaaggugu ccaccggcag gcaccuauu ucuauggugg  
cucugucucc ucugggagcc 1140cugguggcuu guuauaaggg cguguccugu agcaucggca gcaacagagu gggcaucauc  
1200aagcagcuga acaagggcug cagcuacauc accaaccagg acgccgauac cgugaccauc 1260gacaacaccg uguaucagcu  
gagcaaggug gaaggcgaac agcacgugau caagggcaga 1320ccugugucca gcagcuucga ccuaucag uucccugagg  
aucaguucca gguggcccug 1380gaccaggugu ucgagaacau cgagaauucc caggcucugg uggaccaguc caacagauc  
1440cugucuagcg ccgagaaggg aacaccggc uucaucaucg ugaucuccu gaucgccgug 1500cugggcagcu ccaugauccu  
gguguccauc uucaucauu ucaagaagac caagaagccc 1560accggcgcuc cuccagaacu gagcggagug accaacaug  
gcuucaucce ucacaac 1617

\* \* \* \* \*

